[heart failure]

heart failure, Heart failure, Heart Failure

[patient with heart failure]

patients with heart failure, Patients with heart failure, patient with heart failure, Patients With Heart Failure

[ejection fraction]

ejection fraction, ejection fractions, Ejection fraction, Ejection Fraction

[heart failure HF]

heart failure HF, Heart failure HF

[heart]

heart, Heart, hearts

[patient]

patient, patients, Patients, PATIENTS, Patient

[ventricular ejection fraction]

ventricular ejection fraction, ventricular ejection fractions

[hazard ratio]

hazard ratio, hazard ratios

[left ventricular ejection fraction]

left ventricular ejection fraction

[chronic heart failure]

chronic heart failure

[left ejection fraction]

left ejection fraction

[patients with HF]

patients with HF, Patients with HF

[heart failure patients]

heart failure patients, Heart Failure Patients

[quality of life]

quality of life, Quality of life, Quality of Life

[congestive heart failure]

congestive heart failure

[HF]

HF

[heart failure with ejection fraction]

heart failure with ejection fraction, Heart failure with ejection fraction, Heart Failure With Ejection Fraction

[systolic heart failure]

systolic heart failure

[acute heart failure]

acute heart failure, Acute heart failure

[myocardial infarction]

myocardial infarction, Myocardial infarction

[ventricular assist device]

ventricular assist devices, ventricular assist device

[P]

p, P

[heart rate]

heart rate, Heart rate

[ventricular ejection]

ventricular ejection

[heart disease]

heart disease, Heart disease

[HF hospitalization]

HF hospitalization, HF hospitalizations

[exercise training]

exercise training

[patients with HFpEF]

patients with HFpEF, Patients with HFPEF, patients with HFPEF

[atrial fibrillation]

atrial fibrillation, Atrial fibrillation

[functional capacity]

functional capacity

[glomerular filtration rate]

glomerular filtration rate

[assist device]

assist devices, assist device

[cardiac resynchronization therapy]

cardiac resynchronization therapy

[renal function]

renal function, Renal function

[heart failure CHF]

heart failure CHF

[study]

study, studies, Study, STUDY

[risk of heart failure]

risk of heart failure

[patients with heart failure HF]

patients with heart failure HF

[Heart Failure]

Heart Failure

[outcome]

Outcomes, OUTCOMES, outcomes, outcome, OUTCOME

[result]

results, RESULTS, resulting, Results, result

[acute myocardial infarction]

acute myocardial infarction

[resynchronization therapy]

resynchronization therapy, Resynchronization Therapy

[blood pressure]

blood pressure, Blood pressure

[hazard ratio HR]

hazard ratio HR

[body mass index]

body mass index

[primary outcome]

primary outcome, Primary outcomes, Primary outcome

[follow-up visits]

follow-up visits

[renal dysfunction]

renal dysfunction, Renal dysfunction

[consecutive patients]

consecutive patients

[all-cause mortality]

All-cause mortality, all-cause mortality

[odds ratio]

odds ratios, odds ratio, Odds ratios, Odds Ratio

[risk factor]

Risk factors, risk factors, risk factor

[risk]

risk, Risk, risks

[ventricular assist]

ventricular assist, Ventricular Assist

[ejection fraction HFpEF]

ejection fraction HFpEF, ejection fraction HFPEF

[chronic heart failure CHF]

chronic heart failure CHF

[treatment of heart failure]

treatment of heart failure, Treatment of Heart Failure

[right heart failure]

right heart failure

[mortality]

mortality, Mortality

[New York]

New York

[ejection]

ejection, Ejection

[HF patients]

HF patients

[clinical trial]

clinical trials, clinical trial

[cardiovascular event]

cardiovascular events, cardiovascular event

[LV ejection fraction]

LV ejection fraction

[treatment]

Treatment, treatment, treatments, TREATMENT

[body mass]

body mass

[rhythm control therapy]

Rhythm control therapy, rhythm control therapy

[York Heart Association class]

York Heart Association classes, York Heart Association class

[advanced heart failure]

advanced heart failure

[CONCLUSION]

CONCLUSIONS, Conclusion, CONCLUSION, conclusion

[peak VO2]

peak VO2, Peak VO2

[6 months]

6 months

[exercise]

exercise

[predictor of mortality]

Predictors of mortality, predictors of mortality, predictor of mortality

[higher risk]

higher risk, higher risks, high risk

[systolic HF]

systolic HF

[body composition]

body composition, Body composition

[clinical outcome]

clinical outcomes, clinical outcome

[adverse event]

adverse events, adverse event

[functional MS]

functional MS

[control group]

control group

[7-day follow-up visits]

7-day follow-up visits

[risk of death]

risk of death

[end point]

end points, end point

[patient with chronic heart failure]

patients with chronic heart failure, patient with chronic heart failure

[1.73 m 2]

1.73 m 2

[acute infarction]

acute infarction

[1.73 m]

1.73 m

[HR]

HR

[New York Heart Association]

New York Heart Association

[year]

years, year

[mm Hg]

mm Hg

[Cox hazards models]

Cox hazard models, Cox hazards models

[filtration rate]

filtration rate

[ventricular dysfunction]

ventricular dysfunction, vEntricular dysfunction

[cardiovascular death]

cardiovascular death

[diabetes mellitus]

diabetes mellitus

[congestive heart failure CHF]

congestive heart failure CHF

[mL per m]

mL per m

[patients with CHF]

patients with CHF

[length of stay]

length of stay

[angiotensin receptor blockers]

angiotensin receptor blockers

[30-day readmission rate]

30-day readmission rates, 30-day readmission rate

[diagnosis of heart failure]

Diagnosis of heart failure, diagnosis of heart failure

[coronary artery disease]

coronary artery disease

[Cox proportional hazards models]

Cox proportional hazards models, Cox proportional hazard models

[objective of this study]

objective of this study

[mL per 1.73 m]

mL per 1.73 m

[outcome in patients]

outcome in patients, outcomes in patients

[risk stratification]

risk stratification, Risk stratification

[HeartMate II]

HeartMate II

[artery disease]

artery disease

[event rate]

event rates, event rate

[patients with heart disease]

patients with heart disease

[natriuretic peptide]

natriuretic peptide, natriuretic peptides

[exercise capacity]

exercise capacity

[METHODS]

METHODS

[rhythm control]

Rhythm control, rhythm control

[LV]

LV

[end-stage heart failure]

end-stage heart failure

[peak oxygen uptake]

peak oxygen uptake

[York Heart Association]

York Heart Association

[effect]

effects, effect, Effect

[CV events]

CV events

[cardiovascular disease]

cardiovascular diseases, cardiovascular disease

[Heart Association]

Heart Association

[cardiac function]

cardiac function, cardiac functions

[death]

death, deaths

[pulmonary hypertension]

pulmonary hypertension

[ventricular function]

ventricular function

[readmission rate]

readmission rates, readmission rate

[function]

function, functions, Function

[hazard]

hazard, hazards

[left ventricle]

left ventricle

[New York Heart Association class]

New York Heart Association classes, New York Heart Association class

[BACKGROUND]

Background, BACKGROUND, background

[cohort study]

cohort studies, cohort study, Cohort Study

[older patients]

older patients, Older Patients

[systematic review]

systematic review, Systematic review

[significant improvement]

significant improvement, significant improvements

[adults with heart failure]

adults with heart failure

[development of heart failure]

development of heart failure

[Health Buddy Program]

Health Buddy Program

[aim of this study]

aim of this study

[cohort of patients]

cohort of patients

[chronic obstructive pulmonary disease]

chronic obstructive pulmonary disease

[N-terminal pro-brain natriuretic peptide]

N-terminal pro-brain natriuretic peptide

[acute myocardial infarction AMI]

acute myocardial infarction AMI

[B-type natriuretic peptide]

B-type natriuretic peptide

[ANG II infusion]

ANG II infusion

[purpose of this study]

purpose of this study

[cardiac resynchronization therapy CRT]

cardiac resynchronization therapy CRT

[angiotensin-converting enzyme inhibitors]

angiotensin-converting enzyme inhibitors

[ejection fraction EF]

ejection fraction EF, Ejection fraction EF

[mortality in patients]

mortality in patients

[acute kidney injury]

acute kidney injury

[coronary heart disease]

coronary heart disease

[systolic blood pressure]

systolic blood pressure

[ventricular-arterial coupling]

ventricular-arterial coupling

[functional class]

functional class

[long-term mortality]

long-term mortality

[diastolic dysfunction]

diastolic dysfunction

[LV dysfunction]

LV dysfunction

[follow-up of years]

follow-up of years

[acute infarction AMI]

acute infarction AMI

[patients with hypertension]

patients with hypertension

[disease]

disease, diseases

[management of patients]

Management of patients, management of patients

[severe heart failure]

severe heart failure

[HR variability]

HR variability

[outcome measures]

outcome measures, OUTCOME MEASURES

[CHF]

CHF

[change]

changes, change, Changes, changing

[clinical practice]

clinical practice

[all-cause hospitalization]

all-cause hospitalization, all-cause hospitalizations

[older adults]

older adults

[independent predictor]

independent predictors, Independent predictors, independent predictor

[chronic disease]

chronic disease

[follow-up]

follow-up

[angiotensin receptor]

angiotensin receptor, angiotensin receptors

[medical treatment]

medical treatment

[chronic pulmonary disease]

chronic pulmonary disease

[ventricular LV ejection fraction]

ventricular LV ejection fraction

[trial]

trial, trials, Trials

[baseline]

baseline, Baseline

[reverse remodeling]

reverse remodeling

[New York Heart Association NYHA]

New York Heart Association NYHA

[mitral regurgitation]

mitral regurgitation, Mitral regurgitation

[dysfunction]

dysfunction

[cardiac resynchronization]

cardiac resynchronization

[respectively p]

respectively p, respectively P

[sympathetic activity]

sympathetic activity

[patients with systolic heart failure]

patients with systolic heart failure

[gastrointestinal bleeding]

Gastrointestinal bleeding, gastrointestinal bleeding

[biological phenotype]

biological phenotype

[catheter ablation]

catheter ablation, Catheter ablation

[deficit index]

deficit index

[systolic function]

systolic function

[gene expression]

gene expression, gene expressions, Gene expression

[1 year]

1 year

[3 months]

3 months

[sympathetic tone]

sympathetic tone

[prospective study]

prospective study, prospective studies

[interquartile range]

interquartile range

[insulin resistance]

insulin resistance, Insulin resistance

[major complications]

major complications

[biomedical treatment]

biomedical treatment

[mechanical support]

mechanical support

[event]

event, events

[mL]

mL, ml

[age]

age, ages

[adverse CV events]

adverse CV events

[pro-B-type natriuretic peptide]

pro-B-type natriuretic peptide, pro-B-type natriuretic peptides

[Retrospective cohort study]

Retrospective cohort study, Retrospective Cohort Study

[period versus 1]

period versus 1

[sudden cardiac death]

sudden cardiac death, sudden cardiac deaths

[risk for heart failure]

risk for heart failure, Risk for Heart Failure

[heart failure HF patients]

heart failure HF patients

[acute coronary syndrome]

acute coronary syndrome, acute coronary syndromes

[bundle branch block]

bundle branch block

[HF risk factors]

HF risk factors

[time of admission]

time of admission

[patients with systolic HF]

Patients with systolic HF, patients with systolic HF

[Kansas City Cardiomyopathy Questionnaire]

Kansas City Cardiomyopathy Questionnaire

[peak oxygen consumption]

peak oxygen consumption, Peak oxygen consumption

[right ventricular reserve]

right ventricular reserve

[chronic obstructive disease]

chronic obstructive disease

[low-volume ED cases]

low-volume ED cases

[Mediterranean diet score]

Mediterranean diet scores, Mediterranean diet score

[mechanical cardiac support]

mechanical cardiac support

[patients with atrial fibrillation]

patients with atrial fibrillation, Patients with atrial fibrillation

[patients with ejection fraction]

patients with ejection fraction

[right ventricular contractile reserve]

right ventricular contractile reserve

[heart failure hospitalization]

heart failure hospitalization, heart failure hospitalizations

[cardiopulmonary exercise testing]

cardiopulmonary exercise testing, Cardiopulmonary exercise testing

[outcome of death]

outcome of death

[peripheral vascular disease]

peripheral vascular disease

[implantable cardioverter defibrillator-CRT]

implantable cardioverter defibrillator-CRT

[right contractile reserve]

right contractile reserve

[cause of death]

cause of death, causes of death

[chronic myocardial ischemia]

chronic myocardial ischemia

[ejection fraction HFrEF]

ejection fraction HFrEF

[ejection fraction HFPEF]

ejection fraction HFPEF

[risk of events]

risk of events, Risk of event

[LV end-diastolic pressure]

LV end-diastolic pressure

[prediction rule]

prediction rule

[sinus rhythm]

sinus rhythm

[RV failure]

RV failure

[CI]

CI

[sudden death]

sudden death, sudden deaths

[beneficial effect]

beneficial effect, beneficial effects

[m 2]

m 2

[endothelial function]

endothelial function, Endothelial function

[valve plasty]

valve plasty

[group]

groups, group

[hospital]

hospitals, hospital

[min]

min, minutes

[York Heart Association NYHA]

York Heart Association NYHA

[patients with pulmonary hypertension]

patients with pulmonary hypertension

[type 2 diabetes]

type 2 diabetes, Type 2 diabetes

[annular size reduction]

annular size reduction

[patients with fibrillation]

patients with fibrillation, Patients with fibrillation

[treatment for HF]

treatment for HF

[Cardiac Resynchronization Therapy]

Cardiac resynchronization therapy, Cardiac Resynchronization Therapy

[n]

n

[confidence]

confidence, Confidence

[high mortality]

higher mortality, high mortality

[medical management]

medical management

[end stage]

end stage

[2 weeks]

2 weeks

[long-term outcomes]

long-term outcomes

[systolic dysfunction]

systolic dysfunction

[transcription factor]

transcription factor, transcription factors

[adverse outcome]

adverse outcomes, adverse outcome

[degenerative MR]

degenerative MR

[chronic HF]

chronic HF

[mortality rate]

mortality rates, mortality rate

[receptor antagonist]

receptor antagonists, receptor antagonist

[failing heart]

failing heart, failing hearts

[4 years]

4 years

[low-dose dopamine]

low-dose dopamine

[idiopathic cardiomyopathy]

idiopathic cardiomyopathy

[low-dose nesiritide]

low-dose nesiritide

[salt loading]

salt loading

[usual care]

usual care, Usual care

[severe CAD]

severe CAD

[health outcomes]

health outcomes

[baseline characteristics]

Baseline characteristics, baseline characteristics

[Physician volume]

Physician volume, physician volume

[familiar physician]

familiar physician

[clinical status]

clinical status

[membrane oxygenation]

membrane oxygenation

[Exercise Training]

Exercise training, Exercise Training, Exercise TraiNing

[systolic pressure]

systolic pressure

[breast cancer]

breast cancer, Breast cancer

[inappropriate therapy]

inappropriate therapy

[pulmonary embolism]

pulmonary embolism

[medical records]

medical records

[15 mL]

15 mL, 15 ml

[further study]

further study, Further studies, further studies

[type 2]

type 2

[Concurrent HF]

Concurrent HF, concurrent HF

[social support]

social support

[patient population]

patient population

[exercise rehabilitation]

exercise rehabilitation

[Multivariate analysis]

Multivariate analysis

[cardiac hypertrophy]

cardiac hypertrophy

[mitral valve]

mitral valve

[mean age]

mean age, Mean age

[Similar results]

Similar results

[HR reduction]

HR reduction

[dialysis patients]

dialysis patients, Dialysis patients

[RV dysfunction]

RV dysfunction

[cardiac transplant]

cardiac transplant, cardiac transplants

[Nordic walking]

Nordic walking

[NYHA class]

NYHA class

[diet score]

diet scores, diet score, Diet score

[MAIN OUTCOME]

MAIN OUTCOMES, MAIN OUTCOME

[present study]

present study

[follow-up period]

follow-up period

[contextual reasons]

contextual reasons, Contextual reasons

[CHF patients]

CHF patients

[implantable cardioverter-defibrillator deactivation discussions]

implantable cardioverter-defibrillator deactivation discussions

[successful valve plasty]

successful valve plasty

[myocardial infarction AMI]

myocardial infarction AMI

[obstructive pulmonary disease]

obstructive pulmonary disease

[effect of exercise training]

effects of exercise training, effect of exercise training

[resynchronization therapy CRT]

resynchronization therapy CRT

[hospitalization]

hospitalization, hospitalizations

[care]

care, Care, caring

[improvement]

improvements, improvement, Improvement

[month]

months, month

[patient with heart failure CHF]

patients with heart failure CHF, patient with heart failure CHF

[LV ejection]

LV ejection

[beta-blocker therapy]

beta-blocker therapy

[control]

controls, control, controlling

[prognostic factor]

prognostic factor, prognostic factors

[ED visits]

ED visits

[TNF antagonist]

TNF antagonist, TNF antagonists

[HFpEF]

HFpEF, HFPEF

[physician]

Physicians, physicians, physician, Physician

[significant difference]

significant difference, significant differences

[ECMO group]

ECMO group

[severe hypertension]

severe hypertension

[data]

data

[m]

m, ms

[myocardial ischemia]

myocardial ischemia

[enzyme inhibitor]

enzyme inhibitors, enzyme inhibitor

[cardioverter-defibrillator deactivation]

cardioverter-defibrillator deactivation

[disease management]

disease management

[albumin level]

albumin levels, albumin level

[peak oxygen]

peak oxygen, Peak oxygen

[quality]

quality, Quality

[analysis]

analysis, analyses, Analyses, Analysis

[hypertension]

hypertension

[health]

health, Health

[therapy]

therapy, therapies, Therapies, Therapy

[day]

days, day

[survival]

survival, SurvIval

[advanced heart failure HF]

advanced heart failure HF

[Human heart failure]

human heart failure, Human heart failure

[functional enrichment analysis]

functional enrichment analysis

[LV end-diastolic volume]

LV end-diastolic volume

[N-terminal pro-B-type natriuretic peptide]

N-terminal pro-B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptides

[end of life]

end of life

[treatment for heart failure]

treatment for heart failure

[ventricular assist devices LVADs]

ventricular assist devices LVADs

[Right atrial myxoma]

Right atrial myxoma, right atrial myxoma

[biomedical reasons for nonprescribing]

biomedical reasons for nonprescribing

[creatine kinase activity]

creatine kinase activity

[effects on cardiac function]

effects on cardiac function

[events in patients]

events in patients

[renal function in children]

renal function in children

[left assist device]

left assist devices, left assist device

[HF hospital admissions]

HF hospital admissions

[HF with EF]

HF with EF

[aortic blood flow]

aortic blood flow

[8 months of treatment]

8 months of treatment

[Relationship between sex]

Relationship between sex, relationship between sex

[heart failure after CABG]

heart failure after CABG

[stable heart failure]

stable heart failure

[diastolic mitral valve tethering]

diastolic mitral valve tethering

[ventricular contractile reserve]

ventricular contractile reserve

[prevention of HF]

prevention of HF

[refractory heart failure]

refractory heart failure

[worsening of heart failure]

worsening of heart failure

[high risk for hyperkalemia]

high risk for hyperkalemia

[medical treatment for HF]

medical treatment for HF

[ambulatory patients with HF]

ambulatory patients with HF

[NYHA functional class]

NYHA functional class

[pathophysiology of HF]

pathophysiology of HF

[mortality hazard ratio]

mortality hazard ratio

[systolic heart failure HF]

systolic heart failure HF

[higher furosemide dose]

higher furosemide dose

[left ventricular assist device]

left ventricular assist devices, left ventricular assist device

[Cox regression analysis]

Cox regression analyses, Cox regression analysis

[predicting CV events]

predicting CV events

[patients with precapillary PH]

patients with precapillary PH

[severe pulmonary hypertension]

severe pulmonary hypertension

[early rhythm control therapy]

early rhythm control therapy, Early rhythm control therapy

[implantable cardioverter-defibrillator deactivation]

implantable cardioverter-defibrillator deactivation

[low testosterone status]

low testosterone status

[proportion of patients]

proportion of patients

[Heart Failure Survey]

Heart Failure Survey

[less than 130 msec]

less than 130 msec

[risk of mortality]

risk of mortality

[end stage heart failure]

end stage heart failure

[chronic heart failure HF]

chronic heart failure HF

[median rate ratio]

median rate ratio

[MVA of 1.2 cm2]

MVA of 1.2 cm2

[mitral annulus velocity]

mitral annulus velocity, mitral annulus velocities

[predictive cutoff value]

predictive cutoff value

[goal of this study]

goal of this study

[predictor of outcomes]

predictors of outcome, predictor of outcomes, predictor of outcome

[cardiovascular risk factors]

cardiovascular risk factors

[acute heart failure HF]

acute heart failure HF

[risk of inappropriate therapy]

risk of inappropriate therapy

[cardiac autonomic balance]

cardiac autonomic balance

[heart failure in patients]

heart failure in patients, Heart failure in patients

[left assist device implantation]

left assist device implantation

[management of heart failure]

management of heart failure, Management of heart failure

[treatment with carvedilol]

treatment with carvedilol, Treatment with carvedilol

[mean follow-up of years]

mean follow-up of years

[skeletal muscle mass]

skeletal muscle mass

[mitral valve opening]

mitral valve opening

[72-hour cumulative urine volume]

72-hour cumulative urine volume

[primary end point]

primary end point

[Therapy with ivabradine]

Therapy with ivabradine, therapy with ivabradine

[narrow QRS complex]

narrow QRS complex

[post-acute care transfer policy]

post-acute care transfer policy

[adverse event rates]

adverse event rates

[HeartMate II LVAD]

HeartMate II LVAD

[Multicenter Automatic Defibrillator]

Multicenter Automatic Defibrillator

[outpatients with heart failure]

outpatients with heart failure

[mild reduction in LVEF]

mild reductions in LVEF, mild reduction in LVEF

[history of myocardial infarction]

history of myocardial infarction

[primary outcome of death]

primary outcome of death

[percentage of myocardial collagen]

percentage of myocardial collagen

[N-terminal pro-B-type peptide]

N-terminal pro-B-type peptide, N-terminal pro-B-type peptides

[heart rate reduction]

heart rate reduction, Heart rate reduction

[treating patients with DCM]

treating patients with DCM

[study end point]

study end point

[mineralocorticoid receptor antagonists]

mineralocorticoid receptor antagonists

[adenine nucleotides contents]

adenine nucleotides contents

[patients with PAD]

patients with PAD

[coronary artery disease CAD]

coronary artery disease CAD

[atrial fibrillation AF]

atrial fibrillation AF

[effects on function]

effects on function

[mean ejection fraction]

mean ejection fraction

[normalization of albumin levels]

normalization of albumin levels, normalization of albumin level

[kg body mass]

kg body mass

[6-month risk of death]

6-month risk of death

[transverse aortic constriction TAC]

transverse aortic constriction TAC

[other outcome measures]

other outcome measures

[non-ischemic heart failure]

non-ischemic heart failure

[patients with PH]

patients with PH

[exercise group P]

exercise group P

[survival of patients]

survival of patients

[cause of systolic HF]

cause of systolic HF

[association between frailty]

association between frailty

[hospitalization for HF]

hospitalization for HF

[history of valve plasty]

history of valve plasty

[Chronic heart failure]

Chronic heart failure

[maintenance of sinus rhythm]

maintenance of sinus rhythm

[acute RV failure]

acute RV failure

[transverse aortic constriction]

transverse aortic constriction

[quality improvement initiative]

quality improvement initiative

[preoperative renal dysfunction]

preoperative renal dysfunction

[Treatment with CRT-D]

Treatment with CRT-D, treatment with CRT-D

[breast cancer patients]

Breast cancer patients, breast cancer patients

[Heart Failure Cost-Effectiveness Model]

Heart Failure Cost-Effectiveness Model

[P for trend]

P for trend

[use of medications]

use of medications

[patients aged years]

patients aged years, Patients aged years

[prevalence of HF]

prevalence of HF

[patients receiving carvedilol]

patients receiving carvedilol

[pulmonary arterial pressure]

pulmonary arterial pressure

[patients with disease]

patients with disease

[left ventricular diastolic function]

left ventricular diastolic function

[need of diuretics]

need of diuretics

[mitral valve plasty]

mitral valve plasty

[ability of BNP]

ability of BNP

[heart rate HR]

heart rate HR, Heart rate HR

[LV assist device implantation]

LV assist device implantation, LV assist device implantations

[Cox proportional hazards analyses]

Cox proportional hazards analyses, Cox proportional hazard analyses

[mL per m 2]

mL per m 2

[patients with cardiomyopathy]

patients with cardiomyopathy

[patients with diabetes]

patients with diabetes

[Patients with low sST2]

Patients with low sST2

[number of patients]

number of patients

[evidence from trials]

evidence from trials

[kg]

kg

[body]

body, Body

[role]

role, roles

[difference]

difference, differences

[rate]

Rates, rates, rate

[peak]

peak, Peak

[LV volume]

LV volume

[LCX model]

LCX model, LCX models

[survival rates]

survival rates

[general population]

general population, general populations

[cardiac remodeling]

cardiac remodeling

[acute care]

Acute care, acute care

[HFVT(+) group]

HFVT(+) group, HFVT(+) groups

[treatment strategies]

treatment strategies

[dyssynchronous HF]

dyssynchronous HF

[RS synchrony]

RS synchrony

[health care]

health care

[LV pressure]

LV pressure

[preoperative hypoalbuminemia]

preoperative hypoalbuminemia

[guideline-recommended medications]

guideline-recommended medications

[cardiac output]

cardiac output

[2 groups]

2 groups

[HF mortality]

HF mortality

[spironolactone use]

spironolactone use

[left ventricular LV ejection fraction]

left ventricular LV ejection fraction

[medical therapy]

medical therapy

[severe HF]

severe HF

[ambulatory patients]

ambulatory patients

[primary endpoint]

primary endpoint

[cardiovascular mortality]

cardiovascular mortality

[ventricular filling]

ventricular filling

[cardiac index]

cardiac index

[longitudinal strain]

longitudinal strain

[other conditions]

other conditions

[age group]

age group, age groups

[high sST2]

high sST2

[mitral stenosis]

Mitral stenosis, mitral stenosis

[health status]

health status

[BNP level]

BNP levels, BNP level

[muscle mass]

muscle mass

[HF symptom]

HF symptom, HF symptoms

[LVAD implantation]

LVAD implantation

[beta blockers]

beta blockers, Beta blockers

[Fontan failure]

Fontan failure

[4 wk]

4 wk

[significant MS]

significant MS

[arterial pressure]

arterial pressure

[12 months]

12 months

[physician continuity]

physician continuity

[first month]

first months, first month

[young adults]

young adults

[heart transplantation]

heart transplantation, heart transplantations

[inhospital mortality]

inhospital mortality, Inhospital mortality

[cardiac death]

cardiac death, cardiac deaths

[bottleneck stent]

bottleneck stent

[new targets]

new targets

[care management]

care management, Care management

[pro-B-type peptide]

pro-B-type peptide, pro-B-type peptides

[adult patients]

adult patients

[LV dilatation]

LV dilatation

[shock therapy]

shock therapy

[human resistin]

Human resistin, human resistin

[implantable cardioverter-defibrillator]

implantable cardioverter-defibrillator

[One patient]

One patient, one patient

[emergency department]

emergency department

[cardiac nurse]

cardiac nurse, cardiac nurses

[12 weeks]

12 weeks

[unclear etiology]

unclear etiology

[mild MR]

mild MR

[30 days]

30 days

[filling pressure]

filling pressures, filling pressure

[black race]

black race

[DASH diet]

DASH diet

[office hours]

office hours

[hospital discharge]

hospital discharge

[observational study]

observational studies, observational study

[cardiac patients]

cardiac patients

[cardiac rehabilitation]

cardiac rehabilitation

[myocardial collagen]

Myocardial collagen, myocardial collagen

[ANS mice]

ANS mice

[pulmonary artery]

pulmonary artery

[cardiac event]

cardiac event, cardiac events

[all-cause readmission]

all-cause readmission, all-cause readmissions

[long-term survival]

long-term survival

[three groups]

three groups

[STUDY DESIGN]

study design, STUDY DESIGN, study designs

[human HF]

human HF

[air pollution]

air pollution

[patients with acute heart failure]

patients with acute heart failure

[low-dose BB]

low-dose BB

[vascular resistance]

vascular resistance

[signaling pathway]

signaling pathway, signaling pathways

[unfit men]

unfit men

[acute HF]

acute HF

[lung weight]

lung weight

[Hum-Retn mice]

Hum-Retn mice

[arterial elastance]

arterial elastance

[20 weeks]

20 weeks

[high-dose BB]

high-dose BB

[diagnostic procedure]

diagnostic procedures, diagnostic procedure

[cardiac cachexia]

cardiac cachexia

[body weight]

body weight, Body weight

[echocardiographic score]

echocardiographic score

[biventricular support]

biventricular support

[aldosterone antagonist]

aldosterone antagonist

[recent years]

recent years

[30 mL]

30 mL, 30 ml

[cardiac dysfunction]

cardiac dysfunction

[standard criteria]

standard criteria

[ECMO+VAD group]

ECMO+VAD group

[right reserve]

right reserve

[early diastolic mitral annular velocity]

early diastolic mitral annular velocity

[participant]

PARTICIPANTS, Participants, participants, participant

[model]

model, models

[receptor]

receptor, receptors

[diabetes]

diabetes

[cohort]

cohort, Cohort, cohorts

[benefit]

benefits, benefit, Benefits

[life]

life, Life

[use]

use, Use

[development]

development, developments

[increase]

increases, increase, increasing

[management]

Management, management

[readmission]

readmission, Readmission, readmissions

[aortic constriction]

aortic constriction

[gene program]

gene programs, gene program

[exercise testing]

exercise testing

[resource use]

resource use

[type diabetes]

type diabetes, Type diabetes

[size reduction]

size reduction

[mRNA level]

mRNA levels, mRNA level

[association]

association, associations, Association

[adult]

adult, adults

[cell]

cells, cell, Cell, Cells

[including]

including

[evidence]

evidence

[intervention]

INTERVENTIONS, interventions, intervention, Interventions, INTERVENTION

[symptom]

symptoms, Symptom, symptom

[time]

time, Time, times

[blood]

blood, Blood

[exercise group]

exercise group

[obstructive disease]

obstructive disease

[QRS duration]

QRS duration

[Minnesota Living]

Minnesota Living

[kidney injury]

kidney injury

[male patients]

male patients, Male patients

[study patients]

study patients, studies patients

[pulmonary disease]

pulmonary disease

[autonomic balance]

autonomic balance

[UM cohort]

UM cohort, UM cohorts

[blood flow]

blood flow

[p value]

p value, p values, P value

[index]

index, Indices, indices, Index

[week]

weeks, week

[support]

support, Support

[gene]

gene, genes, Gene, Genes

[device]

device, devices, Devices

[measure]

MEASURES, measure, measures, MEASURE, Measures

[cumulative urine volume]

cumulative urine volume

[Treatment in patients]

Treatment in patients, treatment in patients

[ventricular assist device implantation]

ventricular assist device implantation

[Trial Investigating Outcomes]

Trial Investigating Outcomes

[72-hour urine volume]

72-hour urine volume

[early annular velocity]

early annular velocity

[early diastolic mitral velocity]

early diastolic mitral velocity

[Patients with sST2]

Patients with sST2

[mitral annular velocity]

mitral annular velocity

[diastolic mitral velocity]

diastolic mitral velocity

[assist device implantation]

assist device implantation

[early mitral annular velocity]

early mitral annular velocity

[diastolic mitral annular velocity]

diastolic mitral annular velocity

[early mitral velocity]

early mitral velocity

[patients with RAS]

patients with RAS

[early diastolic annular velocity]

early diastolic annular velocity

[Treatment of anemia]

Treatment of anemia, treatment of anemia

[reduction in LVEF]

reductions in LVEF, reduction in LVEF

[early diastolic velocity]

early diastolic velocity

[LV reverse remodeling]

LV reverse remodeling

[diastolic annular velocity]

diastolic annular velocity

[reasons for nonprescribing]

reasons for nonprescribing

[risk stratification of patients]

risk stratification of patient, risk stratification of patients

[filtration rate of ml]

filtration rate of mL, filtration rate of ml

[outcomes in heart failure]

outcomes in heart failure

[left ventricular function]

left ventricular function

[artery disease CAD]

artery disease CAD

[patients at risk]

patients at risk

[eplerenone in patients]

eplerenone in patients

[predictor]

Predictors, predictors, predictor

[CRT]

CRT

[objective]

OBJECTIVES, objective

[reduction]

reductions, reduction, Reductions, Reduction

[artery]

artery, arteries

[protein]

proteins, protein

[NT-proBNP]

NT-proBNP, NT-ProBNP

[pressure]

pressure

[end]

end

[impact]

impact

[diagnosis]

Diagnosis, diagnosis, diagnoses

[review]

review, REVIEW, Reviews

[SETTING]

settings, SETTING, setting

[factor]

factors, factor, Factors

[mechanism]

mechanism, mechanisms

[Cox]

Cox

[valve]

valve

[RV]

RV

[infarction]

infarction

[EF]

EF

[study cohort]

study cohort

[20 years]

20 years

[linear models]

linear models

[common condition]

common conditions, common condition

[lower rate]

lower rates, lower rate

[systolic HF of unclear etiology]

systolic HF of unclear etiology

[pulmonary pressure]

pulmonary pressure

[1.8 cm2]

1.8 cm2

[2 receptors]

2 receptors

[mL per 1.73 m 2]

mL per 1.73 m 2

[patients with ventricular assist devices]

patients with ventricular assist devices

[extracellular matrix]

extracellular matrix, Extracellular matrix

[poor prognosis]

poor prognosis

[restricting the anterior leaflet opening]

restricting the anterior leaflet opening

[prediction of LV reverse remodeling]

prediction of LV reverse remodeling

[grip strength]

grip strength

[ventricular pressure]

ventricular pressure

[outcomes in heart failure HF]

outcomes in heart failure HF

[dialysis-dependent patients]

dialysis-dependent patients

[total expenditure]

total expenditures, total expenditure

[Exercise intolerance]

Exercise intolerance

[unfamiliar physician]

unfamiliar physician, unfamiliar physicians

[physician adherence]

physician adherence

[coronary artery]

coronary artery, coronary arteries

[RV function]

RV function

[cardiovascular hospitalization]

cardiovascular hospitalization

[titin modification]

titin modification

[DNA fragmentation]

DNA fragmentation

[progenitor cells]

progenitor cells

[stable HF]

stable HF

[significant interaction]

significant interaction

[Minnesota Living with Heart Failure Questionnaire]

Minnesota Living with Heart Failure Questionnaire

[cardiovascular complications]

cardiovascular complications

[Heart failure disease management programs]

Heart failure disease management programs, heart failure disease management programs

[major role]

major role

[B treatment]

B treatment

[potential benefit]

potential benefit, potential benefits

[laboratory report]

laboratory report

[clinical care]

clinical care

[similar distribution]

similar distribution

[heart team]

heart team

[coronary angiography]

coronary angiography

[8296 mL]

8296 mL

[chart review]

chart review

[age years]

age years

[Ninth Revision]

Ninth Revision

[total mortality]

total mortality

[Two reviewers]

Two reviewers, two reviewers

[1-year survival]

1-year survival

[RAS uptitration]

RAS uptitrations, RAS uptitration

[electrical activation]

electrical activation

[clinical benefit]

clinical benefit

[metoprolol]

metoprolol

[1.2 cm2]

1.2 cm2

[HF epidemiology]

HF epidemiology

[HF risk]

HF risk

[eplerenone in patients at risk]

eplerenone in patients at risk

[Dobutamine requirement]

Dobutamine requirement, dobutamine requirement

[HM II]

HM II

[70 bpm]

70 bpm

[outcome in heart failure patients]

outcome in heart failure patients, Outcomes in Heart Failure Patients

[3.5 mmol]

3.5 mmol

[2.5 years]

2.5 years

[beneficial effect of exercise training]

beneficial effect of exercise training

[primary end]

primary end

[diastolic function]

diastolic function

[7 days]

7 days

[placebo group]

placebo group

[fractional shortening]

fractional shortening

[cardiac angiogenesis]

cardiac angiogenesis

[LVEF HR]

LVEF HR

[diet group]

diet group

[exercise tolerance]

exercise tolerance

[patients undergoing assist device implantation]

patients undergoing assist device implantation

[cardiac support]

cardiac support

[five patients]

five patients

[muscular strength]

muscular strength

[30-day readmission]

30-day readmissions, 30-day readmission

[β-adrenoceptor blockade]

β-adrenoceptor blockade

[Nursing-sensitive outcome]

Nursing-sensitive outcome, nursing-sensitive outcome

[high-volume physicians]

high-volume physicians

[IVC occlusion]

IVC occlusion

[therapeutic implications]

Therapeutic implications, therapeutic implications

[Kansas City Cardiomyopathy Questionnaire KCCQ]

Kansas City Cardiomyopathy Questionnaire KCCQ

[total adiponectin]

total adiponectin

[total sample]

total sample

[resistin levels]

resistin levels

[left ventricular assist device implantation]

left ventricular assist device implantation

[inflammatory markers]

inflammatory markers

[bundle branch]

bundle branch

[volume index]

volume index

[Cochrane Library]

Cochrane Library

[1.7 cm2]

1.7 cm2

[CHF-INV rabbits]

CHF-INV rabbits

[long time]

long time

[erythropoiesis-stimulating agents]

erythropoiesis-stimulating agents

[skeletal muscle]

skeletal muscle

[6-month survival]

6-month survival

[discrimination improvement]

discrimination improvement

[exercise performance]

exercise performance

[high-volume EDs]

high-volume EDs

[protein expression]

protein expression

[lower mortality]

lower mortality

[ultrastructural changes]

ultrastructural changes

[patients with severe heart failure]

patients with severe heart failure

[NT-proBNP levels]

NT-proBNP levels

[620 feet]

620 feet

[exercise time]

exercise time

[clinical variables]

clinical variables

[several cancers]

several cancers

[patients with left ejection fraction]

patients with left ejection fraction

[myocardial function]

myocardial function

[adipose tissue]

adipose tissue

[Fontan circulation]

Fontan circulation

[quality-of-life score]

quality-of-life score, quality-of-life scores

[elderly patients]

elderly patients

[cognitive impairment]

cognitive impairment

[flow-mediated dilatation]

flow-mediated dilatation

[adult population]

adult population

[baseline Hgb]

baseline Hgb

[physical activity]

physical activity

[network meta-analysis]

network meta-analysis

[contractile reserve]

contractile reserve

[QRS prolongation]

QRS prolongation

[VAD group]

VAD groups, VAD group

[surgical indication]

surgical indication, surgical indications

[Functional MS]

Functional MS

[124 patients]

124 patients

[6 min]

6 min, 6 minutes

[physical examination]

physical examination, Physical examination

[271 patients]

271 patients

[children with end-stage heart failure]

children with end-stage heart failure

[Adding cTnT]

Adding cTnT, adding cTnT

[QRS duration of 130 msec]

QRS duration of 130 msec

[relative risk]

relative risk

[fat mass]

fat mass

[clinical data]

clinical data

[late-onset HF]

late-onset HF

[male mice]

male mice

[two groups]

two groups

[weight loss]

weight loss

[acute syndrome]

acute syndrome, acute syndromes

[disease progression]

disease progression

[caloric restriction]

Caloric Restriction, caloric restriction

[frequency of 7-day follow-up visits]

frequency of 7-day follow-up visits, Frequency of 7-day follow-up visits

[low sST2]

low sST2

[iron deficiency]

iron deficiency

[new approach]

new approaches, new approach

[4-year survival]

4-year survival

[rheumatic fever]

rheumatic fever

[mean difference]

mean difference

[test-retest reliability]

test-retest reliability

[patients with severe pulmonary hypertension]

patients with severe pulmonary hypertension

[functional status]

functional status

[younger patients]

younger patients, youngest patients

[Data Extraction]

Data Extraction, DATA EXTRACTION

[apical rotation]

apical rotations, apical rotation

[atherosclerotic CAD]

atherosclerotic CAD

[favorable outcome]

favorable outcome, favorable outcomes

[high BNP]

high BNP

[risk stratification of cardiac patients]

risk stratification of cardiac patients

[chronic ischemia]

chronic ischemia

[trastuzumab users]

trastuzumab users, Trastuzumab users

[protein kinase]

protein kinase

[rate control]

rate control

[AVD variation]

AVD variations, AVD variation

[intensive transitions of care program]

intensive transitions of care program

[myocardial perfusion]

myocardial perfusion

[clinical characteristics]

clinical characteristics

[Higher EO-CFUs]

Higher EO-CFUs

[adjunctive treatment]

adjunctive treatment

[Univariate analysis]

Univariate analyses, Univariate analysis

[lean mass]

lean mass

[molecular mechanism]

molecular mechanism

[regression analysis]

regression analyses, Regression analysis, regression analysis

[β coefficient]

β coefficient

[prior HF]

prior HF

[intravenous iron]

intravenous iron, Intravenous iron

[mitochondrial function]

mitochondrial function

[using models]

Using models, using models

[contractile function]

contractile function

[New York Heart Association class]

New York Heart Association class

[therapeutic strategy]

therapeutic strategies, therapeutic strategy

[progressive disease]

progressive disease

[parasympathetic tone]

parasympathetic tone

[T1 time]

T1 times, T1 time

[HDL healthy]

HDL healthy

[Gill index]

Gill index

[poor outcome]

poor outcomes, poor outcome

[Small studies]

Small studies, small studies

[transverse constriction]

transverse constriction

[diagnostic performance]

diagnostic performance

[extreme decile]

extreme deciles, extreme decile

[LV strain]

LV strain

[ED cases]

ED cases

[mitral annulus]

mitral annulus

[6 patients]

6 patients

[pulmonary resistance]

pulmonary resistance

[regression models]

regression models

[leading cause]

leading cause, leading causes

[Early physician follow-up after discharge]

Early physician follow-up after discharge

[precapillary PH with heart failure]

precapillary PH with heart failure

[ischemic events]

ischemic events

[Inappropriate therapy]

Inappropriate therapy

[heart transplant]

heart transplant

[incident HF]

incident HF

[mitochondrial dysfunction]

mitochondrial dysfunction

[ANG infusion]

ANG infusion

[DATA SOURCES]

Data Sources, DATA SOURCES

[myofiber shortening]

myofiber shortening

[inotropic effect]

inotropic effects, inotropic effect

[Cox regression]

Cox regression

[healthy control]

healthy controls, healthy control

[237 milliseconds]

237 milliseconds

[using data]

using data, Using data

[0.11 mg]

0.11 mg

[Patients with atrial fibrillation AF]

Patients with atrial fibrillation AF, patients with atrial fibrillation AF

[precapillary PH]

precapillary PH

[exclusion criteria]

exclusion criteria

[atrial area]

atrial area

[cardioverter defibrillator-CRT]

cardioverter defibrillator-CRT

[Treatment group]

Treatment group, treatment groups, treatment group

[60 years]

60 years

[resting HR]

resting HR

[derivation cohort]

derivation cohort

[Mediterranean diet]

Mediterranean diet

[older age]

older age

[collateral growth]

collateral growth

[first HF hospitalization hazard ratio]

first HF hospitalization hazard ratio

[≥160 ms]

≥160 ms

[20 mm]

20 mm

[Chromatin-associated proteins]

Chromatin-associated proteins, chromatin-associated proteins

[ventricular reserve]

ventricular reserve

[ACS consultation]

ACS consultation, ACS consultations

[magnetic resonance]

magnetic resonance

[6-minute walk]

6-minute walk

[patients with advanced heart failure]

patients with advanced heart failure

[3 weeks]

3 weeks

[5 day]

5 days, 5 day

[further investigation]

further investigation

[HDL function]

HDL function

[angiotensin-receptor blocker]

angiotensin-receptor blocker, angiotensin-receptor blockers

[ankle-brachial index]

ankle-brachial index

[Time-dependent analysis]

Time-dependent analysis

[large cohort]

large cohort

[annular size reduction by surgery]

annular size reduction by surgery

[Evidence-based treatment]

Evidence-based treatment, evidence-based treatments

[Secondary outcomes]

Secondary outcomes

[target dose]

target dose, target doses

[healthy individuals]

healthy individuals, Healthy individuals

[thromboembolic events]

thromboembolic events

[LV hypertrophy]

LV hypertrophy

[sarcomeric microstructure]

sarcomeric microstructure

[edge-to-edge anastomosis]

edge-to-edge anastomosis

[2 patients]

2 patients

[vascular disease]

vascular disease, vascular diseases

[Few studies]

Few studies

[following variables]

following variables

[important role]

important role

[patient preferences]

patient preferences

[higher PASP]

higher PASP, high PASP

[Rad Q66P]

Rad Q66P

[patients with ventricular ejection fraction]

patients with ventricular ejection fraction

[advanced HF]

advanced HF

[male sex]

male sex

[peripheral disease]

peripheral disease

[pilot study]

pilot study

[wall stress]

wall stress

[selecting patients]

selecting patients, select patients

[contrast agent]

contrast agent

[chromatin structure]

chromatin structure

[adaptive remodelling]

adaptive remodelling

[remodeling aspects]

remodeling aspects

[response]

response, responses

[remodeling]

remodeling

[safety]

safety

[cause]

cause, causes

[assist]

assist

[mouse]

mouse, mice

[target]

target, targets, targeting

[stroke]

strokes, stroke, Stroke

[CAD]

CAD

[MS]

MS

[HFpEF]

HFpEF

[β-blocker]

β-blockers, β-blocker

[placebo]

placebo

[biomarker]

Biomarkers, biomarkers, biomarker

[hypertrophy]

hypertrophy

[diet]

diet, Diet

[rat]

rats, rat, Rats

[case]

case, Cases, cases

[prognosis]

prognosis

[range]

range, ranging

[finding]

FINDINGS, findings, Findings, finding

[ratio]

ratio, Ratio

[man]

men, man, Men

[population]

population, populations

[PASP]

PASP

[AMI]

AMI

[admission]

admission, admissions

[surgery]

surgery, Surgery

[LVAD]

LVAD

[cause of hospitalization]

cause of hospitalization

[low-dose nesiritide 0.005 μg]

low-dose nesiritide 0.005 μg

[varying atrioventricular delay AVD]

varying atrioventricular delay AVD

[novel treatment strategies]

novel treatment strategies

[ejection fraction outcomes trial]

ejection fraction outcomes trial

[obese diabetic ZSF1 rats]

obese diabetic ZSF1 rats

[new-onset post-LVAD AI]

new-onset post-LVAD AI

[cardiac β-AR responsiveness]

cardiac β-AR responsiveness

[potentially higher risks]

potentially higher risks

[maximal spironolactone dose]

maximal spironolactone dose

[HR per kg]

HR per kg

[American College of Cardiology]

American College of Cardiology

[hyperkalemia of study medication]

hyperkalemia of study medication

[long-term 4 wk effects]

long-term 4 wk effects

[safety of spironolactone]

safety of spironolactone

[Most adverse events]

Most adverse events

[young normal reference mean]

young normal reference mean

[cohort of ambulatory patients]

cohort of ambulatory patients

[CRT OFF P=0.06]

CRT OFF P=0.06

[patients with HFpEF]

patients with HFpEF

[index of QTV]

index of QTV

[routine BNP measurements]

routine BNP measurements

[patients with cardiomyopathy DCM]

patients with cardiomyopathy DCM

[angiotensin receptor blockers median]

angiotensin receptor blockers median

[reversibility of heart failure]

reversibility of heart failure

[cardiac Mena deletion]

cardiac Mena deletion

[Reasons for nontreatment]

Reasons for nontreatment

[ejection fraction treatment options]

ejection fraction treatment options

[blood cell transfusion]

blood cell transfusion

[idiopathic cardiomyopathy in Tuscany]

idiopathic cardiomyopathy in Tuscany

[Aerobic Exercise Training]

Aerobic Exercise Training

[bioprosthetic aortic valve replacement]

bioprosthetic aortic valve replacement

[implantable cardioverter-defibrillator device]

implantable cardioverter-defibrillator device

[ventricular systolic strain]

ventricular systolic strain

[AAs with HF]

AAs with HF

[Measurement of peptides]

Measurement of peptides, measurement of peptides

[eccentric hypertrophy EH]

eccentric hypertrophy EH

[overall financial burden]

overall financial burden

[rise in cAMP levels]

rise in cAMP levels

[specific diagnostic strategies]

specific diagnostic strategies

[increase in incidence]

increases in incidence, increase in incidence

[loss of full-length SCN5A]

loss of full-length SCN5A

[all-cause death hazard ratio]

all-cause death hazard ratio

[abnormal body composition]

abnormal body composition

[exercise training on KCCQ]

exercise training on KCCQ

[few HF studies]

few HF studies

[HF in non-AAs]

HF in non-AAs

[left end diameter]

left end diameter

[patients with HFpEF P]

patients with HFpEF P

[myocardial T1 in swine]

myocardial T1 in swine

[chemical instability of nitrite]

chemical instability of nitrite

[pluripotency marker Nanog]

pluripotency marker Nanog

[processes of care delivery]

processes of care delivery

[activation of VEGF pathway]

activation of VEGF pathway

[Studies on biomedical treatment]

Studies on biomedical treatment

[left ventricular systolic strain]

left ventricular systolic strain

[BMI-matched apparently healthy volunteers]

BMI-matched apparently healthy volunteers

[diastolic filling formalism]

diastolic filling formalism

[number of explant c-Kit]

number of explant c-Kit

[dyssynchronous failing heart]

dyssynchronous failing heart

[symptoms of heart failure]

symptoms of heart failure

[three trainings per week]

three trainings per week

[Western blot analysis]

Western blot analysis

[aspects of remodeling]

aspects of remodeling

[approximately 2900 HM II]

approximately 2900 HM II

[therapy refractory cardiogenic shock]

therapy refractory cardiogenic shock

[patients with non-LBBB]

patients with non-LBBB

[two 6-wk periods]

two 6-wk periods

[right heart circulatory failure]

right heart circulatory failure

[expression of type]

expression of type

[3 months p=0·035]

3 months p=0·035

[hazard ratio for mortality]

hazard ratio for mortality

[recent hospital discharge]

recent hospital discharge

[improving HF prediction]

improving HF prediction

[Centre for Reviews]

Centre for Reviews

[LV end-diastolic dimension P]

LV end-diastolic dimension P

[longitudinal strain of ventricle]

longitudinal strain of ventricle

[left diastolic end diameter]

left diastolic end diameter

[Concomitant treatment with SS31]

Concomitant treatment with SS31

[similar cardiovascular mortality]

similar cardiovascular mortality

[advanced human HF]

advanced human HF

[future prospective experimental research]

future prospective experimental research

[aggressive treatment for HF]

aggressive treatment for HF

[cohort of elderly patients]

cohort of elderly patients

[aortic pressure curve]

aortic pressure curve

[HF patient plasma]

HF patient plasma

[surface ECGs at baseline]

surface ECGs at baseline

[lessons for nurse leaders]

lessons for nurse leaders

[P .001 relative decrease]

P .001 relative decrease

[other outcomes in patients]

other outcomes in patients

[homogeneous sandwich AlphaLISA® immunoassays]

homogeneous sandwich AlphaLISA® immunoassays

[incident cardiovascular events]

incident cardiovascular events

[free-breathing pulse sequence]

free-breathing pulse sequence

[risk of CHF]

risk of CHF

[speckle tracking echocardiography STE]

speckle tracking echocardiography STE

[absence of fluid overload]

absence of fluid overload

[five patients with HF]

five patients with HF

[systolic dysfunction treatment paradigm]

systolic dysfunction treatment paradigm

[new onset heart failure]

new onset heart failure

[t1 of 2 minutes]

t1 of 2 minutes

[higher baseline SDQT-to-SDRR ratio]

higher baseline SDQT-to-SDRR ratio

[group of patients]

group of patients

[only in patients]

only in patients

[POC measurement of NPs]

POC measurement of NPs

[traditional myocardial enhancement imaging]

traditional myocardial enhancement imaging

[AAs hazard ratio]

AAs hazard ratio

[incessant ventricular tachycardia storm]

incessant ventricular tachycardia storm

[outcomes in HF]

outcomes in HF

[Multicenter Automatic Defibrillator Implantation]

Multicenter Automatic Defibrillator Implantation

[surgical ring implantation]

surgical ring implantation

[Heart Failure Trial]

Heart Failure Trial

[Support with the LVAS]

Support with the LVAS

[relationship among ST2]

relationship among ST2

[High-cost Medicare fee-for-service beneficiaries]

High-cost Medicare fee-for-service beneficiaries

[natriuretic peptide system]

natriuretic peptide system

[preventing the breakdown]

preventing the breakdown

[dyssynchronous heart failure HF]

dyssynchronous heart failure HF

[heart failure treatment eras]

heart failure treatment eras

[RS synchrony P]

RS synchrony P

[converting enzyme inhibitors intolerance]

converting enzyme inhibitors intolerance

[chronic pulmonary hypertension]

chronic pulmonary hypertension

[stress Doppler echocardiography]

stress Doppler echocardiography, Stress Doppler echocardiography

[risk for all outcomes]

risk for all outcomes

[catabolic isoenzymes PAF-acetylhydrolase]

catabolic isoenzymes PAF-acetylhydrolase

[animals with heart failure]

animals with heart failure

[sampling frame selecting controls]

sampling frame selecting controls

[30-day risk-adjusted mortality]

30-day risk-adjusted mortality

[pathological gene induction]

pathological gene induction

[pulmonary arterial hypertension]

pulmonary arterial hypertension

[endpoint of cardioverter-defibrillator therapy]

endpoint of cardioverter-defibrillator therapy

[mean score of 44·3]

mean score of 44·3

[such as anemia]

such as anemia

[direct effects on macrophages]

direct effects on macrophages

[HFrEF 30 days]

HFrEF 30 days

[suggesting myocardial angiogenesis]

suggesting myocardial angiogenesis

[exercise with testosterone group]

exercise with testosterone group

[2005 2008 performance]

2005 2008 performance

[median 388.3 ms]

median 388.3 ms

[women vs men]

women vs men

[using angiotensin-converting enzyme inhibitors]

using angiotensin-converting enzyme inhibitors

[ivabradine 7.5 mg]

ivabradine 7.5 mg

[patients with degenerative MR]

patients with degenerative MR

[different gastrointestinal regions]

different gastrointestinal regions

[human myocardial tissue]

human myocardial tissue

[benefit of CRT-D]

benefit of CRT-D

[prior myocardial infarction-both n]

prior myocardial infarction-both n

[higher risk for hHF]

higher risk for hHF

[Global longitudinal strain]

Global longitudinal strain

[ventricular end diameter]

ventricular end diameter

[regional circumferential strain CS]

regional circumferential strain CS

[Xanthine oxidase XO]

Xanthine oxidase XO

[endothelial NO synthase activation]

endothelial NO synthase activation

[end-systolic elastance Ees]

end-systolic elastance Ees

[change in clinical status]

change in clinical status

[ventricular assist device LVAD]

ventricular assist device LVAD

[CHF including fat]

CHF including fat

[antihypertensive medication use]

antihypertensive medication use

[limitations in economic models]

limitations in economic models

[mortality in Western society]

mortality in Western society

[Peripheral artery disease PAD]

Peripheral artery disease PAD

[3 experienced electrocardiographers]

3 experienced electrocardiographers

[present consensus report]

present consensus report

[different hospital rankings]

different hospital rankings

[composite of cardiovascular death]

composite of cardiovascular death

[different Raf-MEK1 scaffold proteins]

different Raf-MEK1 scaffold proteins

[Four treatment groups]

Four treatment groups

[Biomarkers of neurohormonal stimulation]

Biomarkers of neurohormonal stimulation

[assist device LVAD]

assist device LVAD

[remodeling in heart failure]

remodeling in heart failure

[strict statistical standards]

strict statistical standards

[competing risk HR]

competing risk HR

[mean ejection fraction EF]

mean ejection fraction EF

[end of the trial]

end of the trial

[Clinical artery tonometry variables]

Clinical artery tonometry variables

[change in thigh muscle]

change in thigh muscle

[mitochondrial oxidative metabolism]

mitochondrial oxidative metabolism

[risk of hospital admission]

risk of hospital admission

[goal-directed lipid-lowering therapy]

goal-directed lipid-lowering therapy

[Cardiac-resynchronization therapy CRT]

Cardiac-resynchronization therapy CRT

[mitral filling flow]

mitral filling flow

[High confidence in estimates]

High confidence in estimates

[increase in follow-up visits]

increase in follow-up visits

[quality of life QOL]

quality of life QOL

[chronic heart failure patients]

chronic heart failure patients

[strata of hospital volume]

strata of hospital volume

[presence of EH]

presence of EH

[203 HeartMate II devices]

203 HeartMate II devices

[s'lateral of cm]

s'lateral of cm

[major health problem]

major health problem

[improvement in functional capacity]

improvement in functional capacity, improvements in functional capacity

[interaction with exercise training]

interactions with exercise training, interaction with exercise training

[cytotoxic effect of doxorubicin]

cytotoxic effect of doxorubicin

[postoperative mortality in patients]

postoperative mortality in patients

[whole grain intake]

whole grain intake

[odds ratio aOR]

odds ratio aOR

[pace non-DNx CHF-INV]

pace non-DNx CHF-INV

[≥70 years respectively p]

≥70 years respectively p

[stable chronic heart failure]

stable chronic heart failure

[selecting appropriate end points]

selecting appropriate end points

[4 Fontan subjects]

4 Fontan subjects

[role in CC]

role in CC

[surgery 3 months]

surgery 3 months

[impact of normalization]

impact of normalization

[Renal Atherosclerotic Lesions CORAL]

Renal Atherosclerotic Lesions CORAL

[higher activities of PAF-AH]

higher activities of PAF-AH

[196 persistent AF patients]

196 persistent AF patients

[shaping the future]

shaping the future

[long-term clinical outcomes]

long-term clinical outcomes

[composite quality measure]

Composite quality measures, composite quality measure

[Chinese herbal medicine]

Chinese herbal medicine

[role of IRS1]

role of IRS1

[Various transcatheter approaches]

Various transcatheter approaches

[receiver curve AUC]

receiver curve AUC

[clear organic lesion]

clear organic lesion

[significant interaction by EF]

significant interaction by EF

[ventricular ejection fraction HFpEF]

ventricular ejection fraction HFpEF

[myocardial extracellular matrix accumulation]

myocardial extracellular matrix accumulation

[use of these devices]

use of these devices

[decline in renal function]

decline in renal function

[blockers at final evaluation]

blockers at final evaluation

[Gene Expression Omnibus]

Gene Expression Omnibus

[Systolic blood pressure]

Systolic blood pressure

[health-related quality of life]

health-related quality of life

[Tools for Analysis]

Tools for Analysis

[Effectiveness of spironolactone]

Effectiveness of spironolactone, effectiveness of spironolactone

[wide QRS complex]

wide QRS complex

[of stenting in RAS]

of stenting in RAS

[HF heart failure]

HF heart failure

[257 milliseconds 237 milliseconds]

257 milliseconds 237 milliseconds

[monitoring of the patient]

monitoring of the patient

[implantable cardioverter-defibrillator deactivation preferences]

implantable cardioverter-defibrillator deactivation preferences

[hypertensive LV dysfunction]

hypertensive LV dysfunction

[independent predictor of mortality]

independent predictors of mortality, independent predictor of mortality

[two patients undergoing MT]

two patients undergoing MT

[normal ventricular ejection fraction]

normal ventricular ejection fraction

[symptomatic systolic heart failure]

symptomatic systolic heart failure

[careful clinical evaluation]

careful clinical evaluation

[implantable cardioverter defibrillators ICDs]

implantable cardioverter defibrillators ICDs

[three patients undergoing VAD]

three patients undergoing VAD

[Findings from this study]

Findings from this study

[case of a patient]

case of a patient

[experience with CRT]

experience with CRT

[rate constant k]

rate constant k

[symptom of HFPEF]

symptoms of HFpEF, symptom of HFPEF

[large outcomes trial]

large outcomes trial

[assessment of barriers]

assessment of barriers

[Using each metric]

Using each metric

[myocardial infarction MI]

myocardial infarction MI

[people with heart failure]

people with heart failure

[possible contribution of nursing]

possible contribution of nursing

[guideline-recommended target dose]

guideline-recommended target dose, guideline-recommended target doses

[first 2 trials]

first 2 trials

[Single tertiary referral centre]

Single tertiary referral centre

[inappropriate implantable cardioverter-defibrillator therapy]

inappropriate implantable cardioverter-defibrillator therapy

[propensity score decile]

propensity score decile

[use of ERC]

use of ERC

[CHF atrial explants]

CHF atrial explants

[other antihyperglycemic agents]

other antihyperglycemic agents

[aldosterone antagonist spironolactone]

aldosterone antagonist spironolactone

[30-day all-cause readmissions]

30-day all-cause readmissions

[lower Killip class]

lower Killip class

[risk for IE]

risk for IE

[surprisingly Kv4.3 channel mRNAs]

surprisingly Kv4.3 channel mRNAs

[function in vitro]

function in vitro

[Observational cohort study]

Observational cohort study

[completion of the study]

completion of the study

[62 primary care clinicians]

62 primary care clinicians

[Multivariable hierarchical regression models]

Multivariable hierarchical regression models

[percentage of ED visits]

percentage of ED visits

[very few PDrelated complications]

very few PDrelated complications

[plasma membrane translocation]

plasma membrane translocation

[outcomes for patients]

outcomes for patients

[systemic UV treatment]

systemic UV treatment

[19 CV deaths]

19 CV deaths

[side effects of interventions]

side effects of interventions

[Seattle Heart Failure Model]

Seattle Heart Failure Model

[5 exercise patients]

5 exercise patients

[total of 293 DEGs]

total of 293 DEGs

[Communities ARIC study]

Communities ARIC study

[MADIT-CRT trial Defibrillator Implantation]

MADIT-CRT trial Defibrillator Implantation

[refill compliance strata]

refill compliance strata

[Ambulatory Heart Failure Trial]

Ambulatory Heart Failure Trial

[expression of pluripotency markers]

expression of pluripotency markers

[LV internal diameter]

LV internal diameter

[cardiac index score P]

cardiac index score P

[6-min walk test]

6-min walk test

[cardiac transplant survival]

cardiac transplant survival

[solid Ehrlich carcinoma]

solid Ehrlich carcinoma

[Physicians in public health]

Physicians in public health

[commoner among women]

commoner among women

[interleukin receptor family member]

interleukin receptor family member

[RR intervals SDRR]

RR intervals SDRR

[relative value of MDC]

relative value of MDC

[dialysis-dependent patients with HF]

dialysis-dependent patients with HF

[ratio better disclosing prognosis]

ratio better disclosing prognosis

[human-to-machine interface HM]

human-to-machine interface HM

[events at follow-up visits]

events at follow-up visits

[non-dilated left ventricle]

non-dilated left ventricle

[brief hypothermic circulatory arrest]

brief hypothermic circulatory arrest

[myocardial phosphodiesterase-2 PDE2]

myocardial phosphodiesterase-2 PDE2

[AUCs of E]

AUCs of E

[presence of diastolic dysfunction]

presence of diastolic dysfunction, Presence of diastolic dysfunction

[aortic valve oversewing]

aortic valve oversewing

[clinical signs of HF]

clinical signs of HF

[MS before the surgery]

MS before the surgery

[DASH diet score]

DASH diet score, DASH diet scores

[central venous pressure 18]

central venous pressure 18

[2,462 cardiovascular events]

2,462 cardiovascular events

[total ED visits]

total ED visits

[other ethnic groups]

other ethnic groups

[transcription factor GATA4]

transcription factor GATA4

[need for angiography]

need for angiography

[peak quadriceps force]

peak quadriceps force

[Self-Care Management Scale]

Self-Care Management Scale

[mortality in nondiabetic patients]

mortality in nondiabetic patients

[hospitals on the basis]

hospitals on the basis

[International Classification of Diseases]

International Classification of Diseases

[highest cumulative hazard]

highest cumulative hazard

[amino-terminal pro-B-type natriuretic peptide]

amino-terminal pro-B-type natriuretic peptide

[converting enzyme inhibitors]

converting enzyme inhibitors, converting enzyme inhibitor

[521 patients spironolactone]

521 patients spironolactone

[principal discharge diagnosis]

principal discharge diagnosis

[recent studies including RELAX-AHF]

recent studies including RELAX-AHF

[high-cost Medicare beneficiaries]

high-cost Medicare beneficiaries

[benefit of AF ablation]

benefit of AF ablation

[signs of heart failure]

signs of heart failure

[heart failure in pigs]

heart failure in pigs

[higher risk for HF]

higher risk for HF

[more than 14 days]

more than 14 days

[patients with thalassaemia major]

patients with thalassaemia major

[CPET guiding exercise rehabilitation]

CPET guiding exercise rehabilitation

[small subgroup of children]

small subgroup of children

[(31)P magnetic resonance spectroscopy]

(31)P magnetic resonance spectroscopy

[point of care POC]

point of care POC

[pathological gene expression]

pathological gene expression

[left bundle branch block]

left bundle branch block

[RVPO with BiVP]

RVPO with BiVP

[serial measurements of CPCs]

serial measurements of CPCs

[purpose of this article]

purpose of this article

[completion of training protocol]

completion of training protocol

[Rates of patients]

Rates of patients

[patients with DCM]

patients with DCM

[American Heart Association AHA]

American Heart Association AHA

[co-activating transcription factor networks]

co-activating transcription factor networks

[increase in parasympathetic tone]

increase in parasympathetic tone

[myocardial oxygen consumption]

myocardial oxygen consumption

[targets of BETs]

targets of BETs

[steady decline in eGFR]

steady decline in eGFR

[LVADs CF devices]

LVADs CF devices

[rhythm-control vs. rate-control strategies]

rhythm-control vs. rate-control strategies

[TAPSE vs. PASP relationship]

TAPSE vs. PASP relationship

[peak o2 per kilogram]

peak o2 per kilogram

[quality of life score]

quality of life score

[considerable number of patients]

considerable number of patients

[Survival after LVAD surgery]

Survival after LVAD surgery

[cardiac function in B-treated]

cardiac function in B-treated

[larger randomized control studies]

larger randomized control studies

[levels of plasma catecholamines]

levels of plasma catecholamines

[relation of hemoglobin Hgb]

relation of hemoglobin Hgb

[mortality using random-effects models]

mortality using random-effects models

[left main 3-vessel CAD]

left main 3-vessel CAD

[heart failure nurse practitioner]

heart failure nurse practitioner

[Exertional Shortness of Breath]

Exertional Shortness of Breath

[38 controls non-cachectic CHF]

38 controls non-cachectic CHF

[benefits in exercise capacity]

benefits in exercise capacity

[heart failure Health Initiative]

heart failure Health Initiative

[patients requiring biventricular support]

patients requiring biventricular support

[resting HR 70 bpm]

resting HR 70 bpm

[nonpace DNx sham-DNx]

nonpace DNx sham-DNx

[Anecdotal evidence of benefit]

Anecdotal evidence of benefit

[dysfunction in molecular pathways]

dysfunction in molecular pathways

[parameters between the groups]

parameters between the groups

[mitochondrial phosphorylation capacity]

mitochondrial phosphorylation capacity

[band of Caspase]

band of Caspase

[proportion of deficits present]

proportion of deficits present

[other tonometric indices]

other tonometric indices

[P for trend 0.01]

P for trend 0.01

[leading causes of death]

leading causes of death

[Clinical symptoms in HFpEF]

Clinical symptoms in HFpEF

[patients without diabetes]

patients without diabetes

[ventricular ejection time]

ventricular ejection time

[right ventricular contractile function]

right ventricular contractile function

[vivo coronary perfusion]

vivo coronary perfusion

[Raf-MEK1 signalling pathway]

Raf-MEK1 signalling pathway

[P for heterogeneity]

P for heterogeneity

[Medicare demonstration participating clinics]

Medicare demonstration participating clinics

[measuring hospital longitudinal change]

measuring hospital longitudinal change

[Comparison of baseline characteristics]

Comparison of baseline characteristics

[comanagement with other clinicians]

comanagement with other clinicians

[acute pulmonary embolism]

acute pulmonary embolism

[higher PDE2 activity]

higher PDE2 activity

[Enhancement of Evidence-based care]

Enhancement of Evidence-based care

[grade 2 systolic]

grade 2 systolic

[efficacy in vivo]

efficacy in vivo

[benefits of involvement]

benefits of involvement

[patients requiring HeartMate II]

patients requiring HeartMate II

[cardiac troponin T cTnT]

cardiac troponin T cTnT

[underlying clinical trials]

underlying clinical trials

[0.81 percentage points]

0.81 percentage points

[Recent clinical studies]

Recent clinical studies

[association between psoriasis]

association between psoriasis

[stimulation of cGMP synthesis]

stimulation of cGMP synthesis

[LV diastolic dysfunction]

LV diastolic dysfunction

[risk of GLS]

risk of GLS

[primary efficacy end points]

primary efficacy end points

[clinical variables contributing]

clinical variables contributing

[ICD shocks during follow-up]

ICD shocks during follow-up

[different types of beta-blockers]

different types of beta-blockers

[120 mm Hg]

120 mm Hg

[unfavourable clinical outcome]

unfavourable clinical outcome

[Patients undergoing MT]

Patients undergoing MT, patients undergoing MT

[HF hospitalization HR 1.46]

HF hospitalization HR 1.46

[new pharmacologic targets]

new pharmacologic targets

[worsening GLS HR]

worsening GLS HR

[measure of reserve]

measure of reserve

[Biventricular pacing BiVP]

Biventricular pacing BiVP

[end point including death]

end point including death

[various physiologic processes]

various physiologic processes

[Texas Cancer Registry–Medicare databases]

Texas Cancer Registry–Medicare databases

[urgent all-cause readmission]

urgent all-cause readmission

[using a taxonomy]

using a taxonomy

[estimates of resource use]

estimates of resource use

[use of trastuzumab]

use of trastuzumab

[standard clinical practice]

standard clinical practice

[adherence with exercise training]

adherence with exercise training

[hazard ratios of 0.86]

hazard ratios of 0.86

[terms of recruitment]

terms of recruitment

[vasopressin receptor antagonist tolvaptan]

vasopressin receptor antagonist tolvaptan

[Heart Failure Index Version]

Heart Failure Index Version

[fat free mass FFM]

fat free mass FFM

[acute HF 4 years]

acute HF 4 years

[efficiency of c-Kit]

efficiency of c-Kit

[controlling for patient]

controlling for patient

[right reserve in patients]

right reserve in patients

[aortic valve replacement]

aortic valve replacement

[healthy volunteers--a pilot study]

healthy volunteers--a pilot study

[Exclusion of one trial]

Exclusion of one trial

[Effectiveness of Chinese medicine]

Effectiveness of Chinese medicine, effectiveness of Chinese medicine

[monomeric G proteins]

monomeric G proteins

[Ontario Case Costing Initiative]

Ontario Case Costing Initiative

[spontaneous cardiac dysfunction]

spontaneous cardiac dysfunction

[cardiac output CO]

cardiac output CO

[obese ZSF1 groups]

obese ZSF1 groups

[CF LVAD patients]

CF LVAD patients

[use of cardioverter defibrillators]

use of cardioverter defibrillators

[patients in this study]

patients in this study

[heart failure of therapies]

heart failure of therapies

[exploratory factor analysis]

exploratory factor analysis

[simple experimental procedures]

simple experimental procedures

[largest increases in incidence]

largest increases in incidence

[etiology of the MR]

etiology of the MR

[Evidence Practice Centres]

Evidence Practice Centres

[Low-sodium DASH diet]

Low-sodium DASH diet

[140 80 mm]

140 80 mm

[approximately 4.5 seconds]

approximately 4.5 seconds

[cohort of older patients]

cohort of older patients

[abdominal aortic constriction AAC]

abdominal aortic constriction AAC

[impact on medical resources]

impact on medical resources

[chromatin-dependent signal transduction]

chromatin-dependent signal transduction

[1 bioprosthetic valve replacement]

1 bioprosthetic valve replacement

[300 ms respectively]

300 ms respectively

[left ventricular dilatation]

left ventricular dilatation

[exercise training in patients]

exercise training in patients

[HF risk prediction]

HF risk prediction

[state of PKA subunits]

state of PKA subunits

[impaired systolic function]

impaired systolic function

[Patients resting HR]

Patients resting HR

[metabolic enzymes in patients]

metabolic enzymes in patients

[end of diastole]

end of diastole

[number of studies]

number of studies

[human embryonic kidney]

human embryonic kidney

[nontraumatic death during sport]

nontraumatic death during sport

[ischemic events IEs]

ischemic events IEs

[disappearance of MR]

disappearance of MR

[Changes circulating progenitor cells]

Changes circulating progenitor cells

[aortic valve surgery]

aortic valve surgery

[findings from the Get]

findings from the Get

[exercise with placebo group]

exercise with placebo group

[same community HF cohort]

same community HF cohort

[lower peak VO2]

lower peak VO2

[ability of cardiomyocytes]

ability of cardiomyocytes

[possibly worsening of disease]

possibly worsening of disease

[baseline glomerular filtration rate]

baseline glomerular filtration rate

[injections in patients]

injections in patients

[Obese ZSF1 rats]

Obese ZSF1 rats

[N-terminal pro-B-type NP]

N-terminal pro-B-type NP

[small pilot study]

small pilot study

[parallel-group study designs]

parallel-group study designs

[patients with CAD]

patients with CAD

[Renal artery stenosis]

Renal artery stenosis

[ratio of the SDQT]

ratio of the SDQT

[long-term ventricular assist device]

long-term ventricular assist device

[assessment of volume status]

assessment of volume status

[markers for coagulability]

markers for coagulability

[transverse constriction TAC]

transverse constriction TAC

[L-type channel inhibition]

L-type channel inhibition

[mortality in ICD-HF patients]

mortality in ICD-HF patients

[efficacy of CHM]

efficacy of CHM

[confirmation on other populations]

confirmation on other populations

[mild mitral regurgitation]

mild mitral regurgitation

[rheumatoid arthritis RA]

rheumatoid arthritis RA

[conventional clinical systolic parameters]

conventional clinical systolic parameters

[hospitalisation for heart failure]

hospitalisation for heart failure, hospitalisations for heart failure

[public health problem]

public health problem

[14 consecutive patients]

14 consecutive patients

[initial diagnosis of AF]

initial diagnosis of AF

[trial involving 115 centers]

trial involving 115 centers

[minimal physical exertion]

minimal physical exertion

[PAF DTT]-insensitive CDP choline]

PAF DTT]-insensitive CDP choline

[visits with a physician]

visits with a physician

[uncontrolled hypertension P=0.049]

uncontrolled hypertension P=0.049

[risk for stroke]

risk for stroke

[rate of death]

rate of death, rates of death

[patients with LBBB]

patients with LBBB

[enrollment of older patients]

enrollment of older patients

[Contemporary heart failure HF]

Contemporary heart failure HF

[MVA velocity time integral]

MVA velocity time integral

[LV diastolic stiffness]

LV diastolic stiffness

[guidelines for the recognition]

guidelines for the recognition

[G-protein-coupled receptor kinase-2]

G-protein-coupled receptor kinase-2

[cardiac explant c-Kit]

cardiac explant c-Kit

[uptitration after a hospitalization]

uptitration after a hospitalization

[clinical CHF predictive model]

clinical CHF predictive model

[Using this process]

Using this process

[weekly trastuzumab administration]

weekly trastuzumab administration

[inflammatory biomarkers hsCRP]

inflammatory biomarkers hsCRP

[15 mL per m]

15 mL per m

[equivalent adverse outcomes]

equivalent adverse outcomes

[Medicare fee-for-service beneficiaries]

Medicare fee-for-service beneficiaries

[least 66 years]

least 66 years

[Cardiac cachexia CC]

Cardiac cachexia CC

[Macrophages from Hum-Retn mice]

Macrophages from Hum-Retn mice

[use of biomarkers]

use of biomarkers

[Multivariable-adjusted hazard ratios]

Multivariable-adjusted hazard ratios

[first HF hospitalization]

first HF hospitalization

[Male patients with CHF]

Male patients with CHF, male patients with CHF

[HF with EF r=-0.55]

HF with EF r=-0.55

[hospitalization for WRF]

hospitalization for WRF

[presence of JQ1]

presence of JQ1

[Seattle Heart Failure survival]

Seattle Heart Failure survival

[echocardiographic score for prediction]

echocardiographic score for prediction

[Newer imaging techniques]

Newer imaging techniques

[structure of the SCHFI]

structure of the SCHFI

[weak grip strength]

weak grip strength

[Subjects with advanced HF]

Subjects with advanced HF

[patients with AHF]

patients with AHF

[R-like ER kinase PERK]

R-like ER kinase PERK

[significant economic considerations]

significant economic considerations

[capillary wedge pressure]

capillary wedge pressure

[seven ischemic abdominal problems]

seven ischemic abdominal problems

[right ventricular assist devices]

right ventricular assist devices

[Contextual reasons prescribing angiotensin]

Contextual reasons prescribing angiotensin

[TAC-induced proteomic alterations]

TAC-induced proteomic alterations

[right ventricular RV function]

right ventricular RV function

[voltage-gated cardiac Na]

voltage-gated cardiac Na

[such as septal defects]

such as septal defects

[proximal LAD model]

proximal LAD model

[measure of ventricular reserve]

measure of ventricular reserve

[non-ischemic heart failure samples]

non-ischemic heart failure samples

[postmenopausal women with HF]

postmenopausal women with HF

[implications of biomarkers]

implications of biomarkers

[poorly contracting ventricles]

poorly contracting ventricles

[In-trial resource utilization]

In-trial resource utilization

[3.5-fold risk of hyperkalemia]

3.5-fold risk of hyperkalemia

[normal mouse heart]

normal mouse heart

[secondary study end point]

secondary study end point

[decline in ejection fraction]

decline in ejection fraction

[body composition study]

body composition study

[tumor necrosis factor TNF)α]

tumor necrosis factor TNF)α

[percent lean body mass]

percent lean body mass

[cardiopulmonary exercise test]

cardiopulmonary exercise test

[surgical indication for MS]

surgical indication for MS

[onset heart failure]

onset heart failure

[emergency setting current status]

emergency setting current status

[Other Antihyperglycemic Drugs]

Other Antihyperglycemic Drugs

[hospitalization for acute HF]

hospitalization for acute HF

[pulmonary arterial systolic pressure]

pulmonary arterial systolic pressure

[role treating heart failure]

role treating heart failure

[Hence of critical importance]

Hence of critical importance

[patients with HR variability]

patients with HR variability

[particularly high mortality]

particularly high mortality

[circulatory assist device]

circulatory assist device

[ventricular assist device VAD]

ventricular assist device VAD

[adverse neurohormonal activation]

adverse neurohormonal activation

[Functional electrical stimulation FES]

Functional electrical stimulation FES

[independent predictor of outcomes]

independent predictor of outcomes, independent predictor of outcome

[above comparisons statistically significant]

above comparisons statistically significant

[transition from compensatory hypertrophy]

transition from compensatory hypertrophy

[serum of participants]

serum of participants

[change in peak VO2]

change in peak VO2

[Discussion In this review]

Discussion In this review

[eGFR group III P]

eGFR group III P

[use of immunoprecipitation]

use of immunoprecipitation

[results of patients]

results of patients

[development of trastuzumab-related CHF]

development of trastuzumab-related CHF

[diastolic end diameter]

diastolic end diameter

[examination of DNA fragmentation]

examination of DNA fragmentation

[multivariable Cox modeling]

multivariable Cox modeling

[characteristics of young adults]

characteristics of young adults

[use in clinical practice]

use in clinical practice

[video edge detection]

video edge detection

[recent onset heart failure]

recent onset heart failure

[CI 9.4 ml]

CI 9.4 ml

[measure of right reserve]

measure of right reserve

[subjects with HF]

subjects with HF, Subjects with HF

[Randomized factorial trial]

Randomized factorial trial

[patients with HF-REF]

patients with HF-REF

[One hundred forty-six patients]

One hundred forty-six patients

[patients A Trial]

patients A Trial

[1 year after discharge]

1 year after discharge

[CRF after 2 trials]

CRF after 2 trials

[lower costs related]

lower costs related

[moderate heart failure]

moderate heart failure

[right-sided cardiac catheterization]

right-sided cardiac catheterization

[Functional electrical stimulation]

Functional electrical stimulation

[subgroups of patients]

subgroups of patients

[driving these gene programs]

driving these gene programs

[systolic pressure PASP]

systolic pressure PASP

[intervention post study]

intervention post study

[safety proof-of-principle cohort study]

safety proof-of-principle cohort study

[failure detecting AT]

failure detecting AT

[single-center retrospective chart review]

single-center retrospective chart review

[bundle branch morphology]

bundle branch morphology

[very common condition]

very common condition

[Data on study design]

Data on study design

[social support score PSSS]

social support score PSSS

[unadjusted practice-level prescription rates]

unadjusted practice-level prescription rates

[evidence of reverse remodeling]

evidence of reverse remodeling

[lower mortality for HF]

lower mortality for HF

[association between the development]

association between the development

[left heart twist]

left heart twist

[other cardiovascular conditions]

other cardiovascular conditions

[Interaction term analysis]

Interaction term analysis

[young adults with HF]

young adults with HF

[urban academic medical center]

urban academic medical center

[main effects analysis]

main effects analysis

[Contrasting groups validity]

Contrasting groups validity

[atherosclerosis the Rotterdam Study]

atherosclerosis the Rotterdam Study

[maximal cardiopulmonary exercise test]

maximal cardiopulmonary exercise test

[simpler laboratory report model]

simpler laboratory report model

[long-term mortality in patients]

long-term mortality in patients

[basis of the assumption]

basis of the assumption

[10-cell decrease in CD34+VEGFR2]

10-cell decrease in CD34+VEGFR2

[regulation of feeding]

regulation of feeding

[subgroups at risk]

subgroups at risk

[absence of changes]

absence of changes

[dual x-ray absorptiometry DXA]

dual x-ray absorptiometry DXA

[mitochondrial ultrastructural changes]

mitochondrial ultrastructural changes

[Higher transfusion thresholds]

Higher transfusion thresholds

[specific research questions]

specific research questions

[age 60 years P=0.016]

age 60 years P=0.016

[sitagliptin versus pioglitazone CI]

sitagliptin versus pioglitazone CI

[fat-free mass index]

fat-free mass index

[score range 0]

score range 0

[body mass index levels]

body mass index levels

[myocardial insulin resistance]

myocardial insulin resistance

[cardiac filling pressures]

cardiac filling pressures

[throughput of at-risk patients]

throughput of at-risk patients

[salt loading ANS]

salt loading ANS

[heart failure AHF]

heart failure AHF

[Inhibitor Ivabradine Trial]

Inhibitor Ivabradine Trial

[new therapeutic approach]

new therapeutic approaches, new therapeutic approach

[pressure-overload-induced heart failure]

pressure-overload-induced heart failure

[Certain dialysis patients]

Certain dialysis patients

[regarding appropriate referrals]

regarding appropriate referrals

[lean ZSF1 group]

lean ZSF1 group

[permanent periodic breathing PB]

permanent periodic breathing PB

[posterior wall infarction]

posterior wall infarction

[participant satisfaction responses]

participant satisfaction responses

[similar cardiac index]

similar cardiac index

[low eGFR 60 years]

low eGFR 60 years

[symptoms of anxiety]

symptoms of anxiety

[concentric remodeling CR]

concentric remodeling CR

[months of follow-up]

months of follow-up

[34 16-month follow-up period]

34 16-month follow-up period

[RAS β-blocker dose changes]

RAS β-blocker dose changes

[more hypokalemia with spironolactone]

more hypokalemia with spironolactone

[human failing hearts]

human failing hearts

[distressing implantable cardioverter-defibrillator shocks]

distressing implantable cardioverter-defibrillator shocks

[protein response UPR]

protein response UPR

[brain natriuretic peptide]

brain natriuretic peptide

[history of HF]

history of HF

[2 weeks post-AAC]

2 weeks post-AAC

[Cardiac resynchronization therapy CRT]

Cardiac resynchronization therapy CRT

[available outpatient models]

available outpatient models

[lower rate in patients]

lower rate in patients

[time of discharge]

time of discharge

[national patient safety initiatives]

national patient safety initiatives

[mechanical support devices]

mechanical support devices

[Frailty for heart failure]

Frailty for heart failure, frailty for heart failure

[rat metabolic risk model]

rat metabolic risk model

[biomarkers in the treatment]

biomarkers in the treatment

[prognosis in HFPEF]

prognosis in HFPEF

[Two final multivariate models]

Two final multivariate models

[debilitating chronic disease]

debilitating chronic disease

[patient-operated electrocardiographic device]

patient-operated electrocardiographic device

[left ventricular LV dilatation]

left ventricular LV dilatation

[exercise training on outcomes]

exercise training on outcomes

[Ser83 mutant RIα proteins]

Ser83 mutant RIα proteins

[attenuation in LV dilatation]

attenuation in LV dilatation

[diuretic resistant volume overload]

diuretic resistant volume overload

[age of legal majority]

age of legal majority

[HeartMate II insertion]

HeartMate II insertion

[Abnormal cardiac T2 values]

Abnormal cardiac T2 values

[cost of the intervention]

cost of the intervention

[web of complicity]

web of complicity

[set of transcription factors]

set of transcription factors

[impact of RM]

impact of RM

[HFPEF animal models]

HFPEF animal models

[risk developing heart failure]

risk developing heart failure

[other device therapies]

other device therapies

[users of alendronate]

users of alendronate

[multivariable logistic analysis]

multivariable logistic analysis

[clinical prediction rule]

clinical prediction rule

[disease risk score]

disease risk score

[Self-Care Confidence scale]

Self-Care Confidence scale

[five ACS procedures]

five ACS procedures

[Abnormal HR variability]

Abnormal HR variability

[acute RV decompensation]

acute RV decompensation

[performance in patients]

performance in patients

[adjusting for confounders]

adjusting for confounders

[value of MDC]

value of MDC

[high-volume ED cases]

high-volume ED cases

[patient with diagnosis]

patient with diagnosis

[ambulatory ICD patients]

ambulatory ICD patients

[trial of exercise training]

trial of exercise training

[Beck Depression Inventory]

Beck Depression Inventory

[left systolic strain]

left systolic strain

[expressing human resistin Retn]

expressing human resistin Retn

[strain rate at systole]

strain rate at systole

[duration of support]

duration of support

[early myocardial fibrosis]

early myocardial fibrosis

[increase in 30-day rehospitalization]

increase in 30-day rehospitalization

[respiratory gas analysis]

respiratory gas analysis

[favorable adverse event profile]

favorable adverse event profile

[nationwide retrospective cohort study]

nationwide retrospective cohort study

[adults with heart disease]

adults with heart disease

[American Heart Association]

American Heart Association

[chronic end-stage heart failure]

chronic end-stage heart failure

[Measurement of natriuretic peptides]

Measurement of natriuretic peptides, measurement of natriuretic peptides

[16 healthy controls HDL]

16 healthy controls HDL

[similar efficacy outcomes]

similar efficacy outcomes

[cerebral blood flow]

cerebral blood flow

[trial of monitoring devices]

trial of monitoring devices

[Medicare inpatient data]

Medicare inpatient data

[extensive changes on exercise]

extensive changes on exercise

[nuclear factor-κB NF-κB]

nuclear factor-κB NF-κB

[ratio of phosphocreatine]

ratio of phosphocreatine

[chronic stable HFPEF]

chronic stable HFPEF

[excellent fit indices]

excellent fit indices

[12 556 patients]

12 556 patients

[cystatin C level nesiritide]

cystatin C level nesiritide

[open 1:1 allocation ratio]

open 1:1 allocation ratio

[CH LV end-diastolic volume]

CH LV end-diastolic volume

[reporting in Cell]

reporting in Cell

[concept of a disorder]

concept of a disorder

[considerable national attention]

considerable national attention

[Effectiveness of implementation strategies]

Effectiveness of implementation strategies

[Uptitration in patients]

Uptitration in patients

[non-linear HR variability measures]

non-linear HR variability measures

[Novel noninvasive tools]

Novel noninvasive tools

[N-terminal fragment NT-proBNP]

N-terminal fragment NT-proBNP

[myocardial T1 changes]

myocardial T1 changes

[predictors after resynchronization therapy]

predictors after resynchronization therapy

[ventricular action potential]

ventricular action potentials, ventricular action potential

[circulation of HF patients]

circulation of HF patients

[development of events]

development of events

[Xanthine oxidase inhibition]

Xanthine oxidase inhibition

[Cox regression models]

Cox regression models

[high risk developing hyperkalemia]

high risk developing hyperkalemia

[569 individuals aged 55]

569 individuals aged 55

[heart failure scans]

heart failure scans

[intermediate outcomes 0.92 events]

intermediate outcomes 0.92 events

[future AMI mortality rates]

future AMI mortality rates

[predicting future high performers]

predicting future high performers

[primary safety end point]

primary safety end point

[use of antibodies]

use of antibodies

[Guideline-Heart Failure Registry]

Guideline-Heart Failure Registry

[global proteomics changes]

global proteomics changes

[Randomized Aldactone Evaluation Study]

Randomized Aldactone Evaluation Study

[impact of PD]

impact of PD

[Caspase-3 gene expression]

Caspase-3 gene expression

[coronary artery bypass grafting]

coronary artery bypass grafting

[RV dysfunction hazard ratio]

RV dysfunction hazard ratio

[Diagnosis of HFpEF]

Diagnosis of HFpEF

[Changes in patient presentation]

Changes in patient presentation

[athletes under 35]

athletes under 35

[left-to-right interatrial shunting]

left-to-right interatrial shunting

[heart failure admission]

heart failure admissions, heart failure admission

[optimal treatment measure]

optimal treatment measure

[ventricular diastolic function]

ventricular diastolic function

[indications for LVAS support]

indications for LVAS support

[fixed-rate atrial pacing]

fixed-rate atrial pacing

[obese older patients]

obese older patients

[International Classification of Diseases]

International Classification of Diseases

[LV assist device]

LV assist device

[percentage of CHF patients]

percentage of CHF patients

[Witness with severe anemia]

Witness with severe anemia

[renal function end point]

renal function end point

[effect on HDL function]

effect on HDL function

[congenital heart lesions]

congenital heart lesions

[pathophysiology of HFpEF]

pathophysiology of HFpEF

[postischemic heart failure]

postischemic heart failure

[TAPSE vs. PASP relationship]

TAPSE vs. PASP relationship

[99 patients with dyspnea]

99 patients with dyspnea

[impact of the intervention]

impact of the intervention

[presence of peripheral oedema]

presence of peripheral oedema

[diabetes odds ratio]

diabetes odds ratio

[link between inflammation]

link between inflammation

[treatment of HFpEF]

treatment of HFpEF

[2-fold cAMP hydrolytic activity]

2-fold cAMP hydrolytic activity

[1.5-T MRI scanner]

1.5-T MRI scanner

[range of health outcomes]

range of health outcomes

[hospital length of stay]

hospital length of stay

[American College of Physicians]

American College of Physicians

[coronary microembolization-induced HF]

coronary microembolization-induced HF

[consequence of the increase]

consequence of the increase

[trend for improvement]

trend for improvement

[article by Dodson]

article by Dodson

[A peptides NPs]

A peptides NPs

[Clinical Modification codes 402.x1]

Clinical Modification codes 402.x1

[HF hospitalization hazard ratio]

HF hospitalization hazard ratio

[incidence of ESRD]

incidence of ESRD

[Bcl-2 mRNA expression]

Bcl-2 mRNA expression

[Learning from recent trials]

Learning from recent trials

[tobacco use odds ratio]

tobacco use odds ratio

[reverse cardiac remodeling]

reverse cardiac remodeling

[heart rate response]

heart rate response

[onset of heart failure]

onset of heart failure

[lower BTES All P]

lower BTES All P

[acute settings for management]

acute settings for management

[Exercise time at 3]

Exercise time at 3

[patients with assist devices]

patients with assist devices

[doxorubicin 25mg kg ip]

doxorubicin 25mg kg ip

[6-minute walk test 6MWT]

6-minute walk test 6MWT

[Implantable cardioverter-defibrillators ICDs]

Implantable cardioverter-defibrillators ICDs

[improvement in eGFR]

improvement in eGFR

[one centre in Canada]

one centre in Canada

[cardiac magnetic resonance]

cardiac magnetic resonance

[Further large-scale randomised studies]

Further large-scale randomised studies

[conducting long-term cost-effectiveness analyses]

conducting long-term cost-effectiveness analyses

[albeit with limited ability]

albeit with limited ability

[cardiac specialty hospital]

cardiac specialty hospital

[Using national Medicare data]

Using national Medicare data

[Extracorporeal life support]

Extracorporeal life support

[patients with cardiovascular disease]

patients with cardiovascular disease

[observational studies of transfusion]

observational studies of transfusion

[American HF guidelines]

American HF guidelines

[salt loading AS]

salt loading AS

[targeting of signal transduction]

targeting of signal transduction

[biomarker-guided clinical trials]

biomarker-guided clinical trials

[Examination of PKA subunits]

Examination of PKA subunits

[pulmonary systolic pressure]

pulmonary systolic pressure

[mean of mm Hg]

mean of mm Hg

[tool conducting cost-effectiveness analyses]

tool conducting cost-effectiveness analyses

[aspects of nursing care]

aspects of nursing care

[myofiber shortening onset]

myofiber shortening onset

[clinical data among groups]

clinical data among groups

[lower fat mass index]

lower fat mass index

[year of the study]

year of the study

[right atrial mass removal]

right atrial mass removal

[left pulmonary artery]

left pulmonary artery

[myocardial glycolysis rates]

myocardial glycolysis rates

[age-dependent increase in incidence]

age-dependent increase in incidence

[Projections of resource use]

Projections of resource use

[Nutrition in heart failure]

Nutrition in heart failure

[early transmitral flow]

early transmitral flow

[Latin America LA]

Latin America LA

[first time feasible]

first time feasible

[stable pulmonary hypertension medication]

stable pulmonary hypertension medication

[angiotensin converting enzyme inhibitor]

angiotensin converting enzyme inhibitor

[rates of trastuzumb-related CHF]

rates of trastuzumb-related CHF

[small GTPase Rac1 activity]

small GTPase Rac1 activity

[effective practice within domain]

effective practice within domain

[Student t test]

Student t test

[good long-term value]

good long-term value

[leg strength P]

leg strength P

[adjustment for covariates]

adjustment for covariates

[date of HF hospitalization]

date of HF hospitalization

[patients with systolic dysfunction]

patients with systolic dysfunction

[septal wall CS]

septal wall CS

[treatments for this complication]

treatments for this complication

[lower SVR index]

lower SVR index

[index beat method]

index beat method

[ED visits for CHF]

ED visits for CHF

[ivabradine on exercise capacity]

ivabradine on exercise capacity

[more comorbid conditions]

more comorbid conditions

[lesions such as defects]

lesions such as defects

[adjustment for age]

adjustment for age

[HFrEF hazard ratio HR]

HFrEF hazard ratio HR

[association between social support]

association between social support

[Hazard ratios for variables]

Hazard ratios for variables

[content-driven telehealth technology]

content-driven telehealth technology

[outpatients with HF]

outpatients with HF

[quality of care]

quality of care

[signs of HF]

signs of HF

[Population-based new-user cohort study]

Population-based new-user cohort study

[study-related serious adverse events]

study-related serious adverse events

[health care system]

health care system

[post hoc analysis]

post hoc analysis

[expression of target genes]

expression of target genes

[proof-of-principle cohort study]

proof-of-principle cohort study

[median of 4.6 years]

median of 4.6 years

[radial strain RS]

radial strain RS

[surviving left ventricle]

surviving left ventricle

[history of cardiovascular disease]

history of cardiovascular disease

[more remarkable role]

more remarkable role

[Total Symptom domains]

Total Symptom domains

[with similar values]

with similar values

[left ventricular strain]

left ventricular strain

[Variability in QT intervals]

Variability in QT intervals

[rapid right ventricular pacing]

rapid right ventricular pacing

[lower systolic blood pressure]

lower systolic blood pressure

[risk of thromboembolic events]

risk of thromboembolic events

[consequence of pathological remodelling]

consequence of pathological remodelling

[transcatheter aortic valve procedure]

transcatheter aortic valve procedure

[Functional mitral stenosis MS]

Functional mitral stenosis MS

[venous thromboembolic events]

venous thromboembolic events

[Preoperative clinical characteristics]

Preoperative clinical characteristics

[control adenovirus Ad-C]

control adenovirus Ad-C

[HeartMate II exchange]

HeartMate II exchange

[Within-day test-retest reliability]

Within-day test-retest reliability, within-day test-retest reliability

[mitochondrial oxidative stress]

mitochondrial oxidative stress

[Immunodetection of NT-proBNP]

Immunodetection of NT-proBNP

[frequency of administration]

frequency of administration

[ET of CHF-NYHA-IIIb]

ET of CHF-NYHA-IIIb

[Danish Heart Failure database]

Danish Heart Failure database

[normal coronary arteries]

normal coronary arteries

[activation of the pathway]

activation of the pathway

[simple clinical prediction rule]

simple clinical prediction rule

[indicating a change]

indicating a change

[B-type natriuretic peptide BNP]

B-type natriuretic peptide BNP

[heart failure discharges]

heart failure discharges

[risk of long-term mortality]

risk of long-term mortality

[Outcomes of Exercise Training]

Outcomes of Exercise Training

[development of therapeutic approaches]

development of therapeutic approaches

[nitroxyl HNO donor salt]

nitroxyl HNO donor salt

[Haematopoietic cell transplantation HCT]

Haematopoietic cell transplantation HCT

[18 health insurance]

18 health insurance

[hypertensive heart disease]

hypertensive heart disease

[elevated atrial pressure]

elevated atrial pressure

[Isoelectric focusing of RIα]

Isoelectric focusing of RIα

[improving patient outcomes]

improving patient outcomes

[appropriate ICD shocks]

appropriate ICD shocks

[causing a stenotic physiology]

causing a stenotic physiology

[refractory congestive heart failure]

refractory congestive heart failure

[risk for ESRD]

risk for ESRD

[93 heart failure admissions]

93 heart failure admissions

[large idiopathic cardiomyopathy cohort]

large idiopathic cardiomyopathy cohort

[short-term mortality rates]

short-term mortality rates

[estimation of caspase-3 activity]

estimation of caspase-3 activity

[case of angiotensin]

case of angiotensin

[obese patients with HFPEF]

obese patients with HFPEF

[Myocyte hypertrophy antecedent]

Myocyte hypertrophy antecedent

[increase in glycolysis rates]

increase in glycolysis rates

[further review of preferences]

further review of preferences

[pg BNP group]

pg BNP group

[additional models varying combinations]

additional models varying combinations

[systolic blood pressure HR]

systolic blood pressure HR

[749 self-identified black patients]

749 self-identified black patients

[treatment of HFrEF]

treatment of HFrEF

[net reclassification improvement NRI]

net reclassification improvement NRI

[developmental chromatin remodeling events]

developmental chromatin remodeling events

[pace DNx CHF-DNx]

pace DNx CHF-DNx

[symptomatic severe AI]

symptomatic severe AI

[Patients with fibrillation AF]

Patients with fibrillation AF, patients with fibrillation AF

[patients in many regions]

patients in many regions

[prognosis of idiopathic cardiomyopathy]

prognosis of idiopathic cardiomyopathy

[nanomolar doses of JQ1]

nanomolar doses of JQ1

[heart failure hHF]

heart failure hHF

[effects of a decade]

effects of a decade

[other subspecialty groups]

other subspecialty groups

[metoprolol hazard ratio HR]

metoprolol hazard ratio HR

[Cardiovascular Disease Registry Innovation]

Cardiovascular Disease Registry Innovation

[label-free shotgun proteomics approach]

label-free shotgun proteomics approach

[DASH target sodium]

DASH target sodium

[Subjects with RV dysfunction]

Subjects with RV dysfunction, subjects with RV dysfunction

[such as early detection]

such as early detection

[positron emission tomography imaging]

positron emission tomography imaging

[process of endothelial repair]

process of endothelial repair

[exercise group hazard ratio]

exercise group hazard ratio

[≥5 mg HR 1.54]

≥5 mg HR 1.54

[stem cell source allogeneic]

stem cell source allogeneic

[characteristics of adults]

characteristics of adults

[levels of plasma norepinephrine]

levels of plasma norepinephrine

[control case cohort analysis]

control case cohort analysis

[myofilament Ca 2 sensitivity]

myofilament Ca 2 sensitivity

[4 enrollment periods]

4 enrollment periods

[Multivariate logistic regression analysis]

Multivariate logistic regression analysis

[small high-risk group]

small high-risk group

[benefits of trials]

benefits of trials

[health system data partners]

health system data partners

[cardiovascular events stroke]

cardiovascular events stroke

[PCWP of mm Hg]

PCWP of mm Hg

[III HF ejection fractions]

III HF ejection fractions

[pressure volume relation]

pressure volume relation

[top 10 NOC outcomes]

top 10 NOC outcomes

[assumption a measure]

assumption a measure

[especially 160 ms]

especially 160 ms

[progress in anticoagulation]

progress in anticoagulation

[separate Cox regression]

separate Cox regression

[hemodynamically stable situation]

hemodynamically stable situation

[right atrium mass]

right atrium mass

[shuttle walk test]

shuttle walk test

[Wasting of fat]

Wasting of fat

[1-year mortality rate]

1-year mortality rate

[currently under investigation]

currently under investigation

[Japanese heart failure patients]

Japanese heart failure patients

[cystatin C level]

cystatin C level

[development of cardiac hypertrophy]

development of cardiac hypertrophy

[Peak oxygen consumption range]

Peak oxygen consumption range

[skeletal muscle mass T-score]

skeletal muscle mass T-score

[impact of RV function]

impact of RV function

[PARADIGM-HF a paradigm shift]

PARADIGM-HF a paradigm shift

[validity of individual scales]

validity of individual scales

[RGK Rem family]

RGK Rem family

[addition of salt loading]

addition of salt loading

[interesting therapeutic concepts]

interesting therapeutic concepts

[incident HF cases]

incident HF cases

[variants of genes coding]

variants of genes coding

[structure of the RV]

structure of the RV

[26 observational studies]

26 observational studies

[sphingosine-1-phosphate receptor 1 S1PR1]

sphingosine-1-phosphate receptor 1 S1PR1

[effect on CRT]

effect on CRT

[LV diastolic dysfunction alone]

LV diastolic dysfunction alone

[sitagliptin for sitagliptin]

sitagliptin for sitagliptin

[quality of LV dysfunction]

quality of LV dysfunction

[interventricular delay VVD]

interventricular delay VVD

[Using Cox regression]

Using Cox regression

[HF of etiology]

HF of etiology

[sarcomeric microstructure at baseline]

sarcomeric microstructure at baseline

[Interactors of the DEGs]

Interactors of the DEGs

[year after 2011]

year after 2011

[pathological changes in cardiomyocytes]

pathological changes in cardiomyocytes

[Nurses in all settings]

Nurses in all settings

[adjusting for important covariates]

adjusting for important covariates

[lack of benefit]

lack of benefit

[liberal transfusion protocols]

liberal transfusion protocols

[development of lifesaving drugs]

development of lifesaving drugs

[brain natriuretic peptide BNP]

brain natriuretic peptide BNP

[dipeptidyl peptidase-4 DPP-4 inhibitors]

dipeptidyl peptidase-4 DPP-4 inhibitors

[Higher DASH diet scores]

Higher DASH diet scores

[specific PDE2 inhibition]

specific PDE2 inhibition

[older adults with HF]

older adults with HF

[death confidence interval 0.60]

death confidence interval 0.60

[2 chordal ruptures]

2 chordal ruptures

[such as defects]

such as defects

[using Doppler echocardiography]

using Doppler echocardiography

[categories of actin cytoskeleton]

categories of actin cytoskeleton

[dyssynchronous heart failure]

dyssynchronous heart failure

[LV contractile function]

LV contractile function

[extent of RV dysfunction]

extent of RV dysfunction

[cornerstone in the assessment]

cornerstone in the assessment

[Systolic Heart Failure Treatment]

Systolic Heart Failure Treatment

[mechanisms underlying these defects]

mechanisms underlying these defects

[mitochondrial oxidation of glucose]

mitochondrial oxidation of glucose

[left ventricular longitudinal strain]

left ventricular longitudinal strain

[having ≥3 co-morbidities]

having ≥3 co-morbidities

[management of heart lesions]

management of heart lesions

[changing association with DNA]

changing association with DNA

[higher glomerular filtration rate]

higher glomerular filtration rate

[correlation of remaining indices]

correlation of remaining indices

[many risk factors]

many risk factors

[Ka chloride channel gene]

Ka chloride channel gene

[result of an constriction]

result of an constriction

[.001 all comparisons]

.001 all comparisons

[transplantation eligibility status]

transplantation eligibility status

[systemic adverse events evaluation]

systemic adverse events evaluation

[youngest patients with HF]

youngest patients with HF

[Declines in early-onset]

Declines in early-onset

[conditional gene-targeted Hand2 mice]

conditional gene-targeted Hand2 mice

[associations of Mediterranean Approaches]

associations of Mediterranean Approaches

[transmitral flow velocities E]

transmitral flow velocities E

[tachycardia-induced heart failure]

tachycardia-induced heart failure

[total of 139 patients]

total of 139 patients

[P-value for difference 0.001]

P-value for difference 0.001

[confirmatory factor analysis CFA]

confirmatory factor analysis CFA

[systolic mitral leaflet motions]

systolic mitral leaflet motions

[human-to-human contact HH]

human-to-human contact HH

[role in cardiac pathogenesis]

role in cardiac pathogenesis

[higher amount of malondialdehyde]

higher amount of malondialdehyde

[caring for these patients]

caring for these patients

[peak respiratory quotient]

peak respiratory quotient

[costs across volume groups]

costs across volume groups

[Rad a member]

Rad a member

[Anemia in HF]

Anemia in HF

[angiotensin II infusion]

angiotensin II infusion

[management of gastrointestinal bleeding]

management of gastrointestinal bleeding

[peak VO2 P]

peak VO2 P

[similar distribution in HFrEF]

similar distribution in HFrEF

[biomarker of anthracycline-induced cardiotoxicity]

biomarker of anthracycline-induced cardiotoxicity

[mean of 244 m]

mean of 244 m

[patient with a history]

patients with a history, patient with a history

[progenitor cells CPCs]

progenitor cells CPCs

[Overall significant improvements]

Overall significant improvements

[57±22 months of follow-up]

57±22 months of follow-up

[approximately 200 HeartWare patients]

approximately 200 HeartWare patients

[development of cardiac insulin-resistance]

development of cardiac insulin-resistance

[HDL-mediated vascular effects]

HDL-mediated vascular effects

[patients with severe HF]

patients with severe HF

[30 mL per m]

30 mL per m

[1-year mortality in survivors]

1-year mortality in survivors

[eGFR group IV P]

eGFR group IV P

[spontaneous ventricular tachycardia HFVT(+)]

spontaneous ventricular tachycardia HFVT(+)

[0.1 unit increase]

0.1 unit increase

[trend toward fewer days]

trend toward fewer days

[pressure-volume conductance catheter system]

pressure-volume conductance catheter system

[emergency department volume]

emergency department volume

[ventricular LV dysfunction]

ventricular LV dysfunction

[cardiovascular events for psoriasis]

cardiovascular events for psoriasis

[administration of contrast agent]

administration of contrast agent

[optimal treatment median]

optimal treatment median

[lean mass quantification]

lean mass quantification

[mortality hazard ratio HR]

mortality hazard ratio HR

[Use of Exercise]

Use of Exercise

[temporary CentriMag RVAD]

temporary CentriMag RVAD

[subjects with mild HF]

subjects with mild HF

[coronary artery disease HR]

coronary artery disease HR

[unique post-translational states]

unique post-translational states

[majority of patients]

majority of patients

[adult male Wistar rats]

adult male Wistar rats

[mean SD of 0.25]

mean SD of 0.25

[occurrence of heart failure]

occurrence of heart failure

[same exercise time tests]

same exercise time tests

[64.26 years vs 72.83]

64.26 years vs 72.83

[aortocaval fistula ACF]

aortocaval fistula ACF

[managing the device]

managing the device

[mean LV ejection fraction]

mean LV ejection fraction

[impact of self-management counseling]

impact of self-management counseling

[EF EF≤ 40]

EF EF≤ 40

[significant improvement in 6-minute]

significant improvement in 6-minute

[patients with concurrent HF]

patients with concurrent HF

[454 patients ECCT]

454 patients ECCT

[average of 7 months]

average of 7 months

[Duke Activity Status Index]

Duke Activity Status Index

[improvement in contractile function]

improvement in contractile function

[blood urea nitrogen]

blood urea nitrogen

[special therapeutic interventions]

special therapeutic interventions

[stable severe systolic HF]

stable severe systolic HF

[acute HF diagnosis]

acute HF diagnosis

[setting of pulmonary embolism]

setting of pulmonary embolism

[quick safe pump-exchange technique]

quick safe pump-exchange technique

[NAD(P) H-oxidase subunit RAC2]

NAD(P) H-oxidase subunit RAC2

[purely hemodynamic disorder]

purely hemodynamic disorder

[higher BNP levels]

higher BNP levels, high BNP levels

[plasma NPs at baseline]

plasma NPs at baseline

[significant cardioprotection via inhibition]

significant cardioprotection via inhibition

[passive k constants]

passive k constants

[Connecticut Heart Failure Center]

Connecticut Heart Failure Center

[differential effect of LVEF]

differential effect of LVEF

[180 days of inclusion]

180 days of inclusion

[using small-molecule inhibitors c-Kit]

using small-molecule inhibitors c-Kit

[past 30 years]

past 30 years

[25.6 kg 2]

25.6 kg 2

[Tools for Economic Analysis]

Tools for Economic Analysis

[goal achieving a level]

goal achieving a level

[Beneficial effect of ARNI]

Beneficial effect of ARNI

[older patients with HFPEF]

older patients with HFPEF

[reoperation for bleeding]

reoperation for bleeding

[HABC Battery score]

HABC Battery score, HABC Battery scores

[degenerative mitral valve]

degenerative mitral valve

[using the PPR]

using the PPR

[seven ischemic problems]

seven ischemic problems

[treatment with ejection fraction]

treatment with ejection fraction

[mechanisms of disease unique]

mechanisms of disease unique

[first diagnosis of AF]

first diagnosis of AF

[left ventricular function assessment]

left ventricular function assessment

[effect of IE]

effect of IE

[1,045 patients with IC]

1,045 patients with IC

[Heart Failure Cost-Effectiveness Model]

Heart Failure Cost-Effectiveness Model

[Pulmonary capillary wedge pressure]

Pulmonary capillary wedge pressure

[only ANS mice]

only ANS mice

[soluble guanylate cyclase]

soluble guanylate cyclase

[relationship between TAPSE force]

relationship between TAPSE force

[cardiac transplant recipients]

cardiac transplant recipients

[using linear models]

using linear models

[swine with heart failure]

swine with heart failure

[treatment of a patient]

treatment of a patient

[major cardiovascular complications stroke]

major cardiovascular complications stroke

[right ventricular function]

right ventricular function

[heart failure with dysfunction]

heart failure with dysfunction

[2,374,428 ED visits 32,036]

2,374,428 ED visits 32,036

[atheromatous coronary disease]

atheromatous coronary disease

[onset of myofiber shortening]

onset of myofiber shortening

[quality of care programme]

quality of care programme

[T1 time R=0.98]

T1 time R=0.98

[Major clinical trials]

Major clinical trials

[inferior vena cava IVC]

inferior vena cava IVC

[Multicenter Automatic Defibrillator]

Multicenter Automatic Defibrillator

[β1-adrenergic receptor β1AR]

β1-adrenergic receptor β1AR

[data regarding risk factors]

data regarding risk factors

[MVA of 1.8 cm2]

MVA of 1.8 cm2

[City of Hope]

City of Hope

[laboratory report model]

laboratory report model

[benefit of BB therapy]

benefit of BB therapy

[functional class II]

functional class II

[pulseless ventricular fibrillation PVF]

pulseless ventricular fibrillation PVF

[adaptive cardiac remodelling]

adaptive cardiac remodelling

[increases in the percentage]

increases in the percentage

[ventricular action potential duration]

ventricular action potential duration

[ratio Ees Ea]

ratio Ees Ea

[adverse outcomes related]

adverse outcomes related

[arterial tonometry study]

arterial tonometry study

[flow-mediated dilatation diameter]

flow-mediated dilatation diameter

[aortic valve procedure]

aortic valve procedure, aortic valve procedures

[ventricular LV hypertrophy]

ventricular LV hypertrophy

[interval from consultation]

interval from consultation

[role of vasopressin]

role of vasopressin

[mouse HF model]

mouse HF model

[harms including hypertension]

harms including hypertension

[wide blood-flow paths]

wide blood-flow paths

[Heart Failure Pathophysiology]

Heart Failure Pathophysiology

[effect of low-dose dopamine]

effect of low-dose dopamine

[High-density lipoprotein HDL]

High-density lipoprotein HDL

[caspase 3 expression]

caspase 3 expression

[patients with baseline EF]

patients with baseline EF

[electrocardiographic Q waves]

electrocardiographic Q waves

[Zung depression scores]

Zung depression scores

[interventricular septum biopsies]

interventricular septum biopsies

[repeat procedures in patients]

repeat procedures in patients

[Myocardial loss of IRS1]

Myocardial loss of IRS1

[congestive heart failure exacerbation]

congestive heart failure exacerbation

[limited mitral valve opening]

limited mitral valve opening

[guideline-recommended medications for patients]

guideline-recommended medications for patients

[renin-angiotensin-aldosterone nervous systems]

renin-angiotensin-aldosterone nervous systems

[final data analysis]

final data analysis

[treatment of HF]

treatment of HF

[lifesaving drugs for HF]

lifesaving drugs for HF

[development of RV dysfunction]

development of RV dysfunction

[HeartMate II implantation]

HeartMate II implantation

[structure of medical records]

structure of medical records

[outcomes in HF patients]

outcomes in HF patients

[improving processes of care]

improving processes of care

[hearts of ANS mice]

hearts of ANS mice

[systolic dysfunction LV EF]

systolic dysfunction LV EF

[test for interaction]

test for interaction

[even after adjustment]

even after adjustment

[composite of repeat procedures]

composite of repeat procedures

[randomization group P=0.035]

randomization group P=0.035

[lipoprotein-associated phospholipase A2 Lp-PLA2]

lipoprotein-associated phospholipase A2 Lp-PLA2

[predicting death hospitalization]

predicting death hospitalization

[left longitudinal strain]

left longitudinal strain

[myofiber shortening velocity]

myofiber shortening velocity

[differential G-protein coupling]

differential G-protein coupling

[cardiomyopathy in patients]

cardiomyopathy in patients

[systemic hypertension SH]

systemic hypertension SH

[patients with ambulatory HF]

patients with ambulatory HF

[gene expressions of Bax]

gene expressions of Bax

[Remote monitoring RM strategies]

Remote monitoring RM strategies

[90 days of follow-up]

90 days of follow-up

[Kaiser Permanente Northern California]

Kaiser Permanente Northern California

[rehospitalization for stroke]

rehospitalization for stroke

[human Rad Q66P]

human Rad Q66P

[catheter ablation relating]

catheter ablation relating

[emergency department ED]

emergency department ED

[developments in diagnostic procedure]

developments in diagnostic procedure

[298 124 sitagliptin users]

298 124 sitagliptin users

[MT group 50 days]

MT group 50 days

[mitochondrial oxidative phosphorylation capacity]

mitochondrial oxidative phosphorylation capacity

[therapeutic strategies capable]

therapeutic strategies capable

[Patients in sinus rhythm]

Patients in sinus rhythm

[difference in HF hospitalizations]

difference in HF hospitalizations

[12 non-fatal stroke]

12 non-fatal stroke

[adherence in this study]

adherence in this study

[sphingosine-1-phosphate an S1PR1 agonist]

sphingosine-1-phosphate an S1PR1 agonist

[age 65 years]

age 65 years

[other guideline-recommended medications]

other guideline-recommended medications

[patients with dysfunction]

patients with dysfunction

[Statewide Health Planning]

Statewide Health Planning

[present study population]

present study population

[SCHFI v.6.2 scales]

SCHFI v.6.2 scales

[terminal heart failure]

terminal heart failure

[dual-energy X-ray absorptiometry]

dual-energy X-ray absorptiometry

[moderate LV dilatation]

moderate LV dilatation

[Orthotopic heart transplantation OHT]

Orthotopic heart transplantation OHT

[lower event rate HR]

lower event rate HR

[lower exercise performance]

lower exercise performance

[decrease in CD34+VEGFR2]

decrease in CD34+VEGFR2

[diffuse myocardial changes]

diffuse myocardial changes

[unfamiliar physician s]

unfamiliar physician s

[patients from Québec]

patients from Québec

[death for heart failure]

death for heart failure

[Three-year HF hospitalization rates]

Three-year HF hospitalization rates

[contemporaneous control group]

contemporaneous control group

[endothelial function flow-mediated dilatation]

endothelial function flow-mediated dilatation

[left ventricular midpapillary level]

left ventricular midpapillary level

[heart failure therapy]

heart failure therapy

[impact of HR reduction]

impact of HR reduction

[scientific literature January]

scientific literature January

[many reasons for nonprescribing]

many reasons for nonprescribing

[last participant contact]

last participant contact

[QT variability QTV]

QT variability QTV

[6 fragments of NT-proBNP]

6 fragments of NT-proBNP

[containing chronic heart failure]

containing chronic heart failure

[small retrospective studies]

small retrospective studies

[exercise-induced PASP increase]

exercise-induced PASP increase, Exercise-induced PASP increase

[mortality in modern society]

mortality in modern society

[measure of health status]

measure of health status

[Wilcoxon matched-pairs signed-rank tests]

Wilcoxon matched-pairs signed-rank tests

[diagnosis of therapy]

diagnosis of therapy

[MAIN OUTCOME MEASURES]

MAIN OUTCOME MEASURES

[filtration rate ml]

filtration rate ml

[failure of XO inhibition]

failure of XO inhibition

[KCCQ Summary scores]

KCCQ Summary scores, KCCQ summary scores

[mechanisms of regulation]

mechanisms of regulation

[health service planning]

health service planning

[less renal impairment]

less renal impairment

[PURPOSE OF REVIEW]

PURPOSE OF REVIEW

[III heart failure HF]

III heart failure HF

[neprilysin inhibitor prodrug]

neprilysin inhibitor prodrug

[risk of hyperkalemia]

risk of hyperkalemia

[professionals from multiple disciplines]

professionals from multiple disciplines

[average weight loss]

average weight loss

[reduction in oxidation]

reduction in oxidation

[temporary right ventricular support]

temporary right ventricular support

[communication among cardiologists]

communication among cardiologists

[left-hand grip strength]

left-hand grip strength

[confidence in estimates]

confidence in estimates

[once at baseline]

once at baseline

[incidence of hyperkalemia]

incidence of hyperkalemia

[2.8 0.7 L 2]

2.8 0.7 L 2

[GDMT-treated NYHA functional class]

GDMT-treated NYHA functional class

[classic signaling paradigms]

classic signaling paradigms

[extracorporeal membrane oxygenation]

extracorporeal membrane oxygenation

[congenital accessory pathways]

congenital accessory pathways

[prolonged electromechanical delay]

prolonged electromechanical delay

[heart disease in patients]

heart disease in patients

[efficacy of catheter ablation]

efficacy of catheter ablation

[apparent circulating NT-proBNP concentration]

apparent circulating NT-proBNP concentration

[membrane oxygenation on function]

membrane oxygenation on function

[HeartMate II LVAD]

HeartMate II LVAD

[patients with preoperative hypoalbuminemia]

patients with preoperative hypoalbuminemia

[ischemic HF pathogenesis]

ischemic HF pathogenesis

[analysis of HF-ACTION]

analysis of HF-ACTION

[lack of hypertension]

lack of hypertension

[novel pure HNO donor]

novel pure HNO donor

[Heart Association class II]

Heart Association class II

[849 patients 200]

849 patients 200

[general linear models]

general linear models

[affecting antitumor activity]

affecting antitumor activity

[clinically stable HFPEF]

clinically stable HFPEF

[E all p values]

E all p values

[ventricular longitudinal systolic strain]

ventricular longitudinal systolic strain

[lowest cumulative hazard]

lowest cumulative hazard

[testing a cardioverter-defibrillator device]

testing a cardioverter-defibrillator device

[effect on the efficacy]

effect on the efficacy

[effectiveness of resynchronization therapy]

effectiveness of resynchronization therapy

[biomedical treatment alone]

biomedical treatment alone

[vs without diabetes]

vs without diabetes

[long-term survival rates]

long-term survival rates

[proximal left descending artery]

proximal left descending artery

[cardiac index 2.2]

cardiac index 2.2

[following an unplanned admission]

following an unplanned admission

[systematic review protocol]

systematic review protocol

[predicting adverse CV events]

predicting adverse CV events

[New-onset aortic insufficiency AI]

New-onset aortic insufficiency AI

[ejection fraction development]

ejection fraction development

[decreases in ejection fraction]

decreases in ejection fraction

[measurement of HR variability]

measurement of HR variability

[only among patients]

only among patients

[modest reduction in MVA]

modest reduction in MVA

[β-adrenergic receptor activation]

β-adrenergic receptor activation

[users of saxagliptin]

users of saxagliptin

[0.53 events P=0.001]

0.53 events P=0.001

[quality of life assessment]

quality of life assessment

[LV end-systolic volume]

LV end-systolic volume

[target patient population]

target patient population

[T2D Type 2 diabetes]

T2D Type 2 diabetes

[significant liver disease]

significant liver disease

[Acute heart failure AHF]

Acute heart failure AHF

[highlighting diastolic dysfunction]

highlighting diastolic dysfunction

[14 HF units]

14 HF units

[different mechanism of action]

different mechanism of action

[ventricular structure geometry]

ventricular structure geometry

[role of appropriate timing]

role of appropriate timing

[β-adrenergic receptor blocker therapy]

β-adrenergic receptor blocker therapy

[cause of morbidity]

cause of morbidity

[ED outpatient settings]

ED outpatient settings

[4.6 mm Hg Fig]

4.6 mm Hg Fig

[After percutaneous coronary revascularization]

After percutaneous coronary revascularization

[heart magnetic resonance imaging]

heart magnetic resonance imaging

[individual quality measures]

individual quality measures

[development of pacing-induced cardiomyopathy]

development of pacing-induced cardiomyopathy

[Effectiveness of medicine]

Effectiveness of medicine, effectiveness of medicine

[LVET at ICU admission]

LVET at ICU admission

[simple clinical tool]

simple clinical tool

[Myocardial PDE2 expression]

Myocardial PDE2 expression

[total arterial compliance TAC]

total arterial compliance TAC

[majority of potential candidates]

majority of potential candidates

[overview of these miRNAs]

overview of these miRNAs

[multiparametric echocardiographic score]

multiparametric echocardiographic score

[reduction of sympathetic tone]

reduction of sympathetic tone

[BET bromodomain-containing protein BRD4]

BET bromodomain-containing protein BRD4

[best quintile of hospitals]

best quintile of hospitals

[KCCQ Overall Summary]

KCCQ Overall Summary

[data examining long-term outcomes]

data examining long-term outcomes

[first AMI between 1996]

first AMI between 1996

[women undergoing anthracycline-containing chemotherapy]

women undergoing anthracycline-containing chemotherapy

[α-myosin heavy chain]

α-myosin heavy chain

[small noncoding RNAs]

small noncoding RNAs

[expression during cardiac hypertrophy]

expression during cardiac hypertrophy

[interpretation of exercise testing]

interpretation of exercise testing

[implantable cardiac arrhythmia devices]

implantable cardiac arrhythmia devices

[provision of life-sustaining treatment]

provision of life-sustaining treatment

[peak aerobic capacity]

peak aerobic capacity

[medical therapy MT]

medical therapy MT

[using a stent]

using a stent

[new chromatin subproteome]

new chromatin subproteome

[primary composite endpoint]

primary composite endpoint

[device-related adverse events]

device-related adverse events

[mean of 11 years]

mean of 11 years

[KCCQ Overall Summary scores]

KCCQ Overall Summary scores

[adults aged 20 years]

adults aged 20 years

[VVD variation P]

VVD variation P

[excellent prognostic ability]

excellent prognostic ability

[expression of Bax proteins]

expression of Bax proteins

[Renal artery stenosis RAS]

Renal artery stenosis RAS

[treatment of several cancers]

treatment of several cancers

[Magnet(®) research requirements]

Magnet(®) research requirements

[Confirmatory diagnostic tests]

Confirmatory diagnostic tests

[Key adverse events]

Key adverse events

[serum potassium 5.0 mmol]

serum potassium 5.0 mmol

[5 age groups 20]

5 age groups 20

[Fifty-one percent of patients]

Fifty-one percent of patients

[baseline KCCQ scales]

baseline KCCQ scales

[development of hypertrophy]

development of hypertrophy

[net economic savings]

net economic savings

[5.0 42.4 g P=0.04]

5.0 42.4 g P=0.04

[cardioprotective effect of nicorandil]

cardioprotective effect of nicorandil

[compliance with treatment]

compliance with treatment, Compliance with treatment

[diagnosis of AF]

diagnosis of AF

[Coronary artery disease CAD]

Coronary artery disease CAD

[expression of exogenous variants]

expression of exogenous variants

[association between race]

association between race

[over 12 months]

over 12 months

[Framingham Heart Study criteria]

Framingham Heart Study criteria

[end stage kidney failure]

end stage kidney failure

[hospital quality improvement initiative]

hospital quality improvement initiative

[renin-angiotensin system RAS]

renin-angiotensin system RAS

[targeting nonterminal epitopes]

targeting nonterminal epitopes

[pediatric mechanical cardiac support]

pediatric mechanical cardiac support

[heart failure HR 1.07]

heart failure HR 1.07

[novel bottleneck stent]

novel bottleneck stent

[having ≥1 independent predictor]

having ≥1 independent predictor

[influx via L-type Ca]

influx via L-type Ca

[increasing ejection fraction]

increasing ejection fraction

[1.73 m 2 age]

1.73 m 2 age

[decrease in EO-CFUs]

decrease in EO-CFUs

[least 55 years]

least 55 years

[including intravenous inotropes]

including intravenous inotropes

[predictors of primary outcome]

predictors of primary outcome

[difference in the risk]

difference in the risk

[Echocardiography at 8 wk]

Echocardiography at 8 wk

[6 CF LVAD patients]

6 CF LVAD patients

[patients requiring isolated LVAD]

patients requiring isolated LVAD

[maximum O2 consumption rate]

maximum O2 consumption rate

[combination with anticoagulants]

combination with anticoagulants

[log rank P]

log rank P

[long-standing persistent AF]

long-standing persistent AF

[conscious HF rats]

conscious HF rats

[clinical characteristics of EH]

clinical characteristics of EH

[vasopressin receptor antagonist therapy]

vasopressin receptor antagonist therapy

[chronic renal failure CRF]

chronic renal failure CRF

[late-activated lateral wall]

late-activated lateral wall

[focus of research investigations]

focus of research investigations

[World Health Organization website]

World Health Organization website

[LV reverse remodeling n=161]

LV reverse remodeling n=161

[Advances in treatment]

Advances in treatment, advances in treatment

[intervention with TGF-β signaling]

intervention with TGF-β signaling

[Eplerenone Post myocardial infarction]

Eplerenone Post myocardial infarction

[two L-type channel isoforms]

two L-type channel isoforms

[elastic N2Bus segment]

elastic N2Bus segment

[cause of heart failure]

cause of heart failure

[aerobic exercise training]

aerobic exercise training

[257,692 ICD patients]

257,692 ICD patients

[Gene expression of Bax]

Gene expression of Bax

[ESRD 1.3 patient-years]

ESRD 1.3 patient-years

[using a cost-minimization approach]

using a cost-minimization approach

[association between any predictor]

association between any predictor

[thromboembolic events in patients]

thromboembolic events in patients

[attenuation by mitochondrial-targeted peptides]

attenuation by mitochondrial-targeted peptides

[ejection fraction rEF]

ejection fraction rEF

[P value for interaction=0.032]

P value for interaction=0.032

[predominantly rural South Dakota]

predominantly rural South Dakota

[accumulation of deficits]

accumulation of deficits

[CLCNKA GG genotype]

CLCNKA GG genotype

[DRS-stratified hazard ratios]

DRS-stratified hazard ratios

[stroke volume SV]

stroke volume SV

[adverse health outcomes]

adverse health outcomes

[sodium-restricted dietary approaches]

sodium-restricted dietary approaches

[additive adverse impact]

additive adverse impact

[adults with HF]

adults with HF

[Atrial fibrillation AF]

Atrial fibrillation AF

[additional prospective studies]

additional prospective studies

[Further elevation in resistin]

Further elevation in resistin

[free wall RS P]

free wall RS P

[point of care]

point of care

[functional etiology of MR]

functional etiology of MR

[increasing cardiac volume index]

increasing cardiac volume index

[findings through briefing reports]

findings through briefing reports

[idiopathic-dilated cardiomyopathy all p]

idiopathic-dilated cardiomyopathy all p

[moderate-severe right ventricular dysfunction]

moderate-severe right ventricular dysfunction

[patients with LVEF]

patients with LVEF

[changes in energy metabolism]

changes in energy metabolism

[pathway alterations in TAC]

pathway alterations in TAC

[3.01 1.39 years]

3.01 1.39 years

[Dual RAS inhibition]

Dual RAS inhibition

[beta receptor blockers]

beta receptor blockers

[2 months post-procedure]

2 months post-procedure

[incremental shuttle walk test]

incremental shuttle walk test

[Kansas City Cardiomyopathy Questionnaire]

Kansas City Cardiomyopathy Questionnaire

[NYHA class III]

NYHA class III

[negative inotropic effect]

negative inotropic effect

[calcineurin Nfat signalling]

calcineurin Nfat signalling

[older breast cancer patients]

older breast cancer patients

[right coronary artery]

right coronary artery

[most ethically complex situations]

most ethically complex situations

[extent of CAD]

extent of CAD

[ventricular diastolic end diameter]

ventricular diastolic end diameter

[changes in atrial pressure]

changes in atrial pressure

[Gene expression profile GSE9128]

Gene expression profile GSE9128

[therefore afterload burden]

therefore afterload burden

[subgroups at high risk]

subgroups at high risk

[adjunctive treatment for cardiomyopathy]

adjunctive treatment for cardiomyopathy

[exercise rehabilitation in patients]

exercise rehabilitation in patients, exercise rehabilitation in patient

[left ventricular mechanics]

left ventricular mechanics

[readily available data]

readily available data

[using 2005 2008 composite]

using 2005 2008 composite

[bone 4 expression]

bone 4 expression

[Beck Depression Inventory]

Beck Depression Inventory

[renin angiotensin-aldosterone pathway]

renin angiotensin-aldosterone pathway

[consecutive case series]

consecutive case series

[univariate models p]

univariate models p

[patients without uptitration]

patients without uptitration

[Tricuspid annular plane excursion]

Tricuspid annular plane excursion, tricuspid annular plane excursion

[using ingenuity pathway analysis]

using ingenuity pathway analysis

[successful reperfusion therapy]

successful reperfusion therapy

[cystatin C level dopamine]

cystatin C level dopamine

[cardiac surgery patients]

cardiac surgery patients

[Adequate blood pressure control]

Adequate blood pressure control

[prognosis in heart failure]

prognosis in heart failure

[prevalence of heart failure]

prevalence of heart failure

[Multivariate Cox regression analyses]

Multivariate Cox regression analyses

[peak oxygen uptake P]

peak oxygen uptake P

[cardiac transplant n=36]

cardiac transplant n=36

[systolic blood pressure median]

systolic blood pressure median

[Key secondary outcomes]

Key secondary outcomes

[mice via phenylephrine]

mice via phenylephrine

[higher readmission rates P]

higher readmission rates P

[longitudinal systolic strain]

longitudinal systolic strain

[sympathetic parasympathetic activity]

sympathetic parasympathetic activity

[cardiac vagal tone]

cardiac vagal tone

[higher rate of rehospitalization]

higher rate of rehospitalization

[evidence for these drugs]

evidence for these drugs

[rate of CHF]

rate of CHF, rates of CHF

[atrial natriuretic peptide]

atrial natriuretic peptide

[cardiac gene expression]

cardiac gene expression

[cyclic adenosine monophosphate cAMP]

cyclic adenosine monophosphate cAMP

[Stroke prevention Trial]

Stroke prevention Trial

[Exercise Training HF-ACTION]

Exercise Training HF-ACTION

[1 year of OHT]

1 year of OHT

[Cases post-HCT CHF]

Cases post-HCT CHF

[IEs in this population]

IEs in this population

[free wall CS]

free wall CS

[6 minutes walking]

6 minutes walking

[actions of receptor kinase-2]

actions of receptor kinase-2

[other dietary measures]

other dietary measures

[prior 1 months]

prior 1 months

[median body mass index]

median body mass index

[predictor using multivariable regression]

predictor using multivariable regression

[acute anthracycline-induced cardiotoxicity]

acute anthracycline-induced cardiotoxicity

[invasive haemodynamic assessment]

invasive haemodynamic assessment

[defibrillator-only therapy HR 0.87]

defibrillator-only therapy HR 0.87

[genomic reprogramming events]

genomic reprogramming events

[full length NT-proBNP molecule]

full length NT-proBNP molecule

[EMPHASIS-HF study subgroups Eplerenone]

EMPHASIS-HF study subgroups Eplerenone

[16 candidate genes]

16 candidate genes

[lower body mass index]

lower body mass index

[chronic insulin exposure]

chronic insulin exposure

[basal resistin levels similar]

basal resistin levels similar

[bHLH transcription factor Hand2]

bHLH transcription factor Hand2

[net reclassification improvement]

net reclassification improvement

[number of cases]

number of cases

[negative binomial regression models]

negative binomial regression models

[significant mitral stenosis]

significant mitral stenosis

[otherwise effective rate control]

otherwise effective rate control

[activating myocardial PDE2]

activating myocardial PDE2

[rapid onset of]

rapid onset of

[typical adverse event]

typical adverse event

[bioprosthetic valve replacement]

bioprosthetic valve replacement

[higher stroke volume]

higher stroke volume

[correction for age]

correction for age

[3 weeks after AAC]

3 weeks after AAC

[chronic systolic heart failure]

chronic systolic heart failure

[range 51 years]

range 51 years

[increase of 0.2 mL]

increase of 0.2 mL

[dietary sodium restriction]

dietary sodium restriction

[measure of contractile reserve]

measure of contractile reserve

[factors of SH]

factors of SH

[total of patients]

total of patients

[cumulative anthracycline exposure]

cumulative anthracycline exposure

[advanced structural heart disease]

advanced structural heart disease

[initial functional class]

initial functional class

[Coprimary end points]

Coprimary end points

[Sixty-one patients with HFPEF]

Sixty-one patients with HFPEF

[combination of exercise]

combination of exercise

[Heart Failure Adherence Trial]

Heart Failure Adherence Trial

[anaerobic threshold AT]

anaerobic threshold AT

[aggressive dose uptitration]

aggressive dose uptitration

[mean follow-up times]

mean follow-up times

[further remodeling aspects]

further remodeling aspects

[managing this disease]

managing this disease

[better outcomes among patients]

better outcomes among patients

[disappointments in large phase]

disappointments in large phase

[activation of p38]

activation of p38

[similar baseline covariates]

similar baseline covariates

[0.5 kg p]

0.5 kg p

[average age of patients]

average age of patients

[maladaptive molecular processes]

maladaptive molecular processes

[perspective on the timing]

perspective on the timing

[early-outgrowth colony-forming units EO-CFUs]

early-outgrowth colony-forming units EO-CFUs

[role of Nucleolin]

role of Nucleolin

[possibility of MS]

possibility of MS

[SkM mitochondrial structure]

SkM mitochondrial structure

[development of IE]

development of IE

[excellent HF prediction model]

excellent HF prediction model

[essential role supporting patients]

essential role supporting patients

[first-in-class inhibitor JQ1]

first-in-class inhibitor JQ1

[odds ratio of 0.50]

odds ratio of 0.50

[postnatal mammalian myocardium]

postnatal mammalian myocardium

[hospitalization for hyperkalemia]

hospitalization for hyperkalemia

[potassium 5.0 mmol]

potassium 5.0 mmol

[resistin in heart failure]

resistin in heart failure

[endothelial function in HFpEF]

endothelial function in HFpEF

[development of CHF]

development of CHF

[logistic regression analysis]

logistic regression analysis

[18 heart transplantations]

18 heart transplantations

[possible biomarker for HFPEF]

possible biomarker for HFPEF

[cardiac L-type channel activity]

cardiac L-type channel activity

[concordance c statistics]

concordance c statistics

[peak work rate]

peak work rate

[inappropriate cardioverter-defibrillator therapy]

inappropriate cardioverter-defibrillator therapy

[stand-alone diagnostic devices]

stand-alone diagnostic devices

[similar rates of hypertension]

similar rates of hypertension

[Severe LV fibrosis]

Severe LV fibrosis

[correlation with baseline Hgb]

correlation with baseline Hgb

[hypertension diet DASH]

hypertension diet DASH

[25 heart failure patients]

25 heart failure patients

[global longitudinal strain]

global longitudinal strain

[4-year follow-up period]

4-year follow-up period

[median high PASP]

median high PASP

[Exercise training in patients]

Exercise training in patients

[vivo inhibition of miR-25]

vivo inhibition of miR-25

[phenylephrine-mediated hypertrophy of cardiomyocytes]

phenylephrine-mediated hypertrophy of cardiomyocytes

[SkM growth consistent]

SkM growth consistent

[patients with AF]

patients with AF

[area under the curve]

area under the curve

[consultation for abdominal problems]

consultation for abdominal problems

[LV contractility lower LVEF]

LV contractility lower LVEF

[interventions atrial pacing]

interventions atrial pacing

[insulin-stimulated rates of glycolysis]

insulin-stimulated rates of glycolysis

[distinct subset of HFpEF]

distinct subset of HFpEF

[difference among EF]

difference among EF

[patients with mild anemia]

patients with mild anemia

[collaborative research initiatives]

collaborative research initiatives

[normal albumin levels]

normal albumin levels

[targeting the right patients]

targeting the right patients

[β-adrenergic receptor agonist treatment]

β-adrenergic receptor agonist treatment

[predictors of ESRD]

predictors of ESRD

[Trial Investigating Outcomes HF-ACTION]

Trial Investigating Outcomes HF-ACTION

[having heart failure]

having heart failure

[Carvedilol a nonselective β-blocker]

Carvedilol a nonselective β-blocker

[similar clinical benefit]

similar clinical benefit

[relative risk among trials]

relative risk among trials

[membrane oxygenation ECMO]

membrane oxygenation ECMO

[lower von Willebrand factor]

lower von Willebrand factor

[heart failure population]

heart failure population

[prevalent coronary heart disease]

prevalent coronary heart disease

[inappropriate shock therapy HR]

inappropriate shock therapy HR

[Grade recommendation evidence]

Grade recommendation evidence

[prognostic indicator in patients]

prognostic indicator in patients

[diuretic use in HF]

diuretic use in HF

[using medicare data]

using medicare data, Using Medicare data

[pulmonary vascular resistance]

pulmonary vascular resistance

[reality of heart failure]

reality of heart failure

[control group P]

control group P

[categories of fit]

categories of fit

[Medicare hospital claims]

Medicare hospital claims

[preliminary descriptive study]

preliminary descriptive study

[percent of hospitals]

percent of hospitals

[Cardiac overexpression of Mammalian]

Cardiac overexpression of Mammalian

[Beck Depression Inventory P]

Beck Depression Inventory P

[603 consecutive patients age]

603 consecutive patients age

[experiencing heart failure]

experiencing heart failure

[type II regulatory RIIα]

type II regulatory RIIα

[diagnostic procedures for]

diagnostic procedures for

[changes in abundance]

changes in abundance

[presence of signs]

presence of signs

[institutional experience between 2008]

institutional experience between 2008

[continuous flow CF]

continuous flow CF

[Effectiveness of herbal medicine]

Effectiveness of herbal medicine, effectiveness of herbal medicine

[Web-based simulation tool]

Web-based simulation tool

[outcomes except mortality]

outcomes except mortality

[systolic human heart failure]

systolic human heart failure

[SHIFT Heart Failure Treatment]

SHIFT Heart Failure Treatment

[implantable cardioverter-defibrillator therapy]

implantable cardioverter-defibrillator therapy

[better renal function]

better renal function

[Thirteen patients with hypertension]

Thirteen patients with hypertension

[repeat metabolic evaluations]

repeat metabolic evaluations

[left ventricular end diameter]

left ventricular end diameter

[risk of new HF]

risk of new HF

[including quality of life]

including quality of life

[growth of Ehrlich carcinoma]

growth of Ehrlich carcinoma

[metoprolol 50 mg]

metoprolol 50 mg

[basal heart rate]

basal heart rate

[evidence in HFpEF]

evidence in HFpEF

[acute hospital facilities]

acute hospital facilities

[duration of the symptoms]

duration of the symptoms

[peak oxygen consumption VO2]

peak oxygen consumption VO2

[23 mm Hg SD]

23 mm Hg SD

[HRQoL changes in HRQoL]

HRQoL changes in HRQoL

[English language on anemia]

English language on anemia

[DAPC dystrophin-associated protein complex]

DAPC dystrophin-associated protein complex

[site specific RIIα Ser96]

site specific RIIα Ser96

[conditions requiring surgery]

conditions requiring surgery

[simple sex-specific model]

simple sex-specific model

[fluorescence resonance energy assays]

fluorescence resonance energy assays

[fewer CHF patients presenting]

fewer CHF patients presenting

[clinical circumstances common]

clinical circumstances common

[severe developmental impairment]

severe developmental impairment

[cyclic guanosine monophosphate cGMP]

cyclic guanosine monophosphate cGMP

[adjusting decrease in score]

adjusting decrease in score

[patients with IC]

patients with IC

[70 years Q]

70 years Q

[levels of NPs]

levels of NPs

[ischemic mitral regurgitation]

ischemic mitral regurgitation

[patients with EH]

patients with EH

[Nonidentification of AT]

Nonidentification of AT

[regulation of cell death]

regulation of cell death

[early beneficial clinical outcomes]

early beneficial clinical outcomes

[absence of atrial fibrillation]

absence of atrial fibrillation

[data from non-HF populations]

data from non-HF populations

[phosphorylation of eNOS-Ser]

phosphorylation of eNOS-Ser

[patients at higher risk]

patients at higher risk, patients at high risk

[promising field of investigation]

promising field of investigation

[median of 1,080 days]

median of 1,080 days

[key health outcomes]

key health outcomes

[significantly lower HF mortality]

significantly lower HF mortality

[use HR 1.30]

use HR 1.30

[further rigorous investigation]

further rigorous investigation

[Mean age of participants]

Mean age of participants

[10-week treatment period]

10-week treatment period

[double-blind 2:1 ratio]

double-blind 2:1 ratio

[such as HF]

such as HF

[respective age categories]

respective age categories

[cardiac function via echocardiography]

cardiac function via echocardiography

[cardiomyocytes in the presence]

cardiomyocytes in the presence

[physiological proteolysis between Pro2-Leu3]

physiological proteolysis between Pro2-Leu3

[IRS2 double-knockout L-DKO mice]

IRS2 double-knockout L-DKO mice

[increase in parasympathetic function]

increase in parasympathetic function

[percentage of fibrosis]

percentage of fibrosis

[angiotensin receptor antagonist valsartan]

angiotensin receptor antagonist valsartan

[1 large trial]

1 large trial

[using Cox models]

using Cox models

[less ischemic etiology]

less ischemic etiology

[outcomes of nursing care]

outcomes of nursing care

[CRT ON assignment]

CRT ON assignment

[However a single-arm analysis]

However a single-arm analysis

[novel therapeutic approaches]

novel therapeutic approaches

[(TAC)-induced heart failure]

(TAC)-induced heart failure

[centrifugal flow pump]

centrifugal flow pump

[Eight-week-old C57BL 6]

Eight-week-old C57BL 6

[potentially significant cost savings]

potentially significant cost savings

[increasing population of anthracycline]

increasing population of anthracycline

[bHLH transcription factor]

bHLH transcription factor

[higher diastolic blood pressure]

higher diastolic blood pressure

[underlying myocardial DD]

underlying myocardial DD

[effects of air pollution]

effects of air pollution

[cause among the elderly]

cause among the elderly, causes among the elderly

[heart failure a study]

heart failure a study

[minutes of exercise]

minutes of exercise

[composite of death]

composite of death

[major public health problem]

major public health problem

[so-called end stage]

so-called end stage

[maximal systolic elastance]

maximal systolic elastance

[all-cause mortality in patients]

all-cause mortality in patients

[S1PR1 cardiac gene therapy]

S1PR1 cardiac gene therapy

[cardiac arrest in humans]

cardiac arrest in humans

[unloading of the heart]

unloading of the heart

[Trends from 1996]

Trends from 1996

[Prospective two-center pilot project]

Prospective two-center pilot project

[vasopressin receptor antagonist]

vasopressin receptor antagonist

[most urban areas]

most urban areas

[Pediatric heart failure HF]

Pediatric heart failure HF

[receptor 1 S1PR1]

receptor 1 S1PR1

[suppression of downstream signalling]

suppression of downstream signalling

[follow-up visits 16]

follow-up visits 16

[diagnosis of ischemic-hypertensive cardiomyiopathy]

diagnosis of ischemic-hypertensive cardiomyiopathy

[2 aortic valve repairs]

2 aortic valve repairs

[score with death]

score with death

[human HF tissues]

human HF tissues

[study drug dose]

study drug dose

[patient with comorbidities]

patient with comorbidities

[striking differences in presentation]

striking differences in presentation

[CHF-developed infarcted animals]

CHF-developed infarcted animals

[higher oxygen flow]

higher oxygen flow

[small trial of patients]

small trial of patients

[other study drugs]

other study drugs

[Sixty-one patients with HFpEF]

Sixty-one patients with HFpEF

[reduction in Ea p]

reduction in Ea p

[use of erythropoiesis-stimulating agents]

use of erythropoiesis-stimulating agents

[Medical Treatment Guidelines]

Medical Treatment Guidelines

[carotid intima-media thickness]

carotid intima-media thickness

[greater self-reported physical activity]

greater self-reported physical activity

[Congestive heart failure visits]

Congestive heart failure visits

[baseline serum creatinine level]

baseline serum creatinine level

[using strong acid]

using strong acid

[higher fat mass]

higher fat mass

[allopurinol 100 mg·kg(-1)·day(-1)]

allopurinol 100 mg·kg(-1)·day(-1)

[Patients aged 18 years]

Patients aged 18 years

[sodium-restricted DASH diet]

sodium-restricted DASH diet

[differences in longitudinal performance]

differences in longitudinal performance

[transient receptor potential]

transient receptor potential

[mean of 19.4 months]

mean of 19.4 months

[Systolic vEntricular dysfunction REVERSE]

Systolic vEntricular dysfunction REVERSE

[left longitudinal systolic strain]

left longitudinal systolic strain

[penalties for higher-than-expected rates]

penalties for higher-than-expected rates

[Cox-proportional hazard models]

Cox-proportional hazard models

[principles of pharmacologic treatment]

principles of pharmacologic treatment

[renin-angiotensin-aldosterone system RAAS]

renin-angiotensin-aldosterone system RAAS

[role of human resistin]

role of human resistin

[complex set of variables]

complex set of variables

[heart failure home]

heart failure home

[LV end-diastolic pressure P]

LV end-diastolic pressure P

[EC coupling gain]

EC coupling gain

[channel α-subunit SCN5A]

channel α-subunit SCN5A

[Addressing practice-level differences]

Addressing practice-level differences

[functional mitral stenosis]

functional mitral stenosis

[erythropoiesis-stimulating agent therapy]

erythropoiesis-stimulating agent therapy

[only at higher doses]

only at higher doses

[Preventable Readmission PPR]

Preventable Readmission PPR

[cardiac index score value]

cardiac index score value

[HF with ejection fraction]

HF with ejection fraction

[6-minute hall walk distance]

6-minute hall walk distance

[reserve in patients]

reserve in patients

[CLCNKA polymorphism rs10927887 p]

CLCNKA polymorphism rs10927887 p

[even mild dysfunction]

even mild dysfunction

[high-volume physicians a difference]

high-volume physicians a difference

[right grip strength]

right grip strength

[other vascular diseases]

other vascular diseases

[profound change in Paco2]

profound change in Paco2

[clinical composite response]

clinical composite response

[exercise programme for patients]

exercise programme for patients

[bundle-branch block LBBB]

bundle-branch block LBBB

[namely direct renin inhibitors]

namely direct renin inhibitors

[program of exercise rehabilitation]

program of exercise rehabilitation

[adjustment for differences]

adjustment for differences

[clinically significant gastrointestinal bleeding]

clinically significant gastrointestinal bleeding

[similar long-term mortality]

similar long-term mortality

[functional capacity peak VO2]

functional capacity peak VO2

[prognostic significance of BNP]

prognostic significance of BNP

[CHF patients 778]

CHF patients 778

[age-matched reference values Z-score]

age-matched reference values Z-score

[lower rates of hypokalemia]

lower rates of hypokalemia

[majority of studies]

majority of studies

[nitric oxide donors]

nitric oxide donors

[1.61 vs. 1.39 times]

1.61 vs. 1.39 times

[subset of 910 patients]

subset of 910 patients

[patients with rheumatoid arthritis]

patients with rheumatoid arthritis

[epigenetic erasers histone deacetylases]

epigenetic erasers histone deacetylases

[Chronic heart failure CHF]

Chronic heart failure CHF

[dietary patterns with outcomes]

dietary patterns with outcomes

[acute β-AR stimulation]

acute β-AR stimulation

[HR reduction by ivabradine]

HR reduction by ivabradine

[urgent cardiac transplant]

urgent cardiac transplant

[databases of MEDLINE]

databases of MEDLINE

[new antiarrhythmic drugs]

new antiarrhythmic drugs

[adjustment for clinical variables]

adjustment for clinical variables

[Contemporary therapeutic options]

Contemporary therapeutic options

[Rates of ED visits]

Rates of ED visits, rates of ED visits

[improvement in long-term prognosis]

improvement in long-term prognosis

[Chinese herbal medicine CHM]

Chinese herbal medicine CHM

[50 μmol L]

50 μmol L

[2 simple ECG parameters]

2 simple ECG parameters

[1.35 kg p]

1.35 kg p

[mandatory 7-day follow-up visits]

mandatory 7-day follow-up visits

[153 HF deaths]

153 HF deaths

[specifically on idiopathic cardiomyopathy]

specifically on idiopathic cardiomyopathy

[connection between experienced centers]

connection between experienced centers

[Lp-PLA2 than controls]

Lp-PLA2 than controls

[SAF versus PF mean]

SAF versus PF mean

[control group patients]

control group patients

[LVEF on long-term mortality]

LVEF on long-term mortality

[rheumatic causes of MS]

rheumatic causes of MS

[beat-to-beat QT interval]

beat-to-beat QT interval

[other major databases]

other major databases

[cell expansion protocols]

cell expansion protocols

[regulation of Rad Q66P]

regulation of Rad Q66P

[44 674 men]

44 674 men

[superior reverse remodeling]

superior reverse remodeling

[Risk stratification for death]

Risk stratification for death

[appropriate risk stratification]

appropriate risk stratification

[cause of cardiovascular hospitalization]

cause of cardiovascular hospitalization

[0.4 mm Hg]

0.4 mm Hg

[contributions of titin]

contributions of titin

[randomised-controlled trials RCTs]

randomised-controlled trials RCTs

[risk of incident CVD]

risk of incident CVD

[gating movement of channels]

gating movement of channels

[mitochondrial energy production]

mitochondrial energy production

[mass spectrometric analysis]

mass spectrometric analysis

[peak Ca 2]

peak Ca 2

[changes in SR Ca]

changes in SR Ca

[shorter 6-minute walk distance]

shorter 6-minute walk distance

[ACS problems in patients]

ACS problems in patients

[discharge follow-up medication lists]

discharge follow-up medication lists

[cardiac VEGF expression]

cardiac VEGF expression

[doxorubicin efflux transporter ABCC2]

doxorubicin efflux transporter ABCC2

[prospective observational study]

prospective observational study

[Major right ventricle overload]

Major right ventricle overload

[Patients with T1 times]

Patients with T1 times

[ischemic heart failure stent]

ischemic heart failure stent

[100 pg BNP group]

100 pg BNP group

[new prevention strategies]

new prevention strategies

[STE analysis of twist]

STE analysis of twist

[duration of antiplatelet medication]

duration of antiplatelet medication

[common inpatient medical conditions]

common inpatient medical conditions

[intravenous bolus of metoprolol]

intravenous bolus of metoprolol

[poorer VO2 max]

poorer VO2 max

[mean score of 13]

mean score of 13

[combination with other factors]

combination with other factors

[cardiovascular event rate]

cardiovascular event rate

[improving functional capacity]

improving functional capacity

[long-term administration of pyridostigmine]

long-term administration of pyridostigmine

[large cohort study]

large cohort study

[use of loop diuretics]

use of loop diuretics

[single drug-free success rates]

single drug-free success rates

[adopting evidence-based practices]

adopting evidence-based practices

[health care providers]

health care providers

[signal transduction cascade]

signal transduction cascade

[subsequent heart failure]

subsequent heart failure

[success in future trials]

success in future trials

[prediction of CV events]

prediction of CV events

[risk of hospitalization]

risk of hospitalization, risks of hospitalization

[creatinine hazard ratio]

creatinine hazard ratio

[severe frailty HR]

severe frailty HR

[left LV ejection fraction]

left LV ejection fraction

[individuals with heart failure]

individuals with heart failure

[mitochondrial complex V activity]

mitochondrial complex V activity

[artery bypass grafting]

artery bypass grafting

[cardiac transplant ECCT programs]

cardiac transplant ECCT programs

[older age group]

older age group

[signaling pathway changes]

signaling pathway changes

[UTI with major complications]

UTI with major complications

[reaching statitistical significance]

reaching statitistical significance

[standing blood pressure]

standing blood pressure

[enhancing medical management]

enhancing medical management

[following myocardial infarction]

following myocardial infarction

[increase circulating plasma NE]

increase circulating plasma NE

[2 distinct G-protein-coupled receptors]

2 distinct G-protein-coupled receptors

[stable clinical conditions]

stable clinical conditions

[ingenuity pathway analysis]

ingenuity pathway analysis

[fit versus unfit men]

fit versus unfit men

[Nicorandil 3 mg]

Nicorandil 3 mg

[arterial systolic pressure]

arterial systolic pressure

[quarterly inpatient admissions]

quarterly inpatient admissions

[terminal stage of CHF]

terminal stage of CHF

[cardiac sympathetic activity]

cardiac sympathetic activity

[1.05 per 0.1 mg]

1.05 per 0.1 mg

[MS at that time]

MS at that time

[treatment of severe hyponatremia]

treatment of severe hyponatremia

[antitachycardia pacing ATP]

antitachycardia pacing ATP

[transition from LV hypertrophy]

transition from LV hypertrophy

[higher metabolic exercise]

higher metabolic exercise

[Association with functional capacity]

Association with functional capacity

[heart failure T1-mapping values]

heart failure T1-mapping values

[Kv4.3 mRNA levels resulting]

Kv4.3 mRNA levels resulting

[6-month observation period]

6-month observation period

[peripheral muscle pump]

peripheral muscle pump

[contrast agent administration]

contrast agent administration

[reclassification of risk]

reclassification of risk

[absolute value of MDC]

absolute value of MDC

[relationship between pathobiology]

relationship between pathobiology

[HF risk factors present]

HF risk factors present

[patients receiving these agents]

patients receiving these agents

[presence of dysfunction]

presence of dysfunction, Presence of dysfunction

[inducible myocardial ischemia]

inducible myocardial ischemia

[Reduction in Mortality]

Reduction in Mortality, reduction in mortality

[total of 151 subjects]

total of 151 subjects

[change in LVET]

change in LVET

[thereby re-activating transcription]

thereby re-activating transcription

[more recent enrollment period]

more recent enrollment period

[maximal treadmill exercise testing]

maximal treadmill exercise testing

[death in CRT-D recipients]

death in CRT-D recipients

[patients with functional MS]

patients with functional MS

[hazard ratio 0.73]

hazard ratio 0.73

[less severe systolic dysfunction]

less severe systolic dysfunction

[General use of beta-blockers]

General use of beta-blockers

[Using sex-specific models]

Using sex-specific models

[hazard ratio 0.93]

hazard ratio 0.93

[prior cardiovascular disease]

prior cardiovascular disease

[particularly in low-volume institutions]

particularly in low-volume institutions

[LV filling pressure]

LV filling pressures, LV filling pressure

[important metabolic risk factors]

important metabolic risk factors

[readmission metric choice]

readmission metric choice

[Therapeutic implications of biomarkers]

Therapeutic implications of biomarkers, therapeutic implications of biomarkers

[cardiac explant-derived cells]

cardiac explant-derived cells

[progression of heart failure]

progression of heart failure

[development of IEs]

development of IEs

[Unilateral renal denervation]

Unilateral renal denervation

[24 hours of admission]

24 hours of admission

[fat mass FM]

fat mass FM

[future prospective research]

future prospective research

[magnetic resonance angiography]

magnetic resonance angiography

[SVR index 1,680]

SVR index 1,680

[degree of functional MS]

degree of functional MS

[early risk of stroke]

early risk of stroke

[acetylcholinesterase inhibitor pyridostigmine]

acetylcholinesterase inhibitor pyridostigmine

[most common contextual reasons]

most common contextual reasons

[Half of these patients]

Half of these patients

[small muscle strips]

small muscle strips

[β-blocker enzyme inhibitor]

β-blocker enzyme inhibitor

[province of Québec Canada]

province of Québec Canada

[surgery by echocardiography]

surgery by echocardiography

[thorough medical history]

thorough medical history

[thus reducing Ea]

thus reducing Ea

[primary efficacy outcome]

primary efficacy outcome

[mitral filling flow volume]

mitral filling flow volume

[oxidative stress markers]

oxidative stress markers

[Self-Care Maintenance Scale]

Self-Care Maintenance Scale

[Poor social support]

Poor social support

[Szeto-Schiller SS 31]

Szeto-Schiller SS 31

[failure of cardiovascular reserve]

failure of cardiovascular reserve

[Using data from HF-ACTION]

Using data from HF-ACTION

[including fewer ST-segment-elevation MIs]

including fewer ST-segment-elevation MIs

[Correlations among metrics]

Correlations among metrics

[worsening renal function]

worsening renal function

[exercise training therapy]

exercise training therapy

[Dynamic collateral growth patterns]

Dynamic collateral growth patterns

[benefits of participation]

benefits of participation

[lowest event rate]

lowest event rate, lower event rate

[left-to-right interatrial shunt]

left-to-right interatrial shunt

[1 valve replacement]

1 valve replacement

[catecholamine infusions in rats]

catecholamine infusions in rats

[contractile reserve in patients]

contractile reserve in patients

[lower risk-adjusted all-cause mortality]

lower risk-adjusted all-cause mortality

[5-year follow-up period]

5-year follow-up period

[traditional cost-effectiveness limits]

traditional cost-effectiveness limits

[s'lateral of 4.5 cm]

s'lateral of 4.5 cm

[present preliminary study]

present preliminary study

[changes in myofiber dynamics]

changes in myofiber dynamics

[complications after implantation]

complications after implantation

[than in littermate controls]

than in littermate controls

[clinical evaluations at baseline]

clinical evaluations at baseline

[lower exercise time]

lower exercise time

[caloric restriction diet]

caloric restriction diet

[total cost per patient]

total cost per patient

[abnormal chamber patterning]

abnormal chamber patterning

[annually up years]

annually up years

[s'lateral of ≤4.5 cm]

s'lateral of ≤4.5 cm

[practical Recommendations for application]

practical Recommendations for application

[markers of hemostasis]

markers of hemostasis

[heart failure-related mortality]

heart failure-related mortality

[heart failure rats]

heart failure rats

[medical resource use]

medical resource use

[safety of these agents]

safety of these agents

[beneficial effect on mortality]

beneficial effect on mortality

[risk for hHF]

risk for hHF

[approximately 1.6 seconds]

approximately 1.6 seconds

[5.1 million Americans aged]

5.1 million Americans aged

[true change in measures]

true change in measures

[providing guideline-recommended care]

providing guideline-recommended care

[risk of HF]

risk of HF

[descriptive research design]

descriptive research design

[Fractional flow reserve measurements]

Fractional flow reserve measurements

[implantable cardioverter defibrillators]

implantable cardioverter defibrillators

[death hazard ratio]

death hazard ratio

[effective arterial elastance Ea]

effective arterial elastance Ea

[setting of ATP demand]

setting of ATP demand

[implantable cardiac defibrillator]

implantable cardiac defibrillator

[Health ABC HF Model]

Health ABC HF Model

[cardiomyocyte-like cells in vitro]

cardiomyocyte-like cells in vitro

[changes in FM]

changes in FM

[clinical diastolic dysfunction]

clinical diastolic dysfunction

[inclusion of the parameters]

inclusion of the parameters

[ability of GLS]

ability of GLS

[right heart circulation]

right heart circulation

[atrial area 26 cm]

atrial area 26 cm

[biomarker in heart failure]

biomarker in heart failure, biomarkers in heart failure

[Attention correcting nutrition function]

Attention correcting nutrition function

[reduction of sympathetic outflow]

reduction of sympathetic outflow

[advanced chronic organ failure]

advanced chronic organ failure

[gadolinium-chelate contrast agent]

gadolinium-chelate contrast agent

[Aldosterone receptor antagonists]

Aldosterone receptor antagonists

[heart disease HHD]

heart disease HHD

[tissue from control animals]

tissue from control animals

[HR reduction in patients]

HR reduction in patients

[patients with lower BTES]

patients with lower BTES

[ivabradine group p]

ivabradine group p

[association of the score]

association of the score

[standard error of measurement]

standard error of measurement

[effects of Nordic walking]

effects of Nordic walking

[diuretic refractory severe-end-stage HF]

diuretic refractory severe-end-stage HF

[Public reporting on quality]

Public reporting on quality

[less aggressive protocols]

less aggressive protocols

[good diagnostic performance]

good diagnostic performance

[over 2 weeks]

over 2 weeks

[most studies in HF]

most studies in HF

[early follow-up visits]

early follow-up visits

[total of 1483 patients]

total of 1483 patients

[total of 8204 patients]

total of 8204 patients

[left heart filling pressures]

left heart filling pressures

[decisions about life-sustaining treatment]

decisions about life-sustaining treatment

[strong predictor of mortality]

strong predictors of mortality, strong predictor of mortality

[left ejection fraction HFpEF]

left ejection fraction HFpEF

[left ventricular end-diastolic pressure]

left ventricular end-diastolic pressure

[shortcomings in research studies]

shortcomings in research studies

[controlling for demographic characteristics]

controlling for demographic characteristics

[30 days than medium]

30 days than medium

[multivariate Cox model analysis]

multivariate Cox model analysis

[having systolic heart failure]

having systolic heart failure

[models using historical data]

models using historical data

[78 553 saxagliptin users]

78 553 saxagliptin users

[Primary study end point]

Primary study end point, primary study end point

[regulatory subunit RI]

regulatory subunit RI

[Power spectral analysis]

Power spectral analysis

[mild heart failure]

mild heart failure

[use of spironolactone]

use of spironolactone

[Logistic regression models]

Logistic regression models

[8,009 reference subjects]

8,009 reference subjects

[low-volume physicians P]

low-volume physicians P

[three groups of samples]

three groups of samples

[heart failure myocardial tissue]

heart failure myocardial tissue

[efficacy of the device]

efficacy of the device

[99,930 HF patients]

99,930 HF patients

[data from clinical trials]

data from clinical trials

[rest of the group]

rest of the group

[relationships with mortality]

relationships with mortality

[outcomes among patients]

outcomes among patients

[24 373 patients]

24 373 patients

[ventricular reserve in patients]

ventricular reserve in patients

[two groups patients P]

two groups patients P

[reduction in the ratio]

reduction in the ratio

[20-week time span]

20-week time span

[reliability in stable HF]

reliability in stable HF

[myofibrillar Ca ATPase activity]

myofibrillar Ca ATPase activity

[central end-systolic pressure]

central end-systolic pressure

[ring annuloplasty for regurgitation]

ring annuloplasty for regurgitation

[adjunctive treatment for patients]

adjunctive treatment for patients

[composite vs. Hospital Compare]

composite vs. Hospital Compare

[community of 150,000 population]

community of 150,000 population

[10 patients with CHF]

10 patients with CHF

[prescribing of guideline-recommended medications]

prescribing of guideline-recommended medications

[requiring biventricular support]

requiring biventricular support

[improvements from baseline]

improvements from baseline

[subjects without psoriasis]

subjects without psoriasis

[case-control study design]

case-control study design

[CHF Inhibition of AVP]

CHF Inhibition of AVP

[maximal ventricular power index]

maximal ventricular power index

[QT intervals SDQT]

QT intervals SDQT

[odds ratio hazard ratio]

odds ratio hazard ratio

[long-term continuity of care]

long-term continuity of care

[features of heart failure]

features of heart failure

[typical amyloidotic pattern]

typical amyloidotic pattern

[cardiac benign tumors]

cardiac benign tumors

[use of guideline-recommended medications]

use of guideline-recommended medications

[selecting controls without CHF]

selecting controls without CHF

[significant interaction with LVEF]

significant interaction with LVEF

[timing of myocardial infarction]

timing of myocardial infarction

[patients with hypoalbuminemia]

patients with hypoalbuminemia

[Human heart failure HF]

Human heart failure HF

[MS in this patient]

MS in this patient

[July 2005 performance]

July 2005 performance

[factors predicting survival]

factors predicting survival

[same signalling proteins]

same signalling proteins

[mouse TAC model]

mouse TAC model

[vivo experiments of HF]

vivo experiments of HF

[risk for adverse events]

risk for adverse events

[NYHA Class II]

NYHA Class II

[less invasive alternatives]

less invasive alternatives

[median follow-up duration]

median follow-up duration

[Using nursing terminologies]

Using nursing terminologies

[right pulmonary artery]

right pulmonary artery

[secondary end point]

secondary end points, secondary end point

[higher phosphorylation at eNOS-Thr]

higher phosphorylation at eNOS-Thr

[spironolactone in clinical practice]

spironolactone in clinical practice

[clinical practice guideline]

clinical practice guideline, clinical practice guidelines

[similar dose uptitration]

similar dose uptitration

[relative wall thickness]

relative wall thickness

[years of age]

years of age

[aerobic exercise training exercise]

aerobic exercise training exercise

[worsening heart failure]

worsening heart failure

[subjects with a history]

subjects with a history

[basis of systematic review]

basis of systematic review

[College of Cardiology]

College of Cardiology

[onset of symptoms]

onset of symptoms

[diagnosis of CHF dysfunction]

diagnosis of CHF dysfunction

[Health Initiative participants]

Health Initiative participants

[diseases such as HF]

diseases such as HF

[correlation coefficient R]

correlation coefficient R

[other preventive measures]

other preventive measures

[refractory cardiogenic shock]

refractory cardiogenic shock

[IV heart failure]

IV heart failure

[6-MWT of 620 feet]

6-MWT of 620 feet

[magnetic resonance postcontrast]

magnetic resonance postcontrast

[Soluble concentrations ST2]

Soluble concentrations ST2

[2-fold risk of death]

2-fold risk of death

[determination of therapeutic options]

determination of therapeutic options

[grade 4 holosystolic murmur]

grade 4 holosystolic murmur

[new severe AI]

new severe AI

[6 wk of treatment]

6 wk of treatment

[79.9 years in 2011]

79.9 years in 2011

[invasive hemodynamic assessments]

invasive hemodynamic assessments

[ventricular longitudinal strain]

ventricular longitudinal strain

[2 highest DRS deciles]

2 highest DRS deciles

[200 minutes of exercise]

200 minutes of exercise

[such functional MS]

such functional MS

[changes in body composition]

changes in body composition

[heart failure HF therapy]

heart failure HF therapy

[CRT hazard ratio]

CRT hazard ratio

[particularly poor prognosis]

particularly poor prognosis

[treatment of CHF]

treatment of CHF

[effect of CRT]

effect of CRT

[Patients with high sST2]

Patients with high sST2

[recent onset HFrEF]

recent onset HFrEF

[3 clinical trials]

3 clinical trials

[Australian reference data]

Australian reference data

[pathophysiology of chronic HF]

pathophysiology of chronic HF

[patients with hypertensive HFPEF]

patients with hypertensive HFPEF

[incidence of pump dysfunction]

incidence of pump dysfunction

[including 3 normal samples]

including 3 normal samples

[index ED visit]

index ED visit

[≤75 years HR]

≤75 years HR

[Overall ATP production rates]

Overall ATP production rates

[endothelial-protective effects via stimulation]

endothelial-protective effects via stimulation

[Organisation of Care Taxonomy]

Organisation of Care Taxonomy

[hand-searching relevant articles]

hand-searching relevant articles

[Danish Registry on Dialysis]

Danish Registry on Dialysis

[nonmitochondrial protein changes]

nonmitochondrial protein changes

[atrial area cm]

atrial area cm

[choice of chelation regimens]

choice of chelation regimens

[relationship between physician volume]

relationship between physician volume

[idiopathic dilated cardiomyopathy]

idiopathic dilated cardiomyopathy

[cardiovascular disease CVD]

cardiovascular disease CVD

[unilateral renal DNx]

unilateral renal DNx

[documentation of contextual reasons]

documentation of contextual reasons

[further heart failure research]

further heart failure research

[developing heart failure]

developing heart failure

[low 50 mg]

low 50 mg

[incidence of attributable]

incidence of attributable

[pathogenesis of heart failure]

pathogenesis of heart failure

[measures of functional capacity]

measures of functional capacity

[percutaneous coronary intervention HR]

percutaneous coronary intervention HR

[increase in rehospitalization]

increase in rehospitalization

[continuous wave Doppler echocardiography]

continuous wave Doppler echocardiography

[lack of Canadian data]

lack of Canadian data

[Diet score components]

Diet score components

[improvement in capacity]

improvement in capacity, improvements in capacity

[single-arm prospective multicenter study]

single-arm prospective multicenter study

[normalizing Mena levels]

normalizing Mena levels

[primary oscillations originating]

primary oscillations originating

[Swedish National Inpatient Registry]

Swedish National Inpatient Registry

[Patients with HFPEF n=100]

Patients with HFPEF n=100

[stage I-III breast cancer]

stage I-III breast cancer

[heart failure clinic outpatients]

heart failure clinic outpatients

[reduction in blood pressure]

reduction in blood pressure

[understanding of this topic]

understanding of this topic

[ejection fraction HFrEF]

ejection fraction HFrEF

[velocity of circumferential shortening]

velocity of circumferential shortening

[Results from the Resynchronization-Defibrillation]

Results from the Resynchronization-Defibrillation

[Thirty-day all-cause readmissions]

Thirty-day all-cause readmissions

[limited number of patients]

limited number of patients

[402 patients 48]

402 patients 48

[next generation NT-proBNP assay]

next generation NT-proBNP assay

[arguments for beta-blocker hypo-response]

arguments for beta-blocker hypo-response

[outcomes for adults]

outcomes for adults

[emergency cardiac catheterization]

emergency cardiac catheterization

[exercise training on HRQoL]

exercise training on HRQoL

[treatment heart failure]

treatment heart failure

[2331 patients with HF]

2331 patients with HF

[actin cytoskeleton pathways]

actin cytoskeleton pathways

[min without bolus]

min without bolus

[coronary artery calcium scores]

coronary artery calcium scores

[patients with artery disease]

patients with artery disease

[proportion of eligible patients]

proportion of eligible patients

[phenotype of pathological hypertrophy]

phenotype of pathological hypertrophy

[attenuating cardiac remodeling]

attenuating cardiac remodeling

[Secondary outcome measures related]

Secondary outcome measures related

[greater antecedent weight loss]

greater antecedent weight loss

[such as venous thromboembolism]

such as venous thromboembolism

[Ambient air pollution]

Ambient air pollution

[L-type channel-dependent processes]

L-type channel-dependent processes

[once at heart failure]

once at heart failure

[impact of implementation strategies]

impact of implementation strategies

[risk for adverse outcomes]

risk for adverse outcomes

[ANG II infusion AT]

ANG II infusion AT

[Further molecular analysis]

Further molecular analysis

[ischemic cerebrovascular events]

ischemic cerebrovascular events

[intraclass correlation coefficient ICC]

intraclass correlation coefficient ICC

[greatest difference among EF]

greatest difference among EF

[hazard ratio HR 1.41]

hazard ratio HR 1.41

[serum resistin levels]

serum resistin levels

[transcription factor Hand2]

transcription factor Hand2

[Data supporting iron use]

Data supporting iron use

[Aldosterone a neurohormone]

Aldosterone a neurohormone

[β-Adrenergic receptor blockade]

β-Adrenergic receptor blockade

[Hg β coefficient]

Hg β coefficient

[glomerular filtration rate ml]

glomerular filtration rate ml

[concomitant downregulation of Na]

concomitant downregulation of Na

[Complete coronary occlusion]

Complete coronary occlusion

[novel mouse HF model]

novel mouse HF model

[population-based Rotterdam Study]

population-based Rotterdam Study

[performance of this LVAS]

performance of this LVAS

[congestive heart failure phenotypes]

congestive heart failure phenotypes

[LVEF hazard ratio HR]

LVEF hazard ratio HR

[unintentional weight loss]

unintentional weight loss

[odds of CHF]

odds of CHF

[few TUNEL-positive cells]

few TUNEL-positive cells

[therefore of significant value]

therefore of significant value

[mortality in women]

mortality in women

[right atrial pressure]

right atrial pressure

[change in distribution]

change in distribution

[Peak oxygen consumption VO2max]

Peak oxygen consumption VO2max

[instituting mechanical circulatory support]

instituting mechanical circulatory support

[proteome of HDL particles]

proteome of HDL particles

[past 3 decades]

past 3 decades

[congestive heart failure patients]

congestive heart failure patients

[accounting for hospital clustering]

accounting for hospital clustering

[peripheral arterial disease]

peripheral arterial disease

[benefits of exercise]

benefits of exercise

[right ventricle RV]

right ventricle RV

[optimal medical management]

optimal medical management

[data safety monitoring board]

data safety monitoring board

[kappa coefficients from .49]

kappa coefficients from .49

[Regular physical activity controls]

Regular physical activity controls

[left ventricular pressure]

left ventricular pressure

[Catheter ablation for AF]

Catheter ablation for AF

[abnormal liver texture changes]

abnormal liver texture changes

[heart failure. miRNAs]

heart failure. miRNAs

[4 ischemic samples]

4 ischemic samples

[many acute HF trials]

many acute HF trials

[January 2000 2009]

January 2000 2009

[post-TAC cardiac functional deterioration]

post-TAC cardiac functional deterioration

[urinary tract infection UTI]

urinary tract infection UTI

[30-day risk-standardized mortality]

30-day risk-standardized mortality

[Morpholino-based knockdown of nucleolin]

Morpholino-based knockdown of nucleolin

[review of this drug]

review of this drug

[appropriate out-patient follow-up]

appropriate out-patient follow-up

[future high performers]

future high performers

[College of Physicians]

College of Physicians

[adult mouse ventricular myocytes]

adult mouse ventricular myocytes

[Acute care surgery]

Acute care surgery, acute care surgery

[especially in elderly people]

especially in elderly people

[ventricular ejection time LVET]

ventricular ejection time LVET

[Fontan adults versus controls]

Fontan adults versus controls

[vivo RV length-force relationship]

vivo RV length-force relationship

[Canadian special access programme]

Canadian special access programme

[identifying superior hospitals]

identifying superior hospitals

[Higher baseline CRF]

Higher baseline CRF

[projecting long-term costs]

projecting long-term costs

[benefit of RAS uptitration]

benefit of RAS uptitration

[involving young adults]

involving young adults

[Muscle aerobic capacity]

Muscle aerobic capacity

[mutant mice overexpressing Hand2]

mutant mice overexpressing Hand2

[higher hemoglobin levels]

higher hemoglobin levels

[improvements in the distance]

improvements in the distance

[large-scale clinical trial]

large-scale clinical trial

[MADIT-CRT With study]

MADIT-CRT With study

[embryonic gene programs]

embryonic gene programs

[LVET between admission measurement]

LVET between admission measurement

[Recent postmarketing trials]

Recent postmarketing trials

[patients in atrial fibrillation]

patients in atrial fibrillation

[late-onset 8 days]

late-onset 8 days

[proximal circumflex artery LCX]

proximal circumflex artery LCX

[Morbidity in HFpEF]

Morbidity in HFpEF

[depressive symptoms Beck]

depressive symptoms Beck

[various cardiovascular diseases]

various cardiovascular diseases

[higher BB doses]

higher BB doses

[heart failure development]

heart failure development

[Skeletal muscle mass]

Skeletal muscle mass

[length of follow-up]

length of follow-up

[Twenty weeks of diet]

Twenty weeks of diet

[acute heart failure trials]

acute heart failure trials

[base of treatment]

base of treatment

[prevalence of systolic HF]

prevalence of systolic HF

[intramuscular testosterone supplementation]

intramuscular testosterone supplementation

[HR 1.58 CI 1.27]

HR 1.58 CI 1.27

[Clinical signs of HF]

Clinical signs of HF

[Depression Scale score]

Depression Scale score

[relationship between the intervention]

relationship between the intervention

[improvement of hemodynamic perturbations]

improvement of hemodynamic perturbations

[function in heart failure]

function in heart failure

[ventricular wall stress]

ventricular wall stress

[interval from transplantation]

interval from transplantation

[improvement in one domains]

improvement in one domains

[patients with reduction]

patients with reduction, patients with reductions

[basis of these data]

basis of these data

[subsequent heart failure HF]

subsequent heart failure HF

[mortality in survivors]

mortality in survivors

[differences in baseline characteristics]

differences in baseline characteristics

[impact of evidence-based management]

impact of evidence-based management

[1 Dacron patch closure]

1 Dacron patch closure

[such opposing responses]

such opposing responses

[prospective open-label crossover study]

prospective open-label crossover study

[systemic vascular resistance]

systemic vascular resistance

[Exercise TraiNing HF-ACTION]

Exercise TraiNing HF-ACTION, Exercise Training HF-ACTION

[HF hospitalization HR]

HF hospitalization HR

[concentric hypertrophy CH]

concentric hypertrophy CH

[cardiac sympathetic activity (123)I-meta-iodobenzylguanidine]

cardiac sympathetic activity (123)I-meta-iodobenzylguanidine

[NYHA functional class ranking]

NYHA functional class ranking

[SkM skeletal muscle structure]

SkM skeletal muscle structure

[history of atrial fibrillation]

history of atrial fibrillation

[6-minute walk test]

6-minute walk test

[eight healthy age-matched controls]

eight healthy age-matched controls

[Acute right heart failure]

Acute right heart failure, acute right heart failure

[clinical models alone]

clinical models alone

[substantial proportion of patients]

substantial proportion of patients

[heart failure atherosclerosis risk]

heart failure atherosclerosis risk

[effects of FES]

effects of FES

[significantly more hypertension]

significantly more hypertension

[centrifugal-flow chronic LVAS]

centrifugal-flow chronic LVAS

[ejection fraction HFpEF]

ejection fraction HFpEF

[more careful management]

more careful management

[age-specific low CRF categories]

age-specific low CRF categories

[less clinical benefit]

less clinical benefit

[median baseline ST2 level]

median baseline ST2 level

[basis for these differences]

basis for these differences

[dogs with HF]

dogs with HF

[important therapeutic implications]

important therapeutic implications

[renal chloride channel]

renal chloride channel

[neutral endopeptidase inhibitors]

neutral endopeptidase inhibitors

[use of bisoprolol]

use of bisoprolol

[21 beagle dogs]

21 beagle dogs

[SR Ca 2+)-pump function]

SR Ca 2+)-pump function

[using a different metric]

using a different metric

[great number of studies]

great number of studies

[diabetes mellitus at baseline]

diabetes mellitus at baseline

[middle-aged recreational athletes]

middle-aged recreational athletes

[reduction in risk]

reduction in risk

[Myocardial titin hypophosphorylation]

Myocardial titin hypophosphorylation

[ischemic mitral regurgitation MR]

ischemic mitral regurgitation MR

[development of ischemic events]

development of ischemic events

[twice a day]

twice a day

[degenerative mitral regurgitation]

degenerative mitral regurgitation

[eligibility for heart transplantation]

eligibility for heart transplantation

[10.7 nmol 309 ng]

10.7 nmol 309 ng

[intrinsic ventricular dysfunction]

intrinsic ventricular dysfunction

[investigation for the development]

investigation for the development

[cognitive impairment at hospitalization]

cognitive impairment at hospitalization

[malfunctioning HeartMate II LVADs]

malfunctioning HeartMate II LVADs

[care transfer policy]

care transfer policy

[increases in all]

increases in all

[clinical deterioration of HFPEF]

clinical deterioration of HFPEF

[cardiac sympathovagal balance]

cardiac sympathovagal balance

[several key genes related]

several key genes related

[22 HVAD devices]

22 HVAD devices

[ventilatory efficiency slope]

ventilatory efficiency slope

[affecting basal contractility]

affecting basal contractility

[haematopoietic cell transplantation]

haematopoietic cell transplantation, Haematopoietic cell transplantation

[4-year survival rates]

4-year survival rates

[biomarker-guided clinical trial design]

biomarker-guided clinical trial design

[objective of the measure]

objective of the measure

[Cardiac symptoms in children]

Cardiac symptoms in children

[increasing body of evidence]

increasing body of evidence

[testing of cardiac biomarkers]

testing of cardiac biomarkers

[mm]

mm

[Exercise]

Exercise

[addition]

addition

[regression]

regression, Regression

[practice]

practice, practices, Practice

[efficacy]

efficacy, Efficacy

[fibrillation]

fibrillation

[subject]

subjects, Subjects, subject

[resynchronization]

resynchronization, REsynchronization, Resynchronization

[peptide]

peptide, peptides

[race]

race

[energy metabolism]

energy metabolism

[valve opening]

valve opening

[relationship]

Relationship, relationship, relationships, Relationships

[diastolic velocity]

diastolic velocity

[coronary syndrome]

coronary syndrome, coronary syndromes

[ring annuloplasty]

ring annuloplasty

[mild reduction]

mild reductions, mild reduction

[early velocity]

early velocity

[study end]

study end

[cutoff value]

cutoff value

[signaling]

signaling, signalling, signal

[protective effects]

Protective effects, protective effects

[QRS]

QRS

[PASP increase]

PASP increase

[common form]

common forms, common form

[strategy]

strategy, strategies

[left function]

left function

[annular velocity]

annular velocity

[optimal treatment]

optimal treatment

[therapeutic approach]

therapeutic approaches, therapeutic approach

[testosterone status]

testosterone status

[SR Ca]

SR Ca

[valve replacement]

valve replacement

[urine volume]

urine volume

[HeartMate LVAD]

HeartMate LVAD

[DESIGN]

DESIGN, design

[standard error]

standard error

[QRS complex]

QRS complex

[mitral velocity]

mitral velocity

[cardiomyopathy]

cardiomyopathy, Cardiomyopathy

[type]

types, type, Type

[volume]

volume, volumes

[trend]

trends, trend, Trends

[LVEF]

LVEF

[failure]

failure, Failure

[odds]

odds, Odds

[activity]

activity, activities

[SD]

SD

[AF]

AF

[York]

York

[cost]

costs, cost

[spironolactone]

spironolactone

[medication]

medication, Medication, medications

[E]

E

[cardiomyocyte]

cardiomyocytes, cardiomyocyte

[reason]

reasons, Reasons, reason

[complication]

complications, Complications, complication

[ventricle]

ventricle, ventricles

[mg]

mg

[assessment]

assessments, assessment

[T1]

t1, T1

[channel]

channel, channels

[period]

period, periods

[woman]

Women, women, woman

[hyperkalemia]

hyperkalemia

[Health]

Health

[score]

score, scores

[muscle]

muscle, muscles, Muscle

[individuals]

individuals, Individuals

[capacity]

capacity

[HDL]

HDL

[Data]

Data, DATA

[number]

numbers, number

[ED]

ED, EDs

[frailty]

Frailty, frailty

[echocardiography]

echocardiography, Echocardiography

[guideline]

guidelines, guideline

[research]

research, Research, RESEARCH

[performance]

performance, Performance

[RAS]

RAS

[resistin]

resistin, Resistin

[plasma]

plasma, Plasma

[ST2]

ST2

[recommendation]

recommendations, Recommendation, recommendation, Recommendations

[value]

value, Values, values

[drug]

drug, drugs, Drugs, Drug

[transplant]

transplant, transplants

[BNP]

BNP

[class]

class

[interaction]

Interaction, interaction, interactions

[status]

status, Status

[level]

level, levels

[kidney]

kidney

[MR]

MR

[cardioverter-defibrillator]

cardioverter-defibrillator

[measurement]

measurements, measurement, Measurement, MEASUREMENTS

[anemia]

anemia, Anemia

[subgroup]

subgroups, subgroup

[emergency]

emergency, Emergency

[evaluation]

Evaluation, evaluations, evaluation

[approach]

approaches, approach

[morbidity]

morbidity, Morbidity

[stress]

stress, Stress

[insulin]

insulin, Insulin

[BNP]

BNP

[angiotensin]

angiotensin

[condition]

conditions, condition

[discharge]

discharge

[incidence]

incidence, Incidence

[filling]

filling

[decrease]

decrease, decreases

[expression]

expression

[enzyme]

enzyme, enzymes

[encouraging declines in the incidence]

encouraging declines in the incidence

[potential candidates]

potential candidates

[Hgb level]

Hgb level

[diagnostic testing]

diagnostic testing

[clinical tool]

clinical tool

[two distinct populations of patients]

two distinct populations of patients

[less comorbidities]

less comorbidities

[Patient Safety Monitoring System MPSMS]

Patient Safety Monitoring System MPSMS

[post-LVAD AI with valve oversewing]

post-LVAD AI with valve oversewing

[etiologic causes of RV failure]

etiologic causes of RV failure

[patients with peripheral artery disease]

patients with peripheral artery disease

[hazard ratio for the outcome]

hazard ratio for the outcome

[Composite quality]

Composite quality, composite quality

[continuous relationship between broader QRS]

continuous relationship between broader QRS

[high risk of hyperkalemia patients]

high risk of hyperkalemia patients

[HDL NYHA-IIIb]

HDL NYHA-IIIb

[renin-angiotensin system blocker beta-blocker therapy]

renin-angiotensin system blocker beta-blocker therapy

[five patients IL 0.5 mg]

five patients IL 0.5 mg

[transthoracic echocardiography]

transthoracic echocardiography

[Rankin Score]

Rankin Score

[predictor of mortality in patients]

Predictors of mortality in patients, predictor of mortality in patients

[maladaptive remodelling]

maladaptive remodelling

[fit men]

fit men

[separate cohort]

separate cohort

[Most patients]

Most patients

[ratio form]

ratio form

[beta-adrenergic responses]

beta-adrenergic responses

[even after multivariable adjustment hazard ratio]

even after multivariable adjustment hazard ratio

[next generation]

next generation

[predictors after cardiac resynchronization therapy]

predictors after cardiac resynchronization therapy

[Determination of risk treatment strategies]

Determination of risk treatment strategies

[area under the curve AUC]

area under the curve AUC

[self-care education]

self-care education

[undergoing left ventricular assist device implantation]

undergoing left ventricular assist device implantation

[exogenous variants]

exogenous variants

[glomerular filtration]

glomerular filtration

[single diagnostic test for HFpEF]

single diagnostic test for HFpEF

[Low skeletal muscle mass r=0.67]

Low skeletal muscle mass r=0.67

[recent trials]

recent trials

[24 h]

24 h

[using exercise testing guide exercise rehabilitation]

using exercise testing guide exercise rehabilitation

[mild anemia]

mild anemia

[patients with normal albumin levels]

patients with normal albumin levels

[flow-mediated dilatation improvement by ET]

flow-mediated dilatation improvement by ET

[rationale of the Early treatment]

rationale of the Early treatment

[better understanding of the mechanism]

better understanding of the mechanism

[T1 changes]

T1 changes

[heart failure in this model]

heart failure in this model

[vivo assessment of cardiac function]

vivo assessment of cardiac function

[awful paradox]

awful paradox

[larger fluctuations in beat-to-beat QT intervals]

larger fluctuations in beat-to-beat QT intervals

[15 mL per 1.73 m 2]

15 mL per 1.73 m 2

[HNorm group]

HNorm group

[baseline ECGs]

baseline ECGs

[interview data]

interview data

[simultaneous reduction in exercise-induced increase]

simultaneous reduction in exercise-induced increase

[ivabradine group]

ivabradine group

[practitioners in office-based emergency room practice]

practitioners in office-based emergency room practice

[atropine infusion]

atropine infusion

[244 m]

244 m

[3.4 years]

3.4 years

[target audience for this guideline]

target audience for this guideline

[sonographic abnormalities]

sonographic abnormalities

[Crude rates of severe hyperkalemia]

Crude rates of severe hyperkalemia

[insulin action]

insulin action

[VEGF inhibition]

VEGF inhibition

[Neurohormonal abnormalities]

Neurohormonal abnormalities

[2-vessel model]

2-vessel model

[coming decades]

coming decades

[cumulative dose of 18 mg]

cumulative dose of 18 mg

[severe anemia]

severe anemia

[subscales relative]

subscales relative

[advanced COPD]

advanced COPD

[first-ever MI]

first-ever MI

[English language]

English language

[SNP rs10927887]

SNP rs10927887

[significant difference in outcome ratings]

significant difference in outcome ratings

[update on exercise parameters for diagnosis]

update on exercise parameters for diagnosis

[final diagnosis of multiple myeloma]

final diagnosis of multiple myeloma

[antiplatelet agents]

antiplatelet agents

[bpm P]

bpm P

[Hemodynamic phenotype of the failing Fontan]

Hemodynamic phenotype of the failing Fontan

[2100 kcal]

2100 kcal

[transplant process]

transplant process

[B-type NP]

B-type NP

[ECCT patients]

ECCT patients

[cardiac comorbidities]

cardiac comorbidities

[real-time HFPSI use VA-RT cohort]

real-time HFPSI use VA-RT cohort

[β-AR responsiveness]

β-AR responsiveness

[implementation issues]

implementation issues

[duration of treadmill exercise testing]

duration of treadmill exercise testing

[users of bisphophonates crude RR]

users of bisphophonates crude RR

[study closure]

study closure

[case report of a patient]

case report of a patient

[patients with HFrEF versus HFpEF]

patients with HFrEF versus HFpEF

[advanced phase]

advanced phase

[fewer depressive symptoms Hospital Anxiety]

fewer depressive symptoms Hospital Anxiety

[139 patients]

139 patients

[30 mm]

30 mm

[sST2]

sST2

[resistin levels with the development]

resistin levels with the development

[resting hemodynamics]

resting hemodynamics

[Chronic HF]

Chronic HF

[treating patients with advanced heart failure]

treating patients with advanced heart failure

[6-month echocardiograms]

6-month echocardiograms

[Incubation of EC with HDL NYHA-IIIb]

Incubation of EC with HDL NYHA-IIIb

[relevant health service provision related]

relevant health service provision related

[fat loss]

fat loss

[combining parameters]

combining parameters

[smoking cessation]

smoking cessation

[older persons]

older persons

[patients irrespective of disease phase]

patients irrespective of disease phase

[mortality risk]

mortality risk

[patients receiving membrane oxygenation membrane support]

patients receiving membrane oxygenation membrane support

[less hyperkalemia]

less hyperkalemia

[therapeutic alternative]

therapeutic alternative

[dogs with coronary microembolization-induced HF]

dogs with coronary microembolization-induced HF

[September 2010]

September 2010

[salt intake]

salt intake

[Akt→forkhead box class O-1 signaling]

Akt→forkhead box class O-1 signaling

[Liver disease in the adults]

Liver disease in the adults

[CHF visit rates as a percentage]

CHF visit rates as a percentage

[virtual cohorts]

virtual cohorts

[physician continuity on death readmission]

physician continuity on death readmission

[Ten-year experience with criteria cardiac transplantation]

Ten-year experience with criteria cardiac transplantation

[Overall ICU mortality median stay]

Overall ICU mortality median stay

[left ventricular longitudinal systolic strain]

left ventricular longitudinal systolic strain

[Internal reliability]

Internal reliability

[sympathovagal balance]

sympathovagal balance

[collagen cross-linking]

collagen cross-linking

[explaining variation in future mortality]

explaining variation in future mortality

[food-frequency questionnaires]

food-frequency questionnaires

[7 kg]

7 kg

[right ventricular ejection fraction R=0.28 P=0.01]

right ventricular ejection fraction R=0.28 P=0.01

[ANG II]

ANG II

[pathological remodelling]

pathological remodelling

[mean duration of biventricular support]

mean duration of biventricular support

[21 days]

21 days

[glucose oxidation]

glucose oxidation

[29 subjects]

29 subjects

[tachypacing-induced HF]

tachypacing-induced HF

[5 minutes]

5 minutes

[stable phenotypes]

stable phenotypes

[promise in a pilot trial]

promise in a pilot trial

[reversible myocardial ischemia open stent]

reversible myocardial ischemia open stent

[direct comparison]

direct comparison

[ED patients]

ED patients

[patient outcomes]

patient outcomes

[Heart failure a disease complex]

Heart failure a disease complex

[normal hearts]

normal hearts

[pharmacologic treatment]

pharmacologic treatment

[9,535 patients]

9,535 patients

[diagnostic approaches]

diagnostic approaches

[ventricular cardiomyocytes]

ventricular cardiomyocytes

[exercise test]

exercise test

[infarct size]

infarct size

[preoperative albumin]

preoperative albumin

[4372 hospitals]

4372 hospitals

[hearts of TTA TgTetMena mice]

hearts of TTA TgTetMena mice

[herbal medicine]

herbal medicine

[left pressure]

left pressure

[KCl-KI treatment]

KCl-KI treatment

[ultimately leading]

ultimately leading

[chronic pulmonary arterial hypertension PAH]

chronic pulmonary arterial hypertension PAH

[renal disease]

renal disease

[older adults with heart failure]

older adults with heart failure

[Self-Care Management]

Self-Care Management

[SkM biopsies]

SkM biopsies

[congestive heart failure in humans]

congestive heart failure in humans

[hemolysis events]

hemolysis events

[304 patients]

304 patients

[Bisphosphonate users]

Bisphosphonate users

[3-month survival]

3-month survival

[90-day survivors]

90-day survivors

[clinical prognostic diastolic dysfunction leading]

clinical prognostic diastolic dysfunction leading

[Study Selection]

Study Selection, STUDY SELECTION

[paediatric cardiac transplants in children]

paediatric cardiac transplants in children

[120 consecutive patients with PAD]

120 consecutive patients with PAD

[improvement in the composite response]

improvement in the composite response

[periprocedural deaths]

periprocedural deaths

[HF-ACTION trial]

HF-ACTION trial

[left ventricular assist device LVAD implantation]

left ventricular assist device LVAD implantation

[diagnostic purposes]

diagnostic purposes

[adults with the Fontan circulation exhibit]

adults with the Fontan circulation exhibit

[patients with pulmonary arterial hypertension]

patients with pulmonary arterial hypertension

[pre-CRT LV end-diastolic dimension index]

pre-CRT LV end-diastolic dimension index

[peak VO2 of 0.28 mL]

peak VO2 of 0.28 mL

[baseline Ea]

baseline Ea

[Impact of heart magnetic resonance imaging]

Impact of heart magnetic resonance imaging

[lower socioeconomic status versus whites]

lower socioeconomic status versus whites

[Early treatment of Atrial fibrillation]

Early treatment of Atrial fibrillation

[conscious dogs with tachypacing-induced HF]

conscious dogs with tachypacing-induced HF

[modern society]

modern society

[Intermediate frailty]

Intermediate frailty

[molecular dysfunction]

molecular dysfunction

[composite response]

composite response

[30-day readmission rate for patients]

30-day readmission rate for patients

[1:1 allocation]

1:1 allocation

[electronic databases]

electronic databases

[recent data]

recent data

[systolic tethering]

systolic tethering

[clinical usefulness]

clinical usefulness

[150,000 population]

150,000 population

[understanding of the role of resistin]

understanding of the role of resistin

[ED]

ED

[median age]

median age

[2950 patients]

2950 patients

[resistive afterload of the heart]

resistive afterload of the heart

[electron microscopy]

electron microscopy

[STS interventions]

STS interventions

[pro-B-type natriuretic peptide a biomarker approach]

pro-B-type natriuretic peptide a biomarker approach

[569 individuals]

569 individuals

[cardiac fibrosis]

cardiac fibrosis

[financial costs]

financial costs

[Psychosocial Factors]

Psychosocial Factors, Psychosocial factors

[ranging from 1 in 50,000]

ranging from 1 in 50,000

[remaining patients]

remaining patients

[New York Heart Association class I]

New York Heart Association class I

[changes in CO. During RVPO]

changes in CO. During RVPO

[prognosis of C 'D HF]

prognosis of C 'D HF

[serious harms]

serious harms

[echocardiographic measures]

echocardiographic measures

[diastole with early transmitral flow]

diastole with early transmitral flow

[Bioinformatic analysis of microarray data]

Bioinformatic analysis of microarray data

[harms such as venous thromboembolism]

harms such as venous thromboembolism

[patients with an eGFR mL]

patients with an eGFR mL

[level of epithelial transition markers]

level of epithelial transition markers

[healthcare staff]

healthcare staff

[28 consultations]

28 consultations

[walk test]

walk test

[control animals]

control animals

[T1 times below the median]

T1 times below the median

[patients with glomerular filtration rate]

patients with glomerular filtration rate

[200 beats]

200 beats

[trastuzumb-related CHF]

trastuzumb-related CHF

[changes in prognosis of a cohort]

changes in prognosis of a cohort

[XO-mediated ROS]

XO-mediated ROS

[Na channel mRNA splice variants]

Na channel mRNA splice variants

[secondary outcome]

secondary outcome, secondary outcomes

[receiving guideline-recommended drugs for heart failure]

receiving guideline-recommended drugs for heart failure

[adjusting for over 20 clinical variables]

adjusting for over 20 clinical variables

[Heart Failure Assessment of Reduction]

Heart Failure Assessment of Reduction

[Eplerenone in Mild Patients Hospitalization]

Eplerenone in Mild Patients Hospitalization

[total cholesterol]

total cholesterol

[Grade evidence]

Grade evidence

[average age]

average age

[health system]

health systems, health system

[patient-level regression]

patient-level regression

[risk avoidance]

risk avoidance

[human monocytes]

human monocytes

[Canadian data]

Canadian data

[annual ED]

annual ED

[67 years]

67 years

[CHF-derived c-Kit]

CHF-derived c-Kit

[systolic volume]

systolic volume

[proteomic remodeling]

proteomic remodeling

[trigger for excitation-contraction EC coupling]

trigger for excitation-contraction EC coupling

[implementation strategies improving physician adherence]

implementation strategies improving physician adherence

[stenting respectively]

stenting respectively

[Implantation With Cardiac Resynchronization Therapy]

Implantation With Cardiac Resynchronization Therapy

[group with particularly high mortality]

group with particularly high mortality

[61.6 mL]

61.6 mL

[CHF n=68]

CHF n=68

[energy expenditure]

energy expenditure

[hemoglobin Hgb with HRQoL changes]

hemoglobin Hgb with HRQoL changes

[common DEGs]

common DEGs

[HF care]

HF care

[same number]

same number

[impact on embryonic gene programs]

impact on embryonic gene programs

[additional benefit in the prediction]

additional benefit in the prediction

[ED use]

ED use

[annulus velocity]

annulus velocities, annulus velocity

[current measurements]

current measurements

[family of acetyl-lysine reader proteins]

family of acetyl-lysine reader proteins

[inflammatory biomarkers]

inflammatory biomarkers

[epigenetic changes in chromatin structure]

epigenetic changes in chromatin structure

[67.2 years]

67.2 years

[LV filling]

LV filling

[predicting survival]

predicting survival

[evaluation of the muscular strength]

evaluation of the muscular strength

[74 years]

74 years

[disease-specific costs]

disease-specific costs

[Patients with end stage heart failure]

Patients with end stage heart failure

[sex-specific model]

sex-specific models, sex-specific model

[clinical deterioration]

clinical deterioration

[large trial]

large trial, large trials

[previous spironolactone use from 2006]

previous spironolactone use from 2006

[inflammation interventions]

inflammation interventions

[preliminary data for key health outcomes]

preliminary data for key health outcomes

[Cα Thr197]

Cα Thr197

[evidence-based medications]

evidence-based medications

[particularly between a large low-risk group]

particularly between a large low-risk group

[major branches]

major branches

[objective of this clinical trial]

objective of this clinical trial

[tissue Doppler]

tissue Doppler

[PD on clinical status hospitalizations]

PD on clinical status hospitalizations

[risk for subsequent heart failure]

risk for subsequent heart failure

[kappa coefficient]

kappa coefficient, kappa coefficients

[Using time-dependent Cox regression analysis]

Using time-dependent Cox regression analysis

[P respectively]

P respectively

[anaerobic threshold]

anaerobic threshold

[cardiac tone]

cardiac tone

[present report]

present report

[intravenous metoprolol]

intravenous metoprolol

[pediatric cohort]

pediatric cohort

[protein content for SR Ca 2+)-pump]

protein content for SR Ca 2+)-pump

[significant alterations in energy metabolism]

significant alterations in energy metabolism

[patients with an filtration rate]

patients with an filtration rate

[Baroreflex sensitivity]

Baroreflex sensitivity

[natural vasodilatory]

natural vasodilatory

[cardiovascular health]

cardiovascular health

[patients with congestive heart failure]

patients with congestive heart failure

[pathological changes]

pathological changes

[rhythm]

Rhythm, rhythm

[IRS1 proteins]

IRS1 proteins

[most countries]

most countries

[118.5 minutes]

118.5 minutes

[pathophysiological origin]

pathophysiological origin

[notable example]

notable example

[impaired function]

impaired function

[changes in platelet-activating factor PAF]

changes in platelet-activating factor PAF

[abnormal Ca]

abnormal Ca

[kidney infection]

kidney infection

[5 years]

5 years

[recent studies]

recent studies

[encoding a decoy VEGF receptor Ad-Flk]

encoding a decoy VEGF receptor Ad-Flk

[Using a quality improvement database]

Using a quality improvement database

[pro-adrenomedullin MR-proADM]

pro-adrenomedullin MR-proADM

[subsequent meta-analyses]

subsequent meta-analyses

[short-term outcomes]

short-term outcomes

[rates of treatment for outpatients]

rates of treatment for outpatients

[outpatient setting]

outpatient setting

[patients in the ECMO group]

patients in the ECMO group

[early research]

early research

[PRINCIPAL FINDINGS]

PRINCIPAL FINDINGS

[50 days]

50 days

[Various measures]

Various measures, various measures

[mitochondrial-targeted antioxidant]

mitochondrial-targeted antioxidant

[well-treated cohort]

well-treated cohort

[40 years]

40 years

[muscle-wasting syndrome]

muscle-wasting syndrome

[ED physicians]

ED physicians

[human models]

human models

[cardiovascular reason]

cardiovascular reason

[patients receiving angiotensin-converting enzyme inhibitors]

patients receiving angiotensin-converting enzyme inhibitors

[two types of heart failure]

two types of heart failure

[Many advances]

Many advances

[pathological remodelling of the heart]

pathological remodelling of the heart

[Kansas City Cardiomyopathy Questionnaire summary]

Kansas City Cardiomyopathy Questionnaire summary

[64.26 years vs 72.83 years]

64.26 years vs 72.83 years

[Results from the 1:1 propensity analyses]

Results from the 1:1 propensity analyses

[coronary disease]

coronary disease

[90 days of the index]

90 days of the index

[VAD group]

VAD group

[sequence-specific binding]

sequence-specific binding

[intubations for congestive heart failure]

intubations for congestive heart failure

[cardiac apoptosis]

cardiac apoptosis

[repolarization lability]

repolarization lability

[large phase]

large phase

[using International Classification of Diseases]

using International Classification of Diseases

[most countries including the States]

most countries including the States

[current study]

current study

[cardiopulmonary exercise testing guide exercise rehabilitation]

cardiopulmonary exercise testing guide exercise rehabilitation

[ED patients with heart failure]

ED patients with heart failure

[clear lesion]

clear lesion

[stable HFPEF]

stable HFPEF

[4.5 cm]

4.5 cm

[EMPHASIS-HF Study]

EMPHASIS-HF Study

[saxagliptin versus pioglitazone for saxagliptin]

saxagliptin versus pioglitazone for saxagliptin

[wild-type Rad]

wild-type Rad

[Using neonatal rat ventricular cardiomyocytes]

Using neonatal rat ventricular cardiomyocytes

[low-volume hospitals]

low-volume hospitals

[gender-matched control]

gender-matched control

[describing trends in HF after MI]

describing trends in HF after MI

[peak quotient]

peak quotient

[originally part of this study]

originally part of this study

[patients with HF with ejection fraction]

patients with HF with ejection fraction

[receiving chemotherapy]

receiving chemotherapy

[examining long-term outcomes with this strategy]

examining long-term outcomes with this strategy

[same period]

same period

[obese older patients with HFPEF]

obese older patients with HFPEF

[outcome assessments]

outcome assessments

[ultimately targeting specific effector molecules]

ultimately targeting specific effector molecules

[liver texture]

liver texture

[noncardiologist physicians]

noncardiologist physicians

[single parameters]

single parameters

[higher expenditures]

higher expenditures

[follow]

follow, following

[individualized assessment]

individualized assessment

[TUG test]

TUG test

[Previous studies investigating HF-related cachexia]

Previous studies investigating HF-related cachexia

[538 proteins]

538 proteins

[4.6 mm]

4.6 mm

[new understanding of the structure]

new understanding of the structure

[open stent]

open stent

[2 years]

2 years

[using CardioPulmonary Exercise Testing CPET guide]

using CardioPulmonary Exercise Testing CPET guide

[end-systolic elastance]

end-systolic elastance

[7.1 years]

7.1 years

[left-to-right interatrial]

left-to-right interatrial

[transplant pool]

transplant pool

[comparing B-treated with drug-untreated failing hearts]

comparing B-treated with drug-untreated failing hearts

[different mechanism]

Different mechanisms, different mechanism

[variation in AMI mortality rates]

variation in AMI mortality rates

[Cardiac-resynchronization therapy]

Cardiac-resynchronization therapy

[VAD support]

VAD support

[association between preoperative renal dysfunction]

association between preoperative renal dysfunction

[beyond meeting]

beyond meeting

[murine myocardium]

murine myocardium

[Systems proteomics of cardiac chromatin]

Systems proteomics of cardiac chromatin

[noncardiovascular drugs in the rate-control group]

noncardiovascular drugs in the rate-control group

[beneficial adaptation]

beneficial adaptation

[ischemic regurgitation]

ischemic regurgitation

[TUNEL method from autopsy samples]

TUNEL method from autopsy samples

[life expectancy]

life expectancy

[catheter-based revascularization]

catheter-based revascularization

[advantage of the period of fibrillation]

advantage of the period of fibrillation

[prevention of HF in LA]

prevention of HF in LA

[Presence of diastolic dysfunction in patients]

Presence of diastolic dysfunction in patients

[Relationships between right ventricular function]

Relationships between right ventricular function

[hypotension however without a need]

hypotension however without a need

[lower gross national income per capita]

lower gross national income per capita

[HFpEF EF≥50]

HFpEF EF≥50

[targeting individuals with congestive heart failure]

targeting individuals with congestive heart failure

[emotional status]

emotional status

[quality-adjusted survival]

quality-adjusted survival

[high-risk patient]

high-risk patient, high-risk patients

[noninvasive assessments including stress echocardiography]

noninvasive assessments including stress echocardiography

[3 electrocardiographers]

3 electrocardiographers

[MT group]

MT group

[patients with coronary heart disease]

patients with coronary heart disease

[Significant progress]

Significant progress

[Residual confounding]

Residual confounding

[similar incidence in VAD groups]

similar incidence in VAD groups

[Investigating Outcomes of Exercise Training HF-ACTION]

Investigating Outcomes of Exercise Training HF-ACTION

[Study Short-Form]

Study Short-Form

[guideline-recommended target doses for beta-blocker therapy]

guideline-recommended target doses for beta-blocker therapy

[blood transfusions]

blood transfusions

[diastolic end]

diastolic end

[third trial]

third trial

[case-fatality rate]

case-fatality rate

[fewer cardiac procedures 146 vs. 238]

fewer cardiac procedures 146 vs. 238

[low BP]

low BP

[Multicenter Defibrillator]

Multicenter Defibrillator

[therapeutic functions]

therapeutic functions

[Cardiovascular events]

Cardiovascular events

[exercise rehabilitation in male patients]

exercise rehabilitation in male patients

[Transoesophageal echocardiography at 1 month]

Transoesophageal echocardiography at 1 month

[Using multivariate logistic regression analysis]

Using multivariate logistic regression analysis

[endothelial repair]

endothelial repair

[left ventricular ejection fraction 0.35]

left ventricular ejection fraction 0.35

[competing priorities]

competing priorities

[Czech Republic]

Czech Republic

[cardiac biomarkers]

cardiac biomarkers

[2 practices]

2 practices

[risk factor for poor outcomes]

risk factor for poor outcomes

[3-min records of surface ECGs]

3-min records of surface ECGs

[unplanned readmission]

unplanned readmission

[2 diabetes]

2 diabetes

[30 percent]

30 percent

[Exercise attendance]

Exercise attendance

[expression mistargeting]

expression mistargeting

[inactive CXL-1051]

inactive CXL-1051

[odds of future July 30-day]

odds of future July 30-day

[6 wk]

6 wk

[Right myxoma]

Right myxoma, right myxoma

[tendency toward E wave ratio]

tendency toward E wave ratio

[UPR effectors]

UPR effectors

[resting HR 70 versus ≥70]

resting HR 70 versus ≥70

[driveline infection]

driveline infection

[Recent evidence]

Recent evidence

[8 weeks]

8 weeks

[measurable benefits]

measurable benefits

[early-onset HF for late-onset HF]

early-onset HF for late-onset HF

[receiving extracorporeal membrane oxygenation membrane support]

receiving extracorporeal membrane oxygenation membrane support

[Preliminary report]

Preliminary report

[2-way ANOVA]

2-way ANOVA

[pulmonary congestion]

pulmonary congestion

[Treatment group effects on HRQoL]

Treatment group effects on HRQoL

[16 mm]

16 mm

[undergoing left assist device implantation]

undergoing left assist device implantation

[having the HF risk factors]

having the HF risk factors

[intestinal barrier]

intestinal barrier

[advanced phase of the disease]

advanced phase of the disease

[mitochondrial respiration]

mitochondrial respiration

[PB cycle]

PB cycle

[first research]

first research

[using the extracellular flux analyzer]

using the extracellular flux analyzer

[angiotensin II receptor blocker use]

angiotensin II receptor blocker use

[Determination of a predictive cutoff value]

Determination of a predictive cutoff value

[10-EO-CFU increase]

10-EO-CFU increase

[receiving metoprolol]

receiving metoprolol

[hemoglobin levels]

hemoglobin levels

[liver-specific IRS1]

liver-specific IRS1

[composite end-point]

composite end-point

[therapy of underlying heart disease]

therapy of underlying heart disease

[ventricular-arterial coupling in hypertensive HFPEF]

ventricular-arterial coupling in hypertensive HFPEF

[Eighty-one percent of 7-day visits]

Eighty-one percent of 7-day visits

[115 centers]

115 centers

[uncontrolled hypertension]

uncontrolled hypertension

[changes in NYHA functional class]

changes in NYHA functional class

[undergoing ventricular assist device implantation]

undergoing ventricular assist device implantation

[current smoking]

current smoking

[Peak Oxygen Consumption in Patients]

Peak Oxygen Consumption in Patients

[2825 participants aged 70 years]

2825 participants aged 70 years

[30 days of ACS consultation]

30 days of ACS consultation

[severe hyperkalemia]

severe hyperkalemia

[chronic HFPEF]

chronic HFPEF

[SkM growth consistent with regeneration]

SkM growth consistent with regeneration

[80 participation]

80 participation

[three days]

three days

[vasopeptidase inhibitors]

vasopeptidase inhibitors

[metabolic exercise]

metabolic exercise

[Two networks]

Two networks

[LV end-diastolic volume LV end-systolic volume]

LV end-diastolic volume LV end-systolic volume

[aggressive medical treatment for HF]

aggressive medical treatment for HF

[severe MR]

severe MR

[cardiac washout]

cardiac washout

[electromechanical delay]

electromechanical delay

[MLHF Questionnaire]

MLHF Questionnaire

[coronary artery bypass grafting CABG]

coronary artery bypass grafting CABG

[cost-effectiveness of disease management programs]

cost-effectiveness of disease management programs

[multiple cardiac genes in HF]

multiple cardiac genes in HF

[general anaesthesia]

general anaesthesia

[remaining in extreme deciles of agreement]

remaining in extreme deciles of agreement

[global longitudinal strain of left ventricle]

global longitudinal strain of left ventricle

[PERK activation]

PERK activation

[further validation in larger studies]

further validation in larger studies

[4.6 years]

4.6 years

[HF risk prediction Atherosclerosis Risk]

HF risk prediction Atherosclerosis Risk

[post-translational modification of PKA subunits]

post-translational modification of PKA subunits

[sex differences in BNP values]

sex differences in BNP values

[diuretic HF]

diuretic HF

[absolute risk of heart failure]

absolute risk of heart failure

[little impact on gross morphological development]

little impact on gross morphological development

[Joanna Briggs Institute Evidence Practice]

Joanna Briggs Institute Evidence Practice

[First-in-class angiotensin receptor neprilysin inhibitor]

First-in-class angiotensin receptor neprilysin inhibitor

[temporal incidence]

temporal incidence

[long-term prognosis]

long-term prognosis

[additional risk]

additional risk

[beta-blocker therapy in chronic heart failure]

beta-blocker therapy in chronic heart failure

[haemodynamic abnormalities]

haemodynamic abnormalities

[technical advisors]

technical advisors

[restoration of high-density lipoprotein functional properties]

restoration of high-density lipoprotein functional properties

[inhibition of apoptotic signaling pathway]

inhibition of apoptotic signaling pathway

[Catheter-based percutaneous revascularization with angioplasty]

Catheter-based percutaneous revascularization with angioplasty

[miR-25 by a specific antagomir]

miR-25 by a specific antagomir

[1.2 mL]

1.2 mL

[impaired cardiac metabolic gene expression]

impaired cardiac metabolic gene expression

[renin-angiotensin system]

renin-angiotensin system

[Induction of SCN5A variants with AngII]

Induction of SCN5A variants with AngII

[severe AI]

severe AI

[Values of standard error of measurement]

Values of standard error of measurement

[novel heart failure mice model]

novel heart failure mice model

[Rate-control patients]

Rate-control patients

[magnetic resonance postcontrast T1 time]

magnetic resonance postcontrast T1 time

[rheumatoid arthritis]

rheumatoid arthritis

[15-mL decrease]

15-mL decrease

[uptake of Practice Guideline recommendations]

uptake of Practice Guideline recommendations

[patients with type 2 diabetes]

patients with type 2 diabetes

[100 pg low BNP group]

100 pg low BNP group

[cardiovascular morbidity]

cardiovascular morbidity

[study sites]

study sites

[mouse heart failure HF model]

mouse heart failure HF model

[standard practice]

standard practice

[other outcomes]

other outcomes

[71.1 years]

71.1 years

[parasympathetic function]

parasympathetic function

[37 patients in the ECMO group]

37 patients in the ECMO group

[comprehensive echocardiography]

comprehensive echocardiography

[emotional stress]

emotional stress

[Psoriasis patients with predominantly mild disease]

Psoriasis patients with predominantly mild disease

[P .001]

P .001

[cardiac filling]

cardiac filling

[effect on heart rate HR]

effect on heart rate HR

[Similar improvements in shuttle walk test]

Similar improvements in shuttle walk test

[effectiveness of bisoprolol reducing mortality]

effectiveness of bisoprolol reducing mortality

[clinical outcome in patients with HFrEF]

clinical outcome in patients with HFrEF

[scaffold protein]

scaffold protein

[growing population within cardiac rehabilitation]

growing population within cardiac rehabilitation

[patients participating]

patients participating

[LVAD surgery]

LVAD surgery

[59.4 m]

59.4 m

[cardiac insulin-resistance]

cardiac insulin-resistance

[mild reductions in LVEF respectively]

mild reductions in LVEF respectively

[patients with right heart failure]

patients with right heart failure

[particularly in patients with systolic dysfunction]

particularly in patients with systolic dysfunction

[left remodeling in heart failure]

left remodeling in heart failure

[intervention compliance]

intervention compliance

[inverse association]

inverse association

[Ethics Rounds]

Ethics Rounds

[HDL-induced NO production by EC]

HDL-induced NO production by EC

[Southeastern Minnesota residents with HF]

Southeastern Minnesota residents with HF

[National Inpatient]

National Inpatient

[CRF categories]

CRF categories

[evidence gaps]

evidence gaps

[HFVT(-) groups]

HFVT(-) groups

[732 pg]

732 pg

[HFpEF α=0.96]

HFpEF α=0.96

[Ischemic cardiomyopathy]

Ischemic cardiomyopathy

[spontaneous VT]

spontaneous VT

[mitochondrial structure]

mitochondrial structure

[conjoint education]

conjoint education

[literature search in the databases]

literature search in the databases

[cardiac IRS1]

cardiac IRS1

[first week]

first week

[hypertrophic response]

hypertrophic responses, hypertrophic response

[General hospital]

General hospital

[non-fatal stroke]

non-fatal stroke

[contractility of the left ventricle]

contractility of the left ventricle

[66 mL]

66 mL

[Oral glucocorticoids]

Oral glucocorticoids

[pump replacement]

pump replacement

[PERK inhibition]

PERK inhibition

[induction of a fetal gene program]

induction of a fetal gene program

[three variants consistent with reports]

three variants consistent with reports

[FES group]

FES group

[three years]

three years

[sex differences]

sex differences

[additional studies]

additional studies

[means of stress Doppler echocardiography]

means of stress Doppler echocardiography

[male patients with heart failure]

male patients with heart failure

[American Heart Association guidelines on evaluation]

American Heart Association guidelines on evaluation

[haemodynamic stress]

haemodynamic stress

[outcomes in a well-treated cohort]

outcomes in a well-treated cohort

[further examination]

further examination

[such as short-term fractal scaling exponent]

such as short-term fractal scaling exponent

[normal body mass index categories]

normal body mass index categories

[heart muscle]

heart muscle

[right ventricular fractional area change]

right ventricular fractional area change

[important tool in the diagnosis]

important tool in the diagnosis

[71 years]

71 years

[usually the result of congenital lesions]

usually the result of congenital lesions

[population characteristics]

population characteristics

[continuous NRIs]

continuous NRIs

[23.7 ng interquartile range 18.6]

23.7 ng interquartile range 18.6

[aldosterone blockade]

aldosterone blockade

[clinician expertise]

clinician expertise

[molecular pathways]

molecular pathways

[change in the case mix]

change in the case mix

[prognostic assessment]

prognostic assessment

[care outcomes]

care outcomes

[broad panel of noninvasive assessments]

broad panel of noninvasive assessments

[using an arbitrary start date]

using an arbitrary start date

[Results—Retrospective cohort of all adults]

Results—Retrospective cohort of all adults

[inappropriate ATP]

inappropriate ATP

[heart failure with inhospital outcomes]

heart failure with inhospital outcomes

[renin-angiotensin-aldosterone system]

renin-angiotensin-aldosterone systems, renin-angiotensin-aldosterone system

[independent prognostic role in HF]

independent prognostic role in HF

[increase rate]

increase rate

[Campbell Collaboration]

Campbell Collaboration

[patients HDL]

patients HDL

[disease complex with challenging therapeutics]

disease complex with challenging therapeutics

[6-week follow-up]

6-week follow-up

[study period]

study period

[accurate recognition of advanced disease]

accurate recognition of advanced disease

[chronic hypertension]

chronic hypertension

[nontrastuzumab users hazard ratio HR]

nontrastuzumab users hazard ratio HR

[catabolic imbalance]

catabolic imbalance

[limited evidence]

limited evidence

[primary symptom of chronic HFPEF]

primary symptom of chronic HFPEF

[factor analysis]

factor analysis

[events such as pressure ulcers]

events such as pressure ulcers

[effective way]

effective way

[change in 30-day readmission rate]

change in 30-day readmission rate

[number of Raf-MEK1 scaffold proteins]

number of Raf-MEK1 scaffold proteins

[financial incentives]

financial incentives

[I recommendations]

I recommendations

[541 days]

541 days

[ABCD classification]

ABCD classification

[sST2 concentrations]

sST2 concentrations

[T1-mapping technique]

T1-mapping technique

[63 predictors on 257,692 ICD patients]

63 predictors on 257,692 ICD patients

[Current dietary recommendations for patients]

Current dietary recommendations for patients

[symptomatic improvement]

symptomatic improvement

[PDE2-overexpressing cardiomyocytes]

PDE2-overexpressing cardiomyocytes

[QT interval]

QT interval, QT intervals

[11 patients]

11 patients

[patients in the MADIT-CRT study]

patients in the MADIT-CRT study

[50 years]

50 years

[several markers indicative of autonomic balance]

several markers indicative of autonomic balance

[above comparisons]

above comparisons

[targeting epitopes]

targeting epitopes

[new therapeutic targets for HHD]

new therapeutic targets for HHD

[quality measures]

quality measures

[guideline-recommended treatment]

guideline-recommended treatment

[saxagliptin versus sitagliptin for saxagliptin]

saxagliptin versus sitagliptin for saxagliptin

[5 mg]

5 mg

[inhibition of protein kinase A]

inhibition of protein kinase A

[45 practices]

45 practices

[oxygen consumption]

oxygen consumption

[parasympathetic activity]

parasympathetic activity

[BiVP setting for STE analysis]

BiVP setting for STE analysis

[dose-related benefits across all study participants]

dose-related benefits across all study participants

[coprimary outcome]

coprimary outcome

[thigh muscle intermuscular fat ratio]

thigh muscle intermuscular fat ratio

[histological analysis]

histological analysis

[CLINICAL FINDINGS]

CLINICAL FINDINGS

[literature in the English language]

literature in the English language

[high-risk patient with heart failure]

high-risk patient with heart failure

[prognostic meaning]

prognostic meaning

[pump dysfunction requiring pump replacement]

pump dysfunction requiring pump replacement

[subsequent events]

subsequent events

[appropriate timing of patient enrollment]

appropriate timing of patient enrollment

[lack of achievement of metabolism]

lack of achievement of metabolism

[intestinal dysfunction]

intestinal dysfunction

[application in the clinical setting]

application in the clinical setting

[three stages]

three stages

[best quintile]

best quintile

[decreasing albumin levels during LVAD support]

decreasing albumin levels during LVAD support

[matching donors]

matching donors

[evaluating the changes in platelet-activating factor]

evaluating the changes in platelet-activating factor

[progressive improvement]

progressive improvement

[immunoreactive NT-proBNP]

immunoreactive NT-proBNP

[Myxomas in the right atrium]

Myxomas in the right atrium

[ivabradine patients]

ivabradine patients

[Presentation Canadian Cardiovascular Society guidelines]

Presentation Canadian Cardiovascular Society guidelines

[100 participants]

100 participants

[high sensitivity]

high sensitivity

[0.1 unit]

0.1 unit

[nonstandardized N-terminal pro-B-type natriuretic peptide]

nonstandardized N-terminal pro-B-type natriuretic peptide

[using Cytoscape]

using Cytoscape

[implantation of a bottleneck stent]

implantation of a bottleneck stent

[Accumulating evidence]

Accumulating evidence

[leaflet motion]

leaflet motions, leaflet motion

[Hand2-dependent manner]

Hand2-dependent manner

[better survival]

better survival

[Identifying CAD as a cause]

Identifying CAD as a cause

[concentric hypertrophy]

concentric hypertrophy

[albumin levels during LVAD support]

albumin levels during LVAD support

[Cardiac failure]

Cardiac failure

[ongoing GDMT]

ongoing GDMT

[central region of this molecule]

central region of this molecule

[hemoglobin threshold of 7 g]

hemoglobin threshold of 7 g

[stretch rate]

stretch rate

[HF in patients with PAD]

HF in patients with PAD

[HF readmissions]

HF readmissions

[case of a 57-year-old man]

case of a 57-year-old man

[baseline electrocardiogram]

baseline electrocardiogram

[obese ZSF1 with high-fat diet n=11]

obese ZSF1 with high-fat diet n=11

[potential candidates for cell therapy]

potential candidates for cell therapy

[hemodynamic alterations]

hemodynamic alterations

[143 patients]

143 patients

[new strategies]

new strategies

[pulsatile devices]

pulsatile devices

[redo sternotomy]

redo sternotomy

[peak oxygen uptake with simultaneous reduction]

peak oxygen uptake with simultaneous reduction

[921 patients]

921 patients

[15 mL per 1.73 m]

15 mL per 1.73 m

[Ejection Fraction A Clinical Trial]

Ejection Fraction A Clinical Trial

[porcine model]

porcine model

[617 deaths]

617 deaths

[psoriasis as a time-dependent variable]

psoriasis as a time-dependent variable

[individuals with pre-HCT chest radiation]

individuals with pre-HCT chest radiation

[trastuzumab in the adjuvant setting]

trastuzumab in the adjuvant setting

[62.4 years]

62.4 years

[Preoperative demographics]

Preoperative demographics

[Utilizing voluntary testimonies with participating nurses]

Utilizing voluntary testimonies with participating nurses

[Sham-operated animals]

Sham-operated animals

[cardiovascular system]

cardiovascular system

[operative outcomes]

operative outcomes

[even in the presence of MR]

even in the presence of MR

[contextual factors]

contextual factors

[patients with ischemic cardiomyopathy IC]

patients with ischemic cardiomyopathy IC

[older athletes]

older athletes

[0.5 mg]

0.5 mg

[feasibility of a 12-week program]

feasibility of a 12-week program

[reduction in the primary outcome]

reduction in the primary outcome

[venous pressure]

venous pressure

[Thirty-day rehospitalization]

Thirty-day rehospitalization

[circulating NT-proBNP]

circulating NT-proBNP

[protection from norepinephrine-induced hypertrophic responses]

protection from norepinephrine-induced hypertrophic responses

[echocardiographic substudy]

echocardiographic substudy

[Minnesota Living with Heart Failure Questionnaire]

Minnesota Living with Heart Failure Questionnaire

[8.8±6.3 years]

8.8±6.3 years

[changes in HDL-induced NO production]

changes in HDL-induced NO production

[using MEDLINE]

using MEDLINE

[current knowledge]

current knowledge

[relaxation c]

relaxation c

[heart failure-related hospitalization in patients]

heart failure-related hospitalization in patients

[prognostic value]

prognostic value

[cardiac insulin-resistance by 2 weeks post-AAC]

cardiac insulin-resistance by 2 weeks post-AAC

[prevalence of chronic heart failure]

prevalence of chronic heart failure

[Treatment in patients with heart disease]

Treatment in patients with heart disease

[echocardiographic assessment of myocardial function]

echocardiographic assessment of myocardial function

[baseline HRQoL]

baseline HRQoL

[279 mL]

279 mL

[patients with heart failure prone]

patients with heart failure prone

[RV function on body composition]

RV function on body composition

[implantable cardioverter-defibrillator deactivation at implant]

implantable cardioverter-defibrillator deactivation at implant

[Covariate adjustment]

Covariate adjustment

[volume overload]

volume overload

[diagnosis of myocarditis versus cardiomyopathy]

diagnosis of myocarditis versus cardiomyopathy

[recent trials in acute HF]

recent trials in acute HF

[higher rates of hyperkalemia potassium]

higher rates of hyperkalemia potassium

[improving uptake of class CPG recommendations]

improving uptake of class CPG recommendations

[major development]

major development

[Self-Care Maintenance with limited success]

Self-Care Maintenance with limited success

[therapeutic interruption of neurohormonal systems]

therapeutic interruption of neurohormonal systems

[temporal trends]

temporal trends

[Thirty-day mortality]

Thirty-day mortality

[TUNEL assay]

TUNEL assay

[Hereditary abnormalities of the heart]

Hereditary abnormalities of the heart

[1,080 days]

1,080 days

[Using a cutoff of 8]

Using a cutoff of 8

[Echocardiographic measures]

Echocardiographic measures

[analysis using 2005 2008 performance]

analysis using 2005 2008 performance

[important determinants of long-term survival]

important determinants of long-term survival

[CI for early HF respectively]

CI for early HF respectively

[recommendation for implantable cardioverter-defibrillator deactivation discussions]

recommendation for implantable cardioverter-defibrillator deactivation discussions

[8204 patients]

8204 patients

[clinical recommendations]

clinical recommendations

[Clinical Practice Guideline CPG recommendations]

Clinical Practice Guideline CPG recommendations

[relation with commissioning on completion]

relation with commissioning on completion

[developing certain malignancies including cancer]

developing certain malignancies including cancer

[trastuzumab-treated patients]

trastuzumab-treated patients

[atrial mass]

atrial mass

[main cause of cardiovascular hospitalization]

main cause of cardiovascular hospitalization

[STS HM]

STS HM

[Investigating Outcomes]

Investigating Outcomes

[of remodeling]

of remodeling

[vitro model]

vitro model

[health behaviors]

health behaviors

[early diastolic mitral annulus velocity E]

early diastolic mitral annulus velocity E

[rats possible mechanism of cardioprotection]

rats possible mechanism of cardioprotection

[significant reduction]

significant reductions, significant reduction

[Western society]

Western society

[modest conservation]

modest conservation

[1 study]

1 study

[EF≤ 40]

EF≤ 40

[left ventricular ejection fraction LVEF]

left ventricular ejection fraction LVEF

[high-sensitivity assay]

high-sensitivity assay

[clinical evaluation]

clinical evaluation, clinical evaluations

[Subgroup analysis of patients with hypoalbuminemia]

Subgroup analysis of patients with hypoalbuminemia

[artery bypass]

artery bypass

[physiological significance]

physiological significance

[massive embolism]

massive embolism

[role of readers bromodomain proteins]

role of readers bromodomain proteins

[much work]

much work

[consistent approach extrapolating short-term outcomes]

consistent approach extrapolating short-term outcomes

[subsequent HF]

subsequent HF

[Renal denervation DNx in CHF patients]

Renal denervation DNx in CHF patients

[RECENT FINDINGS]

RECENT FINDINGS

[past decades]

past decades

[year 2008]

year 2008

[HR reduction with beta blockers]

HR reduction with beta blockers

[heart failure hospitalizations in patients]

heart failure hospitalizations in patients

[at-risk patients]

at-risk patients

[insurance status]

insurance status

[serious complications]

serious complications

[post-acute care]

post-acute care

[low-dose BB]

low-dose BB

[Kd for the double mutant]

Kd for the double mutant

[future performers]

future performers

[independent predictors of severe CAD]

independent predictors of severe CAD

[patients in the terminal phase]

patients in the terminal phase

[MI animals]

MI animals

[CC patients]

CC patients

[CHF-INV animals]

CHF-INV animals

[blood work]

blood work

[sST2 measurement]

sST2 measurement

[blood loss]

blood loss

[patients above the median BNP level]

patients above the median BNP level

[levels of various serum factors]

levels of various serum factors

[cardiac arrest]

cardiac arrest

[young adults with heart failure]

young adults with heart failure

[contractile response]

contractile response

[hemodynamic status]

hemodynamic status

[Patients with end-stage heart failure]

Patients with end-stage heart failure

[2 handling]

2 handling

[similar mortality]

similar mortality

[growing needs]

growing needs

[150 events]

150 events

[system major adverse neurological events]

system major adverse neurological events

[ACR metrics]

ACR metrics

[regardless of serum sodium levels]

regardless of serum sodium levels

[underlying hypertension]

underlying hypertension

[DNA accessibility]

DNA accessibility

[using relationships]

using relationships

[myofibre regeneration]

myofibre regeneration

[thromboembolic events in heart failure]

thromboembolic events in heart failure

[biomarkers in chronic heart failure]

biomarkers in chronic heart failure

[legal majority]

legal majority

[heart rate reduction with ivabradine]

heart rate reduction with ivabradine

[non-AA participants]

non-AA participants

[across-the-board improvements]

across-the-board improvements

[309 ng]

309 ng

[administrative databases for all adults]

administrative databases for all adults

[HFPEF]

HFPEF

[8.4 mm]

8.4 mm

[capillary perfusion in B-treated rats]

capillary perfusion in B-treated rats

[even with normal systolic ventricular function]

even with normal systolic ventricular function

[LVAD implantation hazard ratio 0.521]

LVAD implantation hazard ratio 0.521

[breathing control]

breathing control

[reference subjects]

reference subjects

[1483 patients]

1483 patients

[association with outcomes for diseases]

association with outcomes for diseases

[other settings]

other settings

[medication changes]

medication changes

[2 trials]

2 trials

[one mechanism]

one mechanism

[2 complexities]

2 complexities

[3.5 kg]

3.5 kg

[cross talk]

cross talk

[25th-75th percentiles]

25th-75th percentiles

[3 trials of intravenous iron]

3 trials of intravenous iron

[XO inhibition]

XO inhibition

[Two Cox proportional hazards models]

Two Cox proportional hazards models

[Investigating Outcomes of Exercise Training]

Investigating Outcomes of Exercise Training

[multivariable regression]

multivariable regression

[10,420 studies]

10,420 studies

[destination therapy]

destination therapy

[patients with vs without diabetes]

patients with vs without diabetes

[10 transplant]

10 transplant

[Skeletal muscle abnormalities in adults]

Skeletal muscle abnormalities in adults

[30±2 years]

30±2 years

[hazard ratios across high CRF categories]

hazard ratios across high CRF categories

[difference among the three groups]

difference among the three groups

[left bundle branch block pattern]

left bundle branch block pattern

[possible causes of the array]

possible causes of the array

[therapeutic options]

therapeutic options

[CMS metric]

CMS metric

[8-fluo-cAMP binding by wild type]

8-fluo-cAMP binding by wild type

[HFrEF patients]

HFrEF patients

[Baseline eGFR group II P]

Baseline eGFR group II P

[July 2008]

July 2008

[aforementioned parameters]

aforementioned parameters

[cardiac diameters]

cardiac diameters

[fluid retention]

fluid retention

[4 kg]

4 kg

[high-quality work]

high-quality work

[15 minutes]

15 minutes

[mouse heart]

mouse heart, mouse hearts

[LV structure]

LV structure

[partly a result of shortcomings]

partly a result of shortcomings

[0.2 mL]

0.2 mL

[Correlations between the ACR metrics]

Correlations between the ACR metrics

[Median age of the entire cohort]

Median age of the entire cohort

[leading cause of heart failure]

leading cause of heart failure

[requirement for assist device use]

requirement for assist device use

[activation of p38α protein kinase p38]

activation of p38α protein kinase p38

[vagal tone]

vagal tone

[ventricular DD]

ventricular DD

[cellular dysfunction]

cellular dysfunction

[Impact of QRS morphology on outcomes]

Impact of QRS morphology on outcomes

[left ventricular ejection fraction mean difference]

left ventricular ejection fraction mean difference

[dietary recommendations]

dietary recommendations

[first wk]

first wk

[health problem]

health problem

[28 hospitalisations for heart failure]

28 hospitalisations for heart failure

[perhaps the single most important component]

perhaps the single most important component

[STE analysis]

STE analysis

[pressure-overload hypertrophy]

pressure-overload hypertrophy

[state of mitochondrial oxidative stress]

state of mitochondrial oxidative stress

[extending EMD]

extending EMD

[even mild clinical diastolic dysfunction]

even mild clinical diastolic dysfunction

[development of systolic heart failure]

development of systolic heart failure

[treating heart failure in the absence]

treating heart failure in the absence

[left ventricular ejection fraction P]

left ventricular ejection fraction P

[970 participants]

970 participants

[molecular level]

molecular level

[maximal exercise]

maximal exercise

[frailty for heart failure HF]

frailty for heart failure HF

[30 mm Hg low PASP]

30 mm Hg low PASP

[predictive value for heart failure]

predictive value for heart failure

[Seven days]

Seven days

[case-control analysis matching for age]

case-control analysis matching for age

[cardiac murmurs]

cardiac murmurs

[healthy cardiomyocytes]

healthy cardiomyocytes

[relationship between length of stay]

relationship between length of stay

[overview of the sonographic abnormalities]

overview of the sonographic abnormalities

[first hospitalization worsening heart failure]

first hospitalization worsening heart failure

[Healthcare Common Procedure Coding System codes]

Healthcare Common Procedure Coding System codes

[subpulmonary ventricle the Fontan circulation]

subpulmonary ventricle the Fontan circulation

[141 outcomes]

141 outcomes

[kg 2]

kg 2

[540 pg]

540 pg

[risk for stroke CHA₂DS₂VASc score]

risk for stroke CHA₂DS₂VASc score

[successful interventions]

successful interventions

[rates of energy substrate metabolism]

rates of energy substrate metabolism

[having HFpEF]

having HFpEF

[several Medical Outcomes Study Short-Form quality]

several Medical Outcomes Study Short-Form quality

[distance Kansas City Cardiomyopathy Questionnaire]

distance Kansas City Cardiomyopathy Questionnaire

[low PASP]

low PASP, Low PASP

[follow-up with local cardiology services]

follow-up with local cardiology services

[Investigating the role of BETs]

Investigating the role of BETs

[Survival projections]

Survival projections

[Perturbations in skeletal muscle sarcomere structure]

Perturbations in skeletal muscle sarcomere structure

[kg p]

kg p

[trastuzumab-related CHF]

trastuzumab-related CHF

[Centers for Medicare 30-day readmission CMS]

Centers for Medicare 30-day readmission CMS

[post-LVAD AI]

post-LVAD AI

[core laboratory]

core laboratory

[antirheumatic drug]

antirheumatic drug

[Bradycardia indicative of cardiac sympathetic tone]

Bradycardia indicative of cardiac sympathetic tone

[fragments of N-terminal pro-B-type natriuretic peptides]

fragments of N-terminal pro-B-type natriuretic peptides

[possibly diminishing the XO-mediated ROS effects]

possibly diminishing the XO-mediated ROS effects

[inpatient use]

inpatient use

[South Dakota]

South Dakota

[patients with pulmonary hypertension PH]

patients with pulmonary hypertension PH

[of nursing]

of nursing

[ventricular stiffness]

ventricular stiffness

[following ring annuloplasty for ischemic MR]

following ring annuloplasty for ischemic MR

[L-DKO mice]

L-DKO mice

[right ventricle in heart failure]

right ventricle in heart failure

[Patients with York Heart Association class]

Patients with York Heart Association class

[research design]

research design, RESEARCH DESIGN

[risk of fatal arrhythmia events]

risk of fatal arrhythmia events

[existing quality indicators including mortality]

existing quality indicators including mortality

[3.0 years]

3.0 years

[transfusion requirements]

transfusion requirements

[prognostic factor in cardiovascular diseases]

prognostic factor in cardiovascular diseases

[right atrium]

right atrium

[implantation of a assist device]

implantation of a assist device

[Renal Optimization Strategies Evaluation ROSE]

Renal Optimization Strategies Evaluation ROSE

[reversible causes]

reversible causes

[symptoms of heart failure HF]

symptoms of heart failure HF

[quarterly admissions]

quarterly admissions

[Twenty-one RCTs]

Twenty-one RCTs

[16 procedures]

16 procedures

[Beta-blocker dose after 12 months]

Beta-blocker dose after 12 months

[Renal DNx]

Renal DNx

[53 consecutive patients with PH]

53 consecutive patients with PH

[adequacy of health service provision]

adequacy of health service provision

[developing hyperkalemia]

developing hyperkalemia

[enhancing neoangiogenesis in the failing heart]

enhancing neoangiogenesis in the failing heart

[pharmacologic therapies]

pharmacologic therapies

[cost analysis]

cost analysis

[patient categorization in the emergency department]

patient categorization in the emergency department

[measurement of natriuretic peptides NPs]

measurement of natriuretic peptides NPs

[death during the observation period]

death during the observation period

[low activity]

low activity, lower activities

[equitable access]

equitable access

[left ventricular ejection fraction LVEF]

left ventricular ejection fraction LVEF

[AF-free probability]

AF-free probability

[beneficial results]

beneficial results

[overall summary in all subdomains]

overall summary in all subdomains

[resonance imaging]

resonance imaging

[cardiac tissue]

cardiac tissues, cardiac tissue

[murine equivalent of Rad Q66P]

murine equivalent of Rad Q66P

[widespread use]

widespread use

[activation of VEGF signaling pathway]

activation of VEGF signaling pathway

[high BNP levels in patients]

high BNP levels in patients

[same assessors]

same assessors

[compelling improvement after device implantation]

compelling improvement after device implantation

[myocardial tissue]

myocardial tissues, myocardial tissue

[mixed-methods study]

mixed-methods study, Mixed-methods study

[HeartWare Intl]

HeartWare Intl

[hyperkalemia leading]

hyperkalemia leading

[generating variants encoding nonfunctional channels]

generating variants encoding nonfunctional channels

[metric choice for common applications]

metric choice for common applications

[functional decline atrial explant-derived c-Kit]

functional decline atrial explant-derived c-Kit

[cornerstone of heart failure therapy]

cornerstone of heart failure therapy

[concentrating on the pathophysiologic mechanisms]

concentrating on the pathophysiologic mechanisms

[end-diastolic pressure]

end-diastolic pressure

[T1-mapping values]

T1-mapping values

[β-blockers therapy for optimal treatment]

β-blockers therapy for optimal treatment

[Functional electrical stimulation of peripheral muscles]

Functional electrical stimulation of peripheral muscles

[groups 95.2]

groups 95.2

[mediating a negative cross talk]

mediating a negative cross talk

[artery stenosis]

artery stenosis

[central pressure]

central pressure

[calf muscle]

calf muscle

[better outcomes]

better outcomes

[taking advantage of the period]

taking advantage of the period

[post-LVAD AI]

post-LVAD AI

[efficacy outcome]

efficacy outcomes, efficacy outcome

[model using simple experimental procedures]

model using simple experimental procedures

[715 patients]

715 patients

[ANG II]

ANG II

[New Jersey]

New Jersey

[long-term mortality in this population]

long-term mortality in this population

[pump malfunctions]

pump malfunctions

[Data Synthesis]

Data Synthesis

[Concentrations of soluble s ST2]

Concentrations of soluble s ST2

[significant MS]

significant MS

[myocardial events]

myocardial events

[thus leading]

thus leading

[atrial pacing]

atrial pacing

[cardiac disease including heart failure]

cardiac disease including heart failure

[advanced disease]

advanced disease

[BET inhibition]

BET inhibition

[diagnostic test]

diagnostic tests, diagnostic test

[cumulative hazard]

cumulative hazard

[normal albumin concentration ≥3.5 g]

normal albumin concentration ≥3.5 g

[ejection fraction in these women]

ejection fraction in these women

[usual care by antiarrhythmic drugs]

usual care by antiarrhythmic drugs

[Ca handling]

Ca handling

[clinic notes]

clinic notes

[descriptive assessment of these patients]

descriptive assessment of these patients

[vascular effects]

vascular effects

[limited value]

limited value

[using Spearman correlations with differences]

using Spearman correlations with differences

[tidal respiration]

tidal respiration

[class III]

class III

[circulatory support]

circulatory support

[serial evaluation]

serial evaluation

[2005 2008 composite vs. Hospital Compare]

2005 2008 composite vs. Hospital Compare

[HF resources within health systems]

HF resources within health systems

[anthracycline-containing chemotherapy]

anthracycline-containing chemotherapy

[common problem with high mortality]

common problem with high mortality

[risk for acute RV failure]

risk for acute RV failure

[significant improvement in functional capacity]

significant improvement in functional capacity

[systolic dysfunction by 3 weeks]

systolic dysfunction by 3 weeks

[cost-effective participatory population-specific health interventions]

cost-effective participatory population-specific health interventions

[Vascular endothelial growth factor blockade]

Vascular endothelial growth factor blockade

[hypoxia activators of SCN5A mRNA splicing]

hypoxia activators of SCN5A mRNA splicing

[11 studies]

11 studies

[dose-dependent reduction]

dose-dependent reduction

[broader QRS]

broader QRS

[several trials of TNF antagonists]

several trials of TNF antagonists

[current strategies for the treatment]

current strategies for the treatment

[BB therapy]

BB therapy

[hyperkalemia in African Americans AAs]

hyperkalemia in African Americans AAs

[Yorkshire swine]

Yorkshire swine

[echocardiographic evidence of left ventricular dyssynchrony]

echocardiographic evidence of left ventricular dyssynchrony

[diastole e]

diastole e

[all-cause hospitalizations with no difference]

all-cause hospitalizations with no difference

[wall stiffness]

wall stiffness

[mitochondrial dysfunction in doxorubicin-induced heart failure]

mitochondrial dysfunction in doxorubicin-induced heart failure

[significant effect on IE risk]

significant effect on IE risk

[serum resistin levels in women]

serum resistin levels in women

[baseline exercise capacity 4.2 METs]

baseline exercise capacity 4.2 METs

[significant deterioration]

significant deterioration

[multivariable adjustment]

multivariable adjustment

[glomerular filtration rate of 15 mL]

glomerular filtration rate of 15 mL

[HFpEF α=0.96 for overall summary]

HFpEF α=0.96 for overall summary

[careful evaluation]

careful evaluation

[incorporating a rotor with blood-flow paths]

incorporating a rotor with blood-flow paths

[Management of end stage heart failure]

Management of end stage heart failure

[practice guideline]

practice guideline, practice guidelines

[Medicaid Services]

Medicaid Services

[longitudinal study]

longitudinal study

[subject of this brief review]

subject of this brief review

[Cardiac insulin-resistance]

Cardiac insulin-resistance

[Contemporary trends in heart failure]

Contemporary trends in heart failure

[PB in patients with HF]

PB in patients with HF

[Insights From Heart Failure A Trial]

Insights From Heart Failure A Trial

[relative appendicular lean mass index]

relative appendicular lean mass index

[Kaplan-Meier curves for death hospitalization]

Kaplan-Meier curves for death hospitalization

[76 patients]

76 patients

[SCN5A variants]

SCN5A variants

[19.8±10.4 years]

19.8±10.4 years

[physical exhaustion]

physical exhaustion

[cardioverter-defibrillator therapy]

cardioverter-defibrillator therapy

[new HF]

new HF

[Median age]

Median age

[LVAD use]

LVAD use

[mitochondrial damage]

mitochondrial damage

[multivariate Cox proportional hazards regression modeling]

multivariate Cox proportional hazards regression modeling

[57-year-old man]

57-year-old man

[epifluorescence microscopy]

epifluorescence microscopy

[statistical model]

statistical model

[extracorporeal membrane oxygenation on function]

extracorporeal membrane oxygenation on function

[rehospitalization of medicare fee-for-service beneficiaries]

rehospitalization of medicare fee-for-service beneficiaries

[unfavorable outcome]

unfavorable outcome

[surgical ring]

surgical ring

[myocardial DD]

myocardial DD

[mouse model lacking murine resistin]

mouse model lacking murine resistin

[occlusion time]

occlusion time

[uninephrectomy AN]

uninephrectomy AN

[pathological hypertrophy]

pathological hypertrophy

[PDE2 overexpression in healthy cardiomyocytes]

PDE2 overexpression in healthy cardiomyocytes

[congestive symptoms]

congestive symptoms

[heart failure patients with devices]

heart failure patients with devices

[proximal LAD]

proximal LAD

[chronic HF-REF]

chronic HF-REF

[lower TAPSE]

lower TAPSE

[prognosis of patients with CHF]

prognosis of patients with CHF

[aerobic exercise]

aerobic exercise

[cognitive impairment with 6-month mortality]

cognitive impairment with 6-month mortality

[5.5 mmol]

5.5 mmol

[reference lists]

reference lists

[statistical parameters]

statistical parameters

[interactions with exercise training in patients]

interactions with exercise training in patients

[young athletes]

young athletes

[Mitral regurgitation as well as]

Mitral regurgitation as well as

[HR 1.30]

HR 1.30

[HR 1.36]

HR 1.36

[TAPSE longitudinal RV fiber shortening]

TAPSE longitudinal RV fiber shortening

[ischemic right]

ischemic right

[11 years]

11 years

[initial results]

initial results

[Heart rate variability in risk stratification]

Heart rate variability in risk stratification

[myocardial infarction a community study]

myocardial infarction a community study

[bisoprolol B]

bisoprolol B

[cell yield]

cell yield

[sinus rhythm hazard ratio HR]

sinus rhythm hazard ratio HR

[home environment]

home environment

[HR 1.07]

HR 1.07

[duration of mechanical cardiac support]

duration of mechanical cardiac support

[intact hearts in experimental models]

intact hearts in experimental models

[patients with ejection fraction HFpEF]

patients with ejection fraction HFpEF

[examining the major safety measures]

examining the major safety measures

[contractile efficiency]

contractile efficiency

[however an important disease accounting]

however an important disease accounting

[left bundle branch block odds ratio]

left bundle branch block odds ratio

[Gene expression profiling of cardiomyocytes]

Gene expression profiling of cardiomyocytes

[eplerenone in patients with HF-REF]

eplerenone in patients with HF-REF

[Gly16 haplotype of the β2-receptor]

Gly16 haplotype of the β2-receptor

[end-diastolic volume]

end-diastolic volume

[many patients]

many patients

[aberrant reactivation of embryonic gene programs]

aberrant reactivation of embryonic gene programs

[serum]

serum

[Understanding of chronic heart failure HF]

Understanding of chronic heart failure HF

[anthracycline metabolism]

anthracycline metabolism

[newer drugs]

newer drugs, new drugs

[Ser83 phosphorylation]

Ser83 phosphorylation

[6-month period]

6-month period

[bradycardic response]

bradycardic response

[activators of abnormal SCN5A mRNA splicing]

activators of abnormal SCN5A mRNA splicing

[need for strict statistical standards]

need for strict statistical standards

[CS P]

CS P

[Median follow-up]

Median follow-up

[ventricular strain]

ventricular strain

[valve procedure]

valve procedure, valve procedures

[Resynchronization-Defibrillation for Heart Failure Trial]

Resynchronization-Defibrillation for Heart Failure Trial

[echocardiographic outcomes]

echocardiographic outcomes

[Medical Outcomes]

Medical Outcomes

[statistical improvement]

statistical improvement

[Different approaches]

Different approaches

[acute kidney injury during spironolactone use]

acute kidney injury during spironolactone use

[current cardiology]

current cardiology

[biventricular dysfunction]

biventricular dysfunction

[annular size]

annular size

[metoprolol HR]

metoprolol HR

[CRT implantation]

CRT implantation

[Exercise Adherence]

Exercise Adherence

[enhancement of DAPC protein levels]

enhancement of DAPC protein levels

[individual measures]

individual measures

[evaluation of patients with RAS]

evaluation of patients with RAS

[mitochondrial pathways]

mitochondrial pathways

[HF tissue]

HF tissue, HF tissues

[ms respectively]

ms respectively

[30-day death]

30-day death

[heart failure a common disorder]

heart failure a common disorder

[protein kinase A subunit expression]

protein kinase A subunit expression

[75 years]

75 years

[current status]

current status

[follow-up 1385]

follow-up 1385

[previous pacemaker]

previous pacemaker

[LV end-diastolic pressure in 20 weeks]

LV end-diastolic pressure in 20 weeks

[diabetes status]

diabetes status

[baseline HRQoL]

baseline HRQoL

[2.0±3.2 mL increase in VO2max]

2.0±3.2 mL increase in VO2max

[vs kg]

vs kg

[promising biomarker]

promising biomarker, promising biomarkers

[6-month mortality]

6-month mortality

[LVAD support on postoperative survival]

LVAD support on postoperative survival

[≥70 years]

≥70 years

[50 mg]

50 mg

[reports in vivo phosphorylation sites]

reports in vivo phosphorylation sites

[SCHFI v.6.2]

SCHFI v.6.2

[POC technology]

POC technology

[lower mitral E wave ratio]

lower mitral E wave ratio

[cardiac surgery]

cardiac surgery

[Many multisite studies in practice settings]

Many multisite studies in practice settings

[implantation strategies]

implantation strategies

[adjustment for age sex fraction]

adjustment for age sex fraction

[TUG test]

TUG test

[pulse-wave velocity]

pulse-wave velocity

[adenoviral vector]

adenoviral vector

[certain stimuli]

certain stimuli

[1.5 m]

1.5 m

[Witness with sickle cell disease]

Witness with sickle cell disease

[275 patients]

275 patients

[Grade weak recommendation low-quality evidence]

Grade weak recommendation low-quality evidence

[Average hospital rates for HF patients]

Average hospital rates for HF patients

[waist circumference]

waist circumference

[Cox regression with time-varying covariates]

Cox regression with time-varying covariates

[Measuring heart failure care by readmission]

Measuring heart failure care by readmission

[wild-type Rad]

wild-type Rad

[6317 patients]

6317 patients

[changes in the C statistic]

changes in the C statistic

[second HF]

second HF

[additive for peak VO2 joint effect]

additive for peak VO2 joint effect

[Main etiologies of HF in LA]

Main etiologies of HF in LA

[anterior descending]

anterior descending

[experimental procedures]

experimental procedures

[specific antagomir]

specific antagomir

[subcellular alterations]

subcellular alterations

[adult patients with heart disease]

adult patients with heart disease

[promising alternative for this population]

promising alternative for this population

[echo-Doppler cardiography]

echo-Doppler cardiography

[bottleneck shape]

bottleneck shape

[3 trials]

3 trials

[30-day readmission rates using three metrics]

30-day readmission rates using three metrics

[diseased cardiomyocytes]

diseased cardiomyocytes

[plateau phase of action potentials]

plateau phase of action potentials

[sitagliptin for saxagliptin versus pioglitazone]

sitagliptin for saxagliptin versus pioglitazone

[rate-control groups]

rate-control groups, rate-control group

[10,000 pairs of virtual cohorts]

10,000 pairs of virtual cohorts

[prognostic implications]

prognostic implications

[left atrium]

left atrium

[ischemic MR with LV dilatation]

ischemic MR with LV dilatation

[primary mechanism]

primary mechanism

[receptor kinase-2]

receptor kinase-2

[presenting with a most responsible diagnosis]

presenting with a most responsible diagnosis

[safe means improving muscle function]

safe means improving muscle function

[having NYHA class IIIB symptoms]

having NYHA class IIIB symptoms

[International Classification]

International Classification

[statistical significance]

statistical significance

[plasma of heart failure patients]

plasma of heart failure patients

[body composition a prospective study]

body composition a prospective study

[significant morbidity]

significant morbidity

[arterial hypertension]

arterial hypertension

[right ventricle]

right ventricle

[62 years]

62 years

[100 older obese participants mean]

100 older obese participants mean

[cardiac vagal]

cardiac vagal

[≥1 year]

≥1 year

[sham group]

sham group

[statistically significant improvement in outcome ratings]

statistically significant improvement in outcome ratings

[Peritoneal dialysis PD for long-term management]

Peritoneal dialysis PD for long-term management

[lower NO production of EC]

lower NO production of EC

[terminal regions]

terminal regions

[pathophysiologic mechanism]

pathophysiologic mechanisms, pathophysiologic mechanism

[driveline injury]

driveline injury

[sham explants]

sham explants

[coronary intervention]

coronary interventions, coronary intervention

[metabolic abnormalities]

metabolic abnormalities

[settings other than hospital discharge]

settings other than hospital discharge

[Cardiac c-Kit]

Cardiac c-Kit

[4.2 METs vs. 5.7 METs]

4.2 METs vs. 5.7 METs

[vasopressin type 2 receptor antagonist]

vasopressin type 2 receptor antagonist

[prognostic information]

prognostic information

[Chronic Kidney]

Chronic Kidney

[2.1 kg vs 2.5 kg]

2.1 kg vs 2.5 kg

[prescribing guideline-recommended medications with heart failure]

prescribing guideline-recommended medications with heart failure

[Participating in a multihospital study]

Participating in a multihospital study

[AlphaLISA immunoassays]

AlphaLISA immunoassays

[apoptotic cells]

apoptotic cells

[receiver curve]

receiver curve

[behavioural-change interventions in chronic disease]

behavioural-change interventions in chronic disease

[4.4 mm]

4.4 mm

[time-dependent covariates]

time-dependent covariates

[limited data]

limited data

[Intubation rates]

Intubation rates

[aim of the present study]

aim of the present study

[By imaging]

By imaging

[patients A Trial Investigating Outcomes]

patients A Trial Investigating Outcomes

[long-term 4-year survival of patients]

long-term 4-year survival of patients

[atrial pressure]

atrial pressure

[21 patients]

21 patients

[Renin-angiotensin-aldosterone system inhibitors in heart failure]

Renin-angiotensin-aldosterone system inhibitors in heart failure

[basic helix-loop-helix bHLH transcription factor]

basic helix-loop-helix bHLH transcription factor

[inverse correlation]

inverse correlation

[exercise protocol with gas analysis]

exercise protocol with gas analysis

[long axis]

long axis

[Interaction term]

Interaction term, interaction terms

[antibodies targeting nonglycosylated epitopes P]

antibodies targeting nonglycosylated epitopes P

[Treatment of MI animals with metoprolol]

Treatment of MI animals with metoprolol

[Point-of-care systems]

Point-of-care systems

[requiring support]

requiring support

[membrane oxygenation on renal function]

membrane oxygenation on renal function

[novel finding]

novel finding

[Heart Failure Index Version SCHFI]

Heart Failure Index Version SCHFI

[leaflet resection]

leaflet resection

[important comorbidities]

important comorbidities

[HDL-bound malondialdehyde]

HDL-bound malondialdehyde

[crucial problem of current cardiology]

crucial problem of current cardiology

[right function]

right function

[Fourteen electronic databases including MEDLINE]

Fourteen electronic databases including MEDLINE

[Depression Inventory]

Depression Inventory

[HF concurrent with AMI admission]

HF concurrent with AMI admission

[careful evaluation of the surgical indications]

careful evaluation of the surgical indications

[liver disease]

liver disease, Liver disease

[nine pigs]

nine pigs

[multicenter study of exercise training]

multicenter study of exercise training

[individualized approaches]

individualized approaches

[uneventful recovery]

uneventful recovery

[life-threatening anemia]

life-threatening anemia

[only modest effects on heart failure]

only modest effects on heart failure

[transforming growth factor beta-dependent yield]

transforming growth factor beta-dependent yield

[policy recommendations]

policy recommendations

[Combination into an echocardiographic score]

Combination into an echocardiographic score

[CaV1.2 channels]

CaV1.2 channels

[cardiac activity]

cardiac activity

[preceding mechanisms]

preceding mechanisms

[common applications of readmission metrics]

common applications of readmission metrics

[myocardial washout]

myocardial washout

[time death]

time death

[LV ejection fraction of 0.40]

LV ejection fraction of 0.40

[BET family bromodomain proteins BETs]

BET family bromodomain proteins BETs

[higher PSSS]

higher PSSS

[Thirty HFpEF patients aged 69 years]

Thirty HFpEF patients aged 69 years

[online material]

online material

[higher levels of social support]

higher levels of social support

[regional strain]

regional strain

[Major changes]

Major changes

[atrial tachyarrhythmias]

atrial tachyarrhythmias

[cGMP synthesis via oxide donors]

cGMP synthesis via oxide donors

[11 kg in the exercise]

11 kg in the exercise

[readmission quality]

readmission quality

[otherwise healthy heart muscle cells]

otherwise healthy heart muscle cells

[follow-up echocardiograms]

follow-up echocardiograms

[using trichrome blue histologic analysis]

using trichrome blue histologic analysis

[second evaluation]

second evaluation

[Four years]

Four years

[genomic scale]

genomic scale

[Secondary endpoints]

Secondary endpoints

[measurement value of 1.6 seconds]

measurement value of 1.6 seconds

[diuretic effect of natriuretic peptides]

diuretic effect of natriuretic peptides

[end-stage renal disease in outpatients]

end-stage renal disease in outpatients

[pre-participation screening of young athletes]

pre-participation screening of young athletes

[CI 0.018]

CI 0.018

[exercise variables]

exercise variables

[Two hundred ninety-three HF patients HFrEF]

Two hundred ninety-three HF patients HFrEF

[Mass spectrometry]

Mass spectrometry

[cellular metabolism]

cellular metabolism

[February 2009]

February 2009

[2137 patients]

2137 patients

[independent association between spironolactone use]

independent association between spironolactone use

[Pharmacological treatment]

Pharmacological treatment, pharmacological treatment

[809 patients]

809 patients

[eventual resort]

eventual resort

[muscle strength]

muscle strength

[NT-pro BNP]

NT-pro BNP

[percentage points]

percentage points

[regarding the circulating forms of NT-proBNP]

regarding the circulating forms of NT-proBNP

[transgenic mice]

transgenic mice

[X-ray absorptiometry]

X-ray absorptiometry, x-ray absorptiometry

[second-generation sulfonylureas]

second-generation sulfonylureas

[Composite measures of quality for HF]

Composite measures of quality for HF

[other groups]

other groups

[physical therapy]

physical therapy

[mouse HF]

mouse HF

[TissueFAXS technology]

TissueFAXS technology

[less c-Kit]

less c-Kit

[users of bisphosphonates between 1996]

users of bisphosphonates between 1996

[diagnostic evaluations]

diagnostic evaluations

[current status of NP measurement]

current status of NP measurement

[protective peptides]

protective peptides

[health service]

health service

[left ventricular diastolic end diameter]

left ventricular diastolic end diameter

[HR 0.90]

HR 0.90

[HR 0.91]

HR 0.91

[sarcomere shortening]

sarcomere shortening

[90-day mortality]

90-day mortality

[paucity of data examining outcomes]

paucity of data examining outcomes

[HR 0.87]

HR 0.87

[using the Process Redesign contextual framework]

using the Process Redesign contextual framework

[Age dysfunction]

Age dysfunction

[cardiac progenitor]

cardiac progenitor

[beneficial effects of beta-blocker therapy]

beneficial effects of beta-blocker therapy

[hospital characteristics]

hospital characteristics

[thereby altering the gene expression profile]

thereby altering the gene expression profile

[differences in plasma B-type peptide levels]

differences in plasma B-type peptide levels

[Bromodomain inhibition]

Bromodomain inhibition

[56 years]

56 years

[HR 0.51]

HR 0.51

[clinical symptoms]

clinical symptoms

[cardiac gene]

cardiac gene, cardiac genes

[STS HH]

STS HH

[ongoing rhythm]

ongoing rhythm

[Health ABC Short Performance Battery]

Health ABC Short Performance Battery

[addition of low-dose dopamine 2 μg]

addition of low-dose dopamine 2 μg

[Ambulatory Heart Failure Trial RAFT]

Ambulatory Heart Failure Trial RAFT

[using Nursing Outcomes Classification NOC]

using Nursing Outcomes Classification NOC

[severe ischemia]

severe ischemia

[Careful consideration]

Careful consideration

[HNorm subjects]

HNorm subjects

[clinical implications]

clinical implications

[longitudinal analysis using medicare data]

longitudinal analysis using medicare data

[Mechanical dyssynchrony]

Mechanical dyssynchrony

[absolute change]

absolute change

[indeterminable threshold in heart failure]

indeterminable threshold in heart failure

[Comparison of predictors of hospitalization]

Comparison of predictors of hospitalization

[inclusion criteria]

inclusion criteria

[sST2 concentrations]

sST2 concentrations

[antibodies targeting the extreme N termini]

antibodies targeting the extreme N termini

[effective target in the treatment]

effective target in the treatment

[Heterogenous improvement in ejection fraction]

Heterogenous improvement in ejection fraction

[rat model]

rat model

[Cardiorespiratory fitness]

Cardiorespiratory fitness, cardiorespiratory fitness

[improvement in the VAD group]

improvement in the VAD group, Improvement in the VAD group

[peritoneal dialysis]

peritoneal dialysis, Peritoneal dialysis

[polytetrafluoroethylene tube]

polytetrafluoroethylene tube

[renal DNx]

renal DNx

[four groups]

four groups, Four groups

[underlying pathophysiology of heart failure]

underlying pathophysiology of heart failure

[multivariable analysis]

multivariable analysis

[Connecticut Health Center 398 patients]

Connecticut Health Center 398 patients

[postoperative survival]

postoperative survival

[left atrial area hazard ratio]

left atrial area hazard ratio

[higher risk of 30-day death]

higher risk of 30-day death

[congestive HF]

congestive HF

[41-year-old man with cardiac arrest]

41-year-old man with cardiac arrest

[better-than-usual support]

better-than-usual support

[major parameter]

major parameter

[median BNP in women vs men]

median BNP in women vs men

[cardiac hypertrophy in TTA animals]

cardiac hypertrophy in TTA animals

[224 men mean 65±12 years]

224 men mean 65±12 years

[antiarrhythmic medication]

antiarrhythmic medication

[5 patients as control without exercise]

5 patients as control without exercise

[toxicity on systemic blood pressure]

toxicity on systemic blood pressure

[30-day mortality]

30-day mortality

[higher mortality than several cancers]

higher mortality than several cancers

[originating from the central pattern generator]

originating from the central pattern generator

[active individuals]

active individuals

[Baseline follow-up levels of PAF]

Baseline follow-up levels of PAF

[MI-induced decreases in septum systolic thickness]

MI-induced decreases in septum systolic thickness

[using cardiac magnetic resonance T1 mapping]

using cardiac magnetic resonance T1 mapping

[survivors of childhood malignant disease]

survivors of childhood malignant disease

[time-dependent variable]

time-dependent variable

[performance measurement]

performance measurement

[internal consistency]

internal consistency

[right artery]

right artery

[pathological cardiac gene expression programme]

pathological cardiac gene expression programme

[resynchronization therapy with a defibrillator]

resynchronization therapy with a defibrillator

[average length of stay 37]

average length of stay 37

[fundamental definitions of the distinctive components]

fundamental definitions of the distinctive components

[older counterparts]

older counterparts

[Candesartan in Heart Failure Assessment]

Candesartan in Heart Failure Assessment

[outcomes among patients with HF]

outcomes among patients with HF

[antiplatelet drugs]

antiplatelet drugs

[Most data]

Most data

[log-rank testing]

log-rank testing

[Self-Care Confidence]

Self-Care Confidence

[nursing actions]

nursing actions

[pulmonary embolectomy]

pulmonary embolectomy

[50 mmol]

50 mmol

[LV systolic indices LV ejection fraction]

LV systolic indices LV ejection fraction

[Besides targets]

Besides targets

[primary outcome hospitalization for HF]

primary outcome hospitalization for HF

[regression line]

regression line

[need of cardiopulmonary resuscitation CPR]

need of cardiopulmonary resuscitation CPR

[only after 4 weeks of pacing]

only after 4 weeks of pacing

[relative importance for myocardial DD]

relative importance for myocardial DD

[clinical studies]

clinical studies

[9868 participants without prevalent HF]

9868 participants without prevalent HF

[1-year period]

1-year period

[Aldosterone antagonism in heart failure]

Aldosterone antagonism in heart failure

[obese men]

obese men

[transforming growth factor-β TGF-β signaling level]

transforming growth factor-β TGF-β signaling level

[further studies with long-term follow-up]

further studies with long-term follow-up

[patients having HFrEF on diuretics]

patients having HFrEF on diuretics

[7 days of hospital discharge]

7 days of hospital discharge

[S12884 site]

S12884 site

[antiarrhythmic drugs]

antiarrhythmic drugs

[cardiac inflammatory IL6 hsCRP biomarkers]

cardiac inflammatory IL6 hsCRP biomarkers

[even accounting for the cost]

even accounting for the cost

[appropriate timing]

appropriate timing

[0.2 mg]

0.2 mg

[pharmacologic management for acute HF]

pharmacologic management for acute HF

[chronic heart failure in Hungary]

chronic heart failure in Hungary

[overall improvements]

overall improvements, Overall improvements

[cardiomyocyte bioenergetics]

cardiomyocyte bioenergetics

[4 months]

4 months

[autonomic imbalance]

autonomic imbalance

[serum potassium level of mEq]

serum potassium level of mEq

[initial approach]

initial approach

[hearts with levels of Mena]

hearts with levels of Mena

[implantable defibrillator]

implantable defibrillator

[participants with acute heart failure]

participants with acute heart failure

[multiple domains]

multiple domains

[36 patients]

36 patients

[Treatment algorithms]

Treatment algorithms

[Improving outcomes in patients with fibrillation]

Improving outcomes in patients with fibrillation

[S3991 site]

S3991 site

[health benefits]

health benefits

[Twenty-seven studies with 1887 patients]

Twenty-seven studies with 1887 patients

[HFpEF patients]

HFpEF patients

[CRT group]

CRT group

[selectively potentiating the adaptive response]

selectively potentiating the adaptive response

[1.2±7.7 mL]

1.2±7.7 mL

[Fontan subjects]

Fontan subjects

[high barriers]

high barriers

[proximal LCX later 2-vessel model]

proximal LCX later 2-vessel model

[ascending phase]

ascending phase

[association in the care group]

association in the care group

[β-blockers median]

β-blockers median

[renal DNx]

renal DNx

[qualitative study]

qualitative study

[nutritional abnormalities]

nutritional abnormalities

[Few treatments]

Few treatments

[nurse assessment of cognitive impairment]

nurse assessment of cognitive impairment

[post-transplant morbidity]

post-transplant morbidity

[patients in small retrospective studies]

patients in small retrospective studies

[ivabradine]

ivabradine

[CHF-INV group]

CHF-INV group

[changes in]

changes in

[patients receiving ventricular assist device support]

patients receiving ventricular assist device support

[Four groups of rats Wistar-Kyoto]

Four groups of rats Wistar-Kyoto

[HF progression]

HF progression

[baseline echocardiography]

baseline echocardiography

[effective rate]

effective rate

[cardiac looping]

cardiac looping

[novel approach]

novel approach, novel approaches

[residents of Olmsted County Minnesota]

residents of Olmsted County Minnesota

[Hospital-to-Home a hospital readmission reduction program]

Hospital-to-Home a hospital readmission reduction program

[55 years]

55 years

[special treatment]

special treatment

[potential for success in trials]

potential for success in trials

[interleukin receptor]

interleukin receptor

[7 weeks]

7 weeks

[changing doses of β-blocker BB]

changing doses of β-blocker BB

[functional deficits]

functional deficits

[area under the receiver curve]

area under the receiver curve

[overlapping part of the network]

overlapping part of the network

[fibrosis of heart failure tissue]

fibrosis of heart failure tissue

[Economic Analysis]

Economic Analysis

[Low-strength evidence from 6 trials]

Low-strength evidence from 6 trials

[1.02±0.16 mm]

1.02±0.16 mm

[urgent readmission]

urgent readmission

[Mediterranean diet scores with heart failure]

Mediterranean diet scores with heart failure

[mean age of the patients]

mean age of the patients

[restoring mitochondrial oxidative phosphorylation capacity]

restoring mitochondrial oxidative phosphorylation capacity

[outcomes in chronic heart failure]

outcomes in chronic heart failure

[novel useful mouse HF model]

novel useful mouse HF model

[medicare data]

medicare data, Medicare data

[good results]

good results

[prediction rule for severe CAD]

prediction rule for severe CAD

[simulation results]

simulation results

[potential usefulness]

potential usefulness

[miR-25 expression]

miR-25 expression

[ring annuloplasty for ischemic regurgitation]

ring annuloplasty for ischemic regurgitation

[19.4 months]

19.4 months

[reducing the risk of thromboembolic events]

reducing the risk of thromboembolic events

[dearth of biomarker-guided clinical trials]

dearth of biomarker-guided clinical trials

[BB dose]

BB dose, BB doses

[LAD model]

LAD model

[single-arm study]

single-arm study

[major concerns]

major concerns

[many regions]

many regions

[HR for the TNF antagonists]

HR for the TNF antagonists

[patients with QRS 160 ms]

patients with QRS 160 ms

[low-volume sites]

low-volume sites

[leaflet repair]

leaflet repair

[early measurement of HR variability]

early measurement of HR variability

[ventricular pump]

ventricular pump

[PDE superfamily]

PDE superfamily

[CO. Lack of correlation of indices]

CO. Lack of correlation of indices

[160 ms]

160 ms

[interval 0.290]

interval 0.290

[metoprolol irrespective of β2-adrenergic receptor haplotype]

metoprolol irrespective of β2-adrenergic receptor haplotype

[Centers for Medicare Services CMS]

Centers for Medicare Services CMS

[reduction in LV end-diastolic volume]

reduction in LV end-diastolic volume

[patients with stable heart failure]

patients with stable heart failure, Patients with stable heart failure

[heart failure patients a study]

heart failure patients a study

[30 mL per 1.73 m 2]

30 mL per 1.73 m 2

[titin isoforms]

titin isoforms

[chronic ACF in the rat]

chronic ACF in the rat

[stable CAD]

stable CAD

[92 participants]

92 participants

[divergent etiology]

divergent etiology

[increasing BTES in the exercise group]

increasing BTES in the exercise group

[sST2 values]

sST2 values

[with ICC values ranging from .85]

with ICC values ranging from .85

[ventricular action]

ventricular action

[standard therapy with beta blockade]

standard therapy with beta blockade

[heart failure among older persons]

heart failure among older persons

[frequent comorbidities in heart failure]

frequent comorbidities in heart failure

[respective molecular pathways in patients]

respective molecular pathways in patients

[action potential]

action potentials, action potential

[2.4 years]

2.4 years

[surgical conditions]

surgical conditions

[significant differences in those parameters]

significant differences in those parameters

[prevalence of HF in patients]

prevalence of HF in patients

[Diastolic function]

Diastolic function

[majority of patients with RAS]

majority of patients with RAS

[910 patients]

910 patients

[1-year mortality in 28-day survivors]

1-year mortality in 28-day survivors

[Global proteomics]

Global proteomics

[median left ventricular ejection fraction]

median left ventricular ejection fraction

[beta-blockers on the primary endpoint]

beta-blockers on the primary endpoint

[heart failure mortality in men]

heart failure mortality in men

[lower expenditure]

lower expenditure

[Western blot]

Western blot, Western blots

[functional capacity for CF LVAD patients]

functional capacity for CF LVAD patients

[SurvIval Study in Heart Failure]

SurvIval Study in Heart Failure

[young woman]

young woman

[decreases in heart failure-related mortality period]

decreases in heart failure-related mortality period

[myocardial DD of collagen deposition]

myocardial DD of collagen deposition

[carotid baroreflex activation therapy BAT]

carotid baroreflex activation therapy BAT

[compliance with treatment of heart disease]

compliance with treatment of heart disease

[cardiopulmonary exercise test a quality]

cardiopulmonary exercise test a quality

[vascular endothelial growth factor VEGF]

vascular endothelial growth factor VEGF

[emphasizing the importance of follow-up]

emphasizing the importance of follow-up

[greater benefit from implantable cardioverter defibrillator-CRT]

greater benefit from implantable cardioverter defibrillator-CRT

[ratio Bcl-2]

ratio Bcl-2

[8 min]

8 min

[Western Australia]

Western Australia

[IV HF]

IV HF

[testosterone supplementation]

testosterone supplementation

[23 mm]

23 mm

[hallmark of type 2 diabetes]

hallmark of type 2 diabetes

[increase in low-frequency LF ratio]

increase in low-frequency LF ratio

[8.4 mm Hg Fig 1B]

8.4 mm Hg Fig 1B

[April 2013]

April 2013

[single-institution cohort]

single-institution cohort

[failing myocardium]

failing myocardium

[physician specialty]

physician specialty

[Guidelines-Heart Failure]

Guidelines-Heart Failure

[pulmonary vascular resistance hazard ratio]

pulmonary vascular resistance hazard ratio

[Heart failure in the young]

Heart failure in the young

[conducting studies in this area]

conducting studies in this area

[effect on PB characteristics period]

effect on PB characteristics period

[hospitals in an extreme decile]

hospitals in an extreme decile

[hospital quality]

hospital quality

[Multicenter trial]

Multicenter trial, multicenter trial

[extracorporeal membrane oxygenation on renal function]

extracorporeal membrane oxygenation on renal function

[fewer days]

fewer days

[experienced centers]

experienced centers

[total of 44 674 men]

total of 44 674 men

[upcoming years]

upcoming years

[sympathetic outflow]

sympathetic outflow

[profile of PAF biosynthetic enzymes]

profile of PAF biosynthetic enzymes

[Three trials]

Three trials

[voltage-gated Na]

voltage-gated Na

[high-risk subgroups]

high-risk subgroups

[ejection fraction after myocardial infarction]

ejection fraction after myocardial infarction

[insulin-stimulated rates]

insulin-stimulated rates

[early modern rhythm control therapy]

early modern rhythm control therapy

[cardiac centre]

cardiac centre

[advanced chronic obstructive pulmonary disease]

advanced chronic obstructive pulmonary disease

[Sham-Innervated Sham-INV]

Sham-Innervated Sham-INV

[≥65 years]

≥65 years

[odds ratio of 6.77 P]

odds ratio of 6.77 P

[program infrastructure]

program infrastructure

[β-blockers HR]

β-blockers HR

[Ca 2]

Ca 2

[treadmill testing VO2max maximum oxygen consumption]

treadmill testing VO2max maximum oxygen consumption

[endothelial growth]

endothelial growth

[CRF n=72]

CRF n=72

[study objectives]

study objectives

[worldwide epidemic]

worldwide epidemic

[good model]

good model

[multivariate assessment with the inclusion]

multivariate assessment with the inclusion

[including death heart failure related]

including death heart failure related

[separate sub-sample]

separate sub-sample

[collaboration of professionals from disciplines]

collaboration of professionals from disciplines

[risk of potassium 5.5 mmol]

risk of potassium 5.5 mmol

[3 decades]

3 decades

[opposing actions on adenylyl cyclase]

opposing actions on adenylyl cyclase

[S1PR1 downregulation]

S1PR1 downregulation

[periprocedural complications]

periprocedural complications

[cellular plasticity]

cellular plasticity

[Coronary angiography]

Coronary angiography

[time domain heart rate variability HRV]

time domain heart rate variability HRV

[patient compliance]

patient compliance

[visits with a familiar physician]

visits with a familiar physician

[cAMP hydrolysis]

cAMP hydrolysis

[significant trends in the risk]

significant trends in the risk

[health-related quality-of-life]

health-related quality-of-life

[AMI patient]

AMI patient

[multicenter study]

multicenter study

[downstream signaling]

downstream signaling

[possibly transplantation]

possibly transplantation

[mRNA level for β-myosin heavy chain]

mRNA level for β-myosin heavy chain

[5 m]

5 m

[53±12 years]

53±12 years

[opening without any clear organic lesion]

opening without any clear organic lesion

[30-day rehospitalization]

30-day rehospitalization

[estimating LV filling pressure in HF]

estimating LV filling pressure in HF

[exercise tolerance in heart failure]

exercise tolerance in heart failure

[0.07 mg]

0.07 mg

[confidence interval]

confidence interval

[two groups with heart failure]

two groups with heart failure

[Effectiveness of Chinese herbal medicine]

Effectiveness of Chinese herbal medicine, effectiveness of Chinese herbal medicine

[reciprocal regulation in mouse hearts]

reciprocal regulation in mouse hearts

[26 participants]

26 participants

[vehicle-treated rats]

vehicle-treated rats

[management of patients with hypertension]

management of patients with hypertension

[mitral filling]

mitral filling

[1 kg]

1 kg

[role of PDE2 in HF]

role of PDE2 in HF

[60 ml]

60 ml

[Multiple procedures]

Multiple procedures

[indicators of functional status 6-MWT]

indicators of functional status 6-MWT

[mild HF]

mild HF

[sheet orientation]

sheet orientation

[autonomic dysbalance]

autonomic dysbalance

[cardioverter defibrillators]

cardioverter defibrillators

[refractory end-stage congestive heart failure]

refractory end-stage congestive heart failure

[additional benefit]

additional benefit

[insulin receptor substrates 1 IRS1]

insulin receptor substrates 1 IRS1

[practice site]

practice site

[American College of Physicians ACP]

American College of Physicians ACP

[circulating CD34]

circulating CD34

[filling flow]

filling flow

[Surgical tactics]

Surgical tactics

[patients receiving implantable cardioverter defibrillator-CRT]

patients receiving implantable cardioverter defibrillator-CRT

[such as poor patient compliance]

such as poor patient compliance

[disease unique]

disease unique

[air pollution on heart failure]

air pollution on heart failure

[Erythropoiesis-stimulating agents]

Erythropoiesis-stimulating agents

[substantial subset]

substantial subset

[survivors of haematopoietic cell transplantation]

survivors of haematopoietic cell transplantation

[predicting CV events in AF]

predicting CV events in AF

[continuous-flow LVADs]

continuous-flow LVADs

[mRNA levels for SR Ca 2+)-pump]

mRNA levels for SR Ca 2+)-pump

[left ventricular assist device use]

left ventricular assist device use

[outcomes after cardiac resynchronization therapy]

outcomes after cardiac resynchronization therapy

[1 wk]

1 wk

[other factors]

other factors, Other factors

[fundamental mechanism of cardiac dysfunction]

fundamental mechanism of cardiac dysfunction

[66.6 years versus 53.2 years]

66.6 years versus 53.2 years

[RAS-blocker uptitration]

RAS-blocker uptitration

[Measuring frailty in heart failure]

Measuring frailty in heart failure

[multivariate regression]

multivariate regression

[16 patients]

16 patients

[period versus 1 hazard ratio]

period versus 1 hazard ratio

[moderate-intensity aerobic exercise per week]

moderate-intensity aerobic exercise per week

[peak quadriceps]

peak quadriceps

[ring size]

ring size

[suggesting a surrogate of catabolism]

suggesting a surrogate of catabolism

[rRNA transcription]

rRNA transcription

[reflecting rapid R-R interval oscillations]

reflecting rapid R-R interval oscillations

[321 proteins]

321 proteins

[20.8 mo]

20.8 mo

[outcomes in patients with atrial fibrillation]

outcomes in patients with atrial fibrillation

[45 centers in the States]

45 centers in the States

[health-related quality of life Minnesota Living]

health-related quality of life Minnesota Living

[effects of a HNO donor]

effects of a HNO donor

[ambulatory patients with heart failure]

ambulatory patients with heart failure

[47,025 patients]

47,025 patients

[β-AR stimulation]

β-AR stimulation

[using Cox proportional hazards models]

using Cox proportional hazards models

[CRT ON versus CRT OFF]

CRT ON versus CRT OFF

[treatment for heart failure HF]

treatment for heart failure HF

[Higher PSSS]

Higher PSSS

[using the Health ABC Performance Battery]

using the Health ABC Performance Battery

[chronic PAH]

chronic PAH

[management of acute heart failure]

management of acute heart failure

[patients with a QRS complex]

patients with a QRS complex

[refill compliance]

refill compliance

[inhospital mortality among these subgroups]

inhospital mortality among these subgroups

[global attenuation]

global attenuation

[5 d]

5 d

[Western Australian administrative health data]

Western Australian administrative health data

[discharge 5336]

discharge 5336

[enrollment period]

enrollment periods, enrollment period

[common elements of successful interventions]

common elements of successful interventions

[study population]

study population

[afterload of patients with heart failure]

afterload of patients with heart failure

[changes in global gene expression]

changes in global gene expression

[hearts of fish lacking Nucleolin]

hearts of fish lacking Nucleolin

[improvement of the mitral valve opening]

improvement of the mitral valve opening

[health care expenditures of patients]

health care expenditures of patients

[cardiovascular risk factors such as obesity]

cardiovascular risk factors such as obesity

[postoperative echocardiography]

postoperative echocardiography

[myocardial ischaemia]

myocardial ischaemia

[number of hospital days for participants]

number of hospital days for participants

[community perspective]

community perspective

[dual energy X-ray absorptiometry DXA]

dual energy X-ray absorptiometry DXA

[patient circulation]

patient circulation

[month 1]

month 1

[Recent studies]

Recent studies

[life-sustaining treatment]

life-sustaining treatment

[worse heart failure-related QOL co-primary outcome]

worse heart failure-related QOL co-primary outcome

[ischemic cardiomyopathy]

ischemic cardiomyopathy

[phenylephrine-induced genes]

phenylephrine-induced genes

[non-AAs 4.29±0.5-4.55±0.49]

non-AAs 4.29±0.5-4.55±0.49

[Q65P substitution]

Q65P substitution

[prevalent HF]

prevalent HF

[42 percent]

42 percent

[better ways]

better ways

[future perspectives]

future perspectives

[laboratory variables]

laboratory variables

[blockade of the neuro-hormonal system]

blockade of the neuro-hormonal system

[7 months of follow-up data]

7 months of follow-up data

[incremental cost-effectiveness ratios from user inputs]

incremental cost-effectiveness ratios from user inputs

[hospital admission]

hospital admission

[8 patients with CHF-NYHA-II HDL]

8 patients with CHF-NYHA-II HDL

[older patients with breast cancer]

older patients with breast cancer

[multiple disciplines]

multiple disciplines

[466 participants]

466 participants

[endothelial dysfunction]

endothelial dysfunction

[tissue from healthy control animals]

tissue from healthy control animals

[PDE2 expression]

PDE2 expression

[more barriers]

more barriers

[interval between local myocyte depolarization]

interval between local myocyte depolarization

[angiotensin II]

angiotensin II

[Grade strong recommendation moderate-quality evidence]

Grade strong recommendation moderate-quality evidence

[having CHF]

having CHF

[14.4±3.3 mL]

14.4±3.3 mL

[surgical palliation]

surgical palliation

[228 milliseconds]

228 milliseconds

[maintaining sinus rhythm at follow-up]

maintaining sinus rhythm at follow-up

[24 telephone support STS programmes]

24 telephone support STS programmes

[Several POC systems measuring NP levels]

Several POC systems measuring NP levels

[current assays]

current assays

[STS HH with medical support]

STS HH with medical support

[Discharge Data]

Discharge Data

[pathophysiologic state]

pathophysiologic state

[68 years]

68 years

[detrimental alterations in sarcomeric microstructure]

detrimental alterations in sarcomeric microstructure

[worst quintile]

worst quintile

[circulating mediator of insulin resistance]

circulating mediator of insulin resistance

[90 days]

90 days

[12-week program]

12-week program

[endoplasmic reticulum]

endoplasmic reticulum

[Fontan]

Fontan

[134 deaths]

134 deaths

[1 month]

1 months, 1 month

[arrhythmia substrate]

arrhythmia substrate

[≥7 rats]

≥7 rats

[fewer cardioversions]

fewer cardioversions

[HF pathogenesis]

HF pathogenesis

[178 controls]

178 controls

[RGK proteins]

RGK proteins

[LV ejection fraction velocity of shortening]

LV ejection fraction velocity of shortening

[4.9 years for alendronate- patients respectively]

4.9 years for alendronate- patients respectively

[patient safety]

patient safety

[risk-adjusted mortality]

risk-adjusted mortality

[improving outcomes]

improving outcomes, Improving outcomes

[criterion standard]

criterion standard

[H-DKO mice]

H-DKO mice

[exercise-induced increase in the ratio]

exercise-induced increase in the ratio

[beta-blocker therapy on cardiac function]

beta-blocker therapy on cardiac function

[recent hospital discharge in patients]

recent hospital discharge in patients

[stroke volume]

stroke volume

[104 mm]

104 mm

[thus giving rise in dyssynchronous HF]

thus giving rise in dyssynchronous HF

[serum potassium]

serum potassium

[myocyte differentiation]

myocyte differentiation

[Care packages]

Care packages

[gross income]

gross income

[2.0±3.2 mL]

2.0±3.2 mL

[anaerobic metabolism peak respiratory quotient]

anaerobic metabolism peak respiratory quotient

[baseline sST2 status low ≤35]

baseline sST2 status low ≤35

[577 participants]

577 participants

[ventricular dilatation]

ventricular dilatation

[ARNI LCZ696]

ARNI LCZ696

[151 subjects]

151 subjects

[Clinician interviews]

Clinician interviews

[predicting 4-year survival at the time]

predicting 4-year survival at the time

[2005 2008 performance on quality indicators]

2005 2008 performance on quality indicators

[right atrial area 20 cm 2]

right atrial area 20 cm 2

[Robot-assisted training for heart failure patients]

Robot-assisted training for heart failure patients

[breakdown of peptide B-type peptide]

breakdown of peptide B-type peptide

[naturally occurring]

naturally occurring

[alternative treatments]

alternative treatments

[prevalence of modifiable risk factors]

prevalence of modifiable risk factors

[Experimental evidence]

Experimental evidence

[one way]

one way

[Shunt implants]

Shunt implants

[median rate]

median rate

[success rate]

success rates, success rate

[nonadherence in youngest vs. oldest]

nonadherence in youngest vs. oldest

[molecular biomarkers]

molecular biomarkers

[Investigating Outcomes in Exercise TraiNing HF-ACTION]

Investigating Outcomes in Exercise TraiNing HF-ACTION

[cardiac dysfunction with conduction abnormalities]

cardiac dysfunction with conduction abnormalities

[pre-post comparisons]

pre-post comparisons

[isolated LVAD]

isolated LVAD

[haemodynamic stressors]

haemodynamic stressors

[case report]

case report

[Multiacquisition T1-mapping MRI during tidal respiration]

Multiacquisition T1-mapping MRI during tidal respiration

[optimal therapy]

optimal therapy

[working hearts]

working hearts

[Testosterone therapy during exercise rehabilitation]

Testosterone therapy during exercise rehabilitation

[Rotterdam Study]

Rotterdam Study

[hazard ratios for log2 ng]

hazard ratios for log2 ng

[associations of hHF with saxagliptin]

associations of hHF with saxagliptin

[positive inotropic effects in vivo]

positive inotropic effects in vivo

[Background—Heart failure]

Background—Heart failure

[Thoratec Corp]

Thoratec Corp

[Assessing the link between air pollution]

Assessing the link between air pollution

[composite end point of ESRD]

composite end point of ESRD

[Stage 3 chronic kidney disease CKD]

Stage 3 chronic kidney disease CKD

[6 min walk test distance]

6 min walk test distance

[increasing evidence]

increasing evidence

[TREATMENT COURSE]

TREATMENT COURSE

[elderly male patients with CHF]

elderly male patients with CHF

[clinician belief]

clinician belief

[exertional increase]

exertional increase

[low left ventricular ejection fraction]

low left ventricular ejection fraction

[subsequent cardiotoxicity]

subsequent cardiotoxicity

[case series]

case series

[2300 pg]

2300 pg

[partial pressure of end-tidal CO2 PETCO2]

partial pressure of end-tidal CO2 PETCO2

[Δ50%W intensity]

Δ50%W intensity

[beneficial trends]

beneficial trends

[safety of eplerenone in patients]

safety of eplerenone in patients

[pure epicatechin]

pure epicatechin

[Fatal outcomes]

Fatal outcomes

[resting HR]

resting HR

[3 hours]

3 hours

[echo-Doppler studies]

echo-Doppler studies

[improvement range]

improvement range

[several N forms circulating NT-proBNP]

several N forms circulating NT-proBNP

[quantitative proteomics]

quantitative proteomics

[RM strategies]

RM strategies

[NT-proBNP testing]

NT-proBNP testing

[16 patients in the ECMO+VAD group]

16 patients in the ECMO+VAD group

[composite measure]

composite measure, Composite measures

[vascular endothelial growth factor protein]

vascular endothelial growth factor protein

[B-type natriuretic peptide levels in patients]

B-type natriuretic peptide levels in patients

[religious beliefs]

religious beliefs

[Heart T2]

Heart T2

[71.3 m]

71.3 m

[Chinese medicine]

Chinese medicine

[Sixteen New York Heart Association Class]

Sixteen New York Heart Association Class

[2 institutions]

2 institutions

[step forward]

step forward

[downstream signalling]

downstream signalling

[clinical dysfunction]

clinical dysfunction

[restorative effects of (-)-epicatechin-rich cocoa]

restorative effects of (-)-epicatechin-rich cocoa

[I phosphorylation]

I phosphorylation

[clinical outcomes using an aldosterone antagonist]

clinical outcomes using an aldosterone antagonist

[cardiac pathology]

cardiac pathology

[benefits of spironolactone in practice]

benefits of spironolactone in practice

[shunt implantation]

shunt implantation

[Heart failure risk among patients]

Heart failure risk among patients

[U.S. Food]

U.S. Food

[left ventricular assist devices LVADs]

left ventricular assist devices LVADs

[median follow-up]

median follow-up

[adverse event rates between 2005]

adverse event rates between 2005

[prognostic indicator]

prognostic indicator

[pump exchanges]

pump exchanges

[citrate cycle]

citrate cycle

[hallmark feature of heart failure]

hallmark feature of heart failure

[failing]

failing

[9 studies]

9 studies

[exercise modality]

exercise modality

[medical literature]

medical literature

[outpatients with systolic heart failure]

outpatients with systolic heart failure

[interaction between these ECG parameters]

interaction between these ECG parameters

[longitudinal strain of left ventricle]

longitudinal strain of left ventricle

[28-day survivors]

28-day survivors

[Heart Association]

Heart Association

[If-channel inhibition on hemodynamic status]

If-channel inhibition on hemodynamic status

[LA countries]

LA countries

[chromatin subproteome]

chromatin subproteomes, chromatin subproteome

[preoperative dysfunction]

preoperative dysfunction

[epigenetic writer proteins histone acetyltransferases]

epigenetic writer proteins histone acetyltransferases

[significant challenges]

significant challenges

[levels 100 pg high BNP group]

levels 100 pg high BNP group

[morphogenetic protein]

morphogenetic protein

[life-threatening situation]

life-threatening situation

[3 scenarios]

3 scenarios

[Trial Investigating Outcomes multicenter study]

Trial Investigating Outcomes multicenter study

[presence of separate scale dimensions]

presence of separate scale dimensions

[212 milliseconds]

212 milliseconds

[mortality effects of an intervention]

mortality effects of an intervention

[protective mechanisms]

protective mechanisms

[end diameter]

end diameter

[other reasons]

other reasons

[cardiogenic shock]

cardiogenic shock

[iron-deficient adult patients with heart disease]

iron-deficient adult patients with heart disease

[Conclusions—Low-volume EDs]

Conclusions—Low-volume EDs

[Functional stimulation]

Functional stimulation

[prognosis in patients with heart failure]

prognosis in patients with heart failure

[cellular responses]

cellular responses

[treatment aims]

treatment aims

[lack of improvement in prognosis]

lack of improvement in prognosis

[surgical patients]

surgical patients

[multiple non-diastolic abnormalities in cardiovascular function]

multiple non-diastolic abnormalities in cardiovascular function

[communities study]

communities study, community study

[recent discharge]

recent discharge

[treatments for anemia in adults]

treatments for anemia in adults

[markers of SkM growth consistent]

markers of SkM growth consistent

[youngest group]

youngest group

[stable body weight in CC]

stable body weight in CC

[score of Minnesota quality of life]

score of Minnesota quality of life

[genuine effect]

genuine effect

[Gly16 individuals]

Gly16 individuals

[same day]

same day

[over 80 years of age]

over 80 years of age

[more severe LV systolic dysfunction]

more severe LV systolic dysfunction

[intrinsic dysfunction]

intrinsic dysfunction

[Exercise intolerance in heart failure]

Exercise intolerance in heart failure

[Safety of eplerenone in patients analyses]

Safety of eplerenone in patients analyses

[principal mechanisms]

principal mechanisms

[alcohol related]

alcohol related

[positive effects]

positive effects

[outcomes such as heart failure HF]

outcomes such as heart failure HF

[Cardiac hypertrophy]

Cardiac hypertrophy

[28 days]

28 days

[feasible alternative]

feasible alternative

[Seventy-seven cases with pre-HCT germline DNA]

Seventy-seven cases with pre-HCT germline DNA

[antihyperglycemic agents]

antihyperglycemic agents

[pacing-induced cardiomyopathy]

pacing-induced cardiomyopathy

[Arrhythmia-related costs]

Arrhythmia-related costs

[greater risk of heart failure]

greater risk of heart failure

[52-year-old man]

52-year-old man

[preliminary study]

preliminary study

[E e]

E e

[isoprenaline infusion]

isoprenaline infusion

[limited mortality]

limited mortality

[8574 mL]

8574 mL

[participating in the pilot program]

participating in the pilot program

[Michigan HF clinic UM cohort]

Michigan HF clinic UM cohort

[mild restriction of leaflet motion]

mild restriction of leaflet motion

[transplantation eligibility]

transplantation eligibility

[common applications]

common applications

[evidence on associations of dietary patterns]

evidence on associations of dietary patterns

[computational study]

computational study

[ion channelopathies]

ion channelopathies

[Further adjustment for patient characteristics]

Further adjustment for patient characteristics

[opposing action on cAMP production]

opposing action on cAMP production

[compensatory hypertrophy]

compensatory hypertrophy

[≤90 days]

≤90 days

[Mena expression]

Mena expression

[contextual factors on physician adherence]

contextual factors on physician adherence

[28-day mortality]

28-day mortality

[abdominal problems]

abdominal problems

[demographic characteristics]

demographic characteristics

[exercise adherence]

exercise adherence

[long-term effects]

long-term effects

[anthracycline-induced cardiotoxicity]

anthracycline-induced cardiotoxicity

[CRF distribution]

CRF distribution

[LV ejection fraction of a ventricle]

LV ejection fraction of a ventricle

[prognostic composite]

prognostic composite

[health-related quality]

health-related quality

[Subjects with RA receiving methotrexate]

Subjects with RA receiving methotrexate

[higher serum levels of creatinine]

higher serum levels of creatinine

[Further research]

Further research

[case-control analysis]

case-control analysis

[adults with heart failure HF]

adults with heart failure HF

[length-force relationship]

length-force relationship

[1≤5 mg]

1≤5 mg

[packages of R. Cluster analysis]

packages of R. Cluster analysis

[cardiac resynchronization therapy with a defibrillator]

cardiac resynchronization therapy with a defibrillator

[Human resistin in heart failure]

Human resistin in heart failure, human resistin in heart failure

[little information]

little information

[uniform nomenclature]

uniform nomenclature

[local depolarization]

local depolarization

[Even on optimal therapy including anticoagulation]

Even on optimal therapy including anticoagulation

[total myosin binding protein-C phosphorylation]

total myosin binding protein-C phosphorylation

[Québec Health Insurance Board databases]

Québec Health Insurance Board databases

[quartiles of the diet score]

quartiles of the diet score

[indicating possible suboptimal care of patients]

indicating possible suboptimal care of patients

[long-term support]

long-term support

[14.0 ml vs. 17.0 ml]

14.0 ml vs. 17.0 ml

[4.4 mm Hg Fig 1A]

4.4 mm Hg Fig 1A

[protein response]

protein response

[Kaplan-Meier analyses]

Kaplan-Meier analyses

[clear evidence]

clear evidence

[beta1-adrenergic receptor]

beta1-adrenergic receptor

[neuro-hormonal system]

neuro-hormonal system

[HF with ejection fraction HFpEF]

HF with ejection fraction HFpEF

[better hospitals]

better hospitals

[cardiac β-AR]

cardiac β-AR

[identifying death in the ICU]

identifying death in the ICU

[aerobic training intervention with feedback]

aerobic training intervention with feedback

[protocol-driven POC testing of NP]

protocol-driven POC testing of NP

[Nitroxyl HNO]

Nitroxyl HNO

[cardiovascular outcomes]

cardiovascular outcomes

[increase in peak oxygen uptake]

increase in peak oxygen uptake

[sarcoplasmic reticular SR Ca 2+)-uptake]

sarcoplasmic reticular SR Ca 2+)-uptake

[Patients requiring temporary RV support]

Patients requiring temporary RV support

[depressive symptoms]

depressive symptoms

[postcontrast T1]

postcontrast T1

[394 m]

394 m

[predictive value]

predictive value

[8656 new users of a nbDMARD]

8656 new users of a nbDMARD

[Estimating the jugular venous pressure]

Estimating the jugular venous pressure

[nonsurvivors with a similar distribution]

nonsurvivors with a similar distribution

[right failure]

right failure

[baseline in peak oxygen uptake]

baseline in peak oxygen uptake

[Epidemiology of chronic heart failure]

Epidemiology of chronic heart failure

[post-translational state]

post-translational state, post-translational states

[different regions]

different regions

[swine model]

swine model

[original construct]

original construct

[differential response]

differential response

[care surgery]

care surgery

[diastolic murmurs]

diastolic murmurs

[ongoing GDMT alone control group]

ongoing GDMT alone control group

[baseline examination]

baseline examination

[energy deficit]

energy deficit

[catheterization findings]

catheterization findings

[treatment plans]

treatment plans

[P trend=0.01]

P trend=0.01

[model fit]

model fit

[all-cause hospitalisations for TM interventions]

all-cause hospitalisations for TM interventions

[end-diastolic area]

end-diastolic area

[patients with prior cardiovascular disease]

patients with prior cardiovascular disease

[N-terminal proBNP NT-proBNP midregional proANP MR-proANP]

N-terminal proBNP NT-proBNP midregional proANP MR-proANP

[63 patients]

63 patients

[hazard ratio for 10-year increase]

hazard ratio for 10-year increase

[Natriuretic peptide levels like other biomarkers]

Natriuretic peptide levels like other biomarkers

[upstream signal]

upstream signal

[Troponin T]

Troponin T, troponin T

[class recommendation]

class recommendation

[trastuzumab-related CHF among older patients]

trastuzumab-related CHF among older patients

[healthcare utilization]

healthcare utilization

[interventions exercise]

interventions exercise

[association between treatment variation independent]

association between treatment variation independent

[ED volume]

ED volume

[higher BTES]

higher BTES

[survival estimates]

survival estimates

[therapeutic targets]

therapeutic targets

[4.6 years of follow-up 1385]

4.6 years of follow-up 1385

[attention control]

attention control

[76 years]

76 years

[L-type Ca2]

L-type Ca2

[Multivariate models]

Multivariate models

[cardiovascular surgeons]

cardiovascular surgeons

[Interagency Registry for Circulatory performance goal]

Interagency Registry for Circulatory performance goal

[chronic heart failure with ejection fraction]

chronic heart failure with ejection fraction

[P3 prolapse]

P3 prolapse

[even after adjustment for all confounders]

even after adjustment for all confounders

[LCZ696 an receptor neprilysin inhibitor]

LCZ696 an receptor neprilysin inhibitor

[1-year mortality]

1-year mortality

[conscious rabbits]

conscious rabbits

[two bisphosphonates]

two bisphosphonates

[diastolic failure from cardiomyopathic restriction]

diastolic failure from cardiomyopathic restriction

[advancement of the pathophysiologic state]

advancement of the pathophysiologic state

[Baseline Hgb]

Baseline Hgb

[clinical application]

clinical application

[clinical composite]

clinical composite

[exercise-induced increase]

exercise-induced increase

[heart iron]

heart iron

[Forty-one patients]

Forty-one patients

[4 non-ischemic heart failure samples]

4 non-ischemic heart failure samples

[respiratory gas]

respiratory gas

[degenerative regurgitation]

degenerative regurgitation

[challenging therapeutics]

challenging therapeutics

[Chronic β-AR stimulation via catecholamine infusions]

Chronic β-AR stimulation via catecholamine infusions

[ROSE acute heart failure trial]

ROSE acute heart failure trial

[early-onset 0 days after MI]

early-onset 0 days after MI

[Defibrillator Implantation]

Defibrillator Implantation

[lean ZSF1]

lean ZSF1

[brief review]

brief review

[70 years]

70 years

[6.0 mmol]

6.0 mmol

[Up test]

Up test

[HF rats]

HF rats

[cardiovascular function with echocardiographic measures]

cardiovascular function with echocardiographic measures

[outcomes in the REsynchronization reVErses Remodeling]

outcomes in the REsynchronization reVErses Remodeling

[University Health Network Toronto Canada]

University Health Network Toronto Canada

[100 pg]

100 pg

[8524 mL]

8524 mL

[ischemic cause]

ischemic cause

[venoarterial dilation]

venoarterial dilation

[long-acting insulin products from 2006]

long-acting insulin products from 2006

[diastolic properties]

diastolic properties

[E ratios for PCWP estimation]

E ratios for PCWP estimation

[Future studies]

Future studies

[multivariate model]

multivariate models, multivariate model

[monomeric G]

monomeric G

[unfavourable outcome]

unfavourable outcome

[clinical setting]

clinical setting

[acute dyspnea]

acute dyspnea

[low-volume EDs]

low-volume EDs

[using the implementation as a quasi-experiment]

using the implementation as a quasi-experiment

[24-hour brachial systolic pressure 155 35]

24-hour brachial systolic pressure 155 35

[quality improvement]

quality improvement

[major public health problem worldwide]

major public health problem worldwide

[absorption function in patients with CHF]

absorption function in patients with CHF

[right after coronary artery ligation]

right after coronary artery ligation

[debilitating stroke]

debilitating stroke

[following hospital stay for heart failure]

following hospital stay for heart failure

[carvedilol]

carvedilol

[fatty acids]

fatty acids

[several studies]

several studies

[Cardiorespiratory fitness Cooper Center Longitudinal Study]

Cardiorespiratory fitness Cooper Center Longitudinal Study

[insignificant MS]

insignificant MS

[death visit in the subsequent]

death visit in the subsequent

[United States]

United States

[1,790 patients]

1,790 patients

[SVR index]

SVR index

[protein levels of these genes]

protein levels of these genes

[cardiac angiogenesis in heart failure]

cardiac angiogenesis in heart failure

[≥18 years]

≥18 years

[prognosis in advanced heart failure]

prognosis in advanced heart failure

[initiative frequency]

initiative frequency

[4.2 METs]

4.2 METs

[mortality hospitalization]

mortality hospitalization

[Mena overexpression in TTA mice]

Mena overexpression in TTA mice

[combining salt loading with ANG infusion]

combining salt loading with ANG infusion

[future trials]

future trials, Future trials

[Heart failure with ejection fraction HFPEF]

Heart failure with ejection fraction HFPEF

[initial safety]

initial safety

[mechanical stimuli]

mechanical stimuli

[possible HF]

possible HF

[Validation studies in the model system]

Validation studies in the model system

[key biosynthetic enzymes lyso-PAF acetyltransferase]

key biosynthetic enzymes lyso-PAF acetyltransferase

[modification of diet in renal disease]

modification of diet in renal disease

[full length]

full length

[information regarding conditions in Turkey]

information regarding conditions in Turkey

[downward regression]

downward regression

[shuttle walk]

shuttle walk

[cardiopulmonary bypass]

cardiopulmonary bypass

[Patients with a RAS dose increase]

Patients with a RAS dose increase

[10 months]

10 months

[Postoperative normalization of albumin level]

Postoperative normalization of albumin level

[postsystolic function]

postsystolic function

[affecting the levels of epinephrine]

affecting the levels of epinephrine

[Cox hazard models for time]

Cox hazard models for time

[ACF rats]

ACF rats

[full-length SCN5A]

full-length SCN5A

[aerobic training]

aerobic training

[acute treatment]

acute treatment

[linear pathway]

linear pathway

[295 patients]

295 patients

[Northwest States]

Northwest States

[hemodynamic perturbations]

hemodynamic perturbations

[Anoop Shah]

Anoop Shah

[Surgical treatment of post-LVAD AI]

Surgical treatment of post-LVAD AI

[Good agreement]

Good agreement

[blood testing]

blood testing

[even in patients with a history]

even in patients with a history

[Retrospective cohort]

Retrospective cohort

[bottleneck stent model for ischemia]

bottleneck stent model for ischemia

[295 veterans aged 50 years]

295 veterans aged 50 years

[patients with without ejection fraction]

patients with without ejection fraction

[sequential phosphorylation]

sequential phosphorylation

[Clinical Trial]

Clinical Trial

[wall CS]

wall CS

[clinical trials-Enriching patient identification by Collins]

clinical trials-Enriching patient identification by Collins

[Taking into account all follow-up visits]

Taking into account all follow-up visits

[remodeling parameters]

remodeling parameters

[cardiomyopathy origin]

cardiomyopathy origin

[coronary interventions during the trial]

coronary interventions during the trial

[testosterone supplementation during a program]

testosterone supplementation during a program

[few years]

few years

[major adverse neurological event-free rate]

major adverse neurological event-free rate

[p value for age-by-LVEF interaction]

p value for age-by-LVEF interaction

[analyses of the EMPHASIS-HF study subgroups]

analyses of the EMPHASIS-HF study subgroups

[significant difference in the ability]

significant difference in the ability

[Psychometric testing of the Self-Care]

Psychometric testing of the Self-Care

[placebo-treated group]

placebo-treated group

[using clinical practice guidelines grading system]

using clinical practice guidelines grading system

[main objective of this study]

main objective of this study

[effects of treatment with ivabradine]

effects of treatment with ivabradine

[scar size]

scar size

[lower median activities of lyso-PAF-AT P]

lower median activities of lyso-PAF-AT P

[using the Grading Assessment GRADE methodology]

using the Grading Assessment GRADE methodology

[inconsistent results]

inconsistent results

[four different US healthcare programmes]

four different US healthcare programmes

[nontrastuzumab users]

nontrastuzumab users

[turning off Mena overexpression immediately]

turning off Mena overexpression immediately

[congestion-like symptoms]

congestion-like symptoms

[expressing Na channel mRNA splice variants]

expressing Na channel mRNA splice variants

[Excessive secretion of arginine vasopressin AVP]

Excessive secretion of arginine vasopressin AVP

[LV compliance]

LV compliance

[including the establishment of responsiveness]

including the establishment of responsiveness

[involvement in a multisite study]

involvement in a multisite study

[example antagonizing excessive β-AR drive]

example antagonizing excessive β-AR drive

[health-related quality of life HRQoL]

health-related quality of life HRQoL

[group III]

group III

[event-free rate]

event-free rates, event-free rate

[differential analysis]

differential analysis

[Mini-Sentinel program]

Mini-Sentinel program

[LV size]

LV size

[anti-oxidant defence]

anti-oxidant defence

[HFrEF therapy]

HFrEF therapy

[overwhelming contribution of atherosclerotic CAD]

overwhelming contribution of atherosclerotic CAD

[metabolic gene]

metabolic gene

[prevalence of high BNP levels]

prevalence of high BNP levels

[regarding effective treatment of older adults]

regarding effective treatment of older adults

[better well-being in all participants]

better well-being in all participants

[Current guidelines]

Current guidelines

[annular size reduction for degenerative MR]

annular size reduction for degenerative MR

[cell senescence]

cell senescence

[ZSF1 rats]

ZSF1 rats

[current knowledge of nutritional abnormalities]

current knowledge of nutritional abnormalities

[4 VA health care systems]

4 VA health care systems

[CI 1.34]

CI 1.34

[Doppler mitral inflow velocity contours]

Doppler mitral inflow velocity contours

[TTA mice]

TTA mice

[only in patients maintaining sinus rhythm]

only in patients maintaining sinus rhythm

[59.6 m vs. 1.5 m]

59.6 m vs. 1.5 m

[valvular disease]

valvular disease

[patient consultation]

patient consultation

[CI 1.59]

CI 1.59

[most common cause of RAS]

most common cause of RAS

[co-primary outcome]

co-primary outcome

[support for the concept also appropriate]

support for the concept also appropriate

[recent onset HFrEF 30 days]

recent onset HFrEF 30 days

[patients with Heart Association class]

patients with Heart Association class

[myocardial ischemic events in patients]

myocardial ischemic events in patients

[long-term survival in ED patients]

long-term survival in ED patients

[detrimental alterations]

detrimental alterations

[renal denervation]

renal denervation, Renal denervation

[CI 1.02]

CI 1.02

[ambulatory HF]

ambulatory HF

[CI 1.00]

CI 1.00

[left ventricular ejection fraction HFpEF]

left ventricular ejection fraction HFpEF

[x12 w]

x12 w

[subgroups of patients with disease]

subgroups of patients with disease

[median eGFR]

median eGFR

[changes in treatment in most subjects]

changes in treatment in most subjects

[just size]

just size

[improving quality of care for patients]

improving quality of care for patients

[also evaluating the effect of interventions]

also evaluating the effect of interventions

[elevations in tumor necrosis factor]

elevations in tumor necrosis factor

[measurable overall improvements for patients]

measurable overall improvements for patients

[vasopressin in congestive heart failure]

vasopressin in congestive heart failure

[adult patients with failing Fontan circulation]

adult patients with failing Fontan circulation

[sustaining the workload during stress]

sustaining the workload during stress

[NP levels]

NP levels

[elevations in BNP NT-proBNP levels]

elevations in BNP NT-proBNP levels

[Titin hypophosphorylation]

Titin hypophosphorylation

[HFPSI model]

HFPSI model

[Tricuspid annular plane systolic excursion]

Tricuspid annular plane systolic excursion, tricuspid annular plane systolic excursion

[cell phenotype]

cell phenotype

[T1-mapping sequence]

T1-mapping sequence

[blood cell]

blood cell

[peripheral edema]

peripheral edema

[PEVK segment]

PEVK segment

[telephone calls]

telephone calls

[creating uncertainty about the safety]

creating uncertainty about the safety

[high incidence]

high incidence

[historical data]

historical data

[control model]

control model

[aims of the consensus report]

aims of the consensus report

[future expansion]

future expansion

[Rethinking the quality of outcome measures]

Rethinking the quality of outcome measures

[real world]

real world

[implementation strategies]

implementation strategies

[rotor with wide blood-flow paths]

rotor with wide blood-flow paths

[three kinases]

three kinases

[CHM versus biomedical treatment alone]

CHM versus biomedical treatment alone

[overexpressing Hand2 in heart muscle cells]

overexpressing Hand2 in heart muscle cells

[desensitization processes]

desensitization processes

[triangular resection]

triangular resection

[increase in LV posterior wall thickness]

increase in LV posterior wall thickness

[Twenty-seven symptomatic adult Fontan SAF patients]

Twenty-seven symptomatic adult Fontan SAF patients

[descriptive statistics]

descriptive statistics

[systolic mitral annulus velocity Sa]

systolic mitral annulus velocity Sa

[receiving the last dose of doxorubicin]

receiving the last dose of doxorubicin

[4 groups]

4 groups

[interatrial shunting]

interatrial shunting

[echocardiographic examination]

echocardiographic examination

[CRT-D recipients]

CRT-D recipients

[update on cardiopulmonary exercise variables]

update on cardiopulmonary exercise variables

[MR-proADM p]

MR-proADM p

[test results]

test results

[DXA results]

DXA results

[neurohumoral blockers]

neurohumoral blockers

[Global strain]

Global strain

[neurohormonal systems]

neurohormonal systems

[26 sites in North America]

26 sites in North America

[artificial pulse]

artificial pulse

[Diuretic use in heart failure]

Diuretic use in heart failure

[short follow-up]

short follow-up

[Periodic breathing with no heart beat]

Periodic breathing with no heart beat

[plasma samples]

plasma samples, Plasma samples

[cation channel M7 TRPM7 channel mRNA]

cation channel M7 TRPM7 channel mRNA

[hospital days]

hospital days

[global strain]

global strain

[device implantation]

device implantation

[translational repression]

translational repression

[heterogeneous group of patients consisting]

heterogeneous group of patients consisting

[229 mL]

229 mL

[signalosome complex]

signalosome complex

[Left ventricular assist devices LVADs]

Left ventricular assist devices LVADs

[nursing interventions]

nursing interventions

[Heart failure with ejection fraction HFpEF]

Heart failure with ejection fraction HFpEF

[CI 0.85]

CI 0.85

[dose uptitration]

dose uptitration

[prespecified criteria]

prespecified criteria

[left ventricular LV systolic pressure]

left ventricular LV systolic pressure

[three modes]

three modes

[atrial structure]

atrial structure

[surviving an acute myocardial infarction AMI]

surviving an acute myocardial infarction AMI

[one setting]

one setting

[–17.4 points vs. 2.1 points]

–17.4 points vs. 2.1 points

[useful tool for prognostic assessment]

useful tool for prognostic assessment

[CI 0.45]

CI 0.45

[Medical Therapies]

Medical Therapies

[hospital performance of readmission metrics]

hospital performance of readmission metrics

[Exercise capacity]

Exercise capacity

[systolic strain]

systolic strain

[CI 0.39]

CI 0.39

[Clinical comparisons]

Clinical comparisons

[proteomics changes]

proteomics changes

[7 months]

7 months

[same indication]

same indication

[Sprague-Dawley rats]

Sprague-Dawley rats

[≥2 nondiabetes risk factors age men]

≥2 nondiabetes risk factors age men

[β1AR downregulation]

β1AR downregulation

[foundation of management of patients]

foundation of management of patients

[spite of developments in procedure]

spite of developments in procedure

[Data processing]

Data processing

[cardiac catheterization]

cardiac catheterization

[inducing hyperkalemia in high-risk patients]

inducing hyperkalemia in high-risk patients

[lower EO-CFUs]

lower EO-CFUs

[important comorbidities such as anemia]

important comorbidities such as anemia

[other outcomes in patients with moderate]

other outcomes in patients with moderate

[cardiac development]

cardiac development

[cognitive function]

cognitive function

[cardiac performance]

cardiac performance

[proximal left anterior descending artery]

proximal left anterior descending artery

[12 male]

12 male

[plasma B-type natriuretic peptide BNP]

plasma B-type natriuretic peptide BNP

[costs for patients with heart failure]

costs for patients with heart failure

[heart failure in older adults]

heart failure in older adults

[2,101,481 hospitalizations]

2,101,481 hospitalizations

[developing congestive heart failure CHF]

developing congestive heart failure CHF

[Global longitudinal strain of left ventricle]

Global longitudinal strain of left ventricle

[Web-based program]

Web-based program

[ERK1 signalling]

ERK1 signalling

[Hazard ratios]

Hazard ratios

[risk of acute heart failure]

risk of acute heart failure

[hypothesis-generating findings]

hypothesis-generating findings

[Individuals with acute RV failure]

Individuals with acute RV failure

[messenger RNA]

messenger RNA

[New York Heart Association classification]

New York Heart Association classification

[onset HFrEF]

onset HFrEF

[Comparative effects of ventricular assist device]

Comparative effects of ventricular assist device

[patient needs at follow-up visits]

patient needs at follow-up visits

[Doppler mitral inflow velocity E-wave]

Doppler mitral inflow velocity E-wave

[LVAD therapy]

LVAD therapy

[transmitral E-wave]

transmitral E-wave

[Impact of frailty on HF risk]

Impact of frailty on HF risk

[kidney infection without major complications]

kidney infection without major complications

[higher risk of death visit]

higher risk of death visit

[patients with HF with EF]

patients with HF with EF

[primary symptom]

primary symptoms, primary symptom

[patients consisting after myocardial infarction]

patients consisting after myocardial infarction

[mitral]

Mitral, mitral

[little HR reduction with beta-blocker therapy]

little HR reduction with beta-blocker therapy

[severe hyponatremia]

severe hyponatremia

[RM interventions]

RM interventions

[other patients]

other patients

[388.3 ms]

388.3 ms

[systolic function in HFpEF patients]

systolic function in HFpEF patients

[common Emergency Department ED presentation]

common Emergency Department ED presentation

[62 primary care clinicians caring]

62 primary care clinicians caring

[CRT capability]

CRT capability

[induction of a substantial subset]

induction of a substantial subset

[multivariable models]

multivariable models

[adults with a Fontan circulation]

adults with a Fontan circulation

[obese patients]

obese patients

[change in 7-day follow-up visits]

change in 7-day follow-up visits

[lower CD34+VEGFR2]

lower CD34+VEGFR2

[DAVID tools]

DAVID tools

[little attention]

little attention

[84 mL]

84 mL

[role determining the adaptive cardiac remodelling]

role determining the adaptive cardiac remodelling

[mouse Rad Q65P the murine equivalent]

mouse Rad Q65P the murine equivalent

[real-world setting]

real-world setting

[9 patients]

9 patients

[rates of annual ED visits]

rates of annual ED visits

[nine patients]

nine patients

[Clinical Practice]

Clinical Practice

[adult patients undergoing isolated heart transplant]

adult patients undergoing isolated heart transplant

[ratio of systolic blood pressure]

ratio of systolic blood pressure

[absolute minimal detectable change MDC values]

absolute minimal detectable change MDC values

[rate-control treatment]

rate-control treatment

[carrying two increase in cardiac risk]

carrying two increase in cardiac risk

[Relation of preoperative serum albumin levels]

Relation of preoperative serum albumin levels

[ventricular mass]

ventricular mass

[Oxidative stress]

Oxidative stress, oxidative stress

[anti-inflammatory effects in the treatment]

anti-inflammatory effects in the treatment

[prognostic power of various measures]

prognostic power of various measures

[ring annuloplasty with a Physio Ring]

ring annuloplasty with a Physio Ring

[obese ZSF1]

obese ZSF1

[NT-proBNP levels at the time]

NT-proBNP levels at the time

[404 patients]

404 patients

[slower increase in heart rate]

slower increase in heart rate

[assessing ventricular filling pressure in patients]

assessing ventricular filling pressure in patients

[exercise duration]

exercise duration

[human myocardium]

human myocardium

[CHF p]

CHF p

[above parameters]

above parameters

[sympathetic control of heart rate]

sympathetic control of heart rate

[all-cause mortality in heart failure]

all-cause mortality in heart failure

[other etiologies]

other etiologies

[AA participants]

AA participants

[worsening renal function WRF in EMPHASIS-HF]

worsening renal function WRF in EMPHASIS-HF

[heart failure in the heart]

heart failure in the heart

[invasive assessment]

invasive assessments, invasive assessment

[Economic Analysis]

Economic Analysis

[2 molecular scaffolds in heart pathology]

2 molecular scaffolds in heart pathology

[mortality in heart failure HF]

mortality in heart failure HF

[Cardiac amyloidosis about an atypical case]

Cardiac amyloidosis about an atypical case

[chronic advanced heart failure patients]

chronic advanced heart failure patients

[valvular regurgitation]

valvular regurgitation

[overall summary]

overall summary

[ejection fraction arguments for hypo-response]

ejection fraction arguments for hypo-response

[QRS width]

QRS width

[least a level of CRF]

least a level of CRF

[patients with heart failure irrespective]

patients with heart failure irrespective

[Selective heart rate reduction with ivabradine]

Selective heart rate reduction with ivabradine

[Western blots with site-specific monoclonal antibodies]

Western blots with site-specific monoclonal antibodies

[metabolic enzymes]

metabolic enzymes

[significant value in HF risk prediction]

significant value in HF risk prediction

[10.4 years]

10.4 years

[consistent benefits]

consistent benefits

[nervous system]

nervous systems, nervous system

[myocardial remodelling]

myocardial remodelling

[Using a prospective HF registry]

Using a prospective HF registry

[2.5 mL]

2.5 mL

[Variation in the use of medications]

Variation in the use of medications

[Early treatment]

Early treatment

[4±15 bpm]

4±15 bpm

[major underlying mechanism of HFPEF]

major underlying mechanism of HFPEF

[32 deficits]

32 deficits

[Health Initiative]

Health Initiative

[24 troponin]

24 troponin

[severe hyponatremia in most countries]

severe hyponatremia in most countries

[HFPSI in Affairs HF clinic]

HFPSI in Affairs HF clinic

[less hypertension]

less hypertension

[available studies]

available studies

[1-day reduction in hospital length]

1-day reduction in hospital length

[208 patients]

208 patients

[reciprocal downregulation]

reciprocal downregulation

[Patients In York Heart Association]

Patients In York Heart Association

[tomographic angiography]

tomographic angiography

[stage D]

stage D

[454 patients]

454 patients

[gait therapy]

gait therapy

[HF volume management between 2007]

HF volume management between 2007

[adults with ejection fraction without inotropes]

adults with ejection fraction without inotropes

[variance in future hospital mortality]

variance in future hospital mortality

[Fifty patients]

Fifty patients

[Nursing Management]

Nursing Management

[cachexia hazard ratio in univariate analyses]

cachexia hazard ratio in univariate analyses

[meeting specific inclusion including an eGFR]

meeting specific inclusion including an eGFR

[rate-control strategies]

rate-control strategies

[IRS2 proteins]

IRS2 proteins

[osteomedullary biopsy]

osteomedullary biopsy

[209 HFrEF]

209 HFrEF

[low apparent concentration circulating NT-proBNP]

low apparent concentration circulating NT-proBNP

[Hypertension DASH diet scores with mortality]

Hypertension DASH diet scores with mortality

[cardioverter-defibrillator device]

cardioverter-defibrillator device

[converting enzyme inhibitors angiotensin receptor blockers]

converting enzyme inhibitors angiotensin receptor blockers

[phosphomimic Ser77]

phosphomimic Ser77

[LV end systolic volume index]

LV end systolic volume index

[pressure PASP]

pressure PASP

[dialysis-dependent patients with heart failure]

dialysis-dependent patients with heart failure

[Management of patients with heart failure]

Management of patients with heart failure, management of patients with heart failure

[growth factor]

growth factor

[diet adherence]

diet adherence

[3.1 cm]

3.1 cm

[Cardiac function]

Cardiac function, Cardiac Function

[diastolic mitral]

diastolic mitral

[decisions about implantable cardioverter-defibrillator deactivation]

decisions about implantable cardioverter-defibrillator deactivation

[Surgical revascularization]

Surgical revascularization

[patients having heart failure HF]

patients having heart failure HF

[doxorubicin treatment]

doxorubicin treatment

[fundamental hypothesis]

fundamental hypothesis

[therapeutic interventions]

therapeutic interventions

[patients with acute coronary syndromes]

patients with acute coronary syndromes

[HABC Battery]

HABC Battery

[efficacy of mineralocorticoid receptor antagonists]

efficacy of mineralocorticoid receptor antagonists

[higher frequency of diabetes mellitus]

higher frequency of diabetes mellitus

[survival rates of patients with cardiomyopathy]

survival rates of patients with cardiomyopathy

[transfusions in patients with heart disease]

transfusions in patients with heart disease

[Half of patients with heart failure]

Half of patients with heart failure

[cardioprotective signaling]

cardioprotective signaling

[conflicting results about the risk]

conflicting results about the risk

[implementation of care transfer policy]

implementation of care transfer policy

[ring annuloplasty for mitral regurgitation]

ring annuloplasty for mitral regurgitation

[hypertensive HFPEF]

hypertensive HFPEF

[ATP content]

ATP content

[cardiomyocytes using the flux analyzer]

cardiomyocytes using the flux analyzer

[p38alpha MAPK]

p38alpha MAPK

[receiving ECMO]

receiving ECMO

[device consideration]

device consideration

[common language]

common language

[robust predictor of subsequent HF]

robust predictor of subsequent HF

[β-blockers at guideline-recommended target dose]

β-blockers at guideline-recommended target dose

[With therapies ranging from medication]

With therapies ranging from medication

[full potential]

full potential

[negative predictive value of E]

negative predictive value of E

[Clinical Excellence]

Clinical Excellence

[Data Sources MEDLINE databases trial registries]

Data Sources MEDLINE databases trial registries

[L-type currents]

L-type currents

[HF admissions]

HF admissions

[undergoing chronic β-adrenergic receptor stimulation]

undergoing chronic β-adrenergic receptor stimulation

[national efforts]

national efforts

[Health ABC]

Health ABC

[progressive development of cardiac hypertrophy]

progressive development of cardiac hypertrophy

[other potential predictors particularly biomarkers]

other potential predictors particularly biomarkers

[primary care]

primary care

[deficits present out of deficits]

deficits present out of deficits

[effect of CRT in patients]

effect of CRT in patients

[1.73 m2]

1.73 m2

[Other prognostic factors at admission]

Other prognostic factors at admission

[402 patients]

402 patients

[index admission]

index admission

[listing criteria]

listing criteria

[multisite study]

multisite studies, multisite study

[0.12 mg]

0.12 mg

[sound mind]

sound mind

[1,113 pg]

1,113 pg

[wasting T-score]

wasting T-score

[incidence of]

incidence of

[effective treatment]

effective treatment

[Psoriasis patients]

Psoriasis patients

[3.1 kg]

3.1 kg

[20-week time]

20-week time

[temporary support]

temporary support

[arm cuff]

arm cuff

[17 days range 6 days]

17 days range 6 days

[Outcomes of Exercise Training HF-ACTION]

Outcomes of Exercise Training HF-ACTION

[sacubiltril valsartan]

sacubiltril valsartan

[multimarker-based strategy]

multimarker-based strategy

[human pluripotent stem cardiomyocytes hiPSC-CMs]

human pluripotent stem cardiomyocytes hiPSC-CMs

[pulmonary arterial systolic pressure PASP]

pulmonary arterial systolic pressure PASP

[absolute improvements]

absolute improvements

[N-terminal pro-brain-type natriuretic peptide assessment]

N-terminal pro-brain-type natriuretic peptide assessment

[T1 mapping]

T1 mapping

[MEDLINE databases clinical trial registries]

MEDLINE databases clinical trial registries

[multiple myeloma]

multiple myeloma

[30 min]

30 min

[0.36 mm]

0.36 mm

[58 patients]

58 patients

[1.3 mL]

1.3 mL

[1-year mortality in 90-day survivors]

1-year mortality in 90-day survivors

[Cardiac magnetic resonance postcontrast T1 time]

Cardiac magnetic resonance postcontrast T1 time

[lower resting HR P value=0.033]

lower resting HR P value=0.033

[all-cause death]

all-cause death

[71 mL]

71 mL

[study group]

study group

[poorly contracting]

poorly contracting

[adequate self-management training of patients]

adequate self-management training of patients

[continuity equation]

continuity equation

[Rhythm strategies]

Rhythm strategies

[268 inpatient records of patients]

268 inpatient records of patients

[many miRNAs]

many miRNAs

[novel targets]

novel targets

[risk for the primary outcome]

risk for the primary outcome

[primary CABG]

primary CABG

[VEN slope]

VEN slope

[lower BTES]

lower BTES

[Hemoglobin in patients with heart failure]

Hemoglobin in patients with heart failure

[Kaplan-Meier curves]

Kaplan-Meier curves

[acute β-adrenoceptor blockade with esmolol]

acute β-adrenoceptor blockade with esmolol

[TGF-β inhibition]

TGF-β inhibition

[high muscle]

high muscle

[Investigating Outcomes of Exercise Training HF-ACTION]

Investigating Outcomes of Exercise Training HF-ACTION

[Medication regimen]

Medication regimen

[≥60 mL per 1.73 m 2]

≥60 mL per 1.73 m 2

[significant improvements showing minor improvement]

significant improvements showing minor improvement

[improvements in NYHA classification from class]

improvements in NYHA classification from class

[pluripotency marker]

pluripotency markers, pluripotency marker

[short-term exercise tolerance in patients]

short-term exercise tolerance in patients

[BTES with higher exercise time]

BTES with higher exercise time

[heart failure in Latin America]

heart failure in Latin America

[mitral annulus velocities during systole s]

mitral annulus velocities during systole s

[collagen deposition]

collagen deposition

[doxorubicin-induced cardiotoxicity]

doxorubicin-induced cardiotoxicity

[highlighting the contribution of nursing care]

highlighting the contribution of nursing care

[noncardiovascular diagnoses]

noncardiovascular diagnoses

[using techniques]

using techniques

[significant decreases in LV fractional shortening]

significant decreases in LV fractional shortening

[regarding risk factors for the development]

regarding risk factors for the development

[differential impact on hospital performance]

differential impact on hospital performance

[cardiovascular function]

cardiovascular function

[outcomes for patients with heart failure]

outcomes for patients with heart failure

[Short-Form quality of life domains]

Short-Form quality of life domains

[stent occlusion]

stent occlusion

[exercise than in the group]

exercise than in the group

[2 minutes]

2 minutes

[pre initiation]

pre initiation

[21 months]

21 months

[uptake of class I CPG recommendations]

uptake of class I CPG recommendations

[normal LV ejection fraction of 0.70]

normal LV ejection fraction of 0.70

[transduction pathways]

transduction pathways

[Data in patients with systolic function]

Data in patients with systolic function

[alleviating the decrement of heart rate]

alleviating the decrement of heart rate

[electrical stimulation]

electrical stimulation

[favorable outcome at 1 year]

favorable outcome at 1 year

[future of heart failure trials]

future of heart failure trials

[Future trials using HR variability]

Future trials using HR variability

[HDL-mediated effects]

HDL-mediated effects

[AT nonidentification]

AT nonidentification

[tachycardic response]

tachycardic response

[iron homeostasis]

iron homeostasis

[characteristics mortality]

characteristics mortality

[3M Potential]

3M Potential

[median of 123 mm Hg]

median of 123 mm Hg

[restoration of cardiac plasma membrane levels]

restoration of cardiac plasma membrane levels

[2.1 17.6 mL 2 P=0.01]

2.1 17.6 mL 2 P=0.01

[left ventricular filling pressure response]

left ventricular filling pressure response

[noninvasive assessments]

noninvasive assessments

[unit costs]

unit costs

[trastuzumab use]

trastuzumab use

[125.6 minutes]

125.6 minutes

[new users]

new users

[Cardiopulmonary exercise testing with echocardiographic assessment]

Cardiopulmonary exercise testing with echocardiographic assessment

[pharmacological armamentarium]

pharmacological armamentarium

[significant value]

significant value

[18 mg]

18 mg

[transmitral E-wave early diastolic mitral velocity]

transmitral E-wave early diastolic mitral velocity

[assembly of these three kinases]

assembly of these three kinases

[Treating Advanced HF A Multicenter Study]

Treating Advanced HF A Multicenter Study

[stimulation of cell oxide production]

stimulation of cell oxide production

[Xanthine oxidase]

Xanthine oxidase

[Rad Q65P]

Rad Q65P

[inoperable chronic thromboembolic pulmonary hypertension]

inoperable chronic thromboembolic pulmonary hypertension

[cardiovascular death for heart failure]

cardiovascular death for heart failure

[large registry]

large registry

[6 wk after the procedures]

6 wk after the procedures

[normal reference]

normal reference

[good performance]

good performance

[Diuretic efficacy]

Diuretic efficacy

[patients with HF under drug treatment]

patients with HF under drug treatment

[nbDMARDs in this RA population]

nbDMARDs in this RA population

[cross talk between these receptors]

cross talk between these receptors

[10 lb in 1 year]

10 lb in 1 year

[resulting in the suppression of signalling]

resulting in the suppression of signalling

[18 female]

18 female

[SAF cohort]

SAF cohort

[signal transduction]

signal transduction

[ARNI inhibitors angiotensin-receptor neprilysin inhibitors]

ARNI inhibitors angiotensin-receptor neprilysin inhibitors

[Eight weeks from myocardial infarction]

Eight weeks from myocardial infarction

[common disorder]

common disorder

[social mandate]

social mandate

[4 patients]

4 patients

[once during the index admission]

once during the index admission

[70 bpm with beta-blocker therapy]

70 bpm with beta-blocker therapy

[age risk]

age risk

[myocyte diameter]

myocyte diameter

[adverse outcomes in other patients]

adverse outcomes in other patients

[using a blood cell transfusion strategy]

using a blood cell transfusion strategy

[infarction-related refractory right heart failure]

infarction-related refractory right heart failure

[involving families]

involving families

[odds ratio 1.76 even after adjustment]

odds ratio 1.76 even after adjustment

[intestinal morphology]

intestinal morphology

[acetylcholinesterase inhibition]

acetylcholinesterase inhibition

[strain rate]

strain rate

[patients age]

patients age

[1,620 patients]

1,620 patients

[36,284 patients]

36,284 patients

[higher scores]

higher scores

[LV function]

LV function

[lower natremia]

lower natremia

[30 mL per 1.73 m]

30 mL per 1.73 m

[QT intervals]

QT intervals

[Insights from the NCDR PINNACLE program]

Insights from the NCDR PINNACLE program

[multiparametric score]

multiparametric score

[early transmitral blood flow velocity]

early transmitral blood flow velocity

[pneumonia PNA]

pneumonia PNA

[independent predictor of long-term mortality]

independent predictor of long-term mortality

[advanced stages of heart failure]

advanced stages of heart failure

[BNP group]

BNP group

[valid measure of health status]

valid measure of health status

[cardiac energy]

cardiac energy

[cell adhesion]

cell adhesion

[important component]

important component

[possible index]

possible index

[diverse aspects of cardiac remodeling]

diverse aspects of cardiac remodeling

[greater reduction of sympathetic activity]

greater reduction of sympathetic activity

[conjunction with a CentriMag RVAD]

conjunction with a CentriMag RVAD

[combinations of the four remodeling aspects]

combinations of the four remodeling aspects

[adoption of heart failure guidelines lessons]

adoption of heart failure guidelines lessons

[10 centers]

10 centers

[visits during the 2-year study period]

visits during the 2-year study period

[disease severity]

disease severity

[Resting tension (Fpassive)-sarcomere length relations]

Resting tension (Fpassive)-sarcomere length relations

[75 years of age with diabetes]

75 years of age with diabetes

[safety of mineralocorticoid receptor antagonists]

safety of mineralocorticoid receptor antagonists

[Evidence-based care]

Evidence-based care

[early-activated septum]

early-activated septum

[intermediate metabolism]

intermediate metabolism

[inpatient admissions]

inpatient admissions

[Only the obese ZSF1 groups]

Only the obese ZSF1 groups

[LV remodeling]

LV remodeling

[cardiac magnetic resonance postcontrast T1 time]

cardiac magnetic resonance postcontrast T1 time

[restrictive blood cell transfusion strategy]

restrictive blood cell transfusion strategy

[ejection time]

ejection time

[doxorubicin-induced heart failure in rats]

doxorubicin-induced heart failure in rats

[varying combinations of the remodeling aspects]

varying combinations of the remodeling aspects

[LVET at entry 237 milliseconds]

LVET at entry 237 milliseconds

[Heart Failure Patient Severity Index]

Heart Failure Patient Severity Index

[double-blind trial]

double-blind trial

[inhibiting TGF-β receptor type I]

inhibiting TGF-β receptor type I

[medication dose]

medication dose

[adult medicine]

adult medicine

[particularly reducing all-cause mortality for patients]

particularly reducing all-cause mortality for patients

[extracorporeal membrane]

extracorporeal membrane

[CV death]

CV death, CV deaths

[PAF-CPT in parallel with PAF levels]

PAF-CPT in parallel with PAF levels

[optimal cutoff level of NT-proBNP]

optimal cutoff level of NT-proBNP

[cardiac sympathetic activity in patients]

cardiac sympathetic activity in patients

[prospective studies evaluating implementation interventions]

prospective studies evaluating implementation interventions

[postoperative normalization of albumin levels]

postoperative normalization of albumin levels

[outcome performance]

outcome performance

[use of medications among outpatients]

use of medications among outpatients

[aortic pressure]

aortic pressure

[routine measurement of HR variability]

routine measurement of HR variability

[PAF-CPT levels]

PAF-CPT levels

[clinical outcomes such as hospitalisations]

clinical outcomes such as hospitalisations

[Background uncertain]

Background uncertain

[Grade recommendation]

Grade recommendation

[urgent need]

urgent need

[cardiac Na]

cardiac Na

[SRD brachial]

SRD brachial

[eligible patients]

eligible patients

[paradigm shift in the treatment]

paradigm shift in the treatment

[other systems]

other systems

[oxygen flow]

oxygen flow

[HF risk factors of countries]

HF risk factors of countries

[HF prediction]

HF prediction

[univariable analysis]

univariable analysis

[extracorporeal support]

extracorporeal support

[systems level]

systems level

[exercise-induced PASP]

exercise-induced PASP

[stable severe systolic heart failure]

stable severe systolic heart failure

[left strain]

left strain

[disease C]

disease C

[pump thrombosis]

pump thrombosis

[potentially beneficial new therapeutic approach]

potentially beneficial new therapeutic approach

[hypothetical programs]

hypothetical programs

[β-Blocker-induced enhancement of cardiac angiogenesis]

β-Blocker-induced enhancement of cardiac angiogenesis

[CentriMag RVAD]

CentriMag RVAD

[peripheral oedema]

peripheral oedema

[trial results]

trial results

[measuring the peak quadriceps force]

measuring the peak quadriceps force

[complicating AMI]

complicating AMI

[prognostic resolution]

prognostic resolution

[signalling cascades]

signalling cascades

[KCCQ domains]

KCCQ domains

[epigenetic readers in cardiac biology]

epigenetic readers in cardiac biology

[parasympathetic neurotransmission]

parasympathetic neurotransmission

[23 patients in the VAD group]

23 patients in the VAD group

[nosignificant changes in control group P]

nosignificant changes in control group P

[cardiac mRNA levels of inflammatory genes]

cardiac mRNA levels of inflammatory genes

[psychometric profile]

psychometric profile

[worse outcomes]

worse outcomes

[standard error of measurement value]

standard error of measurement value

[RENASTUR cohort]

RENASTUR cohort

[primary CABG]

primary CABG

[Heart block]

Heart block

[perfusion of the carotid bodies]

perfusion of the carotid bodies

[ICD shocks]

ICD shocks

[top pathways]

top pathways

[two Centers]

two Centers

[electromechanical behavior of the heart]

electromechanical behavior of the heart

[lower limbs]

lower limbs

[Additional progress]

Additional progress

[management of patients with RAS]

management of patients with RAS

[262 psoriasis systemic UV treatment]

262 psoriasis systemic UV treatment

[potential benefit with few adverse consequences]

potential benefit with few adverse consequences

[Neprilysin inhibitors]

Neprilysin inhibitors

[interaction effect]

interaction effect

[chromatin hyperacetylation]

chromatin hyperacetylation

[doxorubicin cardiotoxicity]

doxorubicin cardiotoxicity

[parasympathetic control of the heart]

parasympathetic control of the heart

[association with exercise training response]

association with exercise training response

[standard care]

standard care

[women respectively]

women respectively

[race by treatment interaction P=0.03]

race by treatment interaction P=0.03

[Exertional Shortness]

Exertional Shortness

[HF-related morbidity]

HF-related morbidity

[Remote monitoring]

Remote monitoring

[GDMT-treated NYHA]

GDMT-treated NYHA

[65±12 years]

65±12 years

[especially lyso-PAF-AT]

especially lyso-PAF-AT

[selective beta-blockers]

selective beta-blockers

[foundation describing a uniform nomenclature]

foundation describing a uniform nomenclature

[bottleneck stenting]

bottleneck stenting

[outcomes of care for patients]

outcomes of care for patients

[unique property]

unique property

[sarcopenic range muscle wasting T-score]

sarcopenic range muscle wasting T-score

[Few trials]

Few trials

[HF-ACTION cohort]

HF-ACTION cohort

[ischemic-hypertensive cardiomyiopathy]

ischemic-hypertensive cardiomyiopathy

[characteristics]

characteristics

[beta-blocker]

beta-blocker, beta-blockers, Beta-blocker

[NYHA]

NYHA

[wall]

wall

[procedure]

procedures, procedure

[HFrEF]

HFrEF

[MI]

MI

[sex]

sex

[oxygen]

oxygen, Oxygen

[area]

areas, area

[all-cause]

all-cause

[history]

history, HISTORY

[activation]

activation, Activation

[onset]

onset

[dopamine]

dopamine

[CRF]

CRF

[CV]

CV

[MS]

MS

[r]

r

[system]

Systems, systems, system

[deficit]

deficits, deficit

[correlation]

correlation, Correlations

[HeartMate]

HeartMate

[strain]

strain

[resonance]

resonance

[psoriasis]

Psoriasis, psoriasis

[mmol]

mmol

[doxorubicin]

doxorubicin

[energy]

energy

[F]

F

[comorbidity]

comorbidities, comorbidity

[Mena]

Mena

[LA]

LA

[fat]

fat, Fat

[BB]

BB

[adjustment]

adjustment

[KCCQ]

KCCQ

[dose]

dose, doses

[phenotype]

phenotype, phenotypes

[regard]

regard, regarding

[prediction]

prediction

[Medicare]

Medicare

[nesiritide]

nesiritide

[testosterone]

Testosterone, testosterone

[Self-Care]

Self-Care, self-care

[pathway]

pathways, pathway

[children]

children

[prevalence]

prevalence, Prevalence

[contribution]

contributions, contribution

[reference]

reference

[TAPSE]

TAPSE

[BET]

BET, BETs

[wk]

wk

[etiology]

etiology, etiologies

[nursing]

Nursing, nursing

[agent]

agents, agent

[phosphorylation]

phosphorylation

[albumin]

albumin

[tool]

tools, tool, Tools

[growth]

growth

[variable]

variables, variable

[nurse]

nurse, nurses, Nurses

[potential]

potential

[pathophysiology]

pathophysiology, Pathophysiology

[VAD]

VADs, VAD

[tone]

tone

[need]

needs, need

[composite]

composite

[L]

L

[l]

l

[mass]

Mass, mass

[transcription]

transcription

[report]

reports, report, reporting

[leading]

leading

[animal]

animal, Animals, animals

[filtration]

filtration

[resistance]

resistance

[sample]

sample, samples

[TAC]

TAC

[parameter]

parameters, parameter

[center]

Centers, center, centers

[saxagliptin]

saxagliptin

[IRS1]

IRS1

[IRS2]

IRS2

[eGFR]

eGFR

[aOR]

aOR

[tissue]

tissue, tissues

[investigation]

Investigation, investigation, investigations, INVESTIGATIONS

[indication]

indication, indications

[process]

processes, process, Process

[sitagliptin]

sitagliptin

[cardiotoxicity]

cardiotoxicity

[cost-effectiveness]

cost-effectiveness, Cost-Effectiveness

[stay]

stay

[iron]

iron

[RS]

RS

[cachexia]

cachexia

[LVEF]

LVEF

[diuretic]

diuretic, diuretics, Diuretics

[length]

length

[ESRD]

ESRD

[NYHA]

NYHA

[E]

E

[S1PR1]

S1PR1, S1PR1s

[HF-ACTION]

HF-ACTION

[CO]

CO

[IE]

IE

[VA]

VA

[AT]

AT

[EH]

EH

[ability]

ability

[MT]

MT

[OR]

OR

[GLS]

GLS

[article]

articles, article

[dietary]

dietary

[abnormalities]

abnormalities

[inclusion]

inclusion

[comparison]

comparisons, comparison

[importance]

importance, IMPORTANCE

[trastuzumab]

trastuzumab, Trastuzumab

[L-type]

L-type

[aldosterone]

Aldosterone, aldosterone

[pump]

pump

[c-Kit]

c-Kit

[percent]

percent

[B-type]

B-type

[SCN5A]

SCN5A

[rate-control]

rate-control, Rate-control

[summary]

Summary, summary, SUMMARY

[vivo]

vivo

[β-AR]

β-AR

[rehospitalization]

rehospitalization

[STS]

STS

[test]

test, tests

[training]

training, trainings

[barrier]

barrier, barriers

[laboratory]

laboratory

[bottleneck]

bottleneck

[myocardium]

myocardium

[rest]

rest, resting

[meta-analysis]

meta-analysis, Meta-analysis

[enrollment]

enrollment, Enrollment

[stimulation]

stimulation

[user]

users, Users, user

[PDE2]

PDE2

[potassium]

potassium, Potassium

[DASH]

DASH

[ATP]

ATP

[cAMP]

cAMP

[markers]

markers

[elastance]

elastance

[alterations]

alterations

[remodelling]

remodelling

[mRNA]

mRNA

[action]

actions, action

[chromatin]

chromatin

[structure]

structure

[percentage]

percentage

[membrane]

membrane

[leaflet]

leaflet

[dialysis]

dialysis, Dialysis

[decline]

decline, Declines, declines

[examination]

examination, Examination

[combination]

combination, Combination, combinations

[salt]

salt

[NT-proBNP]

NT-proBNP

[effectiveness]

Effectiveness, effectiveness

[coupling]

coupling

[criteria]

criterion, criteria

[mean]

mean

[fibrosis]

fibrosis

[community]

communities, community

[CC]

CC

[ET]

ET

[PD]

PD

[cm]

cm

[CS]

CS

[Na]

Na

[hemoglobin]

hemoglobin, Hemoglobin

[pg]

pg

[TM]

TM

[FFM]

FFM

[simulation]

simulation, Simulations

[BiVP]

BiVP

[distance]

distance

[inflammation]

inflammation

[pyridostigmine]

pyridostigmine

[Kansas]

Kansas

[pilot]

pilot

[Minnesota]

Minnesota

[LAD]

LAD

[HRQoL]

HRQoL

[LCX]

LCX

[HFrEF]

HFrEF

[MVA]

MVA

[atherosclerosis]

atherosclerosis, Atherosclerosis

[survivors]

survivors

[presence]

presence, Presence

[component]

component, components

[Rad]

Rad

[transplantation]

transplantation

[incident]

incident

[stage]

stage, Stage, stages

[TNF]

TNF

[work]

work, Work, Working

[monitoring]

monitoring

[metric]

metrics, metric

[attention]

attention, Attention

[contrast]

contrast, Contrasting

[e]

e

[insight]

Insights, insight

[implementation]

implementation

[basis]

basis

[hypoalbuminemia]

hypoalbuminemia

[alternative]

alternatives, alternative

[sham]

sham, shams

[application]

applications, application

[collagen]

collagen

[breast]

breast, Breast

[ring]

ring

[country]

countries, country

[program]

program, programs

[sinus]

sinus

[walk]

walk

[interval]

interval

[implications]

Implications, implications

[endpoint]

endpoint, endpoints

[angiogenesis]

angiogenesis

[syndrome]

syndrome, syndromes

[Doppler]

Doppler

[titin]

titin

[CRT-D]

CRT-D

[resource]

resources, resource

[decade]

decade, decades

[transition]

transition, transitions

[inhibition]

inhibition

[flow]

flow

[median]

median

[EO-CFUs]

EO-CFUs

[City]

City

[bleeding]

bleeding

[B]

B

[β]

β

[shock]

shock

[purpose]

Purpose, purpose, purposes, PURPOSE

[dilatation]

dilatation

[worsening]

worsening

[catheter]

catheter, Catheter

[duration]

duration

[LVET]

LVET

[ischemia]

ischemia

[state]

state, states

[C]

C

[N]

N

[s]

s

[information]

information

[pacing]

pacing

[CHM]

CHM

[CPCs]

CPCs

[EF]

EF

[Ea]

Ea

[EMBASE]

EMBASE

[fit]

fit

[growing]

growing

[CH]

CH

[EMD]

EMD

[HM]

HM

[authors]

authors

[NP]

NP

[pro-B-type]

pro-B-type

[atrial]

atrial, Atrial

[hHF]

hHF

[weight]

weight

[beta]

beta, Beta

[outpatients]

outpatients

[ICD]

ICDs, ICD

[ICU]

ICU

[proteomics]

proteomics

[uptitration]

Uptitration, uptitration

[blocker]

blockers, blocker

[JQ1]

JQ1

[records]

records

[prevention]

prevention

[LVH]

LVH

[progenitor]

progenitor, progenitors

[relevance]

RELEVANCE, relevance

[e'septal]

e'septal

[PAF]

PAF

[ZSF1]

ZSF1

[POC]

POC

[Patient]

Patient, Patients

[non-AA]

non-AA, non-AAs

[nicorandil]

nicorandil

[QTV]

QTV

[HFVT(+)]

HFVT(+)

[metabolism]

metabolism

[HNorm]

HNorm

[cutoff]

cutoff

[University]

University

[cardioverter]

cardioverter

[telehealth]

telehealth

[transfusion]

transfusion, transfusions

[progression]

progression

[administration]

administration

[β1AR]

β1AR, β1ARs

[literature]

literature, Literature

[Disease]

Diseases, Disease

[point]

point, points

[stent]

stent, stenting

[unit]

unit, units

[neprilysin]

neprilysin

[signs]

signs

[Bisphosphonate]

bisphosphonates, Bisphosphonate

[ECCT]

ECCT

[attenuation]

attenuation

[ECMO]

ECMO

[decongestion]

decongestion

[rehabilitation]

rehabilitation

[region]

regions, region

[method]

Methods, method

[regurgitation]

regurgitation

[cardiology]

Cardiology, cardiology

[pneumonia]

pneumonia

[AUC]

AUC

[defibrillator]

defibrillator, Defibrillator

[databases]

databases

[Ca]

Ca

[Relation]

relations, Relation, relation

[impairment]

impairment

[velocity]

velocity

[implantation]

implantation, Implantation

[usefulness]

usefulness, Usefulness

[Depression]

Depression

[bpm]

bpm

[understanding]

understanding

[DNA]

DNA

[athletes]

athletes

[milliseconds]

milliseconds

[lesion]

lesions, lesion

[angiography]

angiography

[consequence]

consequences, consequence

[Hand2]

Hand2

[cm2]

cm2

[Bax]

Bax

[walking]

walking

[AF]

AF

[Trial]

Trial

[bundle]

bundle

[catheterization]

catheterization

[network]

network, networks

[clinic]

clinic

[size]

size

[myofiber]

myofiber

[reserve]

reserve

[variation]

variation, Variation

[I]

I

[AN]

AN, A

[Q]

Q

[CMS]

CMS

[CPR]

CPR

[BTT]

BTT

[vasopressin]

vasopressin

[CFI]

CFI

[ECMO+VAD]

ECMO+VAD

[progress]

progress

[FM]

FM

[IV]

IV

[g]

g

[B-treated]

B-treated

[FES]

FES

[extent]

extent

[dL]

dL

[renal]

renal

[expenditure]

expenditures, expenditure

[dl]

dl

[EC]

EC

[FM]

FM

[ERC]

ERC

[m2]

m2

[PH]

PH

[January]

January

[phase]

phase

[institution]

institution, institutions

[cGMP]

cGMP

[embolism]

embolism

[Development]

Development

[reverse]

reverse, REVERSE

[CXL-1020]

CXL-1020

[IEs]

IEs

[HHD]

HHD

[Multicenter]

Multicenter, multicenter

[hypothesis]

hypothesis

[LIMITATION]

Limitations, limitations, LIMITATION

[pioglitazone]

pioglitazone

[downregulation]

downregulation

[Covariate]

Covariate, covariates

[validity]

validity

[variants]

variants

[inhibitor]

inhibitors, inhibitor

[HFPSI]

HFPSI

[experience]

experience, Experience

[lyso-PAF-AT]

lyso-PAF-AT

[glycolysis]

glycolysis

[MDC]

MDC

[matrix]

matrix

[Bcl-2]

Bcl-2

[NPs]

NPs

[urine]

urine

[recovery]

recovery

[phosphocreatine]

phosphocreatine

[PAD]

PAD

[restriction]

restriction

[signalling]

signalling

[QOL]

QOL

[CLCNKA]

CLCNKA

[HART]

HART

[future]

future, Future

[Grade]

Grade, grade

[absence]

absence

[RWT]

RWT

[CHF-INV]

CHF-INV

[timing]

timing

[RAS]

RAS

[delay]

delay

[RGK]

RGK

[Outcomes]

Outcomes

[efficiency]

efficiency

[SAF]

SAF

[Rad]

Rad

[harms]

harms

[SRD]

SRD

[alendronate]

alendronate

[Hum-Retn]

Hum-Retn

[STE]

STE

[anticoagulants]

anticoagulants

[revascularization]

revascularization

[participating]

Participating, participating

[Cochrane]

Cochrane

[angiotensin-converting]

angiotensin-converting

[TAC]

TAC

[SkM]

SkM

[RMSEA]

RMSEA

[gender]

gender

[Seattle]

Seattle

[ARIC]

ARIC

[UPR]

UPR

[consensus]

consensus, Consensus

[tachycardia]

tachycardia

[visit]

visit, visits

[Nicorandil]

Nicorandil

[perturbations]

perturbations, Perturbations

[success]

success

[uninephrectomy]

uninephrectomy

[twist]

twist

[vitro]

vitro

[apoptosis]

apoptosis

[Cardiology]

Cardiology

[adherence]

adherence

[lung]

lung

[total]

total

[miRNAs]

miRNAs

[site]

sites, site

[circulating]

Circulating, circulating

[means]

means

[part]

part

[arrhythmia]

arrhythmia

[chemotherapy]

chemotherapy, Chemotherapy

[Canada]

Canada

[clinician]

clinicians, clinician

[enhancement]

enhancement, Enhancement

[Eplerenone]

Eplerenone

[June]

June

[significance]

significance

[n=11]

n=11

[PCWP]

PCWP

[CXL-1020]

CXL-1020

[Medicare]

Medicare, medicare

[material]

material, MATERIALS

[AAs]

AAs

[others]

others

[air]

air

[rhythm-control]

rhythm-control

[T1-mapping]

T1-mapping

[latter]

latter

[BAT]

BAT

[MADIT-CRT]

MADIT-CRT

[eGFR]

eGFR

[antiplatelet]

antiplatelet

[office]

office

[ANS]

ANS

[BTES]

BTES

[contractility]

contractility

[perfusion]

perfusion

[problem]

problems, problem

[DD]

DD

[atrium]

atrium

[UM]

UM

[regulation]

regulation

[deactivation]

deactivation

[constriction]

constriction

[antibodies]

antibodies

[strength]

strengths, strength

[quality-of-life]

quality-of-life

[Survival]

Survival

[majority]

majority

[Cardiomyopathy]

Cardiomyopathy

[CABG]

CABG

[frequency]

frequency, Frequency

[chelation]

chelation

[order]

order

[sympathovagal]

sympathovagal

[porcine]

porcine

[capita]

capita

[TUNEL]

TUNEL

[DEGs]

DEGs

[average]

average

[allopurinol]

allopurinol

[PAF-AH]

PAF-AH

[dogs]

dogs

[TGF-β]

TGF-β

[childhood]

childhood

[modification]

modification

[stem]

stemming, stem

[DCM]

DCM

[BB]

BB

[CF]

CF

[DT]

DT

[EH]

EH

[HH]

HH

[DNx]

DNx

[MR]

MR

[QT]

QT

[remaining]

remaining

[RA]

RA

[RM]

RM

[Blacks]

Blacks

[Sa]

Sa

[carotid]

carotid

[septum]

septum

[grip]

grip

[LBBB]

LBBB

[al]

al

[DT]

DT

[Ea]

Ea

[Go]

Go

[form]

forms, form

[Hg]

Hg

[context]

CONTEXT, context

[ng]

ng

[PB]

PB

[PF]

PF

[sham-INV]

sham-INV

[bridge]

bridge

[RR]

RR

[SV]

SV

[LVAS]

LVAS

[XO]

XO

[power]

power, Power

[FES]

FES

[Ees]

Ees

[scale]

scale, scales

[reader]

reader, readers

[TgTetMena]

TgTetMena

[discussion]

discussion, Discussion, discussions

[accounting]

accounting

[wave]

wave

[6-MWT]

6-MWT

[Connecticut]

Connecticut

[diastole]

diastole

[Hospital]

Hospital

[non-LBBB]

non-LBBB

[preferences]

preferences

[kinase]

kinase, kinases

[presenting]

presenting

[(123)I-MIBG]

(123)I-MIBG

[HCT]

HCT

[Abstract]

Abstract

[Japan]

Japan

[Echocardiograms]

Echocardiograms, echocardiograms

[HNO]

HNO

[production]

production

[testing]

testing

[RVAD]

RVAD, RVADs

[Studies]

Studies

[demographics]

demographics

[methylatropine]

methylatropine

[randomization]

randomization

[vehicle]

vehicle

[Shunt]

Shunt, shunt, shunts

[medicine]

medicine

[adjusting]

adjusting

[subset]

subset

[Kaplan-Meier]

Kaplan-Meier

[interatrial]

interatrial

[lean]

lean

[glucose]

glucose

[bHLH]

bHLH

[CaV1.3]

CaV1.3

[CINAHL]

CINAHL

[technique]

technique, techniques

[doctors]

doctors

[VA-RT]

VA-RT

[situation]

situation, situations

[Mice]

Mice

[acetylcholinesterase]

acetylcholinesterase

[VEGF]

VEGF

[test-retest]

test-retest

[VO2max]

VO2max

[β-adrenoceptor]

β-adrenoceptor

[Nucleolin]

Nucleolin

[arrhythmias]

arrhythmias

[PSSS]

PSSS

[normalization]

normalization

[crude]

Crude, crude

[professionals]

professionals

[CD34+VEGFR2]

CD34+VEGFR2

[attrition]

attrition, Attrition

[VEGF]

VEGF

[actin]

actin

[burden]

burden

[Pyridostigmine]

Pyridostigmine

[codes]

codes, coding

[phospholamban]

phospholamban

[SCHFI]

SCHFI

[estimates]

estimates

[ISrael]

ISrael

[COPD]

COPD

[blot]

blot, blots

[raloxifene]

raloxifene

[challenge]

challenge, challenges

[PAH]

PAH

[medium]

medium

[pigs]

pigs

[sulfonylureas]

sulfonylureas

[e'lateral]

e'lateral

[mixed-methods]

mixed-methods, Mixed-methods

[validation]

Validation, validation

[induction]

induction, Induction

[PNA]

PNA

[perspective]

perspectives, perspective

[operating]

operating

[operation]

operation, operations

[HABC]

HABC

[bisoprolol]

bisoprolol

[aspects]

aspects

[swine]

swine

[post-LVAD]

post-LVAD

[likelihood]

likelihood

[participation]

Participation, participation

[SCN5A]

SCN5A

[assignment]

assignment

[fluid]

fluid

[HFVT(-)]

HFVT(-)

[Québec]

Québec

[Race]

Race

[sensitivity]

sensitivity

[features]

features

[afterload]

afterload

[provider]

provider, providers

[cTnT]

cTnT

[TTA]

TTA

[TUG]

TUG

[SVR]

SVR

[concept]

concept, concepts

[bypass]

bypass

[TgTetMena]

TgTetMena

[SDQT]

SDQT

[BTES]

BTES

[sodium]

sodium

[deterioration]

deterioration

[UPR]

UPR

[scaffold]

scaffolds, scaffold

[isoproterenol]

isoproterenol

[loss]

loss

[microRNAs]

microRNAs, MicroRNAs

[apex]

apex

[ARNI]

ARNI

[way]

ways, way

[feasibility]

feasibility, Feasibility

[arrest]

arrest

[PROTOCOL]

protocols, PROTOCOL, protocol

[gait]

gait

[option]

option, options

[contributing]

contributing

[SDQT]

SDQT

[INTERPRETATION]

interpretation, INTERPRETATION

[interview]

interviews, interview

[VVD]

VVD

[brain]

brain

[States]

States

[WRF]

WRF

[retrospective]

retrospective

[focus]

focus, focusing

[hsCRP]

hsCRP

[chart]

chart

[antagonist]

antagonists, antagonist

[Raf-MEK1]

Raf-MEK1

[p=0·016]

p=0·016

[eNOS-Thr]

eNOS-Thr

[aging]

aging

[eplerenone]

eplerenone

[Practice]

Practice

[Presentation]

Presentation, presentation, presentations

[RATIONALE]

RATIONALE, rationale

[healthcare]

healthcare

[nontrastuzumab]

nontrastuzumab

[pre-HCT]

pre-HCT

[emean]

emean

[North]

North

[output]

output

[proportion]

proportion

[South]

South

[Europe]

Europe

[cystatin]

cystatin

[Gill]

Gill

[LVADs]

LVADs

[insulin-resistance]

insulin-resistance

[Obesity]

Obesity, obesity

[turbulence]

turbulence

[College]

College

[propranolol]

propranolol

[consultation]

consultations, consultation

[midpapillary]

midpapillary

[Lp-PLA2]

Lp-PLA2

[EAST]

EAST

[cardiologist]

cardiologist, cardiologists

[domain]

domains, domain

[PDE2]

PDE2

[March]

March

[shotgun]

shotgun

[DASH]

DASH

[Assessment]

Assessment

[July]

July

[agreement]

agreement

[creatinine]

creatinine

[troponin]

Troponin, troponin

[family]

family, families

[tonometry]

tonometry

[quintile]

quintile, quintiles

[ECMO]

ECMO

[liver]

liver, Liver

[parallel]

parallel

[Rotterdam]

Rotterdam

[mutant]

mutant

[existing]

existing

[CentriMag]

CentriMag

[assay]

assay, assays

[microstructure]

microstructure

[nbDMARD]

nbDMARD, nbDMARDs

[kilogram]

kilogram

[quartile]

quartiles, quartile

[PERK]

PERK

[infancy]

infancy

[tolvaptan]

tolvaptan

[sphingosine-1-phosphate]

sphingosine-1-phosphate

[anthracycline]

anthracycline

[people]

people

[update]

update

[definition]

definition, definitions

[hospitalisation]

hospitalisation, hospitalisations

[MDC95]

MDC95

[derivation]

derivation

[ACF]

ACF

[ACS]

ACS

[ACR]

ACR

[CHF-INV]

CHF-INV

[defects]

defects

[MEDLINE]

MEDLINE

[ANG]

ANG

[Intubation]

intubations, Intubation, intubation

[refill]

refill

[AVD]

AVD

[resting]

Resting, resting

[depression]

depression

[ACF]

ACF

[ACP]

ACP

[SS20]

SS20

[breathing]

breathing

[AHF]

AHF

[bromodomain]

Bromodomain, bromodomain

[BTT]

BTT

[myocyte]

myocytes, myocyte

[fragment]

fragment, fragments

[Beck]

Beck

[DXA]

DXA

[SR]

SR

[AI]

AI

[respiration]

respiration

[advances]

advances, Advances

[shortening]

shortening

[discrimination]

discrimination

[fee-for-service]

fee-for-service

[pathogenesis]

pathogenesis

[Determination]

Determination, determination

[elevation]

elevations, elevation

[exclusion]

Exclusion, exclusion

[T-score]

T-score

[maintenance]

maintenance, Maintenance

[indicator]

indicators, indicator

[compliance]

compliance, Compliance

[goal]

goal

[-]

-

[Nfat]

Nfat

[A]

A

[R]

R

[T]

T

[C]

C, c

[pluripotency]

pluripotency

[SUrvival]

SUrvival

[HeartWare]

HeartWare

[Dialysis]

Dialysis

[ascending]

ascending

[noncardiac]

noncardiac

[late-onset]

late-onset

[Age]

Age

[PARADIGM-HF]

PARADIGM-HF

[MedLine]

MedLine

[CO.]

CO.

[protection]

protection

[renin-angiotensin]

renin-angiotensin

[BMI]

BMI

[Akt]

Akt

[Bcl2]

Bcl2

[ROSE]

ROSE

[Ann]

Ann

[Framingham]

Framingham

[flux]

flux

[Pro75-Arg76]

Pro75-Arg76

[Sweden]

Sweden

[micronutrients]

micronutrients

[thigh]

thigh

[budget]

budget

[dyslipidemia]

dyslipidemia

[consistency]

consistency

[calreticulin]

calreticulin

[Δ]

Δ

[α]

α

[etidronate]

etidronate

[Introduction]

Introduction

[concentration]

Concentrations, concentration

[CFA]

CFA

[non-DNx]

non-DNx

[E-wave]

E-wave

[L-type]

L-type

[therapeutics]

therapeutics

[CIs]

CIs

[(-)-ERC]

(-)-ERC

['D]

'D

[attempt]

attempt

[lying]

lying

[curve]

curve

[cogeneration]

cogeneration

[DRS]

DRS

[fulfilling]

fulfilling

[case-fatality]

case-fatality

[CVD]

CVD

[male]

male, males

[Australia]

Australia

[interest]

interest

[China]

China

[step]

step

[base]

base

[theory]

theory

[foundation]

foundation

[Osprey]

Osprey

[ECG]

ECG

[Ees]

Ees

[advantage]

advantage

[DTT]-insensitive]

DTT]-insensitive

[valvular]

valvular

[branch]

branches, branch

[version]

version

[CA]

CA

[case-control]

case-control

[CH]

CH

[CR]

CR

[rs10927887]

rs10927887

[EC]

EC

[signalosome]

signalosome

[education]

education

[L.]

L.

[Implantation]

Implantation

[cardioprotection]

cardioprotection

[CrI]

CrI

[bridging]

bridging

[pressure-volume]

pressure-volume

[PF]

PF

[anaesthesia]

anaesthesia

[R.]

R.

[RR]

RR

[SH]

SH

[figure]

figure

[UK]

UK

[US]

US

[duplicate]

duplicate

[VT]

VT

[WT]

WT

[window]

window

[physiology]

physiology

[ECG]

ECG

[pharmaceuticals]

pharmaceuticals

[NT-ProBNP]

NT-ProBNP

[ECs]

ECs

[nutrition]

nutrition, Nutrition

[candidate]

candidates, candidate

[Nfat]

Nfat, NFAT

[assumption]

assumption

[AS]

AS

[panel]

panel

[ABCD]

ABCD

[feet]

feet

[CF]

CF

[bradyarrhythmias]

bradyarrhythmias

[language]

language

[eg]

eg

[ET]

ET

[I2]

I2

[IC]

IC

[ie]

ie

[additive]

additive

[ESC]

ESC

[Ka]

Ka

[oxidation]

oxidation

[disposition]

disposition

[renin]

renin

[LF]

LF

[seconds]

seconds

[NYHA-II]

NYHA-II

[O2]

O2

[disciplines]

disciplines

[METs]

METs

[QT]

QT

[RM]

RM

[se]

se

[SH]

SH

[SR]

SR

[Up]

Up

[plasticity]

plasticity

[VO]

VO

[outcome-monitoring]

outcome-monitoring

[CHF-DNx]

CHF-DNx

[force]

force

[Gem]

Gem

[Cα]

Cα

[Zealand]

Zealand

[hyperinsulinemia]

hyperinsulinemia

[Maisel]

Maisel

[7508T→A]

7508T→A

[n=238]

n=238

[epitopes]

epitopes

[phenylephrine]

phenylephrine

[ingenuity]

ingenuity

[pulmonary]

pulmonary

[pediatrics]

pediatrics

[implant]

implant

[fiber]

fiber

[HRQoL]

HRQoL

[gut]

gut

[messenger]

messenger

[anticoagulation]

anticoagulation

[norepinephrine]

norepinephrine

[Caspase-3]

Caspase-3

[Placebo]

Placebo

[clarity]

clarity

[nonadherence]

nonadherence

[nephropathy]

nephropathy

[HFE]

HFE

[lessons]

lessons

[Hgb]

Hgb

[Fig]

Fig

[HNO]

HNO

[nitrite]

nitrite

[organ]

organ

[n=120]

n=120

[Ceballos]

Ceballos

[Perkins]

Perkins

[(123)I-meta-iodobenzylguanidine]

(123)I-meta-iodobenzylguanidine

[Ad-C]

Ad-C

[CHOP]

CHOP

[trigger]

trigger

[Mena]

Mena

[breathlessness]

breathlessness

[DAVID]

DAVID

[sustainability]

sustainability

[°C]

°C

[Hum-Retn]

Hum-Retn

[ICC]

ICC

[HEK]

HEK

[ablation]

ablation

[Society]

Society

[Clin]

Clin

[IL6]

IL6

[Dodson]

Dodson

[immunohistochemistry]

immunohistochemistry

[dementia]

dementia

[p70S6K]

p70S6K

[post]

post

[post-AAC]

post-AAC

[respect]

respect

[euthanization]

euthanization

[income]

income

[pre-PD]

pre-PD

[IVC]

IVC

[HFPSI]

HFPSI

[property]

properties, property

[study-drug]

study-drug

[Safety]

Safety

[Aldactone]

Aldactone

[ICD]

ICD

[ERK1]

ERK1

[telephone]

telephone

[Description]

Description

[Hgb]

Hgb

[plateau]

plateau

[IL6]

IL6

[RVPO]

RVPO

[β-Blockade]

β-Blockade

[n=431]

n=431

[PAF-CPT]

PAF-CPT

[pay-for-performance]

pay-for-performance

[Tolvaptan]

Tolvaptan

[lactate]

lactate

[colony-forming]

colony-forming

[bolus]

bolus

[fatigue]

fatigue

[publications]

publications

[cross]

cross

[pulse]

pulse

[specialty]

specialty

[varying]

varying

[access]

access

[specificity]

specificity

[atropine]

atropine

[SEER-Medicare]

SEER-Medicare

[NYHA-IIIb]

NYHA-IIIb

[PSSS]

PSSS

[lifesaving]

lifesaving

[repolarization]

repolarization

[Inc]

Inc

[S1PR1]

S1PR1

[d]

d

[antitachycardia]

antitachycardia

[MR-proANP]

MR-proANP

[example]

example

[feeding]

feeding

[VA-RT]

VA-RT

[Ventricular]

Ventricular

[CaV1.2]

CaV1.2

[capillary]

capillary

[discontinuation]

discontinuation

[citations]

citations

[nonpace]

nonpace

[knockdown]

knockdown

[conjunction]

conjunction

[MR-proADM]

MR-proADM

[sport]

sport

[scenario]

scenario, scenarios

[subproteome]

subproteomes, subproteome

[fashion]

fashion

[detergent]

detergent

[shuttle]

shuttle

[reliability]

reliability

[murine]

murine

[pause]

pause

[August]

August

[ICD-HF]

ICD-HF

[KCCQ]

KCCQ

[stiffness]

stiffness

[Oct]

Oct

[Hogan]

Hogan

[n=9]

n=9

[T1-mapping]

T1-mapping

[Sitagliptin]

Sitagliptin

[VCO2]

VCO2

[Olmsted]

Olmsted

[Addition]

Addition

[differentiation]

differentiation

[LC-MS]

LC-MS

[receiver]

receiver

[1515G→A]

1515G→A

[self-management]

self-management

[PubMed]

PubMed

[Kir]

Kir

[regulator]

regulator

[vegetables]

vegetables

[nonsurvivors]

nonsurvivors

[MLHF]

MLHF

[age-]

age-

[Pro2-Leu3]

Pro2-Leu3

[Edwards]

Edwards

[COPD]

COPD

[nmol]

nmol

[post-DASH]

post-DASH

[TNF)α]

TNF)α

[female]

female, females

[viscoelastic]

viscoelastic

[EPHESUS]

EPHESUS

[postexercise]

postexercise

[Caucasian]

Caucasian

[turnaround]

turnaround

[UV]

UV

[ZSF1]

ZSF1

[precipitating]

precipitating

[CPET]

CPET

[Taub]

Taub

[nonprescribing]

nonprescribing

[imaging]

imaging

[thrombosis]

thrombosis

[p38]

p38

[delivery]

delivery

[continuity]

continuity

[colon]

colon

[Fibrillation]

Fibrillation

[MRI]

MRI

[organizations]

organizations

[nuts]

nuts

[MVA]

MVA

[adiponectin]

adiponectin

[63C→G]

63C→G

[terminal]

terminal

[consideration]

consideration, considerations

[vena]

vena

[polytetrafluoroethylene]

polytetrafluoroethylene

[May]

May

[OHT]

OHT

[NHS]

NHS

[Duke]

Duke

[Lipolysis]

Lipolysis

[one]

one

[S3991]

S3991

[Zung]

Zung

[futility]

futility

[NOC]

NOC

[MLHF]

MLHF

[NPs]

NPs

[Optimization]

Optimization, optimization

[inability]

inability

[researchers]

researchers

[coming]

coming

[Cardiac-resynchronization]

Cardiac-resynchronization

[adipokines]

adipokines

[World]

World

[core]

core

[Q65P]

Q65P

[line]

line

[link]

link

[3-vessel]

3-vessel

[TissueFAXS]

TissueFAXS

[C-statistics]

C-statistics

[w]

w

[per]

per

[VEGFR2]

VEGFR2

[LDL-cholesterol]

LDL-cholesterol

[e'mean]

e'mean

[OHT]

OHT

[stenting]

stenting

[PKA]

PKA

[blood-flow]

blood-flow

[determinant]

determinants, determinant

[sham-INV]

sham-INV

[PNA]

PNA

[cytochrome]

cytochrome

[PPR]

PPR

[mmHg]

mmHg

[substudy]

substudy

[post-PD]

post-PD

[zebrafish]

zebrafish

[transmitral]

transmitral

[PVF]

PVF

[Resynchronization]

Resynchronization

[murmurs]

murmurs

[uptake]

uptake

[G-protein]

G-protein

[6MWT]

6MWT

[knowledge]

knowledge

[California]

California

[involvement]

involvement

[slowness]

slowness

[PDE]

PDE

[Henry]

Henry

[dipeptidyl]

dipeptidyl

[Guideline-Heart]

Guideline-Heart

[instance]

instance

[occurring]

occurring

[PKA]

PKA

[HEALTHSTAR]

HEALTHSTAR

[Gln27]

Gln27

[PVF]

PVF

[discrepancy]

discrepancy

[Caloric]

Caloric

[X-ray]

X-ray, x-ray

[eseptal]

eseptal

[RAAS]

RAAS

[nephrectomy]

nephrectomy

[early-onset]

early-onset

[collateral]

collateral

[health-care]

health-care

[re-hospitalization]

re-hospitalization

[carbohydrates]

carbohydrates

[Pigs]

Pigs

[closure]

closure

[tachy]

tachy

[HNorm]

HNorm

[ROS]

ROS

[T2D]

T2D

[non-HF]

non-HF

[immunoprecipitation]

immunoprecipitation

[caspase-3]

caspase-3

[sampling]

sampling

[Pol]

Pol

[organisation]

organisation

[N-terminal]

N-terminal

[Resynchronization-Defibrillation]

Resynchronization-Defibrillation

[pattern]

pattern

[disorder]

disorder

[angina]

angina

[RCTs]

RCTs

[completion]

completion

[set]

set

[HF-REF]

HF-REF

[osteomedullary]

osteomedullary

[reducing]

reducing

[nucleolin]

nucleolin

[RNA]

RNA

[Alberta]

Alberta

[myofilament]

myofilament

[PKC-βII-Ser]

PKC-βII-Ser

[CHF-NYHA-II]

CHF-NYHA-II

[Ser23]

Ser23

[pump-exchange]

pump-exchange

[MADIT-CRT]

MADIT-CRT

[intraclass]

intraclass

[RWT]

RWT

[Lancet]

Lancet

[prescription]

prescription

[Hungary]

Hungary

[sub-groups]

sub-groups

[Ser77]

Ser77

[interplay]

interplay

[Ser83]

Ser83

[hand]

hand

[Hypoalbuminemia]

Hypoalbuminemia

[coagulability]

coagulability

[exertion]

exertion

[Ontario]

Ontario

[RENASTUR]

RENASTUR

[EMPHASIS-HF]

EMPHASIS-HF

[(eGFR)-group]

(eGFR)-group

[start]

start

[borderline]

borderline

[recipients]

recipients

[TAPSE-to-PASP]

TAPSE-to-PASP

[Diuretic]

Diuretic

[surviving]

surviving

[infusion]

infusion

[water]

water

[6-wk]

6-wk

[food-frequency]

food-frequency

[colleagues]

colleagues

[Sci]

Sci

[METHODOLOGY]

METHODOLOGY

[Gln27]

Gln27

[Arbor]

Arbor

[Macrophages]

Macrophages, macrophages

[terms]

terms

[right]

right

[hemocompatibility]

hemocompatibility

[December]

December

[log2]

log2

[Lokomat®]

Lokomat®

[UTI]

UTI

[originating]

originating

[TTA]

TTA

[smoking]

smoking

[TUG]

TUG

[synchrony]

synchrony

[loop]

loop

[contraindications]

contraindications

[utilization]

utilization

[Variability]

Variability, variability

[Arg16]

Arg16

[propensity-score]

propensity-score

[threshold]

threshold

[Revision]

Revision, revision

[DPP-4]

DPP-4

[adolescence]

adolescence

[rs1799945]

rs1799945

[Michigan]

Michigan

[Epidemiology]

Epidemiology

[VO2]

VO2

[inroads]

inroads

[concordance]

concordance

[von]

von

[degradation]

degradation

[cTnT]

cTnT

[renin-angiotensin-aldosterone]

renin-angiotensin-aldosterone

[hypokalemia]

hypokalemia

[Mammalian]

Mammalian

[net-reclassification-improvement]

net-reclassification-improvement

[RTQ-PCR]

RTQ-PCR

[incorporating]

incorporating

[severity]

severity

[VAD]

VAD

[β-blockade]

β-blockade

[topic]

topics, topic

[hyperlipidaemia]

hyperlipidaemia

[ACTRN12610001087044]

ACTRN12610001087044

[pacemaker]

pacemaker, pacemakers

[decile]

deciles, decile

[occlusion]

occlusion

[2+)-pump]

2+)-pump

[WRF]

WRF

[portal]

portal

[etiologic]

etiologic

[expansion]

expansion

[adaptation]

adaptation

[decision-support]

decision-support

[nodularity]

nodularity

[Rem2]

Rem2

[15-mL]

15-mL

[Gene]

Gene

[GDMT]

GDMT

[confounders]

confounders

[sound]

sound

[translating]

translating

[Glu27]

Glu27

[CORAL]

CORAL

[CD133]

CD133

[Retn]

Retn

[Kaiser]

Kaiser

[Caspase]

Caspase, caspase

[hypoxia]

hypoxia

[sex-]

sex-

[Communities]

Communities

[Lung]

Lung

[Americans]

Americans

[Cardiovascular]

Cardiovascular

[30-day]

30-day

[Tuscany]

Tuscany

[molecule]

molecule

[Guidelines-Heart]

Guidelines-Heart

[defense]

defense

[oxide]

oxide

[effort]

efforts, effort

[p=0·035]

p=0·035

[histone]

histone

[Leu3-Gly4]

Leu3-Gly4

[AUCs]

AUCs

[haplotype]

haplotype

[breath-holding]

breath-holding

[NAD(P)]

NAD(P)

[ethnicity]

ethnicity

[dyspnea]

dyspnea

[promise]

promise

[Multicenter]

Multicenter

[Medicaid]

Medicaid

[permeability]

permeability

[Latin]

Latin

[binding]

binding

[amplitude]

amplitude

[Nonpublic]

Nonpublic

[GDMT]

GDMT

[gating]

gating

[Dietary]

Dietary

[eNOS-Ser]

eNOS-Ser

[complicity]

complicity

[neurohormone]

neurohormones, neurohormone

[osteoporosis]

osteoporosis

[hybrid]

hybrid

[unanchors]

unanchors

[TM24]

TM24

[Association]

Association

[U.S.]

U.S.

[debate]

debate

[sternotomy]

sternotomy

[surrogate]

surrogates, surrogate

[driveline]

driveline

[pathobiology]

pathobiology

[radioenzymatic]

radioenzymatic

[correction]

correction

[thalassaemia]

thalassaemia

[Retn]

Retn

[PASP]

PASP

[Centers]

Centers

[preceding]

preceding

[PRONTO]

PRONTO

[auscultation]

auscultation

[side]

side

[Glu27]

Glu27

[Spironolactone]

Spironolactone

[gluconeogenesis]

gluconeogenesis

[initiation]

initiation

[miR-25]

miR-25

[dissemination]

dissemination

[leukocytes]

leukocytes

[place]

place

[observation]

observation

[S12884]

S12884

[LVET]

LVET

[computing]

computing

[matching]

matching

[Ciaraldi]

Ciaraldi

[transduction]

transduction

[centrifugal-flow]

centrifugal-flow

[Dissemination]

Dissemination

[November]

November

[Phosphodiesterase-2]

Phosphodiesterase-2

[Aldactone]

Aldactone

[possibility]

possibility

[systole]

systole

[Collaboration]

Collaboration

[pace]

pace

[prolapse]

prolapse

[Congestive]

Congestive

[cornerstone]

cornerstone

[Calif]

Calif

[chest]

chest

[p38alpha]

p38alpha

[recruitment]

recruitment

[esmolol]

esmolol

[centre]

centre

[Affairs]

Affairs

[Murphy]

Murphy

[HeartWare]

HeartWare

[profile]

profile

[time-varying]

time-varying

[conduction]

conduction

[s'lateral]

s'lateral

[KCl-KI]

KCl-KI

[hemostasis]

hemostasis

[humans]

humans

[recognition]

recognition

[rs8187710]

rs8187710

[Breath]

Breath

[repeat]

repeat

[circulation]

circulation

[crossover]

crossover

[collaboration]

collaboration

[geometry]

geometry

[tobacco]

tobacco

[subdomains]

subdomains

[Ehrlich]

Ehrlich

[registry]

registry, registries

[Ea=1.5]

Ea=1.5

[washout]

washout

[Naviaux]

Naviaux

[Trans]

Trans

[imbalance]

imbalance

[Myxomas]

Myxomas

[science]

science

[utility]

utility

[hand-searching]

hand-searching

[descending]

descending

[canine]

canine

[Pro6-Gly7]

Pro6-Gly7

[Screening]

Screening

[Ad-Flk]

Ad-Flk

[new-onset]

new-onset

[difference-in-differences]

difference-in-differences

[Student]

Student

[(DRS)-stratified]

(DRS)-stratified

[Hope]

Hope

[ECCT]

ECCT

[P-value]

P-value

[Baroreflex]

Baroreflex

[shift]

shift, SHIFT

[10-EO-CFU]

10-EO-CFU

[proteome]

proteome

[flutter]

flutter

[Texas]

Texas

[September]

September

[miR-25]

miR-25

[ischemic]

ischemic

[rise]

rise

[length-force]

length-force

[contention]

contention

[PEVK]

PEVK

[dHAND]

dHAND

[echo-Doppler]

echo-Doppler

[electrolytes]

electrolytes

[Smad]

Smad

[stimuli]

stimuli

[Denmark]

Denmark

[n=22]

n=22

[n=95]

n=95

[ECMO+VAD]

ECMO+VAD

[RIIα]

RIIα

[surveys]

surveys

[regeneration]

regeneration

[province]

province

[CHF-DNx]

CHF-DNx

[N2Bus]

N2Bus

[awareness]

awareness

[epidemic]

epidemic

[s'septal]

s'septal

[destination]

destination

[CHA₂DS₂VASc]

CHA₂DS₂VASc

[DAPC]

DAPC

[Care]

Care

[distribution]

distribution

[INTERMACS]

INTERMACS

[vasodilator]

vasodilators, vasodilator

[conversations]

conversations

[CHF-NYHA-III]

CHF-NYHA-III

[co-morbidity]

co-morbidity, co-morbidities

[VO2max]

VO2max

[Anand]

Anand

[sepsis]

sepsis

[N-terminal]

N-terminal

[working]

working

[Retention]

Retention

[adjuvant]

adjuvant

[prostate]

prostate

[lipoprotein]

lipoprotein

[isoprenaline]

isoprenaline

[infection]

infection

[pre-CRT]

pre-CRT

[choice]

choice

[μg]

μg

[propensity]

propensity

[explant]

explant

[treadmill]

treadmill

[competing]

competing

[home]

home

[Paco2]

Paco2

[i.p.]

i.p.

[polymorphisms]

polymorphisms

[hours]

hours

[CLCNKA]

CLCNKA

[beagle]

beagle

[rankings]

rankings

[elateral]

elateral

[conflicting]

conflicting

[HF-ACTION]

HF-ACTION

[NYHA-IIIb]

NYHA-IIIb

[Inhibitor]

Inhibitor

[consisting]

consisting

[PsycINFO]

PsycINFO

[Nights]

Nights

[array]

array

[adenosine]

adenosine

[malondialdehyde]

malondialdehyde

[consenting]

consenting

[SS20]

SS20

[Willebrand]

Willebrand

[aim]

aim, aims

[nbDMARD]

nbDMARD

[arm]

arm

[AT1]

AT1

[tumor]

tumors, tumor

[AVP]

AVP

[vagal]

vagal

[Atrial]

Atrial

[Arg83Gly]

Arg83Gly

[ASTRONAUT]

ASTRONAUT

[Irvine]

Irvine

[Pleasanton]

Pleasanton

[amount]

amount

[Ramirez-Sanchez]

Ramirez-Sanchez

[AAC]

AAC

[ABC]

ABC

[rs13058338]

rs13058338

[ACS]

ACS

[Doxorubicin]

Doxorubicin

[LCZ696]

LCZ696

[AHA]

AHA

[surface]

surface

[AIM]

AIM

[Medicaid]

Medicaid

[AngII]

AngII

[currents]

currents

[dyssynchrony]

dyssynchrony

[migration]

migration

[off-pump]

off-pump

[Ca2]

Ca2

[hallmark]

hallmark

[BAT]

BAT

[p70S6K-Ser]

p70S6K-Ser

[dose of doxorubicin]

dose of doxorubicin

[Ventricular Assist System]

Ventricular Assist System

[Implications of metric choice for applications]

Implications of metric choice for applications

[ventricular biopsies]

ventricular biopsies

[relative importance for DD]

relative importance for DD

[III HF]

III HF

[arterial elastance end-systolic elastance Ees]

arterial elastance end-systolic elastance Ees

[sternotomy for valve procedures]

sternotomy for valve procedures

[experimental research]

experimental research

[decade of national efforts]

decade of national efforts

[CHM versus treatment]

CHM versus treatment

[atrial peptide]

atrial peptide

[conventional systolic parameters in AF]

conventional systolic parameters in AF

[groups with heart failure]

groups with heart failure

[Addition discrimination change in C-index]

Addition discrimination change in C-index

[study sample with patients]

study sample with patients

[BB dose versus mg daily dose]

BB dose versus mg daily dose

[H-DKO]

H-DKO

[left remodeling]

left remodeling

[target of heart failure research]

target of heart failure research

[TTA animals]

TTA animals

[Excellence]

Excellence

[endothelial cell EC]

endothelial cell EC

[change with exercise main effect]

change with exercise main effect

[independent correlates of increase]

independent correlates of increase

[ethnic groups]

ethnic groups

[Biventricular support]

Biventricular support

[LV pressure P]

LV pressure P

[pulmonary arterial pressure PASP]

pulmonary arterial pressure PASP

[patients with low ejection fraction]

patients with low ejection fraction

[protein levels]

protein levels

[disclosing prognosis]

disclosing prognosis

[patients geometry]

patients geometry

[characteristics use of evidence-based medications]

characteristics use of evidence-based medications

[larger control studies]

larger control studies

[Atherosclerotic Lesions CORAL]

Atherosclerotic Lesions CORAL

[relative value]

relative value

[left function in cardiac volume overload]

left function in cardiac volume overload

[CHF predictive model]

CHF predictive model

[V]

V

[Grading of Recommendations Assessment methodology]

Grading of Recommendations Assessment methodology

[turnaround times]

turnaround times

[resuscitation]

resuscitation

[review of preferences]

review of preferences

[telehealth system with care management]

telehealth system with care management

[G]

G

[h]

h

[Peritoneal dialysis for long-term management]

Peritoneal dialysis for long-term management

[53 consecutive patients]

53 consecutive patients

[men without a history]

men without a history

[Depression Scale]

Depression Scale

[most common type]

most common type

[troponin T cTnT]

troponin T cTnT

[patients with an eGFR]

patients with an eGFR

[Practice Guideline CPG]

Practice Guideline CPG

[using an start date]

using an start date

[statistically significant change main effect]

statistically significant change main effect

[lowest hazard]

lowest hazard

[treatment of heart failure treatment]

treatment of heart failure treatment

[Key role of ERK1 molecular scaffolds]

Key role of ERK1 molecular scaffolds

[strong predictor]

strong predictors, strong predictor

[morbidity especially in people]

morbidity especially in people

[placebo for days in this trial]

placebo for days in this trial

[failing Fontan]

failing Fontan

[54 patients]

54 patients

[net reclassification]

net reclassification

[2 distinct receptors]

2 distinct receptors

[QOL outcome]

QOL outcome

[relative risk RR]

relative risk RR

[patients requiring HeartMate]

patients requiring HeartMate

[measure of right ventricular reserve]

measure of right ventricular reserve

[blockers at evaluation]

blockers at evaluation

[arterial elastance Ea end-systolic elastance]

arterial elastance Ea end-systolic elastance

[EC coupling]

EC coupling

[safety end]

safety end

[indicating care of patients]

indicating care of patients

[Treating HF]

Treating HF

[10 heart failure HF patients]

10 heart failure HF patients

[left LV systolic pressure]

left LV systolic pressure

[care clinicians caring]

care clinicians caring

[transcriptional analysis]

transcriptional analysis

[effects of (-)-epicatechin-rich cocoa]

effects of (-)-epicatechin-rich cocoa

[novel antiadrenergic strategy in HF]

novel antiadrenergic strategy in HF

[modifying antirheumatic drug]

modifying antirheumatic drug

[7.5 mg]

7.5 mg

[cutoff level]

cutoff level

[even with systolic function]

even with systolic function

[ongoing Cardiovascular Outcomes in Lesions]

ongoing Cardiovascular Outcomes in Lesions

[playing a major role]

playing a major role

[Québec Canada]

Québec Canada

[three patients]

three patients

[ventricular base during baseline]

ventricular base during baseline

[m age]

m age

[correcting nutrition function]

correcting nutrition function

[independent hypotheses addition μg]

independent hypotheses addition μg

[descending artery]

descending artery

[partial attenuation]

partial attenuation

[changes in HDL-induced]

changes in HDL-induced

[constriction TAC]

constriction TAC

[depressive symptoms Hospital Anxiety]

depressive symptoms Hospital Anxiety

[Other prognostic factors]

Other prognostic factors

[cancers]

cancers

[weeks after AAC]

weeks after AAC

[associations of hHF]

associations of hHF

[Skeletal muscle abnormalities]

Skeletal muscle abnormalities

[Bradycardia indicative of sympathetic tone]

Bradycardia indicative of sympathetic tone

[Specific signalling pathways activating cardiac remodelling]

Specific signalling pathways activating cardiac remodelling

[strong mortality predictors]

strong mortality predictors

[rigorous investigation]

rigorous investigation

[Patient perceptions of cardioverter-defibrillator deactivation discussions]

Patient perceptions of cardioverter-defibrillator deactivation discussions

[Doppler mitral inflow velocity]

Doppler mitral inflow velocity

[difference among EF BNP]

difference among EF BNP

[L-type channel isoforms]

L-type channel isoforms

[cardioverter-defibrillators]

cardioverter-defibrillators

[specific inclusion]

specific inclusion

[pressure relationship in heart failure]

pressure relationship in heart failure

[partly a result]

partly a result

[treatment of acute heart failure treatment]

treatment of acute heart failure treatment

[predictor period versus 1]

predictor period versus 1

[unique indication]

unique indication

[Objective institution]

Objective institution

[predictor of all-cause mortality]

predictor of all-cause mortality

[blot analysis]

blot analysis

[cytoskeleton]

cytoskeleton

[mL P=0.01]

mL P=0.01

[state of mitochondrial stress]

state of mitochondrial stress

[need of resuscitation CPR]

need of resuscitation CPR

[enzyme inhibitors angiotensin receptor blockers]

enzyme inhibitors angiotensin receptor blockers

[Two hundred HF patients HFrEF]

Two hundred HF patients HFrEF

[derangement]

derangement

[membrane oxygenation on function in children]

membrane oxygenation on function in children

[lateral wall]

lateral wall

[relevance of right ventricular reserve]

relevance of right ventricular reserve

[differences in performance]

differences in performance

[degree of MS early]

degree of MS early

[CO2]

CO2

[index of right ventricular function]

index of right ventricular function

[renal disease in outpatients]

renal disease in outpatients

[growing subclass]

growing subclass

[2 scaffolds]

2 scaffolds

[mg daily equivalent dose]

mg daily equivalent dose

[levels of epinephrine]

levels of epinephrine

[end-point of all-cause mortality]

end-point of all-cause mortality

[association between dysfunction]

association between dysfunction

[reductions in the composite end-point]

reductions in the composite end-point

[effect of ejection fraction on mortality]

effect of ejection fraction on mortality

[trend toward days]

trend toward days

[obese ZSF1 rats]

obese ZSF1 rats

[evaluating the changes]

evaluating the changes

[right ventricular plane systolic excursion TAPSE]

right ventricular plane systolic excursion TAPSE

[–17.4 points]

–17.4 points

[bone expression]

bone expression

[increase in LV pressure]

increase in LV pressure

[defense mechanism during stress]

defense mechanism during stress

[basic relevance carrying increase]

basic relevance carrying increase

[databases for all adults]

databases for all adults

[function in chronic heart failure]

function in chronic heart failure

[cardiac Mena overexpression TTA comparable]

cardiac Mena overexpression TTA comparable

[infarction-related right heart failure]

infarction-related right heart failure

[reoperation]

reoperation

[phosphorylation capacity]

phosphorylation capacity

[records of surface ECGs]

records of surface ECGs

[extrapolating short-term outcomes]

extrapolating short-term outcomes

[similar risk of long-term mortality]

similar risk of long-term mortality

[receptor antagonist tolvaptan]

receptor antagonist tolvaptan

[including risk of blood glucose levels]

including risk of blood glucose levels

[subjects with hearts]

subjects with hearts

[relationship with adverse CV events AF]

relationship with adverse CV events AF

[Heart Failure Treatment]

Heart Failure Treatment

[undergoing assist device LVAD implantation]

undergoing assist device LVAD implantation

[platelet-activating factor]

platelet-activating factor

[prognostic relevance of ventricular contractile reserve]

prognostic relevance of ventricular contractile reserve

[achievement of metabolism quotient]

achievement of metabolism quotient

[true change]

true change

[standard rehabilitation care on functional capacity]

standard rehabilitation care on functional capacity

[prospective assessment of body composition]

prospective assessment of body composition

[Automatic Defibrillator Implantation]

Automatic Defibrillator Implantation

[significant reduction in mortality]

significant reduction in mortality

[P-value 0.001]

P-value 0.001

[chloride]

chloride

[CPG]

CPG

[hearts lacking Nucleolin]

hearts lacking Nucleolin

[presenting with a responsible diagnosis]

presenting with a responsible diagnosis

[ESRD patient-years]

ESRD patient-years

[including nuclear factor of T cells]

including nuclear factor of T cells

[developing malignancies]

developing malignancies

[Natriuretic peptide levels]

Natriuretic peptide levels

[Hereditary abnormalities]

Hereditary abnormalities

[Multiacquisition]

Multiacquisition

[characteristics eg]

characteristics eg

[trastuzumab-related CHF among patients]

trastuzumab-related CHF among patients

[care program]

care program

[brain natriuretic peptide levels pg]

brain natriuretic peptide levels pg

[Moderate evidence]

Moderate evidence

[catheterisation with echocardiographic guidance]

catheterisation with echocardiographic guidance

[decongestion end point]

decongestion end point

[alendronate- patients respectively]

alendronate- patients respectively

[increasing refill compliance P for trend]

increasing refill compliance P for trend

[HeartMate II]

HeartMate II

[changing doses of β-blocker]

changing doses of β-blocker

[Global strain of ventricle]

Global strain of ventricle

[Function]

Function

[undergoing DNx]

undergoing DNx

[improvement of cardiac performance]

improvement of cardiac performance

[predominantly mild disease]

predominantly mild disease

[cardiac death in athletes under 35]

cardiac death in athletes under 35

[more than a decade]

more than a decade

[temporary RV support]

temporary RV support

[types of continuous-flow LVADs HeartMate]

types of continuous-flow LVADs HeartMate

[left ventricular biopsies n=9]

left ventricular biopsies n=9

[1.61 times]

1.61 times

[discharge among patients]

discharge among patients

[Multicenter placebo-controlled trial of patients]

Multicenter placebo-controlled trial of patients

[cardiac sodium current]

cardiac sodium current

[transplant survival]

transplant survival

[334 patients 224 men]

334 patients 224 men

[change in follow-up visits]

change in follow-up visits

[rare with.estimates ranging]

rare with.estimates ranging

[ventricular-pulmonary coupling pulmonary vascular resistance]

ventricular-pulmonary coupling pulmonary vascular resistance

[Practice-level variation in use of medications]

Practice-level variation in use of medications

[603 patients]

603 patients

[prognostic information for an clinical outcome]

prognostic information for an clinical outcome

[Diagnostic role in coronary artery disease]

Diagnostic role in coronary artery disease

[heart failure in mice]

heart failure in mice

[ED visits years]

ED visits years

[baseline serum]

baseline serum

[4 wk effects]

4 wk effects

[Latin America]

Latin America

[patients with chronic disease COPD]

patients with chronic disease COPD

[hypertrophy a predictor of subsequent HF]

hypertrophy a predictor of subsequent HF

[walk test of feet]

walk test of feet

[clinical practice with these populations]

clinical practice with these populations

[elements]

elements

[Web-system]

Web-system

[end point of ESRD]

end point of ESRD

[reversible myocardial ischemia]

reversible myocardial ischemia

[valve area]

valve area

[Tools for Analysis A program]

Tools for Analysis A program

[impact of ventricular assist device]

impact of ventricular assist device

[simultaneous activation]

simultaneous activation

[stable body weight]

stable body weight

[creatine]

creatine

[general models]

general models

[clinical conditions]

clinical conditions

[all-cause hospitalization within the months]

all-cause hospitalization within the months

[mean of m]

mean of m

[fastest subclass of diseases]

fastest subclass of diseases

[ZSF1 with diet]

ZSF1 with diet

[walk distance]

walk distance

[Frailty an indicator]

Frailty an indicator

[HFpEF patients aged years]

HFpEF patients aged years

[Cardiomyopathy Questionnaire]

Cardiomyopathy Questionnaire

[2,538 eligible patients]

2,538 eligible patients

[using trichrome histologic analysis]

using trichrome histologic analysis

[prevalence ranging]

prevalence ranging

[PASP relationship]

PASP relationship

[definitions of the components]

definitions of the components

[cardiac myocyte-specific Mena overexpression]

cardiac myocyte-specific Mena overexpression

[measures explaining variation]

measures explaining variation

[writer proteins histone acetyltransferases]

writer proteins histone acetyltransferases

[incident CVD]

incident CVD

[transseptal catheterisation with guidance]

transseptal catheterisation with guidance

[development among CRT-D recipients]

development among CRT-D recipients

[Student t]

Student t

[group II mL per m]

group II mL per m

[fat mass index]

fat mass index

[several Outcomes Study Short-Form quality]

several Outcomes Study Short-Form quality

[varying regional strain contributions]

varying regional strain contributions

[6-month event rates]

6-month event rates

[CHF patients presenting]

CHF patients presenting

[embryonic kidney cells]

embryonic kidney cells

[frailty in heart failure]

frailty in heart failure

[limits of agreement difference]

limits of agreement difference

[connection between centers]

connection between centers

[treatment iron deficiency]

treatment iron deficiency

[LV ejection fraction velocity]

LV ejection fraction velocity

[with values]

with values

[beta-adrenergic receptor β-AR]

beta-adrenergic receptor β-AR

[ratio of blood flow velocity]

ratio of blood flow velocity

[chronic arterial hypertension]

chronic arterial hypertension

[common cause in young athletes]

common cause in young athletes

[good diagnostic performance in patients]

good diagnostic performance in patients

[demonstrating development]

demonstrating development

[coronary artery ligation]

coronary artery ligation

[use of devices in heart failure]

use of devices in heart failure

[intermediate outcomes events]

intermediate outcomes events

[restoring mitochondrial phosphorylation capacity]

restoring mitochondrial phosphorylation capacity

[elastance Ea elastance Ees]

elastance Ea elastance Ees

[outcome vs milliseconds]

outcome vs milliseconds

[outcome hospitalization]

outcome hospitalization

[cardiopulmonary resuscitation]

cardiopulmonary resuscitation

[hazards of events for psoriasis]

hazards of events for psoriasis

[long-term costs]

long-term costs

[diagnostic test for HFpEF]

diagnostic test for HFpEF

[LV volume LV]

LV volume LV

[New York Heart]

New York Heart

[Medicare hospital]

Medicare hospital

[Outcomes of Exercise Training study]

Outcomes of Exercise Training study

[final BB dose versus mg dose]

final BB dose versus mg dose

[health service provision related]

health service provision related

[optimal NT-proBNP cutoff point]

optimal NT-proBNP cutoff point

[internists P]

internists P

[improvements showing improvement]

improvements showing improvement

[Dual inhibition neprilysin blocks renin-angiotensin-aldosteron axis]

Dual inhibition neprilysin blocks renin-angiotensin-aldosteron axis

[gait therapy with the Lokomat® system]

gait therapy with the Lokomat® system

[Impaired angiogenesis]

Impaired angiogenesis

[non-biological disease nbDMARD]

non-biological disease nbDMARD

[difference between groups patients]

difference between groups patients

[subclinical atherosclerosis using models]

subclinical atherosclerosis using models

[subset of genes]

subset of genes

[wall infarction]

wall infarction

[aerobic training intervention]

aerobic training intervention

[serum sodium levels]

serum sodium levels

[especially in patients]

especially in patients

[with.estimates ranging from 1]

with.estimates ranging from 1

[thrombotic obstruction]

thrombotic obstruction

[diagnostic biomarkers]

diagnostic biomarkers

[strict standards]

strict standards

[avoiding the central region]

avoiding the central region

[further validation]

further validation

[DAPC protein complex]

DAPC protein complex

[fitness CRF]

fitness CRF

[influence on the financial burden]

influence on the financial burden

[(31)P resonance spectroscopy]

(31)P resonance spectroscopy

[range 18.6]

range 18.6

[295 veterans]

295 veterans

[wk per os]

wk per os

[magnetic resonance T1 mapping]

magnetic resonance T1 mapping

[varying atrioventricular delay]

varying atrioventricular delay

[savings]

savings

[risk developing malignancies]

risk developing malignancies

[catheter ablation for fibrillation]

catheter ablation for fibrillation

[tracking VA patients for months]

tracking VA patients for months

[inhibition of growth factor VEGF]

inhibition of growth factor VEGF

[PETCO2]

PETCO2

[role of ERK1 2 scaffolds]

role of ERK1 2 scaffolds

[improvement of NT-ProBNP inflammatory biomarkers]

improvement of NT-ProBNP inflammatory biomarkers

[production of EC]

production of EC

[Measuring frailty]

Measuring frailty

[global ventricular longitudinal strain GLS]

global ventricular longitudinal strain GLS

[safe pump-exchange technique]

safe pump-exchange technique

[heart sound]

heart sound

[6 months of follow-up]

6 months of follow-up

[anti-neoplastic agent in the treatment]

anti-neoplastic agent in the treatment

[consecutive ambulatory HF patients]

consecutive ambulatory HF patients

[primary diagnosis]

primary diagnosis

[Particular topics in heart failure concern]

Particular topics in heart failure concern

[possible measure]

possible measure

[high morbidity]

high morbidity

[guidance under general anaesthesia]

guidance under general anaesthesia

[similar risk]

similar risk

[HF diagnosis]

HF diagnosis

[resulting in the social support score]

resulting in the social support score

[physician continuity death]

physician continuity death

[describing a uniform nomenclature]

describing a uniform nomenclature

[important tool]

important tool

[serious events]

serious events

[cardiac index 0.7 L]

cardiac index 0.7 L

[14 studies 2900 HM II]

14 studies 2900 HM II

[milliseconds milliseconds]

milliseconds milliseconds

[systematic review of the effects]

systematic review of the effects

[undergoing resynchronization therapy with a defibrillator]

undergoing resynchronization therapy with a defibrillator

[Twenty-seven adult Fontan SAF patients]

Twenty-seven adult Fontan SAF patients

[fundamental mechanism during insulin resistance]

fundamental mechanism during insulin resistance

[transfusion protocols]

transfusion protocols

[Studies of predictors]

Studies of predictors

[systolic ventricular ejection fraction HF]

systolic ventricular ejection fraction HF

[regarding the need in combination]

regarding the need in combination

[performers]

performers

[time 4 years]

time 4 years

[survival of patients with preoperative hypoalbuminemia]

survival of patients with preoperative hypoalbuminemia

[BNP in women vs men]

BNP in women vs men

[BNP levels in patients]

BNP levels in patients

[heterogeneity]

heterogeneity

[chronic stable medical therapy GDMT]

chronic stable medical therapy GDMT

[health outcomes in male patients]

health outcomes in male patients

[effects of types]

effects of types

[additional benefit over conventional parameters]

additional benefit over conventional parameters

[rehabilitation care]

rehabilitation care

[hypertrophy EH]

hypertrophy EH

[most common form]

most common form

[greater risk]

greater risk

[several changes including hypertrophy]

several changes including hypertrophy

[MVA of cm2]

MVA of cm2

[body mass index ≥35 kg]

body mass index ≥35 kg

[MicroRNAs in heart failure targets]

MicroRNAs in heart failure targets

[pilot project]

pilot project

[EAST Early treatment of fibrillation]

EAST Early treatment of fibrillation

[Study Selection English-language trials in adults]

Study Selection English-language trials in adults

[protein complex]

protein complex

[afterload burden]

afterload burden

[diagnostic roles of BNP]

diagnostic roles of BNP

[156 consecutive HF patients]

156 consecutive HF patients

[replicating resource use from clinical trials]

replicating resource use from clinical trials

[voluntary testimonies]

voluntary testimonies

[economic evaluations HM]

economic evaluations HM

[Subgroup analysis of patients]

Subgroup analysis of patients

[competing risk]

competing risk

[first-in-man experience]

first-in-man experience

[patients with artery disease CAD]

patients with artery disease CAD

[nuclear factor-κB]

nuclear factor-κB

[vascular growth]

vascular growth

[ARNI inhibitors neprilysin inhibitors]

ARNI inhibitors neprilysin inhibitors

[hypertrophy CH]

hypertrophy CH

[Even on therapy including anticoagulation]

Even on therapy including anticoagulation

[controlling heart rate]

controlling heart rate

[achievement of metabolism peak quotient]

achievement of metabolism peak quotient

[Heart failure data in Latin America]

Heart failure data in Latin America

[distinct derangement albeit with ability]

distinct derangement albeit with ability

[highly effective anti-neoplastic agent]

highly effective anti-neoplastic agent

[Trastuzumab-related cardiotoxicity among older patients]

Trastuzumab-related cardiotoxicity among older patients

[heart pathology]

heart pathology

[HeartMate II devices]

HeartMate II devices

[dyssynchronous heart]

dyssynchronous heart

[Renal Lesions CORAL]

Renal Lesions CORAL

[composite primary outcome]

composite primary outcome

[hospital readmission]

hospital readmission

[exercise capacity in patients with HFPEF]

exercise capacity in patients with HFPEF

[such as exercise programmes]

such as exercise programmes

[type regulatory RIIα subunit expression]

type regulatory RIIα subunit expression

[CV events in univariate models p]

CV events in univariate models p

[HF in patients]

HF in patients

[measures of quality for HF]

measures of quality for HF

[valve procedures 1 valve replacement]

valve procedures 1 valve replacement

[hospital facilities]

hospital facilities

[trainings per week]

trainings per week

[dilatation improvement by ET]

dilatation improvement by ET

[incident HF in participants aged]

incident HF in participants aged

[thirds]

thirds

[diagnosis of dysfunction]

diagnosis of dysfunction

[first AMI]

first AMI

[obese ZSF1 with high-fat diet]

obese ZSF1 with high-fat diet

[evaluations using simulation models]

evaluations using simulation models

[Four groups of rats]

Four groups of rats

[2.1 points]

2.1 points

[interaction by EF]

interaction by EF

[Older Patients With Heart Failure]

Older Patients With Heart Failure

[antitumor]

antitumor

[sarcoplasmic reticular Ca]

sarcoplasmic reticular Ca

[relevance of contractile reserve in patients]

relevance of contractile reserve in patients

[year of OHT]

year of OHT

[pro-brain natriuretic peptide]

pro-brain natriuretic peptide

[2.1 kg]

2.1 kg

[right plane excursion from the end]

right plane excursion from the end

[dysfunction with conduction abnormalities]

dysfunction with conduction abnormalities

[sampling frame]

sampling frame

[modest benefit for patients in studies]

modest benefit for patients in studies

[ventricular plane excursion TAPSE]

ventricular plane excursion TAPSE

[Multicenter double-blind placebo-controlled trial]

Multicenter double-blind placebo-controlled trial

[GTPase]

GTPase

[ingenuity pathway]

ingenuity pathway

[addition indicating care of patients]

addition indicating care of patients

[Biventricular]

Biventricular

[promoting filling]

promoting filling

[HF years]

HF years

[stable arterial hypertension medication]

stable arterial hypertension medication

[culprit extending EMD]

culprit extending EMD

[outcome vs 257 milliseconds]

outcome vs 257 milliseconds

[transplant programs]

transplant programs

[≤4.5 cm]

≤4.5 cm

[rare with.estimates ranging in 50,000]

rare with.estimates ranging in 50,000

[223 patients]

223 patients

[applications of readmission metrics]

applications of readmission metrics

[diet n=11]

diet n=11

[age of majority]

age of majority

[downward regression line shift]

downward regression line shift

[global left ventricular longitudinal strain GLS]

global left ventricular longitudinal strain GLS

[25.6 kg]

25.6 kg

[nucleotides contents]

nucleotides contents

[consenting HF patients left ejection fraction]

consenting HF patients left ejection fraction

[self-management counseling]

self-management counseling

[mean duration of support]

mean duration of support

[start After 10 weeks]

start After 10 weeks

[reducing mortality]

reducing mortality

[individual contributions of remodeling aspects]

individual contributions of remodeling aspects

[use in patients with non-LBBB]

use in patients with non-LBBB

[exercise testing guide exercise rehabilitation]

exercise testing guide exercise rehabilitation

[children with heart failure]

children with heart failure

[men mean 65±12 years]

men mean 65±12 years

[open-label crossover study]

open-label crossover study

[130 msec]

130 msec

[dying]

dying

[treatment for acute myocardial infarction]

treatment for acute myocardial infarction

[role scaffolds]

role scaffolds

[new review]

new review

[Twenty weeks]

Twenty weeks

[diagnosis of clinical prognostic dysfunction]

diagnosis of clinical prognostic dysfunction

[drugs for heart failure]

drugs for heart failure

[≤75 years]

≤75 years

[including heart failure]

including heart failure

[Magnet(®)]

Magnet(®)

[outcome hospitalization for HF]

outcome hospitalization for HF

[peptide SS31]

peptide SS31

[with ICC values]

with ICC values

[cardiac rehabilitation care]

cardiac rehabilitation care

[changes in subproteomes]

changes in subproteomes

[IRS1 IRS2 gene double-knockout mice]

IRS1 IRS2 gene double-knockout mice

[absolute minimal change MDC values]

absolute minimal change MDC values

[Postoperative survival of patients g]

Postoperative survival of patients g

[obese ZSF1 groups]

obese ZSF1 groups

[rates of hypertension]

rates of hypertension

[Prognostic value of anaerobic threshold]

Prognostic value of anaerobic threshold

[score of 44·3]

score of 44·3

[2005 2008 composite]

2005 2008 composite

[end-stage disease in outpatients]

end-stage disease in outpatients

[possible suboptimal care]

possible suboptimal care

[MRI scanner]

MRI scanner

[epidemiology of infarction]

epidemiology of infarction

[research investigations]

research investigations

[Data in patients]

Data in patients

[interquartile range 22.8 with COPD]

interquartile range 22.8 with COPD

[n=44 925 ED visits age years]

n=44 925 ED visits age years

[ICD patients]

ICD patients

[quality measures for inpatient conditions]

quality measures for inpatient conditions

[odds ratio even after adjustment]

odds ratio even after adjustment

[CKD]

CKD

[myocardial changes]

myocardial changes

[leaflet opening]

leaflet opening

[evidence of ventricular dyssynchrony]

evidence of ventricular dyssynchrony

[mouse myocytes]

mouse myocytes

[Factors Insights A Trial Investigating Outcomes]

Factors Insights A Trial Investigating Outcomes

[Using regression analysis]

Using regression analysis

[blood pressure median]

blood pressure median

[peptide B-type natriuretic peptide]

peptide B-type natriuretic peptide

[fewer symptoms Hospital Anxiety]

fewer symptoms Hospital Anxiety

[cardiovascular risk factors in fit]

cardiovascular risk factors in fit

[National trends for four common conditions]

National trends for four common conditions

[stable therapy]

stable therapy

[construct]

construct

[independent risk factor]

independent risk factor

[over 20 clinical variables]

over 20 clinical variables

[sickle cell disease]

sickle cell disease

[secondary outcome from any cause]

secondary outcome from any cause

[neutral results]

neutral results

[left end-diastolic pressure]

left end-diastolic pressure

[human pluripotent stem cardiomyocytes]

human pluripotent stem cardiomyocytes

[balance]

balance

[Patients from the Heart Function Clinic]

Patients from the Heart Function Clinic

[7-day follow-up]

7-day follow-up

[absolute detectable change values]

absolute detectable change values

[rare with.estimates]

rare with.estimates

[659 heart failure patients]

659 heart failure patients

[relationships between RV function]

relationships between RV function

[change between performance the percent]

change between performance the percent

[CAD involving the proximal descending artery]

CAD involving the proximal descending artery

[such as myocardial infarction with expansion]

such as myocardial infarction with expansion

[points vs. points]

points vs. points

[instituting mechanical support]

instituting mechanical support

[CMS]

CMS

[end-stage congestive heart failure CHF]

end-stage congestive heart failure CHF

[CLCNKA polymorphism]

CLCNKA polymorphism

[cause of morbidity in childhood]

cause of morbidity in childhood

[postoperative months]

postoperative months

[DNx]

DNx

[Cardiovascular Society guidelines]

Cardiovascular Society guidelines

[surviving an acute infarction AMI]

surviving an acute infarction AMI

[chronotropic response]

chronotropic response

[16 patients HDL]

16 patients HDL

[Presentation Cardiovascular Society guidelines]

Presentation Cardiovascular Society guidelines

[myocardial PDE2]

myocardial PDE2

[brain peptide BNP levels 100 pg]

brain peptide BNP levels 100 pg

[energy X-ray]

energy X-ray

[risk of events in patients]

risk of events in patients

[post-TAC cardiac deterioration]

post-TAC cardiac deterioration

[Eighty-one percent of visits]

Eighty-one percent of visits

[Secondary outcome measures]

Secondary outcome measures

[IRS2 double-knockout L-DKO]

IRS2 double-knockout L-DKO

[hospitals from January through September]

hospitals from January through September

[fundamental definitions of the components]

fundamental definitions of the components

[professionals from disciplines]

professionals from disciplines

[association between serial measurements]

association between serial measurements

[Yorkshire]

Yorkshire

[artery tonometry variables]

artery tonometry variables

[clinical exercise test investigations]

clinical exercise test investigations

[insulin receptor substrates]

insulin receptor substrates

[reperfusion]

reperfusion

[period of pulseless fibrillation]

period of pulseless fibrillation

[TUNEL method]

TUNEL method

[arrhythmia devices]

arrhythmia devices

[model using experimental procedures]

model using experimental procedures

[proximal artery]

proximal artery

[ATP HR]

ATP HR

[studies 2900 HM II]

studies 2900 HM II

[odds ratios for events P=0.18]

odds ratios for events P=0.18

[lower mortality in women]

lower mortality in women

[management of diuretic volume overload]

management of diuretic volume overload

[years HR]

years HR

[CPG]

CPG

[reports demonstrating development of functional MS]

reports demonstrating development of functional MS

[myofiber dynamics]

myofiber dynamics

[measurement value of seconds]

measurement value of seconds

[baseline Hgb]

baseline Hgb

[nontraumatic death]

nontraumatic death

[event rate at events]

event rate at events

[determinant of quality of life]

determinant of quality of life

[8000 individuals]

8000 individuals

[baseline serum creatinine]

baseline serum creatinine

[bridging therapy]

bridging therapy

[beta-adrenergic receptor signaling]

beta-adrenergic receptor signaling

[particularly between a group]

particularly between a group

[ventricular LV ejection fraction LVEF]

ventricular LV ejection fraction LVEF

[status hospitalizations]

status hospitalizations

[strip]

strip

[factor for clinical deterioration]

factor for clinical deterioration

[including factor of T cells]

including factor of T cells

[such as patient compliance]

such as patient compliance

[protective effects of mitochondrial-targeted antioxidant]

protective effects of mitochondrial-targeted antioxidant

[Incubation of EC with HDL]

Incubation of EC with HDL

[underlying trials]

underlying trials

[hospitalization for heart failure]

hospitalization for heart failure

[high-strength evidence]

high-strength evidence

[Heart Failure Trial RAFT]

Heart Failure Trial RAFT

[protective role of S1PR1 gene therapy]

protective role of S1PR1 gene therapy

[patients with chronic HF-REF]

patients with chronic HF-REF

[using inhibitors c-Kit]

using inhibitors c-Kit

[other potential predictors biomarkers]

other potential predictors biomarkers

[analysis with eGFR]

analysis with eGFR

[thus providing information for an outcome]

thus providing information for an outcome

[composite HF index]

composite HF index

[valve procedures valve replacement]

valve procedures valve replacement

[SV p]

SV p

[C 'D HF]

C 'D HF

[ventricular-pulmonary coupling vascular resistance P]

ventricular-pulmonary coupling vascular resistance P

[low-risk group]

low-risk group

[studies with follow-up]

studies with follow-up

[mechanism of dysfunction]

mechanism of dysfunction

[case of survival]

case of survival

[use of pro-B-type peptide assays]

use of pro-B-type peptide assays

[improvement at stages]

improvement at stages

[inoperable chronic pulmonary hypertension]

inoperable chronic pulmonary hypertension

[fibrillation AF]

fibrillation AF

[Extracellular matrix of left biopsies n=9]

Extracellular matrix of left biopsies n=9

[NYHA functional class III HF]

NYHA functional class III HF

[including cancer of the prostate]

including cancer of the prostate

[dose-related gradient]

dose-related gradient

[atherosclerosis using general models]

atherosclerosis using general models

[practice guidelines grading system]

practice guidelines grading system

[hospitalizations with no difference]

hospitalizations with no difference

[EAST treatment]

EAST treatment

[patients with a follow-up]

patients with a follow-up

[hospital in the quintile]

hospital in the quintile

[findings of causes]

findings of causes

[features similar]

features similar

[Mild Patients Hospitalization]

Mild Patients Hospitalization

[Effect on Peak Oxygen Consumption]

Effect on Peak Oxygen Consumption

[targets in disease management]

targets in disease management

[Interagency]

Interagency

[transition from hypertrophy]

transition from hypertrophy

[economic evaluations HM using simulation models]

economic evaluations HM using simulation models

[dearth]

dearth

[routine tool]

routine tool

[eGFR group III]

eGFR group III

[QRS duration of benefit]

QRS duration of benefit

[muscle function]

muscle function

[monitoring strategies]

monitoring strategies

[4.9 years for alendronate- patients]

4.9 years for alendronate- patients

[cell nitric oxide NO production]

cell nitric oxide NO production

[meaning]

meaning

[coupling pulmonary vascular resistance P]

coupling pulmonary vascular resistance P

[cholesterol]

cholesterol

[band]

band

[3-year event rates HF hospitalization]

3-year event rates HF hospitalization

[managing clinically significant bleeding]

managing clinically significant bleeding

[Measurement of peptides at the point]

Measurement of peptides at the point

[Comparison Of Outcomes In Patients]

Comparison Of Outcomes In Patients

[years of follow-up]

years of follow-up

[rats mechanism of cardioprotection]

rats mechanism of cardioprotection

[cardiac index L]

cardiac index L

[shortcomings]

shortcomings

[self-management training of patients]

self-management training of patients

[readers in cardiac biology]

readers in cardiac biology

[increase in LF ratio]

increase in LF ratio

[important outcomes in patients]

important outcomes in patients

[right ejection fraction]

right ejection fraction

[Interagency Registry]

Interagency Registry

[invasive alternatives]

invasive alternatives

[LVAS support]

LVAS support

[secretion of arginine vasopressin]

secretion of arginine vasopressin

[patients with coronary artery disease]

patients with coronary artery disease

[dopamine on end points]

dopamine on end points

[soluble ST2]

soluble ST2

[blood urea]

blood urea

[adults with symptomatic heart failure]

adults with symptomatic heart failure

[renal function WRF]

renal function WRF

[proximal LCX 2-vessel model]

proximal LCX 2-vessel model

[isoenzymes PAF-acetylhydrolase]

isoenzymes PAF-acetylhydrolase

[ventricular ejection time complicating hypertension]

ventricular ejection time complicating hypertension

[assessment of function]

assessment of function

[rates among patients]

rates among patients

[change in heart failure]

change in heart failure

[4 hospitals in New Jersey]

4 hospitals in New Jersey

[Global longitudinal strain of ventricle]

Global longitudinal strain of ventricle

[impairment with mortality]

impairment with mortality

[abnormalities in cardiovascular function]

abnormalities in cardiovascular function

[cardiac sodium current in heart failure]

cardiac sodium current in heart failure

[potential benefit with adverse consequences]

potential benefit with adverse consequences

[74 patients]

74 patients

[ng interquartile range]

ng interquartile range

[alternative mRNA splicing]

alternative mRNA splicing

[risk factor for disease CVD]

risk factor for disease CVD

[development of approaches]

development of approaches

[improvement in rate relative risk]

improvement in rate relative risk

[other conditions such as infarction]

other conditions such as infarction

[Z-score]

Z-score

[treating patients]

treating patients

[CardioPulmonary]

CardioPulmonary

[risk-adjusted all-cause mortality]

risk-adjusted all-cause mortality

[common form of arterial disease]

common form of arterial disease

[development of cardiomyopathy]

development of cardiomyopathy

[care of patients with this condition]

care of patients with this condition

[3M]

3M

[regulatory involvement of receptor kinase-2]

regulatory involvement of receptor kinase-2

[B act]

B act

[diabetic ZSF1 rats]

diabetic ZSF1 rats

[left midpapillary level]

left midpapillary level

[Safe effective off-pump sparing approach]

Safe effective off-pump sparing approach

[myocarditis]

myocarditis

[heterogeneous region]

heterogeneous region

[Exercise Testing]

Exercise Testing

[benefit over conventional parameters]

benefit over conventional parameters

[130 consecutive patients]

130 consecutive patients

[hazard ratio of 2.7]

hazard ratio of 2.7

[isolated heart rate reduction with ivabradine]

isolated heart rate reduction with ivabradine

[hazard ratio of 2.2]

hazard ratio of 2.2

[smallest difference among EF BNP EF]

smallest difference among EF BNP EF

[ventricular-pulmonary coupling pulmonary resistance P]

ventricular-pulmonary coupling pulmonary resistance P

[institution for the treatment of HF]

institution for the treatment of HF

[peak mitral flow velocity]

peak mitral flow velocity

[clinical relevance]

clinical relevance

[number of quarterly admissions]

number of quarterly admissions

[culprit extending EMD in HF]

culprit extending EMD in HF

[problem with mortality]

problem with mortality

[treatments targeting exercise status]

treatments targeting exercise status

[twofold increase in lung weight]

twofold increase in lung weight

[diet in disease]

diet in disease

[Gene expression profile]

Gene expression profile

[protective effects on cardiac function]

protective effects on cardiac function

[sodium current in heart failure]

sodium current in heart failure

[prospective multicenter trial with individuals]

prospective multicenter trial with individuals

[heart failure exacerbation]

heart failure exacerbation

[modest benefit]

modest benefit

[potential implications of promising biomarkers]

potential implications of promising biomarkers

[lower resting HR]

lower resting HR

[Circulatory]

Circulatory

[incentives]

incentives

[relating]

relating

[conscious dogs]

conscious dogs

[Effects a analysis using medicare data]

Effects a analysis using medicare data

[aerobic exercise per week]

aerobic exercise per week

[reciprocal regulation]

reciprocal regulation

[ICD-HF]

ICD-HF

[biology]

biology

[2.1 mL 2 P=0.01]

2.1 mL 2 P=0.01

[even after multivariable adjustment]

even after multivariable adjustment

[guideline-directed therapy]

guideline-directed therapy

[P relative decrease]

P relative decrease

[plasma NPs]

plasma NPs

[6 min m vs. m]

6 min m vs. m

[resistance SVR]

resistance SVR

[little HR reduction]

little HR reduction

[negative predictive value]

negative predictive value

[cGMP signaling]

cGMP signaling

[prognostic relevance of right reserve]

prognostic relevance of right reserve

[risk predictor for death]

risk predictor for death

[model system of zebrafish]

model system of zebrafish

[cachexia hazard ratio in analyses]

cachexia hazard ratio in analyses

[Two final models]

Two final models

[three disease groups heart failure]

three disease groups heart failure

[common forms of remodeling]

common forms of remodeling

[with.estimates ranging in 50,000]

with.estimates ranging in 50,000

[long-term assist device]

long-term assist device

[transoesophageal guidance under anaesthesia]

transoesophageal guidance under anaesthesia

[HFpEF with left ejection fraction]

HFpEF with left ejection fraction

[oxygen pulse in four of patients]

oxygen pulse in four of patients

[sternotomy for valve procedures valve replacement]

sternotomy for valve procedures valve replacement

[achieving a moderate level]

achieving a moderate level

[internal validity replicating resource use]

internal validity replicating resource use

[individuals with pulmonary disease]

individuals with pulmonary disease

[pressure relationship]

pressure relationship

[Process Redesign contextual framework]

Process Redesign contextual framework

[experiencing implantable cardioverter-defibrillator shocks at end]

experiencing implantable cardioverter-defibrillator shocks at end

[common type of cardiac tumors]

common type of cardiac tumors

[ventricular remodeling]

ventricular remodeling

[re-activating transcription]

re-activating transcription

[infarction in Western Australia]

infarction in Western Australia

[postexercise phosphocreatine resynthesis]

postexercise phosphocreatine resynthesis

[impact of assist device]

impact of assist device

[baseline exercise capacity METs]

baseline exercise capacity METs

[function in EMPHASIS-HF]

function in EMPHASIS-HF

[arterial systolic pressure relationship an index]

arterial systolic pressure relationship an index

[resource utilization]

resource utilization

[cardiac myocyte-specific Mena overexpression TTA]

cardiac myocyte-specific Mena overexpression TTA

[pure HNO donor CXL-1020]

pure HNO donor CXL-1020

[cardiovascular CV events AF]

cardiovascular CV events AF

[cardiac hospital]

cardiac hospital

[4 suburban hospitals in Jersey]

4 suburban hospitals in Jersey

[334 patients]

334 patients

[quintile of hospitals]

quintile of hospitals

[worst quintile of performance]

worst quintile of performance

[treatment with ivabradine exercise capacity]

treatment with ivabradine exercise capacity

[elderly patients with CHF]

elderly patients with CHF

[53 patients with PH]

53 patients with PH

[similar benefit]

similar benefit

[hospital programmes]

hospital programmes

[Heart Failure database]

Heart Failure database

[6 days]

6 days

[Impact on inappropriate implantable cardioverter-defibrillator therapy]

Impact on inappropriate implantable cardioverter-defibrillator therapy

[mammalian myocardium]

mammalian myocardium

[large study sample with patients]

large study sample with patients

[2.8 0.7 L]

2.8 0.7 L

[variants consistent with reports]

variants consistent with reports

[Seventy-seven cases]

Seventy-seven cases

[consecutive HF patients]

consecutive HF patients

[considerable attention]

considerable attention

[prevalent heart disease]

prevalent heart disease

[Cardiovascular Outcomes in Renal Lesions]

Cardiovascular Outcomes in Renal Lesions

[cardioverter-defibrillator therapy Automatic Defibrillator Implantation]

cardioverter-defibrillator therapy Automatic Defibrillator Implantation

[hospital mortality]

hospital mortality

[transplant-ineligible patients as destination therapy]

transplant-ineligible patients as destination therapy

[improvements showing minor improvement]

improvements showing minor improvement

[Impact of ejection fraction]

Impact of ejection fraction

[few complications]

few complications

[AAs race by treatment interaction]

AAs race by treatment interaction

[Effectiveness for heart failure]

Effectiveness for heart failure

[underlying pathophysiology]

underlying pathophysiology

[nervous system modulation on QTV]

nervous system modulation on QTV

[difference histologically control]

difference histologically control

[significant change effect exercise]

significant change effect exercise

[York Heart Association classification]

York Heart Association classification

[first-time diagnosis]

first-time diagnosis

[inhibition of signaling pathway]

inhibition of signaling pathway

[evidence of benefit]

evidence of benefit

[Society of Cardiology guidelines definition]

Society of Cardiology guidelines definition

[Participation of apoptosis]

Participation of apoptosis

[vascular growth factor protein]

vascular growth factor protein

[form of disease]

form of disease

[100 obese participants mean]

100 obese participants mean

[Baroreflex Activation Therapy]

Baroreflex Activation Therapy

[evidence-based management]

evidence-based management

[efficient RV function evaluation]

efficient RV function evaluation

[development via effects]

development via effects

[trial of patients]

trial of patients

[difference between numbers of cells]

difference between numbers of cells

[674 men]

674 men

[Composite quality measures for medical conditions]

Composite quality measures for medical conditions

[oscillations]

oscillations

[health-related quality Minnesota Living]

health-related quality Minnesota Living

[hours of admission]

hours of admission

[most areas]

most areas

[5.0 g P=0.04]

5.0 g P=0.04

[length NT-proBNP molecule]

length NT-proBNP molecule

[controls HDL]

controls HDL

[effects of 2 types HeartMate]

effects of 2 types HeartMate

[event rates for infarction]

event rates for infarction

[guideline-recommended drugs for heart failure]

guideline-recommended drugs for heart failure

[cocoa]

cocoa

[After percutaneous revascularization]

After percutaneous revascularization

[Nursing]

Nursing

[artery stenosis RAS]

artery stenosis RAS

[single test]

single test

[smallest difference BNP in women EF]

smallest difference BNP in women EF

[BP]

BP

[only in patients with s'lateral]

only in patients with s'lateral

[assist devices LVADs]

assist devices LVADs

[pre-specified analysis with eGFR]

pre-specified analysis with eGFR

[fibrillation for Stroke prevention Trial]

fibrillation for Stroke prevention Trial

[patients with recent onset HFrEF days]

patients with recent onset HFrEF days

[patients with mean SD testosterone levels]

patients with mean SD testosterone levels

[TGF-β]

TGF-β

[17 trials]

17 trials

[dramatic induction]

dramatic induction

[several genes related]

several genes related

[development of insulin-resistance]

development of insulin-resistance

[strata]

strata

[especially ms]

especially ms

[Experience of a receptor antagonist tolvaptan]

Experience of a receptor antagonist tolvaptan

[highest event rate 2.08 events]

highest event rate 2.08 events

[ventricular support]

ventricular support

[PKA subunits]

PKA subunits

[relationship force]

relationship force

[increasing body]

increasing body

[range with COPD]

range with COPD

[partial pressure of CO2]

partial pressure of CO2

[334 patients men]

334 patients men

[age of the CHF patients]

age of the CHF patients

[ED visits age years]

ED visits age years

[R-R interval oscillations]

R-R interval oscillations

[ejection fraction on mortality]

ejection fraction on mortality

[power of measures]

power of measures

[1.6 reasons per patient]

1.6 reasons per patient

[new targets in disease management]

new targets in disease management

[metoprolol irrespective of receptor haplotype]

metoprolol irrespective of receptor haplotype

[confidence interval 0.60]

confidence interval 0.60

[improvement in effective rate relative risk]

improvement in effective rate relative risk

[indices E ratio]

indices E ratio

[3058 patients with ejection fraction HF]

3058 patients with ejection fraction HF

[embolectomy]

embolectomy

[symptomatic heart failure patients]

symptomatic heart failure patients

[key enzymes]

key enzymes

[sST2]

sST2

[reliable biomarkers in patients]

reliable biomarkers in patients

[HeartMate LVAD]

HeartMate LVAD

[insulin-resistance by 2 weeks post-AAC]

insulin-resistance by 2 weeks post-AAC

[lowest event rate at events]

lowest event rate at events

[Analysis of Patient Management Interventions]

Analysis of Patient Management Interventions

[outcome measures in prospective experimental research]

outcome measures in prospective experimental research

[consenting HF patients ejection fraction]

consenting HF patients ejection fraction

[N-terminal proBNP NT-proBNP proANP MR-proANP]

N-terminal proBNP NT-proBNP proANP MR-proANP

[hypertension diet]

hypertension diet

[distinct populations]

distinct populations

[early outcomes]

early outcomes

[number of admissions]

number of admissions

[consecutive patients 209 HFrEF]

consecutive patients 209 HFrEF

[paucity]

paucity

[underlying characteristics using Cochrane Effective Practice]

underlying characteristics using Cochrane Effective Practice

[PDE2 overexpression]

PDE2 overexpression

[4.9 years]

4.9 years

[artery disease PAD]

artery disease PAD

[multivariate logistic regression analysis]

multivariate logistic regression analysis

[obese patients with stable HFPEF]

obese patients with stable HFPEF

[reliable mortality predictors in ICD-HF patients]

reliable mortality predictors in ICD-HF patients

[relevance of right reserve]

relevance of right reserve

[asymptomatic Fontan PF patients]

asymptomatic Fontan PF patients

[membrane oxygenation in infarction-related heart failure]

membrane oxygenation in infarction-related heart failure

[E-wave mitral annular velocity ratio]

E-wave mitral annular velocity ratio

[urinary tract infection]

urinary tract infection

[chromatin-mediated signal transduction]

chromatin-mediated signal transduction

[involving the left artery]

involving the left artery

[middle-aged athletes]

middle-aged athletes

[flow pump]

flow pump

[2.1 kg vs kg]

2.1 kg vs kg

[nursing-sensitive outcome measures]

nursing-sensitive outcome measures

[greater risk of events]

greater risk of events

[EOV]

EOV

[hypertension of mm Hg]

hypertension of mm Hg

[Investigating Outcomes multicenter study]

Investigating Outcomes multicenter study

[low ventricular ejection fraction]

low ventricular ejection fraction

[Heart rate variability]

Heart rate variability

[combinations of the remodeling aspects]

combinations of the remodeling aspects

[haemodynamic assessment]

haemodynamic assessment

[Future of advanced heart failure]

Future of advanced heart failure

[statistically significant percent relative reduction]

statistically significant percent relative reduction

[IL]

IL

[outcome measures in future experimental research]

outcome measures in future experimental research

[prognostic significance]

prognostic significance

[management for acute HF]

management for acute HF

[knowledge of abnormalities]

knowledge of abnormalities

[pre-specified subgroup analyses including quality]

pre-specified subgroup analyses including quality

[studies in practice settings]

studies in practice settings

[endothelial function dilatation]

endothelial function dilatation

[ventricular systolic function]

ventricular systolic function

[common Emergency Department presentation]

common Emergency Department presentation

[heart failure in Hungary]

heart failure in Hungary

[response protective role]

response protective role

[lower rates of death]

lower rates of death

[heterogeneous group of patients]

heterogeneous group of patients

[mitral valve area MVA]

mitral valve area MVA

[requiring surgery]

requiring surgery

[modest clinical benefit]

modest clinical benefit

[Mechanistic insight in heart failure]

Mechanistic insight in heart failure

[presence of mild diastolic dysfunction]

presence of mild diastolic dysfunction

[cardiac insulin-resistance by weeks]

cardiac insulin-resistance by weeks

[N-terminal peptide assessment]

N-terminal peptide assessment

[concentric hypertrophy in heart failure]

concentric hypertrophy in heart failure

[role in HF]

role in HF

[strong acid]

strong acid

[norepinephrine-induced hypertrophic responses]

norepinephrine-induced hypertrophic responses

[consecutive patients aged years]

consecutive patients aged years

[comorbidities in heart failure]

comorbidities in heart failure

[3 evaluations]

3 evaluations

[reducing all-cause mortality]

reducing all-cause mortality

[reducing the primary endpoint]

reducing the primary endpoint

[tone resulting in autonomic imbalance]

tone resulting in autonomic imbalance

[reflecting decreases period versus 1]

reflecting decreases period versus 1

[pathways in patients]

pathways in patients

[mechanism of cardiac dysfunction]

mechanism of cardiac dysfunction

[arterial hypertension medication]

arterial hypertension medication

[fewer symptoms]

fewer symptoms

[internal consistency among patients]

internal consistency among patients

[Screening]

Screening

[role determining the adaptive remodelling]

role determining the adaptive remodelling

[beta-blockers on the endpoint]

beta-blockers on the endpoint

[perceptions]

perceptions

[advanced heart failure patients]

advanced heart failure patients

[left ventricular LV remodeling]

left ventricular LV remodeling

[v.6.2]

v.6.2

[larger fluctuations]

larger fluctuations

[heart dilatation after transverse aortic constriction]

heart dilatation after transverse aortic constriction

[Usefulness assessing ventricular filling pressure]

Usefulness assessing ventricular filling pressure

[123 mm Hg]

123 mm Hg

[contemporary heart failure population]

contemporary heart failure population

[altering the gene expression profile]

altering the gene expression profile

[β-blockers at target dose]

β-blockers at target dose

[activity controls]

activity controls

[HFPSI use VA-RT cohort]

HFPSI use VA-RT cohort

[prognostic factor in diseases]

prognostic factor in diseases

[Tools for Analysis A Web-based program]

Tools for Analysis A Web-based program

[tricuspid plane excursion TAPSE]

tricuspid plane excursion TAPSE

[role molecular scaffolds in heart pathology]

role molecular scaffolds in heart pathology

[protein content for SR Ca]

protein content for SR Ca

[early-onset HF for HF]

early-onset HF for HF

[peak Ca]

peak Ca

[highly effective agent]

highly effective agent

[Heart Association class]

Heart Association class

[maximal power index]

maximal power index

[total of subjects]

total of subjects

[74 patients with HFPEF]

74 patients with HFPEF

[benefits of anemia treatment]

benefits of anemia treatment

[PB]

PB

[Many multisite studies]

Many multisite studies

[continuous relationship]

continuous relationship

[significant considerations]

significant considerations

[adjusting decrease]

adjusting decrease

[ventricular plane systolic excursion TAPSE]

ventricular plane systolic excursion TAPSE

[artery ligation]

artery ligation

[Fifty-one percent]

Fifty-one percent

[children with heart disease of HF]

children with heart disease of HF

[pharmacologic studies including calcium-sensitizing agents]

pharmacologic studies including calcium-sensitizing agents

[potentially anti-inflammatory effects]

potentially anti-inflammatory effects

[cardiac rehabilitation care on capacity]

cardiac rehabilitation care on capacity

[Current dietary recommendations]

Current dietary recommendations

[295 veterans aged years]

295 veterans aged years

[other staff]

other staff

[Rethinking the quality]

Rethinking the quality

[past years]

past years

[prescribing of medications]

prescribing of medications

[Safety of eplerenone analyses]

Safety of eplerenone analyses

[relevance of reserve]

relevance of reserve

[24 patients]

24 patients

[add-on features such as detection]

add-on features such as detection

[1.6 seconds]

1.6 seconds

[care hospital]

care hospital

[care hospital for HF]

care hospital for HF

[Global left ventricular systolic strain]

Global left ventricular systolic strain

[radial strain]

radial strain

[RI]

RI

[aggressive medical treatment with vasodilators]

aggressive medical treatment with vasodilators

[H-oxidase]

H-oxidase

[fluctuations]

fluctuations

[patients with ejection fraction 0.35]

patients with ejection fraction 0.35

[chronic kidney disease]

chronic kidney disease

[noncoding]

noncoding

[stable situation]

stable situation

[Nursing-sensitive outcome change scores]

Nursing-sensitive outcome change scores

[heart failure in clinical practice]

heart failure in clinical practice

[Usefulness assessing filling pressure]

Usefulness assessing filling pressure

[Occurrence within days]

Occurrence within days

[follow-up of 21 months]

follow-up of 21 months

[participant satisfaction]

participant satisfaction

[chest model noninvasive surrogates]

chest model noninvasive surrogates

[great number]

great number

[heart failure in hypertension]

heart failure in hypertension

[scaling]

scaling

[looping]

looping

[Users of Saxagliptin]

Users of Saxagliptin

[important contribution of abnormalities]

important contribution of abnormalities

[days P-value 0.001]

days P-value 0.001

[150 minutes of moderate-intensity exercise]

150 minutes of moderate-intensity exercise

[consecutive patients with onset HFrEF days]

consecutive patients with onset HFrEF days

[symptoms in children]

symptoms in children

[monocytes]

monocytes

[alterations in SkM muscle structure]

alterations in SkM muscle structure

[effective rate control]

effective rate control

[reduction of Na current]

reduction of Na current

[confirmation on populations]

confirmation on populations

[Tools for Economic Analysis A program]

Tools for Economic Analysis A program

[basic bHLH transcription factor]

basic bHLH transcription factor

[method of transverse constriction]

method of transverse constriction

[role in signal transduction]

role in signal transduction

[LV posterior wall thickness]

LV posterior wall thickness

[efficacy of receptor antagonists]

efficacy of receptor antagonists

[Baseline eGFR group]

Baseline eGFR group

[mg HR 1.54]

mg HR 1.54

[implantable cardioverter-defibrillator therapy Defibrillator Implantation]

implantable cardioverter-defibrillator therapy Defibrillator Implantation

[care by antiarrhythmic drugs]

care by antiarrhythmic drugs

[need for strict standards]

need for strict standards

[terminal stage]

terminal stage

[hospitals nationwide through September]

hospitals nationwide through September

[diagnostic performance detecting filling pressures]

diagnostic performance detecting filling pressures

[ventricular tissue]

ventricular tissue

[LCX later]

LCX later

[more than 60,000 patients]

more than 60,000 patients

[benefit from implantable cardioverter defibrillator-CRT]

benefit from implantable cardioverter defibrillator-CRT

[safety cohort study]

safety cohort study

[economic evaluations HM II]

economic evaluations HM II

[extending EMD in the dyssynchronous heart]

extending EMD in the dyssynchronous heart

[first results]

first results

[several Medical Outcomes Study]

several Medical Outcomes Study

[small group]

small group

[3 economic evaluations HM II]

3 economic evaluations HM II

[studies of therapeutics including calcium-sensitizing agents]

studies of therapeutics including calcium-sensitizing agents

[matrix of ventricular biopsies n=9]

matrix of ventricular biopsies n=9

[phenotype of the Fontan]

phenotype of the Fontan

[activation PKC-βII by HDL]

activation PKC-βII by HDL

[common type of tumors]

common type of tumors

[clinical effects]

clinical effects

[Carvedilol]

Carvedilol

[Minnesota quality]

Minnesota quality

[combination of size reduction]

combination of size reduction

[score of Minnesota quality]

score of Minnesota quality

[outcome median]

outcome median

[receiving assist device support]

receiving assist device support

[regional circumferential strain]

regional circumferential strain

[lower rates among patients]

lower rates among patients

[k constants]

k constants

[Catheter-based revascularization]

Catheter-based revascularization

[life score]

life score

[less benefit]

less benefit

[ratio disclosing prognosis]

ratio disclosing prognosis

[Studies of predictors after resynchronization therapy]

Studies of predictors after resynchronization therapy

[thirty-seven hospitals nationwide from January]

thirty-seven hospitals nationwide from January

[outcome-monitoring phase mean]

outcome-monitoring phase mean

[peptide levels like other biomarkers]

peptide levels like other biomarkers

[activation of p70S6K]

activation of p70S6K

[Patient Severity]

Patient Severity

[favour of apoptosis]

favour of apoptosis

[BET bromodomain-containing protein]

BET bromodomain-containing protein

[24 telephone support programmes]

24 telephone support programmes

[T cells NFAT]

T cells NFAT

[agents in patients]

agents in patients

[strain of ventricle]

strain of ventricle

[experiencing cardioverter-defibrillator shocks at end]

experiencing cardioverter-defibrillator shocks at end

[sarcoplasmic reticular Ca 2+)-uptake]

sarcoplasmic reticular Ca 2+)-uptake

[larger studies]

larger studies

[changes with regional strain contributions]

changes with regional strain contributions

[mRNA levels of genes]

mRNA levels of genes

[artery pressure increase by means]

artery pressure increase by means

[lower expenditure on health per capita]

lower expenditure on health per capita

[few perioperative deaths]

few perioperative deaths

[biomedical reasons]

biomedical reasons

[prognostic composite HF index]

prognostic composite HF index

[similar incidence]

similar incidence

[PKC-βII by HDL NYHA-IIIb]

PKC-βII by HDL NYHA-IIIb

[case-control study]

case-control study

[dipeptidyl peptidase-4]

dipeptidyl peptidase-4

[use of antagonists]

use of antagonists

[heart failure with impaired function]

heart failure with impaired function

[improvement at stages of heart failure]

improvement at stages of heart failure

[electrical stimulation of peripheral muscles]

electrical stimulation of peripheral muscles

[improvement by β-adrenoceptor blockade at stages]

improvement by β-adrenoceptor blockade at stages

[lyso-PAF]

lyso-PAF

[Cooper Center Longitudinal Study]

Cooper Center Longitudinal Study

[ST2 in patients]

ST2 in patients

[cardiotoxicity a effective agent]

cardiotoxicity a effective agent

[end-diastolic area index]

end-diastolic area index

[arterial pressure PASP]

arterial pressure PASP

[pace non-DNx]

pace non-DNx

[chronic pulmonary arterial hypertension]

chronic pulmonary arterial hypertension

[other agents]

other agents

[fever]

fever

[pg high BNP group]

pg high BNP group

[Society of Cardiology]

Society of Cardiology

[enhancement of angiogenesis]

enhancement of angiogenesis

[Joanna Briggs Institute Evidence]

Joanna Briggs Institute Evidence

[left descending]

left descending

[patients in the VAD group]

patients in the VAD group

[(eGFR)-group I mL]

(eGFR)-group I mL

[clinical studies HM II]

clinical studies HM II

[accessory pathways]

accessory pathways

[filtration rate of eGFR]

filtration rate of eGFR

[stroke CHA₂DS₂VASc score]

stroke CHA₂DS₂VASc score

[European Society of Cardiology]

European Society of Cardiology

[growth factor-β TGF-β signaling level]

growth factor-β TGF-β signaling level

[disease phase]

disease phase

[patients with recent onset AF]

patients with recent onset AF

[patient with valve plasty]

patient with valve plasty

[neurohormonal stimulation]

neurohormonal stimulation

[myocardial matrix]

myocardial matrix

[field of investigation]

field of investigation

[Detailed analysis of cardiac tissue]

Detailed analysis of cardiac tissue

[lacking murine resistin]

lacking murine resistin

[neurological event-free rate]

neurological event-free rate

[third heart sound]

third heart sound

[catheterisation with guidance]

catheterisation with guidance

[medical conditions]

medical conditions

[Multicenter trial Renal Optimization Strategies Evaluation]

Multicenter trial Renal Optimization Strategies Evaluation

[LV volume of 66 mL]

LV volume of 66 mL

[Validating outcome measures in research]

Validating outcome measures in research

[lower volumes]

lower volumes

[simulation tool]

simulation tool

[normal body mass index strata]

normal body mass index strata

[systolic parameters]

systolic parameters

[30 days P-value]

30 days P-value

[pathology]

pathology

[sitagliptin versus pioglitazone]

sitagliptin versus pioglitazone

[heart disease of possible HF]

heart disease of possible HF

[rRNA]

rRNA

[consecutive patients with recent onset]

consecutive patients with recent onset

[left ventricular longitudinal systolic strain GLS]

left ventricular longitudinal systolic strain GLS

[effect of doxorubicin]

effect of doxorubicin

[10 HF patients]

10 HF patients

[total of 569 individuals]

total of 569 individuals

[case-control analysis matching]

case-control analysis matching

[effect of system modulation]

effect of system modulation

[925 ED visits]

925 ED visits

[Fifty patients with recent onset]

Fifty patients with recent onset

[improvement of perturbations]

improvement of perturbations

[pioglitazone for saxagliptin versus sulfonylureas]

pioglitazone for saxagliptin versus sulfonylureas

[Previous studies investigating cachexia]

Previous studies investigating cachexia

[response in activity (123)I-meta-iodobenzylguanidine]

response in activity (123)I-meta-iodobenzylguanidine

[diastolic end diameter mean difference]

diastolic end diameter mean difference

[right ventricular plane systolic excursion]

right ventricular plane systolic excursion

[descriptive assessment]

descriptive assessment

[literature search]

literature search

[male gender]

male gender

[Fig]

Fig

[health problem worldwide]

health problem worldwide

[Subgroup]

Subgroup

[distinct derangement]

distinct derangement

[results of studies with ARNI inhibitors]

results of studies with ARNI inhibitors

[model using procedures]

model using procedures

[reticulum]

reticulum

[Mechanistic insight]

Mechanistic insight

[involving 115 centers]

involving 115 centers

[Physio Ring]

Physio Ring

[partial pressure]

partial pressure

[hyperkalemia patients]

hyperkalemia patients

[AA]

AA

[single-arm multicenter study]

single-arm multicenter study

[Practice-level variation in use]

Practice-level variation in use

[baseline EF]

baseline EF

[20 812 consecutive patients]

20 812 consecutive patients

[coronary occlusion]

coronary occlusion

[receiving PD]

receiving PD

[effect on cumulative urine volume]

effect on cumulative urine volume

[context of liver disease]

context of liver disease

[addition of GLS]

addition of GLS

[plasma B-type peptide levels]

plasma B-type peptide levels

[parameters in AF]

parameters in AF

[individuals with obstructive pulmonary disease]

individuals with obstructive pulmonary disease

[right ventricular area index]

right ventricular area index

[revealing a mechanism of dysfunction]

revealing a mechanism of dysfunction

[crucial role including factor]

crucial role including factor

[Postoperative survival g]

Postoperative survival g

[Grade moderate-quality evidence]

Grade moderate-quality evidence

[additive for peak VO2]

additive for peak VO2

[presence of MR]

presence of MR

[actin cytoskeleton]

actin cytoskeleton

[right ventricular annular plane excursion]

right ventricular annular plane excursion

[β1AR overstimulation in heart failure]

β1AR overstimulation in heart failure

[Comparison]

Comparison

[Validating outcome measures]

Validating outcome measures

[trends for four common conditions]

trends for four common conditions

[interruption of neurohormonal systems]

interruption of neurohormonal systems

[insight in heart failure a study]

insight in heart failure a study

[left ejection fraction P]

left ejection fraction P

[iron-deficient adult patients]

iron-deficient adult patients

[effect on mortality]

effect on mortality

[monitoring a systematic review]

monitoring a systematic review

[induction of hRetn human resistin mRNA]

induction of hRetn human resistin mRNA

[Multiacquisition T1-mapping MRI during respiration]

Multiacquisition T1-mapping MRI during respiration

[CR]

CR

[difference among EF median BNP EF]

difference among EF median BNP EF

[Trial Investigating Outcomes study]

Trial Investigating Outcomes study

[ventricular function in cardiac volume overload]

ventricular function in cardiac volume overload

[months post-procedure]

months post-procedure

[actions the L-type channel isoforms]

actions the L-type channel isoforms

[higher exercise]

higher exercise

[recent onset HFrEF days]

recent onset HFrEF days

[composite from any cause]

composite from any cause

[HR 70 bpm]

HR 70 bpm

[ventricular filling pressure response]

ventricular filling pressure response

[derangement with hemodynamic features]

derangement with hemodynamic features

[Many current predictors of mortality]

Many current predictors of mortality

[reserve in patients with hypertension]

reserve in patients with hypertension

[information for an unfavourable outcome]

information for an unfavourable outcome

[TTA TgTetMena mice]

TTA TgTetMena mice

[aortocaval fistula]

aortocaval fistula

[psoriasis as a variable]

psoriasis as a variable

[epitopes P]

epitopes P

[ER]

ER

[study-related events]

study-related events

[NP assessment of ED patients]

NP assessment of ED patients

[674 men without a history]

674 men without a history

[C57BL]

C57BL

[agreement mean difference]

agreement mean difference

[Left assist devices LVADs]

Left assist devices LVADs

[staff responsible]

staff responsible

[ventricular systolic function in volume overload]

ventricular systolic function in volume overload

[following 3-year event rates]

following 3-year event rates

[prospective assessment]

prospective assessment

[crucial target]

crucial target

[electromechanical delay EMD the time]

electromechanical delay EMD the time

[patients men years]

patients men years

[ventricular RV annular plane excursion]

ventricular RV annular plane excursion

[practice for a limited number]

practice for a limited number

[patient with myxoma]

patient with myxoma

[impaired right ventricular pump function]

impaired right ventricular pump function

[1.02±0.18 mm for psoriasis]

1.02±0.18 mm for psoriasis

[monitoring RM]

monitoring RM

[effects of beta-blocker therapy]

effects of beta-blocker therapy

[Point-of-care]

Point-of-care

[risk for HF]

risk for HF

[GG]

GG

[HF patients without VT]

HF patients without VT

[levels pg]

levels pg

[splice]

splice

[downregulation of multiple cardiac genes]

downregulation of multiple cardiac genes

[downregulation of genes in HF]

downregulation of genes in HF

[suboptimal care]

suboptimal care

[CHF among patients]

CHF among patients

[effects on the endpoint]

effects on the endpoint

[new therapeutic targets]

new therapeutic targets

[potential of diuretics]

potential of diuretics

[non-diastolic abnormalities in cardiovascular function]

non-diastolic abnormalities in cardiovascular function

[markers indicative of autonomic balance]

markers indicative of autonomic balance

[time domain]

time domain

[plasma B-type peptide]

plasma B-type peptide

[kg with improvement in diuretic response]

kg with improvement in diuretic response

[stemming from cardiomyopathies]

stemming from cardiomyopathies

[regulator of growth]

regulator of growth

[heart failure guidelines]

heart failure guidelines

[min m vs. 1.5 m]

min m vs. 1.5 m

[pulmonary hypertension medication]

pulmonary hypertension medication

[benefit for patients]

benefit for patients

[left LV ejection fraction LVEF]

left LV ejection fraction LVEF

[pediatric support]

pediatric support

[additive effect of an number]

additive effect of an number

[increasing refill compliance]

increasing refill compliance

[predictor of long-term outcomes]

predictor of long-term outcomes

[secondary end points reflective]

secondary end points reflective

[ventricular-pulmonary coupling resistance]

ventricular-pulmonary coupling resistance

[R-like]

R-like

[using cardiac resonance T1 mapping]

using cardiac resonance T1 mapping

[manipulation of gene control]

manipulation of gene control

[IV]

IV

[β-Blocker-induced enhancement]

β-Blocker-induced enhancement

[requiring RV support]

requiring RV support

[clinical studies 2900 HM II]

clinical studies 2900 HM II

[Bradycardia]

Bradycardia

[Ca 2 handling]

Ca 2 handling

[age group of years]

age group of years

[Utilizing testimonies with nurses]

Utilizing testimonies with nurses

[complications of therapy in HF]

complications of therapy in HF

[Occurrence]

Occurrence, occurrence

[originally part]

originally part

[Clinician]

Clinician

[readmission rates P]

readmission rates P

[heart twist]

heart twist

[higher hospitalization rates]

higher hospitalization rates

[Two hundred HF patients]

Two hundred HF patients

[mechanism during insulin resistance]

mechanism during insulin resistance

[Association with capacity]

Association with capacity

[aortic constriction AAC]

aortic constriction AAC

[Kd]

Kd

[Safe off-pump sternal sparing approach]

Safe off-pump sternal sparing approach

[30 mL per m 2]

30 mL per m 2

[binomial regression]

binomial regression

[mean duration]

mean duration

[Implantable cardioverter-defibrillators]

Implantable cardioverter-defibrillators

[treatment of heart failure current treatment]

treatment of heart failure current treatment

[B-type natriuretic peptide]

B-type natriuretic peptide

[lb]

lb

[Fifty-four asymptomatic pediatric Fontan PF patients]

Fifty-four asymptomatic pediatric Fontan PF patients

[arguments for hypo-response]

arguments for hypo-response

[low vascular resistance SVR index]

low vascular resistance SVR index

[If-channel inhibition]

If-channel inhibition

[HVAD]

HVAD

[sitagliptin versus pioglitazone for sitagliptin]

sitagliptin versus pioglitazone for sitagliptin

[outcomes in patients with moderate]

outcomes in patients with moderate

[role for microRNAs miRNAs]

role for microRNAs miRNAs

[diverse aspects of remodeling]

diverse aspects of remodeling

[G proteins]

G proteins

[days range 6 days]

days range 6 days

[70 versus ≥70 bpm respectively P]

70 versus ≥70 bpm respectively P

[global strain of left ventricle]

global strain of left ventricle

[proteomics changes in transverse constriction]

proteomics changes in transverse constriction

[giving rise in HF]

giving rise in HF

[communication]

communication

[prognostic dysfunction leading]

prognostic dysfunction leading

[structurally normal hearts HNorm]

structurally normal hearts HNorm

[mo]

mo

[ejection time complicating hypertension]

ejection time complicating hypertension

[rehabilitation care on capacity]

rehabilitation care on capacity

[Heart failure with left ejection fraction]

Heart failure with left ejection fraction

[presence of even mild dysfunction]

presence of even mild dysfunction

[entry]

entry

[serum levels of peptide]

serum levels of peptide

[events during the postoperative months]

events during the postoperative months

[targeting individuals]

targeting individuals

[6 min m]

6 min m

[elevations in BNP]

elevations in BNP

[NO]

NO

[P3]

P3

[set of variables]

set of variables

[new review of the effects]

new review of the effects

[greater benefit]

greater benefit

[serum levels of peptide BNP]

serum levels of peptide BNP

[veterans aged years]

veterans aged years

[history of infarction]

history of infarction

[myocardial infarction with major complications]

myocardial infarction with major complications

[state of stress]

state of stress

[additional prognostic benefit]

additional prognostic benefit

[impaired gene expression]

impaired gene expression

[ischemic etiology]

ischemic etiology

[endpoint of therapy]

endpoint of therapy

[acute myocardial infarction in Australia]

acute myocardial infarction in Australia

[transition markers]

transition markers

[Unidirectional interatrial shunting]

Unidirectional interatrial shunting

[LCX 2-vessel model]

LCX 2-vessel model

[first days]

first days

[having heart failure HF]

having heart failure HF

[using magnetic resonance T1 mapping]

using magnetic resonance T1 mapping

[radial tonometry]

radial tonometry

[Renal Optimization Strategies]

Renal Optimization Strategies

[156 HF patients ventricular ejection fraction]

156 HF patients ventricular ejection fraction

[titin hypophosphorylation]

titin hypophosphorylation

[importance in the pathophysiology]

importance in the pathophysiology

[N termini]

N termini

[decrease in re-hospitalization]

decrease in re-hospitalization

[independent risk factor for disease]

independent risk factor for disease

[proteomics analysis of pressure-overload-induced heart failure]

proteomics analysis of pressure-overload-induced heart failure

[adverse CV events in models p]

adverse CV events in models p

[E-wave diastolic mitral velocity]

E-wave diastolic mitral velocity

[partial improvement at advanced stages]

partial improvement at advanced stages

[effects on receptor β-AR signaling]

effects on receptor β-AR signaling

[global longitudinal strain GLS]

global longitudinal strain GLS

[admission measurement]

admission measurement

[Self-Care Maintenance with success]

Self-Care Maintenance with success

[encoding a decoy VEGF receptor]

encoding a decoy VEGF receptor

[molecular pathways in patients]

molecular pathways in patients

[ventricular contractile reserve in patients]

ventricular contractile reserve in patients

[studies investigating HF-related cachexia]

studies investigating HF-related cachexia

[history of mitral valve plasty]

history of mitral valve plasty

[index 0.7 L]

index 0.7 L

[opposing]

opposing

[outcome median vs 257 milliseconds]

outcome median vs 257 milliseconds

[assessing filling pressure in patients]

assessing filling pressure in patients

[cardiomyocyte-like cells]

cardiomyocyte-like cells

[T2]

T2

[Connecticut Health Center]

Connecticut Health Center

[obstructive disease COPD]

obstructive disease COPD

[electrical stimulation FES]

electrical stimulation FES

[2 types HeartMate]

2 types HeartMate

[validation cohort of patients]

validation cohort of patients

[myocytes from hearts]

myocytes from hearts

[walking in patients]

walking in patients

[benefit over systolic parameters]

benefit over systolic parameters

[deciles of agreement]

deciles of agreement

[total of men]

total of men

[P-value for difference]

P-value for difference

[mitochondrial stress]

mitochondrial stress

[SS]

SS

[decisions]

decisions

[deleterious effects on various processes]

deleterious effects on various processes

[dose of 18 mg]

dose of 18 mg

[Self-Care Maintenance]

Self-Care Maintenance

[percutaneous intervention]

percutaneous intervention

[patients men]

patients men

[arterial coupling]

arterial coupling

[reactivation]

reactivation

[Exclusion of trial]

Exclusion of trial

[lipoprotein HDL]

lipoprotein HDL

[pharmacologic studies]

pharmacologic studies

[BTES All P]

BTES All P

[non-dilated ventricle]

non-dilated ventricle

[circulatory derangement with features similar]

circulatory derangement with features similar

[ventricular longitudinal strain GLS]

ventricular longitudinal strain GLS

[insight into the potential as targets]

insight into the potential as targets

[effect of dopamine]

effect of dopamine

[Cox proportional hazards regression modeling]

Cox proportional hazards regression modeling

[with axis function]

with axis function

[practice with these populations]

practice with these populations

[survival of patients g]

survival of patients g

[Michigan HF clinic]

Michigan HF clinic

[type V cardiac Na]

type V cardiac Na

[Reversal of cardiac dysfunction by metoprolol]

Reversal of cardiac dysfunction by metoprolol

[common forms of ventricular LV remodeling]

common forms of ventricular LV remodeling

[total compliance TAC]

total compliance TAC

[instability of nitrite]

instability of nitrite

[evidence of diastolic dysfunction]

evidence of diastolic dysfunction

[involving ventricular assist devices]

involving ventricular assist devices

[daily practice with these populations]

daily practice with these populations

[left ejection fraction 0.35]

left ejection fraction 0.35

[Cross-talk between the heart]

Cross-talk between the heart

[stable hypertension medication]

stable hypertension medication

[favorable outcome at year]

favorable outcome at year

[IRS2 double-knockout]

IRS2 double-knockout

[joint effect]

joint effect

[gaps]

gaps

[gas]

gas

[changes in cardiomyocytes]

changes in cardiomyocytes

[insight into prolonged delay]

insight into prolonged delay

[guanylate]

guanylate

[decrease in length of stay]

decrease in length of stay

[uptitration of neurohumoral blockers]

uptitration of neurohumoral blockers

[consecutive patients 224 men mean]

consecutive patients 224 men mean

[final evaluation]

final evaluation

[with.estimates]

with.estimates

[carrying two increase in risk]

carrying two increase in risk

[transplant ineligible patients]

transplant ineligible patients

[overview of the abnormalities]

overview of the abnormalities

[high 30-day survival rates]

high 30-day survival rates

[participant contact]

participant contact

[common characteristics using Cochrane Practice]

common characteristics using Cochrane Practice

[undiagnosed heart disease]

undiagnosed heart disease

[costs for patients]

costs for patients

[Tricuspid annular]

Tricuspid annular

[seven problems]

seven problems

[chronic stable guideline-directed therapy]

chronic stable guideline-directed therapy

[patients with infarction]

patients with infarction

[important defense mechanism during stress]

important defense mechanism during stress

[impact of carvedilol]

impact of carvedilol

[approach extrapolating short-term outcomes]

approach extrapolating short-term outcomes

[symptom CPET in 10 patients]

symptom CPET in 10 patients

[analysis of cardiac tissue]

analysis of cardiac tissue

[vs. 1.39 times]

vs. 1.39 times

[chronic heart failure population]

chronic heart failure population

[trend toward enrollment with dilatation]

trend toward enrollment with dilatation

[several genes]

several genes

[first acute myocardial infarction]

first acute myocardial infarction

[associations of Approaches]

associations of Approaches

[other important outcomes]

other important outcomes

[pharmacologic management]

pharmacologic management

[1.3 patient-years]

1.3 patient-years

[pulmonary artery systolic pressure PASP increase]

pulmonary artery systolic pressure PASP increase

[outcomes such as heart failure]

outcomes such as heart failure

[Particular topics of debate]

Particular topics of debate

[strength as an independent predictor]

strength as an independent predictor

[arterial tonometry]

arterial tonometry

[4.4 mm Hg]

4.4 mm Hg

[subgroups at risk of hyperkalemia]

subgroups at risk of hyperkalemia

[common inpatient conditions]

common inpatient conditions

[heart failure clinical studies]

heart failure clinical studies

[longitudinal systolic strain GLS]

longitudinal systolic strain GLS

[2 hypotheses addition 2 μg]

2 hypotheses addition 2 μg

[evidence on effects of types]

evidence on effects of types

[median follow-up of years]

median follow-up of years

[deaths in the procedures]

deaths in the procedures

[disease complex with therapeutics]

disease complex with therapeutics

[median BNP level]

median BNP level

[first myocardial infarction]

first myocardial infarction

[English-language trials in adults with anemia]

English-language trials in adults with anemia

[twofold increase]

twofold increase

[alleviating the decrement]

alleviating the decrement

[left LV myocytes]

left LV myocytes

[1.6 reasons P]

1.6 reasons P

[Get]

Get

[early diastolic velocity 3.1 vs. 1.3]

early diastolic velocity 3.1 vs. 1.3

[application of mitochondrial-targeted peptide drugs]

application of mitochondrial-targeted peptide drugs

[cardiovascular events P=0.18]

cardiovascular events P=0.18

[Canadian access programme]

Canadian access programme

[event rate at 0.53 events]

event rate at 0.53 events

[participatory population-specific health interventions]

participatory population-specific health interventions

[assessments of patients within days]

assessments of patients within days

[developments in procedure]

developments in procedure

[significance of BNP]

significance of BNP

[Coronary artery disease]

Coronary artery disease

[initial class]

initial class

[worst best quintile]

worst best quintile

[full advantage]

full advantage

[reductions in the number of admissions]

reductions in the number of admissions

[significant decline]

significant decline

[104 mm Hg]

104 mm Hg

[factors at admission]

factors at admission

[history with normal arteries]

history with normal arteries

[low mg]

low mg

[relevance of reserve in patients]

relevance of reserve in patients

[arterial hypertension PAH]

arterial hypertension PAH

[worsening GLS]

worsening GLS

[fat mass FFM]

fat mass FFM

[broad panel of assessments]

broad panel of assessments

[reversible ischemia open stent]

reversible ischemia open stent

[mitral valve tethering]

mitral valve tethering

[use of the nervous systems]

use of the nervous systems

[systolic elastance]

systolic elastance

[harms such as thromboembolism]

harms such as thromboembolism

[especially in patients surviving an infarction]

especially in patients surviving an infarction

[2 types for BTT patients]

2 types for BTT patients

[2+)-uptake]

2+)-uptake

[Renin-angiotensin-aldosterone system]

Renin-angiotensin-aldosterone system

[VA health care systems]

VA health care systems

[ED settings]

ED settings

[major safety measures]

major safety measures

[corporeal membrane oxygenation]

corporeal membrane oxygenation

[most common cause of hospitalization]

most common cause of hospitalization

[acute cardiotoxicity]

acute cardiotoxicity

[Multicenter double-blind placebo-controlled trial of patients]

Multicenter double-blind placebo-controlled trial of patients

[Outcomes multicenter study]

Outcomes multicenter study

[partial improvement at stages]

partial improvement at stages

[women undergoing chemotherapy]

women undergoing chemotherapy

[peripheral muscles]

peripheral muscles

[deleterious effects on processes]

deleterious effects on processes

[standards in biomarker studies]

standards in biomarker studies

[right assist]

right assist

[dopamine in heart failure with dysfunction]

dopamine in heart failure with dysfunction

[typical pattern]

typical pattern

[resting HR 70 bpm P]

resting HR 70 bpm P

[myoctyes]

myoctyes

[cardiac risk]

cardiac risk

[Patients aged]

Patients aged

[perceptions of cardioverter-defibrillator deactivation discussions]

perceptions of cardioverter-defibrillator deactivation discussions

[little influence on the overall burden]

little influence on the overall burden

[von Willebrand factor]

von Willebrand factor

[data on the potential of diuretics]

data on the potential of diuretics

[lower median activities P]

lower median activities P

[transforming growth factor yield]

transforming growth factor yield

[os]

os

[heart failure a disorder]

heart failure a disorder

[acute ventricular pressure overload]

acute ventricular pressure overload

[resting HR bpm]

resting HR bpm

[major components]

major components

[left ventricular diastolic end diameter difference]

left ventricular diastolic end diameter difference

[beta blockers in onset HFrEF]

beta blockers in onset HFrEF

[age 60 years]

age 60 years

[end point of death]

end point of death

[chronic guideline-directed medical therapy]

chronic guideline-directed medical therapy

[smallest difference BNP in women]

smallest difference BNP in women

[models p]

models p

[decrease in length]

decrease in length

[arterial systolic pressure relationship]

arterial systolic pressure relationship

[significant gaps in impact]

significant gaps in impact

[estimating capillary wedge pressure]

estimating capillary wedge pressure

[race by treatment interaction]

race by treatment interaction

[tonometric indices]

tonometric indices

[BNP levels 100 pg]

BNP levels 100 pg

[thigh muscle fat ratio]

thigh muscle fat ratio

[inoperable thromboembolic hypertension]

inoperable thromboembolic hypertension

[advanced management involving assist devices]

advanced management involving assist devices

[Concentrations of s ST2]

Concentrations of s ST2

[patients with advanced organ failure]

patients with advanced organ failure

[156 HF patients ejection fraction]

156 HF patients ejection fraction

[increasing refill compliance for etidronate P]

increasing refill compliance for etidronate P

[function via echocardiography]

function via echocardiography

[sensitive measure of mechanics]

sensitive measure of mechanics

[collateral growth patterns]

collateral growth patterns

[Key events]

Key events

[reference mean]

reference mean

[Improvement in eGFR]

Improvement in eGFR

[right atrial area cm]

right atrial area cm

[time of HF years]

time of HF years

[improving quality for patients]

improving quality for patients

[trials of TNF antagonists]

trials of TNF antagonists

[correction after assist device implantation]

correction after assist device implantation

[over 80 years]

over 80 years

[evidence from trials of intravenous iron]

evidence from trials of intravenous iron

[conducting cost-effectiveness analyses]

conducting cost-effectiveness analyses

[one model for myocardial ischemia]

one model for myocardial ischemia

[nurse assessment of impairment]

nurse assessment of impairment

[subject of this review]

subject of this review

[apparently healthy volunteers]

apparently healthy volunteers

[925 ED visits 76.4 years]

925 ED visits 76.4 years

[exercise-induced pulmonary artery systolic pressure increase]

exercise-induced pulmonary artery systolic pressure increase

[role of S1PR1 gene therapy]

role of S1PR1 gene therapy

[interleukin receptor family]

interleukin receptor family

[Grade weak recommendation evidence]

Grade weak recommendation evidence

[possible contribution]

possible contribution

[out-patient follow-up]

out-patient follow-up

[prognostic relevance of reserve]

prognostic relevance of reserve

[Renin-angiotensin-aldosterone system inhibitors]

Renin-angiotensin-aldosterone system inhibitors

[composite end-point in HFrEF]

composite end-point in HFrEF

[component improving quality for patients]

component improving quality for patients

[intracellular therapeutic strategy]

intracellular therapeutic strategy

[resting HR bpm P]

resting HR bpm P

[suggesting T1 as possible biomarker]

suggesting T1 as possible biomarker

[Global strain of left ventricle]

Global strain of left ventricle

[inhibition neprilysin blocks renin-angiotensin-aldosteron axis]

inhibition neprilysin blocks renin-angiotensin-aldosteron axis

[therapeutic concepts]

therapeutic concepts

[effects in the treatment]

effects in the treatment

[Western administrative health data]

Western administrative health data

[global gene expression]

global gene expression

[8-fluo-cAMP]

8-fluo-cAMP

[vascular endothelial growth]

vascular endothelial growth

[oxidative phosphorylation]

oxidative phosphorylation

[lack]

lack

[effective off-pump sternal sparing approach]

effective off-pump sternal sparing approach

[administrative health data]

administrative health data

[Fifty-four pediatric Fontan patients]

Fifty-four pediatric Fontan patients

[event rate at events P=0.001]

event rate at events P=0.001

[dose-related benefits]

dose-related benefits

[single center retrospective study]

single center retrospective study

[influence on the burden]

influence on the burden

[powerful composite HF index]

powerful composite HF index

[epigenetic readers]

epigenetic readers

[low-dose nesiritide μg]

low-dose nesiritide μg

[LV systolic dysfunction]

LV systolic dysfunction

[patients in the ECMO+VAD group]

patients in the ECMO+VAD group

[MLHF total score]

MLHF total score

[January 2000]

January 2000

[intracellular therapeutic strategy in HF]

intracellular therapeutic strategy in HF

[cross talk between cGMP signaling]

cross talk between cGMP signaling

[natremia]

natremia

[types of heart failure]

types of heart failure

[January 2009]

January 2009

[lb in year]

lb in year

[blockade of the system]

blockade of the system

[epifluorescence]

epifluorescence

[Organisation]

Organisation

[Subjects with RA]

Subjects with RA

[control studies]

control studies

[novel intracellular therapeutic strategy]

novel intracellular therapeutic strategy

[total expenditure on health per capita]

total expenditure on health per capita

[events stroke]

events stroke

[272 consecutive patients]

272 consecutive patients

[relationship with adverse CV events]

relationship with adverse CV events

[quantification of myocardial T1]

quantification of myocardial T1

[Stroke prevention]

Stroke prevention

[case mix after MI]

case mix after MI

[1-day reduction]

1-day reduction

[Patients with New York Heart Association]

Patients with New York Heart Association

[outpatient assessments of patients]

outpatient assessments of patients

[Usefulness of tissue Doppler imaging]

Usefulness of tissue Doppler imaging

[emergency setting]

emergency setting

[59.6 m]

59.6 m

[compelling improvement]

compelling improvement

[consecutive patients men]

consecutive patients men

[ventricular end diameter mm mean difference]

ventricular end diameter mm mean difference

[targeting the extreme N termini]

targeting the extreme N termini

[Automatic Defibrillator]

Automatic Defibrillator

[left anterior descending artery]

left anterior descending artery

[deactivation preferences]

deactivation preferences

[development of strategies capable]

development of strategies capable

[PD initiation almost 7 kg]

PD initiation almost 7 kg

[Understanding]

Understanding

[fastest subclass]

fastest subclass

[insight into electromechanical delay]

insight into electromechanical delay

[receptor agonist treatment]

receptor agonist treatment

[antiadrenergic therapeutic strategy in HF]

antiadrenergic therapeutic strategy in HF

[information for an outcome]

information for an outcome

[Several POC systems]

Several POC systems

[interval between myocyte depolarization]

interval between myocyte depolarization

[3 studies of therapeutics]

3 studies of therapeutics

[cachectic heart failure patients]

cachectic heart failure patients

[POC testing of NP]

POC testing of NP

[involving the anterior descending artery]

involving the anterior descending artery

[refractory heart failure CHF]

refractory heart failure CHF

[end-stage disease]

end-stage disease

[patients 224 men years]

patients 224 men years

[257 milliseconds]

257 milliseconds

[echocardiographic evidence of dyssynchrony]

echocardiographic evidence of dyssynchrony

[arterial elastance elastance Ees]

arterial elastance elastance Ees

[diagnostic features such as detection]

diagnostic features such as detection

[nutritional strategies with potentially anti-inflammatory effects]

nutritional strategies with potentially anti-inflammatory effects

[Remote monitoring after hospital discharge]

Remote monitoring after hospital discharge

[Relation between dysfunction]

Relation between dysfunction

[experience between 2008]

experience between 2008

[tricuspid valve]

tricuspid valve

[improvement initiative]

improvement initiative

[cause of systolic heart failure]

cause of systolic heart failure

[healthy age-matched controls]

healthy age-matched controls

[risk RR of heart failure]

risk RR of heart failure

[right ventricular RV plane systolic excursion]

right ventricular RV plane systolic excursion

[first results of studies]

first results of studies

[remaining indices]

remaining indices

[quality measures for medical conditions]

quality measures for medical conditions

[MR with LV dilatation]

MR with LV dilatation

[using a HeartMate II LVAD]

using a HeartMate II LVAD

[minor improvement]

minor improvement

[ventricular end-diastolic area index 10.0 cm(2)]

ventricular end-diastolic area index 10.0 cm(2)

[participating nurses]

participating nurses

[fastest growing subclass of diseases]

fastest growing subclass of diseases

[baseline sST2 status ≤35]

baseline sST2 status ≤35

[contextual factors such as patient preferences]

contextual factors such as patient preferences

[left ventricular end diameter difference]

left ventricular end diameter difference

[hypertension of 191 mm Hg]

hypertension of 191 mm Hg

[potential efficacy of therapeutic interatrial shunting]

potential efficacy of therapeutic interatrial shunting

[incident HF in 2825 participants]

incident HF in 2825 participants

[role of autonomic system activity]

role of autonomic system activity

[primary endpoint of therapy]

primary endpoint of therapy

[reclassification]

reclassification

[consecutive ambulatory HF patients ejection fraction]

consecutive ambulatory HF patients ejection fraction

[multivariate model a predictor]

multivariate model a predictor

[trial of walking]

trial of walking

[extending EMD in the failing heart]

extending EMD in the failing heart

[concept appropriate in patients]

concept appropriate in patients

[state of oxidative stress]

state of oxidative stress

[months of artery bypass grafting]

months of artery bypass grafting

[understanding of the mechanism]

understanding of the mechanism

[moderate-intensity exercise per week]

moderate-intensity exercise per week

[baseline covariates]

baseline covariates

[vasopressin type receptor antagonist]

vasopressin type receptor antagonist

[mild restriction]

mild restriction

[diet scores with heart failure]

diet scores with heart failure

[magnetic resonance imaging]

magnetic resonance imaging

[response in cardiac activity (123)I-meta-iodobenzylguanidine]

response in cardiac activity (123)I-meta-iodobenzylguanidine

[low BNP group]

low BNP group

[role of Mena in pathophysiology]

role of Mena in pathophysiology

[central pattern generator]

central pattern generator

[significant alterations]

significant alterations

[Retn gene Hum-Retn mice]

Retn gene Hum-Retn mice

[tachycardia indicative of vagal tone]

tachycardia indicative of vagal tone

[10 HF patients without VT]

10 HF patients without VT

[important prognostic indicator]

important prognostic indicator

[insulin-signaling components]

insulin-signaling components

[study of 20,812 patients]

study of 20,812 patients

[support score PSSS]

support score PSSS

[novel antiadrenergic therapeutic strategy]

novel antiadrenergic therapeutic strategy

[8 patients with CHF-NYHA-II]

8 patients with CHF-NYHA-II

[impact on inappropriate therapy]

impact on inappropriate therapy

[heart failure a preliminary study]

heart failure a preliminary study

[Northwest]

Northwest

[chronic stable therapy]

chronic stable therapy

[hyponatremia]

hyponatremia

[increase in life expectancy]

increase in life expectancy

[novel stable HNO donor]

novel stable HNO donor

[main objective]

main objective

[rehabilitation care on functional capacity]

rehabilitation care on functional capacity

[time period]

time period

[Echocardiograms of the left midpapillary level]

Echocardiograms of the left midpapillary level

[care surgery ACS consultations]

care surgery ACS consultations

[animal model]

animal model

[advanced chronic pulmonary disease]

advanced chronic pulmonary disease

[markers indicative]

markers indicative

[NF-κB]

NF-κB

[useful technique]

useful technique

[pressure overload RVPO]

pressure overload RVPO

[growing epidemic]

growing epidemic

[patients with HFpEF geometry]

patients with HFpEF geometry

[subjects with hearts HNorm]

subjects with hearts HNorm

[Cardiac magnetic resonance postcontrast]

Cardiac magnetic resonance postcontrast

[baseline CRF]

baseline CRF

[Sham-INV]

Sham-INV

[matching for age]

matching for age

[evidence of remodeling]

evidence of remodeling

[association between treatment variation]

association between treatment variation

[starting a TNF antagonist]

starting a TNF antagonist

[patients with CHF-NYHA-II]

patients with CHF-NYHA-II

[HF deaths]

HF deaths

[intracellular strategy in HF]

intracellular strategy in HF

[mRNA levels resulting]

mRNA levels resulting

[development after HCT]

development after HCT

[generating variants]

generating variants

[extreme deciles of agreement]

extreme deciles of agreement

[black patients]

black patients

[cardiomyopathy including angiography]

cardiomyopathy including angiography

[reversible ischemia]

reversible ischemia

[suppression of signalling]

suppression of signalling

[n=44 925 ED visits mean age]

n=44 925 ED visits mean age

[Fontan patients]

Fontan patients

[NYHA classification from class]

NYHA classification from class

[however an disease accounting]

however an disease accounting

[insight into delay in heart failure]

insight into delay in heart failure

[population within cardiac rehabilitation]

population within cardiac rehabilitation

[mitral velocity 3.1 vs. 1.3]

mitral velocity 3.1 vs. 1.3

[major cardiovascular complications]

major cardiovascular complications

[diagnosis of clinical diastolic dysfunction]

diagnosis of clinical diastolic dysfunction

[patient awareness of cardioverter-defibrillator deactivation discussions]

patient awareness of cardioverter-defibrillator deactivation discussions

[Multicenter Defibrillator Implantation]

Multicenter Defibrillator Implantation

[natriuretic peptide B-type peptide]

natriuretic peptide B-type peptide

[explant-derived cells]

explant-derived cells

[involving the left descending artery]

involving the left descending artery

[treating heart failure]

treating heart failure

[short-term exercise tolerance]

short-term exercise tolerance

[valve insufficiency]

valve insufficiency

[obstruction of the right artery]

obstruction of the right artery

[pharmacologic studies of therapeutics]

pharmacologic studies of therapeutics

[complementary model system]

complementary model system

[B-treated rats]

B-treated rats

[ejection fraction R=0.28]

ejection fraction R=0.28

[Impact of physician continuity]

Impact of physician continuity

[routine measurement]

routine measurement

[LV EF]

LV EF

[such MS]

such MS

[LV with an volume index]

LV with an volume index

[lower NO production]

lower NO production

[cardioverter-defibrillator therapy Defibrillator Implantation]

cardioverter-defibrillator therapy Defibrillator Implantation

[Investigation in a canine model]

Investigation in a canine model

[Collins]

Collins

[assist device VAD]

assist device VAD

[insulin products]

insulin products

[right coupling pulmonary vascular resistance]

right coupling pulmonary vascular resistance

[PD initiation 7 kg]

PD initiation 7 kg

[autonomic system activity on QTV]

autonomic system activity on QTV

[Future A Surgery Consensus Report]

Future A Surgery Consensus Report

[812 consecutive patients]

812 consecutive patients

[evaluating predictors on ICD patients]

evaluating predictors on ICD patients

[video]

video

[therapy refractory shock]

therapy refractory shock

[tracking VA patients]

tracking VA patients

[lacking Nucleolin]

lacking Nucleolin

[definitions of the distinctive components]

definitions of the distinctive components

[studies approximately 2900 HM]

studies approximately 2900 HM

[patients in NYHA class]

patients in NYHA class

[end-diastolic dimension]

end-diastolic dimension

[impaired energy metabolism gene expression]

impaired energy metabolism gene expression

[63 predictors]

63 predictors

[association between spironolactone use]

association between spironolactone use

[156 consecutive ambulatory HF patients]

156 consecutive ambulatory HF patients

[predictor period hazard ratio]

predictor period hazard ratio

[trials RCTs]

trials RCTs

[hospital in the worst quintile]

hospital in the worst quintile

[oral glucocorticoid dosage]

oral glucocorticoid dosage

[participants mean]

participants mean

[following hospital stay]

following hospital stay

[ratio of LV strain rate]

ratio of LV strain rate

[2 hypotheses addition]

2 hypotheses addition

[inoperable chronic thromboembolic hypertension]

inoperable chronic thromboembolic hypertension

[left assist device LVAD]

left assist device LVAD

[ejection fraction arguments]

ejection fraction arguments

[extending EMD with the aspects contributing]

extending EMD with the aspects contributing

[determining the cardiac remodelling]

determining the cardiac remodelling

[patients with a median follow-up]

patients with a median follow-up

[consenting HF patients]

consenting HF patients

[patient-years]

patient-years

[role in diverse aspects]

role in diverse aspects

[sodium current in human heart failure]

sodium current in human heart failure

[non-AAs]

non-AAs

[CV events in atrial fibrillation]

CV events in atrial fibrillation

[management of intrinsic dysfunction]

management of intrinsic dysfunction

[time interval between myocyte depolarization]

time interval between myocyte depolarization

[Hemoglobin in patients]

Hemoglobin in patients

[6-min]

6-min

[use of the renin-angiotensin-aldosterone systems]

use of the renin-angiotensin-aldosterone systems

[involving the proximal left artery]

involving the proximal left artery

[Detailed transcriptional analysis]

Detailed transcriptional analysis

[cachexia CC]

cachexia CC

[older obese participants mean]

older obese participants mean

[guideline-directed therapy GDMT]

guideline-directed therapy GDMT

[playing a role in patients]

playing a role in patients

[relationship between length]

relationship between length

[abnormal SCN5A mRNA splicing]

abnormal SCN5A mRNA splicing

[greater impact]

greater impact

[daily clinical practice]

daily clinical practice

[significant reductions in the end-point]

significant reductions in the end-point

[useful tool]

useful tool

[Stage 3 kidney disease]

Stage 3 kidney disease

[enzymes lyso-PAF acetyltransferase]

enzymes lyso-PAF acetyltransferase

[estimating LV filling pressure]

estimating LV filling pressure

[RVPO]

RVPO

[left assist devices LVADs]

left assist devices LVADs

[vena cava IVC]

vena cava IVC

[Stage kidney disease]

Stage kidney disease

[100 older obese participants]

100 older obese participants

[outcomes in patients with fibrillation]

outcomes in patients with fibrillation

[English-language trials in adults]

English-language trials in adults

[Effects of cardiac support on function]

Effects of cardiac support on function

[range with COPD n=95]

range with COPD n=95

[restoring phosphorylation capacity]

restoring phosphorylation capacity

[surviving an myocardial infarction AMI]

surviving an myocardial infarction AMI

[type regulatory RIIα]

type regulatory RIIα

[using metrics for disease groups]

using metrics for disease groups

[factors such as patient preferences]

factors such as patient preferences

[infarction patients with heart failure]

infarction patients with heart failure

[rate risk]

rate risk

[acute autonomic system modulation]

acute autonomic system modulation

[delay the time interval]

delay the time interval

[criteriabased institution of PD]

criteriabased institution of PD

[cause of heart failure HF]

cause of heart failure HF

[treatments targeting abnormal exercise hemodynamic status]

treatments targeting abnormal exercise hemodynamic status

[Patients With Shortness of Breath]

Patients With Shortness of Breath

[treatment treatment]

treatment treatment

[Estimating the jugular pressure]

Estimating the jugular pressure

[14 studies 2900 HM]

14 studies 2900 HM

[regarding effective treatment of adults]

regarding effective treatment of adults

[therapy HR 0.87]

therapy HR 0.87

[high consistency]

high consistency

[beats]

beats

[molecular analysis]

molecular analysis

[less severe dilatation]

less severe dilatation

[Australian administrative health data]

Australian administrative health data

[patients with the coronary syndrome]

patients with the coronary syndrome

[2.1 mL P=0.01]

2.1 mL P=0.01

[metabolic changes]

metabolic changes

[tract infection UTI]

tract infection UTI

[chronic medical therapy GDMT]

chronic medical therapy GDMT

[New Zealand rabbits undergoing DNx]

New Zealand rabbits undergoing DNx

[exercise capacity in patients]

exercise capacity in patients

[using procedures]

using procedures

[behavior of the heart]

behavior of the heart

[stable medical therapy GDMT]

stable medical therapy GDMT

[20,812 patients with infarction]

20,812 patients with infarction

[death hospitalization]

death hospitalization

[improving muscle function]

improving muscle function

[economic climate]

economic climate

[little impact on gross development]

little impact on gross development

[334 consecutive patients men years]

334 consecutive patients men years

[Moderate high-strength evidence]

Moderate high-strength evidence

[presumably decreasing risk of HF mortality]

presumably decreasing risk of HF mortality

[PDE2-mediated effects on receptor signaling]

PDE2-mediated effects on receptor signaling

[Chronic β-AR stimulation]

Chronic β-AR stimulation

[total of individuals]

total of individuals

[diagnosis of prognostic dysfunction]

diagnosis of prognostic dysfunction

[experiencing distressing implantable cardioverter-defibrillator shocks]

experiencing distressing implantable cardioverter-defibrillator shocks

[Fifty consecutive patients with onset]

Fifty consecutive patients with onset

[evidence-based practices]

evidence-based practices

[analysis of a chromatin subproteome]

analysis of a chromatin subproteome

[Estimating the pressure]

Estimating the pressure

[Functional electrical stimulation of muscles]

Functional electrical stimulation of muscles

[reducing all-cause mortality for patients]

reducing all-cause mortality for patients

[gene programs in heart failure]

gene programs in heart failure

[2825 participants aged]

2825 participants aged

[type V voltage-gated Na]

type V voltage-gated Na

[underlying mechanism of HFPEF]

underlying mechanism of HFPEF

[Outcomes Study Short-Form quality]

Outcomes Study Short-Form quality

[left systolic function in volume overload]

left systolic function in volume overload

[early velocity 3.1 vs. 1.3]

early velocity 3.1 vs. 1.3

[smallest difference median BNP EF]

smallest difference median BNP EF

[self-management training]

self-management training

[cost-effectiveness ratios from user inputs]

cost-effectiveness ratios from user inputs

[Patients Hospitalization]

Patients Hospitalization

[risk than the rest]

risk than the rest

[risk developing hyperkalemia]

risk developing hyperkalemia

[selecting controls]

selecting controls

[early annular velocity 3.1]

early annular velocity 3.1

[334 patients men mean years]

334 patients men mean years

[self-reported physical activity]

self-reported physical activity

[outcomes P]

outcomes P

[Using a improvement database]

Using a improvement database

[ratio early mitral annulus velocity]

ratio early mitral annulus velocity

[vivo RV length-force]

vivo RV length-force

[myocyte-specific Mena overexpression comparable]

myocyte-specific Mena overexpression comparable

[overwhelming contribution]

overwhelming contribution

[artery occlusion]

artery occlusion

[increase for acute infarction]

increase for acute infarction

[assessments of patients]

assessments of patients

[mouse heart failure HF]

mouse heart failure HF

[n=100]

n=100

[achievement of anaerobic metabolism quotient]

achievement of anaerobic metabolism quotient

[other important outcomes in patients]

other important outcomes in patients

[sustaining the workload]

sustaining the workload

[10 heart failure patients]

10 heart failure patients

[patients as destination therapy DT]

patients as destination therapy DT

[group mL per m]

group mL per m

[events for psoriasis]

events for psoriasis

[123 mm]

123 mm

[case mix]

case mix

[group IV]

group IV

[positive effects in vivo]

positive effects in vivo

[possible mechanism of cardioprotection]

possible mechanism of cardioprotection

[improving the prognosis of patients]

improving the prognosis of patients

[matrix using resonance T1 mapping]

matrix using resonance T1 mapping

[BMI-matched healthy volunteers]

BMI-matched healthy volunteers

[group II]

group II

[catabolism]

catabolism

[function in HFpEF patients]

function in HFpEF patients

[Large-scale multicenter trial with 8000 individuals]

Large-scale multicenter trial with 8000 individuals

[METs vs. 5.7 METs]

METs vs. 5.7 METs

[ejection time complicating precapillary hypertension]

ejection time complicating precapillary hypertension

[patients with HR bpm]

patients with HR bpm

[Biventricular support using a HeartMate LVAD]

Biventricular support using a HeartMate LVAD

[3 trials of iron]

3 trials of iron

[magnetic resonance imaging including T1 mapping]

magnetic resonance imaging including T1 mapping

[large cardiomyopathy cohort]

large cardiomyopathy cohort

[CI for sitagliptin for sitagliptin]

CI for sitagliptin for sitagliptin

[median activities of lyso-PAF-AT P]

median activities of lyso-PAF-AT P

[only modest effects]

only modest effects

[user inputs]

user inputs

[nonglycosylated epitopes P]

nonglycosylated epitopes P

[factor-β TGF-β]

factor-β TGF-β

[cardiac progenitor function]

cardiac progenitor function

[malignancies]

malignancies

[underperfusion resulting]

underperfusion resulting

[days P-value]

days P-value

[effect of natriuretic peptides]

effect of natriuretic peptides

[principles of treatment]

principles of treatment

[predictor of long-term mortality]

predictor of long-term mortality

[somewhat better prognostic information]

somewhat better prognostic information

[blockade]

blockade

[Procedure]

Procedure

[strain as a predictor of events]

strain as a predictor of events

[conditions such as infarction]

conditions such as infarction

[average follow-up of months]

average follow-up of months

[nonfunctional channels]

nonfunctional channels

[normal arteries]

normal arteries

[Validating outcome measures in future research]

Validating outcome measures in future research

[population-based study]

population-based study

[ventricular tricuspid plane systolic excursion TAPSE]

ventricular tricuspid plane systolic excursion TAPSE

[diastolic mitral annulus velocity E]

diastolic mitral annulus velocity E

[CXL-1051]

CXL-1051

[albeit with ability]

albeit with ability

[evidence from 3 trials of iron]

evidence from 3 trials of iron

[relationship between QRS]

relationship between QRS

[mortality at years]

mortality at years

[major cause of heart failure]

major cause of heart failure

[indeterminable threshold]

indeterminable threshold

[developmental impairment]

developmental impairment

[channel mRNA]

channel mRNA

[left ventricular systolic pressure]

left ventricular systolic pressure

[two increase in cardiac risk]

two increase in cardiac risk

[24 per cent with deaths occurring]

24 per cent with deaths occurring

[x-ray absorptiometry DXA]

x-ray absorptiometry DXA

[model a predictor]

model a predictor

[efficiency slope]

efficiency slope

[pulmonary systolic pressure relationship an index]

pulmonary systolic pressure relationship an index

[population of anthracycline]

population of anthracycline

[average of months]

average of months

[HFrEF hazard ratio]

HFrEF hazard ratio

[estimating pulmonary capillary wedge pressure PCWP]

estimating pulmonary capillary wedge pressure PCWP

[following β-AR stimulation]

following β-AR stimulation

[decreases in septum thickness]

decreases in septum thickness

[prospective multicenter trial PARADIGM-HF with individuals]

prospective multicenter trial PARADIGM-HF with individuals

[important implications]

important implications

[CO. Lack]

CO. Lack

[elderly male patients]

elderly male patients

[diagnosis of cardiomyiopathy]

diagnosis of cardiomyiopathy

[patients with HF of etiology]

patients with HF of etiology

[receiving the last dose]

receiving the last dose

[inappropriate shock therapy]

inappropriate shock therapy

[evaluations HM]

evaluations HM

[tool for prognostic assessment]

tool for prognostic assessment

[effects of 2 types]

effects of 2 types

[plasma N-terminal pro-B-type peptide]

plasma N-terminal pro-B-type peptide

[matrix using cardiac resonance T1 mapping]

matrix using cardiac resonance T1 mapping

[biomarker for HFPEF]

biomarker for HFPEF

[effective target]

effective target

[metric choice]

metric choice

[Joanna]

Joanna

[Heterogenous improvement]

Heterogenous improvement

[role in aspects]

role in aspects

[difference among EF BNP EF]

difference among EF BNP EF

[ring implantation]

ring implantation

[coupling resistance]

coupling resistance

[direct interaction]

direct interaction

[normal LV ejection fraction]

normal LV ejection fraction

[predictor of outcome period]

predictor of outcome period

[carotid baroreflex activation]

carotid baroreflex activation

[skinfold]

skinfold

[application of peptide drugs]

application of peptide drugs

[N-terminal pro-B-type natriuretic peptide NT-proBNP]

N-terminal pro-B-type natriuretic peptide NT-proBNP

[diminishing the XO-mediated ROS effects]

diminishing the XO-mediated ROS effects

[trends for four conditions]

trends for four conditions

[stable HNO donor]

stable HNO donor

[medical management of HF]

medical management of HF

[anterior descending LAD]

anterior descending LAD

[Validating nursing-sensitive outcome measures in research]

Validating nursing-sensitive outcome measures in research

[magnetic resonance T1 time hazard ratio]

magnetic resonance T1 time hazard ratio

[failure CRF]

failure CRF

[frequency of follow-up visits]

frequency of follow-up visits, Frequency of follow-up visits

[option in end-stage heart failure]

option in end-stage heart failure

[events during the first months]

events during the first months

[periodic breathing PB]

periodic breathing PB

[malfunctioning]

malfunctioning

[Survival after assist device]

Survival after assist device

[left ventricular end diameter mean difference]

left ventricular end diameter mean difference

[activities of lyso-PAF-AT]

activities of lyso-PAF-AT

[ml odds ratio 1.76]

ml odds ratio 1.76

[highest quartile]

highest quartile

[structural heart disease]

structural heart disease

[excellent risk stratification between a group]

excellent risk stratification between a group

[LVAD support]

LVAD support

[noncardiovascular drugs]

noncardiovascular drugs

[receptor neprilysin]

receptor neprilysin

[bundle-branch]

bundle-branch

[efficacy of a HNO donor]

efficacy of a HNO donor

[measure of HF]

measure of HF

[reductions in the end-point]

reductions in the end-point

[Diagnosis role of clinical Doppler echocardiography]

Diagnosis role of clinical Doppler echocardiography

[major predictor of events]

major predictor of events

[Extracellular matrix of biopsies]

Extracellular matrix of biopsies

[Right Heart Foundation]

Right Heart Foundation

[relevance of right ventricular contractile reserve]

relevance of right ventricular contractile reserve

[HF hospitalization HR 1.58]

HF hospitalization HR 1.58

[myocardial infarction with complications]

myocardial infarction with complications

[multisite studies in practice settings]

multisite studies in practice settings

[trichrome histologic analysis]

trichrome histologic analysis

[activities P]

activities P

[diastolic mitral flow]

diastolic mitral flow

[decline in function]

decline in function

[enormous clinical burden]

enormous clinical burden

[beta1-adrenergic]

beta1-adrenergic

[national income per capita]

national income per capita

[effects of assist device]

effects of assist device

[echocardiographic evidence of ventricular dyssynchrony]

echocardiographic evidence of ventricular dyssynchrony

[adults with anemia]

adults with anemia

[support score]

support score

[type regulatory]

type regulatory

[cystatin C]

cystatin C

[group mL per m 2]

group mL per m 2

[global ventricular longitudinal systolic strain]

global ventricular longitudinal systolic strain

[patients maintaining sinus rhythm]

patients maintaining sinus rhythm

[individuals with congestive heart failure]

individuals with congestive heart failure

[adoption of heart failure guidelines]

adoption of heart failure guidelines

[beta-blockers on cardiac sympathetic activity]

beta-blockers on cardiac sympathetic activity

[higher levels of support]

higher levels of support

[maladaptive processes]

maladaptive processes

[test-retest reliability in patients]

test-retest reliability in patients

[coupling pulmonary resistance P]

coupling pulmonary resistance P

[patients with ischemic cardiomyopathy]

patients with ischemic cardiomyopathy

[severe perturbations]

severe perturbations

[catheter ablation of atrial fibrillation]

catheter ablation of atrial fibrillation

[infarction-related refractory heart failure]

infarction-related refractory heart failure

[60 years P=0.016]

60 years P=0.016

[ratio better]

ratio better

[short-term improvements in functioning of treatments]

short-term improvements in functioning of treatments

[trial registries]

trial registries

[treatment for infarction]

treatment for infarction

[thirty-seven hospitals from January through September]

thirty-seven hospitals from January through September

[Minnesota residents]

Minnesota residents

[examining outcomes]

examining outcomes

[subgroups of patients at risk]

subgroups of patients at risk

[common form of disease]

common form of disease

[Heart Failure Index]

Heart Failure Index

[complicating hypertension]

complicating hypertension

[Health Insurance Board]

Health Insurance Board

[consecutive patients with ejection fraction]

consecutive patients with ejection fraction

[Reversal by metoprolol in heart failure]

Reversal by metoprolol in heart failure

[Understanding of heart failure HF]

Understanding of heart failure HF

[treatment for end-stage heart failure]

treatment for end-stage heart failure

[amelioration]

amelioration

[Minnesota residents with HF]

Minnesota residents with HF

[biopsies]

biopsies

[lowest cardiovascular event rate]

lowest cardiovascular event rate

[restoring capacity for CF LVAD patients]

restoring capacity for CF LVAD patients

[Cross-talk in cachectic heart failure patients]

Cross-talk in cachectic heart failure patients

[mitral stenosis MS]

mitral stenosis MS

[capillary perfusion]

capillary perfusion

[support for the concept]

support for the concept

[decongestion end]

decongestion end

[start date]

start date

[also in patients with heart failure]

also in patients with heart failure

[aspects contributing insignificantly]

aspects contributing insignificantly

[undergoing anthracycline-containing chemotherapy]

undergoing anthracycline-containing chemotherapy

[studies including RELAX-AHF]

studies including RELAX-AHF

[training period with three trainings]

training period with three trainings

[rates for outpatients]

rates for outpatients

[commissioning of hospital programmes]

commissioning of hospital programmes

[IRS2 gene]

IRS2 gene

[primary outcome hospitalization]

primary outcome hospitalization

[receptor signaling in cardiomyocytes]

receptor signaling in cardiomyocytes

[development of strategies]

development of strategies

[10.0 cm(2)]

10.0 cm(2)

[including angiography]

including angiography

[systemic resistance]

systemic resistance

[cardiomyopathy including negative angiography]

cardiomyopathy including negative angiography

[transmitral E-wave early mitral annular velocity]

transmitral E-wave early mitral annular velocity

[right ventricular tricuspid annular plane excursion]

right ventricular tricuspid annular plane excursion

[Multicenter trial Optimization Strategies Evaluation]

Multicenter trial Optimization Strategies Evaluation

[determining individualized assessment]

determining individualized assessment

[subspecialty groups]

subspecialty groups

[NCDR PINNACLE program]

NCDR PINNACLE program

[patients with first acute infarction]

patients with first acute infarction

[risk of mortality as patients]

risk of mortality as patients

[cause in young athletes]

cause in young athletes

[20 cm 2]

20 cm 2

[hypertensive heart failure]

hypertensive heart failure

[propensity analyses]

propensity analyses

[Doppler echocardiography]

Doppler echocardiography

[risk of outcomes]

risk of outcomes

[readmission rates using three metrics]

readmission rates using three metrics

[potential application of peptide drugs]

potential application of peptide drugs

[positron]

positron

[crossover study]

crossover study

[Management stemming]

Management stemming

[Participation during the development]

Participation during the development

[treatment of Atrial fibrillation]

treatment of Atrial fibrillation

[dysfunction in pathways]

dysfunction in pathways

[validity of scales]

validity of scales

[simultaneous activation of β1ARs]

simultaneous activation of β1ARs

[few deaths in the experimental procedures]

few deaths in the experimental procedures

[regulator in cardiomyocytes]

regulator in cardiomyocytes

[groups Wistar-Kyoto]

groups Wistar-Kyoto

[Various measures of HR dynamics]

Various measures of HR dynamics

[indicators of status]

indicators of status

[N-terminal pro-brain-type peptide assessment]

N-terminal pro-brain-type peptide assessment

[change values]

change values

[Reasons prescribing guideline-recommended medications]

Reasons prescribing guideline-recommended medications

[aim of the study]

aim of the study

[symptom CPET]

symptom CPET

[Effective elastance elastance]

Effective elastance elastance

[Recommendations for advanced management]

Recommendations for advanced management

[cardiac gene control]

cardiac gene control

[World Health Organization criteria for cardiomyopathy]

World Health Organization criteria for cardiomyopathy

[T2D Type]

T2D Type

[following ring annuloplasty for MR]

following ring annuloplasty for MR

[subjects with heart failure attributable]

subjects with heart failure attributable

[tidal respiration for quantification]

tidal respiration for quantification

[respiration for quantification]

respiration for quantification

[York Heart Association class II]

York Heart Association class II

[statistically significant 42 percent reduction]

statistically significant 42 percent reduction

[quality for HF]

quality for HF

[large-scale trial]

large-scale trial

[care surgery consultations in recipients]

care surgery consultations in recipients

[stenosis]

stenosis

[benefit for patients in small studies]

benefit for patients in small studies

[hazard ratios of 0.67]

hazard ratios of 0.67

[changes During RVPO]

changes During RVPO

[fluorescence resonance]

fluorescence resonance

[five patients IL]

five patients IL

[prospective multicenter trial with 8000 individuals]

prospective multicenter trial with 8000 individuals

[telephone support]

telephone support

[circulating plasma NE]

circulating plasma NE

[hypoxia activators]

hypoxia activators

[diet score P trend=0.08]

diet score P trend=0.08

[refill compliance P]

refill compliance P

[PAF-CPT]

PAF-CPT

[right ventricular plane excursion TAPSE]

right ventricular plane excursion TAPSE

[14 patients]

14 patients

[trials of intravenous iron]

trials of intravenous iron

[patients with the acute syndrome]

patients with the acute syndrome

[frequency of diabetes mellitus]

frequency of diabetes mellitus

[BB dose versus 50 mg dose]

BB dose versus 50 mg dose

[human embryonic kidney cells overexpressing β1AR]

human embryonic kidney cells overexpressing β1AR

[tract infection]

tract infection

[fundamental mechanism]

fundamental mechanism

[Black race in patients with HF]

Black race in patients with HF

[pulse sequence]

pulse sequence

[257 milliseconds milliseconds]

257 milliseconds milliseconds

[Tools A Web-based program]

Tools A Web-based program

[common forms of ventricular remodeling]

common forms of ventricular remodeling

[Coding]

Coding

[transplants in children]

transplants in children

[Renal artery]

Renal artery

[contributions of remodeling aspects]

contributions of remodeling aspects

[total of psoriasis]

total of psoriasis

[onset HFrEF days]

onset HFrEF days

[subgroup analyses]

subgroup analyses

[electrocardiographers]

electrocardiographers

[heart failure patients with respect]

heart failure patients with respect

[potential benefit with consequences]

potential benefit with consequences

[clinical CHF model]

clinical CHF model

[patients with HFpEF treatment]

patients with HFpEF treatment

[indicator in heart failure]

indicator in heart failure

[using 2005 2008 performance]

using 2005 2008 performance

[several Outcomes Study]

several Outcomes Study

[postoperative normalization]

postoperative normalization

[Crude rates of hyperkalemia]

Crude rates of hyperkalemia

[2 types of LVADs]

2 types of LVADs

[early-onset HF]

early-onset HF

[beta-blockers on cardiac activity]

beta-blockers on cardiac activity

[consistency among patients with HFpEF α=0.96]

consistency among patients with HFpEF α=0.96

[study sample]

study sample

[infarction MI]

infarction MI

[exercise time tests]

exercise time tests

[long-standing AF]

long-standing AF

[refractory HF]

refractory HF

[providing information]

providing information

[provision of treatment]

provision of treatment

[carrying increase in risk]

carrying increase in risk

[kidney injury during spironolactone use]

kidney injury during spironolactone use

[Medicare 30-day readmission]

Medicare 30-day readmission

[still a effective agent]

still a effective agent

[having predictor]

having predictor

[most common type of tumors]

most common type of tumors

[HDL-induced NO production]

HDL-induced NO production

[arterial coupling pulmonary vascular resistance]

arterial coupling pulmonary vascular resistance

[shorter walk distance]

shorter walk distance

[quintile of performance]

quintile of performance

[post-myocardial infarction heart]

post-myocardial infarction heart

[trend toward an inverse association]

trend toward an inverse association

[CI for sitagliptin CI for sitagliptin]

CI for sitagliptin CI for sitagliptin

[fashion alterations]

fashion alterations

[benefit over clinical systolic parameters]

benefit over clinical systolic parameters

[multivariate Cox proportional hazards]

multivariate Cox proportional hazards

[descending]

descending

[ED visits 76.4 years]

ED visits 76.4 years

[functional etiology]

functional etiology

[spite]

spite

[effect exercise]

effect exercise

[Biomarkers of stimulation]

Biomarkers of stimulation

[atrial explant-derived c-Kit]

atrial explant-derived c-Kit

[ratio mitral annulus velocity]

ratio mitral annulus velocity

[National trends for conditions]

National trends for conditions

[Heart Failure Questionnaire]

Heart Failure Questionnaire

[Aldactone Evaluation Study RALES]

Aldactone Evaluation Study RALES

[conventional clinical parameters in AF]

conventional clinical parameters in AF

[inducing hyperkalemia]

inducing hyperkalemia

[Twenty-seven studies]

Twenty-seven studies

[CHA₂DS₂VASc score]

CHA₂DS₂VASc score

[difference among the groups]

difference among the groups

[matrix of left ventricular biopsies n=9]

matrix of left ventricular biopsies n=9

[artery calcium scores]

artery calcium scores

[composite HF index P]

composite HF index P

[mortality all hazard ratios]

mortality all hazard ratios

[Diagnostic role]

Diagnostic role

[functional decline atrial c-Kit]

functional decline atrial c-Kit

[patients men 65±12 years]

patients men 65±12 years

[Classification of Diseases]

Classification of Diseases

[crucial problem of cardiology]

crucial problem of cardiology

[developing certain malignancies]

developing certain malignancies

[LV mass 42.4 g]

LV mass 42.4 g

[PDE2 activity]

PDE2 activity

[patients with pulmonary disease COPD]

patients with pulmonary disease COPD

[membrane oxygenation in refractory heart failure]

membrane oxygenation in refractory heart failure

[including the establishment]

including the establishment

[evidence from trials of iron]

evidence from trials of iron

[descending coronary artery occlusion]

descending coronary artery occlusion

[common problem]

common problem

[≥5 mg HR]

≥5 mg HR

[cardiomyiopathy]

cardiomyiopathy

[heart failure patients ejection fraction]

heart failure patients ejection fraction

[brief insight]

brief insight

[factorial trial]

factorial trial

[effect of nicorandil]

effect of nicorandil

[combining salt loading]

combining salt loading

[transcription factor networks]

transcription factor networks

[urgent all-cause]

urgent all-cause

[8656 users of a nbDMARD]

8656 users of a nbDMARD

[method of constriction TAC]

method of constriction TAC

[Organisation of Care]

Organisation of Care

[ventricle RV]

ventricle RV

[anterior descending]

anterior descending

[ion]

ion

[Effect of If-channel inhibition on status]

Effect of If-channel inhibition on status

[chronic guideline-directed medical therapy GDMT]

chronic guideline-directed medical therapy GDMT

[less severe dysfunction]

less severe dysfunction

[cardioprotection via inhibition]

cardioprotection via inhibition

[scenario of expenditure]

scenario of expenditure

[passive constants]

passive constants

[targeting the N termini]

targeting the N termini

[response in cardiac activity]

response in cardiac activity

[excellent ability]

excellent ability

[SR Ca]

SR Ca

[apparent NT-proBNP concentration]

apparent NT-proBNP concentration

[nontrastuzumab users hazard ratio]

nontrastuzumab users hazard ratio

[achievement of metabolism]

achievement of metabolism

[human left ventricular LV myocytes]

human left ventricular LV myocytes

[Gly16 haplotype]

Gly16 haplotype

[statistical standards]

statistical standards

[financial burden]

financial burden

[DTT]-insensitive CDP]

DTT]-insensitive CDP

[risk of hyperkalemia patients]

risk of hyperkalemia patients

[34 follow-up period]

34 follow-up period

[odds dying in days P-value]

odds dying in days P-value

[anaerobic metabolism]

anaerobic metabolism

[large-scale studies]

large-scale studies

[6-week follow-up period]

6-week follow-up period

[normal sized LV]

normal sized LV

[sarcoplasmic SR Ca]

sarcoplasmic SR Ca

[treadmill testing]

treadmill testing

[following event rates]

following event rates

[improvement between baseline exercise capacity]

improvement between baseline exercise capacity

[conventional parameters]

conventional parameters

[difference BNP in women EF]

difference BNP in women EF

[population in South Dakota]

population in South Dakota

[ventricular systolic strain as a predictor]

ventricular systolic strain as a predictor

[geometry no LV hypertrophy]

geometry no LV hypertrophy

[bpm respectively P]

bpm respectively P

[acute system modulation]

acute system modulation

[significant cost savings]

significant cost savings

[nonadherence vs. oldest]

nonadherence vs. oldest

[significant percent reduction]

significant percent reduction

[citrate]

citrate

[ventricular assist device use]

ventricular assist device use

[Multicenter double-blind trial]

Multicenter double-blind trial

[transcatheter approaches]

transcatheter approaches

[requiring HeartMate II]

requiring HeartMate II

[outpatient assessments within 7 days]

outpatient assessments within 7 days

[812 patients aged years]

812 patients aged years

[progenitor function]

progenitor function

[independent hypotheses addition 2 μg]

independent hypotheses addition 2 μg

[right ventricular RV tricuspid plane excursion]

right ventricular RV tricuspid plane excursion

[presence of N forms]

presence of N forms

[function assessment]

function assessment

[impact of assist device VAD]

impact of assist device VAD

[pulse-wave]

pulse-wave

[black ethnicity]

black ethnicity

[role of S1PR1 cardiac gene therapy]

role of S1PR1 cardiac gene therapy

[proteins Nucleolin]

proteins Nucleolin

[70 bpm respectively P]

70 bpm respectively P

[HRV]

HRV

[men years]

men years

[Outcomes multicenter study of exercise training]

Outcomes multicenter study of exercise training

[Catheter-based percutaneous revascularization]

Catheter-based percutaneous revascularization

[acid]

acid

[assist device with right support]

assist device with right support

[inhibition of L-type Ca2]

inhibition of L-type Ca2

[hospital volume]

hospital volume

[prognostic markers hazard ratio]

prognostic markers hazard ratio

[global ventricular systolic strain]

global ventricular systolic strain

[acceptable validity replicating resource use]

acceptable validity replicating resource use

[cardiac procedures]

cardiac procedures

[20 consecutive patients aged years]

20 consecutive patients aged years

[nomenclature for failure]

nomenclature for failure

[β-myosin chain]

β-myosin chain

[parallel with an average]

parallel with an average

[patients men mean]

patients men mean

[treatment interaction P=0.03]

treatment interaction P=0.03

[end-tidal CO2]

end-tidal CO2

[differences in presentation]

differences in presentation

[unfavorable outcome vs milliseconds]

unfavorable outcome vs milliseconds

[Echocardiographic predictors of reverse remodeling]

Echocardiographic predictors of reverse remodeling

[patients experiencing cardioverter-defibrillator shocks]

patients experiencing cardioverter-defibrillator shocks

[simple procedures]

simple procedures

[difference BNP EF]

difference BNP EF

[common type of benign tumors]

common type of benign tumors

[Similar improvements]

Similar improvements

[liver texture changes]

liver texture changes

[duration of mechanical support]

duration of mechanical support

[Republic]

Republic

[natriuretic]

natriuretic

[myofilament Ca sensitivity]

myofilament Ca sensitivity

[Evidence]

Evidence

[cohort systolic heart failure]

cohort systolic heart failure

[acute care surgery ACS]

acute care surgery ACS

[Exercise time]

Exercise time

[gross development]

gross development

[body mass index kg]

body mass index kg

[practice within domain]

practice within domain

[following ring annuloplasty]

following ring annuloplasty

[trastuzumab administration]

trastuzumab administration

[end-tidal CO2 PETCO2]

end-tidal CO2 PETCO2

[human hearts]

human hearts

[promoting filling during exercise in subjects]

promoting filling during exercise in subjects

[average length 37]

average length 37

[O2 consumption]

O2 consumption

[arterial elastance Ea]

arterial elastance Ea

[effects analysis]

effects analysis

[Multicenter Defibrillator]

Multicenter Defibrillator

[development of new approaches]

development of new approaches

[fewer depressive symptoms]

fewer depressive symptoms

[obstructive pulmonary disease COPD]

obstructive pulmonary disease COPD

[median filtration rate]

median filtration rate

[pharmacologic management for HF]

pharmacologic management for HF

[trends in HF]

trends in HF

[heart dilatation after transverse constriction]

heart dilatation after transverse constriction

[shortening]

shortening

[Witness]

Witness

[symptom maximal CPET]

symptom maximal CPET

[albumin concentration g]

albumin concentration g

[Extracorporeal membrane oxygenation as bridge]

Extracorporeal membrane oxygenation as bridge

[2 types]

2 types

[chemotherapy-induced heart failure]

chemotherapy-induced heart failure

[aerobic training period]

aerobic training period

[armamentarium]

armamentarium

[wild type]

wild type

[ongoing Cardiovascular Outcomes]

ongoing Cardiovascular Outcomes

[systolic function in cardiac volume overload]

systolic function in cardiac volume overload

[ventricular diastolic end diameter mm difference]

ventricular diastolic end diameter mm difference

[16 patients with CHF-NYHA-III]

16 patients with CHF-NYHA-III

[blood glucose]

blood glucose

[developing malignancies including cancer]

developing malignancies including cancer

[gender odds ratio]

gender odds ratio

[filtration rate 60 ml]

filtration rate 60 ml

[plane excursion TAPSE from the end]

plane excursion TAPSE from the end

[right plane systolic excursion]

right plane systolic excursion

[NCDR PINNACLE]

NCDR PINNACLE

[Postoperative survival of patients 3.5 g]

Postoperative survival of patients 3.5 g

[background in heart failure patients]

background in heart failure patients

[significant change in MLHF score]

significant change in MLHF score

[brachial pressure 155 35]

brachial pressure 155 35

[determining the adaptive cardiac remodelling]

determining the adaptive cardiac remodelling

[assembly of these kinases]

assembly of these kinases

[consecutive HF patients ejection fraction]

consecutive HF patients ejection fraction

[real-time HFPSI use]

real-time HFPSI use

[single-arm prospective study]

single-arm prospective study

[workload]

workload

[literature in the language]

literature in the language

[quality HRQoL]

quality HRQoL

[treatment median]

treatment median

[factor for deterioration]

factor for deterioration

[Patients with York Heart Association]

Patients with York Heart Association

[such as acute myocardial infarction]

such as acute myocardial infarction

[limited amount of recent data]

limited amount of recent data

[Data supporting]

Data supporting

[sample COPD]

sample COPD

[Fifty-four predominantly asymptomatic pediatric Fontan patients]

Fifty-four predominantly asymptomatic pediatric Fontan patients

[safety monitoring]

safety monitoring

[healthy controls HDL]

healthy controls HDL

[Key outcomes]

Key outcomes

[systolic annulus velocity Sa]

systolic annulus velocity Sa

[possible suboptimal care of patients]

possible suboptimal care of patients

[predictor of subsequent HF]

predictor of subsequent HF

[patients geometry no LV hypertrophy]

patients geometry no LV hypertrophy

[evidence from 6 trials]

evidence from 6 trials

[echocardiographic guidance]

echocardiographic guidance

[therapeutic potential of a strategy]

therapeutic potential of a strategy

[using the method of constriction TAC]

using the method of constriction TAC

[ventricular ejection fraction R=0.28]

ventricular ejection fraction R=0.28

[decreases in LV shortening]

decreases in LV shortening

[Predictors a review]

Predictors a review

[April]

April

[chamber patterning]

chamber patterning

[22.9±5.0 months]

22.9±5.0 months

[sphingosine-1-phosphate receptor S1PR1]

sphingosine-1-phosphate receptor S1PR1

[major databases]

major databases

[mitral velocity 3.1]

mitral velocity 3.1

[eGFR 60 years]

eGFR 60 years

[ventricular RV plane systolic excursion]

ventricular RV plane systolic excursion

[number of hospital days]

number of hospital days

[bisphophonates]

bisphophonates

[exercise training exercise]

exercise training exercise

[A subunit]

A subunit

[ventricular area index 10.0 cm(2)]

ventricular area index 10.0 cm(2)

[higher mortality than cancers]

higher mortality than cancers

[With therapies ranging]

With therapies ranging

[subjects with normal hearts]

subjects with normal hearts

[malignancies including cancer of the prostate]

malignancies including cancer of the prostate

[smallest difference median BNP]

smallest difference median BNP

[fibrillation AF]

fibrillation AF

[patients with systolic function]

patients with systolic function

[patients with the syndrome]

patients with the syndrome

[end diameter mm difference]

end diameter mm difference

[LVET at entry milliseconds]

LVET at entry milliseconds

[sham-DNx]

sham-DNx

[Circulatory performance goal]

Circulatory performance goal

[studies investigating cachexia]

studies investigating cachexia

[adverse neurological event-free rate]

adverse neurological event-free rate

[off-pump sternal sparing approach]

off-pump sternal sparing approach

[TGF-β signaling]

TGF-β signaling

[Fourteen databases]

Fourteen databases

[trends in heart failure]

trends in heart failure

[end point for HF]

end point for HF

[isolated heart transplant]

isolated heart transplant

[Conclusions—Low-volume]

Conclusions—Low-volume

[medication use]

medication use

[20 812 consecutive patients aged years]

20 812 consecutive patients aged years

[effects of antioxidant on function]

effects of antioxidant on function

[urban medical center]

urban medical center

[absolute value]

absolute value

[transfusions in patients]

transfusions in patients

[unfavorable outcome vs milliseconds milliseconds]

unfavorable outcome vs milliseconds milliseconds

[(31)P]

(31)P

[chronic kidney disease filtration rate]

chronic kidney disease filtration rate

[population within rehabilitation]

population within rehabilitation

[asymptomatic Fontan patients]

asymptomatic Fontan patients

[underlying characteristics]

underlying characteristics

[odds ratios for events]

odds ratios for events

[favorable changes in diastolic function]

favorable changes in diastolic function

[predictor of favorable outcome period]

predictor of favorable outcome period

[diverse aspects]

diverse aspects

[implications of promising biomarkers]

implications of promising biomarkers

[diuretic severe-end-stage HF]

diuretic severe-end-stage HF

[positive effects of B]

positive effects of B

[prediction rule for CAD]

prediction rule for CAD

[other aspects of remodeling]

other aspects of remodeling

[outcome measures in research]

outcome measures in research

[total of 262 psoriasis]

total of 262 psoriasis

[tactics]

tactics

[increase of mL]

increase of mL

[index versus 2.8 0.7 L]

index versus 2.8 0.7 L

[Detailed analysis of tissue]

Detailed analysis of tissue

[Treatment in patients a systematic review]

Treatment in patients a systematic review

[ventricular annular plane excursion TAPSE]

ventricular annular plane excursion TAPSE

[42.4 g P=0.04]

42.4 g P=0.04

[left ventricular remodeling]

left ventricular remodeling

[0.92 events]

0.92 events

[cardiotoxicity among patients with breast cancer]

cardiotoxicity among patients with breast cancer

[Optimization Strategies Evaluation ROSE]

Optimization Strategies Evaluation ROSE

[end-point in HFrEF]

end-point in HFrEF

[optimizing cardiac progenitor function]

optimizing cardiac progenitor function

[clinical burden in medicine]

clinical burden in medicine

[multicenter trial PARADIGM-HF with individuals]

multicenter trial PARADIGM-HF with individuals

[consensus report]

consensus report

[right area index]

right area index

[plasma membrane levels of S1PR1]

plasma membrane levels of S1PR1

[right ventricular annular plane systolic excursion]

right ventricular annular plane systolic excursion

[New Zealand rabbits]

New Zealand rabbits

[male gender odds ratio]

male gender odds ratio

[rates of hyperkalemia]

rates of hyperkalemia

[outcomes of catheter ablation of fibrillation]

outcomes of catheter ablation of fibrillation

[Data in patients with function]

Data in patients with function

[1-day decrease in length]

1-day decrease in length

[Comparison Heart Failure]

Comparison Heart Failure

[decade of efforts]

decade of efforts

[toxicity]

toxicity

[CV events in univariate models]

CV events in univariate models

[velocity 3.1]

velocity 3.1

[complicating precapillary hypertension]

complicating precapillary hypertension

[levels 100 pg]

levels 100 pg

[Dual inhibition of AT1 receptors]

Dual inhibition of AT1 receptors

[conditions such as myocardial infarction]

conditions such as myocardial infarction

[Surgical treatment]

Surgical treatment

[dysfunction in heart failure]

dysfunction in heart failure

[global left longitudinal systolic strain]

global left longitudinal systolic strain

[Sprague-Dawley]

Sprague-Dawley

[plane systolic excursion]

plane systolic excursion

[14 days]

14 days

[using small-molecule inhibitors]

using small-molecule inhibitors

[pulmonary arterial hypertension medication]

pulmonary arterial hypertension medication

[throughput]

throughput

[tobacco use]

tobacco use

[left mechanics]

left mechanics

[changes in most subjects]

changes in most subjects

[change the percent of hospitals]

change the percent of hospitals

[Combination into an score]

Combination into an score

[year after discharge]

year after discharge

[outcome of cardiovascular death]

outcome of cardiovascular death

[participants with heart failure]

participants with heart failure

[care surgery consultations including inotropes]

care surgery consultations including inotropes

[add-on features]

add-on features

[Mechanistic insight into prolonged delay]

Mechanistic insight into prolonged delay

[models of dyssynchronous canine electromechanics]

models of dyssynchronous canine electromechanics

[panel of 3 electrocardiographers]

panel of 3 electrocardiographers

[including cardiac hypertrophy]

including cardiac hypertrophy

[neprilysin blocks renin-angiotensin-aldosteron]

neprilysin blocks renin-angiotensin-aldosteron

[360 patients]

360 patients

[cardiac hypertrophy a predictor]

cardiac hypertrophy a predictor

[Ethics]

Ethics

[prognosis in patients]

prognosis in patients

[difference in the percentage]

difference in the percentage

[HF for late-onset HF]

HF for late-onset HF

[GSE9128]

GSE9128

[other biomarkers]

other biomarkers

[LV mass]

LV mass

[PDE2 overexpression in cardiomyocytes]

PDE2 overexpression in cardiomyocytes

[GDMT-treated NYHA class]

GDMT-treated NYHA class

[925 ED visits age]

925 ED visits age

[practice-level variation in rates for outpatients]

practice-level variation in rates for outpatients

[deficits present]

deficits present

[9868 participants without HF]

9868 participants without HF

[5.7 METs]

5.7 METs

[beta-blocker hypo-response]

beta-blocker hypo-response

[If-channel inhibition on status]

If-channel inhibition on status

[relevance of ventricular reserve]

relevance of ventricular reserve

[Magnet(®) research]

Magnet(®) research

[hallmark of type diabetes]

hallmark of type diabetes

[of stenting]

of stenting

[period of fibrillation PVF]

period of fibrillation PVF

[role in stable coronary artery disease]

role in stable coronary artery disease

[repolarization instability in patients]

repolarization instability in patients

[age of patients]

age of patients

[24 per cent with deaths]

24 per cent with deaths

[pulmonary resistance hazard ratio]

pulmonary resistance hazard ratio

[impaired metabolic gene expression]

impaired metabolic gene expression

[cell oxide NO production]

cell oxide NO production

[Other cardiovascular risk factors]

Other cardiovascular risk factors

[top NOC outcomes]

top NOC outcomes

[Most heart failure risk stratification models]

Most heart failure risk stratification models

[biomarker-guided trial design]

biomarker-guided trial design

[Specific signalling pathways activating remodelling]

Specific signalling pathways activating remodelling

[early medical management of HF]

early medical management of HF

[follow-up of 2.4 years]

follow-up of 2.4 years

[final BB dose]

final BB dose

[higher SV]

higher SV

[thus providing information]

thus providing information

[error of measurement]

error of measurement

[waist]

waist

[idiopathic cardiomyopathy cohort]

idiopathic cardiomyopathy cohort

[worsening function]

worsening function

[assessments including stress echocardiography]

assessments including stress echocardiography

[17.6 mL]

17.6 mL

[subclinical atherosclerosis]

subclinical atherosclerosis

[idiopathic cardiomyopathy including coronary angiography]

idiopathic cardiomyopathy including coronary angiography

[4.2 METs vs. METs]

4.2 METs vs. METs

[primary diagnosis ejection fraction]

primary diagnosis ejection fraction

[outcomes trial]

outcomes trial

[reversal of alterations]

reversal of alterations

[BNP in women]

BNP in women

[kappa]

kappa

[right ventricular tricuspid plane excursion]

right ventricular tricuspid plane excursion

[current knowledge on use]

current knowledge on use

[ventricular tricuspid plane excursion]

ventricular tricuspid plane excursion

[predicting CRT response]

predicting CRT response

[echocardiographic score predicting CRT response]

echocardiographic score predicting CRT response

[B-type peptide levels]

B-type peptide levels

[Sudden death in athletes under 35]

Sudden death in athletes under 35

[serial measurements]

serial measurements

[2331 patients with ejection fraction]

2331 patients with ejection fraction

[precise role of Mena]

precise role of Mena

[reflecting decreases in heart mortality]

reflecting decreases in heart mortality

[70 versus ≥70 bpm 17.5±5.5]

70 versus ≥70 bpm 17.5±5.5

[evaluating the effect of interventions]

evaluating the effect of interventions

[Low muscle mass]

Low muscle mass

[entire cohort]

entire cohort

[catheter ablation in patients]

catheter ablation in patients

[resynchronization therapy in patients]

resynchronization therapy in patients

[early diastolic mitral annular velocity 3.1]

early diastolic mitral annular velocity 3.1

[3 evaluations HM using simulation models]

3 evaluations HM using simulation models

[trials-Enriching patient identification by Collins]

trials-Enriching patient identification by Collins

[readers in biology]

readers in biology

[pattern generator]

pattern generator

[strategies with potentially anti-inflammatory effects]

strategies with potentially anti-inflammatory effects

[Catheter-based revascularization with angioplasty]

Catheter-based revascularization with angioplasty

[restoration of high-density lipoprotein properties]

restoration of high-density lipoprotein properties

[early risk]

early risk

[veterans]

veterans

[effects of mitochondrial-targeted antioxidant]

effects of mitochondrial-targeted antioxidant

[therapeutic targets for heart failure]

therapeutic targets for heart failure

[left biopsies]

left biopsies

[autopsy]

autopsy

[case of long-term survival]

case of long-term survival

[925 ED visits years]

925 ED visits years

[strategies with anti-inflammatory effects]

strategies with anti-inflammatory effects

[left systolic pressure]

left systolic pressure

[random-effects models]

random-effects models

[versus without left ejection fraction]

versus without left ejection fraction

[fewer procedures]

fewer procedures

[transplant patients]

transplant patients

[sarcoplasmic Ca]

sarcoplasmic Ca

[impact in patients with HFrEF]

impact in patients with HFrEF

[enormous burden]

enormous burden

[possibly the burden]

possibly the burden

[Multicenter clinical trial of 360 patients]

Multicenter clinical trial of 360 patients

[brachial pressure]

brachial pressure

[lesions in the major branches]

lesions in the major branches

[speckle tracking echocardiography]

speckle tracking echocardiography

[resulting with an MVA]

resulting with an MVA

[patients aged 62.4 years]

patients aged 62.4 years

[fundamental definitions]

fundamental definitions

[Fifty patients with recent onset HFrEF]

Fifty patients with recent onset HFrEF

[powerful composite HF index P]

powerful composite HF index P

[optimization of filling time]

optimization of filling time

[autonomic nervous system activity]

autonomic nervous system activity

[ischemic samples]

ischemic samples

[physical exertion]

physical exertion

[ICU mortality median stay]

ICU mortality median stay

[hypertension medication]

hypertension medication

[understanding of the structure]

understanding of the structure

[independent role in HF]

independent role in HF

[plasma membrane levels]

plasma membrane levels

[important role in the pathogenesis]

important role in the pathogenesis

[adenine nucleotides]

adenine nucleotides

[consecutive patients HFrEF]

consecutive patients HFrEF

[3 studies of therapeutics including agents]

3 studies of therapeutics including agents

[LV pressure in weeks]

LV pressure in weeks

[prognosis of a cardiomyopathy cohort]

prognosis of a cardiomyopathy cohort

[genes between non-ischemic heart failure samples]

genes between non-ischemic heart failure samples

[kg vs kg]

kg vs kg

[8.4 mm Hg]

8.4 mm Hg

[heart failure patients left ejection fraction]

heart failure patients left ejection fraction

[predominantly asymptomatic pediatric Fontan patients]

predominantly asymptomatic pediatric Fontan patients

[reduction in exercise-induced increase]

reduction in exercise-induced increase

[participants without HF]

participants without HF

[partial improvement of performance]

partial improvement of performance

[C statistic]

C statistic

[tachycardia indicative of cardiac tone]

tachycardia indicative of cardiac tone

[infarction patients]

infarction patients

[Fifty-four predominantly asymptomatic Fontan PF patients]

Fifty-four predominantly asymptomatic Fontan PF patients

[increasing refill compliance for etidronate]

increasing refill compliance for etidronate

[components of the DAPC]

components of the DAPC

[BNP levels with the difference]

BNP levels with the difference

[data on the potential]

data on the potential

[hypertrophy a predictor]

hypertrophy a predictor

[effective arterial elastance]

effective arterial elastance

[2,538 patients]

2,538 patients

[ANOVA]

ANOVA

[social support score]

social support score

[Survival after assist device with support]

Survival after assist device with support

[Screening with a ECG in athletes]

Screening with a ECG in athletes

[majority of candidates]

majority of candidates

[sodium current in systolic heart failure]

sodium current in systolic heart failure

[different US healthcare programmes]

different US healthcare programmes

[improvement database]

improvement database

[insufficiency]

insufficiency

[time of surgery]

time of surgery

[demonstrating development of MS]

demonstrating development of MS

[insulin-resistance by weeks post-AAC]

insulin-resistance by weeks post-AAC

[left assist device LVAD implantation]

left assist device LVAD implantation

[molecular processes]

molecular processes

[valve opening with a valve area]

valve opening with a valve area

[left ventricular ejection fraction difference]

left ventricular ejection fraction difference

[mitral inflow]

mitral inflow

[membrane oxygenation in heart failure]

membrane oxygenation in heart failure

[saxagliptin versus pioglitazone]

saxagliptin versus pioglitazone

[relevance carrying increase]

relevance carrying increase

[contact]

contact

[Global ventricular longitudinal systolic strain]

Global ventricular longitudinal systolic strain

[novel intracellular strategy in HF]

novel intracellular strategy in HF

[annulus velocities during systole s]

annulus velocities during systole s

[treatment with vasodilators]

treatment with vasodilators

[Fifty-four asymptomatic pediatric Fontan patients]

Fifty-four asymptomatic pediatric Fontan patients

[participants aged 70 years]

participants aged 70 years

[peptide levels]

peptide levels

[myocardial extracellular matrix]

myocardial extracellular matrix

[arbitrary start date]

arbitrary start date

[inpatient records of patients]

inpatient records of patients

[left function in volume overload]

left function in volume overload

[anxiety]

anxiety

[Clinical signs]

Clinical signs

[IVC]

IVC

[biopsies n=9]

biopsies n=9

[ventricular mechanics]

ventricular mechanics

[annular plane excursion]

annular plane excursion

[heart failure in adults]

heart failure in adults

[explant c-Kit]

explant c-Kit

[inhibition of growth factor signaling]

inhibition of growth factor signaling

[mild heart failure HF patients]

mild heart failure HF patients

[significant effect]

significant effect

[LVAD support on survival]

LVAD support on survival

[patients 224 men mean]

patients 224 men mean

[left ejection fraction HF]

left ejection fraction HF

[relevance of right reserve in patients]

relevance of right reserve in patients

[3 studies including calcium-sensitizing agents]

3 studies including calcium-sensitizing agents

[HFrEF days]

HFrEF days

[corporeal membrane oxygenation ECMO]

corporeal membrane oxygenation ECMO

[survival in patients]

survival in patients

[38 controls]

38 controls

[XO-mediated ROS effects]

XO-mediated ROS effects

[decoy]

decoy

[suggesting angiogenesis]

suggesting angiogenesis

[frailty on HF risk]

frailty on HF risk

[strain contributions]

strain contributions

[significant decrease from an average]

significant decrease from an average

[T cells]

T cells

[factor in diseases]

factor in diseases

[increase in the ratio]

increase in the ratio

[Outcomes Study]

Outcomes Study

[Remote monitoring strategies]

Remote monitoring strategies

[HFpEF α=0.96 for summary]

HFpEF α=0.96 for summary

[managing significant bleeding]

managing significant bleeding

[6-minute walk test 6-MWT]

6-minute walk test 6-MWT

[70 bpm 17.5±5.5 versus mL]

70 bpm 17.5±5.5 versus mL

[type regulatory subunit expression]

type regulatory subunit expression

[hemolysis]

hemolysis

[overexpression]

overexpression

[Exercise Training]

Exercise Training

[42 percent reduction]

42 percent reduction

[Poor support]

Poor support

[models of nonfailing canine electromechanics]

models of nonfailing canine electromechanics

[resistin levels similar]

resistin levels similar

[interventions during the trial]

interventions during the trial

[short-term treatment with a contribution]

short-term treatment with a contribution

[lower HF mortality risk]

lower HF mortality risk

[interaction between race training]

interaction between race training

[death in athletes under 35]

death in athletes under 35

[cohort studies with a control group]

cohort studies with a control group

[index of right function]

index of right function

[treatment of post-LVAD AI]

treatment of post-LVAD AI

[abnormal Ca handling in dyssynchronous HF]

abnormal Ca handling in dyssynchronous HF

[serum sodium]

serum sodium

[world]

world

[absolute minimal detectable change values]

absolute minimal detectable change values

[Renal]

Renal

[70 versus ≥70 bpm P]

70 versus ≥70 bpm P

[similar rates]

similar rates

[infarction with major complications]

infarction with major complications

[internal validity]

internal validity

[application in the setting]

application in the setting

[local cardiology services]

local cardiology services

[association with mortality]

association with mortality

[antiadrenergic strategy in HF]

antiadrenergic strategy in HF

[minutes of moderate-intensity aerobic exercise]

minutes of moderate-intensity aerobic exercise

[absolute minimal change values]

absolute minimal change values

[filtration rate of 15 mL]

filtration rate of 15 mL, filtration rate of 15 ml

[commissioning]

commissioning

[adult Wistar rats]

adult Wistar rats

[higher filtration rate]

higher filtration rate

[cardiac activity by ((123)I-MIBG]

cardiac activity by ((123)I-MIBG

[262 psoriasis]

262 psoriasis

[chronic guideline-directed therapy GDMT]

chronic guideline-directed therapy GDMT

[Multicenter clinical trial of patients]

Multicenter clinical trial of patients

[Comparison Of Outcomes]

Comparison Of Outcomes

[adverse cardiovascular CV events AF]

adverse cardiovascular CV events AF

[Ten-year experience with criteria transplantation]

Ten-year experience with criteria transplantation

[hospitals nationwide from January]

hospitals nationwide from January

[deaths in the CRT group]

deaths in the CRT group

[adequacy]

adequacy

[severe LV dysfunction]

severe LV dysfunction

[significant predictor of mortality]

significant predictor of mortality

[time interval between depolarization]

time interval between depolarization

[Many predictors]

Many predictors

[H-DKO]

H-DKO

[hyperkalemia in Americans]

hyperkalemia in Americans

[Screening with a 12-lead ECG]

Screening with a 12-lead ECG

[resulting in imbalance]

resulting in imbalance

[most common cause in athletes]

most common cause in athletes

[cyclic guanosine monophosphate]

cyclic guanosine monophosphate

[collagen density]

collagen density

[After coronary revascularization]

After coronary revascularization

[form of heart failure]

form of heart failure

[increase in LV end-diastolic pressure]

increase in LV end-diastolic pressure

[cm 2]

cm 2

[Medicare readmission]

Medicare readmission

[Multicenter double-blind clinical trial of patients]

Multicenter double-blind clinical trial of patients

[prognostic ability]

prognostic ability

[valve plasty for degenerative regurgitation]

valve plasty for degenerative regurgitation

[Investigating Outcomes of Exercise Training study]

Investigating Outcomes of Exercise Training study

[conscious dogs with HF]

conscious dogs with HF

[striking differences]

striking differences

[economic impact]

economic impact

[support on function in children]

support on function in children

[Psychosocial Factors Insights From Heart Failure]

Psychosocial Factors Insights From Heart Failure

[myosin binding protein-C phosphorylation]

myosin binding protein-C phosphorylation

[pace DNx]

pace DNx

[managing significant gastrointestinal bleeding]

managing significant gastrointestinal bleeding

[indication for MS]

indication for MS

[cumulative dose of mg]

cumulative dose of mg

[measure of left ventricular mechanics]

measure of left ventricular mechanics

[reversibility]

reversibility

[resonance postcontrast T1 time]

resonance postcontrast T1 time

[Usefulness assessing filling pressure in patients]

Usefulness assessing filling pressure in patients

[trichrome analysis]

trichrome analysis

[developing heart failure CHF]

developing heart failure CHF

[HF trials]

HF trials

[protection from hypertrophic responses]

protection from hypertrophic responses

[impact on morphological development]

impact on morphological development

[heart failure guidelines lessons]

heart failure guidelines lessons

[exercise capacity in obese patients]

exercise capacity in obese patients

[readmission metrics]

readmission metrics

[survival in ED patients]

survival in ED patients

[response in activity by ((123)I-MIBG]

response in activity by ((123)I-MIBG

[Occurrence within 90 days]

Occurrence within 90 days

[managing gastrointestinal bleeding]

managing gastrointestinal bleeding

[SR Ca 2+)-pump]

SR Ca 2+)-pump

[anterior descending artery occlusion]

anterior descending artery occlusion

[cause of mortality in society]

cause of mortality in society

[Global left ventricular longitudinal systolic strain]

Global left ventricular longitudinal systolic strain

[interatrial shunting for treatment]

interatrial shunting for treatment

[nondiabetes risk factors]

nondiabetes risk factors

[hospitalization for syndromes]

hospitalization for syndromes

[TGF-β receptor type]

TGF-β receptor type

[hospital length]

hospital length

[cell EC oxide production]

cell EC oxide production

[accurate risk stratification appropriate]

accurate risk stratification appropriate

[lower stimulation at eNOS-Ser]

lower stimulation at eNOS-Ser

[vasopeptidase]

vasopeptidase

[group IV mL per m]

group IV mL per m

[spontaneous ventricular tachycardia]

spontaneous ventricular tachycardia

[oxidative phosphorylation capacity]

oxidative phosphorylation capacity

[AF type other than persistent AF]

AF type other than persistent AF

[strategies for the treatment]

strategies for the treatment

[exercise training in HF]

exercise training in HF

[malfunctioning HeartMate LVADs]

malfunctioning HeartMate LVADs

[rationale of the treatment]

rationale of the treatment

[interviews with care clinicians]

interviews with care clinicians

[age-matched controls]

age-matched controls

[acceptable alternative]

acceptable alternative

[cardiac transplants in children]

cardiac transplants in children

[admissions for individuals with disease]

admissions for individuals with disease

[higher SV p]

higher SV p

[decade of acute heart failure]

decade of acute heart failure

[hallmark of type]

hallmark of type

[solely a consequence]

solely a consequence

[activation of p70S6K PKC-βII]

activation of p70S6K PKC-βII

[mRNA level for β-myosin chain]

mRNA level for β-myosin chain

[future research]

future research

[postmarketing trials]

postmarketing trials

[acceptable validity]

acceptable validity

[forms of left ventricular LV remodeling]

forms of left ventricular LV remodeling

[unloading]

unloading

[single success rates]

single success rates

[describing trends]

describing trends

[equivalent outcomes]

equivalent outcomes

[indicating possible care]

indicating possible care

[following acute β-AR stimulation]

following acute β-AR stimulation

[system modulation on QTV]

system modulation on QTV

[patients on diuretics]

patients on diuretics

[studies with ARNI inhibitors]

studies with ARNI inhibitors

[change from enrollment]

change from enrollment

[regarding the role]

regarding the role

[Diagnosis role of Doppler echocardiography]

Diagnosis role of Doppler echocardiography

[consensus regarding the forms]

consensus regarding the forms

[Frailty an important indicator]

Frailty an important indicator

[particularly between a large group]

particularly between a large group

[cardiac plasma]

cardiac plasma

[CHF among older patients]

CHF among older patients

[years for patients]

years for patients

[flow CF]

flow CF

[American Heart Association guidelines]

American Heart Association guidelines

[low-quality evidence]

low-quality evidence

[decrease in insulin-stimulated rates]

decrease in insulin-stimulated rates

[(eGFR)-group I mL per m 2]

(eGFR)-group I mL per m 2

[LV wall thickness]

LV wall thickness

[cardioverter-defibrillators ICDs]

cardioverter-defibrillators ICDs

[nursing-sensitive outcome measures in future research]

nursing-sensitive outcome measures in future research

[vivo assessment]

vivo assessment

[low 50 mg dose]

low 50 mg dose

[therapy GDMT]

therapy GDMT

[47 percent]

47 percent

[type receptor antagonist]

type receptor antagonist

[adjusting for over 20 variables]

adjusting for over 20 variables

[median glomerular filtration rate]

median glomerular filtration rate

[microarray]

microarray

[Approaches]

Approaches

[Treatment of anemia a review]

Treatment of anemia a review

[significant change main effect]

significant change main effect

[CardioPulmonary Exercise Testing guide]

CardioPulmonary Exercise Testing guide

[precise role]

precise role

[effects with ivabradine]

effects with ivabradine

[global left strain GLS]

global left strain GLS

[feedback]

feedback

[Cardiovascular Society]

Cardiovascular Society

[Protective effects of exercise training]

Protective effects of exercise training

[calcium-sensitizing]

calcium-sensitizing

[disease nbDMARD]

disease nbDMARD

[reference values Z-score]

reference values Z-score

[components regulating cellular metabolism]

components regulating cellular metabolism

[Mechanistic insight in dyssynchronous heart failure]

Mechanistic insight in dyssynchronous heart failure

[NO production]

NO production

[151 subjects with heart failure]

151 subjects with heart failure

[syndrome of heart failure]

syndrome of heart failure

[using a approach]

using a approach

[enzymes over a 6-week follow-up period]

enzymes over a 6-week follow-up period

[circulatory derangement albeit with ability]

circulatory derangement albeit with ability

[basic relevance carrying two increase]

basic relevance carrying two increase

[(eGFR)-group I]

(eGFR)-group I

[15 ml odds ratio 1.76]

15 ml odds ratio 1.76

[abdominal aortic constriction]

abdominal aortic constriction

[longitudinal analysis]

longitudinal analysis

[HF studies]

HF studies

[clinical trial design]

clinical trial design

[monitoring devices]

monitoring devices

[adult patients with Fontan circulation]

adult patients with Fontan circulation

[patients with outcome]

patients with outcome

[elastance elastance Ees]

elastance elastance Ees

[suggesting T1 as biomarker]

suggesting T1 as biomarker

[largely because of the prevalence]

largely because of the prevalence

[unfavorable outcome median]

unfavorable outcome median

[interaction=0.032]

interaction=0.032

[area cm]

area cm

[health service provision]

health service provision

[determinant of quality]

determinant of quality

[Relation between renal dysfunction within months]

Relation between renal dysfunction within months

[prognostic information than the others]

prognostic information than the others

[glomerular filtration rate eGFR]

glomerular filtration rate eGFR

[ischemic regurgitation MR]

ischemic regurgitation MR

[refractory severe-end-stage HF]

refractory severe-end-stage HF

[other aspects contributing insignificantly]

other aspects contributing insignificantly

[care by drugs]

care by drugs

[incremental cost-effectiveness ratios]

incremental cost-effectiveness ratios

[end points reflective of decongestion]

end points reflective of decongestion

[reduction of Na]

reduction of Na

[hazard ratio for 1-year mortality]

hazard ratio for 1-year mortality

[therapeutic treatments targeting exercise hemodynamic status]

therapeutic treatments targeting exercise hemodynamic status

[risk factor for health]

risk factor for health

[patients with BTES]

patients with BTES

[total sample COPD]

total sample COPD

[method of transverse aortic constriction]

method of transverse aortic constriction

[prognostic benefit over conventional parameters]

prognostic benefit over conventional parameters

[14 studies]

14 studies

[crude case-fatality rate]

crude case-fatality rate

[interruption of systems]

interruption of systems

[key biosynthetic enzymes]

key biosynthetic enzymes

[absolute increase in rehospitalization]

absolute increase in rehospitalization

[long-term value]

long-term value

[quality-of-life score points vs. points]

quality-of-life score points vs. points

[effective agent in the treatment]

effective agent in the treatment

[duration of cardiac support]

duration of cardiac support

[Predictors a systematic review]

Predictors a systematic review

[LV end-diastolic]

LV end-diastolic

[trial the effects]

trial the effects

[HF mortality risk in men]

HF mortality risk in men

[systolic strain GLS]

systolic strain GLS

[acute infarction with complications]

acute infarction with complications

[longitudinal systolic strain as a predictor]

longitudinal systolic strain as a predictor

[positive effects on function]

positive effects on function

[monitoring after hospital discharge]

monitoring after hospital discharge

[hallmark of type 2]

hallmark of type 2

[Extracellular matrix of biopsies n=9]

Extracellular matrix of biopsies n=9

[testimonies]

testimonies

[30-day readmission rates using metrics]

30-day readmission rates using metrics

[prediction rule having predictor]

prediction rule having predictor

[caspase expression]

caspase expression

[examining long-term outcomes]

examining long-term outcomes

[platelet-activating]

platelet-activating

[month after discharge 5336]

month after discharge 5336

[involving the descending artery]

involving the descending artery

[usually the result of lesions]

usually the result of lesions

[predictor using regression]

predictor using regression

[GTPase Rac1 activity]

GTPase Rac1 activity

[relationship with CV events AF]

relationship with CV events AF

[BNP in women EF]

BNP in women EF

[multisystem disease]

multisystem disease

[ventricular ejection fraction mean difference]

ventricular ejection fraction mean difference

[Left ejection time complicating precapillary hypertension]

Left ejection time complicating precapillary hypertension

[standard cardiac rehabilitation care]

standard cardiac rehabilitation care

[108 HFpEF with ejection fraction]

108 HFpEF with ejection fraction

[ml odds ratio after adjustment]

ml odds ratio after adjustment

[odds ratio of 6.77]

odds ratio of 6.77

[PD on status hospitalizations]

PD on status hospitalizations

[elements of interventions]

elements of interventions

[non-survivors years vs 72.83]

non-survivors years vs 72.83

[group with high mortality]

group with high mortality

[measures of capacity]

measures of capacity

[predictors biomarkers]

predictors biomarkers

[pathological gene expression programme]

pathological gene expression programme

[telehealth technology]

telehealth technology

[cause especially among the elderly]

cause especially among the elderly

[highlighting dysfunction]

highlighting dysfunction

[right ventricular area index cm(2)]

right ventricular area index cm(2)

[NT-pro]

NT-pro

[Adherence]

Adherence

[tracking VA patients for 6 months]

tracking VA patients for 6 months

[absolute detectable change MDC]

absolute detectable change MDC

[distinct G-protein-coupled receptors]

distinct G-protein-coupled receptors

[contribution of abnormalities]

contribution of abnormalities

[per cent with deaths occurring]

per cent with deaths occurring

[20,812 patients]

20,812 patients

[agent in the treatment]

agent in the treatment

[rabbits]

rabbits

[involving the proximal left descending artery]

involving the proximal left descending artery

[certain malignancies including cancer]

certain malignancies including cancer

[gross morphological development]

gross morphological development

[cardiac resonance T1 mapping]

cardiac resonance T1 mapping

[3 economic evaluations using simulation models]

3 economic evaluations using simulation models

[14 clinical studies approximately 2900 HM]

14 clinical studies approximately 2900 HM

[156 consenting ambulatory HF patients]

156 consenting ambulatory HF patients

[guideline-directed medical therapy GDMT]

guideline-directed medical therapy GDMT

[NT-proBNP concentration]

NT-proBNP concentration

[high internal consistency among patients]

high internal consistency among patients

[current ongoing Cardiovascular Outcomes]

current ongoing Cardiovascular Outcomes

[myocyte-specific Mena overexpression TTA]

myocyte-specific Mena overexpression TTA

[mortality predictors]

mortality predictors

[investigations for onset heart failure]

investigations for onset heart failure

[longitudinal outcome-monitoring phase mean months]

longitudinal outcome-monitoring phase mean months

[clinical composite response P=0.02]

clinical composite response P=0.02

[Mena overexpression]

Mena overexpression

[prospective data]

prospective data

[hypotheses]

hypotheses

[important contribution]

important contribution

[Study Selection trials]

Study Selection trials

[rheumatoid]

rheumatoid

[autopsy samples]

autopsy samples

[Institute]

Institute

[effect on the number]

effect on the number

[HR 70 versus ≥70 bpm]

HR 70 versus ≥70 bpm

[adverse activation]

adverse activation

[Multicenter Automatic Defibrillator Implantation Resynchronization Therapy]

Multicenter Automatic Defibrillator Implantation Resynchronization Therapy

[inhibitory actions on CaV1.2]

inhibitory actions on CaV1.2

[such as acute infarction]

such as acute infarction

[UTI with complications]

UTI with complications

[trigger of myocardial infarction]

trigger of myocardial infarction

[important factor]

important factor

[1.6 vs. 0.8 reasons]

1.6 vs. 0.8 reasons

[diagnostic roles in patients]

diagnostic roles in patients

[obese participants]

obese participants

[fundamental mechanism of dysfunction]

fundamental mechanism of dysfunction

[patients with first infarction]

patients with first infarction

[patients with left LV ejection fraction]

patients with left LV ejection fraction

[regarding treatment]

regarding treatment

[heart mortality]

heart mortality

[change MDC values]

change MDC values

[exercise training on function]

exercise training on function

[older obese participants]

older obese participants

[patients with CHF-NYHA-III HDL]

patients with CHF-NYHA-III HDL

[site RIIα Ser96]

site RIIα Ser96

[days P-value for difference 0.001]

days P-value for difference 0.001

[hand-searching articles]

hand-searching articles

[0.5 kg]

0.5 kg

[routine clinical tool]

routine clinical tool

[several pathological changes including hypertrophy]

several pathological changes including hypertrophy

[multivariate Cox]

multivariate Cox

[good diagnostic performance only in patients]

good diagnostic performance only in patients

[26 sites]

26 sites

[option in heart failure CHF]

option in heart failure CHF

[longitudinal strain as a predictor]

longitudinal strain as a predictor

[heart beat]

heart beat

[enzymes over a follow-up period]

enzymes over a follow-up period

[children with heart disease]

children with heart disease

[proximal circumflex]

proximal circumflex

[diastolic end diameter mm]

diastolic end diameter mm

[role in the pathogenesis]

role in the pathogenesis

[method of constriction]

method of constriction

[larger HR reduction 17±22]

larger HR reduction 17±22

[Western blots with monoclonal antibodies]

Western blots with monoclonal antibodies

[validation in larger studies]

validation in larger studies

[RAS-blocker]

RAS-blocker

[models varying combinations]

models varying combinations

[functional decline explant-derived c-Kit]

functional decline explant-derived c-Kit

[growth in the setting of disease]

growth in the setting of disease

[72 studies evaluating predictors]

72 studies evaluating predictors

[concentrating]

concentrating

[increase in heart rate]

increase in heart rate

[obstruction of the coronary artery]

obstruction of the coronary artery

[worse heart failure-related QOL]

worse heart failure-related QOL

[R-like ER kinase]

R-like ER kinase

[Main etiologies]

Main etiologies

[evaluating implementation interventions]

evaluating implementation interventions

[handling]

handling

[cost-minimization approach]

cost-minimization approach

[ventricular contractile function]

ventricular contractile function

[variants consistent]

variants consistent

[arterial compliance TAC]

arterial compliance TAC

[post-myocardial infarction patients]

post-myocardial infarction patients

[additive impact]

additive impact

[including samples]

including samples

[defibrillator CRT-D]

defibrillator CRT-D

[Circulating fragments of N-terminal pro-B-type peptides]

Circulating fragments of N-terminal pro-B-type peptides

[phenotype of hypertrophy]

phenotype of hypertrophy

[risk factor for cardiovascular health]

risk factor for cardiovascular health

[ED visits for CHF rates]

ED visits for CHF rates

[such as time-domain]

such as time-domain

[attenuation of proteomic alterations]

attenuation of proteomic alterations

[susceptibility in survivors]

susceptibility in survivors

[describing trends after MI]

describing trends after MI

[complications in HF]

complications in HF

[NYHA class III HF]

NYHA class III HF

[promising field]

promising field

[right arterial coupling]

right arterial coupling

[information regarding conditions]

information regarding conditions

[antagomir]

antagomir

[catecholamine]

catecholamine

[worsening renal function WRF]

worsening renal function WRF

[STS HH HR interval CrI]

STS HH HR interval CrI

[lower socioeconomic status]

lower socioeconomic status

[right end-diastolic area index 10.0 cm(2)]

right end-diastolic area index 10.0 cm(2)

[presence with physiological proteolysis]

presence with physiological proteolysis

[diagnostic strategies]

diagnostic strategies

[bpm 17.5±5.5 versus mL respectively P]

bpm 17.5±5.5 versus mL respectively P

[cohort heart failure]

cohort heart failure

[improvement of NT-ProBNP biomarkers]

improvement of NT-ProBNP biomarkers

[refractory shock]

refractory shock

[Moderate-strength evidence from trials of iron]

Moderate-strength evidence from trials of iron

[impact on effects]

impact on effects

[Modification codes 402.x1]

Modification codes 402.x1

[population-based study of patients]

population-based study of patients

[left anterior descending artery occlusion]

left anterior descending artery occlusion

[patients with systolic ejection fraction HF]

patients with systolic ejection fraction HF

[hypertension of 191 104 mm Hg]

hypertension of 191 104 mm Hg

[two patients]

two patients

[0.7 L]

0.7 L

[L 2]

L 2

[wall RS P]

wall RS P

[arterial systolic pressure PASP]

arterial systolic pressure PASP

[impact on development]

impact on development

[change the percent]

change the percent

[function end point]

function end point

[randomized control studies]

randomized control studies

[cardiac T2 values]

cardiac T2 values

[severe LV systolic dysfunction]

severe LV systolic dysfunction

[eGFR group]

eGFR group

[heart failure with systolic function]

heart failure with systolic function

[ventricular-pulmonary arterial coupling vascular resistance]

ventricular-pulmonary arterial coupling vascular resistance

[drug treatment]

drug treatment

[detecting fibrosis]

detecting fibrosis

[relationship with cardiovascular CV events AF]

relationship with cardiovascular CV events AF

[accurate recognition of disease]

accurate recognition of disease

[14 studies approximately 2900 HM]

14 studies approximately 2900 HM

[Cochrane Effective Practice]

Cochrane Effective Practice

[effects of ventricular assist device]

effects of ventricular assist device

[hearts of fish]

hearts of fish

[antiadrenergic strategy]

antiadrenergic strategy

[Heart Association AHA]

Heart Association AHA

[non-AAs with New York Heart Association]

non-AAs with New York Heart Association

[end diameter mm mean difference]

end diameter mm mean difference

[angiotensin converting]

angiotensin converting

[β-adrenergic]

β-adrenergic

[improving the prognosis]

improving the prognosis

[n=44 925 ED visits 76.4 years]

n=44 925 ED visits 76.4 years

[cell EC oxide NO production]

cell EC oxide NO production

[mouse model]

mouse model

[perioperative deaths]

perioperative deaths

[2 treatment strategies]

2 treatment strategies

[elderly people]

elderly people

[minutes of aerobic exercise]

minutes of aerobic exercise

[red blood cell transfusion strategy]

red blood cell transfusion strategy

[detectable change values]

detectable change values

[intravenous bolus]

intravenous bolus

[2331 patients with ventricular ejection fraction]

2331 patients with ventricular ejection fraction

[Gene expression profiling]

Gene expression profiling

[Cardiopulmonary]

Cardiopulmonary

[VEGF pathway]

VEGF pathway

[decreases period]

decreases period

[trial of Nordic walking with moderate]

trial of Nordic walking with moderate

[healthy control animals]

healthy control animals

[potential of a multimarker-based strategy]

potential of a multimarker-based strategy

[treatment options]

treatment options

[framework determining assessment]

framework determining assessment

[findings of causes of MS]

findings of causes of MS

[brachial systolic pressure]

brachial systolic pressure

[resting HR 70 bpm]

resting HR 70 bpm

[3-year mortality rates]

3-year mortality rates

[thirty-seven hospitals through September]

thirty-seven hospitals through September

[catheter ablation for fibrillation AF]

catheter ablation for fibrillation AF

[valve plasty for mitral regurgitation]

valve plasty for mitral regurgitation

[early management of HF in infancy]

early management of HF in infancy

[treatment alone]

treatment alone

[pre-specified subgroup analyses]

pre-specified subgroup analyses

[disease modifying antirheumatic drug nbDMARD]

disease modifying antirheumatic drug nbDMARD

[event rate HR]

event rate HR

[peptide BNP]

peptide BNP

[strategy in HF]

strategy in HF

[tricuspid plane systolic excursion]

tricuspid plane systolic excursion

[playing a role]

playing a role

[LV end-diastolic volume of mL]

LV end-diastolic volume of mL

[stable systolic HF]

stable systolic HF

[diastolic indices ratio]

diastolic indices ratio

[such as pressure ulcers]

such as pressure ulcers

[global ventricular longitudinal strain]

global ventricular longitudinal strain

[indicator in patients]

indicator in patients

[center retrospective]

center retrospective

[disease with comorbidities]

disease with comorbidities

[potential effectiveness]

potential effectiveness

[Composite quality measures for common conditions]

Composite quality measures for common conditions

[Cluster]

Cluster

[ventricular pressure overload RVPO]

ventricular pressure overload RVPO

[leg]

leg

[significant predictor of post-transplant mortality]

significant predictor of post-transplant mortality

[20 consecutive patients aged 40 years]

20 consecutive patients aged 40 years

[nonselective β-blocker]

nonselective β-blocker

[peak o2]

peak o2

[exercise training ET on function]

exercise training ET on function

[heart disease of HF]

heart disease of HF

[prescription rates]

prescription rates

[undergoing MT]

undergoing MT

[revascularization artery bypass surgery]

revascularization artery bypass surgery

[criteria transplantation]

criteria transplantation

[infarction-related heart failure]

infarction-related heart failure

[prognostic benefit]

prognostic benefit

[hazard ratios for early-onset HF]

hazard ratios for early-onset HF

[markers of SkM growth]

markers of SkM growth

[hypotension without a need]

hypotension without a need

[measure of HF in patients]

measure of HF in patients

[Addition discrimination]

Addition discrimination

[dearth of biomarker-guided trials]

dearth of biomarker-guided trials

[portion of the health-care budget]

portion of the health-care budget

[two-center pilot project]

two-center pilot project

[responsiveness]

responsiveness

[outcome change]

outcome change

[patients with acute infarction]

patients with acute infarction

[interquartile range 22.8 with COPD n=95]

interquartile range 22.8 with COPD n=95

[index score P]

index score P

[years of age with diabetes]

years of age with diabetes

[rates of changes in pressure development]

rates of changes in pressure development

[severe refractory heart failure]

severe refractory heart failure

[valve area of cm2]

valve area of cm2

[70 bpm 17.5±5.5 versus mL P]

70 bpm 17.5±5.5 versus mL P

[demographic characteristics use of medications]

demographic characteristics use of medications

[Incidence of disease in outpatients]

Incidence of disease in outpatients

[Multicenter Study]

Multicenter Study

[information for an unfavourable clinical outcome]

information for an unfavourable clinical outcome

[insurance]

insurance

[heart failure related]

heart failure related

[cardiac response role]

cardiac response role

[patients with advanced disease]

patients with advanced disease

[most important component]

most important component

[pressure 18]

pressure 18

[membrane oxygenation in right heart failure]

membrane oxygenation in right heart failure

[evaluating the effect]

evaluating the effect

[resistance SVR index]

resistance SVR index

[Systolic dysfunction]

Systolic dysfunction

[artery pressure PASP increase by means]

artery pressure PASP increase by means

[also evaluating the effect]

also evaluating the effect

[Cardiac Function Among Patients With Shortness]

Cardiac Function Among Patients With Shortness

[clinical effects of types]

clinical effects of types

[possible care]

possible care

[recent onset]

recent onset

[strong reliable mortality predictors]

strong reliable mortality predictors

[70 bpm P]

70 bpm P

[402 patients with HFpEF]

402 patients with HFpEF

[trigger for excitation-contraction coupling]

trigger for excitation-contraction coupling

[disease CVD]

disease CVD

[Studies of predictors of response]

Studies of predictors of response

[cardiac growth in the setting]

cardiac growth in the setting

[myocardial ischemia stent]

myocardial ischemia stent

[RAS blockers]

RAS blockers

[Canadian Cardiovascular Society guidelines]

Canadian Cardiovascular Society guidelines

[gating movement]

gating movement

[adult Fontan patients]

adult Fontan patients

[administration of pyridostigmine]

administration of pyridostigmine

[adverse CV events in fibrillation]

adverse CV events in fibrillation

[understanding of the role]

understanding of the role

[greater reduction]

greater reduction

[surviving an myocardial infarction]

surviving an myocardial infarction

[recovery period of BP]

recovery period of BP

[difference median BNP]

difference median BNP

[human stem cardiomyocytes]

human stem cardiomyocytes

[New York Heart Association class HR]

New York Heart Association class HR

[heart failure patients with ventricular tachycardia]

heart failure patients with ventricular tachycardia

[CO. Lack of correlation]

CO. Lack of correlation

[Impact of physician continuity death]

Impact of physician continuity death

[monitoring after recent hospital discharge]

monitoring after recent hospital discharge

[development of myocardial events]

development of myocardial events

[nitroxyl donor salt]

nitroxyl donor salt

[calcium]

calcium

[Participating in a study]

Participating in a study

[skeletal muscle sarcomere]

skeletal muscle sarcomere

[Safety of eplerenone in patients]

Safety of eplerenone in patients

[mitral E wave ratio]

mitral E wave ratio

[elastance Ea]

elastance Ea

[Study Selection English-language trials]

Study Selection English-language trials

[post-HCT CHF]

post-HCT CHF

[consistent approach extrapolating outcomes]

consistent approach extrapolating outcomes

[composite end point]

composite end point

[eight healthy controls]

eight healthy controls

[Enhancement of care]

Enhancement of care

[odds ratio for mortality]

odds ratio for mortality

[3-year event rates]

3-year event rates

[diastolic dysfunction leading]

diastolic dysfunction leading

[characteristics of EH]

characteristics of EH

[Determination treatment strategies]

Determination treatment strategies

[time years]

time years

[progressive loss of fat mass]

progressive loss of fat mass

[1.61 1.39 times]

1.61 1.39 times

[changes with strain contributions]

changes with strain contributions

[evaluating 63 predictors]

evaluating 63 predictors

[cardiac response]

cardiac response

[LV dimension]

LV dimension

[Moderate high-strength evidence from 17 trials]

Moderate high-strength evidence from 17 trials

[receptor activation]

receptor activation

[findings a Trial Investigating Outcomes]

findings a Trial Investigating Outcomes

[emphasizing the importance]

emphasizing the importance

[oxygen pulse range in four]

oxygen pulse range in four

[central blood pressure via arterial tonometry]

central blood pressure via arterial tonometry

[effective rate relative risk]

effective rate relative risk

[log]

log

[cardiac magnetic resonance imaging]

cardiac magnetic resonance imaging

[avoiding the region]

avoiding the region

[Studies of echocardiographic predictors of response]

Studies of echocardiographic predictors of response

[systolic HF of etiology]

systolic HF of etiology

[possibly worsening]

possibly worsening

[Australian health data]

Australian health data

[arthritis starting a TNF antagonist]

arthritis starting a TNF antagonist

[outcome-monitoring phase mean 22.9±5.0 months]

outcome-monitoring phase mean 22.9±5.0 months

[academic medical center]

academic medical center

[independent markers hazard ratio]

independent markers hazard ratio

[examining the safety measures]

examining the safety measures

[reporting on quality]

reporting on quality

[systematic monitoring of LVAD use]

systematic monitoring of LVAD use

[symptomatic adult Fontan SAF patients]

symptomatic adult Fontan SAF patients

[extending EMD in dyssynchronous HF]

extending EMD in dyssynchronous HF

[20 812 patients aged years]

20 812 patients aged years

[myocardial infarction-both n]

myocardial infarction-both n

[subpulmonary ventricle]

subpulmonary ventricle

[hypertension patients]

hypertension patients

[transoesophageal guidance]

transoesophageal guidance

[Fifty-four pediatric Fontan PF patients]

Fifty-four pediatric Fontan PF patients

[E ratios]

E ratios

[ejection fraction R=0.28 P=0.01]

ejection fraction R=0.28 P=0.01

[array of procedures]

array of procedures

[symptom maximal CPET in patients]

symptom maximal CPET in patients

[restoration of lipoprotein functional properties]

restoration of lipoprotein functional properties

[4-year survival of patients]

4-year survival of patients

[important cause of morbidity]

important cause of morbidity

[heart resonance imaging]

heart resonance imaging

[Data Sources MEDLINE databases]

Data Sources MEDLINE databases

[cardiac insulin-resistance post-AAC]

cardiac insulin-resistance post-AAC

[distinct receptors]

distinct receptors

[right atrial area cm 2]

right atrial area cm 2

[short-term improvements]

short-term improvements

[achieving a level of CRF]

achieving a level of CRF

[remaining in deciles of agreement]

remaining in deciles of agreement

[participants aged years]

participants aged years

[including calcium-sensitizing agents of endothelin]

including calcium-sensitizing agents of endothelin

[heart rate HR reduction]

heart rate HR reduction

[global systolic strain GLS]

global systolic strain GLS

[HF patients without spontaneous VT HFVT(-)]

HF patients without spontaneous VT HFVT(-)

[detectable change]

detectable change

[Q65P]

Q65P

[particularly between a low-risk group]

particularly between a low-risk group

[left longitudinal systolic strain GLS]

left longitudinal systolic strain GLS

[patient awareness]

patient awareness

[kcal]

kcal

[Utilizing voluntary testimonies]

Utilizing voluntary testimonies

[signalling pathways activating adaptive cardiac remodelling]

signalling pathways activating adaptive cardiac remodelling

[effective rate risk]

effective rate risk

[correlates]

correlates

[Individuals with RV failure]

Individuals with RV failure

[reports demonstrating development of MS]

reports demonstrating development of MS

[Q66P]

Q66P

[end-of-life treatment preferences]

end-of-life treatment preferences

[Factors Insights]

Factors Insights

[intensive transitions]

intensive transitions

[lower risk]

lower risk

[surgery months]

surgery months

[nosignificant changes in control group]

nosignificant changes in control group

[acceptable internal validity]

acceptable internal validity

[indices ratio of LV strain rate]

indices ratio of LV strain rate

[effects of exercise training on function]

effects of exercise training on function

[instituting support]

instituting support

[Treatment a review]

Treatment a review

[RA population]

RA population

[collagen density of the left ventricle]

collagen density of the left ventricle

[opening without any lesion]

opening without any lesion

[gas analysis]

gas analysis

[need of cardiopulmonary resuscitation]

need of cardiopulmonary resuscitation

[existing measures]

existing measures

[patients receiving cardioverter defibrillator-CRT]

patients receiving cardioverter defibrillator-CRT

[Various measures such as time-domain measures]

Various measures such as time-domain measures

[intraclass correlation]

intraclass correlation

[underperfusion resulting in the activation]

underperfusion resulting in the activation

[history of disease]

history of disease

[large idiopathic cohort]

large idiopathic cohort

[serum cystatin]

serum cystatin

[improving capacity]

improving capacity

[HeartMate ventricular assist system LVAS]

HeartMate ventricular assist system LVAS

[death confidence interval]

death confidence interval

[NYHA class IIIB symptoms]

NYHA class IIIB symptoms

[Twenty-seven studies patients]

Twenty-seven studies patients

[steady improvement]

steady improvement

[Moderate high-strength evidence from trials]

Moderate high-strength evidence from trials

[days of ACS consultation]

days of ACS consultation

[role for microRNAs]

role for microRNAs

[3-min records]

3-min records

[trials in acute HF]

trials in acute HF

[remodeling CR]

remodeling CR

[difference in outcome ratings]

difference in outcome ratings

[Seattle Heart Failure Model scores]

Seattle Heart Failure Model scores

[reliable biomarkers]

reliable biomarkers

[support devices]

support devices

[actions of Rad on CaV1.2]

actions of Rad on CaV1.2

[response in activity]

response in activity

[benefit from cardioverter defibrillator-CRT]

benefit from cardioverter defibrillator-CRT

[cAMP-dependent protein kinase]

cAMP-dependent protein kinase

[visits during the study period]

visits during the study period

[10 HF patients without VT HFVT(-)]

10 HF patients without VT HFVT(-)

[HFPSI use]

HFPSI use

[exercise per week]

exercise per week

[Advances in treatment for infarction AMI]

Advances in treatment for infarction AMI

[activation of β1ARs in a myocyte]

activation of β1ARs in a myocyte

[ventricular biopsies n=9]

ventricular biopsies n=9

[genes related]

genes related

[receptor neprilysin inhibitor]

receptor neprilysin inhibitor

[particularly in patients]

particularly in patients

[nesiritide μg]

nesiritide μg

[cause of cardiovascular morbidity]

cause of cardiovascular morbidity

[mitochondrial changes]

mitochondrial changes

[heart failure at rest]

heart failure at rest

[SCHFI]

SCHFI

[vascular resistance P]

vascular resistance P

[systolic leaflet motions]

systolic leaflet motions

[heart transplant recipients]

heart transplant recipients

[transplant n=36]

transplant n=36

[role 2 scaffolds in heart pathology]

role 2 scaffolds in heart pathology

[studies in HF]

studies in HF

[KCCQ category among patients]

KCCQ category among patients

[performance detecting filling pressures]

performance detecting filling pressures

[ratio mitral annulus velocity E]

ratio mitral annulus velocity E

[population-based study of 20,812 patients]

population-based study of 20,812 patients

[trials-Enriching patient identification]

trials-Enriching patient identification

[change main effect]

change main effect

[Tools for Economic Analysis]

Tools for Economic Analysis

[annular plane excursion TAPSE]

annular plane excursion TAPSE

[tachycardia indicative of tone]

tachycardia indicative of tone

[bridging therapy in patients]

bridging therapy in patients

[association of cognitive impairment]

association of cognitive impairment

[global changes in subproteomes]

global changes in subproteomes

[clinical parameters]

clinical parameters

[extending EMD in HF]

extending EMD in HF

[resistin in chemotherapy-induced heart failure]

resistin in chemotherapy-induced heart failure

[bpm 17.5±5.5 versus 14.4±3.3 mL]

bpm 17.5±5.5 versus 14.4±3.3 mL

[treatment with ejection fraction HFpEF]

treatment with ejection fraction HFpEF

[individuals with obstructive disease]

individuals with obstructive disease

[Impact of QRS morphology]

Impact of QRS morphology

[Direct observation]

Direct observation

[bleeding in patients]

bleeding in patients

[impact of ET]

impact of ET

[Soluble]

Soluble

[9 subjects with hearts HNorm]

9 subjects with hearts HNorm

[heart failure of unclear etiology]

heart failure of unclear etiology

[pulmonary hypertension PH]

pulmonary hypertension PH

[studies including calcium-sensitizing agents of endothelin]

studies including calcium-sensitizing agents of endothelin

[absolute change the percent remaining]

absolute change the percent remaining

[participants without HF area]

participants without HF area

[ventricular ejection fraction P=0.01]

ventricular ejection fraction P=0.01

[differences in those parameters]

differences in those parameters

[outcome at 1 year]

outcome at 1 year

[period hazard ratio]

period hazard ratio

[diastolic velocity 3.1]

diastolic velocity 3.1

[common cause of death]

common cause of death

[information than the others]

information than the others

[clinical relevance in hypertension patients]

clinical relevance in hypertension patients

[European Society]

European Society

[requiring revision by open surgery]

requiring revision by open surgery

[level of CRF]

level of CRF

[often in the context]

often in the context

[skinfold thickness]

skinfold thickness

[partial pressure of CO2 PETCO2]

partial pressure of CO2 PETCO2

[vasopressin in heart failure]

vasopressin in heart failure

[action on cAMP production]

action on cAMP production

[proof-of-principle cohort]

proof-of-principle cohort

[two types]

two types

[334 patients 224 men years]

334 patients 224 men years

[Reversal of dysfunction]

Reversal of dysfunction

[metoprolol irrespective]

metoprolol irrespective

[VA-RT cohort]

VA-RT cohort

[angiotensin receptor antagonist]

angiotensin receptor antagonist

[individuals with chronic obstructive disease]

individuals with chronic obstructive disease

[extracorporeal membrane oxygenation membrane support]

extracorporeal membrane oxygenation membrane support

[men mean]

men mean

[ventricular end diameter mm difference]

ventricular end diameter mm difference

[colony-forming units EO-CFUs]

colony-forming units EO-CFUs

[BNP levels pg low BNP group]

BNP levels pg low BNP group

[coupling in hypertensive HFPEF]

coupling in hypertensive HFPEF

[life domains]

life domains

[26 cm]

26 cm

[trend with dilatation]

trend with dilatation

[viable option]

viable option

[Classification]

Classification

[test-retest reliability of the Up test]

test-retest reliability of the Up test

[wk of pyridostigmine administration]

wk of pyridostigmine administration

[compliance TAC]

compliance TAC

[field]

field

[conditions such as acute infarction]

conditions such as acute infarction

[Health ABC Performance Battery]

Health ABC Performance Battery

[community-based cohort with incident]

community-based cohort with incident

[16 healthy controls]

16 healthy controls

[delay AVD]

delay AVD

[aggressive protocols]

aggressive protocols

[enrichment analysis]

enrichment analysis

[fewer cardiac procedures]

fewer cardiac procedures

[patients with Fontan circulation]

patients with Fontan circulation

[BNP levels 100 pg BNP group]

BNP levels 100 pg BNP group

[Randomized trial of walking in patients]

Randomized trial of walking in patients

[better prognostic information]

better prognostic information

[concept appropriate]

concept appropriate

[47 percent of hospitals]

47 percent of hospitals

[primary outcome over months]

primary outcome over months

[heart lesions]

heart lesions

[mEq]

mEq

[evidence of left dyssynchrony]

evidence of left dyssynchrony

[pulmonary systolic pressure PASP]

pulmonary systolic pressure PASP

[ICD-HF patients]

ICD-HF patients

[index versus 2.8 0.7 L 2]

index versus 2.8 0.7 L 2

[cardiovascular reserve]

cardiovascular reserve

[BiVP]

BiVP

[measurement value]

measurement value

[334 patients men 65±12 years]

334 patients men 65±12 years

[hazard ratio for peak o2]

hazard ratio for peak o2

[patients 224 men]

patients 224 men

[years Q]

years Q

[years p]

years p

[double-blind feasibility study]

double-blind feasibility study

[modest clinical benefit for patients]

modest clinical benefit for patients

[ejection fraction after infarction]

ejection fraction after infarction

[advanced organ failure]

advanced organ failure

[improvement of performance by β-adrenoceptor blockade]

improvement of performance by β-adrenoceptor blockade

[patients having HFpEF gender]

patients having HFpEF gender

[transcatheter valve procedure]

transcatheter valve procedure

[haplotype status]

haplotype status

[nutritional strategies with anti-inflammatory effects]

nutritional strategies with anti-inflammatory effects

[total compliance]

total compliance

[capillary wedge]

capillary wedge

[mortality among women with HF]

mortality among women with HF

[Effects of support on function]

Effects of support on function

[improvement of biomarkers]

improvement of biomarkers

[quantification of T1]

quantification of T1

[right ventricular ejection fraction R=0.28]

right ventricular ejection fraction R=0.28

[Ca 2 handling in HF]

Ca 2 handling in HF

[cardiac magnetic resonance T1 mapping]

cardiac magnetic resonance T1 mapping

[valve plasty for regurgitation]

valve plasty for regurgitation

[first acute infarction in Australia]

first acute infarction in Australia

[10,000 pairs]

10,000 pairs

[indices ratio at diastole]

indices ratio at diastole

[insight into delay]

insight into delay

[10 patients]

10 patients

[essential role]

essential role

[ACF groups]

ACF groups

[ischemic events in patients]

ischemic events in patients

[HR variability measures]

HR variability measures

[risk for hyperkalemia]

risk for hyperkalemia

[health interventions]

health interventions

[patients with obstructive pulmonary disease]

patients with obstructive pulmonary disease

[enhancement of cardiac angiogenesis]

enhancement of cardiac angiogenesis

[Left ejection time complicating pulmonary hypertension]

Left ejection time complicating pulmonary hypertension

[cation channel M7]

cation channel M7

[heart failure-related QOL outcome]

heart failure-related QOL outcome

[EMPHASIS-HF study subgroups]

EMPHASIS-HF study subgroups

[tumor necrosis]

tumor necrosis

[dietary patterns]

dietary patterns

[using the method]

using the method

[treatment of diuretic HF]

treatment of diuretic HF

[Multicenter placebo-controlled trial]

Multicenter placebo-controlled trial

[CI for sitagliptin]

CI for sitagliptin

[proteolysis between Pro2-Leu3]

proteolysis between Pro2-Leu3

[Cardiac overexpression]

Cardiac overexpression

[high-strength evidence from 17 trials]

high-strength evidence from 17 trials

[patch]

patch

[velocity of shortening]

velocity of shortening

[spironolactone use from 2006]

spironolactone use from 2006

[peak early diastolic flow velocity]

peak early diastolic flow velocity

[furosemide]

furosemide

[Effects of support]

Effects of support

[residents]

residents

[using general models]

using general models

[pharmacologic studies including agents of endothelin]

pharmacologic studies including agents of endothelin

[risk stratification between a group]

risk stratification between a group

[CHF-NYHA-IIIb]

CHF-NYHA-IIIb

[findings a Trial]

findings a Trial

[receiving membrane oxygenation membrane support]

receiving membrane oxygenation membrane support

[detecting AT]

detecting AT

[mortality at 4 years after hospitalization]

mortality at 4 years after hospitalization

[afterload of the heart]

afterload of the heart

[Management stemming from ischemic cardiomyopathies]

Management stemming from ischemic cardiomyopathies

[tachycardia in response]

tachycardia in response

[artery pressure PASP increase]

artery pressure PASP increase

[post-transplant]

post-transplant

[significant improvements showing improvement]

significant improvements showing improvement

[venous events]

venous events

[morbidity in elderly people]

morbidity in elderly people

[system events]

system events

[LV fibrosis]

LV fibrosis

[physicians a difference]

physicians a difference

[O-1]

O-1

[all-cause hospitalization in HF clinic outpatients]

all-cause hospitalization in HF clinic outpatients

[mitochondrial-targeted peptides]

mitochondrial-targeted peptides

[PKC-βII by HDL]

PKC-βII by HDL

[risk factors on HF mortality]

risk factors on HF mortality

[Obese Patients With Heart Failure]

Obese Patients With Heart Failure

[aim of this multicenter study]

aim of this multicenter study

[numbers of apoptotic cells]

numbers of apoptotic cells

[E e]

E e

[users of bisphosphonates]

users of bisphosphonates

[large-scale randomised studies]

large-scale randomised studies

[ventricular RV failure]

ventricular RV failure

[complicating pulmonary hypertension]

complicating pulmonary hypertension

[robot-assisted gait therapy]

robot-assisted gait therapy

[LV contractility]

LV contractility

[major mechanism]

major mechanism

[opening]

opening

[KCCQ Summary]

KCCQ Summary

[Gastrointestinal bleeding in patients]

Gastrointestinal bleeding in patients

[adjustment for variables]

adjustment for variables

[PH with heart failure]

PH with heart failure

[appropriate investigations]

appropriate investigations

[patients A Trial Investigating Outcomes]

patients A Trial Investigating Outcomes

[elastance Ea]

elastance Ea

[Effectiveness as an adjunctive treatment]

Effectiveness as an adjunctive treatment

[BB therapy]

BB therapy

[benefit for patients in retrospective studies]

benefit for patients in retrospective studies

[target in the treatment]

target in the treatment

[regarding the need]

regarding the need

[70 bpm 17.5±5.5 versus 14.4±3.3 mL]

70 bpm 17.5±5.5 versus 14.4±3.3 mL

[occurring within days]

occurring within days

[right arterial coupling resistance]

right arterial coupling resistance

[left diastolic end diameter mm difference]

left diastolic end diameter mm difference

[excitation-contraction]

excitation-contraction

[adverse CV events in univariate models]

adverse CV events in univariate models

[highest cardiovascular event rate]

highest cardiovascular event rate

[isoenzymes]

isoenzymes

[renal underperfusion]

renal underperfusion

[receiving the dose]

receiving the dose

[cell transplantation]

cell transplantation

[usefulness in HF]

usefulness in HF

[abnormal Ca 2 handling]

abnormal Ca 2 handling

[cardiac resonance postcontrast]

cardiac resonance postcontrast

[Impact on the clinical response]

Impact on the clinical response

[contribution of atherosclerotic CAD]

contribution of atherosclerotic CAD

[administrative databases]

administrative databases

[spironolactone dose]

spironolactone dose

[disease COPD]

disease COPD

[Induction of SCN5A variants]

Induction of SCN5A variants

[aspects of cardiac remodeling]

aspects of cardiac remodeling

[cAMP production]

cAMP production

[Extracorporeal membrane oxygenation]

Extracorporeal membrane oxygenation

[system activity on QTV]

system activity on QTV

[late-onset days]

late-onset days

[Potent inhibition of L-type Ca2]

Potent inhibition of L-type Ca2

[2 μg]

2 μg

[HF A Multicenter Study]

HF A Multicenter Study

[Pharmacological treatment of heart failure]

Pharmacological treatment of heart failure

[low-volume physicians]

low-volume physicians

[beneficial outcomes]

beneficial outcomes

[Szeto-Schiller]

Szeto-Schiller

[patients above the BNP level]

patients above the BNP level

[LV mass versus 5.0 42.4 g]

LV mass versus 5.0 42.4 g

[value of anaerobic threshold]

value of anaerobic threshold

[absolute change values]

absolute change values

[albumin concentration ≥3.5 g]

albumin concentration ≥3.5 g

[Incubation of EC]

Incubation of EC

[hyperacetylation]

hyperacetylation

[comprising hospitalization for acute syndromes]

comprising hospitalization for acute syndromes

[echocardiographic predictors after resynchronization therapy]

echocardiographic predictors after resynchronization therapy

[treatment for myocardial infarction]

treatment for myocardial infarction

[proteomics changes in aortic constriction]

proteomics changes in aortic constriction

[molecular scaffolds]

molecular scaffolds

[decline atrial c-Kit]

decline atrial c-Kit

[VO2 max]

VO2 max

[SD testosterone levels]

SD testosterone levels

[C57BL 6]

C57BL 6

[total of psoriasis UV treatment]

total of psoriasis UV treatment

[abnormal exercise hemodynamic status]

abnormal exercise hemodynamic status

[high risk of hyperkalemia]

high risk of hyperkalemia

[HFpEF P]

HFpEF P

[studies including agents]

studies including agents

[including tools regarding the need]

including tools regarding the need

[revascularization hazard ratio]

revascularization hazard ratio

[left base]

left base

[absence of artery disease]

absence of artery disease

[evidence of dysfunction LV relaxation]

evidence of dysfunction LV relaxation

[bundle-branch block]

bundle-branch block

[1 trial]

1 trial

[patients 224 men mean years]

patients 224 men mean years

[determinants of survival]

determinants of survival

[institution for the treatment]

institution for the treatment

[neprilysin blocks]

neprilysin blocks

[receptor signaling]

receptor signaling

[trials-Enriching patient]

trials-Enriching patient

[improvement in prognosis]

improvement in prognosis

[quality indicators]

quality indicators

[heart failure-related QOL]

heart failure-related QOL

[Survival after left assist device]

Survival after left assist device

[period of 3.4 years]

period of 3.4 years

[index beat]

index beat

[diastolic valve tethering]

diastolic valve tethering

[deaths occurring within days]

deaths occurring within days

[HeartMate 3]

HeartMate 3

[heart failure a computational study]

heart failure a computational study

[medicare fee-for-service beneficiaries]

medicare fee-for-service beneficiaries

[reticular SR Ca]

reticular SR Ca

[percent remaining]

percent remaining

[100 older participants]

100 older participants

[ongoing GDMT for months]

ongoing GDMT for months

[pump function]

pump function

[index score value]

index score value

[association of hypoalbuminemia with mortality]

association of hypoalbuminemia with mortality

[(Fpassive)-sarcomere]

(Fpassive)-sarcomere

[including better tools for risk stratification]

including better tools for risk stratification

[symptom maximal CPET in 10 patients]

symptom maximal CPET in 10 patients

[function in volume overload]

function in volume overload

[556 patients]

556 patients

[effects of cocoa]

effects of cocoa

[However a analysis]

However a analysis

[panel of noninvasive assessments]

panel of noninvasive assessments

[receiving carvedilol]

receiving carvedilol

[left LV pressure]

left LV pressure

[significant predictor]

significant predictor

[change with exercise effect]

change with exercise effect

[therapeutic implications of promising biomarkers]

therapeutic implications of promising biomarkers

[cascades]

cascades

[promoting cardiac filling in subjects]

promoting cardiac filling in subjects

[cardiac index L 2]

cardiac index L 2

[exercise-induced artery pressure PASP increase]

exercise-induced artery pressure PASP increase

[PAF of enzymes in patients]

PAF of enzymes in patients

[ECG in athletes]

ECG in athletes

[9 subjects with normal hearts HNorm]

9 subjects with normal hearts HNorm

[interatrial shunting for treatment of patients]

interatrial shunting for treatment of patients

[diagnosis of diastolic dysfunction leading]

diagnosis of diastolic dysfunction leading

[mortality than cancers]

mortality than cancers

[attenuation of global proteomics changes]

attenuation of global proteomics changes

[further validation in studies]

further validation in studies

[significant improvement in capacity]

significant improvement in capacity

[Management stemming from cardiomyopathies]

Management stemming from cardiomyopathies

[difference control]

difference control

[patients with filtration rate]

patients with filtration rate

[study drugs]

study drugs

[systolic HF tissue samples]

systolic HF tissue samples

[pediatric Fontan PF patients]

pediatric Fontan PF patients

[blood pressure via radial arterial tonometry]

blood pressure via radial arterial tonometry

[signalling pathways activating cardiac remodelling]

signalling pathways activating cardiac remodelling

[ventricular plane systolic excursion]

ventricular plane systolic excursion

[adjuvant setting]

adjuvant setting

[Patient Management]

Patient Management

[Relationships between function]

Relationships between function

[ventricular-pulmonary arterial coupling resistance P]

ventricular-pulmonary arterial coupling resistance P

[high muscle strip stiffness]

high muscle strip stiffness

[endothelial growth factor protein]

endothelial growth factor protein

[change in MLHF total score]

change in MLHF total score

[ventricular RV function]

ventricular RV function

[nonstandardized pro-B-type natriuretic peptide]

nonstandardized pro-B-type natriuretic peptide

[phenotype of the failing Fontan]

phenotype of the failing Fontan

[heart failure HF patients with tachycardia]

heart failure HF patients with tachycardia

[resulting in the activation]

resulting in the activation

[ventricular strain as a predictor]

ventricular strain as a predictor

[HR 1.58 CI]

HR 1.58 CI

[Insights From Heart Failure]

Insights From Heart Failure

[Grade recommendation low-quality evidence]

Grade recommendation low-quality evidence

[ventricular ejection fraction on mortality]

ventricular ejection fraction on mortality

[Extracorporeal membrane oxygenation in heart failure]

Extracorporeal membrane oxygenation in heart failure

[function flow-mediated dilatation]

function flow-mediated dilatation

[risk stratification between a low-risk group]

risk stratification between a low-risk group

[multiple abnormalities in function]

multiple abnormalities in function

[disease modifying antirheumatic drug]

disease modifying antirheumatic drug

[higher admission median BNP levels]

higher admission median BNP levels

[outpatient assessments of patients within days]

outpatient assessments of patients within days

[medical resources]

medical resources

[MRI-based models of canine electromechanics]

MRI-based models of canine electromechanics

[concentric ventricular hypertrophy]

concentric ventricular hypertrophy

[myocardial phosphodiesterase-2]

myocardial phosphodiesterase-2

[advanced COPD n=95]

advanced COPD n=95

[rapid onset]

rapid onset

[17.6 mL P=0.01]

17.6 mL P=0.01

[GDMT alone control group]

GDMT alone control group

[All-cause mortality after hospitalization]

All-cause mortality after hospitalization

[Effectiveness as an treatment for cardiomyopathy]

Effectiveness as an treatment for cardiomyopathy

[revealing a mechanism of cardiac dysfunction]

revealing a mechanism of cardiac dysfunction

[modest effects]

modest effects

[risk of outcomes in patients]

risk of outcomes in patients

[permanent periodic breathing]

permanent periodic breathing

[Eplerenone Post]

Eplerenone Post

[23 mm Hg]

23 mm Hg

[models using data]

models using data

[stressors]

stressors

[rates of death among patients]

rates of death among patients

[antibodies targeting the N termini]

antibodies targeting the N termini

[Treating HF A Multicenter Study]

Treating HF A Multicenter Study

[1.39 years]

1.39 years

[severe hyponatremia in countries]

severe hyponatremia in countries

[patients having HFrEF]

patients having HFrEF

[patients aged years with heart failure]

patients aged years with heart failure

[dysbalance]

dysbalance

[sarcoplasmic SR Ca 2+)-uptake]

sarcoplasmic SR Ca 2+)-uptake

[10-cell decrease]

10-cell decrease

[home telemonitoring including monitoring devices]

home telemonitoring including monitoring devices

[types for BTT patients]

types for BTT patients

[heart failure.]

heart failure.

[AMI mortality rates]

AMI mortality rates

[noninvasive surrogates for changes]

noninvasive surrogates for changes

[readers bromodomain proteins]

readers bromodomain proteins

[two distinct populations]

two distinct populations

[certain malignancies]

certain malignancies

[susceptibility in survivors of cell transplantation]

susceptibility in survivors of cell transplantation

[One-year rates by KCCQ category]

One-year rates by KCCQ category

[significant decrease in rates]

significant decrease in rates

[importance of dysfunction]

importance of dysfunction

[MicroRNAs targets in disease management]

MicroRNAs targets in disease management

[wk of treatment]

wk of treatment

[nursing care]

nursing care

[3 studies]

3 studies

[nutritional strategies with effects]

nutritional strategies with effects

[hospitalizations in severe heart failure]

hospitalizations in severe heart failure

[reactivation of embryonic gene programs]

reactivation of embryonic gene programs

[National Inpatient Registry]

National Inpatient Registry

[left-to-right interatrial shunting for treatment]

left-to-right interatrial shunting for treatment

[predicting CV events in univariate models]

predicting CV events in univariate models

[resistance training of the limbs]

resistance training of the limbs

[Hypertension DASH]

Hypertension DASH

[even mild clinical dysfunction]

even mild clinical dysfunction

[including better tools]

including better tools

[variants of genes]

variants of genes

[reduction in mortality for patients]

reduction in mortality for patients

[pulmonary arterial systolic pressure relationship]

pulmonary arterial systolic pressure relationship

[concentration circulating NT-proBNP]

concentration circulating NT-proBNP

[BiVP setting]

BiVP setting

[long-term survival of patients]

long-term survival of patients

[high internal consistency]

high internal consistency

[function in children]

function in children

[discharge diagnosis]

discharge diagnosis

[perioperative deaths in the procedures]

perioperative deaths in the procedures

[practice-level variation in rates of treatment]

practice-level variation in rates of treatment

[reasons per patient]

reasons per patient

[insulin-resistance by weeks]

insulin-resistance by weeks

[such as infarction]

such as infarction

[2.1 mL]

2.1 mL

[Mena deletion]

Mena deletion

[successful mitral valve plasty]

successful mitral valve plasty

[(eGFR)-group I ≥60 mL per m]

(eGFR)-group I ≥60 mL per m

[Heart failure HF data]

Heart failure HF data

[Effective elastance end-systolic elastance]

Effective elastance end-systolic elastance

[potential implications of biomarkers]

potential implications of biomarkers

[management of HF]

management of HF

[patients with infarction in Australia]

patients with infarction in Australia

[patients with evaluable plasma samples]

patients with evaluable plasma samples

[suggesting postcontrast T1 as possible biomarker]

suggesting postcontrast T1 as possible biomarker

[human pluripotent stem]

human pluripotent stem

[very few complications]

very few complications

[decoy VEGF receptor]

decoy VEGF receptor

[patients with clinically stable HFPEF]

patients with clinically stable HFPEF

[Cardiopulmonary exercise testing with assessment]

Cardiopulmonary exercise testing with assessment

[single-centre trial]

single-centre trial

[highest cardiovascular event rate events]

highest cardiovascular event rate events

[subset of patients]

subset of patients

[Echocardiographic predictors after resynchronization therapy]

Echocardiographic predictors after resynchronization therapy

[relevant articles]

relevant articles

[1,045 patients]

1,045 patients

[Recommendations for management]

Recommendations for management

[Relation of serum albumin levels]

Relation of serum albumin levels

[undergoing assist device implantation]

undergoing assist device implantation

[defense mechanism]

defense mechanism

[impact on hospital performance]

impact on hospital performance

[4 wk of pyridostigmine administration]

4 wk of pyridostigmine administration

[body mass index of black ethnicity]

body mass index of black ethnicity

[ACS procedures]

ACS procedures

[hemodynamics]

hemodynamics

[Differential effects of nonselective versus beta-blockers]

Differential effects of nonselective versus beta-blockers

[Investigating the role]

Investigating the role

[Vascular growth factor blockade]

Vascular growth factor blockade

[cardiac resonance imaging including T1 mapping]

cardiac resonance imaging including T1 mapping

[health care expenditures]

health care expenditures

[LV mass g]

LV mass g

[research initiatives]

research initiatives

[eGFR group IV]

eGFR group IV

[vEntricular dysfunction REVERSE]

vEntricular dysfunction REVERSE

[ongoing GDMT alone]

ongoing GDMT alone

[T2 values]

T2 values

[Multicenter double-blind trial of 360 patients]

Multicenter double-blind trial of 360 patients

[cause of death during sport]

cause of death during sport

[safety of eplerenone]

safety of eplerenone

[etiologies of HF]

etiologies of HF

[plasma N-terminal pro-B-type natriuretic peptide]

plasma N-terminal pro-B-type natriuretic peptide

[last decade of heart failure]

last decade of heart failure

[accurate risk stratification with heart failure]

accurate risk stratification with heart failure

[Grading]

Grading

[Insights A Trial]

Insights A Trial

[high-density lipoprotein properties]

high-density lipoprotein properties

[Echocardiograms of the midpapillary level]

Echocardiograms of the midpapillary level

[Remote monitoring after recent hospital discharge]

Remote monitoring after recent hospital discharge

[faster turnaround times]

faster turnaround times

[novel HNO donor]

novel HNO donor

[Swedish Web-system for Enhancement]

Swedish Web-system for Enhancement

[results about the risk]

results about the risk

[case cohort analysis]

case cohort analysis

[first month after discharge]

first month after discharge

[inhibition on hemodynamic status]

inhibition on hemodynamic status

[higher rates potassium]

higher rates potassium

[performance of the prediction rule]

performance of the prediction rule

[inhibition of vascular growth factor]

inhibition of vascular growth factor

[groups of rats Wistar-Kyoto]

groups of rats Wistar-Kyoto

[analysis of cardiac tissue from mice]

analysis of cardiac tissue from mice

[Postoperative normalization]

Postoperative normalization

[Aldactone Evaluation]

Aldactone Evaluation

[clinical practice guidelines grading system]

clinical practice guidelines grading system

[hospitalization for acute syndromes]

hospitalization for acute syndromes

[role of system activity]

role of system activity

[heart sound in the apex]

heart sound in the apex

[accurate recognition]

accurate recognition

[powerful predictor period hazard ratio]

powerful predictor period hazard ratio

[extensive functional characterization]

extensive functional characterization

[elevation in resistin]

elevation in resistin

[lower E wave ratio]

lower E wave ratio

[major neurological event-free rate]

major neurological event-free rate

[prediction rule having ≥1 predictor]

prediction rule having ≥1 predictor

[net]

net

[brain natriuretic peptide BNP levels]

brain natriuretic peptide BNP levels

[renal function in heart failure]

renal function in heart failure

[group II mL per m 2]

group II mL per m 2

[favorable event profile]

favorable event profile

[atrial c-Kit]

atrial c-Kit

[global left longitudinal strain]

global left longitudinal strain

[SkM structure]

SkM structure

[penalties for rates]

penalties for rates

[ST2 levels with functional capacity]

ST2 levels with functional capacity

[beta-blocker therapy on function]

beta-blocker therapy on function

[Abnormal T2]

Abnormal T2

[heart failure ED visits age]

heart failure ED visits age

[suburban hospitals]

suburban hospitals

[forms of NT-proBNP]

forms of NT-proBNP

[still a anti-neoplastic agent]

still a anti-neoplastic agent

[activation of p38α protein kinase]

activation of p38α protein kinase

[age-matched reference values]

age-matched reference values

[home telemonitoring with support]

home telemonitoring with support

[EF≤]

EF≤

[means improving muscle function]

means improving muscle function

[valve repairs]

valve repairs

[large animal model of ischemia]

large animal model of ischemia

[brain natriuretic peptide levels 100 pg]

brain natriuretic peptide levels 100 pg

[patient-operated device]

patient-operated device

[ventricular plane excursion]

ventricular plane excursion

[physician follow-up after discharge]

physician follow-up after discharge

[Clinical Modification codes]

Clinical Modification codes

[Screening with a ECG]

Screening with a ECG

[right end-diastolic area index]

right end-diastolic area index

[Patient Management]

Patient Management

[peak quadriceps force range]

peak quadriceps force range

[range 22.8 with COPD n=95]

range 22.8 with COPD n=95

[Kv4.3 mRNA levels]

Kv4.3 mRNA levels

[decline atrial explant-derived c-Kit]

decline atrial explant-derived c-Kit

[effects of B act]

effects of B act

[alternative for this population]

alternative for this population

[increase for infarction AMI]

increase for infarction AMI

[treatment for acute infarction AMI]

treatment for acute infarction AMI

[crucial role in signal transduction]

crucial role in signal transduction

[oxygen pulse in four]

oxygen pulse in four

[abnormalities in function]

abnormalities in function

[relaxation]

relaxation

[follow-up of 19.8±10.4 years]

follow-up of 19.8±10.4 years

[Obese Patients]

Obese Patients

[lacking resistin]

lacking resistin

[transplant ECCT]

transplant ECCT

[event profile]

event profile

[overview of clinical trial design]

overview of clinical trial design

[double mutant]

double mutant

[positive effects on cardiac function]

positive effects on cardiac function

[failure from cardiomyopathic restriction]

failure from cardiomyopathic restriction

[support using a HeartMate II LVAD]

support using a HeartMate II LVAD

[effect following acute β-AR stimulation]

effect following acute β-AR stimulation

[Effects of mechanical cardiac support]

Effects of mechanical cardiac support

[right ventricular-pulmonary coupling pulmonary resistance]

right ventricular-pulmonary coupling pulmonary resistance

[reversible myocardial ischemia stent]

reversible myocardial ischemia stent

[patients with chronic HF]

patients with chronic HF

[LV volume of mL]

LV volume of mL

[inducing hyperkalemia in patients]

inducing hyperkalemia in patients

[patients irrespective]

patients irrespective

[epicatechin]

epicatechin

[key genes related]

key genes related

[dual energy X-ray absorptiometry]

dual energy X-ray absorptiometry

[endothelin]

endothelin

[recovery period]

recovery period

[multicenter trial PARADIGM-HF]

multicenter trial PARADIGM-HF

[right ventricular-pulmonary arterial coupling resistance]

right ventricular-pulmonary arterial coupling resistance

[multiple N fragments]

multiple N fragments

[Unidirectional left-to-right interatrial shunting]

Unidirectional left-to-right interatrial shunting

[events P=0.18]

events P=0.18

[associations among cardiorespiratory fitness CRF]

associations among cardiorespiratory fitness CRF

[normal filling pressures]

normal filling pressures

[min 59.6 m]

min 59.6 m

[right tricuspid plane systolic excursion TAPSE]

right tricuspid plane systolic excursion TAPSE

[right annular plane excursion TAPSE]

right annular plane excursion TAPSE

[evidence on clinical effects]

evidence on clinical effects

[national trends]

national trends

[global ventricular systolic strain GLS]

global ventricular systolic strain GLS

[noninvasive surrogates for changes in CO.]

noninvasive surrogates for changes in CO.

[electronic databases including MEDLINE]

electronic databases including MEDLINE

[rheumatic causes]

rheumatic causes

[rapid R-R interval oscillations]

rapid R-R interval oscillations

[monitoring of LVAD use]

monitoring of LVAD use

[outcome median vs milliseconds milliseconds]

outcome median vs milliseconds milliseconds

[insight into the potential of miRNAs]

insight into the potential of miRNAs

[arterial elastance Ea end-systolic elastance Ees]

arterial elastance Ea end-systolic elastance Ees

[incidence outcomes after infarction]

incidence outcomes after infarction

[HR reduction 17±22]

HR reduction 17±22

[anti-neoplastic agent]

anti-neoplastic agent

[ARIC HF model]

ARIC HF model

[right ventricular area change]

right ventricular area change

[((123)I-MIBG]

((123)I-MIBG

[impaired cardiac gene expression]

impaired cardiac gene expression

[index of function]

index of function

[activating adaptive remodelling]

activating adaptive remodelling

[pathological stress]

pathological stress

[sympathetic tone resulting]

sympathetic tone resulting

[slower increase]

slower increase

[total of 674 men]

total of 674 men

[relation of hemoglobin]

relation of hemoglobin

[etiology of MR]

etiology of MR

[young reference mean]

young reference mean

[mortality at years after hospitalization]

mortality at years after hospitalization

[CI for HF]

CI for HF

[peptide B-type peptide]

peptide B-type peptide

[Global ventricular strain as a predictor]

Global ventricular strain as a predictor

[survival from the time of inclusion]

survival from the time of inclusion

[incident HF in participants]

incident HF in participants

[amount of data]

amount of data

[error of measurement value]

error of measurement value

[regarding the forms]

regarding the forms

[right ventricular pressure overload RVPO]

right ventricular pressure overload RVPO

[right tricuspid annular plane excursion TAPSE]

right tricuspid annular plane excursion TAPSE

[right coupling pulmonary resistance P]

right coupling pulmonary resistance P

[features such as early detection]

features such as early detection

[atherosclerosis using linear models]

atherosclerosis using linear models

[reperfusion therapy]

reperfusion therapy

[eligibility]

eligibility

[transseptal catheterisation with echocardiographic guidance]

transseptal catheterisation with echocardiographic guidance

[basis end-diastolic pressure]

basis end-diastolic pressure

[Investigating Outcomes study of exercise training]

Investigating Outcomes study of exercise training

[few adverse consequences]

few adverse consequences

[Prognostic value]

Prognostic value

[100 pg high BNP group]

100 pg high BNP group

[reflecting decreases]

reflecting decreases

[consecutive patients men mean]

consecutive patients men mean

[CI ml]

CI ml

[diastolic velocity 3.1 vs. 1.3]

diastolic velocity 3.1 vs. 1.3

[renal impairment]

renal impairment

[predicting performers]

predicting performers

[NRI]

NRI

[probability]

probability

[heart-specific IRS1 IRS2 gene double-knockout mice]

heart-specific IRS1 IRS2 gene double-knockout mice

[score of 13]

score of 13

[hand grip strength 2.1 kg]

hand grip strength 2.1 kg

[useful mouse HF model]

useful mouse HF model

[diastolic failure from restriction]

diastolic failure from restriction

[β1ARs in a myocyte]

β1ARs in a myocyte

[York Heart Association functional class]

York Heart Association functional class

[Optimization Strategies]

Optimization Strategies

[decline in adverse event rates]

decline in adverse event rates

[age of participants]

age of participants

[effectiveness of rhythm control therapy]

effectiveness of rhythm control therapy

[m vs. 1.5 m]

m vs. 1.5 m

[ejection time LVET]

ejection time LVET

[embryonic kidney 293 cells]

embryonic kidney 293 cells

[right tricuspid annular plane systolic excursion]

right tricuspid annular plane systolic excursion

[strict standards in biomarker studies]

strict standards in biomarker studies

[hospitalizations a consecutive case series]

hospitalizations a consecutive case series

[Large-scale prospective multicenter trial PARADIGM-HF]

Large-scale prospective multicenter trial PARADIGM-HF

[treatment of refractory HF]

treatment of refractory HF

[Stage chronic kidney disease CKD]

Stage chronic kidney disease CKD

[low concentration circulating NT-proBNP]

low concentration circulating NT-proBNP

[most common cause]

most common cause

[mean SD]

mean SD

[subjects with structurally normal hearts HNorm]

subjects with structurally normal hearts HNorm

[various forms in the circulation]

various forms in the circulation

[predictors particularly biomarkers]

predictors particularly biomarkers

[Atherosclerosis Risk]

Atherosclerosis Risk

[stimulation of phosphorylation at eNOS-Ser]

stimulation of phosphorylation at eNOS-Ser

[timing of infarction]

timing of infarction

[HF prediction model]

HF prediction model

[Cardiac Resynchronization]

Cardiac Resynchronization

[rotor]

rotor

[exercise tolerance in patients]

exercise tolerance in patients

[causes of the array]

causes of the array

[multiparametric score predicting CRT response]

multiparametric score predicting CRT response

[beneficial impact]

beneficial impact

[important determinants]

important determinants

[important disease accounting]

important disease accounting

[patients undergoing LVAD implantation]

patients undergoing LVAD implantation

[lower total expenditure]

lower total expenditure

[important risk factors]

important risk factors

[Impact]

Impact

[cell expansion]

cell expansion

[right ventricular-pulmonary coupling resistance]

right ventricular-pulmonary coupling resistance

[HF patients left ventricular ejection fraction]

HF patients left ventricular ejection fraction

[extensive functional characterization of one]

extensive functional characterization of one

[cost-effectiveness analyses]

cost-effectiveness analyses

[distinct circulatory derangement with features]

distinct circulatory derangement with features

[Successful approaches]

Successful approaches

[ventricular tricuspid annular plane excursion]

ventricular tricuspid annular plane excursion

[reference data]

reference data

[single center retrospective observational study]

single center retrospective observational study

[end-diastolic volume index]

end-diastolic volume index

[three trainings]

three trainings

[relevance carrying increase in risk]

relevance carrying increase in risk

[N-terminal peptide]

N-terminal peptide

[three disease groups]

three disease groups

[baseline SDQT-to-SDRR ratio]

baseline SDQT-to-SDRR ratio

[playing a role in the progression]

playing a role in the progression

[outcomes for diseases]

outcomes for diseases

[tricuspid plane excursion from the end]

tricuspid plane excursion from the end

[right heart failure in pulmonary hypertension]

right heart failure in pulmonary hypertension

[hearts in models]

hearts in models

[strong predictor of all-cause mortality]

strong predictor of all-cause mortality

[diminishing the ROS effects]

diminishing the ROS effects

[opening without any organic lesion]

opening without any organic lesion

[catheterisation with guidance under anaesthesia]

catheterisation with guidance under anaesthesia

[days than medium]

days than medium

[LV mass versus 5.0 g]

LV mass versus 5.0 g

[larger fluctuations in QT intervals]

larger fluctuations in QT intervals

[few perioperative deaths in the procedures]

few perioperative deaths in the procedures

[pulmonary arterial hypertension PAH]

pulmonary arterial hypertension PAH

[province of Alberta]

province of Alberta

[Medicare Services CMS]

Medicare Services CMS

[aberrant reactivation]

aberrant reactivation

[destination therapy DT]

destination therapy DT

[target genes]

target genes

[median activities of lyso-PAF-AT]

median activities of lyso-PAF-AT

[hospital in the best quintile]

hospital in the best quintile

[44 men]

44 men

[relationship with adverse cardiovascular CV events]

relationship with adverse cardiovascular CV events

[potentially promising biomarker HF]

potentially promising biomarker HF

[common form of heart failure]

common form of heart failure

[consecutive patients undergoing LVAD implantation]

consecutive patients undergoing LVAD implantation

[Patients With Shortness]

Patients With Shortness

[Global systolic strain]

Global systolic strain

[heart failure patients with spontaneous tachycardia]

heart failure patients with spontaneous tachycardia

[assessment of myocardial function]

assessment of myocardial function

[three readmission metrics all-cause readmission]

three readmission metrics all-cause readmission

[varying strain contributions]

varying strain contributions

[end point of mortality]

end point of mortality

[overexpressing Hand2]

overexpressing Hand2

[moderate-intensity exercise]

moderate-intensity exercise

[rate ratio]

rate ratio

[right ejection fraction R=0.28]

right ejection fraction R=0.28

[coupling in HFPEF]

coupling in HFPEF

[nosignificant changes]

nosignificant changes

[anterior]

anterior

[circulatory arrest]

circulatory arrest

[search]

search

[relationship with CV events]

relationship with CV events

[significant change main effect exercise]

significant change main effect exercise

[pulmonary artery pressure PASP increase]

pulmonary artery pressure PASP increase

[rates of glycolysis]

rates of glycolysis

[(eGFR)-group I mL per m]

(eGFR)-group I mL per m

[cumulative dose]

cumulative dose

[patients with HFpEF for summary]

patients with HFpEF for summary

[symptomatic AI]

symptomatic AI

[ventricular annular plane systolic excursion]

ventricular annular plane systolic excursion

[obstruction of the artery]

obstruction of the artery

[involving the artery]

involving the artery

[resonance T1 time hazard ratio]

resonance T1 time hazard ratio

[levels 100 pg BNP group]

levels 100 pg BNP group

[Global left longitudinal strain]

Global left longitudinal strain

[guanosine]

guanosine

[endopeptidase]

endopeptidase

[kg ip]

kg ip

[median ejection fraction]

median ejection fraction

[pressure development]

pressure development

[delay EMD the time interval]

delay EMD the time interval

[change between performance]

change between performance

[annual ED visits]

annual ED visits

[ml vs. ml]

ml vs. ml

[dearth of trials]

dearth of trials

[phosphodiesterase-2 PDE2]

phosphodiesterase-2 PDE2

[Reversal by metoprolol]

Reversal by metoprolol

[insulin-resistance post-AAC]

insulin-resistance post-AAC

[Patients with an implantable cardioverter-defibrillator]

Patients with an implantable cardioverter-defibrillator

[parasympathetic control]

parasympathetic control

[end-stage renal disease]

end-stage renal disease

[benefit over clinical parameters]

benefit over clinical parameters

[Atherosclerotic Lesions]

Atherosclerotic Lesions

[single-centre trial the effects]

single-centre trial the effects

[correction of valve insufficiency]

correction of valve insufficiency

[ejection fraction in York Heart Association]

ejection fraction in York Heart Association

[beneficial new therapeutic approach]

beneficial new therapeutic approach

[LV mass g P=0.04]

LV mass g P=0.04

[Right RV failure after the insertion]

Right RV failure after the insertion

[home telemonitoring TM with support]

home telemonitoring TM with support

[Defibrillator Implantation With Resynchronization Therapy]

Defibrillator Implantation With Resynchronization Therapy

[association between measurements of CPCs]

association between measurements of CPCs

[evaluations HM using simulation models]

evaluations HM using simulation models

[S1PR1 gene therapy]

S1PR1 gene therapy

[hospital clustering]

hospital clustering

[reporting]

reporting

[PB characteristics]

PB characteristics

[murine equivalent]

murine equivalent

[41-year-old man with arrest]

41-year-old man with arrest

[total of 293]

total of 293

[overall improvements for patients]

overall improvements for patients

[amino-terminal natriuretic peptide]

amino-terminal natriuretic peptide

[attenuation of TAC-induced proteomic alterations]

attenuation of TAC-induced proteomic alterations

[types of continuous-flow LVADs]

types of continuous-flow LVADs

[average follow-up]

average follow-up

[nervous system activity on QTV]

nervous system activity on QTV

[Relationships between ventricular function]

Relationships between ventricular function

[restoring oxidative phosphorylation capacity]

restoring oxidative phosphorylation capacity

[brain peptide levels]

brain peptide levels

[14 clinical studies]

14 clinical studies

[rates by KCCQ category among patients]

rates by KCCQ category among patients

[common forms of left ventricular remodeling]

common forms of left ventricular remodeling

[fragments of N-terminal pro-B-type peptides]

fragments of N-terminal pro-B-type peptides

[patients with advanced disease COPD]

patients with advanced disease COPD

[β-blockers therapy]

β-blockers therapy

[impact on HDL-mediated protective effects]

impact on HDL-mediated protective effects

[transoesophageal echocardiographic guidance under anaesthesia]

transoesophageal echocardiographic guidance under anaesthesia

[LV volume LV end-systolic volume]

LV volume LV end-systolic volume

[having HFrEF]

having HFrEF

[pediatric heart failure]

pediatric heart failure

[angiogenesis in the infarction heart]

angiogenesis in the infarction heart

[years of follow-up 1385]

years of follow-up 1385

[heart mass]

heart mass

[rate constant]

rate constant

[worst versus best quintile]

worst versus best quintile

[insight on the contribution of nursing]

insight on the contribution of nursing

[outcomes of catheter ablation]

outcomes of catheter ablation

[With therapies]

With therapies

[≥60 mL per 1.73 m]

≥60 mL per 1.73 m

[normal systolic function]

normal systolic function

[explaining variation]

explaining variation

[anaerobic metabolism peak quotient]

anaerobic metabolism peak quotient

[14.0 ml vs. ml]

14.0 ml vs. ml

[circumstances common]

circumstances common

[first-in-man evidence for usefulness]

first-in-man evidence for usefulness

[extracellular matrix using resonance T1 mapping]

extracellular matrix using resonance T1 mapping

[diastolic indices E ratio]

diastolic indices E ratio

[preliminary data for health outcomes]

preliminary data for health outcomes

[possible causes]

possible causes

[disease from the general population]

disease from the general population

[Occurrence of HF]

Occurrence of HF

[Treatment a systematic review]

Treatment a systematic review

[main cause of hospitalization]

main cause of hospitalization

[serum factors]

serum factors

[other predictors particularly biomarkers]

other predictors particularly biomarkers

[assessment of body composition]

assessment of body composition

[CHM versus biomedical treatment]

CHM versus biomedical treatment

[study of patients]

study of patients

[60,000 patients across hospitals]

60,000 patients across hospitals

[human systolic HF tissue samples]

human systolic HF tissue samples

[primary endpoint death]

primary endpoint death

[ZSF1 with high-fat diet n=11]

ZSF1 with high-fat diet n=11

[Southeastern Minnesota residents]

Southeastern Minnesota residents

[standard practice for a limited number]

standard practice for a limited number

[neoangiogenesis]

neoangiogenesis

[targeting effector molecules]

targeting effector molecules

[apparent concentration]

apparent concentration

[days after MI]

days after MI

[N fragments]

N fragments

[Aldactone Evaluation Study]

Aldactone Evaluation Study

[control of heart rate]

control of heart rate

[using general linear models]

using general linear models

[Clinical symptoms]

Clinical symptoms

[HF with left ejection fraction]

HF with left ejection fraction

[mortality after hospitalization]

mortality after hospitalization

[Practice rates with enzyme inhibitors]

Practice rates with enzyme inhibitors

[heart failure-related QOL co-primary outcome]

heart failure-related QOL co-primary outcome

[proportion of deficits]

proportion of deficits

[additive effect]

additive effect

[Incubation with HDL NYHA-IIIb]

Incubation with HDL NYHA-IIIb

[decade of heart failure]

decade of heart failure

[HF respectively]

HF respectively

[evidence from 3 trials]

evidence from 3 trials

[consecutive consenting HF patients]

consecutive consenting HF patients

[20 812 patients aged 40 years]

20 812 patients aged 40 years

[highlighting the contribution]

highlighting the contribution

[affecting the levels]

affecting the levels

[studies HM II]

studies HM II

[heart failure patients with tachycardia HFVT(+)]

heart failure patients with tachycardia HFVT(+)

[incident HF in 2825 participants aged]

incident HF in 2825 participants aged

[underlying these defects]

underlying these defects

[diastolic indices]

diastolic indices

[lower total expenditure on health]

lower total expenditure on health

[high-fat diet]

high-fat diet

[Human resistin in chemotherapy-induced heart failure]

Human resistin in chemotherapy-induced heart failure

[resistin levels in breast cancer patients]

resistin levels in breast cancer patients

[excitation-contraction coupling]

excitation-contraction coupling

[role scaffolds in heart pathology]

role scaffolds in heart pathology

[internists]

internists

[inhibition signaling]

inhibition signaling

[trial of Nordic walking]

trial of Nordic walking

[Ser77]

Ser77

[post-TAC]

post-TAC

[global left strain]

global left strain

[complications stroke]

complications stroke

[Rad variant]

Rad variant

[MR-proANP]

MR-proANP

[Effectiveness of medicine as an treatment]

Effectiveness of medicine as an treatment

[Ser83]

Ser83

[ivabradine-treated patients]

ivabradine-treated patients

[acetylcholinesterase inhibitor]

acetylcholinesterase inhibitor

[body mass index strata P]

body mass index strata P

[interval CrI]

interval CrI

[Participation during the development of cardiomyopathy]

Participation during the development of cardiomyopathy

[development among study patients]

development among study patients

[pressure of end-tidal CO2]

pressure of end-tidal CO2

[participants low-dose dopamine]

participants low-dose dopamine

[albumin concentration]

albumin concentration

[effects on macrophages]

effects on macrophages

[treatment of patients]

treatment of patients

[follow-up duration]

follow-up duration

[median exercise-induced PASP increase]

median exercise-induced PASP increase

[implementation interventions]

implementation interventions

[comorbidities such as anemia]

comorbidities such as anemia

[cardiac troponin T]

cardiac troponin T

[402 patients geometry no LV hypertrophy]

402 patients geometry no LV hypertrophy

[odds dying]

odds dying

[requiring revision for valve replacement]

requiring revision for valve replacement

[renal underperfusion resulting]

renal underperfusion resulting

[cation]

cation

[extending EMD with the other aspects]

extending EMD with the other aspects

[resulting in autonomic imbalance]

resulting in autonomic imbalance

[significant effect on quality]

significant effect on quality

[higher serum levels]

higher serum levels

[Systems proteomics]

Systems proteomics

[delay EMD the time]

delay EMD the time

[achieving a moderate level of CRF]

achieving a moderate level of CRF

[early diastolic velocity 3.1]

early diastolic velocity 3.1

[side effects]

side effects

[early-outgrowth colony-forming units]

early-outgrowth colony-forming units

[334 consecutive patients 224 men]

334 consecutive patients 224 men

[Effective arterial elastance Ea elastance Ees]

Effective arterial elastance Ea elastance Ees

[significant difference between groups patients]

significant difference between groups patients

[basic relevance]

basic relevance

[Western blots with antibodies]

Western blots with antibodies

[treatment with SS31]

treatment with SS31

[years P=0.016]

years P=0.016

[circulating NT-proBNP concentration]

circulating NT-proBNP concentration

[metabolism peak quotient]

metabolism peak quotient

[use of nonstandardized pro-B-type peptide]

use of nonstandardized pro-B-type peptide

[N-terminal proBNP midregional proANP]

N-terminal proBNP midregional proANP

[Up test in patients]

Up test in patients

[better understanding]

better understanding

[insight on the contribution]

insight on the contribution

[metabolism respiratory quotient]

metabolism respiratory quotient

[cardiac growth]

cardiac growth

[measurement of flow velocities]

measurement of flow velocities

[vector]

vector

[range muscle wasting]

range muscle wasting

[opposing responses]

opposing responses

[non-survivors 64.26 years vs 72.83]

non-survivors 64.26 years vs 72.83

[4.6 years of follow-up]

4.6 years of follow-up

[failure from restriction]

failure from restriction

[diagnosis of dysfunction leading]

diagnosis of dysfunction leading

[Nonidentification]

Nonidentification

[LV indices]

LV indices

[support on renal function]

support on renal function

[magnetic resonance T1 time]

magnetic resonance T1 time

[including death heart failure]

including death heart failure

[artery pressure increase]

artery pressure increase

[epigenetic erasers]

epigenetic erasers

[Hypertension DASH diet scores]

Hypertension DASH diet scores

[lyso-PAF acetyltransferase]

lyso-PAF acetyltransferase

[urban areas]

urban areas

[Investigating Outcomes in Exercise TraiNing]

Investigating Outcomes in Exercise TraiNing

[worsening renal function in EMPHASIS-HF]

worsening renal function in EMPHASIS-HF

[briefing]

briefing

[follow-up of 10.4 years]

follow-up of 10.4 years

[arterial coupling pulmonary resistance]

arterial coupling pulmonary resistance

[diverse cohort heart failure]

diverse cohort heart failure

[transplant patients receiving PD]

transplant patients receiving PD

[Mena overexpression]

Mena overexpression

[site RIIα]

site RIIα

[recommendation for cardioverter-defibrillator deactivation discussions]

recommendation for cardioverter-defibrillator deactivation discussions

[function with echocardiographic measures]

function with echocardiographic measures

[G-protein coupling]

G-protein coupling

[associations among fitness]

associations among fitness

[abnormalities of different regions]

abnormalities of different regions

[development among patients]

development among patients

[right contractile function]

right contractile function

[patients with s'lateral]

patients with s'lateral

[Doppler]

Doppler

[Key role scaffolds]

Key role scaffolds

[care for patients]

care for patients

[studies approximately 2900 HM II]

studies approximately 2900 HM II

[walk test 6MWT]

walk test 6MWT

[common reasons]

common reasons

[Learning]

Learning

[prospective HF registry]

prospective HF registry

[Heart Function Clinic]

Heart Function Clinic

[similar index]

similar index

[Mechanistic insight into delay]

Mechanistic insight into delay

[stimulation at eNOS-Ser]

stimulation at eNOS-Ser

[detrimental alterations in microstructure]

detrimental alterations in microstructure

[2.1 17.6 mL]

2.1 17.6 mL

[16 controls HDL]

16 controls HDL

[male Wistar rats]

male Wistar rats

[low-volume institutions]

low-volume institutions

[patients with unfavorable outcome median]

patients with unfavorable outcome median

[lower walking distance]

lower walking distance

[stable therapy GDMT]

stable therapy GDMT

[composite endpoint]

composite endpoint

[ventricular pump function]

ventricular pump function

[peak VO2 joint effect]

peak VO2 joint effect

[percent reduction in readmission rate]

percent reduction in readmission rate

[catabolic isoenzymes]

catabolic isoenzymes

[hospitalizations in refractory heart failure]

hospitalizations in refractory heart failure

[major adverse neurological rate]

major adverse neurological rate

[right tricuspid plane systolic excursion]

right tricuspid plane systolic excursion

[global ventricular longitudinal systolic strain GLS]

global ventricular longitudinal systolic strain GLS

[connection]

connection

[group II mL per 1.73 m]

group II mL per 1.73 m

[nitric oxide]

nitric oxide

[parallel with attenuation]

parallel with attenuation

[group II 30 mL]

group II 30 mL

[66 years]

66 years

[lower LVEF]

lower LVEF

[lower gross income]

lower gross income

[16 controls]

16 controls

[ACF in the rat]

ACF in the rat

[detectable change MDC]

detectable change MDC

[Previous studies]

Previous studies

[cardiac metabolic gene expression]

cardiac metabolic gene expression

[strength of race]

strength of race

[potential efficacy]

potential efficacy

[one million people in the UK]

one million people in the UK

[relations in patients]

relations in patients

[≥2 nondiabetes risk factors age]

≥2 nondiabetes risk factors age

[first HF]

first HF

[days range]

days range

[health data]

health data

[β-myosin]

β-myosin

[cardiac support on function]

cardiac support on function

[553 saxagliptin users]

553 saxagliptin users

[Effects of biventricular pacing]

Effects of biventricular pacing

[Implications of choice for applications]

Implications of choice for applications

[for failing hearts]

for failing hearts

[kidney cells overexpressing β1AR]

kidney cells overexpressing β1AR

[underlying characteristics eg]

underlying characteristics eg

[Large-scale multicenter trial with individuals]

Large-scale multicenter trial with individuals

[referral]

referral

[human-to-machine]

human-to-machine

[peptide system]

peptide system

[complex situations in pediatrics]

complex situations in pediatrics

[HFpEF with ventricular ejection fraction]

HFpEF with ventricular ejection fraction

[major cause of death]

major cause of death

[risk of HF mortality]

risk of HF mortality

[patients with acute syndromes]

patients with acute syndromes

[improving quality]

improving quality

[underlying mechanism]

underlying mechanism

[body fat distribution]

body fat distribution

[BTT patients]

BTT patients

[complications of therapy in end-stage HF]

complications of therapy in end-stage HF

[72 studies evaluating 63 predictors]

72 studies evaluating 63 predictors

[CHF-developed animals]

CHF-developed animals

[few consequences]

few consequences

[use of pro-B-type peptide]

use of pro-B-type peptide

[diuretic refractory HF]

diuretic refractory HF

[pulmonary capillary wedge pressure PCWP]

pulmonary capillary wedge pressure PCWP

[clinical effects of 2 types]

clinical effects of 2 types

[BNP in women vs men EF]

BNP in women vs men EF

[treatments targeting abnormal exercise status]

treatments targeting abnormal exercise status

[dearth of clinical trials]

dearth of clinical trials

[benefit with few adverse consequences]

benefit with few adverse consequences

[procedures for]

procedures for

[Q66P]

Q66P

[proximal left descending LAD]

proximal left descending LAD

[2,374,428 ED visits]

2,374,428 ED visits

[Global strain as a major predictor]

Global strain as a major predictor

[other potential predictors]

other potential predictors

[diagnosis of systolic HF]

diagnosis of systolic HF

[high performers]

high performers

[plasma catecholamines]

plasma catecholamines

[patients with ejection fraction HF]

patients with ejection fraction HF

[Multicenter placebo-controlled clinical trial]

Multicenter placebo-controlled clinical trial

[ED visits mean age]

ED visits mean age

[growing population within rehabilitation]

growing population within rehabilitation

[limbs]

limbs

[Autonomic modulation of repolarization instability]

Autonomic modulation of repolarization instability

[44 men without a history]

44 men without a history

[chronic obstructive pulmonary disease COPD]

chronic obstructive pulmonary disease COPD

[observational cohort studies]

observational cohort studies

[good diagnostic performance detecting filling pressures]

good diagnostic performance detecting filling pressures

[Relation between renal dysfunction]

Relation between renal dysfunction

[ejection time in heart failure]

ejection time in heart failure

[years vs 72.83 years]

years vs 72.83 years

[patients with left ejection fraction 0.35]

patients with left ejection fraction 0.35

[Black race in patients]

Black race in patients

[even lower volumes of exercise]

even lower volumes of exercise

[method of aortic constriction TAC]

method of aortic constriction TAC

[topics in paediatric heart failure concern]

topics in paediatric heart failure concern

[Cardiovascular Outcomes in Lesions]

Cardiovascular Outcomes in Lesions

[lung weight in ACF groups]

lung weight in ACF groups

[vascular growth factor VEGF]

vascular growth factor VEGF

[heart failure among persons]

heart failure among persons

[change with treatment]

change with treatment

[mediator of insulin resistance]

mediator of insulin resistance

[low CRF categories]

low CRF categories

[long-term follow-up]

long-term follow-up

[improvement by β-adrenoceptor blockade]

improvement by β-adrenoceptor blockade

[benign tumors]

benign tumors

[diffuse changes]

diffuse changes

[grade systolic]

grade systolic

[Excessive secretion]

Excessive secretion

[derangement albeit with ability]

derangement albeit with ability

[reducing Ea]

reducing Ea

[modifying drug]

modifying drug

[resonance postcontrast]

resonance postcontrast

[months after primary CABG]

months after primary CABG

[functioning of evidence-based treatments]

functioning of evidence-based treatments

[even volumes of exercise]

even volumes of exercise

[severe refractory congestive heart failure]

severe refractory congestive heart failure

[major insulin-signaling components]

major insulin-signaling components

[statistically significant percent reduction]

statistically significant percent reduction

[ventricular longitudinal systolic strain GLS]

ventricular longitudinal systolic strain GLS

[urgent transplant]

urgent transplant

[listing]

listing

[correction after left assist device implantation]

correction after left assist device implantation

[patients with failing Fontan circulation]

patients with failing Fontan circulation

[group 30 mL per m]

group 30 mL per m

[Up TUG test]

Up TUG test

[acute autonomic nervous system modulation]

acute autonomic nervous system modulation

[perhaps the component]

perhaps the component

[Predictive validity]

Predictive validity

[108 HFpEF with left ejection fraction]

108 HFpEF with left ejection fraction

[use HR]

use HR

[rat cardiomyocytes]

rat cardiomyocytes

[mild dysfunction]

mild dysfunction

[protein kinase PKA]

protein kinase PKA

[function in heart failure with function]

function in heart failure with function

[estimating pulmonary capillary wedge pressure]

estimating pulmonary capillary wedge pressure

[measuring NP levels]

measuring NP levels

[special access programme]

special access programme

[ratio of blood pressure]

ratio of blood pressure

[repeat evaluations]

repeat evaluations

[patients with ventricular LV ejection fraction]

patients with ventricular LV ejection fraction

[2825 participants]

2825 participants

[most common reasons]

most common reasons

[contributions of HF-induced remodeling aspects]

contributions of HF-induced remodeling aspects

[early velocity 3.1]

early velocity 3.1

[Comments on the role]

Comments on the role

[cardioverter-defibrillator deactivation discussions A study]

cardioverter-defibrillator deactivation discussions A study

[contractility of the ventricle]

contractility of the ventricle

[A peptides]

A peptides

[diuretic volume overload]

diuretic volume overload

[secondary outcome of death]

secondary outcome of death

[8 days]

8 days

[cardiovascular events in patients]

cardiovascular events in patients

[septum systolic thickness]

septum systolic thickness

[role supporting patients]

role supporting patients

[Campbell]

Campbell

[epigenetic writer proteins]

epigenetic writer proteins

[ventricular ejection fraction LVEF]

ventricular ejection fraction LVEF

[Right Heart Foundation Working Group]

Right Heart Foundation Working Group

[Early physician follow-up]

Early physician follow-up

[participants without prevalent HF]

participants without prevalent HF

[systolic mitral annulus velocity]

systolic mitral annulus velocity

[most powerful predictor]

most powerful predictor

[time-dependent Cox regression analysis]

time-dependent Cox regression analysis

[ventricular annular plane excursion]

ventricular annular plane excursion

[change in stable heart failure]

change in stable heart failure

[cardiac remodelling]

cardiac remodelling

[onset AF]

onset AF

[right dysfunction]

right dysfunction

[23 patients]

23 patients

[other populations]

other populations

[International Classification]

International Classification

[achieving at least a moderate level]

achieving at least a moderate level

[Living]

Living

[6-minute hall]

6-minute hall

[protein kinase signaling downstream]

protein kinase signaling downstream

[risk as patients]

risk as patients

[HF patients HFrEF]

HF patients HFrEF

[Cochrane Practice]

Cochrane Practice

[volumes of exercise below these recommendations]

volumes of exercise below these recommendations

[potential as therapeutic targets]

potential as therapeutic targets

[chronic kidney disease glomerular filtration rate]

chronic kidney disease glomerular filtration rate

[high CRF categories]

high CRF categories

[hospitalizations in heart failure]

hospitalizations in heart failure

[Diagnosis role]

Diagnosis role

[presence of oedema]

presence of oedema

[early beneficial outcomes]

early beneficial outcomes

[most responsible diagnosis]

most responsible diagnosis

[Recommendations for application]

Recommendations for application

[prognostic relevance]

prognostic relevance

[Presentation Society guidelines]

Presentation Society guidelines

[profile of PAF enzymes]

profile of PAF enzymes

[pEF]

pEF

[advanced pulmonary disease]

advanced pulmonary disease

[impact on patients]

impact on patients

[mitral regurgitation MR]

mitral regurgitation MR

[patients in studies]

patients in studies

[diverse cohort with incident]

diverse cohort with incident

[range days]

range days

[five deaths occurring]

five deaths occurring

[replicating resource use from trials]

replicating resource use from trials

[Incidence of end-stage renal disease]

Incidence of end-stage renal disease

[patients 200]

patients 200

[further studies with follow-up]

further studies with follow-up

[loss of SCN5A]

loss of SCN5A

[Age-dependent effect of ejection fraction]

Age-dependent effect of ejection fraction

[tachycardia storm]

tachycardia storm

[signalling pathways activating adaptive remodelling]

signalling pathways activating adaptive remodelling

[catheterisation]

catheterisation

[50 mg daily dose]

50 mg daily dose

[right coupling resistance]

right coupling resistance

[mL in peak VO2]

mL in peak VO2

[Early physician]

Early physician

[including anticoagulation]

including anticoagulation

[334 consecutive patients men]

334 consecutive patients men

[prescribing guideline-recommended medications]

prescribing guideline-recommended medications

[conditioning for patients with heart failure]

conditioning for patients with heart failure

[pre]

pre

[HF patients ejection fraction]

HF patients ejection fraction

[testing of biomarkers]

testing of biomarkers

[add-on features such as early detection]

add-on features such as early detection

[Cytoscape]

Cytoscape

[favorable changes in function]

favorable changes in function

[treadmill testing VO2max oxygen consumption]

treadmill testing VO2max oxygen consumption

[predictors of remodeling]

predictors of remodeling

[G-protein-coupled receptors]

G-protein-coupled receptors

[role in pathogenesis]

role in pathogenesis

[impaired pump function]

impaired pump function

[common consensus regarding the forms]

common consensus regarding the forms

[mm Hg Fig 1B]

mm Hg Fig 1B

[diagnosis ejection fraction]

diagnosis ejection fraction

[acute nervous system modulation]

acute nervous system modulation

[absolute detectable change MDC values]

absolute detectable change MDC values

[refractory end-stage heart failure]

refractory end-stage heart failure

[hand grip strength from baseline]

hand grip strength from baseline

[Large-scale multicenter trial PARADIGM-HF]

Large-scale multicenter trial PARADIGM-HF

[mL increase in VO2max]

mL increase in VO2max

[care group hazard ratio]

care group hazard ratio

[reversal of alterations in microstructure]

reversal of alterations in microstructure

[potential usefulness in such patients]

potential usefulness in such patients

[chemotherapy-induced heart failure in mice]

chemotherapy-induced heart failure in mice

[hand grip strength]

hand grip strength

[sample from the first]

sample from the first

[with.estimates ranging from 1 in 50,000]

with.estimates ranging from 1 in 50,000

[optimal therapy including anticoagulation]

optimal therapy including anticoagulation

[advanced obstructive disease COPD]

advanced obstructive disease COPD

[Remote monitoring a review]

Remote monitoring a review

[odds ratios for cardiovascular events P=0.18]

odds ratios for cardiovascular events P=0.18

[maximal exercise test]

maximal exercise test

[defibrillator-only therapy HR]

defibrillator-only therapy HR

[hRetn human resistin]

hRetn human resistin

[settings for management]

settings for management

[smallest difference among EF]

smallest difference among EF

[follow-up with cardiology services]

follow-up with cardiology services

[good performance detecting normal filling pressures]

good performance detecting normal filling pressures

[GDMT treatment group for months]

GDMT treatment group for months

[transcriptional analysis of tissue from mice]

transcriptional analysis of tissue from mice

[Stage chronic kidney disease]

Stage chronic kidney disease

[various forms of NT-proBNP]

various forms of NT-proBNP

[HF hospital]

HF hospital

[disease modifying drug]

disease modifying drug

[atrial area 20 cm]

atrial area 20 cm

[result of congenital lesions]

result of congenital lesions

[systemic blood pressure]

systemic blood pressure

[types HeartMate for BTT patients]

types HeartMate for BTT patients

[chronic β-adrenergic receptor stimulation]

chronic β-adrenergic receptor stimulation

[improvements in clinical composite response]

improvements in clinical composite response

[global left ventricular strain GLS]

global left ventricular strain GLS

[medical staff responsible for patient care]

medical staff responsible for patient care

[patients short-term treatment]

patients short-term treatment

[prognostic information for an unfavourable outcome]

prognostic information for an unfavourable outcome

[with long axis function]

with long axis function

[implantable arrhythmia devices]

implantable arrhythmia devices

[control of the heart]

control of the heart

[well-recognised risk factor]

well-recognised risk factor

[venous pressure 18]

venous pressure 18

[fat free mass]

fat free mass

[evaluations HM II using simulation models]

evaluations HM II using simulation models

[hypertrophy a predictor of HF]

hypertrophy a predictor of HF

[forms of ventricular remodeling]

forms of ventricular remodeling

[abnormalities of regions]

abnormalities of regions

[effects on various processes]

effects on various processes

[elevations NT-proBNP levels]

elevations NT-proBNP levels

[ventricular area change]

ventricular area change

[patients as control]

patients as control

[infarction-both n]

infarction-both n

[strain RS]

strain RS

[Doppler echocardiography]

Doppler echocardiography

[Ventricular Assist System Treating HF]

Ventricular Assist System Treating HF

[time span]

time span

[significant improvement in effective rate]

significant improvement in effective rate

[ultimately targeting effector molecules]

ultimately targeting effector molecules

[central blood pressure]

central blood pressure

[circumflex artery]

circumflex artery

[anterior descending artery]

anterior descending artery

[improvements in shuttle walk test]

improvements in shuttle walk test

[LV indices LV ejection fraction]

LV indices LV ejection fraction

[good performance only in patients]

good performance only in patients

[saxagliptin versus sulfonylureas]

saxagliptin versus sulfonylureas

[symptoms despite maximal treatment]

symptoms despite maximal treatment

[ventricular tricuspid plane systolic excursion]

ventricular tricuspid plane systolic excursion

[reality]

reality

[adverse neurological rate]

adverse neurological rate

[factor in heart failure]

factor in heart failure

[3 pharmacologic studies of therapeutics]

3 pharmacologic studies of therapeutics

[chronic stable therapy GDMT]

chronic stable therapy GDMT

[Impact of frailty]

Impact of frailty

[fetal gene program]

fetal gene program

[history with coronary arteries]

history with coronary arteries

[ranging in 50,000]

ranging in 50,000

[prognostic benefit over clinical parameters]

prognostic benefit over clinical parameters

[activation PKC-βII by HDL NYHA-IIIb]

activation PKC-βII by HDL NYHA-IIIb

[non-AAs with York Heart Association NYHA]

non-AAs with York Heart Association NYHA

[cardiac Mena overexpression TTA]

cardiac Mena overexpression TTA

[Fifty consecutive patients with recent onset]

Fifty consecutive patients with recent onset

[brain peptide levels 100 pg]

brain peptide levels 100 pg

[pharmacologic targets]

pharmacologic targets

[need for statistical standards]

need for statistical standards

[global left ventricular systolic strain]

global left ventricular systolic strain

[ventricular area index]

ventricular area index

[years for patients respectively]

years for patients respectively

[beneficial new approach]

beneficial new approach

[echocardiographic predictors]

echocardiographic predictors

[current knowledge on diuretic use]

current knowledge on diuretic use

[demonstrating development following ring annuloplasty]

demonstrating development following ring annuloplasty

[proximal anterior descending]

proximal anterior descending

[patients with LV ejection fraction]

patients with LV ejection fraction

[Bioinformatic analysis]

Bioinformatic analysis

[unfavorable outcome vs 257 milliseconds]

unfavorable outcome vs 257 milliseconds

[downregulation of multiple genes]

downregulation of multiple genes

[ICD patients]

ICD patients

[still a agent]

still a agent

[mortality after hospitalization for HF]

mortality after hospitalization for HF

[ejection fraction 0.35]

ejection fraction 0.35

[single-arm analysis]

single-arm analysis

[crude case-fatality rate for patients]

crude case-fatality rate for patients

[fatty]

fatty

[Witness with anemia]

Witness with anemia

[VEGF expression]

VEGF expression

[variation in rates for outpatients]

variation in rates for outpatients

[ventricular ejection time complicating precapillary hypertension]

ventricular ejection time complicating precapillary hypertension

[undergoing heart transplant]

undergoing heart transplant

[quality of life HRQoL]

quality of life HRQoL

[cardiac stress]

cardiac stress

[mm for psoriasis]

mm for psoriasis

[improvements in NYHA classification]

improvements in NYHA classification

[low apparent concentration]

low apparent concentration

[National trends]

National trends

[frequent comorbidities]

frequent comorbidities

[choice for applications]

choice for applications

[mechanical support on function]

mechanical support on function

[thirty-seven hospitals nationwide through September]

thirty-seven hospitals nationwide through September

[different types]

different types

[ATPase]

ATPase

[disappointments in phase]

disappointments in phase

[including agents of endothelin]

including agents of endothelin

[MicroRNAs in heart failure new targets]

MicroRNAs in heart failure new targets

[important role for microRNAs]

important role for microRNAs

[patients with arthritis]

patients with arthritis

[risk of adverse outcomes in patients]

risk of adverse outcomes in patients

[Bax proteins]

Bax proteins

[requiring revision]

requiring revision

[miR-25 by a antagomir]

miR-25 by a antagomir

[per cent with deaths]

per cent with deaths

[ejection fraction P]

ejection fraction P

[predicting adverse CV events in models]

predicting adverse CV events in models

[two thirds of patients]

two thirds of patients

[right mass removal]

right mass removal

[Impact after discharge among patients]

Impact after discharge among patients

[increase in lung weight P]

increase in lung weight P

[cause in athletes]

cause in athletes

[pediatric mechanical support]

pediatric mechanical support

[CV events in fibrillation]

CV events in fibrillation

[glucocorticoid dosage prior HF hospitalisations]

glucocorticoid dosage prior HF hospitalisations

[adverse events evaluation]

adverse events evaluation

[HF under drug treatment]

HF under drug treatment

[human embryonic kidney 293 cells]

human embryonic kidney 293 cells

[option in congestive heart failure]

option in congestive heart failure

[heart failure visits]

heart failure visits

[cytoskeletal actin dynamics]

cytoskeletal actin dynamics

[group with mortality]

group with mortality

[risk of arrhythmia events]

risk of arrhythmia events

[furosemide dose]

furosemide dose

[prognostic relevance of right ventricular reserve]

prognostic relevance of right ventricular reserve

[protein kinase A]

protein kinase A

[effects on effective rate]

effects on effective rate

[predictors of reverse remodeling]

predictors of reverse remodeling

[18 years]

18 years

[assist device with ventricular support]

assist device with ventricular support

[multivariable adjustment hazard ratio]

multivariable adjustment hazard ratio

[Eighty-one percent]

Eighty-one percent

[device-related events]

device-related events

[progression of HF]

progression of HF

[alterations in microstructure]

alterations in microstructure

[using the implementation]

using the implementation

[surrogates for changes During RVPO]

surrogates for changes During RVPO

[model using simple procedures]

model using simple procedures

[Using Cox regression analysis]

Using Cox regression analysis

[GLS HR]

GLS HR

[ventricular-pulmonary coupling vascular resistance]

ventricular-pulmonary coupling vascular resistance

[protection from responses]

protection from responses

[somewhat better information than the others]

somewhat better information than the others

[age of the entire cohort]

age of the entire cohort

[HR 1.54]

HR 1.54

[HR 1.58]

HR 1.58

[net savings]

net savings

[value for heart failure]

value for heart failure

[odds of future July]

odds of future July

[foundation describing a nomenclature]

foundation describing a nomenclature

[group IV 15 mL]

group IV 15 mL

[p38α]

p38α

[heart transplantation OHT]

heart transplantation OHT

[monitoring after hospital discharge a review]

monitoring after hospital discharge a review

[6 fragments]

6 fragments

[acute infarction AMI with complications]

acute infarction AMI with complications

[HR 1.41]

HR 1.41

[HR 1.46]

HR 1.46

[clinical studies 2900 HM]

clinical studies 2900 HM

[thereby decreasing risk]

thereby decreasing risk

[IRS2 double-knockout mice]

IRS2 double-knockout mice

[entry 237 milliseconds]

entry 237 milliseconds

[detrimental alterations in SkM structure]

detrimental alterations in SkM structure

[effectiveness of herbal medicine CHM]

effectiveness of herbal medicine CHM

[univariate models]

univariate models

[Olmsted County]

Olmsted County

[RV decompensation]

RV decompensation

[Outcomes in Exercise TraiNing HF-ACTION]

Outcomes in Exercise TraiNing HF-ACTION

[Comment on Baroreflex Activation Therapy]

Comment on Baroreflex Activation Therapy

[pathway alterations]

pathway alterations

[thereby presumably decreasing risk]

thereby presumably decreasing risk

[regulatory subunit]

regulatory subunit

[previous spironolactone use]

previous spironolactone use

[impact of heart resonance imaging]

impact of heart resonance imaging

[patients with low co-morbidity burden]

patients with low co-morbidity burden

[patients with onset]

patients with onset

[Tools A program]

Tools A program

[indices E]

indices E

[index L]

index L

[combination of annular size reduction]

combination of annular size reduction

[Robot-assisted training]

Robot-assisted training

[180 days]

180 days

[diagnosis of myocarditis]

diagnosis of myocarditis

[potential for effects on processes]

potential for effects on processes

[potential usefulness in HF]

potential usefulness in HF

[implications of biomarkers in heart failure]

implications of biomarkers in heart failure

[Six thousand five hundred hospitals nationwide]

Six thousand five hundred hospitals nationwide

[meeting specific inclusion]

meeting specific inclusion

[discussions about end-of-life treatment preferences]

discussions about end-of-life treatment preferences

[genes DEGs]

genes DEGs

[ventricular-pulmonary arterial coupling pulmonary resistance]

ventricular-pulmonary arterial coupling pulmonary resistance

[success in trials]

success in trials

[identifying hospitals]

identifying hospitals

[higher rates of hyperkalemia]

higher rates of hyperkalemia

[hypotheses addition of dopamine μg]

hypotheses addition of dopamine μg

[CI for early HF]

CI for early HF

[right arterial coupling vascular resistance]

right arterial coupling vascular resistance

[inhibition by a Rad variant]

inhibition by a Rad variant

[Practice-level variation]

Practice-level variation, practice-level variation

[myocardial n]

myocardial n

[heart failure in male mice]

heart failure in male mice

[diagnostic devices]

diagnostic devices

[distinct derangement with hemodynamic features]

distinct derangement with hemodynamic features

[patients with ventricular ejection fraction HF]

patients with ventricular ejection fraction HF

[effect of LVEF]

effect of LVEF

[42.4 g]

42.4 g

[effective off-pump sparing approach]

effective off-pump sparing approach

[variation in rates of treatment]

variation in rates of treatment

[One-year event-free rates by KCCQ category]

One-year event-free rates by KCCQ category

[Heart Failure Questionnaire]

Heart Failure Questionnaire

[common elements of interventions]

common elements of interventions

[findings of rheumatic causes]

findings of rheumatic causes

[brain peptide BNP levels pg]

brain peptide BNP levels pg

[Usefulness of resynchronization therapy in patients]

Usefulness of resynchronization therapy in patients

[24 telephone support STS]

24 telephone support STS

[mRNA splicing]

mRNA splicing

[man with arrest]

man with arrest

[using International Classification]

using International Classification

[medical staff]

medical staff

[using three metrics]

using three metrics

[MLHF score]

MLHF score

[useful tool for assessment]

useful tool for assessment

[component improving quality]

component improving quality

[lack of improvement]

lack of improvement

[ED visits 32,036]

ED visits 32,036

[account]

account

[myocyte-specific Mena overexpression]

myocyte-specific Mena overexpression

[106 outcomes]

106 outcomes

[state like South Dakota]

state like South Dakota

[exercise patients]

exercise patients

[use of pro-B-type peptide NT-proBNP]

use of pro-B-type peptide NT-proBNP

[differential effect of LVEF]

differential effect of LVEF

[three variants consistent]

three variants consistent

[patients HDL before ET]

patients HDL before ET

[few PDrelated complications]

few PDrelated complications

[10 lb in year]

10 lb in year

[type regulatory catalytic subunit expression]

type regulatory catalytic subunit expression

[dying in 30 days P-value 0.001]

dying in 30 days P-value 0.001

[LV myocytes]

LV myocytes

[undergoing LVAD implantation at institution]

undergoing LVAD implantation at institution

[involving the proximal artery]

involving the proximal artery

[ventricular RV tricuspid plane excursion TAPSE]

ventricular RV tricuspid plane excursion TAPSE

[Renal denervation in CHF patients]

Renal denervation in CHF patients

[factor in cardiovascular diseases]

factor in cardiovascular diseases

[telephone support STS]

telephone support STS

[myocardial T1]

myocardial T1

[strain CS]

strain CS

[heart rate variation]

heart rate variation

[alterations by the peptide SS31]

alterations by the peptide SS31

[effects of HRQoL]

effects of HRQoL

[value in HF risk prediction]

value in HF risk prediction

[cardiac rehabilitation care on functional capacity]

cardiac rehabilitation care on functional capacity

[prognosis of a cohort]

prognosis of a cohort

[self-reported activity]

self-reported activity

[RV fiber shortening]

RV fiber shortening

[comorbid conditions]

comorbid conditions

[benefit for patients in studies]

benefit for patients in studies

[York Heart Association class I]

York Heart Association class I

[loss of IRS1]

loss of IRS1

[Sudden cardiac death in athletes]

Sudden cardiac death in athletes

[70 bpm 17.5±5.5 respectively P]

70 bpm 17.5±5.5 respectively P

[HR 70 versus ≥70]

HR 70 versus ≥70

[lower rate of ATP]

lower rate of ATP

[PAF]

PAF

[series]

series

[heart failure in patients presenting]

heart failure in patients presenting

[including lower risk]

including lower risk

[high relevance]

high relevance

[130 patients with a ejection fraction]

130 patients with a ejection fraction

[novel strategy]

novel strategy

[more hypokalemia]

more hypokalemia

[cardiopulmonary resuscitation CPR]

cardiopulmonary resuscitation CPR

[patients 209 HFrEF]

patients 209 HFrEF

[extensive characterization of one]

extensive characterization of one

[physiological proteolysis]

physiological proteolysis

[short-term treatment with ivabradine exercise capacity]

short-term treatment with ivabradine exercise capacity

[rEF]

rEF

[Heart Foundation Working Group]

Heart Foundation Working Group

[Defibrillator Implantation Resynchronization Therapy]

Defibrillator Implantation Resynchronization Therapy

[Dobutamine]

Dobutamine, dobutamine

[symptoms of heart failure despite treatment]

symptoms of heart failure despite treatment

[lower volumes of exercise]

lower volumes of exercise

[higher BNP levels with the difference]

higher BNP levels with the difference

[Median age of the cohort]

Median age of the cohort

[Web-system in Heart disease]

Web-system in Heart disease

[results in acute HF trials]

results in acute HF trials

[mild heart failure patients]

mild heart failure patients

[training period with trainings]

training period with trainings

[3 mg]

3 mg

[thus providing prognostic information]

thus providing prognostic information

[Fifty-four Fontan patients]

Fifty-four Fontan patients

[Systolic vEntricular dysfunction]

Systolic vEntricular dysfunction

[incidence outcomes]

incidence outcomes

[LCZ696]

LCZ696

[trigger of infarction]

trigger of infarction

[recognition of advanced disease]

recognition of advanced disease

[24-hour systolic pressure 155]

24-hour systolic pressure 155

[dyssynchronous nonfailing canine electromechanics]

dyssynchronous nonfailing canine electromechanics

[important cause]

important cause

[oxygen pulse range]

oxygen pulse range

[important component improving quality]

important component improving quality

[MPSMS]

MPSMS

[consequence of remodelling]

consequence of remodelling

[risk factor for outcomes]

risk factor for outcomes

[patients IL 0.5 mg]

patients IL 0.5 mg

[receptor β-AR signaling]

receptor β-AR signaling

[potential therapeutic implications of biomarkers]

potential therapeutic implications of biomarkers

[mitochondrial V activity]

mitochondrial V activity

[biomarkers hsCRP]

biomarkers hsCRP

[databases including MEDLINE]

databases including MEDLINE

[resistance P]

resistance P

[epidemic of heart failure]

epidemic of heart failure

[effects on beta-adrenergic receptor signaling]

effects on beta-adrenergic receptor signaling

[amino-terminal pro-B-type peptide]

amino-terminal pro-B-type peptide

[Investigating Outcomes]

Investigating Outcomes

[such as myocardial infarction]

such as myocardial infarction

[injections]

injections

[cardiotoxicity among older patients]

cardiotoxicity among older patients

[diastolic indices E ratio at diastole]

diastolic indices E ratio at diastole

[dramatic induction of hRetn resistin mRNA]

dramatic induction of hRetn resistin mRNA

[meeting inclusion including an eGFR]

meeting inclusion including an eGFR

[excellent risk stratification]

excellent risk stratification

[decreasing risk of HF mortality]

decreasing risk of HF mortality

[patients in small studies]

patients in small studies

[quality measures for common inpatient conditions]

quality measures for common inpatient conditions

[Health Organization]

Health Organization

[left dilatation]

left dilatation

[Many studies]

Many studies

[disease in outpatients]

disease in outpatients

[right coupling vascular resistance P]

right coupling vascular resistance P

[Results from the propensity analyses]

Results from the propensity analyses

[midpapillary level]

midpapillary level

[determining the remodelling]

determining the remodelling

[culprit]

culprit

[Titin]

Titin

[strong mortality predictors in ICD-HF patients]

strong mortality predictors in ICD-HF patients

[users of a nbDMARD]

users of a nbDMARD

[Genetic susceptibility]

Genetic susceptibility

[timing of patient enrollment]

timing of patient enrollment

[negative regression models]

negative regression models

[hypo-response]

hypo-response

[use within the time frame]

use within the time frame

[cardiac resynchronization therapy in patients]

cardiac resynchronization therapy in patients

[heart failure prone]

heart failure prone

[myocardial angiogenesis]

myocardial angiogenesis

[STE analysis of strain CS]

STE analysis of strain CS

[successful valve plasty for MR]

successful valve plasty for MR

[member]

member

[hospital rates for HF patients]

hospital rates for HF patients

[baseline ST2 level]

baseline ST2 level

[saxagliptin for saxagliptin]

saxagliptin for saxagliptin

[lower von Willebrand factor concentrations]

lower von Willebrand factor concentrations

[individual contributions]

individual contributions

[human left LV myocytes]

human left LV myocytes

[large low-risk group]

large low-risk group

[mg dose of metoprolol succinate]

mg dose of metoprolol succinate

[β-blocker dose]

β-blocker dose

[especially in people]

especially in people

[trichrome]

trichrome

[records of patients]

records of patients

[Thirteen patients]

Thirteen patients

[blots with site-specific antibodies]

blots with site-specific antibodies

[cardiac plasma membrane levels]

cardiac plasma membrane levels

[HeartMate insertion]

HeartMate insertion

[prognostic relevance of contractile reserve]

prognostic relevance of contractile reserve

[right coupling pulmonary resistance]

right coupling pulmonary resistance

[VA patients]

VA patients

[high morbidity in elderly people]

high morbidity in elderly people

[history of fibrillation]

history of fibrillation

[repeat procedures]

repeat procedures

[coupling pulmonary resistance]

coupling pulmonary resistance

[presence of scale dimensions]

presence of scale dimensions

[fragments of NT-proBNP]

fragments of NT-proBNP

[higher-than-expected rates]

higher-than-expected rates

[Effect of inhibition on hemodynamic status]

Effect of inhibition on hemodynamic status

[effective evidence-based therapies]

effective evidence-based therapies

[Functional stimulation of muscles]

Functional stimulation of muscles

[4 suburban hospitals]

4 suburban hospitals

[cardiomyopathies]

cardiomyopathies

[Psychosocial Factors Insights A Trial]

Psychosocial Factors Insights A Trial

[survival in patients requiring LVAD]

survival in patients requiring LVAD

[respectively P for trend]

respectively P for trend

[Medicare Services]

Medicare Services

[abundance]

abundance

[2900 HM]

2900 HM

[Mena overexpression comparable]

Mena overexpression comparable

[chronic ACF]

chronic ACF

[120 patients with PAD]

120 patients with PAD

[role in cardiac pathophysiology]

role in cardiac pathophysiology

[HFpEF population]

HFpEF population

[Occurrence of HF within 90 days]

Occurrence of HF within 90 days

[differential response in cardiac activity]

differential response in cardiac activity

[Screening patients for RAS]

Screening patients for RAS

[various diseases]

various diseases

[HF risk factors including risk]

HF risk factors including risk

[57±22 months]

57±22 months

[inoperable pulmonary hypertension]

inoperable pulmonary hypertension

[playing a major role in patients]

playing a major role in patients

[GDMT alone]

GDMT alone

[Unidirectional left-to-right interatrial shunting for treatment]

Unidirectional left-to-right interatrial shunting for treatment

[early mitral velocity 3.1 vs. 1.3]

early mitral velocity 3.1 vs. 1.3

[restorative effects of cocoa]

restorative effects of cocoa

[log2 ng]

log2 ng

[quality QOL]

quality QOL

[812 patients aged 40 years]

812 patients aged 40 years

[rural South Dakota]

rural South Dakota

[patients with chronic pulmonary disease]

patients with chronic pulmonary disease

[low eGFR]

low eGFR

[results of studies]

results of studies

[markers hazard ratio for peak o2]

markers hazard ratio for peak o2

[lower expenditure on health]

lower expenditure on health

[independent predictors of CAD]

independent predictors of CAD

[avoiding the region of this molecule]

avoiding the region of this molecule

[circulating mediator]

circulating mediator

[improvement of cardiac performance at stages]

improvement of cardiac performance at stages

[other staff responsible]

other staff responsible

[circumferential strain]

circumferential strain

[resulting in the support score PSSS]

resulting in the support score PSSS

[HR bpm]

HR bpm

[function in pediatric heart failure]

function in pediatric heart failure

[array of procedures for]

array of procedures for

[first-in-man evidence]

first-in-man evidence

[index of ventricular contractile function]

index of ventricular contractile function

[deleterious effects]

deleterious effects

[fat body mass ratio]

fat body mass ratio

[continuous relationship between QRS]

continuous relationship between QRS

[nomenclature]

nomenclature

[LV pressure of mm]

LV pressure of mm

[subscales]

subscales

[62 care clinicians caring]

62 care clinicians caring

[consecutive patients men 65±12 years]

consecutive patients men 65±12 years

[first myocardial infarction in Australia]

first myocardial infarction in Australia

[quantitative analysis]

quantitative analysis

[World Health Organization criteria]

World Health Organization criteria

[ventricular pacing]

ventricular pacing

[antioxidant]

antioxidant

[beneficial effects of HRQoL]

beneficial effects of HRQoL

[health per capita]

health per capita

[cause of nontraumatic death]

cause of nontraumatic death

[indicator in heart failure HF]

indicator in heart failure HF

[regarding conditions in Turkey]

regarding conditions in Turkey

[Cox models]

Cox models

[evidence of diastolic dysfunction LV relaxation]

evidence of diastolic dysfunction LV relaxation

[coupling vascular resistance P]

coupling vascular resistance P

[promoting pause release during pathological stress]

promoting pause release during pathological stress

[low systemic resistance index]

low systemic resistance index

[lean body mass]

lean body mass

[excitation-contraction EC coupling]

excitation-contraction EC coupling

[Right RV failure]

Right RV failure

[ventricular end diameter mean difference]

ventricular end diameter mean difference

[TRPM7]

TRPM7

[composite response P=0.02]

composite response P=0.02

[infarction a community study]

infarction a community study

[effective therapies]

effective therapies

[Patients with an cardioverter-defibrillator]

Patients with an cardioverter-defibrillator

[heart failure HR]

heart failure HR

[little influence]

little influence

[follow-up of 2.5 years]

follow-up of 2.5 years

[ventricular end-diastolic area index]

ventricular end-diastolic area index

[growth factor protein]

growth factor protein

[blood pressure via radial tonometry]

blood pressure via radial tonometry

[change with treatment in exertional increase]

change with treatment in exertional increase

[patients requiring support]

patients requiring support

[artery systolic pressure increase]

artery systolic pressure increase

[hospitalization for coronary syndromes]

hospitalization for coronary syndromes

[days of follow-up]

days of follow-up

[achievement of anaerobic metabolism]

achievement of anaerobic metabolism

[reductions in the number from baseline]

reductions in the number from baseline

[patients having HFpEF]

patients having HFpEF

[outcomes events]

outcomes events

[925 ED visits age 76.4 years]

925 ED visits age 76.4 years

[angiotensin receptor blocker use]

angiotensin receptor blocker use

[markers hazard ratio]

markers hazard ratio

[renin-angiotensin system blocker]

renin-angiotensin system blocker

[treatment of cancers]

treatment of cancers

[comparisons significant]

comparisons significant

[LV ejection fraction LVEF]

LV ejection fraction LVEF

[selective beta-blockers on cardiac activity]

selective beta-blockers on cardiac activity

[attenuation of mitochondrial proteome changes]

attenuation of mitochondrial proteome changes

[1:1 propensity analyses]

1:1 propensity analyses

[2 hypotheses addition of dopamine]

2 hypotheses addition of dopamine

[proangiogenic effects via activation]

proangiogenic effects via activation

[100 older participants mean]

100 older participants mean

[ratio at diastole]

ratio at diastole

[transseptal catheterisation]

transseptal catheterisation

[type 2 receptor antagonist]

type 2 receptor antagonist

[important trigger of myocardial infarction]

important trigger of myocardial infarction

[stimulation of muscles]

stimulation of muscles

[Prospective pilot project]

Prospective pilot project

[volunteers--a pilot study]

volunteers--a pilot study

[denervation in CHF patients]

denervation in CHF patients

[dopamine in heart failure]

dopamine in heart failure

[hospital rates]

hospital rates

[thus giving rise]

thus giving rise

[improvements in clinical composite response P=0.02]

improvements in clinical composite response P=0.02

[range with advanced COPD]

range with advanced COPD

[left ventricular strain GLS]

left ventricular strain GLS

[diuretic use]

diuretic use

[mouse ventricular myocytes]

mouse ventricular myocytes

[stable guideline-directed medical therapy GDMT]

stable guideline-directed medical therapy GDMT

[insulin exposure]

insulin exposure

[heart circulation]

heart circulation

[cardiac activity in patients]

cardiac activity in patients

[other clinicians]

other clinicians

[remaining in extreme deciles]

remaining in extreme deciles

[clinical models]

clinical models

[brachial systolic pressure 155]

brachial systolic pressure 155

[0.2 mL in peak VO2]

0.2 mL in peak VO2

[cardioprotective effect]

cardioprotective effect

[Modification codes]

Modification codes

[lesions in the branches]

lesions in the branches

[change with exercise]

change with exercise

[antitachycardia pacing]

antitachycardia pacing

[Health Buddy]

Health Buddy

[problem with high mortality]

problem with high mortality

[Affairs HF clinic]

Affairs HF clinic

[trigger of acute infarction]

trigger of acute infarction

[Utilizing voluntary testimonies with nurses]

Utilizing voluntary testimonies with nurses

[metoprolol mg]

metoprolol mg

[decisions about cardioverter-defibrillator deactivation]

decisions about cardioverter-defibrillator deactivation

[increase in LV pressure P]

increase in LV pressure P

[24-hour systolic pressure 155 35]

24-hour systolic pressure 155 35

[infarction AMI with major complications]

infarction AMI with major complications

[concentrating on the mechanisms]

concentrating on the mechanisms

[other pre-specified subgroup analyses]

other pre-specified subgroup analyses

[class I CPG recommendations]

class I CPG recommendations

[component improving quality of care]

component improving quality of care

[risk factor for disease]

risk factor for disease

[most subjects]

most subjects

[POC systems measuring NP levels]

POC systems measuring NP levels

[patients with HR 70 bpm]

patients with HR 70 bpm

[Sham-Innervated]

Sham-Innervated

[quantification]

quantification

[proangiogenic effects]

proangiogenic effects

[long-term continuity]

long-term continuity

[describing a nomenclature for failure]

describing a nomenclature for failure

[transplant ECCT programs]

transplant ECCT programs

[promoting pause release]

promoting pause release

[several markers indicative of balance]

several markers indicative of balance

[ejection fraction mean difference]

ejection fraction mean difference

[greater self-reported activity]

greater self-reported activity

[direct interaction between these receptors]

direct interaction between these receptors

[global left systolic strain]

global left systolic strain

[important trigger]

important trigger

[late-activated wall]

late-activated wall

[response in sympathetic activity]

response in sympathetic activity

[countries including the States]

countries including the States

[single-center chart review]

single-center chart review

[symptom CPET in patients]

symptom CPET in patients

[conscious New Zealand White rabbits]

conscious New Zealand White rabbits

[pluripotent stem cardiomyocytes hiPSC-CMs]

pluripotent stem cardiomyocytes hiPSC-CMs

[severe ventricular dilatation]

severe ventricular dilatation

[differential relations between CPCs]

differential relations between CPCs

[pulmonary artery pressure increase]

pulmonary artery pressure increase

[7 days in this trial]

7 days in this trial

[care group]

care group

[parallel-group trial]

parallel-group trial

[impact on quality HRQoL]

impact on quality HRQoL

[anterior leaflet opening]

anterior leaflet opening

[17.6 mL 2 P=0.01]

17.6 mL 2 P=0.01

[potential of miRNAs]

potential of miRNAs

[pro-brain peptide]

pro-brain peptide

[ischemic cardiomyopathies]

ischemic cardiomyopathies

[stable guideline-directed therapy GDMT]

stable guideline-directed therapy GDMT

[dyssynchronous canine electromechanics]

dyssynchronous canine electromechanics

[normal albumin concentration g]

normal albumin concentration g

[reports demonstrating development]

reports demonstrating development

[Dual inhibition]

Dual inhibition

[chronic therapy GDMT]

chronic therapy GDMT

[trend toward enrollment of patients]

trend toward enrollment of patients

[trials in adults]

trials in adults

[64.26 years]

64.26 years

[modification of PKA subunits]

modification of PKA subunits

[HR reduction with beta-blocker therapy]

HR reduction with beta-blocker therapy

[stimulation of phosphorylation]

stimulation of phosphorylation

[heart failure risk stratification models]

heart failure risk stratification models

[full advantage of the turnaround times]

full advantage of the turnaround times

[bpm 17.5±5.5 versus mL]

bpm 17.5±5.5 versus mL

[kidney disease median filtration rate]

kidney disease median filtration rate

[RAS dose increase]

RAS dose increase

[ischaemia]

ischaemia

[genes in HF]

genes in HF

[difference BNP in women vs men]

difference BNP in women vs men

[arterial coupling vascular resistance P]

arterial coupling vascular resistance P

[endothelial growth factor VEGF]

endothelial growth factor VEGF

[individuals with chronic heart failure]

individuals with chronic heart failure

[transmitral E-wave mitral annular velocity ratio]

transmitral E-wave mitral annular velocity ratio

[hazard ratio in univariate analyses]

hazard ratio in univariate analyses

[left descending LAD]

left descending LAD

[class NYHA II-III with BNP]

class NYHA II-III with BNP

[care POC]

care POC

[mg·kg(-1)·day(-1)]

mg·kg(-1)·day(-1)

[new AI]

new AI

[regulator of cytoskeletal actin dynamics]

regulator of cytoskeletal actin dynamics

[survival through years]

survival through years

[Emergency Department presentation]

Emergency Department presentation

[additional models]

additional models

[effectiveness of bisoprolol]

effectiveness of bisoprolol

[improvement of performance at advanced stages]

improvement of performance at advanced stages

[elastance Ees]

elastance Ees

[addition prior stroke score]

addition prior stroke score

[successful valve plasty for regurgitation]

successful valve plasty for regurgitation

[Akt→forkhead box class]

Akt→forkhead box class

[range muscle wasting T-score]

range muscle wasting T-score

[Systems proteomics of chromatin]

Systems proteomics of chromatin

[deaths occurring]

deaths occurring

[mm Hg SD]

mm Hg SD

[plasma B-type natriuretic peptide]

plasma B-type natriuretic peptide

[mandatory monitoring of LVAD use]

mandatory monitoring of LVAD use

[blood pressure via tonometry]

blood pressure via tonometry

[playing a role particularly in patients]

playing a role particularly in patients

[relative lean mass index]

relative lean mass index

[Relationships between right function]

Relationships between right function

[catecholamine infusions]

catecholamine infusions

[ST2 levels A Trial]

ST2 levels A Trial

[clinical burden in adult medicine]

clinical burden in adult medicine

[HeartMate 3 assist system]

HeartMate 3 assist system

[exercise capacity in older patients]

exercise capacity in older patients

[patients with coronary syndromes]

patients with coronary syndromes

[economic evaluations using simulation models]

economic evaluations using simulation models

[modest reduction]

modest reduction

[abdominal constriction AAC]

abdominal constriction AAC

[knockdown of nucleolin]

knockdown of nucleolin

[inhibition of AT1 receptors]

inhibition of AT1 receptors

[lower national income per capita]

lower national income per capita

[modest benefit for patients]

modest benefit for patients

[diastolic end diameter mm difference]

diastolic end diameter mm difference

[aldosterone antagonist therapy]

aldosterone antagonist therapy

[Functional stimulation of peripheral muscles]

Functional stimulation of peripheral muscles

[9 subjects]

9 subjects

[post-TAC functional deterioration]

post-TAC functional deterioration

[abnormal exercise status]

abnormal exercise status

[information on implantable cardioverter-defibrillator deactivation]

information on implantable cardioverter-defibrillator deactivation

[fewer procedures 146]

fewer procedures 146

[rates of hyperkalemia potassium]

rates of hyperkalemia potassium

[factor-κB NF-κB]

factor-κB NF-κB

[left strain as a predictor]

left strain as a predictor

[drugs in the rate-control group]

drugs in the rate-control group

[early diastolic annular velocity 3.1]

early diastolic annular velocity 3.1

[undergoing ventricular assist device LVAD implantation]

undergoing ventricular assist device LVAD implantation

[Relation between preoperative dysfunction]

Relation between preoperative dysfunction

[restriction diet]

restriction diet

[HeartMate 3 ventricular assist system]

HeartMate 3 ventricular assist system

[Grade weak recommendation]

Grade weak recommendation

[York Heart Association functional class HR]

York Heart Association functional class HR

[Patient Safety Monitoring System]

Patient Safety Monitoring System

[patients having HFpEF male gender]

patients having HFpEF male gender

[systematic search]

systematic search

[nitroxyl HNO donor]

nitroxyl HNO donor

[patients consisting]

patients consisting

[attenuating remodeling]

attenuating remodeling

[μmol]

μmol

[congestion]

congestion

[improvement in effective rate]

improvement in effective rate

[2 ruptures]

2 ruptures

[accurate risk stratification]

accurate risk stratification

[Exercise Testing CPET]

Exercise Testing CPET

[Effective arterial elastance Ea elastance]

Effective arterial elastance Ea elastance

[19 non-diabetic patients]

19 non-diabetic patients

[echocardiographic predictors of response]

echocardiographic predictors of response

[first hospitalization]

first hospitalization

[evidence from trials of agent therapy]

evidence from trials of agent therapy

[resulting in a SV p]

resulting in a SV p

[hallmark of chronic heart failure]

hallmark of chronic heart failure

[institution of PD]

institution of PD

[patients with advanced COPD]

patients with advanced COPD

[All-cause mortality at years]

All-cause mortality at years

[ICU mortality]

ICU mortality

[Implications of choice]

Implications of choice

[impairment at hospitalization]

impairment at hospitalization

[B-type peptide levels in patients]

B-type peptide levels in patients

[Cardiac resonance postcontrast]

Cardiac resonance postcontrast

[characteristics of adults with heart failure]

characteristics of adults with heart failure

[HR CI 1.27]

HR CI 1.27

[69 years]

69 years

[artery bypass grafting CABG]

artery bypass grafting CABG

[echocardiographic evidence of left dyssynchrony]

echocardiographic evidence of left dyssynchrony

[trend toward enrollment]

trend toward enrollment

[54 patients aged years]

54 patients aged years

[ventricular ejection fraction LVEF]

ventricular ejection fraction LVEF

[capillary wedge pressure PCWP]

capillary wedge pressure PCWP

[language on anemia]

language on anemia

[quality of outcome measures]

quality of outcome measures

[156 HF patients]

156 HF patients

[VVD variation]

VVD variation

[transmitral E-wave mitral velocity ratio]

transmitral E-wave mitral velocity ratio

[resting HR 70]

resting HR 70

[1.05 mg]

1.05 mg

[complications in end-stage HF]

complications in end-stage HF

[Within-day test-retest reliability in patients]

Within-day test-retest reliability in patients

[downregulation of genes]

downregulation of genes

[Global longitudinal systolic strain]

Global longitudinal systolic strain

[higher exercise time]

higher exercise time

[even after adjustment hazard ratio]

even after adjustment hazard ratio

[HFpEF for summary]

HFpEF for summary

[Experience of a receptor antagonist]

Experience of a receptor antagonist

[Organisation Taxonomy]

Organisation Taxonomy

[even with function]

even with function

[animal model of ischemia]

animal model of ischemia

[higher doses]

higher doses

[area change]

area change

[levels of serum factors]

levels of serum factors

[cachexia hazard ratio]

cachexia hazard ratio

[broader discussions]

broader discussions

[catheterisation with transoesophageal guidance]

catheterisation with transoesophageal guidance

[prognostic power]

prognostic power

[men mean years]

men mean years

[chronic renal failure]

chronic renal failure

[tendency]

tendency

[Unidirectional interatrial shunting for treatment]

Unidirectional interatrial shunting for treatment

[risk RR]

risk RR

[health-care budget]

health-care budget

[hallmark of heart failure]

hallmark of heart failure

[special interventions]

special interventions

[including an eGFR]

including an eGFR

[non-diastolic abnormalities in function]

non-diastolic abnormalities in function

[disappointments]

disappointments

[patients with organ failure]

patients with organ failure

[urine volume decongestion end point]

urine volume decongestion end point

[blots with site-specific monoclonal antibodies]

blots with site-specific monoclonal antibodies

[such as thromboembolism]

such as thromboembolism

[embryonic kidney 293 cells overexpressing β1AR]

embryonic kidney 293 cells overexpressing β1AR

[failure of reserve]

failure of reserve

[update on exercise variables]

update on exercise variables

[cases with pre-HCT germline DNA]

cases with pre-HCT germline DNA

[mouse heart failure]

mouse heart failure

[assessments within 7 days]

assessments within 7 days

[age subjects from the population]

age subjects from the population

[Values of standard error]

Values of standard error

[open allocation ratio]

open allocation ratio

[activities of lyso-PAF-AT P]

activities of lyso-PAF-AT P

[including factor]

including factor

[even in patients]

even in patients

[blood glucose levels]

blood glucose levels

[predictors for the development]

predictors for the development

[increase in risk]

increase in risk

[neprilysin blocks renin-angiotensin-aldosteron RAS]

neprilysin blocks renin-angiotensin-aldosteron RAS

[varying delay]

varying delay

[sarcopenic range muscle wasting]

sarcopenic range muscle wasting

[evidence of dysfunction impaired LV relaxation]

evidence of dysfunction impaired LV relaxation

[usefulness of CRT in patients]

usefulness of CRT in patients

[physician s]

physician s

[pulmonary pressure relationship an index]

pulmonary pressure relationship an index

[physicians P]

physicians P

[heart failure with peritoneal dialysis]

heart failure with peritoneal dialysis

[Fontan in an population]

Fontan in an population

[hiPSC-CMs]

hiPSC-CMs

[LV diameter]

LV diameter

[change effect]

change effect

[requiring HeartMate]

requiring HeartMate

[postmenopausal women]

postmenopausal women

[stage of CHF]

stage of CHF

[g P=0.04]

g P=0.04

[hRetn resistin]

hRetn resistin

[detecting early myocardial fibrosis]

detecting early myocardial fibrosis

[Global ventricular systolic strain]

Global ventricular systolic strain

[spontaneous dysfunction]

spontaneous dysfunction

[hypertrophy in heart failure]

hypertrophy in heart failure

[College ACP]

College ACP

[inflammatory genes]

inflammatory genes

[262 psoriasis UV treatment]

262 psoriasis UV treatment

[disease including heart failure]

disease including heart failure

[measures explaining variation in mortality]

measures explaining variation in mortality

[particularly in institutions]

particularly in institutions

[Peak Oxygen Consumption]

Peak Oxygen Consumption

[modes]

modes

[myocardial infarction AMI with complications]

myocardial infarction AMI with complications

[events IEs]

events IEs

[R-R]

R-R

[progressive development of hypertrophy]

progressive development of hypertrophy

[information on cardioverter-defibrillator deactivation]

information on cardioverter-defibrillator deactivation

[etiologic causes]

etiologic causes

[range 22.8 with advanced COPD n=95]

range 22.8 with advanced COPD n=95

[predictors of hospitalization in patients]

predictors of hospitalization in patients

[diastolic failure]

diastolic failure

[prognosis of cardiomyopathy]

prognosis of cardiomyopathy

[blood flow velocity]

blood flow velocity

[Frailty for heart failure in adults]

Frailty for heart failure in adults

[reticular Ca]

reticular Ca

[cohort of all adults]

cohort of all adults

[susceptibility]

susceptibility

[patients with an implantable defibrillator]

patients with an implantable defibrillator

[rapid ventricular pacing]

rapid ventricular pacing

[briefing reports]

briefing reports

[cutoff level of NT-proBNP]

cutoff level of NT-proBNP

[favour]

favour

[Outcomes of Exercise Training HF-ACTION study]

Outcomes of Exercise Training HF-ACTION study

[sensitive measure of left mechanics]

sensitive measure of left mechanics

[years for alendronate- patients]

years for alendronate- patients

[NRIs]

NRIs

[ischemic abdominal problems]

ischemic abdominal problems

[annulus]

annulus

[30 years]

30 years

[studies 2900 HM]

studies 2900 HM

[ST2 levels with capacity]

ST2 levels with capacity

[consecutive patients with PH]

consecutive patients with PH

[cardiac tumors]

cardiac tumors

[20 patients aged 40 years]

20 patients aged 40 years

[exercise-induced artery pressure increase]

exercise-induced artery pressure increase

[partial improvement]

partial improvement

[STS HH credible interval]

STS HH credible interval

[4 heart failure samples]

4 heart failure samples

[Surgical correction]

Surgical correction

[targeting nonglycosylated epitopes]

targeting nonglycosylated epitopes

[10 NOC outcomes]

10 NOC outcomes

[College ACC]

College ACC

[negative effect]

negative effect

[Safety analyses]

Safety analyses

[right RV function]

right RV function

[NO production by EC]

NO production by EC

[good performance in patients]

good performance in patients

[cm(2)]

cm(2)

[mechanism of HFPEF]

mechanism of HFPEF

[enrichment]

enrichment

[evaluation of the surgical indications]

evaluation of the surgical indications

[lower risk developing malignancies]

lower risk developing malignancies

[Measurement at the point]

Measurement at the point

[consenting ambulatory HF patients ejection fraction]

consenting ambulatory HF patients ejection fraction

[203 HeartMate devices]

203 HeartMate devices

[Outcomes study of exercise training]

Outcomes study of exercise training

[improvement of performance]

improvement of performance

[124 sitagliptin users]

124 sitagliptin users

[including agents]

including agents

[output CO]

output CO

[smallest difference BNP]

smallest difference BNP

[group 30 mL]

group 30 mL

[distinct circulatory derangement]

distinct circulatory derangement

[models of canine electromechanics]

models of canine electromechanics

[anterior descending coronary artery occlusion]

anterior descending coronary artery occlusion

[impact of management]

impact of management

[first-in-man evidence for usefulness in HF]

first-in-man evidence for usefulness in HF

[defibrillator-only therapy]

defibrillator-only therapy

[index versus 2.8 L]

index versus 2.8 L

[heart failure a descriptive study]

heart failure a descriptive study

[200 minutes]

200 minutes

[receiving guideline-recommended drugs]

receiving guideline-recommended drugs

[paediatric cardiac transplants]

paediatric cardiac transplants

[consecutive patients 224 men years]

consecutive patients 224 men years

[chordal ruptures]

chordal ruptures

[ventricular RV plane systolic excursion TAPSE]

ventricular RV plane systolic excursion TAPSE

[clinical status hospitalizations]

clinical status hospitalizations

[non-AAs with York Heart Association class]

non-AAs with York Heart Association class

[Practice-level variation Insights]

Practice-level variation Insights

[national trends in adverse event rates]

national trends in adverse event rates

[detecting myocardial fibrosis]

detecting myocardial fibrosis

[trends in patient safety]

trends in patient safety

[24 telephone support]

24 telephone support

[chelation choices]

chelation choices

[risk for events]

risk for events

[brief hypothermic arrest]

brief hypothermic arrest

[view]

view

[changes in control group P]

changes in control group P

[grade 2]

grade 2

[Low-dose dopamine in heart failure]

Low-dose dopamine in heart failure

[multiple genes]

multiple genes

[analysis of tissue]

analysis of tissue

[revealing a mechanism]

revealing a mechanism

[molecular scaffolds in heart pathology]

molecular scaffolds in heart pathology

[role of PDE2]

role of PDE2

[2331 patients]

2331 patients

[mortality in heart failure]

mortality in heart failure

[HF in infancy]

HF in infancy

[instability]

instability

[chronic organ failure]

chronic organ failure

[cation channel M7 channel mRNA]

cation channel M7 channel mRNA

[partial improvement of performance at stages]

partial improvement of performance at stages

[enrollment of patients]

enrollment of patients

[bisphophonates crude RR]

bisphophonates crude RR

[significant portion]

significant portion

[non-AAs with York Heart Association]

non-AAs with York Heart Association

[Overall ICU mortality]

Overall ICU mortality

[insulin-resistance by 2 weeks]

insulin-resistance by 2 weeks

[result of lesions]

result of lesions

[care of patients]

care of patients

[energy X-ray absorptiometry DXA]

energy X-ray absorptiometry DXA

[using metrics]

using metrics

[treatment measure]

treatment measure

[Large-scale prospective multicenter trial]

Large-scale prospective multicenter trial

[impact on protective effects]

impact on protective effects

[HeartMate ventricular assist system]

HeartMate ventricular assist system

[mL increase]

mL increase

[heart failure with systolic dysfunction]

heart failure with systolic dysfunction

[predictors of severe CAD]

predictors of severe CAD

[bone]

bone

[Two multivariate models]

Two multivariate models

[HF patients ventricular ejection fraction]

HF patients ventricular ejection fraction

[odds ratio P]

odds ratio P

[trends in adverse event rates]

trends in adverse event rates

[final diagnosis of myeloma]

final diagnosis of myeloma

[pulmonary pressure PASP]

pulmonary pressure PASP

[guidelines definition of HFPEF]

guidelines definition of HFPEF

[surrogates for changes in CO.]

surrogates for changes in CO.

[Cox hazards]

Cox hazards

[improvement in function]

improvement in function

[37 patients]

37 patients

[age subjects]

age subjects

[patients with prior disease]

patients with prior disease

[gene-targeted Hand2 mice]

gene-targeted Hand2 mice

[early mitral annulus velocity]

early mitral annulus velocity

[impact on quality of life]

impact on quality of life

[reaching significance]

reaching significance

[adenylyl cyclase]

adenylyl cyclase

[most common cause of death]

most common cause of death

[patients with dyspnea]

patients with dyspnea

[Twenty-seven studies with 1887]

Twenty-seven studies with 1887

[generation]

generation

[right area change]

right area change

[using the surgical method]

using the surgical method

[unique states]

unique states

[novel pure HNO donor]

novel pure HNO donor

[heart failure samples]

heart failure samples

[factor in patients]

factor in patients

[events in heart failure]

events in heart failure

[insight into the potential]

insight into the potential

[72 studies]

72 studies

[prevalence of disease]

prevalence of disease

[effects on various physiologic processes]

effects on various physiologic processes

[univariate analyses]

univariate analyses

[Potent inhibition]

Potent inhibition

[damage]

damage

[Patients With Exertional Shortness]

Patients With Exertional Shortness

[multiple non-diastolic abnormalities]

multiple non-diastolic abnormalities

[weeks from myocardial infarction]

weeks from myocardial infarction

[infarction heart failure patients]

infarction heart failure patients

[stable systolic heart failure]

stable systolic heart failure

[Global longitudinal strain as a predictor]

Global longitudinal strain as a predictor

[Two Cox hazards models]

Two Cox hazards models

[restorative effects]

restorative effects

[right annular plane systolic excursion TAPSE]

right annular plane systolic excursion TAPSE

[Global left strain as a predictor]

Global left strain as a predictor

[intermediate odds ratios for events P=0.18]

intermediate odds ratios for events P=0.18

[Echocardiographic predictors after cardiac resynchronization therapy]

Echocardiographic predictors after cardiac resynchronization therapy

[prior months]

prior months

[lifesaving drugs]

lifesaving drugs

[150,000 population in South Dakota]

150,000 population in South Dakota

[8656 users]

8656 users

[central blood pressure via tonometry]

central blood pressure via tonometry

[CI 9.4]

CI 9.4

[symptom of chronic HFPEF]

symptom of chronic HFPEF

[technique detecting early fibrosis]

technique detecting early fibrosis

[leading cause of mortality]

leading cause of mortality

[walking distance peak]

walking distance peak

[response in sympathetic activity (123)I-meta-iodobenzylguanidine]

response in sympathetic activity (123)I-meta-iodobenzylguanidine

[explaining variation in mortality]

explaining variation in mortality

[kidney disease glomerular filtration rate]

kidney disease glomerular filtration rate

[mitochondrial dysfunction in heart failure]

mitochondrial dysfunction in heart failure

[Remote monitoring RM]

Remote monitoring RM

[novel HNO donor]

novel HNO donor

[baseline exercise capacity]

baseline exercise capacity

[heart failure glomerular filtration rate]

heart failure glomerular filtration rate

[human kidney 293 cells overexpressing β1AR]

human kidney 293 cells overexpressing β1AR

[single important component]

single important component

[delay EMD]

delay EMD

[Clinical Modification]

Clinical Modification

[potential predictors]

potential predictors

[symptomatic adult Fontan patients]

symptomatic adult Fontan patients

[predicting CV events in models]

predicting CV events in models

[clinical prognostic diastolic dysfunction]

clinical prognostic diastolic dysfunction

[decreasing albumin levels]

decreasing albumin levels

[patients with QRS ms]

patients with QRS ms

[metoprolol in heart failure]

metoprolol in heart failure

[follow-up period of years]

follow-up period of years

[most powerful predictor of outcome]

most powerful predictor of outcome

[24-hour brachial pressure 155 35]

24-hour brachial pressure 155 35

[incorporating a rotor]

incorporating a rotor

[morphological development]

morphological development

[event rates in the UM cohorts]

event rates in the UM cohorts

[catheter ablation for atrial fibrillation]

catheter ablation for atrial fibrillation

[patients undergoing LVAD implantation at institution]

patients undergoing LVAD implantation at institution

[including monitoring devices]

including monitoring devices

[risk HR]

risk HR

[commoner]

commoner

[minutes of exercise per week]

minutes of exercise per week

[group IV mL]

group IV mL

[biventricular pacing on heart twist]

biventricular pacing on heart twist

[patients with HFpEF short-term treatment]

patients with HFpEF short-term treatment

[One-year rates]

One-year rates

[evaluating predictors on 257,692 ICD patients]

evaluating predictors on 257,692 ICD patients

[early-onset days after MI]

early-onset days after MI

[update on exercise parameters]

update on exercise parameters

[large animal model]

large animal model

[dysfunction leading]

dysfunction leading

[derangement with features]

derangement with features

[patients with obstructive disease]

patients with obstructive disease

[cation channel M7 TRPM7]

cation channel M7 TRPM7

[systolic pressure relationship]

systolic pressure relationship

[pressure relationship an index]

pressure relationship an index

[Effects of support on renal function]

Effects of support on renal function

[EF EF≤]

EF EF≤

[worse QOL outcome]

worse QOL outcome

[rapid right pacing]

rapid right pacing

[300 ms]

300 ms

[Myxomas in the atrium]

Myxomas in the atrium

[wk after the procedures]

wk after the procedures

[effects of carvedilol]

effects of carvedilol

[powerful independent predictor period]

powerful independent predictor period

[bundle branch block pattern]

bundle branch block pattern

[biosynthetic enzymes lyso-PAF acetyltransferase]

biosynthetic enzymes lyso-PAF acetyltransferase

[myocardial ischemic events]

myocardial ischemic events

[including normal samples]

including normal samples

[arterial elastance elastance]

arterial elastance elastance

[Risk Among Users]

Risk Among Users

[Usefulness of resynchronization therapy]

Usefulness of resynchronization therapy

[β2-adrenergic receptor haplotype]

β2-adrenergic receptor haplotype

[CAD involving the proximal left artery]

CAD involving the proximal left artery

[atrial area cm 2]

atrial area cm 2

[156 HF patients left ejection fraction]

156 HF patients left ejection fraction

[improving uptake]

improving uptake

[nitroxyl donor]

nitroxyl donor

[New Zealand White rabbits]

New Zealand White rabbits

[matrix using magnetic resonance T1 mapping]

matrix using magnetic resonance T1 mapping

[documentation]

documentation

[nomenclature for right failure]

nomenclature for right failure

[nurse assessment]

nurse assessment

[life support]

life support

[conditional Hand2 mice]

conditional Hand2 mice

[beta blockers on exercise capacity]

beta blockers on exercise capacity

[epidemiology of infarction MI]

epidemiology of infarction MI

[processes of care]

processes of care

[group 30 mL per 1.73 m]

group 30 mL per 1.73 m

[≥70 years p]

≥70 years p

[hypertension P=0.049]

hypertension P=0.049

[CRT OFF]

CRT OFF

[severe end-stage HF]

severe end-stage HF

[responsible diagnosis]

responsible diagnosis

[results in many HF trials]

results in many HF trials

[treatment in adult patients]

treatment in adult patients

[Age-dependent effect]

Age-dependent effect

[modestly lower mortality]

modestly lower mortality

[RIα]

RIα

[non-urbanized state]

non-urbanized state

[right tricuspid plane excursion]

right tricuspid plane excursion

[correlation coefficient]

correlation coefficient

[optimal management]

optimal management

[resynchronization therapy with a defibrillator CRT-D]

resynchronization therapy with a defibrillator CRT-D

[pairs of cohorts]

pairs of cohorts

[atrium mass]

atrium mass

[care clinicians]

care clinicians

[quality indicators including mortality]

quality indicators including mortality

[Clinical characteristics of adults]

Clinical characteristics of adults

[LV end-diastolic pressure in weeks]

LV end-diastolic pressure in weeks

[heart failure stent]

heart failure stent

[268 records]

268 records

[20,812 patients with first infarction]

20,812 patients with first infarction

[AAs 4.32±0.54-4.31±0.49 race]

AAs 4.32±0.54-4.31±0.49 race

[Outcomes study]

Outcomes study

[Six thousand five hundred hospitals]

Six thousand five hundred hospitals

[Relation between dysfunction within three months]

Relation between dysfunction within three months

[dogs with microembolization-induced HF]

dogs with microembolization-induced HF

[following infarction]

following infarction

[various forms]

various forms

[LF ratio in the CHF-INV]

LF ratio in the CHF-INV

[Effects a longitudinal analysis]

Effects a longitudinal analysis

[response role]

response role

[improvement domains]

improvement domains

[York Heart Association class III]

York Heart Association class III

[improvement NT-ProBNP]

improvement NT-ProBNP

[routine tool for risk stratification]

routine tool for risk stratification

[median ms]

median ms

[canine electromechanics]

canine electromechanics

[Eplerenone Post infarction]

Eplerenone Post infarction

[significant change with exercise]

significant change with exercise

[managing bleeding in this population]

managing bleeding in this population

[signalling pathways activating remodelling]

signalling pathways activating remodelling

[peak diastolic mitral flow velocity]

peak diastolic mitral flow velocity

[prior HF hospitalisations]

prior HF hospitalisations

[low 50 mg equivalent dose]

low 50 mg equivalent dose

[cause of death in athletes]

cause of death in athletes

[remodelling of the heart]

remodelling of the heart

[new-onset ESRD from the Registry]

new-onset ESRD from the Registry

[peak VO2 effect]

peak VO2 effect

[Functional mitral stenosis]

Functional mitral stenosis

[eGFR mL]

eGFR mL

[using resonance T1 mapping]

using resonance T1 mapping

[overall burden]

overall burden

[body mass index kg of ethnicity]

body mass index kg of ethnicity

[Cardiac resonance T1 time hazard ratio]

Cardiac resonance T1 time hazard ratio

[CHM versus treatment alone]

CHM versus treatment alone

[several markers]

several markers

[end diameter difference]

end diameter difference

[Clinical characteristics The CHARM programme Candesartan]

Clinical characteristics The CHARM programme Candesartan

[Aerobic Exercise]

Aerobic Exercise

[Renal Optimization Strategies Evaluation]

Renal Optimization Strategies Evaluation

[end-point]

end-point

[group IV mL per 1.73 m]

group IV mL per 1.73 m

[small-molecule inhibitors]

small-molecule inhibitors

[156 ambulatory HF patients ejection fraction]

156 ambulatory HF patients ejection fraction

[Kidney]

Kidney

[4.9 years for patients respectively]

4.9 years for patients respectively

[annulus velocities during systole]

annulus velocities during systole

[Common Procedure]

Common Procedure

[Remote monitoring a systematic review]

Remote monitoring a systematic review

[left ventricular systolic strain GLS]

left ventricular systolic strain GLS

[emergency catheterization]

emergency catheterization

[(eGFR)-group I ≥60 mL]

(eGFR)-group I ≥60 mL

[Mechanistic insight into electromechanical delay]

Mechanistic insight into electromechanical delay

[20 patients aged years]

20 patients aged years

[other predictors]

other predictors

[rates of guideline-recommended treatment]

rates of guideline-recommended treatment

[enzyme inhibitors intolerance]

enzyme inhibitors intolerance

[using a HeartMate LVAD]

using a HeartMate LVAD

[acute right pressure overload RVPO]

acute right pressure overload RVPO

[mm for psoriasis for reference subjects]

mm for psoriasis for reference subjects

[223 patients age]

223 patients age

[8656 new users]

8656 new users

[urban academic center]

urban academic center

[severe hypertension of 191 mm Hg]

severe hypertension of 191 mm Hg

[SCN5A variants with AngII]

SCN5A variants with AngII

[practice settings]

practice settings

[years respectively p]

years respectively p

[Studies of echocardiographic predictors]

Studies of echocardiographic predictors

[neonatal rat cardiomyocytes]

neonatal rat cardiomyocytes

[insight in heart failure]

insight in heart failure

[SurvIval Study]

SurvIval Study

[Nursing-sensitive outcome change]

Nursing-sensitive outcome change

[biomarker-guided trials]

biomarker-guided trials

[current practice]

current practice

[mortality in society]

mortality in society

[observation at the time of surgery]

observation at the time of surgery

[Clinical Practice Guideline recommendations]

Clinical Practice Guideline recommendations

[common cause in athletes]

common cause in athletes

[dipeptidyl peptidase-4 inhibitors]

dipeptidyl peptidase-4 inhibitors

[oxide NO]

oxide NO

[risk stratification of patient appropriate]

risk stratification of patient appropriate

[ring annuloplasty for regurgitation MR]

ring annuloplasty for regurgitation MR

[difference between numbers in any]

difference between numbers in any

[HNO donor in myoctyes]

HNO donor in myoctyes

[muscle strip stiffness]

muscle strip stiffness

[2 molecular scaffolds]

2 molecular scaffolds

[trial of walking with moderate]

trial of walking with moderate

[9868 participants area]

9868 participants area

[link between air pollution]

link between air pollution

[PAF of enzymes]

PAF of enzymes

[usefulness of CRT]

usefulness of CRT

[perhaps the single important component]

perhaps the single important component

[treatment for myocardial infarction AMI]

treatment for myocardial infarction AMI

[ROSE acute heart failure]

ROSE acute heart failure

[medical hospitalization in HF clinic outpatients]

medical hospitalization in HF clinic outpatients

[Postoperative survival]

Postoperative survival

[age of the cohort]

age of the cohort

[156 consecutive consenting HF patients]

156 consecutive consenting HF patients

[beta receptor]

beta receptor

[cardiovascular event rate events]

cardiovascular event rate events

[constants]

constants

[moderate level of CRF]

moderate level of CRF

[targets for heart failure]

targets for heart failure

[nursing terminologies]

nursing terminologies

[partial improvement by β-adrenoceptor blockade]

partial improvement by β-adrenoceptor blockade

[Physio Ring of size]

Physio Ring of size

[peak diastolic flow velocity]

peak diastolic flow velocity

[cardiac arrhythmia devices]

cardiac arrhythmia devices

[even with normal function]

even with normal function

[remarkable role]

remarkable role

[only at doses]

only at doses

[estimating capillary wedge pressure PCWP]

estimating capillary wedge pressure PCWP

[individual associations among fitness]

individual associations among fitness

[early-onset 0 days]

early-onset 0 days

[double-blind ratio]

double-blind ratio

[right ventricular RV plane excursion TAPSE]

right ventricular RV plane excursion TAPSE

[days in this trial]

days in this trial

[efficacy end]

efficacy end

[years in 2011]

years in 2011

[consecutive consenting ambulatory HF patients]

consecutive consenting ambulatory HF patients

[matrix of ventricular biopsies]

matrix of ventricular biopsies

[national income]

national income

[denervation DNx in CHF patients]

denervation DNx in CHF patients

[sparing]

sparing

[nervous system modulation]

nervous system modulation

[heart failure mice model]

heart failure mice model

[common cause of RAS]

common cause of RAS

[MRI-based models of dyssynchronous canine electromechanics]

MRI-based models of dyssynchronous canine electromechanics

[urinary tract]

urinary tract

[RALES]

RALES

[dysfunction impaired LV relaxation]

dysfunction impaired LV relaxation

[Objective institution of PD]

Objective institution of PD

[indicators 6-MWT]

indicators 6-MWT

[Dacron patch closure]

Dacron patch closure

[predominantly asymptomatic Fontan patients]

predominantly asymptomatic Fontan patients

[vivo perfusion]

vivo perfusion

[decrement of heart rate]

decrement of heart rate

[HF remodeling aspects]

HF remodeling aspects

[limited amount of data]

limited amount of data

[Risk Among New Users]

Risk Among New Users

[subset of HFpEF]

subset of HFpEF

[20,812 patients with acute infarction]

20,812 patients with acute infarction

[AT1 receptors]

AT1 receptors

[RV support]

RV support

[nondiabetes risk factors age]

nondiabetes risk factors age

[echocardiographic evidence]

echocardiographic evidence

[mortality for patients]

mortality for patients

[trials using HR variability]

trials using HR variability

[death in patients]

death in patients

[analysis matching for age]

analysis matching for age

[Aldactone Evaluation Study]

Aldactone Evaluation Study

[even with ventricular function]

even with ventricular function

[Impaired angiogenesis in the infarction heart]

Impaired angiogenesis in the infarction heart

[study-related serious events]

study-related serious events

[PDE2-mediated effects]

PDE2-mediated effects

[correlation between changes in HDL-induced]

correlation between changes in HDL-induced

[pairs of virtual cohorts]

pairs of virtual cohorts

[24 per cent with five deaths]

24 per cent with five deaths

[clinical follow-up]

clinical follow-up

[HF concurrent]

HF concurrent

[Composite quality measures for conditions]

Composite quality measures for conditions

[expression of variants]

expression of variants

[Olmsted County Minnesota]

Olmsted County Minnesota

[alcohol]

alcohol

[over 20 variables]

over 20 variables

[potential contribution]

potential contribution

[Toronto Canada]

Toronto Canada

[knowledge of nutritional abnormalities]

knowledge of nutritional abnormalities

[low 50 mg daily dose]

low 50 mg daily dose

[context of HF]

context of HF

[ventricular diastolic end diameter difference]

ventricular diastolic end diameter difference

[benefits of treatments]

benefits of treatments

[adjusting for clinical variables]

adjusting for clinical variables

[porcine model of myocardial ischemia]

porcine model of myocardial ischemia

[electrical stimulation of muscles]

electrical stimulation of muscles

[peak quadriceps force in all participants]

peak quadriceps force in all participants

[Coprimary]

Coprimary

[enhancing neoangiogenesis in the heart]

enhancing neoangiogenesis in the heart

[downward regression line]

downward regression line

[dosage]

dosage

[follow-up of 541 days]

follow-up of 541 days

[gene induction]

gene induction

[diastolic mitral annulus velocity]

diastolic mitral annulus velocity

[CO2 PETCO2]

CO2 PETCO2

[however without a need]

however without a need

[non-survivors]

non-survivors

[Bradycardia indicative]

Bradycardia indicative

[advanced chronic disease COPD]

advanced chronic disease COPD

[resulting in a SV]

resulting in a SV

[brain natriuretic peptide BNP levels pg]

brain natriuretic peptide BNP levels pg

[1.6 reasons]

1.6 reasons

[blots with monoclonal antibodies]

blots with monoclonal antibodies

[12-lead ECG in athletes]

12-lead ECG in athletes

[cell differentiation toward cells in vitro]

cell differentiation toward cells in vitro

[effect on urine volume]

effect on urine volume

[64.26 years years]

64.26 years years

[Outcomes in Exercise TraiNing]

Outcomes in Exercise TraiNing

[however an disease]

however an disease

[global strain of ventricle]

global strain of ventricle

[flow reserve measurements]

flow reserve measurements

[group mL per 1.73 m 2]

group mL per 1.73 m 2

[significant lesions in the branches]

significant lesions in the branches

[224 men 65±12 years]

224 men 65±12 years

[right coupling resistance P]

right coupling resistance P

[statistically significant change effect]

statistically significant change effect

[research questions]

research questions

[Haematopoietic]

Haematopoietic

[17 days range days]

17 days range days

[reversible ischemia stent]

reversible ischemia stent

[relevance in pulmonary hypertension patients]

relevance in pulmonary hypertension patients

[ED visits age 76.4 years]

ED visits age 76.4 years

[worsening of disease]

worsening of disease

[significant amelioration]

significant amelioration

[modestly lower mortality with HF]

modestly lower mortality with HF

[overexpressing β1AR]

overexpressing β1AR

[using experimental procedures]

using experimental procedures

[interviews with primary care clinicians]

interviews with primary care clinicians

[human ventricular LV myocytes]

human ventricular LV myocytes

[DD of collagen deposition]

DD of collagen deposition

[debilitating disease]

debilitating disease

[transforming growth factor-β signaling level]

transforming growth factor-β signaling level

[272 patients]

272 patients

[proximal LCX]

proximal LCX

[volume status]

volume status

[minimal change values]

minimal change values

[adaptive response]

adaptive response

[ECG parameters]

ECG parameters

[HeartMate II LVADs]

HeartMate II LVADs

[subclinical atherosclerosis using general models]

subclinical atherosclerosis using general models

[behavioural-change]

behavioural-change

[flow-mediated dilatation improvement]

flow-mediated dilatation improvement

[benefit over parameters]

benefit over parameters

[left descending artery]

left descending artery

[Effects of mechanical support]

Effects of mechanical support

[precapillary hypertension]

precapillary hypertension

[direct renin inhibitors]

direct renin inhibitors

[type II]

type II

[cardiac Na current during HF]

cardiac Na current during HF

[devices in heart failure]

devices in heart failure

[chronic failure CRF]

chronic failure CRF

[Multicenter trial of 360 patients]

Multicenter trial of 360 patients

[mitral valve area]

mitral valve area

[≥2 nondiabetes risk factors]

≥2 nondiabetes risk factors

[systemic events evaluation]

systemic events evaluation

[hemoglobin with HRQoL changes]

hemoglobin with HRQoL changes

[insulin receptor substrates 1]

insulin receptor substrates 1

[left anterior]

left anterior

[levels of Mena]

levels of Mena

[perturbations in components]

perturbations in components

[neprilysin inhibitors]

neprilysin inhibitors

[2-vessel CAD]

2-vessel CAD

[measurements of CPCs]

measurements of CPCs

[descending artery occlusion]

descending artery occlusion

[nonsignificant trend]

nonsignificant trend

[amount of recent data]

amount of recent data

[using Cox hazards models]

using Cox hazards models

[acute β-adrenoceptor blockade]

acute β-adrenoceptor blockade

[Pediatric heart failure]

Pediatric heart failure

[20 patients]

20 patients

[Insights A Trial Investigating Outcomes]

Insights A Trial Investigating Outcomes

[reliable diagnostic biomarkers in patients]

reliable diagnostic biomarkers in patients

[role in pathophysiology]

role in pathophysiology

[Beta-blocker dose]

Beta-blocker dose

[Postoperative survival 3.5 g]

Postoperative survival 3.5 g

[bromodomain-containing]

bromodomain-containing

[association between support]

association between support

[Function Among Patients With Exertional Shortness]

Function Among Patients With Exertional Shortness

[site specific RIIα]

site specific RIIα

[statistical standards in biomarker studies]

statistical standards in biomarker studies

[accounting for the cost]

accounting for the cost

[time of HF]

time of HF

[resulting in a MS]

resulting in a MS

[Preventable Readmission]

Preventable Readmission

[MicroRNAs in heart failure]

MicroRNAs in heart failure

[Remote conditioning for patients]

Remote conditioning for patients

[internal consistency among patients with HFpEF]

internal consistency among patients with HFpEF

[International Heart Foundation Working Group]

International Heart Foundation Working Group

[saxagliptin versus sitagliptin]

saxagliptin versus sitagliptin

[pulmonary arterial pressure relationship an index]

pulmonary arterial pressure relationship an index

[diastolic dysfunction in patients]

diastolic dysfunction in patients

[socioeconomic status versus whites]

socioeconomic status versus whites

[production by EC]

production by EC

[differential response in sympathetic activity]

differential response in sympathetic activity

[Key role molecular scaffolds]

Key role molecular scaffolds

[pulseless fibrillation PVF]

pulseless fibrillation PVF

[nonstandardized pro-B-type peptide NT-proBNP]

nonstandardized pro-B-type peptide NT-proBNP

[problem of cardiology]

problem of cardiology

[eligible patients with a follow-up]

eligible patients with a follow-up

[systolic ejection fraction HF]

systolic ejection fraction HF

[lower activities of lyso-PAF-AT P]

lower activities of lyso-PAF-AT P

[congestive heart failure with dialysis]

congestive heart failure with dialysis

[greater weight loss]

greater weight loss

[receiving angiotensin-converting enzyme inhibitors]

receiving angiotensin-converting enzyme inhibitors

[aggressive treatment]

aggressive treatment

[1.02±0.18 mm]

1.02±0.18 mm

[reducing the risk of events]

reducing the risk of events

[sensitive measure of ventricular mechanics]

sensitive measure of ventricular mechanics

[atrial peptide B-type natriuretic peptide]

atrial peptide B-type natriuretic peptide

[elastance elastance]

elastance elastance

[functional characterization]

functional characterization

[heart failure patients from Italy]

heart failure patients from Italy

[holosystolic]

holosystolic

[total of 44 men]

total of 44 men

[chronic heart failure with dysfunction]

chronic heart failure with dysfunction

[participants aged]

participants aged

[resonance angiography]

resonance angiography

[strategies with effects in the treatment]

strategies with effects in the treatment

[cardiac support on renal function]

cardiac support on renal function

[common characteristics eg]

common characteristics eg

[increase in lung weight]

increase in lung weight

[consecutive patients men years]

consecutive patients men years

[increase in tone]

increase in tone

[812 consecutive patients aged years]

812 consecutive patients aged years

[Pharmacological treatment of acute heart failure]

Pharmacological treatment of acute heart failure

[Ser96]

Ser96

[three variants]

three variants

[Diagnostic role in artery disease]

Diagnostic role in artery disease

[decreases in heart mortality period]

decreases in heart mortality period

[underlying characteristics eg using Cochrane Practice]

underlying characteristics eg using Cochrane Practice

[primary care clinicians]

primary care clinicians

[contributing insignificantly]

contributing insignificantly

[models alone]

models alone

[hospitalizations in heart failure with dialysis]

hospitalizations in heart failure with dialysis

[N-terminal proBNP proANP MR-proANP]

N-terminal proBNP proANP MR-proANP

[PB characteristics period]

PB characteristics period

[adjustment for baseline characteristics]

adjustment for baseline characteristics

[erythropoiesis-stimulating agents in patients]

erythropoiesis-stimulating agents in patients

[global changes]

global changes

[heart dilatation after aortic constriction TAC]

heart dilatation after aortic constriction TAC

[favorable changes]

favorable changes

[early-onset days]

early-onset days

[role of ERK1 2 molecular scaffolds]

role of ERK1 2 molecular scaffolds

[66.6 years]

66.6 years

[Black race]

Black race

[analysis of microarray data]

analysis of microarray data

[form of peripheral arterial disease]

form of peripheral arterial disease

[multivariate Cox hazards]

multivariate Cox hazards

[adult patients undergoing heart transplant]

adult patients undergoing heart transplant

[LV ejection fraction of 0.70]

LV ejection fraction of 0.70

[separate scale dimensions]

separate scale dimensions

[other aspects contributing]

other aspects contributing

[health outcomes in elderly patients]

health outcomes in elderly patients

[diagnostic performance in patients]

diagnostic performance in patients

[risk mmol]

risk mmol

[intracellular antiadrenergic strategy in HF]

intracellular antiadrenergic strategy in HF

[levels of support]

levels of support

[circulating progenitor cells]

circulating progenitor cells

[non-survivors 64.26 years]

non-survivors 64.26 years

[difference median BNP in women EF]

difference median BNP in women EF

[Soluble concentrations]

Soluble concentrations

[persistent AF patients]

persistent AF patients

[evaluating predictors]

evaluating predictors

[treatments in adults]

treatments in adults

[ventricle in heart failure]

ventricle in heart failure

[growth in the setting]

growth in the setting

[component of the outcome]

component of the outcome

[categories]

categories

[fashion alterations in markers]

fashion alterations in markers

[Subgroup analysis]

Subgroup analysis

[Experience of a vasopressin receptor antagonist]

Experience of a vasopressin receptor antagonist

[Using rat cardiomyocytes]

Using rat cardiomyocytes

[Half]

Half

[function in HFpEF]

function in HFpEF

[Automatic Defibrillator Implantation Cardiac Resynchronization Therapy]

Automatic Defibrillator Implantation Cardiac Resynchronization Therapy

[rat risk model]

rat risk model

[10 transplant patients]

10 transplant patients

[tissue from mice]

tissue from mice

[comparing B-treated with failing hearts]

comparing B-treated with failing hearts

[hall]

hall

[272 patients undergoing LVAD implantation]

272 patients undergoing LVAD implantation

[2 hypotheses addition μg]

2 hypotheses addition μg

[66.6 years versus years]

66.6 years versus years

[surgical method of aortic constriction]

surgical method of aortic constriction

[Right ventricular RV failure]

Right ventricular RV failure

[arrhythmia events]

arrhythmia events

[difference BNP in women]

difference BNP in women

[post-transplant mortality]

post-transplant mortality

[Echocardiographic predictors of remodeling]

Echocardiographic predictors of remodeling

[Surgery Consensus Report]

Surgery Consensus Report

[outcome measures in experimental research]

outcome measures in experimental research

[using Cochrane Practice]

using Cochrane Practice

[race in patients]

race in patients

[global attenuation of alterations]

global attenuation of alterations

[cardiac energy metabolism gene expression]

cardiac energy metabolism gene expression

[abnormal Ca handling in HF]

abnormal Ca handling in HF

[progression in rats]

progression in rats

[concomitant downregulation]

concomitant downregulation

[therapeutic treatments targeting exercise status]

therapeutic treatments targeting exercise status

[using simulation models]

using simulation models

[Experience under the indication]

Experience under the indication

[history of successful valve plasty]

history of successful valve plasty

[QRS 160 ms]

QRS 160 ms

[CAD involving the anterior descending artery]

CAD involving the anterior descending artery

[2 independent hypotheses]

2 independent hypotheses

[one centre]

one centre

[myocardial events in patients]

myocardial events in patients

[recently for patients]

recently for patients

[membrane oxygenation ECMO on renal function]

membrane oxygenation ECMO on renal function

[prospective multicenter study]

prospective multicenter study

[log-rank]

log-rank

[HF clinic outpatients]

HF clinic outpatients

[70 versus ≥70 bpm]

70 versus ≥70 bpm

[effects of types HeartMate]

effects of types HeartMate

[Two hundred ninety-three HF patients]

Two hundred ninety-three HF patients

[min m vs. m]

min m vs. m

[multivariate assessment]

multivariate assessment

[RIα]

RIα

[Beneficial effect]

Beneficial effect

[decreases period versus 1]

decreases period versus 1

[Center]

Center

[days of inclusion]

days of inclusion

[cardioverter-defibrillator deactivation discussions]

cardioverter-defibrillator deactivation discussions

[infarction in Australia]

infarction in Australia

[human-to-machine interface]

human-to-machine interface

[ROS effects]

ROS effects

[end diameter mean difference]

end diameter mean difference

[right ventricular tricuspid plane systolic excursion]

right ventricular tricuspid plane systolic excursion

[Biventricular pacing]

Biventricular pacing

[plane excursion from the end]

plane excursion from the end

[Rem]

Rem

[years versus years]

years versus years

[heart failure patients with tachycardia]

heart failure patients with tachycardia

[mass removal]

mass removal

[statistically significant change with exercise]

statistically significant change with exercise

[heavy chain]

heavy chain

[ventricular ejection time complicating pulmonary hypertension]

ventricular ejection time complicating pulmonary hypertension

[right ventricular-pulmonary arterial coupling]

right ventricular-pulmonary arterial coupling

[chronic pulmonary hypertension PAH]

chronic pulmonary hypertension PAH

[lipoprotein properties]

lipoprotein properties

[cell differentiation toward cardiomyocyte-like cells]

cell differentiation toward cardiomyocyte-like cells

[powerful prognostic composite HF index]

powerful prognostic composite HF index

[LV myocytes with volume overload]

LV myocytes with volume overload

[lower activities of lyso-PAF-AT]

lower activities of lyso-PAF-AT

[revealing a fundamental mechanism]

revealing a fundamental mechanism

[inhibitory actions]

inhibitory actions

[economic models]

economic models

[evidence on associations]

evidence on associations

[CV events in models p]

CV events in models p

[severe impairment]

severe impairment

[sitagliptin versus sulfonylureas for sitagliptin]

sitagliptin versus sulfonylureas for sitagliptin

[patients with HR 70]

patients with HR 70

[severe dilatation during the years]

severe dilatation during the years

[simple tool]

simple tool

[current Cardiovascular Outcomes]

current Cardiovascular Outcomes

[measuring hospital change]

measuring hospital change

[resonance imaging on chelation choices]

resonance imaging on chelation choices

[cardiac insulin-resistance by weeks post-AAC]

cardiac insulin-resistance by weeks post-AAC

[longitudinal outcome-monitoring phase]

longitudinal outcome-monitoring phase

[animal model of chronic ischemia]

animal model of chronic ischemia

[Impact on implantable cardioverter-defibrillator therapy]

Impact on implantable cardioverter-defibrillator therapy

[major predictor]

major predictor

[Low skeletal muscle mass]

Low skeletal muscle mass

[individuals with cardiomyopathy]

individuals with cardiomyopathy

[incidence of HF]

incidence of HF

[study of exercise training in HF]

study of exercise training in HF

[adverse consequences]

adverse consequences

[Projections]

Projections

[HFrEF versus HFpEF]

HFrEF versus HFpEF

[predominantly asymptomatic Fontan PF patients]

predominantly asymptomatic Fontan PF patients

[24-hour brachial systolic pressure 155]

24-hour brachial systolic pressure 155

[prescribing medications with heart failure]

prescribing medications with heart failure

[useful technique detecting early fibrosis]

useful technique detecting early fibrosis

[ongoing GDMT for 6 months]

ongoing GDMT for 6 months

[consenting ambulatory HF patients]

consenting ambulatory HF patients

[clinical studies approximately 2900 HM]

clinical studies approximately 2900 HM

[patients with a left ejection fraction]

patients with a left ejection fraction

[LV contractility LVEF]

LV contractility LVEF

[heart failure filtration rate]

heart failure filtration rate

[metabolic gene expression]

metabolic gene expression

[sandwich AlphaLISA® immunoassays]

sandwich AlphaLISA® immunoassays

[Cardiovascular Disease Registry]

Cardiovascular Disease Registry

[patients with onset AF]

patients with onset AF

[numbers of cells]

numbers of cells

[HF-related cachexia]

HF-related cachexia

[Medical Outcomes Study]

Medical Outcomes Study

[AF type other than AF]

AF type other than AF

[prospective multicenter trial]

prospective multicenter trial

[ventricular-pulmonary coupling]

ventricular-pulmonary coupling

[10 HF patients without spontaneous VT]

10 HF patients without spontaneous VT

[Effects of cardiac support]

Effects of cardiac support

[rate relative risk]

rate relative risk

[minutes of moderate-intensity exercise]

minutes of moderate-intensity exercise

[morphology]

morphology

[using the Grading Assessment methodology]

using the Grading Assessment methodology

[valve tethering]

valve tethering

[self-identified patients]

self-identified patients

[single diagnostic test]

single diagnostic test

[particularly reducing all-cause mortality]

particularly reducing all-cause mortality

[mandatory systematic monitoring]

mandatory systematic monitoring

[significant decreases in LV shortening]

significant decreases in LV shortening

[spontaneous tachycardia]

spontaneous tachycardia

[prognostic assessment in hypertension patients]

prognostic assessment in hypertension patients

[patients with left ejection fraction HF]

patients with left ejection fraction HF

[using practice guidelines grading system]

using practice guidelines grading system

[EF≥50]

EF≥50

[DRS deciles]

DRS deciles

[implantable cardioverter-defibrillator shocks]

implantable cardioverter-defibrillator shocks

[Nursing Outcomes Classification]

Nursing Outcomes Classification

[erasers histone deacetylases]

erasers histone deacetylases

[prospective experimental research]

prospective experimental research

[low ejection fraction]

low ejection fraction

[survivors of cell transplantation]

survivors of cell transplantation

[renal chloride]

renal chloride

[ST2 levels]

ST2 levels

[5 patients as control]

5 patients as control

[MEDLINE databases trial registries]

MEDLINE databases trial registries

[assessment in pulmonary hypertension patients]

assessment in pulmonary hypertension patients

[evidence-based therapies]

evidence-based therapies

[temporary right support]

temporary right support

[consequence of heart rate variation]

consequence of heart rate variation

[mg dose]

mg dose

[downregulation of cardiac genes]

downregulation of cardiac genes

[biomarker HF]

biomarker HF

[right support]

right support

[selecting end points]

selecting end points

[porcine model of ischemia]

porcine model of ischemia

[reflecting R-R interval oscillations]

reflecting R-R interval oscillations

[P .001 decrease]

P .001 decrease

[patient factors]

patient factors

[outcomes related]

outcomes related

[S1PR1 agonist]

S1PR1 agonist

[Fifty patients with onset HFrEF days]

Fifty patients with onset HFrEF days

[predicting CV events in models p]

predicting CV events in models p

[Buddy]

Buddy

[modern rhythm control therapy]

modern rhythm control therapy

[terms of medication]

terms of medication

[older participants mean]

older participants mean

[acute infarction with major complications]

acute infarction with major complications

[important indicator]

important indicator

[advanced management]

advanced management

[IL mg]

IL mg

[higher heart rate]

higher heart rate

[Aldactone Evaluation]

Aldactone Evaluation

[characteristics use of medications]

characteristics use of medications

[right plane excursion TAPSE]

right plane excursion TAPSE

[high morbidity in people]

high morbidity in people

[prior n]

prior n

[45 deaths]

45 deaths

[necessitating a understanding of the mechanism]

necessitating a understanding of the mechanism

[Composite measures of quality]

Composite measures of quality

[patients ECCT]

patients ECCT

[Effective elastance Ea elastance]

Effective elastance Ea elastance

[n=44 925 ED visits years]

n=44 925 ED visits years

[lack of achievement]

lack of achievement

[area index cm(2)]

area index cm(2)

[impaired LV relaxation]

impaired LV relaxation

[speckle]

speckle

[case mix of HF]

case mix of HF

[targeting nonglycosylated epitopes P]

targeting nonglycosylated epitopes P

[chest model]

chest model

[incessant tachycardia storm]

incessant tachycardia storm

[Contemporary use]

Contemporary use

[diastolic annular velocity 3.1 vs. 1.3]

diastolic annular velocity 3.1 vs. 1.3

[Key role 2 scaffolds]

Key role 2 scaffolds

[surgical method of transverse constriction]

surgical method of transverse constriction

[race in patients with chronic HF]

race in patients with chronic HF

[2825 participants aged years]

2825 participants aged years

[promising targets for the prevention]

promising targets for the prevention

[follow-up of days]

follow-up of days

[characterization of one of these proteins]

characterization of one of these proteins

[ED visits age]

ED visits age

[Ca handling in dyssynchronous HF]

Ca handling in dyssynchronous HF

[individuals with disease]

individuals with disease

[Centre]

Centre

[human ventricular HF tissue samples]

human ventricular HF tissue samples

[ejection fraction P=0.01]

ejection fraction P=0.01

[T2D Type diabetes]

T2D Type diabetes

[potential usefulness in patients]

potential usefulness in patients

[Patients functional class]

Patients functional class

[disease groups heart failure]

disease groups heart failure

[data for key health outcomes]

data for key health outcomes

[concerns]

concerns

[Centers for Medicare 30-day readmission]

Centers for Medicare 30-day readmission

[enormous burden in medicine]

enormous burden in medicine

[association with postoperative mortality]

association with postoperative mortality

[Effect of inhibition on status]

Effect of inhibition on status

[promoting transcriptional pause release]

promoting transcriptional pause release

[812 consecutive patients aged 40 years]

812 consecutive patients aged 40 years

[inhospital outcomes]

inhospital outcomes

[age sex fraction]

age sex fraction

[World Health Organization]

World Health Organization

[heart failure ED visits years]

heart failure ED visits years

[even with normal systolic function]

even with normal systolic function

[impact in patients]

impact in patients

[Impact on cardioverter-defibrillator therapy]

Impact on cardioverter-defibrillator therapy

[overview of biomarker-guided trial design]

overview of biomarker-guided trial design

[heart circulatory failure]

heart circulatory failure

[N forms circulating NT-proBNP]

N forms circulating NT-proBNP

[Wasting]

Wasting

[novel therapeutic targets]

novel therapeutic targets

[basis of ventricle]

basis of ventricle

[MRI-based models]

MRI-based models

[Battery]

Battery

[Cross-talk in heart failure patients]

Cross-talk in heart failure patients

[video edge]

video edge

[major health problem worldwide]

major health problem worldwide

[ICU mortality stay]

ICU mortality stay

[14 clinical studies 2900 HM II]

14 clinical studies 2900 HM II

[thirty-seven hospitals from January]

thirty-seven hospitals from January

[Tricuspid]

Tricuspid

[potentially beneficial therapeutic approach]

potentially beneficial therapeutic approach

[cardiotoxicity still a agent]

cardiotoxicity still a agent

[occurring Rad variant Q66P]

occurring Rad variant Q66P

[aspects of remodeling contributing]

aspects of remodeling contributing

[Nursing Outcomes Classification NOC]

Nursing Outcomes Classification NOC

[patient with atrial myxoma]

patient with atrial myxoma

[peptide levels like biomarkers]

peptide levels like biomarkers

[plasma norepinephrine]

plasma norepinephrine

[Spearman correlations]

Spearman correlations

[diastole with transmitral flow]

diastole with transmitral flow

[eGFR 30 mL]

eGFR 30 mL

[range with advanced COPD n=95]

range with advanced COPD n=95

[Impact on inappropriate cardioverter-defibrillator therapy]

Impact on inappropriate cardioverter-defibrillator therapy

[mortality in this population]

mortality in this population

[Emergency Department ED]

Emergency Department ED

[cardiac hypertrophic response]

cardiac hypertrophic response

[autonomic system modulation]

autonomic system modulation

[most studies]

most studies

[resting HR P value=0.033]

resting HR P value=0.033

[predictor of mortality after admission]

predictor of mortality after admission

[health status symptoms]

health status symptoms

[subgroup analyses including quality]

subgroup analyses including quality

[circumflex artery LCX]

circumflex artery LCX

[inoperable hypertension]

inoperable hypertension

[dying in days P-value]

dying in days P-value

[RAAS]

RAAS

[New Zealand White rabbits undergoing DNx]

New Zealand White rabbits undergoing DNx

[hospitals through September]

hospitals through September

[death in athletes]

death in athletes

[right ejection fraction R=0.28 P=0.01]

right ejection fraction R=0.28 P=0.01

[comanagement with clinicians]

comanagement with clinicians

[Validating outcome measures in prospective research]

Validating outcome measures in prospective research

[GDMT for months]

GDMT for months

[adult Fontan SAF patients]

adult Fontan SAF patients

[physiologic processes]

physiologic processes

[coupling pulmonary vascular resistance]

coupling pulmonary vascular resistance

[accurate risk stratification of patient]

accurate risk stratification of patient

[B-type peptide BNP]

B-type peptide BNP

[more concrete data]

more concrete data

[interesting concepts]

interesting concepts

[Wistar rats]

Wistar rats

[140 mm]

140 mm

[ROSE heart failure trial]

ROSE heart failure trial

[Other risk factors]

Other risk factors

[systolic]

systolic

[functional efficacy]

functional efficacy

[diagnostic performance in patients with s'lateral]

diagnostic performance in patients with s'lateral

[factor in patients with PH]

factor in patients with PH

[post-TAC deterioration]

post-TAC deterioration

[difference median BNP EF]

difference median BNP EF

[patients with severe hypertension]

patients with severe hypertension

[percent remaining in deciles]

percent remaining in deciles

[target sodium]

target sodium

[global longitudinal systolic strain GLS]

global longitudinal systolic strain GLS

[alterations in SkM structure]

alterations in SkM structure

[pulmonary vascular resistance P]

pulmonary vascular resistance P

[anti-inflammatory effects]

anti-inflammatory effects

[clinical outcome in patients]

clinical outcome in patients

[wall thickness]

wall thickness

[chronic heart failure with function]

chronic heart failure with function

[left end diameter mm]

left end diameter mm

[Practice Guideline CPG recommendations]

Practice Guideline CPG recommendations

[heart failure attributable]

heart failure attributable

[major adverse event-free rate]

major adverse event-free rate

[patients with cardiomyopathy IC]

patients with cardiomyopathy IC

[effect following β-AR stimulation]

effect following β-AR stimulation

[transplant patients receiving PD solely]

transplant patients receiving PD solely

[Survival after ventricular assist device]

Survival after ventricular assist device

[measure in patients with HFpEF]

measure in patients with HFpEF

[powerful predictor]

powerful predictor

[low systemic vascular resistance index]

low systemic vascular resistance index

[left bundle branch]

left bundle branch

[2 independent hypotheses addition μg]

2 independent hypotheses addition μg

[month after discharge]

month after discharge

[National trends for four conditions]

National trends for four conditions

[Fifty consecutive patients]

Fifty consecutive patients

[PF mean]

PF mean

[suboptimal care of patients]

suboptimal care of patients

[importance for myocardial DD]

importance for myocardial DD

[Eight weeks]

Eight weeks

[statistically significant improvement]

statistically significant improvement

[endothelial cell nitric oxide production]

endothelial cell nitric oxide production

[targeting abnormal exercise hemodynamic status]

targeting abnormal exercise hemodynamic status

[valve oversewing]

valve oversewing

[end point hazard ratio]

end point hazard ratio

[taxonomy]

taxonomy

[sacubiltril]

sacubiltril

[reduction of tone]

reduction of tone

[diastolic blood pressure]

diastolic blood pressure

[RAFT]

RAFT

[lower fat body mass ratio]

lower fat body mass ratio

[period of ventricular fibrillation]

period of ventricular fibrillation

[restoration]

restoration

[arterial pressure relationship an index]

arterial pressure relationship an index

[biomarkers in patients with heart failure]

biomarkers in patients with heart failure

[add-on diagnostic features]

add-on diagnostic features

[gross income per capita]

gross income per capita

[priorities]

priorities

[such as patient preferences]

such as patient preferences

[weeks of diet]

weeks of diet

[low left ejection fraction]

low left ejection fraction

[increasing number]

increasing number

[efficacy of left-to-right interatrial shunting]

efficacy of left-to-right interatrial shunting

[pacing on left heart twist]

pacing on left heart twist

[distinct subset]

distinct subset

[Moderate-strength evidence]

Moderate-strength evidence

[correlation between changes NO production]

correlation between changes NO production

[key health outcomes in patients]

key health outcomes in patients

[TAPSE as measures]

TAPSE as measures

[all-cause hospitalization within the prior months]

all-cause hospitalization within the prior months

[hospitalizations in severe congestive heart failure]

hospitalizations in severe congestive heart failure

[cardiac activity (123)I-meta-iodobenzylguanidine]

cardiac activity (123)I-meta-iodobenzylguanidine

[acute pressure overload RVPO]

acute pressure overload RVPO

[actions on CaV1.2]

actions on CaV1.2

[tomography]

tomography

[serum levels of creatinine]

serum levels of creatinine

[outcomes in other patients]

outcomes in other patients

[group of patients consisting]

group of patients consisting

[sub-sample]

sub-sample

[sitagliptin CI for sitagliptin]

sitagliptin CI for sitagliptin

[therapeutic left-to-right interatrial shunting]

therapeutic left-to-right interatrial shunting

[approximately 3,000 patients]

approximately 3,000 patients

[nucleotides]

nucleotides

[central blood pressure via radial tonometry]

central blood pressure via radial tonometry

[volumes of exercise]

volumes of exercise

[11 587 new users]

11 587 new users

[participants with heart failure dopamine]

participants with heart failure dopamine

[LV assist]

LV assist

[Incubation]

Incubation

[Effective elastance Ea end-systolic elastance Ees]

Effective elastance Ea end-systolic elastance Ees

[studies evaluating predictors on ICD patients]

studies evaluating predictors on ICD patients

[aggressive treatment for HF with vasodilators]

aggressive treatment for HF with vasodilators

[criteriabased institution]

criteriabased institution

[Medicare beneficiaries]

Medicare beneficiaries

[most powerful independent predictor]

most powerful independent predictor

[careful evaluation of the indications]

careful evaluation of the indications

[undergoing left assist device LVAD implantation]

undergoing left assist device LVAD implantation

[age groups 20]

age groups 20

[stages of heart failure]

stages of heart failure

[panel of electrocardiographers]

panel of electrocardiographers

[independent hypotheses addition]

independent hypotheses addition

[universal definition]

universal definition

[4 expression]

4 expression

[undergoing VAD]

undergoing VAD

[Outcomes of Exercise Training]

Outcomes of Exercise Training

[Orthotopic heart transplantation]

Orthotopic heart transplantation

[ventricular ejection fraction 0.35]

ventricular ejection fraction 0.35

[effect of an number]

effect of an number

[evidence of dyssynchrony]

evidence of dyssynchrony

[metabolic changes in the development]

metabolic changes in the development

[patients experiencing distressing cardioverter-defibrillator shocks]

patients experiencing distressing cardioverter-defibrillator shocks

[severe dysfunction]

severe dysfunction

[GRADE]

GRADE

[common underlying characteristics using Cochrane Practice]

common underlying characteristics using Cochrane Practice

[SkM skeletal muscle]

SkM skeletal muscle

[correlation between changes]

correlation between changes

[beta-blocker therapy in heart failure]

beta-blocker therapy in heart failure

[peak flow velocity]

peak flow velocity

[major neurological rate]

major neurological rate

[prevention strategies]

prevention strategies

[percent of hospitals in an decile]

percent of hospitals in an decile

[23.7 ng range 18.6]

23.7 ng range 18.6

[trial with moderate]

trial with moderate

[individuals with chronic pulmonary disease]

individuals with chronic pulmonary disease

[hospitals in Jersey]

hospitals in Jersey

[modification of diet in disease]

modification of diet in disease

[limited amount]

limited amount

[novel intracellular strategy]

novel intracellular strategy

[glucocorticoid dosage]

glucocorticoid dosage

[Process Redesign framework]

Process Redesign framework

[8000 individuals with heart failure]

8000 individuals with heart failure

[myocardial matrix using resonance T1 mapping]

myocardial matrix using resonance T1 mapping

[Advances in treatment for myocardial infarction]

Advances in treatment for myocardial infarction

[arterial coupling vascular resistance]

arterial coupling vascular resistance

[acute right ventricular pressure overload]

acute right ventricular pressure overload

[artery bypass surgery]

artery bypass surgery

[collaboration of professionals]

collaboration of professionals

[ARNI inhibitors]

ARNI inhibitors

[providing prognostic information]

providing prognostic information

[noncoding RNAs]

noncoding RNAs

[risk for outcomes]

risk for outcomes

[using inhibitors]

using inhibitors

[development following ring annuloplasty for MR]

development following ring annuloplasty for MR

[suggesting postcontrast T1]

suggesting postcontrast T1

[treatments for anemia]

treatments for anemia

[system neurological events]

system neurological events

[adaptation of the myocardium]

adaptation of the myocardium

[Rad variant Q66P]

Rad variant Q66P

[17 days]

17 days

[leg strength]

leg strength

[angiotensin-converting enzyme]

angiotensin-converting enzyme

[ventricular strain GLS]

ventricular strain GLS

[PDE2 inhibition]

PDE2 inhibition

[treatment variation]

treatment variation

[significant improvement in rate risk]

significant improvement in rate risk

[ventricular dyssynchrony]

ventricular dyssynchrony

[background for aldosterone antagonist therapy]

background for aldosterone antagonist therapy

[Validating outcome measures in experimental research]

Validating outcome measures in experimental research

[Soluble ST2 in patients]

Soluble ST2 in patients

[chronic failure]

chronic failure

[maximal medical treatment]

maximal medical treatment

[expressing resistin]

expressing resistin

[testing a device]

testing a device

[assessments of patients within 7 days]

assessments of patients within 7 days

[drug-untreated hearts]

drug-untreated hearts

[risk stratification with heart failure appropriate]

risk stratification with heart failure appropriate

[β-blocker metoprolol]

β-blocker metoprolol

[effects in vivo]

effects in vivo

[median ventricular ejection fraction]

median ventricular ejection fraction

[Hazard]

Hazard

[trial of Nordic walking in patients]

trial of Nordic walking in patients

[4 hospitals in Jersey]

4 hospitals in Jersey

[334 patients men mean]

334 patients men mean

[ng range]

ng range

[severe dilatation]

severe dilatation

[staff]

staff

[body mass index categories]

body mass index categories

[varying delay AVD]

varying delay AVD

[determining the adaptive remodelling]

determining the adaptive remodelling

[studies including calcium-sensitizing agents]

studies including calcium-sensitizing agents

[value of indeterminable anaerobic threshold]

value of indeterminable anaerobic threshold

[trends for conditions]

trends for conditions

[interventricular delay]

interventricular delay

[SDRR]

SDRR

[hospital longitudinal change]

hospital longitudinal change

[constriction AAC]

constriction AAC

[role in aspects of remodeling]

role in aspects of remodeling

[BRD4]

BRD4

[plasma B-type peptide BNP]

plasma B-type peptide BNP

[respiratory quotient]

respiratory quotient

[measures such as time-domain measures]

measures such as time-domain measures

[intraclass correlation coefficient]

intraclass correlation coefficient

[angiotensin II receptor]

angiotensin II receptor

[effect with a familiar physician]

effect with a familiar physician

[patients presenting]

patients presenting

[angioplasty]

angioplasty

[NYHA class IV]

NYHA class IV

[Obese Older Patients]

Obese Older Patients

[hospitals nationwide]

hospitals nationwide

[institution of PD for the treatment]

institution of PD for the treatment

[revascularization artery bypass surgery hazard ratio]

revascularization artery bypass surgery hazard ratio

[developing congestive heart failure]

developing congestive heart failure

[peak early flow velocity]

peak early flow velocity

[benefit over conventional systolic parameters]

benefit over conventional systolic parameters

[doses of JQ1]

doses of JQ1

[treatment for patients]

treatment for patients

[L-type channel activity]

L-type channel activity

[potassium mmol]

potassium mmol

[end-diastolic]

end-diastolic

[hospitalization in HF clinic outpatients]

hospitalization in HF clinic outpatients

[survival of patients with hypoalbuminemia]

survival of patients with hypoalbuminemia

[Relation between preoperative renal dysfunction]

Relation between preoperative renal dysfunction

[Hospital-to-Home]

Hospital-to-Home

[ROSE heart failure]

ROSE heart failure

[discussions about treatment preferences]

discussions about treatment preferences

[direct effects]

direct effects

[effects of this therapy]

effects of this therapy

[changes in ventricular diastolic function]

changes in ventricular diastolic function

[gaps in impact]

gaps in impact

[ventricular fibrillation PVF]

ventricular fibrillation PVF

[patients with anemia]

patients with anemia

[global left longitudinal systolic strain GLS]

global left longitudinal systolic strain GLS

[strong predictor after admission]

strong predictor after admission

[Cox proportional hazards]

Cox proportional hazards

[Experience under the unique indication]

Experience under the unique indication

[abnormal Ca 2 handling in HF]

abnormal Ca 2 handling in HF

[Improving survival rates of patients]

Improving survival rates of patients

[treatment of hyponatremia]

treatment of hyponatremia

[cumulative administration of doxorubicin]

cumulative administration of doxorubicin

[CardioPulmonary Exercise Testing CPET guide]

CardioPulmonary Exercise Testing CPET guide

[forms of remodeling]

forms of remodeling

[trichrome blue histologic analysis]

trichrome blue histologic analysis

[Transoesophageal]

Transoesophageal

[crucial problem]

crucial problem

[Function Among Patients With Shortness]

Function Among Patients With Shortness

[outpatients with systolic HF]

outpatients with systolic HF

[onset following myocardial infarction]

onset following myocardial infarction

[268 records of patients]

268 records of patients

[promoting filling especially in subjects]

promoting filling especially in subjects

[early HF]

early HF

[LV shortening]

LV shortening

[Male patients with SD testosterone levels]

Male patients with SD testosterone levels

[therapy with beta blockade]

therapy with beta blockade

[PCWP estimation]

PCWP estimation

[Defibrillator Implantation With Cardiac Resynchronization Therapy]

Defibrillator Implantation With Cardiac Resynchronization Therapy

[cardiotoxicity among patients]

cardiotoxicity among patients

[receptor β-AR]

receptor β-AR

[50 μmol]

50 μmol

[major determinant of quality]

major determinant of quality

[cardiac volume index]

cardiac volume index

[practice guideline from the College]

practice guideline from the College

[mRNA levels for SR Ca]

mRNA levels for SR Ca

[Modification]

Modification

[1-day decrease]

1-day decrease

[College of Physicians ACP]

College of Physicians ACP

[little impact on development]

little impact on development

[mild clinical dysfunction]

mild clinical dysfunction

[meta-analyses]

meta-analyses

[using trichrome analysis]

using trichrome analysis

[porcine model of reversible ischemia]

porcine model of reversible ischemia

[peripheral artery disease]

peripheral artery disease

[independent association]

independent association

[patients in the CRT group]

patients in the CRT group

[100 mg·kg(-1)·day(-1)]

100 mg·kg(-1)·day(-1)

[requiring isolated LVAD]

requiring isolated LVAD

[clinical tool for risk stratification]

clinical tool for risk stratification

[symptomatic heart failure]

symptomatic heart failure

[MicroRNAs new targets]

MicroRNAs new targets

[STS HH HR interval]

STS HH HR interval

[HF volume management]

HF volume management

[exercise-induced artery pressure increase by means]

exercise-induced artery pressure increase by means

[grain]

grain

[wasting]

wasting

[left diastolic end diameter difference]

left diastolic end diameter difference

[including the States]

including the States

[proximal left artery]

proximal left artery

[subjects with heart failure]

subjects with heart failure

[Cardiac symptoms]

Cardiac symptoms

[prognostic relevance of reserve in patients]

prognostic relevance of reserve in patients

[3 pharmacologic studies]

3 pharmacologic studies

[circumferential strain CS]

circumferential strain CS

[left strain GLS]

left strain GLS

[placebo for days]

placebo for days

[Comment for the Treatment]

Comment for the Treatment

[major insulin-signaling components regulating metabolism]

major insulin-signaling components regulating metabolism

[patients with acute myocardial infarction]

patients with acute myocardial infarction

[post hoc]

post hoc

[hospitalization within the prior 1 months]

hospitalization within the prior 1 months

[DPP-4 inhibitors]

DPP-4 inhibitors

[low eGFR years]

low eGFR years

[forms in the circulation]

forms in the circulation

[paradigm]

paradigm

[16 patients with CHF-NYHA-III HDL]

16 patients with CHF-NYHA-III HDL

[regarding conditions]

regarding conditions

[HF ejection fractions]

HF ejection fractions

[prospective data on the potential]

prospective data on the potential

[system adverse neurological events]

system adverse neurological events

[cost-effectiveness analyses of disease management programs]

cost-effectiveness analyses of disease management programs

[change in MLHF score]

change in MLHF score

[paradox]

paradox

[ZSF1 with diet n=11]

ZSF1 with diet n=11

[arginine vasopressin AVP]

arginine vasopressin AVP

[Concentrations of ST2]

Concentrations of ST2

[cGMP synthesis]

cGMP synthesis

[phospholipase]

phospholipase

[differential effect]

differential effect

[lower HF mortality]

lower HF mortality

[assessment of these patients]

assessment of these patients

[bolus of metoprolol]

bolus of metoprolol

[improvements in functioning]

improvements in functioning

[further review]

further review

[proximal anterior descending artery]

proximal anterior descending artery

[membrane oxygenation as bridge]

membrane oxygenation as bridge

[users of bisphophonates]

users of bisphophonates

[edema]

edema

[demonstrating development of functional MS]

demonstrating development of functional MS

[volume overload VO of regurgitation]

volume overload VO of regurgitation

[significantly larger HR reduction 17±22]

significantly larger HR reduction 17±22

[distinct derangement with features]

distinct derangement with features

[Major trials]

Major trials

[heart failure of etiology]

heart failure of etiology

[cardioverter-defibrillator therapy Multicenter Defibrillator Implantation]

cardioverter-defibrillator therapy Multicenter Defibrillator Implantation

[patients treatment]

patients treatment

[same exercise time]

same exercise time

[outcomes such as hospitalisations]

outcomes such as hospitalisations

[receptor agonist]

receptor agonist

[four remodeling aspects]

four remodeling aspects

[chronic arterial hypertension PAH]

chronic arterial hypertension PAH

[adjustment for patient characteristics]

adjustment for patient characteristics

[possible care of patients]

possible care of patients

[predictors on 257,692 ICD patients]

predictors on 257,692 ICD patients

[major underlying mechanism]

major underlying mechanism

[subgroup of children]

subgroup of children

[Inventory]

Inventory

[well-being in all participants]

well-being in all participants

[national attention]

national attention

[full Medicare coverage]

full Medicare coverage

[addition indicating suboptimal care]

addition indicating suboptimal care

[heart failure research]

heart failure research

[difference in the ability]

difference in the ability

[STS HH HR credible interval]

STS HH HR credible interval

[Global ventricular strain]

Global ventricular strain

[von Willebrand factor concentrations in Arg16]

von Willebrand factor concentrations in Arg16

[potential application]

potential application

[incidence in MT VAD groups]

incidence in MT VAD groups

[pulmonary artery systolic pressure increase]

pulmonary artery systolic pressure increase

[role in stable artery disease]

role in stable artery disease

[receiving the dose of doxorubicin]

receiving the dose of doxorubicin

[substantial subset of genes]

substantial subset of genes

[advanced chronic obstructive disease]

advanced chronic obstructive disease

[conventional parameters in AF]

conventional parameters in AF

[independent predictor period versus 1]

independent predictor period versus 1

[autonomic nervous system modulation]

autonomic nervous system modulation

[study of patients with infarction]

study of patients with infarction

[24-hour brachial pressure 155]

24-hour brachial pressure 155

[independent predictor period hazard ratio]

independent predictor period hazard ratio

[neurohormonal activation]

neurohormonal activation

[burden because of the prevalence]

burden because of the prevalence

[NT-proBNP cutoff]

NT-proBNP cutoff

[15 ml odds ratio]

15 ml odds ratio

[maximum oxygen consumption]

maximum oxygen consumption

[intermediate odds ratios]

intermediate odds ratios

[mechanical support on renal function]

mechanical support on renal function

[determinant of quality QOL]

determinant of quality QOL

[heart failure ED visits]

heart failure ED visits

[scar]

scar

[fit versus men]

fit versus men

[risk developing congestive heart failure]

risk developing congestive heart failure

[randomization group]

randomization group

[risk stratification between a large group]

risk stratification between a large group

[patients with ventricular ejection fraction 0.35]

patients with ventricular ejection fraction 0.35

[target audience]

target audience

[metabolism quotient]

metabolism quotient

[ambulatory HF patients ventricular ejection fraction]

ambulatory HF patients ventricular ejection fraction

[difference at the exercise time]

difference at the exercise time

[first infarction in Western Australia]

first infarction in Western Australia

[Heart Study]

Heart Study

[increase for infarction]

increase for infarction

[right ventricular RV annular plane excursion]

right ventricular RV annular plane excursion

[changes in ventricular function]

changes in ventricular function

[lack of data]

lack of data

[matrix of left ventricular biopsies]

matrix of left ventricular biopsies

[hospitalization within the prior months]

hospitalization within the prior months

[mortality predictors in ICD-HF patients]

mortality predictors in ICD-HF patients

[using metrics for three disease groups]

using metrics for three disease groups

[prognostic benefit over systolic parameters]

prognostic benefit over systolic parameters

[investigating cachexia]

investigating cachexia

[Treatment in patients a review]

Treatment in patients a review

[eGFR years]

eGFR years

[surviving an acute infarction]

surviving an acute infarction

[reductions in LV end volume index]

reductions in LV end volume index

[KCCQ category]

KCCQ category

[AMI admission]

AMI admission

[cardiac genes in HF]

cardiac genes in HF

[Stage 3 kidney disease CKD]

Stage 3 kidney disease CKD

[Heart failure with ventricular ejection fraction]

Heart failure with ventricular ejection fraction

[LV dimension P]

LV dimension P

[mechanics]

mechanics

[experiencing implantable cardioverter-defibrillator shocks]

experiencing implantable cardioverter-defibrillator shocks

[risk hazard ratio]

risk hazard ratio

[NP assessment]

NP assessment

[other conditions such as myocardial infarction]

other conditions such as myocardial infarction

[natriuretic peptide B-type natriuretic peptide]

natriuretic peptide B-type natriuretic peptide

[stimulation FES]

stimulation FES

[change in C-index]

change in C-index

[6 min 59.6 m]

6 min 59.6 m

[Fifty-four asymptomatic Fontan PF patients]

Fifty-four asymptomatic Fontan PF patients

[independent markers]

independent markers

[data from trials]

data from trials

[time-varying covariates]

time-varying covariates

[range 6 days]

range 6 days

[Gene expression]

Gene expression

[normal geometry]

normal geometry

[tricuspid annular plane excursion TAPSE]

tricuspid annular plane excursion TAPSE

[150 minutes of aerobic exercise]

150 minutes of aerobic exercise

[all-cause mortality hazard ratio]

all-cause mortality hazard ratio

[insulin products from 2006]

insulin products from 2006

[activators]

activators

[activity by ((123)I-MIBG]

activity by ((123)I-MIBG

[type II regulatory]

type II regulatory

[increase in cardiac risk]

increase in cardiac risk

[treating patients with heart failure]

treating patients with heart failure

[family of reader proteins]

family of reader proteins

[determinants of long-term survival]

determinants of long-term survival

[receiving PD for HF volume management]

receiving PD for HF volume management

[Incidence of end-stage disease]

Incidence of end-stage disease

[proteomics changes in constriction]

proteomics changes in constriction

[annular velocity 3.1]

annular velocity 3.1

[clinical dysfunction leading]

clinical dysfunction leading

[transitions of care program]

transitions of care program

[predictors of remodeling after resynchronization therapy]

predictors of remodeling after resynchronization therapy

[Department in a university hospital]

Department in a university hospital

[Relation within months]

Relation within months

[use of POC testing]

use of POC testing

[Left assist devices]

Left assist devices

[Differential effects]

Differential effects

[6 trials]

6 trials

[lower income]

lower income

[Patient Management Interventions]

Patient Management Interventions

[studies including agents of endothelin]

studies including agents of endothelin

[2 types of LVADs HeartMate]

2 types of LVADs HeartMate

[cohort with incident]

cohort with incident

[nutritional strategies]

nutritional strategies

[causes of MS]

causes of MS

[significant gastrointestinal bleeding]

significant gastrointestinal bleeding

[analysis of subgroups of patients]

analysis of subgroups of patients

[naturally occurring Rad variant]

naturally occurring Rad variant

[histone acetyltransferases]

histone acetyltransferases

[ninety-three HF patients]

ninety-three HF patients

[cAMP levels]

cAMP levels

[334 consecutive patients]

334 consecutive patients

[traditional heart failure]

traditional heart failure

[diastolic filling time]

diastolic filling time

[risk factors such as diabetes mellitus]

risk factors such as diabetes mellitus

[nondiabetes]

nondiabetes

[VEN]

VEN

[Global ventricular longitudinal strain]

Global ventricular longitudinal strain

[beta-adrenergic receptor signaling in cardiomyocytes]

beta-adrenergic receptor signaling in cardiomyocytes

[only a limited amount of data]

only a limited amount of data

[higher rate]

higher rates, higher rate

[regulatory involvement]

regulatory involvement

[NOC outcomes]

NOC outcomes

[disappearance]

disappearance

[diagnosis of HF]

diagnosis of HF

[surgical method of constriction]

surgical method of constriction

[systemic vascular resistance index]

systemic vascular resistance index

[national trends in event rates]

national trends in event rates

[provision]

provision

[change in Paco2]

change in Paco2

[insertion]

insertion

[quasi-experiment]

quasi-experiment

[neprilysin blocks renin-angiotensin-aldosteron RAS axis]

neprilysin blocks renin-angiotensin-aldosteron RAS axis

[neurological rate]

neurological rate

[morbidity in people]

morbidity in people

[systemic resistance index]

systemic resistance index

[higher serum levels of peptide]

higher serum levels of peptide

[risk of adverse outcomes]

risk of adverse outcomes

[quantification of T1 in swine]

quantification of T1 in swine

[subset of phenylephrine-induced genes]

subset of phenylephrine-induced genes

[anaerobic metabolism quotient]

anaerobic metabolism quotient

[endothelial growth factor]

endothelial growth factor

[assist device LVAD implantation]

assist device LVAD implantation

[careful management]

careful management

[requiring revision for aortic valve replacement]

requiring revision for aortic valve replacement

[four HF remodeling aspects]

four HF remodeling aspects

[February]

February

[odds of future]

odds of future

[benefit in the prediction]

benefit in the prediction

[patients with QRS]

patients with QRS

[Outcomes of Exercise Training multicenter study]

Outcomes of Exercise Training multicenter study

[diastolic end diameter difference]

diastolic end diameter difference

[reductions in the number]

reductions in the number

[correction of aortic valve insufficiency]

correction of aortic valve insufficiency

[cardiac disease]

cardiac disease

[including fat]

including fat

[absolute increase]

absolute increase

[cardioverter-defibrillator deactivation preferences]

cardioverter-defibrillator deactivation preferences

[aspects contributing]

aspects contributing

[form of arterial disease]

form of arterial disease

[VEGF signaling pathway]

VEGF signaling pathway

[regarding the role of stenting]

regarding the role of stenting

[array of diagnostic procedures]

array of diagnostic procedures

[alterations in sarcomeric microstructure]

alterations in sarcomeric microstructure

[Protective effects of exercise training ET]

Protective effects of exercise training ET

[New Users]

New Users

[Management of patients stemming]

Management of patients stemming

[high clinical relevance]

high clinical relevance

[with.estimates ranging]

with.estimates ranging

[cardiovascular events during the months]

cardiovascular events during the months

[cause of HF]

cause of HF

[cardiology services]

cardiology services

[number from baseline]

number from baseline

[persistent AF]

persistent AF

[2 DRS deciles]

2 DRS deciles

[NYHA classification]

NYHA classification

[biomarker of cardiotoxicity]

biomarker of cardiotoxicity

[involvement of G-protein-coupled receptor kinase-2]

involvement of G-protein-coupled receptor kinase-2

[women with a history]

women with a history

[10,000 pairs of cohorts]

10,000 pairs of cohorts

[vascular resistance SVR]

vascular resistance SVR

[acute HF years]

acute HF years

[subclinical atherosclerosis using linear models]

subclinical atherosclerosis using linear models

[reducing the endpoint]

reducing the endpoint

[relevance in hypertension patients]

relevance in hypertension patients

[Clinical Practice Guideline]

Clinical Practice Guideline

[median PASP]

median PASP

[predictors on ICD patients]

predictors on ICD patients

[changes with varying strain contributions]

changes with varying strain contributions

[amyloidosis]

amyloidosis

[Peritoneal dialysis PD for management]

Peritoneal dialysis PD for management

[characteristics use]

characteristics use

[Low-dose dopamine]

Low-dose dopamine

[worse heart failure-related QOL outcome]

worse heart failure-related QOL outcome

[trend toward an association]

trend toward an association

[type of cardiac benign tumors]

type of cardiac benign tumors

[BB dose versus mg equivalent dose]

BB dose versus mg equivalent dose

[predictor of HF]

predictor of HF

[common cause of hospitalization]

common cause of hospitalization

[GDMT treatment group]

GDMT treatment group

[association with mortality in patients]

association with mortality in patients

[β-myosin heavy chain]

β-myosin heavy chain

[knowledge on use in HF]

knowledge on use in HF

[drug-free success rates]

drug-free success rates

[development of functional MS]

development of functional MS

[Western health data]

Western health data

[older participants]

older participants

[target doses for beta-blocker therapy]

target doses for beta-blocker therapy

[inferior vena cava]

inferior vena cava

[performance only in patients]

performance only in patients

[generation NT-proBNP assay]

generation NT-proBNP assay

[first postoperative months]

first postoperative months

[symptoms Beck]

symptoms Beck

[reduction in LV volume]

reduction in LV volume

[community-based cohort]

community-based cohort

[metabolic risk factors]

metabolic risk factors

[outcome measures in future prospective research]

outcome measures in future prospective research

[patients men mean 65±12 years]

patients men mean 65±12 years

[dietary measures]

dietary measures

[metric choice for applications]

metric choice for applications

[revealing a mechanism during insulin resistance]

revealing a mechanism during insulin resistance

[targets for the prevention of HF]

targets for the prevention of HF

[using an antagonist]

using an antagonist

[Lokomat® system]

Lokomat® system

[agreement difference]

agreement difference

[4.5 seconds]

4.5 seconds

[also in patients]

also in patients

[decade of heart failure HF]

decade of heart failure HF

[relevance of right contractile reserve]

relevance of right contractile reserve

[impact of RAS uptitrations]

impact of RAS uptitrations

[LV end-diastolic volume LV volume]

LV end-diastolic volume LV volume

[existing quality indicators]

existing quality indicators

[new-onset severe AI requiring intervention]

new-onset severe AI requiring intervention

[stem cell source]

stem cell source

[adjusting for covariates]

adjusting for covariates

[24-hour pressure 155 35]

24-hour pressure 155 35

[dystrophin-associated protein complex]

dystrophin-associated protein complex

[Cooper Center Study]

Cooper Center Study

[uptitration of blockers]

uptitration of blockers

[LV volume LV volume]

LV volume LV volume

[carrying increase in cardiac risk]

carrying increase in cardiac risk

[addition of dopamine 2 μg]

addition of dopamine 2 μg

[suggesting a surrogate]

suggesting a surrogate

[lower 6-minute walking distance]

lower 6-minute walking distance

[GDMT-treated NYHA class III HF]

GDMT-treated NYHA class III HF

[diagnostic performance only in patients]

diagnostic performance only in patients

[body composition a study]

body composition a study

[heart dilatation after constriction TAC]

heart dilatation after constriction TAC

[specific strategies]

specific strategies

[effects on heart failure]

effects on heart failure

[new systematic review]

new systematic review

[334 patients men years]

334 patients men years

[PF cohort]

PF cohort

[interquartile range with advanced COPD]

interquartile range with advanced COPD

[Inpatient Registry]

Inpatient Registry

[synthase]

synthase

[therapy shock]

therapy shock

[fragment NT-proBNP]

fragment NT-proBNP

[msec]

msec

[E-wave early diastolic mitral annular velocity]

E-wave early diastolic mitral annular velocity

[Impact of physician continuity after discharge]

Impact of physician continuity after discharge

[admission NT-proBNP]

admission NT-proBNP

[Abnormal T2 values]

Abnormal T2 values

[coronary artery bypass surgery]

coronary artery bypass surgery

[pro-brain-type peptide assessment]

pro-brain-type peptide assessment

[pacing period]

pacing period

[powerful predictor period versus 1]

powerful predictor period versus 1

[heart failure in children]

heart failure in children

[conventional clinical parameters]

conventional clinical parameters

[fluid overload]

fluid overload

[ejection fraction difference]

ejection fraction difference

[myocardial infarction in Australia]

myocardial infarction in Australia

[beta-dependent yield]

beta-dependent yield

[interval between depolarization]

interval between depolarization

[Many predictors of mortality]

Many predictors of mortality

[deaths occurring within 30 days]

deaths occurring within 30 days

[sinus rhythm hazard ratio]

sinus rhythm hazard ratio

[exercise-induced artery systolic pressure PASP increase]

exercise-induced artery systolic pressure PASP increase

[CAD involving the artery]

CAD involving the artery

[patients with an defibrillator]

patients with an defibrillator

[cells in vitro]

cells in vitro

[interatrial shunt]

interatrial shunt

[low mg daily dose]

low mg daily dose

[loop diuretics]

loop diuretics

[muscle abnormalities]

muscle abnormalities

[doxorubicin kg ip]

doxorubicin kg ip

[guidelines definition]

guidelines definition

[0.005 μg]

0.005 μg

[mortality than several cancers]

mortality than several cancers

[median activities P]

median activities P

[muscle sarcomere structure in patients]

muscle sarcomere structure in patients

[excessive β-AR drive]

excessive β-AR drive

[infarcted animals]

infarcted animals

[anaerobic metabolism respiratory quotient]

anaerobic metabolism respiratory quotient

[Renal Atherosclerotic Lesions]

Renal Atherosclerotic Lesions

[Mena overexpression TTA]

Mena overexpression TTA

[event rates between 2005]

event rates between 2005

[quick pump-exchange technique]

quick pump-exchange technique

[end-stage congestive heart failure]

end-stage congestive heart failure

[quality improvement database]

quality improvement database

[risk developing heart failure CHF]

risk developing heart failure CHF

[oxide donors]

oxide donors

[myosin]

myosin

[healthy heart muscle cells]

healthy heart muscle cells

[validity of the KCCQ Summary scores]

validity of the KCCQ Summary scores

[adults with ejection fraction]

adults with ejection fraction

[pathophysiology of heart failure]

pathophysiology of heart failure

[normal LV]

normal LV

[membrane oxygenation membrane support]

membrane oxygenation membrane support

[improvements in composite response]

improvements in composite response

[bromodomain proteins]

bromodomain proteins

[region of this molecule]

region of this molecule

[reflecting decreases in heart failure-related mortality]

reflecting decreases in heart failure-related mortality

[death visit]

death visit

[patients gender]

patients gender

[disease from the population]

disease from the population

[Many current predictors]

Many current predictors

[common cause among the elderly]

common cause among the elderly

[GATA4]

GATA4

[11 kg]

11 kg

[using a metric]

using a metric

[Cox hazards regression modeling]

Cox hazards regression modeling

[antagonizing excessive β-AR drive]

antagonizing excessive β-AR drive

[giving rise in dyssynchronous HF]

giving rise in dyssynchronous HF

[cumulative administration in rats]

cumulative administration in rats

[fastest subclass of cardiovascular diseases]

fastest subclass of cardiovascular diseases

[ventricular tricuspid annular plane systolic excursion]

ventricular tricuspid annular plane systolic excursion

[significant bleeding]

significant bleeding

[inhibition of growth factor]

inhibition of growth factor

[left ejection fraction difference]

left ejection fraction difference

[change in measures]

change in measures

[attenuation of proteome changes]

attenuation of proteome changes

[cardiac chromatin]

cardiac chromatin

[ST-segment-elevation]

ST-segment-elevation

[cAMP-dependent protein kinase PKA]

cAMP-dependent protein kinase PKA

[value of threshold in heart failure]

value of threshold in heart failure

[undergoing renal DNx]

undergoing renal DNx

[evaluating 63 predictors on ICD patients]

evaluating 63 predictors on ICD patients

[patients with recent onset HFrEF]

patients with recent onset HFrEF

[dysfunction in patients]

dysfunction in patients

[severe systolic heart failure]

severe systolic heart failure

[program with testosterone supplementation]

program with testosterone supplementation

[independent correlates]

independent correlates

[using trichrome blue analysis]

using trichrome blue analysis

[percentage of collagen]

percentage of collagen

[Mild Patients]

Mild Patients

[parallel with global attenuation]

parallel with global attenuation

[cardiac myocyte-specific Mena overexpression comparable]

cardiac myocyte-specific Mena overexpression comparable

[cell death]

cell death

[technique detecting fibrosis]

technique detecting fibrosis

[heart failure HF population]

heart failure HF population

[requirement]

requirement

[HR bpm P]

HR bpm P

[reports demonstrating development following ring annuloplasty]

reports demonstrating development following ring annuloplasty

[economic evaluations]

economic evaluations

[Global left systolic strain]

Global left systolic strain

[people in the UK]

people in the UK

[advancement of the state]

advancement of the state

[atherosclerosis using models]

atherosclerosis using models

[other predictors biomarkers]

other predictors biomarkers

[Szeto-Schiller SS]

Szeto-Schiller SS

[alterations in energy metabolism]

alterations in energy metabolism

[stenotic physiology]

stenotic physiology

[oxygen pulse]

oxygen pulse

[2+)-pump function]

2+)-pump function

[namely renin inhibitors]

namely renin inhibitors

[trigger of acute myocardial infarction]

trigger of acute myocardial infarction

[eGFR mL per m]

eGFR mL per m

[cost-effective health interventions]

cost-effective health interventions

[Estimating the venous pressure]

Estimating the venous pressure

[mechanisms of disease]

mechanisms of disease

[outcome vs milliseconds milliseconds]

outcome vs milliseconds milliseconds

[key genes]

key genes

[changes in function]

changes in function

[follow-up data]

follow-up data

[arterial elastance Ea elastance]

arterial elastance Ea elastance

[atherosclerosis using general linear models]

atherosclerosis using general linear models

[acute infarction in Australia]

acute infarction in Australia

[generating variants encoding channels]

generating variants encoding channels

[status versus whites]

status versus whites

[requiring surgical intervention]

requiring surgical intervention

[providing information for an outcome]

providing information for an outcome

[death during sport]

death during sport

[usual care by drugs]

usual care by drugs

[abdominal constriction]

abdominal constriction

[electrocardiographic device]

electrocardiographic device

[reader proteins]

reader proteins

[major HF remodeling aspects]

major HF remodeling aspects

[assessments within days]

assessments within days

[groups patients P]

groups patients P

[Incidence of end-stage disease in outpatients]

Incidence of end-stage disease in outpatients

[HFPEF n=100]

HFPEF n=100

[EF HFrEF]

EF HFrEF

[muscle pump]

muscle pump

[β-blocker BB]

β-blocker BB

[systolic heart failure in practice]

systolic heart failure in practice

[right ventricular-pulmonary coupling vascular resistance]

right ventricular-pulmonary coupling vascular resistance

[IRS2 gene double-knockout H-DKO]

IRS2 gene double-knockout H-DKO

[whites]

whites

[counterparts]

counterparts

[first-in-class inhibitor]

first-in-class inhibitor

[long-term administration]

long-term administration

[potential implications]

potential implications

[energy metabolism gene expression]

energy metabolism gene expression

[Objective institution for the treatment]

Objective institution for the treatment

[epidemiology of myocardial infarction]

epidemiology of myocardial infarction

[brain natriuretic peptide BNP]

brain natriuretic peptide BNP

[cardiac biology]

cardiac biology

[metabolism peak respiratory quotient]

metabolism peak respiratory quotient

[Rac1]

Rac1

[manipulation of cardiac gene control]

manipulation of cardiac gene control

[Cardiac-resynchronization therapy in heart failure]

Cardiac-resynchronization therapy in heart failure

[consecutive patients with a ejection fraction]

consecutive patients with a ejection fraction

[following an admission]

following an admission

[denervation]

denervation

[more concrete data regarding the role]

more concrete data regarding the role

[use assays]

use assays

[admission median BNP levels]

admission median BNP levels

[4 weeks]

4 weeks

[community-based cohort heart failure]

community-based cohort heart failure

[exercise below these recommendations]

exercise below these recommendations

[heart failure concern]

heart failure concern

[beneficial therapeutic approach]

beneficial therapeutic approach

[spite of developments]

spite of developments

[men 65±12 years]

men 65±12 years

[inhibition neprilysin blocks renin-angiotensin-aldosteron RAS axis]

inhibition neprilysin blocks renin-angiotensin-aldosteron RAS axis

[affecting contractility]

affecting contractility

[extending EMD with the aspects]

extending EMD with the aspects

[need for standards]

need for standards

[Implantation With Resynchronization Therapy]

Implantation With Resynchronization Therapy

[indicating care]

indicating care

[angiotensin receptor neprilysin inhibitor]

angiotensin receptor neprilysin inhibitor

[body fat]

body fat

[patients across hospitals]

patients across hospitals

[versus without ejection fraction]

versus without ejection fraction

[gross national income]

gross national income

[Presence of dysfunction in patients]

Presence of dysfunction in patients

[prevalence of risk factors]

prevalence of risk factors

[electron]

electron

[patients with chronic disease]

patients with chronic disease

[independent hypotheses addition of dopamine]

independent hypotheses addition of dopamine

[attenuation of TAC-induced alterations]

attenuation of TAC-induced alterations

[TAPSE relationship]

TAPSE relationship

[E-wave early diastolic mitral velocity ratio]

E-wave early diastolic mitral velocity ratio

[Soluble ST2 in ambulatory patients]

Soluble ST2 in ambulatory patients

[subclass of cardiovascular diseases]

subclass of cardiovascular diseases

[low systemic resistance SVR index]

low systemic resistance SVR index

[portion]

portion

[patients surviving an acute infarction]

patients surviving an acute infarction

[925 ED visits mean age]

925 ED visits mean age

[left ejection fraction on mortality]

left ejection fraction on mortality

[change in serum cystatin C]

change in serum cystatin C

[Eight weeks from infarction]

Eight weeks from infarction

[ventricular ejection time in heart failure]

ventricular ejection time in heart failure

[major components regulating metabolism]

major components regulating metabolism

[reducing the primary composite endpoint]

reducing the primary composite endpoint

[QRS morphology on outcomes]

QRS morphology on outcomes

[renal function in EMPHASIS-HF]

renal function in EMPHASIS-HF

[improving processes]

improving processes

[web]

web

[3.5-fold risk]

3.5-fold risk

[co-morbidity burden]

co-morbidity burden

[thirty-seven hospitals nationwide]

thirty-seven hospitals nationwide

[26 studies]

26 studies

[advanced chronic pulmonary disease COPD]

advanced chronic pulmonary disease COPD

[climate]

climate

[hospitals in New Jersey]

hospitals in New Jersey

[Discharge]

Discharge

[prediction rule having independent predictor]

prediction rule having independent predictor

[156 consecutive HF patients ejection fraction]

156 consecutive HF patients ejection fraction

[filtration rate eGFR]

filtration rate eGFR

[beat-to-beat QT intervals]

beat-to-beat QT intervals

[groups of samples]

groups of samples

[Low-strength evidence from trials]

Low-strength evidence from trials

[total arterial compliance]

total arterial compliance

[left atrial area]

left atrial area

[sites in North America]

sites in North America

[change main effect exercise]

change main effect exercise

[nurse leaders]

nurse leaders

[role in chromatin-mediated signal transduction]

role in chromatin-mediated signal transduction

[association between measurements]

association between measurements

[Spearman]

Spearman

[N-terminal pro-B-type]

N-terminal pro-B-type

[patients normal geometry]

patients normal geometry

[years vs 72.83]

years vs 72.83

[postoperative mortality]

postoperative mortality

[improvement in rate risk]

improvement in rate risk

[common cause of nontraumatic death]

common cause of nontraumatic death

[lower all-cause mortality]

lower all-cause mortality

[Cardiopulmonary exercise]

Cardiopulmonary exercise

[using Classification]

using Classification

[lower risk developing certain malignancies]

lower risk developing certain malignancies

[14 studies approximately 2900 HM II]

14 studies approximately 2900 HM II

[parallel with PAF levels]

parallel with PAF levels

[trends in patient safety for conditions]

trends in patient safety for conditions

[effect of LVEF]

effect of LVEF

[referral centre]

referral centre

[transseptal catheterisation with transoesophageal guidance]

transseptal catheterisation with transoesophageal guidance

[patients HFrEF]

patients HFrEF

[donors]

donors

[studies evaluating implementation interventions]

studies evaluating implementation interventions

[Soluble ST2]

Soluble ST2

[older women with a history]

older women with a history

[Kv4.3]

Kv4.3

[exercise variables exercise ventilation EOV]

exercise variables exercise ventilation EOV

[inotropic effect following β-AR stimulation]

inotropic effect following β-AR stimulation

[comprising hospitalization]

comprising hospitalization

[angiogenesis in heart failure]

angiogenesis in heart failure

[early mitral annulus velocity E]

early mitral annulus velocity E

[ventricular LV ejection fraction HFpEF]

ventricular LV ejection fraction HFpEF

[interquartile range 22.8 with advanced COPD]

interquartile range 22.8 with advanced COPD

[role of BETs]

role of BETs

[extrapolating outcomes]

extrapolating outcomes

[variance]

variance

[adenine]

adenine

[off-pump sparing approach for HeartMate exchange]

off-pump sparing approach for HeartMate exchange

[percent relative reduction]

percent relative reduction

[emergency room]

emergency room

[hypertrophic response role]

hypertrophic response role

[Effect of If-channel inhibition]

Effect of If-channel inhibition

[dysfunction LV EF]

dysfunction LV EF

[patients with myocardial infarction]

patients with myocardial infarction

[oxidation of glucose]

oxidation of glucose

[alterations in markers]

alterations in markers

[non-biological disease]

non-biological disease

[use of angiotensin]

use of angiotensin

[inhibition on status]

inhibition on status

[impact of carvedilol on therapy]

impact of carvedilol on therapy

[age-by-LVEF interaction]

age-by-LVEF interaction

[All-cause mortality at years after hospitalization]

All-cause mortality at years after hospitalization

[such as infarction with future expansion]

such as infarction with future expansion

[data for health outcomes]

data for health outcomes

[Circulating fragments in plasma]

Circulating fragments in plasma

[Redesign]

Redesign

[receiving drugs]

receiving drugs

[months p=0·035]

months p=0·035

[cardiac balance]

cardiac balance

[home telemonitoring]

home telemonitoring

[Mixed-methods study of 295 veterans]

Mixed-methods study of 295 veterans

[10.7 nmol]

10.7 nmol

[reduction in MVA]

reduction in MVA

[survival of patients 3.5 g]

survival of patients 3.5 g

[Automatic Defibrillator Implantation Resynchronization Therapy]

Automatic Defibrillator Implantation Resynchronization Therapy

[HF 4 years]

HF 4 years

[stable conditions]

stable conditions

[right heart failure in hypertension]

right heart failure in hypertension

[Detailed analysis of tissue from mice]

Detailed analysis of tissue from mice

[patients normal geometry no LV hypertrophy]

patients normal geometry no LV hypertrophy

[refractory heart failure with dialysis]

refractory heart failure with dialysis

[evaluations HM II]

evaluations HM II

[clinical response]

clinical response

[effect of peptides]

effect of peptides

[even in the presence]

even in the presence

[tumor necrosis factor]

tumor necrosis factor

[still a agent in the treatment]

still a agent in the treatment

[idiopathic cardiomyopathy including angiography]

idiopathic cardiomyopathy including angiography

[Fontan PF]

Fontan PF

[dying in days P-value 0.001]

dying in days P-value 0.001

[aggressive medical treatment]

aggressive medical treatment

[volume index of mL]

volume index of mL

[end-diastolic area index cm(2)]

end-diastolic area index cm(2)

[ventricular hypertrophy]

ventricular hypertrophy

[Americans AAs]

Americans AAs

[characteristics eg using Cochrane Practice]

characteristics eg using Cochrane Practice

[variation in rates of guideline-recommended treatment]

variation in rates of guideline-recommended treatment

[human stem cardiomyocytes hiPSC-CMs]

human stem cardiomyocytes hiPSC-CMs

[effect on quality of life]

effect on quality of life

[receiving these agents]

receiving these agents

[3.01 years]

3.01 years

[contribution of POC measurement]

contribution of POC measurement

[excitation-contraction coupling in the myocardium]

excitation-contraction coupling in the myocardium

[mortality effects]

mortality effects

[correlates of increase]

correlates of increase

[reduction of sympathetic activity]

reduction of sympathetic activity

[practice of rhythm control]

practice of rhythm control

[HFpEF for overall summary]

HFpEF for overall summary

[fat lean body mass ratio]

fat lean body mass ratio

[Costing]

Costing

[change with treatment in the ratio]

change with treatment in the ratio

[β-adrenergic receptor stimulation]

β-adrenergic receptor stimulation

[roles of BNP]

roles of BNP

[complex set]

complex set

[four-week training period]

four-week training period

[diastolic mitral annular velocity 3.1]

diastolic mitral annular velocity 3.1

[changes in gene expression]

changes in gene expression

[Differential effects of nonselective]

Differential effects of nonselective

[major adverse rate]

major adverse rate

[HF hospitalization rates]

HF hospitalization rates

[need of resuscitation]

need of resuscitation

[Two models]

Two models

[improvement in 6-minute]

improvement in 6-minute

[effects of nonselective versus selective beta-blockers]

effects of nonselective versus selective beta-blockers

[function dilatation]

function dilatation

[ng interquartile range 18.6]

ng interquartile range 18.6

[ischemic right heart failure]

ischemic right heart failure

[groups patients]

groups patients

[Potent inhibition by a Rad variant]

Potent inhibition by a Rad variant

[significant difference between numbers]

significant difference between numbers

[manipulation]

manipulation

[actin dynamics]

actin dynamics

[cardiac mRNA levels of genes]

cardiac mRNA levels of genes

[first-in-man evidence for potential usefulness]

first-in-man evidence for potential usefulness

[Remote ischemic conditioning for patients]

Remote ischemic conditioning for patients

[Cardiac resonance postcontrast T1 time]

Cardiac resonance postcontrast T1 time

[CRT response]

CRT response

[hRetn mRNA]

hRetn mRNA

[right atrial area 20 cm]

right atrial area 20 cm

[Screening patients with Doppler ultrasonography]

Screening patients with Doppler ultrasonography

[Nursing-sensitive outcome change scores for adults]

Nursing-sensitive outcome change scores for adults

[studies evaluating 63 predictors]

studies evaluating 63 predictors

[Recommendations for management involving assist devices]

Recommendations for management involving assist devices

[right fractional area change]

right fractional area change

[evaluation of the strength]

evaluation of the strength

[high-strength evidence from trials]

high-strength evidence from trials

[expenditure on health per capita]

expenditure on health per capita

[human stem]

human stem

[cardiomyopathy all p]

cardiomyopathy all p

[using Nursing Outcomes Classification]

using Nursing Outcomes Classification

[pre-participation]

pre-participation

[scenario of lower expenditure]

scenario of lower expenditure

[kg in the exercise]

kg in the exercise

[physician follow-up]

physician follow-up

[complex situations]

complex situations

[survival of patients with hypoalbuminemia g]

survival of patients with hypoalbuminemia g

[off-pump sparing approach]

off-pump sparing approach

[mean pressure gradient]

mean pressure gradient

[beliefs]

beliefs

[managing gastrointestinal bleeding in this population]

managing gastrointestinal bleeding in this population

[Sixteen York Heart Association Class]

Sixteen York Heart Association Class

[important defense mechanism]

important defense mechanism

[risk stratification particularly between a group]

risk stratification particularly between a group

[role determining the cardiac remodelling]

role determining the cardiac remodelling

[perhaps the most important component]

perhaps the most important component

[Large-scale multicenter trial]

Large-scale multicenter trial

[Shah]

Shah

[greater risk than the rest]

greater risk than the rest

[clinical prognostic dysfunction leading]

clinical prognostic dysfunction leading

[mm for reference subjects]

mm for reference subjects

[studies of therapeutics]

studies of therapeutics

[endopeptidase inhibitors]

endopeptidase inhibitors

[impact of ET on effects]

impact of ET on effects

[Prognostic value of threshold]

Prognostic value of threshold

[fluorescence]

fluorescence

[limits]

limits

[sample with ICC values]

sample with ICC values

[most powerful independent predictor period]

most powerful independent predictor period

[severe systolic dysfunction]

severe systolic dysfunction

[Multicenter double-blind placebo-controlled clinical trial]

Multicenter double-blind placebo-controlled clinical trial

[role of ERK1 molecular scaffolds]

role of ERK1 molecular scaffolds

[cardiac transplant ECCT]

cardiac transplant ECCT

[doses of β-blocker BB]

doses of β-blocker BB

[ventricular RV tricuspid plane excursion]

ventricular RV tricuspid plane excursion

[ml vs. 17.0 ml]

ml vs. 17.0 ml

[center retrospective observational study]

center retrospective observational study

[14 clinical studies HM]

14 clinical studies HM

[independent prognostic role]

independent prognostic role

[university hospital]

university hospital

[final diagnosis]

final diagnosis

[evidence from 17 trials]

evidence from 17 trials

[use of devices]

use of devices

[province of Québec]

province of Québec

[relationship with cardiovascular CV events]

relationship with cardiovascular CV events

[severe-end-stage HF]

severe-end-stage HF

[undergoing resynchronization therapy]

undergoing resynchronization therapy

[influence on the overall burden]

influence on the overall burden

[managing bleeding]

managing bleeding

[surface ECGs]

surface ECGs

[influx]

influx

[Short-Form]

Short-Form

[growing subclass of diseases]

growing subclass of diseases

[training intervention with feedback]

training intervention with feedback

[early HF respectively]

early HF respectively

[left artery]

left artery

[survival g]

survival g

[perspective using a approach]

perspective using a approach

[eight age-matched controls]

eight age-matched controls

[tertiary referral centre]

tertiary referral centre

[4 hospitals]

4 hospitals

[system activity]

system activity

[New Users of Saxagliptin]

New Users of Saxagliptin

[left end diameter difference]

left end diameter difference

[European Society guidelines definition]

European Society guidelines definition

[left end diameter mean difference]

left end diameter mean difference

[Randomized trial with moderate]

Randomized trial with moderate

[difference among EF BNP in women]

difference among EF BNP in women

[Connecticut Health Center patients]

Connecticut Health Center patients

[inhibitors c-Kit]

inhibitors c-Kit

[Raf-MEK1 scaffold proteins]

Raf-MEK1 scaffold proteins

[redo sternotomy for valve procedures]

redo sternotomy for valve procedures

[dopamine on secondary end points]

dopamine on secondary end points

[respective pathways]

respective pathways

[variants encoding channels]

variants encoding channels

[aim of this single-arm study]

aim of this single-arm study

[trends in event rates]

trends in event rates

[cardiac transplant programs]

cardiac transplant programs

[participants without prevalent HF area]

participants without prevalent HF area

[underlying DD]

underlying DD

[clinical outcomes using an antagonist]

clinical outcomes using an antagonist

[disease groups heart failure HF]

disease groups heart failure HF

[Using a cutoff]

Using a cutoff

[telephone support programmes]

telephone support programmes

[activators of SCN5A mRNA splicing]

activators of SCN5A mRNA splicing

[global longitudinal systolic strain]

global longitudinal systolic strain

[Kd for the mutant]

Kd for the mutant

[extensive changes]

extensive changes

[Ea p]

Ea p

[most appropriate investigations]

most appropriate investigations

[LF ratio]

LF ratio

[prevalence of BNP levels]

prevalence of BNP levels

[Fontan PF patients]

Fontan PF patients

[predictor of events]

predictor of events

[using random-effects models]

using random-effects models

[other conditions such as acute infarction]

other conditions such as acute infarction

[resulting in a significant MS]

resulting in a significant MS

[steady improvement in eGFR]

steady improvement in eGFR

[median of years]

median of years

[including coronary angiography]

including coronary angiography

[complications in severe end-stage HF]

complications in severe end-stage HF

[heart failure with outcomes]

heart failure with outcomes

[restricting the leaflet opening]

restricting the leaflet opening

[setting of disease]

setting of disease

[Fourteen electronic databases]

Fourteen electronic databases

[global longitudinal strain of ventricle]

global longitudinal strain of ventricle

[requiring temporary RV support]

requiring temporary RV support

[suggesting T1 as biomarker for HFPEF]

suggesting T1 as biomarker for HFPEF

[growing subclass of cardiovascular diseases]

growing subclass of cardiovascular diseases

[Safety of eplerenone]

Safety of eplerenone

[GDMT control group]

GDMT control group

[adverse outcomes in patients]

adverse outcomes in patients

[intact hearts]

intact hearts

[rates of treatment]

rates of treatment

[cardiovascular CV events]

cardiovascular CV events

[LV mass 42.4 g P=0.04]

LV mass 42.4 g P=0.04

[diagnosis of prognostic diastolic dysfunction]

diagnosis of prognostic diastolic dysfunction

[overexpression of Mammalian]

overexpression of Mammalian

[characteristics of adults The CHARM programme]

characteristics of adults The CHARM programme

[strategies capable]

strategies capable

[decreases in heart failure-related mortality]

decreases in heart failure-related mortality

[Cost-Effectiveness]

Cost-Effectiveness

[testosterone group]

testosterone group

[serum levels]

serum levels

[potential predictors particularly biomarkers]

potential predictors particularly biomarkers

[patients with plasma samples]

patients with plasma samples

[more recently for patients]

more recently for patients

[modulation]

modulation

[variables exercise]

variables exercise

[chronic disease COPD]

chronic disease COPD

[TAC-induced alterations]

TAC-induced alterations

[LV systolic indices]

LV systolic indices

[Effectiveness as an treatment]

Effectiveness as an treatment

[right end-diastolic area index cm(2)]

right end-diastolic area index cm(2)

[human kidney]

human kidney

[markers indicative of balance]

markers indicative of balance

[determining assessment]

determining assessment

[Extracellular matrix of ventricular biopsies n=9]

Extracellular matrix of ventricular biopsies n=9

[protein changes]

protein changes

[substrate]

substrate

[Using multivariate regression analysis]

Using multivariate regression analysis

[collagen density of the ventricle]

collagen density of the ventricle

[multiple cardiac genes]

multiple cardiac genes

[individual scales]

individual scales

[effects on receptor signaling in cardiomyocytes]

effects on receptor signaling in cardiomyocytes

[predictors after resynchronization therapy CRT]

predictors after resynchronization therapy CRT

[community of population]

community of population

[rehospitalization of percentage points]

rehospitalization of percentage points

[AlphaLISA]

AlphaLISA

[evidence for usefulness]

evidence for usefulness

[left dyssynchrony]

left dyssynchrony

[decreases in heart mortality]

decreases in heart mortality

[aortic constriction TAC]

aortic constriction TAC

[size reduction by surgery]

size reduction by surgery

[atrial area 20 cm 2]

atrial area 20 cm 2

[receiver operating characteristic curve]

receiver operating characteristic curve

[uptitration after an HF hospitalization]

uptitration after an HF hospitalization

[advantage of the turnaround times]

advantage of the turnaround times

[improving physician adherence]

improving physician adherence

[HF registry]

HF registry

[76.4 years]

76.4 years

[Outcomes study-a multicenter study]

Outcomes study-a multicenter study

[measure in patients]

measure in patients

[Patient perceptions]

Patient perceptions

[mild clinical diastolic dysfunction]

mild clinical diastolic dysfunction

[pediatric Fontan patients]

pediatric Fontan patients

[discrimination change]

discrimination change

[patients undergoing procedures]

patients undergoing procedures

[dilated cardiomyopathy]

dilated cardiomyopathy

[ZSF1 groups]

ZSF1 groups

[trials of blood transfusions]

trials of blood transfusions

[fewer CHF patients]

fewer CHF patients

[strategies with effects]

strategies with effects

[pump function despite a hypertension medication]

pump function despite a hypertension medication

[differential impact]

differential impact

[HeartMate devices]

HeartMate devices

[Registry]

Registry

[Interactors]

Interactors

[synthase activation]

synthase activation

[significant improvements in clinical composite response]

significant improvements in clinical composite response

[Advances in treatment for acute infarction]

Advances in treatment for acute infarction

[electromechanical behavior]

electromechanical behavior

[Physicians in health]

Physicians in health

[decrease from an average]

decrease from an average

[activity in patients]

activity in patients

[CHF Inhibition]

CHF Inhibition

[risk for RV failure]

risk for RV failure

[accessory]

accessory

[ischemic conditioning for patients]

ischemic conditioning for patients

[beagle dogs]

beagle dogs

[Relation within three months]

Relation within three months

[decrease from an average 3.2]

decrease from an average 3.2

[signalling proteins]

signalling proteins

[reflecting decreases in heart mortality period]

reflecting decreases in heart mortality period

[saxagliptin versus sulfonylureas for saxagliptin]

saxagliptin versus sulfonylureas for saxagliptin

[age-dependent increase]

age-dependent increase

[distressing cardioverter-defibrillator shocks]

distressing cardioverter-defibrillator shocks

[moderate-quality evidence]

moderate-quality evidence

[filling flow volume]

filling flow volume

[vasopressin type]

vasopressin type

[cardiovascular conditions]

cardiovascular conditions

[contracting]

contracting

[muscle mass T-score]

muscle mass T-score

[documentation of reasons]

documentation of reasons

[profound change]

profound change

[Predictors of mortality a review]

Predictors of mortality a review

[LV end]

LV end

[risk of IE in patients]

risk of IE in patients

[mortality at the worst]

mortality at the worst

[describing a nomenclature]

describing a nomenclature

[stimulation of peripheral muscles]

stimulation of peripheral muscles

[perhaps the single component]

perhaps the single component

[guideline-recommended care]

guideline-recommended care

[iron use]

iron use

[respiration for quantification of T1]

respiration for quantification of T1

[information on cardioverter-defibrillator deactivation at implant]

information on cardioverter-defibrillator deactivation at implant

[cardiac plasma membrane]

cardiac plasma membrane

[paediatric transplants]

paediatric transplants

[little impact]

little impact

[growth factor blockade]

growth factor blockade

[years for alendronate- patients respectively]

years for alendronate- patients respectively

[cardiotoxicity a anti-neoplastic agent]

cardiotoxicity a anti-neoplastic agent

[large limits]

large limits

[Objective criteriabased institution for the treatment]

Objective criteriabased institution for the treatment

[onset of]

onset of

[other subgroup analyses]

other subgroup analyses

[adverse event-free rate]

adverse event-free rate

[tachycardia indicative]

tachycardia indicative

[subclass of diseases]

subclass of diseases

[patients at risk for hyperkalemia]

patients at risk for hyperkalemia

[CHARM programme Candesartan]

CHARM programme Candesartan

[confounding]

confounding

[risk of stroke]

risk of stroke

[patients consisting after infarction]

patients consisting after infarction

[use converting enzyme inhibitors]

use converting enzyme inhibitors

[primary oscillations]

primary oscillations

[treatment period]

treatment period

[markers hazard ratio for peak]

markers hazard ratio for peak

[common syndrome of heart failure]

common syndrome of heart failure

[thromboembolic pulmonary hypertension]

thromboembolic pulmonary hypertension

[promising biomarker HF]

promising biomarker HF

[Autonomic modulation]

Autonomic modulation

[spontaneous tachycardia HFVT(+)]

spontaneous tachycardia HFVT(+)

[β1AR overstimulation]

β1AR overstimulation

[2:1 ratio]

2:1 ratio

[cell EC]

cell EC

[Clinical Practice Guideline CPG]

Clinical Practice Guideline CPG

[relations in patients with without diabetes]

relations in patients with without diabetes

[Bradycardia indicative of cardiac tone]

Bradycardia indicative of cardiac tone

[coronary artery occlusion]

coronary artery occlusion

[therapeutic treatments targeting abnormal exercise status]

therapeutic treatments targeting abnormal exercise status

[median BNP in women]

median BNP in women

[even with systolic ventricular function]

even with systolic ventricular function

[Incidence of disease]

Incidence of disease

[Echocardiographic predictors]

Echocardiographic predictors

[human embryonic kidney cells]

human embryonic kidney cells

[ventricular tachycardia]

ventricular tachycardia

[HF hospitalization HR CI]

HF hospitalization HR CI

[mL 2 P=0.01]

mL 2 P=0.01

[carotid intima-media]

carotid intima-media

[income per capita]

income per capita

[treatment in increase]

treatment in increase

[superior hospitals]

superior hospitals

[admissions for individuals]

admissions for individuals

[quality measures for common medical conditions]

quality measures for common medical conditions

[p38α protein kinase]

p38α protein kinase

[activating remodelling]

activating remodelling

[derangement with features similar]

derangement with features similar

[proximal LCX later]

proximal LCX later

[controlling for characteristics]

controlling for characteristics

[points vs. 2.1 points]

points vs. 2.1 points

[man with cardiac arrest]

man with cardiac arrest

[using the method of transverse constriction]

using the method of transverse constriction

[allopurinol mg·kg(-1)·day(-1)]

allopurinol mg·kg(-1)·day(-1)

[risk of cardiac events]

risk of cardiac events

[dysfunction with LV filling pressures]

dysfunction with LV filling pressures

[20 clinical variables]

20 clinical variables

[other measures]

other measures

[reduction in LVEF hazard ratio]

reduction in LVEF hazard ratio

[therefore of value]

therefore of value

[novel strategy in HF]

novel strategy in HF

[plane excursion TAPSE]

plane excursion TAPSE

[independent predictor period]

independent predictor period

[brain peptide levels pg]

brain peptide levels pg

[trend with severe ventricular dilatation]

trend with severe ventricular dilatation

[forms of left ventricular remodeling]

forms of left ventricular remodeling

[end points reflective]

end points reflective

[prognosis of a idiopathic cohort]

prognosis of a idiopathic cohort

[characteristics using Cochrane Effective Practice]

characteristics using Cochrane Effective Practice

[score for prediction]

score for prediction

[hospital volume groups]

hospital volume groups

[risk in patients]

risk in patients

[populations of patients]

populations of patients

[outcomes for patients undergoing procedures]

outcomes for patients undergoing procedures

[medical treatment with vasodilators]

medical treatment with vasodilators

[regarding referrals]

regarding referrals

[early fibrosis]

early fibrosis

[79.9 years]

79.9 years

[surrogate of catabolism]

surrogate of catabolism

[heart failure phenotypes]

heart failure phenotypes

[training for heart failure patients]

training for heart failure patients

[common characteristics using Cochrane Effective Practice]

common characteristics using Cochrane Effective Practice

[stem cardiomyocytes]

stem cardiomyocytes

[hospital readmission reduction program]

hospital readmission reduction program

[central venous pressure]

central venous pressure

[outcome change scores for adults]

outcome change scores for adults

[3 evaluations HM]

3 evaluations HM

[patients with stable HFPEF]

patients with stable HFPEF

[Analysis]

Analysis

[elastance end-systolic elastance Ees]

elastance end-systolic elastance Ees

[smallest difference]

smallest difference

[Randomized Aldactone Evaluation Study]

Randomized Aldactone Evaluation Study

[such as obesity]

such as obesity

[Baseline eGFR group II]

Baseline eGFR group II

[effect of an increasing number]

effect of an increasing number

[evaluable plasma samples]

evaluable plasma samples

[defence]

defence

[clinical effects of types HeartMate]

clinical effects of types HeartMate

[inhibitory actions of Rad]

inhibitory actions of Rad

[attenuation of alterations]

attenuation of alterations

[outcomes after resynchronization therapy]

outcomes after resynchronization therapy

[recent enrollment period]

recent enrollment period

[annular size reduction for MR]

annular size reduction for MR

[short-term improvements in functioning]

short-term improvements in functioning

[patients with CHF-NYHA-III HDL before ET]

patients with CHF-NYHA-III HDL before ET

[variation in rates]

variation in rates

[performance only in patients with s'lateral]

performance only in patients with s'lateral

[stable HNO donor CXL-1020]

stable HNO donor CXL-1020

[inflammatory IL6 hsCRP biomarkers]

inflammatory IL6 hsCRP biomarkers

[induction of a subset]

induction of a subset

[diastolic end diameter mm mean difference]

diastolic end diameter mm mean difference

[current treatment]

current treatment

[few deaths in the procedures]

few deaths in the procedures

[Addition of HABC Battery scores]

Addition of HABC Battery scores

[right ventricular-pulmonary coupling resistance P]

right ventricular-pulmonary coupling resistance P

[ventricular systolic HF tissue samples]

ventricular systolic HF tissue samples

[severe heart failure with dialysis]

severe heart failure with dialysis

[acetyl-lysine reader proteins]

acetyl-lysine reader proteins

[patients with albumin levels]

patients with albumin levels

[standards]

standards

[chronic pulmonary disease COPD]

chronic pulmonary disease COPD

[flow velocities E]

flow velocities E

[credible interval CrI]

credible interval CrI

[REsynchronization reVErses]

REsynchronization reVErses

[refractory right heart failure]

refractory right heart failure

[high-fat diet n=11]

high-fat diet n=11

[trials of iron]

trials of iron

[percutaneous coronary intervention]

percutaneous coronary intervention

[potentiating the response]

potentiating the response

[Results—Retrospective cohort]

Results—Retrospective cohort

[Pharmacological treatment current treatment]

Pharmacological treatment current treatment

[improvement of inflammatory biomarkers]

improvement of inflammatory biomarkers

[recently for patients as destination therapy]

recently for patients as destination therapy

[consecutive patients aged 40 years]

consecutive patients aged 40 years

[5.1 million Americans]

5.1 million Americans

[two populations]

two populations

[treatment in exertional increase]

treatment in exertional increase

[long-term cost-effectiveness analyses]

long-term cost-effectiveness analyses

[managing significant bleeding in this population]

managing significant bleeding in this population

[demographic characteristics use]

demographic characteristics use

[MEDLINE databases]

MEDLINE databases

[RV failure after the insertion]

RV failure after the insertion

[human resistin Retn]

human resistin Retn

[conscious New Zealand rabbits undergoing DNx]

conscious New Zealand rabbits undergoing DNx

[all-cause hospitalization within the 1 months]

all-cause hospitalization within the 1 months

[improvement of cardiac NT-ProBNP biomarkers]

improvement of cardiac NT-ProBNP biomarkers

[four-week training period with trainings]

four-week training period with trainings

[23.7 ng interquartile range]

23.7 ng interquartile range

[above comparisons significant]

above comparisons significant

[kidney disease median glomerular filtration rate]

kidney disease median glomerular filtration rate

[end-systolic pressure]

end-systolic pressure

[resulting with an MVA of cm2]

resulting with an MVA of cm2

[vivo inhibition]

vivo inhibition

[17 trials of agent therapy]

17 trials of agent therapy

[decoy VEGF receptor Ad-Flk]

decoy VEGF receptor Ad-Flk

[guanylate cyclase]

guanylate cyclase

[tethering]

tethering

[event-free rates by KCCQ category]

event-free rates by KCCQ category

[hazards of cardiovascular events]

hazards of cardiovascular events

[one model]

one model

[early medical management]

early medical management

[smallest difference among EF BNP]

smallest difference among EF BNP

[different metric]

different metric

[brain peptide BNP levels]

brain peptide BNP levels

[fractional area change]

fractional area change

[promising alternative]

promising alternative

[200 HeartWare patients]

200 HeartWare patients

[left diastolic function]

left diastolic function

[Arg16]

Arg16

[days of hospital discharge]

days of hospital discharge

[cost per patient]

cost per patient

[Centers for Medicare Services]

Centers for Medicare Services

[normalizing]

normalizing

[medical treatment for HF with vasodilators]

medical treatment for HF with vasodilators

[association of impairment with mortality]

association of impairment with mortality

[ongoing GDMT treatment group for months]

ongoing GDMT treatment group for months

[150 minutes]

150 minutes

[impact on quality]

impact on quality

[ZSF1 groups]

ZSF1 groups

[circulatory assist]

circulatory assist

[undergoing LVAD implantation from 2000]

undergoing LVAD implantation from 2000

[mouse model lacking resistin]

mouse model lacking resistin

[novel intracellular antiadrenergic strategy]

novel intracellular antiadrenergic strategy

[Ehrlich carcinoma]

Ehrlich carcinoma

[African Americans AAs]

African Americans AAs

[difference histologically]

difference histologically

[system modulation]

system modulation

[right contractile reserve in patients]

right contractile reserve in patients

[data examining outcomes]

data examining outcomes

[Moderate evidence from trials]

Moderate evidence from trials

[medical hospitalization]

medical hospitalization

[basis pressure]

basis pressure

[Beta-blocker dose after months]

Beta-blocker dose after months

[experiencing distressing cardioverter-defibrillator shocks]

experiencing distressing cardioverter-defibrillator shocks

[requiring pump replacement]

requiring pump replacement

[development of MS]

development of MS

[site-specific monoclonal antibodies]

site-specific monoclonal antibodies

[patients requiring LVAD]

patients requiring LVAD

[non-survivors 64.26 years years]

non-survivors 64.26 years years

[ejection fraction pEF]

ejection fraction pEF

[acute HF trials]

acute HF trials

[fatal arrhythmia events]

fatal arrhythmia events

[exercise training on endothelial function]

exercise training on endothelial function

[role including nuclear factor]

role including nuclear factor

[cardioverter defibrillators ICDs]

cardioverter defibrillators ICDs

[use of beta-blockers]

use of beta-blockers

[study-a multicenter study of exercise training]

study-a multicenter study of exercise training

[most powerful predictor period]

most powerful predictor period

[hyperkalemia in Americans AAs]

hyperkalemia in Americans AAs

[ACS problems]

ACS problems

[Fifty-four asymptomatic Fontan patients]

Fifty-four asymptomatic Fontan patients

[≥3 co-morbidities]

≥3 co-morbidities

[Treatment of MI animals]

Treatment of MI animals

[having ≥1 predictor]

having ≥1 predictor

[framework]

framework

[changes NO production]

changes NO production

[difference between two groups patients]

difference between two groups patients

[increase in function]

increase in function

[assessors]

assessors

[management of bleeding]

management of bleeding

[334 patients 224 men mean]

334 patients 224 men mean

[Further adjustment]

Further adjustment

[including factor of T cells NFAT]

including factor of T cells NFAT

[implantable deactivation preferences]

implantable deactivation preferences

[diuretic effect of peptides]

diuretic effect of peptides

[such as hospitalisations]

such as hospitalisations

[272 consecutive patients undergoing LVAD implantation]

272 consecutive patients undergoing LVAD implantation

[ventricular function in volume overload]

ventricular function in volume overload

[myofibrillar]

myofibrillar

[induction of hRetn resistin mRNA]

induction of hRetn resistin mRNA

[endpoint death]

endpoint death

[RV failure in the setting]

RV failure in the setting

[range muscle]

range muscle

[infarction with complications]

infarction with complications

[years years]

years years

[reasons for the reduction]

reasons for the reduction

[older patients with stable HFPEF]

older patients with stable HFPEF

[left anterior descending]

left anterior descending

[response the difference in heart rate]

response the difference in heart rate

[measurement of flow velocities E]

measurement of flow velocities E

[measure of health status symptoms]

measure of health status symptoms

[participatory health interventions]

participatory health interventions

[resonance T1 time]

resonance T1 time

[consecutive patients with recent onset HFrEF]

consecutive patients with recent onset HFrEF

[particularly biomarkers]

particularly biomarkers

[outcome over months]

outcome over months

[growth factor-β signaling level]

growth factor-β signaling level

[writer proteins]

writer proteins

[variants encoding nonfunctional channels]

variants encoding nonfunctional channels

[dysfunction of a Rad variant]

dysfunction of a Rad variant

[children with undiagnosed heart disease]

children with undiagnosed heart disease

[Chinese medicine CHM]

Chinese medicine CHM

[beneficial effects from exercise training]

beneficial effects from exercise training

[moderate-severe right dysfunction]

moderate-severe right dysfunction

[difference in heart rate]

difference in heart rate

[decline in eGFR]

decline in eGFR

[five deaths occurring within days]

five deaths occurring within days

[right pump function]

right pump function

[all-cause readmission ACR]

all-cause readmission ACR

[midregional proANP MR-proANP]

midregional proANP MR-proANP

[consistency among patients]

consistency among patients

[R. Cluster analysis]

R. Cluster analysis

[protective effects on function]

protective effects on function

[Surgical correction of aortic valve insufficiency]

Surgical correction of aortic valve insufficiency

[Mechanistic insight into prolonged electromechanical delay]

Mechanistic insight into prolonged electromechanical delay

[thirty-seven hospitals]

thirty-seven hospitals

[early mitral annular velocity 3.1]

early mitral annular velocity 3.1

[age of years]

age of years

[such as diabetes mellitus]

such as diabetes mellitus

[beta-blockers on activity]

beta-blockers on activity

[powerful independent predictor of outcome]

powerful independent predictor of outcome

[925 ED visits age years]

925 ED visits age years

[trials of agent therapy]

trials of agent therapy

[risk for the outcome]

risk for the outcome

[Global left ventricular strain]

Global left ventricular strain

[contribution of haemodynamic abnormalities]

contribution of haemodynamic abnormalities

[energy X-ray absorptiometry]

energy X-ray absorptiometry

[IIIB]

IIIB

[level of transition markers]

level of transition markers

[similar risk of mortality]

similar risk of mortality

[receptor signaling in healthy cardiomyocytes]

receptor signaling in healthy cardiomyocytes

[porcine model of ischemia stent]

porcine model of ischemia stent

[Healthcare Procedure Coding System codes]

Healthcare Procedure Coding System codes

[disease management programs]

disease management programs

[uniform nomenclature for right failure]

uniform nomenclature for right failure

[longitudinal strain GLS]

longitudinal strain GLS

[age men]

age men

[race in patients with HF]

race in patients with HF

[odds ratio of 2.2]

odds ratio of 2.2

[alterations in markers of SkM growth]

alterations in markers of SkM growth

[using Cochrane Effective Practice]

using Cochrane Effective Practice

[muscle mass r=0.67]

muscle mass r=0.67

[conscious New Zealand rabbits]

conscious New Zealand rabbits

[Detailed analysis]

Detailed analysis

[resistance training]

resistance training

[bundle branch block activation sequence]

bundle branch block activation sequence

[10 transplant patients receiving PD]

10 transplant patients receiving PD

[tachycardia in response indicative]

tachycardia in response indicative

[risk hazard ratio 0.91]

risk hazard ratio 0.91

[study enrollment]

study enrollment

[min walk test distance]

min walk test distance

[index versus 2.8 L 2]

index versus 2.8 L 2

[III heart failure]

III heart failure

[Cardiac amyloidosis]

Cardiac amyloidosis

[patients gender odds ratio]

patients gender odds ratio

[grading]

grading

[patients mean age]

patients mean age

[Multivariate regression analysis]

Multivariate regression analysis

[absolute risk]

absolute risk

[protein content]

protein content

[CHARM]

CHARM

[patients surviving an infarction]

patients surviving an infarction

[percutaneous one model]

percutaneous one model

[addition indicating possible suboptimal care]

addition indicating possible suboptimal care

[ischemic conditioning]

ischemic conditioning

[von Willebrand]

von Willebrand

[relationship between QRS duration of benefit]

relationship between QRS duration of benefit

[Fig 1B]

Fig 1B

[novel approach for the treatment]

novel approach for the treatment

[bottleneck stent model]

bottleneck stent model

[turning off Mena overexpression]

turning off Mena overexpression

[two groups patients]

two groups patients

[2-fold risk]

2-fold risk

[North America]

North America

[Cardiac amyloidosis about an case]

Cardiac amyloidosis about an case

[n=44 925 ED visits age]

n=44 925 ED visits age

[promoting cardiac filling during exercise]

promoting cardiac filling during exercise

[effector molecules]

effector molecules

[requiring intervention]

requiring intervention

[myxoma]

myxoma

[SS 31]

SS 31

[even with normal ventricular function]

even with normal ventricular function

[resonance T1 mapping]

resonance T1 mapping

[aberrant reactivation of gene programs]

aberrant reactivation of gene programs

[cardiac volume overload]

cardiac volume overload

[regional strain contributions]

regional strain contributions

[398 patients]

398 patients

[patients with cardiomyopathy in Tuscany]

patients with cardiomyopathy in Tuscany

[using historical data]

using historical data

[hemodynamic features similar]

hemodynamic features similar

[plane excursion]

plane excursion

[B-type peptide]

B-type peptide

[Large-scale multicenter trial PARADIGM-HF with individuals]

Large-scale multicenter trial PARADIGM-HF with individuals

[colony-forming units]

colony-forming units

[ventricular RV annular plane excursion TAPSE]

ventricular RV annular plane excursion TAPSE

[proteome changes]

proteome changes

[pulmonary artery pressure increase by means]

pulmonary artery pressure increase by means

[impact on therapy]

impact on therapy

[symptoms despite maximal medical treatment]

symptoms despite maximal medical treatment

[LCX later 2-vessel model]

LCX later 2-vessel model

[index L 2]

index L 2

[life assessment]

life assessment

[opposing actions]

opposing actions, opposing action

[HF for HF]

HF for HF

[low mg daily equivalent dose]

low mg daily equivalent dose

[powerful predictor period]

powerful predictor period

[BNP levels pg]

BNP levels pg

[concordance c]

concordance c

[cardiac resonance]

cardiac resonance

[1.6 vs. 0.8 reasons per patient]

1.6 vs. 0.8 reasons per patient

[Fifty-four predominantly asymptomatic Fontan patients]

Fifty-four predominantly asymptomatic Fontan patients

[systolic pressure relationship an index]

systolic pressure relationship an index

[5.0 42.4 g]

5.0 42.4 g

[left function assessment]

left function assessment

[transoesophageal guidance under general anaesthesia]

transoesophageal guidance under general anaesthesia

[130 patients]

130 patients

[heart failure with function]

heart failure with function

[three metrics]

three metrics

[independent prognostic markers]

independent prognostic markers

[repolarization instability]

repolarization instability

[glomerular filtration rate of mL]

glomerular filtration rate of mL, glomerular filtration rate of ml

[Transoesophageal echocardiography]

Transoesophageal echocardiography

[beta-blockers on activity in patients]

beta-blockers on activity in patients

[Peritoneal]

Peritoneal

[idiopathic cardiomyopathy including negative angiography]

idiopathic cardiomyopathy including negative angiography

[2.08 events]

2.08 events

[N-terminal pro-B-type peptide NT-proBNP]

N-terminal pro-B-type peptide NT-proBNP

[Patients class]

Patients class

[septum biopsies]

septum biopsies

[blood pressure control]

blood pressure control

[patient care]

patient care

[8-fluo-cAMP binding by type]

8-fluo-cAMP binding by type

[left ventricular systolic function]

left ventricular systolic function

[conditions such as acute myocardial infarction]

conditions such as acute myocardial infarction

[hazard ratios across CRF categories]

hazard ratios across CRF categories

[systolic function in volume overload]

systolic function in volume overload

[clinical parameters in AF]

clinical parameters in AF

[cardiovascular complications stroke]

cardiovascular complications stroke

[impact on gross development]

impact on gross development

[suburban hospitals in Jersey]

suburban hospitals in Jersey

[ESRD from the Registry on Dialysis]

ESRD from the Registry on Dialysis

[hospitalizations in congestive heart failure]

hospitalizations in congestive heart failure

[Detailed transcriptional analysis of tissue]

Detailed transcriptional analysis of tissue

[improvement in one]

improvement in one

[Psychometric testing]

Psychometric testing

[future 30-day]

future 30-day

[advanced heart disease]

advanced heart disease

[cardiopulmonary exercise variables]

cardiopulmonary exercise variables

[hospitalizations a case series]

hospitalizations a case series

[Impact after discharge]

Impact after discharge

[Using neonatal rat cardiomyocytes]

Using neonatal rat cardiomyocytes

[global systolic strain]

global systolic strain

[left systolic strain GLS]

left systolic strain GLS

[including hypertension]

including hypertension

[model system]

model system

[change with treatment in increase]

change with treatment in increase

[oscillations originating]

oscillations originating

[impact on health-related quality]

impact on health-related quality

[lean mass index]

lean mass index

[chain]

chain

[heart failure with renal dysfunction]

heart failure with renal dysfunction

[signalling pathways]

signalling pathways

[search of the electronic databases]

search of the electronic databases

[relationships between ventricular RV function]

relationships between ventricular RV function

[appropriate end points]

appropriate end points

[amino-terminal peptide]

amino-terminal peptide

[surgical method of constriction TAC]

surgical method of constriction TAC

[necessitating a understanding]

necessitating a understanding

[70 versus ≥70 bpm 17.5±5.5 P]

70 versus ≥70 bpm 17.5±5.5 P

[15 mL per m 2]

15 mL per m 2

[well-treated cohort of patients]

well-treated cohort of patients

[High-density lipoprotein]

High-density lipoprotein

[normal ejection fraction]

normal ejection fraction

[849 patients]

849 patients

[moderate-intensity aerobic exercise]

moderate-intensity aerobic exercise

[insulin-signaling components regulating metabolism]

insulin-signaling components regulating metabolism

[genes DEGs between heart failure samples]

genes DEGs between heart failure samples

[ejection time complicating pulmonary hypertension]

ejection time complicating pulmonary hypertension

[HNO donor CXL-1020]

HNO donor CXL-1020

[exercise parameters for diagnosis]

exercise parameters for diagnosis

[Other factors at admission]

Other factors at admission

[right ejection fraction P=0.01]

right ejection fraction P=0.01

[peptide drugs]

peptide drugs

[antibodies targeting epitopes]

antibodies targeting epitopes

[impact of the treatment strategies]

impact of the treatment strategies

[pulmonary arterial pressure relationship]

pulmonary arterial pressure relationship

[Future A Cardiology-Cardiovascular Surgery Consensus Report]

Future A Cardiology-Cardiovascular Surgery Consensus Report

[Hospital Compare]

Hospital Compare

[Global left longitudinal systolic strain]

Global left longitudinal systolic strain

[Survival after left ventricular assist device]

Survival after left ventricular assist device

[matrix accumulation]

matrix accumulation

[MI animals with metoprolol]

MI animals with metoprolol

[pump dysfunction]

pump dysfunction

[proximal LCX later model]

proximal LCX later model

[deaths in the control group]

deaths in the control group

[AAs race]

AAs race

[restoration of plasma membrane levels]

restoration of plasma membrane levels

[older women]

older women

[protein-C]

protein-C

[situations in pediatrics]

situations in pediatrics

[complex V activity]

complex V activity

[mechanical circulatory support]

mechanical circulatory support

[potential as novel targets]

potential as novel targets

[relative importance]

relative importance

[free wall RS]

free wall RS

[brain natriuretic peptide levels]

brain natriuretic peptide levels

[energy substrate metabolism]

energy substrate metabolism

[hospitalizations in refractory congestive heart failure]

hospitalizations in refractory congestive heart failure

[artery systolic pressure PASP increase]

artery systolic pressure PASP increase

[multivariate-adjusted odds ratio]

multivariate-adjusted odds ratio

[global left ventricular strain]

global left ventricular strain

[angiotensin infusion]

angiotensin infusion

[change in the ratio]

change in the ratio

[treatment for HF with vasodilators]

treatment for HF with vasodilators

[extensive characterization]

extensive characterization

[using the surgical method of constriction]

using the surgical method of constriction

[cardiotoxicity a agent]

cardiotoxicity a agent

[type II regulatory subunit expression]

type II regulatory subunit expression

[time after valve plasty]

time after valve plasty

[muscle sarcomere]

muscle sarcomere

[jugular pressure]

jugular pressure

[race training]

race training

[several changes]

several changes

[better information]

better information

[65 years]

65 years

[area AUC]

area AUC

[investigating HF-related cachexia]

investigating HF-related cachexia

[major components regulating cellular metabolism]

major components regulating cellular metabolism

[CAD involving the left descending artery]

CAD involving the left descending artery

[kidney disease filtration rate]

kidney disease filtration rate

[Swedish Inpatient Registry]

Swedish Inpatient Registry

[sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]

sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG

[hospitals in an decile]

hospitals in an decile

[novel targets for heart failure]

novel targets for heart failure

[index ED]

index ED

[highest event rate]

highest event rate

[ejection fraction HF in conditions]

ejection fraction HF in conditions

[significant improvement in rate]

significant improvement in rate

[center retrospective study in children]

center retrospective study in children

[diuretic response]

diuretic response

[open surgery]

open surgery

[antiadrenergic therapeutic strategy]

antiadrenergic therapeutic strategy

[hazard ratio for peak]

hazard ratio for peak

[significant change with exercise effect]

significant change with exercise effect

[addition indicating possible care]

addition indicating possible care

[obstruction]

obstruction

[absence in patients]

absence in patients

[sternotomy for aortic valve procedures]

sternotomy for aortic valve procedures

[28 hospitalisations]

28 hospitalisations

[Determination of a cutoff value]

Determination of a cutoff value

[thereby decreasing risk of HF mortality]

thereby decreasing risk of HF mortality

[BET family]

BET family

[serious adverse events]

serious adverse events

[assembly]

assembly

[system major events]

system major events

[role of readers]

role of readers

[summary in all subdomains]

summary in all subdomains

[afterload of patients]

afterload of patients

[1.6 reasons per patient P]

1.6 reasons per patient P

[higher frequency]

higher frequency

[treadmill exercise testing]

treadmill exercise testing

[norepinephrine-induced responses]

norepinephrine-induced responses

[All-cause mortality after hospitalization for HF]

All-cause mortality after hospitalization for HF

[beneficial approach]

beneficial approach

[receptor haplotype]

receptor haplotype

[E-wave early mitral velocity]

E-wave early mitral velocity

[transmitral blood flow velocity]

transmitral blood flow velocity

[dopamine on end points reflective]

dopamine on end points reflective

[Direct observation at the time]

Direct observation at the time

[lower walking distance peak]

lower walking distance peak

[broader discussions about treatment preferences]

broader discussions about treatment preferences

[Ca handling in HF]

Ca handling in HF

[2.8 L]

2.8 L

[moderate-severe dysfunction]

moderate-severe dysfunction

[types of LVADs HeartMate]

types of LVADs HeartMate

[process of repair]

process of repair

[levels in anthracycline-treated breast cancer patients]

levels in anthracycline-treated breast cancer patients

[ventricular ejection fraction HF]

ventricular ejection fraction HF

[indices E ratio at diastole]

indices E ratio at diastole

[≥35 kg]

≥35 kg

[patients undergoing LVAD implantation from 2000]

patients undergoing LVAD implantation from 2000

[brief arrest]

brief arrest

[risk of hospitalization hazard ratio]

risk of hospitalization hazard ratio

[development following ring annuloplasty]

development following ring annuloplasty

[Psoriasis patients with mild disease]

Psoriasis patients with mild disease

[originating from the pattern generator]

originating from the pattern generator

[150 minutes of exercise]

150 minutes of exercise

[mutant mice]

mutant mice

[Advances in treatment for infarction]

Advances in treatment for infarction

[months of follow-up data]

months of follow-up data

[hypertrophy of cardiomyocytes]

hypertrophy of cardiomyocytes

[logistic analysis]

logistic analysis

[Measurement at the point of care]

Measurement at the point of care

[Grading Assessment methodology]

Grading Assessment methodology

[Utilizing testimonies]

Utilizing testimonies

[training intervention]

training intervention

[therapeutic strategy in HF]

therapeutic strategy in HF

[activation PKC-βII]

activation PKC-βII

[elevated pressure]

elevated pressure

[new-onset AI requiring surgical intervention]

new-onset AI requiring surgical intervention

[extreme N termini]

extreme N termini

[Factors Insights A Trial]

Factors Insights A Trial

[cardioverter-defibrillator shocks]

cardioverter-defibrillator shocks

[heart dilatation after transverse constriction TAC]

heart dilatation after transverse constriction TAC

[reasons for the modest reduction]

reasons for the modest reduction

[days of the index]

days of the index

[mortality for HF]

mortality for HF

[≥1 independent predictor]

≥1 independent predictor

[score range]

score range

[heterogeneous group]

heterogeneous group

[clinical benefit for patients in studies]

clinical benefit for patients in studies

[filtration rate eGFR ml]

filtration rate eGFR ml

[diastolic annular velocity 3.1]

diastolic annular velocity 3.1

[N-terminal pro-B-type]

N-terminal pro-B-type

[Prognostic value of indeterminable anaerobic threshold]

Prognostic value of indeterminable anaerobic threshold

[Tools of Patient Management Interventions]

Tools of Patient Management Interventions

[endpoint cardiovascular death]

endpoint cardiovascular death

[mitral annulus velocity E]

mitral annulus velocity E

[outcome-monitoring phase]

outcome-monitoring phase

[HFpEF with left ventricular ejection fraction]

HFpEF with left ventricular ejection fraction

[transfusion thresholds]

transfusion thresholds

[change with exercise effect exercise]

change with exercise effect exercise

[receptor family member]

receptor family member

[O2 consumption rate]

O2 consumption rate

[high consistency among patients]

high consistency among patients

[10 heart failure patients with tachycardia]

10 heart failure patients with tachycardia

[role including factor]

role including factor

[tracking]

tracking

[Readmission PPR]

Readmission PPR

[greatest difference]

greatest difference

[age years P=0.016]

age years P=0.016

[Cardiology-Cardiovascular Surgery Consensus Report]

Cardiology-Cardiovascular Surgery Consensus Report

[cardiac hypertrophic response protective role]

cardiac hypertrophic response protective role

[myocardial infarction in Western Australia]

myocardial infarction in Western Australia

[time frame]

time frame

[phospholipase A2]

phospholipase A2

[hypokalemia with spironolactone]

hypokalemia with spironolactone

[evidence for usefulness in HF]

evidence for usefulness in HF

[nonstandardized N-terminal pro-B-type peptide NT-proBNP]

nonstandardized N-terminal pro-B-type peptide NT-proBNP

[Cardiorespiratory fitness Cooper Center Study]

Cardiorespiratory fitness Cooper Center Study

[Lesions CORAL]

Lesions CORAL

[part of this study]

part of this study

[tracking VA patients from HFPSI]

tracking VA patients from HFPSI

[criteria cardiac transplantation]

criteria cardiac transplantation

[New-onset insufficiency]

New-onset insufficiency

[readmission rate for patients]

readmission rate for patients

[Aldosterone receptor]

Aldosterone receptor

[Eplerenone in Patients Hospitalization]

Eplerenone in Patients Hospitalization

[medications among outpatients]

medications among outpatients

[patients with CHF-NYHA-III]

patients with CHF-NYHA-III

[consecutive HF patients ventricular ejection fraction]

consecutive HF patients ventricular ejection fraction

[Registry on Dialysis]

Registry on Dialysis

[ANG II infusion]

ANG II infusion

[nonsurvivors with a distribution]

nonsurvivors with a distribution

[nonfailing canine electromechanics]

nonfailing canine electromechanics

[targeting exercise status]

targeting exercise status

[ambulatory HF patients ejection fraction]

ambulatory HF patients ejection fraction

[AAs 4.32±0.54-4.31±0.49]

AAs 4.32±0.54-4.31±0.49

[right area index 10.0 cm(2)]

right area index 10.0 cm(2)

[adult rats]

adult rats

[stem cardiomyocytes hiPSC-CMs]

stem cardiomyocytes hiPSC-CMs

[Heart failure risk]

Heart failure risk

[rate of rehospitalization]

rate of rehospitalization

[abnormalities of gastrointestinal regions]

abnormalities of gastrointestinal regions

[encoding channels]

encoding channels

[Further analysis]

Further analysis

[consisting after infarction]

consisting after infarction

[days P-value for difference]

days P-value for difference

[Taking all follow-up visits]

Taking all follow-up visits

[transmitral E-wave diastolic mitral velocity]

transmitral E-wave diastolic mitral velocity

[1.56 percentage points]

1.56 percentage points

[still a highly effective agent]

still a highly effective agent

[containing heart failure]

containing heart failure

[BNP levels with the greatest difference]

BNP levels with the greatest difference

[relevance of contractile reserve]

relevance of contractile reserve

[impact on patients with BTES]

impact on patients with BTES

[ambulatory HF patients]

ambulatory HF patients

[LV dysfunction alone]

LV dysfunction alone

[QOL co-primary outcome]

QOL co-primary outcome

[body of evidence]

body of evidence

[significant 42 percent reduction]

significant 42 percent reduction

[limited number]

limited number

[membrane oxygenation ECMO on function]

membrane oxygenation ECMO on function

[Killip]

Killip

[symptoms despite medical treatment]

symptoms despite medical treatment

[changes in control group]

changes in control group

[renin inhibitors]

renin inhibitors

[9 subjects with hearts]

9 subjects with hearts

[CI for HF respectively]

CI for HF respectively

[acute system modulation on QTV]

acute system modulation on QTV

[embryonic kidney]

embryonic kidney

[patients with left ventricular ejection fraction]

patients with left ventricular ejection fraction

[Effective elastance end-systolic elastance Ees]

Effective elastance end-systolic elastance Ees

[amelioration of the ingenuity pathway analysis]

amelioration of the ingenuity pathway analysis

[one model for chronic ischemia]

one model for chronic ischemia

[patients in retrospective studies]

patients in retrospective studies

[Addition of HABC Battery scores discrimination]

Addition of HABC Battery scores discrimination

[MT group days]

MT group days

[cutoff value for survival]

cutoff value for survival

[promoting cardiac filling]

promoting cardiac filling

[lower national income]

lower national income

[dietary approaches]

dietary approaches

[t1 of minutes]

t1 of minutes

[sphingosine-1-phosphate receptor]

sphingosine-1-phosphate receptor

[test for HFpEF]

test for HFpEF

[High confidence]

High confidence

[potentially promising biomarker]

potentially promising biomarker

[Echocardiography at wk]

Echocardiography at wk

[including negative coronary angiography]

including negative coronary angiography

[trials of erythropoiesis-stimulating agent therapy]

trials of erythropoiesis-stimulating agent therapy

[transforming]

transforming

[better prognostic information than the others]

better prognostic information than the others

[foundation of management]

foundation of management

[autonomic system modulation on QTV]

autonomic system modulation on QTV

[well-recognised risk factor for health]

well-recognised risk factor for health

[onset following infarction]

onset following infarction

[ventricular tachycardia storm]

ventricular tachycardia storm

[10 lb]

10 lb

[12-lead ECG]

12-lead ECG

[left longitudinal strain as a predictor]

left longitudinal strain as a predictor

[percutaneous intervention HR]

percutaneous intervention HR

[even in a patient]

even in a patient

[enormous burden in adult medicine]

enormous burden in adult medicine

[surviving ventricle]

surviving ventricle

[Cardiovascular Outcomes in Lesions CORAL]

Cardiovascular Outcomes in Lesions CORAL

[right ventricular plane excursion]

right ventricular plane excursion

[m 2 age]

m 2 age

[common medical conditions]

common medical conditions

[cause of mortality]

cause of mortality

[Ca 2+)-uptake]

Ca 2+)-uptake

[STS HH HR]

STS HH HR

[global left ventricular longitudinal strain]

global left ventricular longitudinal strain

[trends for common conditions]

trends for common conditions

[Disease Registry]

Disease Registry

[rates of hypokalemia]

rates of hypokalemia

[outcomes of catheter ablation in patients]

outcomes of catheter ablation in patients

[antibodies targeting epitopes P]

antibodies targeting epitopes P

[practice for a number]

practice for a number

[cell EC nitric oxide production]

cell EC nitric oxide production

[patients with HR bpm P]

patients with HR bpm P

[E-wave early mitral annular velocity ratio]

E-wave early mitral annular velocity ratio

[greater physical activity]

greater physical activity

[dying in days P-value for difference]

dying in days P-value for difference

[types HeartMate]

types HeartMate

[Effects of care management a analysis]

Effects of care management a analysis

[analysis of tissue from mice]

analysis of tissue from mice

[vascular growth factor]

vascular growth factor

[regulating cellular metabolism]

regulating cellular metabolism

[presence with proteolysis between Pro2-Leu3]

presence with proteolysis between Pro2-Leu3

[mortality among women]

mortality among women

[undergoing procedures]

undergoing procedures

[potential for effects]

potential for effects

[clinical studies HM]

clinical studies HM

[evidence-based therapies in these patients]

evidence-based therapies in these patients

[intracellular antiadrenergic strategy]

intracellular antiadrenergic strategy

[Thirty HFpEF patients aged years]

Thirty HFpEF patients aged years

[similar risk as patients]

similar risk as patients

[improvement in ejection fraction]

improvement in ejection fraction

[factorial]

factorial

[100 obese participants]

100 obese participants

[Investigating Outcomes study-a multicenter study]

Investigating Outcomes study-a multicenter study

[measure of ventricular mechanics]

measure of ventricular mechanics

[transplant ineligible patients receiving PD]

transplant ineligible patients receiving PD

[sitagliptin for saxagliptin]

sitagliptin for saxagliptin

[14 studies HM II]

14 studies HM II

[microstructure at baseline]

microstructure at baseline

[functioning of treatments]

functioning of treatments

[rats possible mechanism]

rats possible mechanism

[left anterior descending LAD]

left anterior descending LAD

[myocytes from normal hearts]

myocytes from normal hearts

[volume overload of regurgitation]

volume overload of regurgitation

[especially in the case of survival]

especially in the case of survival

[indicators of status 6-MWT]

indicators of status 6-MWT

[proBNP NT-proBNP]

proBNP NT-proBNP

[MI-induced decreases]

MI-induced decreases

[stable medical therapy]

stable medical therapy

[1-year survival in patients]

1-year survival in patients

[PAF levels]

PAF levels

[partial attenuation of proteomics changes]

partial attenuation of proteomics changes

[significant improvements in composite response]

significant improvements in composite response

[independent predictor of outcome period]

independent predictor of outcome period

[such as short-term scaling exponent]

such as short-term scaling exponent

[Understanding of heart failure]

Understanding of heart failure

[Learning from trials]

Learning from trials

[history of angina]

history of angina

[ventricular filling pressure]

ventricular filling pressure

[optimizing cardiac progenitor function for application]

optimizing cardiac progenitor function for application

[time domain heart rate variability]

time domain heart rate variability

[efficacy of interatrial shunting]

efficacy of interatrial shunting

[Trial HF-ACTION]

Trial HF-ACTION

[new-onset AI]

new-onset AI

[Effect of inhibition]

Effect of inhibition

[risk factors such as obesity]

risk factors such as obesity

[24 hours]

24 hours

[Multicenter placebo-controlled clinical trial of patients]

Multicenter placebo-controlled clinical trial of patients

[setting of embolism]

setting of embolism

[size reduction by the ring implantation]

size reduction by the ring implantation

[response the difference]

response the difference

[BNP values]

BNP values

[improvement of cardiac biomarkers]

improvement of cardiac biomarkers

[median PASP increase]

median PASP increase

[radial arterial tonometry]

radial arterial tonometry

[ongoing GDMT control group]

ongoing GDMT control group

[experiencing distressing cardioverter-defibrillator shocks at end]

experiencing distressing cardioverter-defibrillator shocks at end

[right after artery ligation]

right after artery ligation

[prolonged delay]

prolonged delay

[rat ventricular cardiomyocytes]

rat ventricular cardiomyocytes

[β-Blocker-induced enhancement of angiogenesis]

β-Blocker-induced enhancement of angiogenesis

[ventricular structure]

ventricular structure

[participants area]

participants area

[Rad Q66P]

Rad Q66P

[heart dilatation after aortic constriction]

heart dilatation after aortic constriction

[including risk]

including risk

[CHF dysfunction]

CHF dysfunction

[York Heart Association class]

York Heart Association class

[additional benefit over parameters]

additional benefit over parameters

[effect of acute system modulation]

effect of acute system modulation

[function with measures]

function with measures

[STS HH interval CrI]

STS HH interval CrI

[pulmonary resistance P]

pulmonary resistance P

[resection]

resection

[access programme]

access programme

[New York Heart Association Class]

New York Heart Association Class

[N-terminal natriuretic peptide]

N-terminal natriuretic peptide

[improvement of the valve opening]

improvement of the valve opening

[characteristics eg using Cochrane Effective Practice]

characteristics eg using Cochrane Effective Practice

[four common conditions]

four common conditions

[chronic obstructive disease COPD]

chronic obstructive disease COPD

[dysfunction treatment paradigm]

dysfunction treatment paradigm

[Comment]

Comments, Comment

[Americans aged]

Americans aged

[DTT]-insensitive CDP choline]

DTT]-insensitive CDP choline

[2-year study period]

2-year study period

[difference among EF median BNP]

difference among EF median BNP

[54 patients aged 62.4 years]

54 patients aged 62.4 years

[other diseases]

other diseases

[bpm 17.5±5.5 versus mL P]

bpm 17.5±5.5 versus mL P

[N-terminal natriuretic peptide assessment]

N-terminal natriuretic peptide assessment

[acute infarction in Western Australia]

acute infarction in Western Australia

[many HF trials]

many HF trials

[systolic strain as a major predictor]

systolic strain as a major predictor

[β-adrenergic receptor agonist]

β-adrenergic receptor agonist

[ventricular plane excursion from the end]

ventricular plane excursion from the end

[tonometry study]

tonometry study

[outcome over 6 months]

outcome over 6 months

[better information than the others]

better information than the others

[global left systolic strain GLS]

global left systolic strain GLS

[Optimization Strategies Evaluation]

Optimization Strategies Evaluation

[associations of dietary patterns]

associations of dietary patterns

[studies of transfusion]

studies of transfusion

[targeting epitopes P]

targeting epitopes P

[transient potential]

transient potential

[LVAS]

LVAS

[lb in 1 year]

lb in 1 year

[mortality at 4 years]

mortality at 4 years

[two thirds]

two thirds

[Akt→forkhead box]

Akt→forkhead box

[systemic hypertension]

systemic hypertension

[Renal Lesions]

Renal Lesions

[59.6 m vs. m]

59.6 m vs. m

[insulin receptor substrates IRS1]

insulin receptor substrates IRS1

[dysfunction by weeks]

dysfunction by weeks

[Baseline]

Baseline

[perhaps the important component]

perhaps the important component

[changes in prognosis]

changes in prognosis

[definition of heart failure]

definition of heart failure

[myocardial ischemia open stent]

myocardial ischemia open stent

[Turkey]

Turkey

[Coprimary end]

Coprimary end

[relevance in the follow-up]

relevance in the follow-up

[odds ratio after adjustment]

odds ratio after adjustment

[STE analysis of strain]

STE analysis of strain

[inoperable chronic hypertension]

inoperable chronic hypertension

[isolated heart rate reduction]

isolated heart rate reduction

[underlying heart disease]

underlying heart disease

[matrix of biopsies n=9]

matrix of biopsies n=9

[QRS morphology]

QRS morphology

[early blood flow velocity]

early blood flow velocity

[benefit over conventional clinical parameters]

benefit over conventional clinical parameters

[limitations in models]

limitations in models

[complications of therapy in severe HF]

complications of therapy in severe HF

[precipitating factor]

precipitating factor

[First-in-class angiotensin receptor]

First-in-class angiotensin receptor

[quality of life Minnesota Living]

quality of life Minnesota Living

[absolute change the percent]

absolute change the percent

[important outcomes]

important outcomes

[severe hypertension of 104 mm Hg]

severe hypertension of 104 mm Hg

[exhaustion]

exhaustion

[ratio at diastole with transmitral flow]

ratio at diastole with transmitral flow

[least a level]

least a level

[changing doses]

changing doses

[23.7 ng]

23.7 ng

[acute ventricular pressure overload RVPO]

acute ventricular pressure overload RVPO

[novel HNO donor CXL-1020]

novel HNO donor CXL-1020

[Grade low-quality evidence]

Grade low-quality evidence

[subclass]

subclass

[left assist device use]

left assist device use

[arterial coupling resistance P]

arterial coupling resistance P

[scaffolds in heart pathology]

scaffolds in heart pathology

[ventricular ejection fraction R=0.28 P=0.01]

ventricular ejection fraction R=0.28 P=0.01

[including tools]

including tools

[right arterial coupling resistance P]

right arterial coupling resistance P

[Permanente]

Permanente

[treatment for acute infarction]

treatment for acute infarction

[kidney cells]

kidney cells

[proximal circumflex artery]

proximal circumflex artery

[HF patients without spontaneous VT]

HF patients without spontaneous VT

[120 consecutive patients]

120 consecutive patients

[cardiomyopathy including coronary angiography]

cardiomyopathy including coronary angiography

[energy production]

energy production

[clinical burden]

clinical burden

[add-on diagnostic features such as detection]

add-on diagnostic features such as detection

[pre-specified analysis]

pre-specified analysis

[conduction abnormalities]

conduction abnormalities

[hospital rankings]

hospital rankings

[using Classification of Diseases]

using Classification of Diseases

[early metabolic changes]

early metabolic changes

[inpatient medical conditions]

inpatient medical conditions

[myocardial enhancement imaging]

myocardial enhancement imaging

[postnatal myocardium]

postnatal myocardium

[numbers of cells in any]

numbers of cells in any

[assessments of patients with heart failure]

assessments of patients with heart failure

[hemodynamic assessments]

hemodynamic assessments

[optimization controlling heart rate]

optimization controlling heart rate

[features such as detection]

features such as detection

[interaction between the randomization group]

interaction between the randomization group

[repair]

repair

[renal function WRF in EMPHASIS-HF]

renal function WRF in EMPHASIS-HF

[exercise parameters]

exercise parameters

[consecutive patients 224 men]

consecutive patients 224 men

[hand grip]

hand grip

[CHF model]

CHF model

[error]

error

[result of shortcomings]

result of shortcomings

[function WRF]

function WRF

[Transoesophageal echocardiography at month]

Transoesophageal echocardiography at month

[function in cardiac volume overload]

function in cardiac volume overload

[cardiac hypertrophy a predictor of HF]

cardiac hypertrophy a predictor of HF

[exercise test investigations at study enrollment]

exercise test investigations at study enrollment

[521 patients]

521 patients

[involving the left anterior descending artery]

involving the left anterior descending artery

[Circulating fragments of pro-B-type peptides]

Circulating fragments of pro-B-type peptides

[mm Hg PASP]

mm Hg PASP

[left ventricular end diameter mm difference]

left ventricular end diameter mm difference

[months of treatment]

months of treatment

[patients with unfavorable outcome]

patients with unfavorable outcome

[percent of patients]

percent of patients

[emergency setting status]

emergency setting status

[brachial pressure 155]

brachial pressure 155

[Sudden cardiac death]

Sudden cardiac death

[Novel tools]

Novel tools

[surviving an acute myocardial infarction]

surviving an acute myocardial infarction

[Stage 3 chronic kidney disease]

Stage 3 chronic kidney disease

[ventricular longitudinal strain as a predictor]

ventricular longitudinal strain as a predictor

[inoperable thromboembolic pulmonary hypertension]

inoperable thromboembolic pulmonary hypertension

[rate in patients]

rate in patients

[nanomolar doses]

nanomolar doses

[ventricular LV systolic pressure]

ventricular LV systolic pressure

[individual associations among cardiorespiratory fitness]

individual associations among cardiorespiratory fitness

[average length of stay]

average length of stay

[health insurance]

health insurance

[structure geometry]

structure geometry

[somewhat better information]

somewhat better information

[precise role in pathophysiology]

precise role in pathophysiology

[resolution]

resolution

[walking distance]

walking distance

[cardiovascular event rate at events]

cardiovascular event rate at events

[relationship between QRS duration]

relationship between QRS duration

[including stress echocardiography]

including stress echocardiography

[fibrillation PVF]

fibrillation PVF

[Relation between preoperative dysfunction within months]

Relation between preoperative dysfunction within months

[determining assessment for patients with RAS]

determining assessment for patients with RAS

[microarray data]

microarray data

[total expenditure on health]

total expenditure on health

[2.0±3.2 mL increase]

2.0±3.2 mL increase

[Sixty-one patients]

Sixty-one patients

[use of implantable cardioverter defibrillator-CRT]

use of implantable cardioverter defibrillator-CRT

[using the Kansas City Cardiomyopathy Questionnaire]

using the Kansas City Cardiomyopathy Questionnaire

[almost 7 kg]

almost 7 kg

[advancement]

advancement

[patients having heart failure]

patients having heart failure

[patients with advanced obstructive disease]

patients with advanced obstructive disease

[syndrome of right heart failure]

syndrome of right heart failure

[such as detection]

such as detection

[potential therapeutic implications]

potential therapeutic implications

[incidence outcomes after myocardial infarction]

incidence outcomes after myocardial infarction

[ventricular systolic pressure]

ventricular systolic pressure

[HR 70]

HR 70

[higher levels]

higher levels

[novel one model for ischemia]

novel one model for ischemia

[Multicenter Defibrillator Implantation Cardiac Resynchronization Therapy]

Multicenter Defibrillator Implantation Cardiac Resynchronization Therapy

[worse QOL]

worse QOL

[surgical method]

surgical method

[such as heart failure]

such as heart failure

[pressure overload]

pressure overload

[changes in NYHA class]

changes in NYHA class

[bpm 17.5±5.5]

bpm 17.5±5.5

[heart failure mortality]

heart failure mortality

[Cardiac Function Among Patients]

Cardiac Function Among Patients

[12 patients]

12 patients

[greater incidence]

greater incidence

[7 kg with improvement]

7 kg with improvement

[activities of PAF-AH]

activities of PAF-AH

[several key genes]

several key genes

[case series of transplant patients]

case series of transplant patients

[rate of ATP]

rate of ATP

[resulting in the patients]

resulting in the patients

[regarding the circulating forms]

regarding the circulating forms

[heart failure HF risk stratification models]

heart failure HF risk stratification models

[characterization]

characterization

[variance in hospital mortality]

variance in hospital mortality

[603 consecutive patients]

603 consecutive patients

[insight into prolonged electromechanical delay]

insight into prolonged electromechanical delay

[measure of mechanics]

measure of mechanics

[primary diagnosis of HF]

primary diagnosis of HF

[RAS blockers HR]

RAS blockers HR

[Further randomised studies]

Further randomised studies

[Cancer Registry–Medicare]

Cancer Registry–Medicare

[measure of HF with EF]

measure of HF with EF

[20 consecutive patients]

20 consecutive patients

[such patients]

such patients

[Duke Activity]

Duke Activity

[consisting after myocardial infarction]

consisting after myocardial infarction

[endothelial-protective effects]

endothelial-protective effects

[Composite quality measures for inpatient conditions]

Composite quality measures for inpatient conditions

[secretion]

secretion

[modest effects on heart failure]

modest effects on heart failure

[ANG infusion]

ANG infusion

[reasons P]

reasons P

[overall effects on rate]

overall effects on rate

[Mediterranean Approaches]

Mediterranean Approaches

[Δ50%W]

Δ50%W

[Echocardiograms of the ventricular midpapillary level]

Echocardiograms of the ventricular midpapillary level

[human HF tissue samples]

human HF tissue samples

[validity replicating resource use]

validity replicating resource use

[consensus regarding the circulating forms]

consensus regarding the circulating forms

[start date for the cohort]

start date for the cohort

[presence of mild clinical dysfunction]

presence of mild clinical dysfunction

[effects on beta-adrenergic receptor β-AR signaling]

effects on beta-adrenergic receptor β-AR signaling

[medicine CHM]

medicine CHM

[2 months]

2 months

[unit increase]

unit increase

[even in subgroups at high risk]

even in subgroups at high risk

[patients with MS]

patients with MS

[patients with MR]

patients with MR

[effect of ejection fraction]

effect of ejection fraction

[reasons per patient P]

reasons per patient P

[effective therapies in these patients]

effective therapies in these patients

[Carvedilol a β-blocker]

Carvedilol a β-blocker

[management involving assist devices]

management involving assist devices

[regression line shift in nonsurvivors]

regression line shift in nonsurvivors

[standard practice for a number]

standard practice for a number

[CHF visit rates]

CHF visit rates

[difference in the percentage control]

difference in the percentage control

[providing prognostic information for an outcome]

providing prognostic information for an outcome

[Hemodynamic phenotype]

Hemodynamic phenotype

[m vs. m]

m vs. m

[PASP relationship]

PASP relationship

[risk 5.5 mmol]

risk 5.5 mmol

[sickle]

sickle

[3 postoperative months]

3 postoperative months

[objective of this trial]

objective of this trial

[risk of potassium mmol]

risk of potassium mmol

[functional decline c-Kit]

functional decline c-Kit

[potential for success]

potential for success

[75 years of age]

75 years of age

[mouse Rad Q65P]

mouse Rad Q65P

[group mL]

group mL

[blood pressure via arterial tonometry]

blood pressure via arterial tonometry

[dual x-ray absorptiometry]

dual x-ray absorptiometry

[large study sample]

large study sample

[hRetn human resistin mRNA]

hRetn human resistin mRNA

[first 7 days]

first 7 days

[improving quality of care]

improving quality of care

[risk of 30-day death]

risk of 30-day death

[402 patients normal geometry]

402 patients normal geometry

[LVET at entry]

LVET at entry

[prognostic markers]

prognostic markers

[left systolic strain as a predictor]

left systolic strain as a predictor

[cell differentiation]

cell differentiation

[program of exercise]

program of exercise

[readmission rates using metrics]

readmission rates using metrics

[effective elastance Ea]

effective elastance Ea

[deleterious β1AR overstimulation]

deleterious β1AR overstimulation

[practice-level differences]

practice-level differences

[lower activities P]

lower activities P

[receptor antagonists in heart failure]

receptor antagonists in heart failure

[additional benefit over systolic parameters]

additional benefit over systolic parameters

[EAST Early treatment]

EAST Early treatment

[protective effects of antioxidant]

protective effects of antioxidant

[8 patients HDL]

8 patients HDL

[yield]

yield

[worse QOL co-primary outcome]

worse QOL co-primary outcome

[ventricular end diameter mm]

ventricular end diameter mm

[3 economic evaluations HM]

3 economic evaluations HM

[assessment in hypertension patients]

assessment in hypertension patients

[studies HM]

studies HM

[clinically significant bleeding]

clinically significant bleeding

[preliminary data]

preliminary data

[patients with HR]

patients with HR

[dogs with tachypacing-induced HF]

dogs with tachypacing-induced HF

[Crude rates]

Crude rates

[absolute detectable change]

absolute detectable change

[2-vessel CAD involving the proximal artery]

2-vessel CAD involving the proximal artery

[Antihyperglycemic Drugs]

Antihyperglycemic Drugs

[new-onset severe AI]

new-onset severe AI

[precise role in cardiac pathophysiology]

precise role in cardiac pathophysiology

[patients surviving an myocardial infarction]

patients surviving an myocardial infarction

[PDE2-mediated effects on receptor β-AR signaling]

PDE2-mediated effects on receptor β-AR signaling

[common type]

common type

[wk effects]

wk effects

[eight controls]

eight controls

[major cause of morbidity]

major cause of morbidity

[pathological changes including cardiac hypertrophy]

pathological changes including cardiac hypertrophy

[ventricular-pulmonary coupling resistance P]

ventricular-pulmonary coupling resistance P

[experiencing cardioverter-defibrillator shocks]

experiencing cardioverter-defibrillator shocks

[therapeutic interruption of systems]

therapeutic interruption of systems

[future experimental research]

future experimental research

[conducting studies]

conducting studies

[Periodic breathing]

Periodic breathing

[General use]

General use

[atypical case]

atypical case

[including calcium-sensitizing agents]

including calcium-sensitizing agents

[B-type peptide]

B-type peptide

[cardiac pathogenesis]

cardiac pathogenesis

[replicating resource use]

replicating resource use

[Comparison Of Outcomes Heart Failure]

Comparison Of Outcomes Heart Failure

[hospitalization within the 1 months]

hospitalization within the 1 months

[novel porcine model of ischemia]

novel porcine model of ischemia

[perioperative deaths in the experimental procedures]

perioperative deaths in the experimental procedures

[IL 0.5 mg]

IL 0.5 mg

[effect on 72-hour urine volume]

effect on 72-hour urine volume

[trend with severe dilatation]

trend with severe dilatation

[AF ablation]

AF ablation

[ESRD from the Danish Registry]

ESRD from the Danish Registry

[minimal exertion]

minimal exertion

[potential clinical application]

potential clinical application

[embryonic kidney cells overexpressing β1AR]

embryonic kidney cells overexpressing β1AR

[adverse rate]

adverse rate

[effect of ARNI]

effect of ARNI

[risk predictor]

risk predictor

[atrial mass removal]

atrial mass removal

[β-AR stimulation via catecholamine infusions]

β-AR stimulation via catecholamine infusions

[20 812 patients]

20 812 patients

[patients with EF]

patients with EF

[predictors of response]

predictors of response

[3,000 patients]

3,000 patients

[measure of right contractile reserve]

measure of right contractile reserve

[CV events AF]

CV events AF

[addition of low-dose dopamine]

addition of low-dose dopamine

[ventricular tricuspid plane excursion TAPSE]

ventricular tricuspid plane excursion TAPSE

[medical center]

medical center

[bpm 17.5±5.5 respectively P]

bpm 17.5±5.5 respectively P

[first months after CABG]

first months after CABG

[consecutive patients with onset]

consecutive patients with onset

[benefits of treatments in adults]

benefits of treatments in adults

[LV strain rate]

LV strain rate

[insight on the possible contribution]

insight on the possible contribution

[atrial natriuretic peptide B-type peptide]

atrial natriuretic peptide B-type peptide

[simulation models]

simulation models

[adult male rats]

adult male rats

[17 days range]

17 days range

[potential benefit with few consequences]

potential benefit with few consequences

[New-onset aortic insufficiency]

New-onset aortic insufficiency

[nervous system activity]

nervous system activity

[strain as a predictor]

strain as a predictor

[including tools for risk stratification]

including tools for risk stratification

[patients with s'lateral of cm]

patients with s'lateral of cm

[PAF biosynthetic enzymes]

PAF biosynthetic enzymes

[left ventricular ejection fraction HF]

left ventricular ejection fraction HF

[CF devices]

CF devices

[trials in HF]

trials in HF

[major rate]

major rate

[option in heart failure]

option in heart failure

[non-survivors years vs 72.83 years]

non-survivors years vs 72.83 years

[IRS2 gene double-knockout]

IRS2 gene double-knockout

[nitroxyl]

nitroxyl

[ventricular LV remodeling]

ventricular LV remodeling

[economic savings]

economic savings

[Left Ventricular Assist System Treating HF]

Left Ventricular Assist System Treating HF

[nesiritide 0.005 μg]

nesiritide 0.005 μg

[detecting normal filling pressures]

detecting normal filling pressures

[≥60 mL per m]

≥60 mL per m

[24-hour brachial pressure]

24-hour brachial pressure

[11 587 users]

11 587 users

[index of contractile function]

index of contractile function

[CH LV volume]

CH LV volume

[psoriasis UV treatment]

psoriasis UV treatment

[Systolic dysfunction REVERSE]

Systolic dysfunction REVERSE

[trichrome blue analysis]

trichrome blue analysis

[mitochondrial-targeted peptide drugs]

mitochondrial-targeted peptide drugs

[prognosis of a large cohort]

prognosis of a large cohort

[estimating capillary wedge pressure in patients]

estimating capillary wedge pressure in patients

[area hazard ratio]

area hazard ratio

[optimizing progenitor function for clinical application]

optimizing progenitor function for clinical application

[Independent predictors for the development]

Independent predictors for the development

[systolic pressure 155 35]

systolic pressure 155 35

[108 HFpEF with ventricular ejection fraction]

108 HFpEF with ventricular ejection fraction

[atrioventricular delay]

atrioventricular delay

[breathing with no heart beat]

breathing with no heart beat

[hyponatremia in most countries]

hyponatremia in most countries

[fluctuations in beat-to-beat QT intervals]

fluctuations in beat-to-beat QT intervals

[REsynchronization reVErses Remodeling]

REsynchronization reVErses Remodeling

[Postoperative survival of patients]

Postoperative survival of patients

[pause release]

pause release

[99 patients]

99 patients

[trial of walking in patients]

trial of walking in patients

[regression line shift]

regression line shift

[reduction in the outcome]

reduction in the outcome

[s ST2]

s ST2

[significantly larger HR reduction]

significantly larger HR reduction

[Circulating fragments]

Circulating fragments

[increase in LV wall thickness]

increase in LV wall thickness

[Web-system for Enhancement]

Web-system for Enhancement

[epinephrine]

epinephrine

[Thirty HFpEF patients]

Thirty HFpEF patients

[selective beta-blockers on sympathetic activity]

selective beta-blockers on sympathetic activity

[Tools for Analysis]

Tools for Analysis

[less severe ventricular dilatation]

less severe ventricular dilatation

[risk of potassium]

risk of potassium

[proangiogenic effects of B act]

proangiogenic effects of B act

[low-frequency LF ratio]

low-frequency LF ratio

[transmitral flow velocities]

transmitral flow velocities

[commissioning on completion]

commissioning on completion

[first trials]

first trials

[percent of hospitals remaining]

percent of hospitals remaining

[variation in use]

variation in use

[mean SD testosterone levels]

mean SD testosterone levels

[treatment of fibrillation]

treatment of fibrillation

[min m]

min m

[N-terminal proBNP NT-proBNP]

N-terminal proBNP NT-proBNP

[HR CI]

HR CI

[goal-directed therapy]

goal-directed therapy

[treatment strategies in patients]

treatment strategies in patients

[ranging from medication]

ranging from medication

[critical importance]

critical importance

[patients with pulmonary disease]

patients with pulmonary disease

[30-day rehospitalization of percentage points]

30-day rehospitalization of percentage points

[reliability in HF]

reliability in HF

[Up TUG]

Up TUG

[Hypertension]

Hypertension

[2331 patients with ejection fraction 0.35]

2331 patients with ejection fraction 0.35

[Baseline follow-up levels]

Baseline follow-up levels

[patients with resting HR bpm]

patients with resting HR bpm

[care surgery in heart transplant recipients]

care surgery in heart transplant recipients

[carotid baroreflex]

carotid baroreflex

[guidance]

guidance

[clinical benefit for patients]

clinical benefit for patients

[associations with saxagliptin]

associations with saxagliptin

[adverse CV events AF]

adverse CV events AF

[aortic insufficiency]

aortic insufficiency

[Sudden death in athletes]

Sudden death in athletes

[growing population]

growing population

[BB dose versus mg dose]

BB dose versus mg dose

[Diuretic use]

Diuretic use

[improvement in diuretic response]

improvement in diuretic response

[role of ERK1 scaffolds]

role of ERK1 scaffolds

[Classification]

Classification

[annular plane excursion from the end]

annular plane excursion from the end

[receptor S1PR1]

receptor S1PR1

[cardiac hypertrophy a robust predictor]

cardiac hypertrophy a robust predictor

[Comparative effects]

Comparative effects

[model a significant predictor]

model a significant predictor

[role 2 scaffolds]

role 2 scaffolds

[randomised-controlled trials]

randomised-controlled trials

[sitagliptin versus insulin]

sitagliptin versus insulin

[HFPEF ventricular LV ejection fraction]

HFPEF ventricular LV ejection fraction

[achievement of metabolism respiratory quotient]

achievement of metabolism respiratory quotient

[kg vs 2.5 kg]

kg vs 2.5 kg

[Global systolic strain as a predictor]

Global systolic strain as a predictor

[diagnostic biomarkers in patients]

diagnostic biomarkers in patients

[idiopathic cohort]

idiopathic cohort

[tone resulting]

tone resulting

[mass quantification]

mass quantification

[ED visits mean age 76.4 years]

ED visits mean age 76.4 years

[Randomized trial of walking]

Randomized trial of walking

[biomarkers in patients]

biomarkers in patients

[quality Minnesota Living]

quality Minnesota Living

[ventricular tachycardia HFVT(+)]

ventricular tachycardia HFVT(+)

[analysis of subgroups]

analysis of subgroups

[PD initiation kg]

PD initiation kg

[symptom CPET in patients with CHF]

symptom CPET in patients with CHF

[higher phosphorylation]

higher phosphorylation

[managing clinically significant gastrointestinal bleeding]

managing clinically significant gastrointestinal bleeding

[cardiac Mena overexpression comparable]

cardiac Mena overexpression comparable

[Multiacquisition T1-mapping MRI]

Multiacquisition T1-mapping MRI

[dying in days]

dying in days

[decreasing risk]

decreasing risk

[outcome at year]

outcome at year

[7 g]

7 g

[rare with.estimates ranging from 1]

rare with.estimates ranging from 1

[left filling pressure response]

left filling pressure response

[Effects of care management]

Effects of care management

[Moderate-strength evidence from trials]

Moderate-strength evidence from trials

[fit indices]

fit indices

[soluble s ST2]

soluble s ST2

[Trastuzumab-related cardiotoxicity]

Trastuzumab-related cardiotoxicity

[part of the network]

part of the network

[association with DNA]

association with DNA

[influence]

influence

[treatment of heart disease]

treatment of heart disease

[hazards of events]

hazards of events

[functional class NYHA II-III]

functional class NYHA II-III

[multihospital study]

multihospital study

[permanent breathing PB]

permanent breathing PB

[serum resistin]

serum resistin

[staff responsible for patient care]

staff responsible for patient care

[mandatory follow-up visits]

mandatory follow-up visits

[rs10927887 p]

rs10927887 p

[Concentrations of soluble ST2]

Concentrations of soluble ST2

[longitudinal performance]

longitudinal performance

[three age subjects from the population]

three age subjects from the population

[diagnostic performance detecting normal filling pressures]

diagnostic performance detecting normal filling pressures

[plasma NE]

plasma NE

[ventricle overload]

ventricle overload

[care surgery consultations]

care surgery consultations

[extra membrane oxygenation ECMO]

extra membrane oxygenation ECMO

[childhood disease]

childhood disease

[sheet]

sheet

[loss of fat free mass]

loss of fat free mass

[Saxagliptin]

Saxagliptin

[resistin Retn]

resistin Retn

[1.73 m age]

1.73 m age

[last dose]

last dose

[crude RR]

crude RR

[role of nervous system activity]

role of nervous system activity

[Possible reasons for the modest reduction]

Possible reasons for the modest reduction

[measures of HR dynamics]

measures of HR dynamics

[restoring capacity]

restoring capacity

[adopting practices]

adopting practices

[Myocardial loss]

Myocardial loss

[mediating a cross talk]

mediating a cross talk

[cardiac magnetic resonance postcontrast]

cardiac magnetic resonance postcontrast

[patients across 4372 hospitals]

patients across 4372 hospitals

[interruption]

interruption

[pro-B-type natriuretic peptide NT-proBNP]

pro-B-type natriuretic peptide NT-proBNP

[plane]

plane

[Reversal of dysfunction by metoprolol]

Reversal of dysfunction by metoprolol

[proximal descending]

proximal descending

[coupling resistance P]

coupling resistance P

[efficacy end points]

efficacy end points

[pressure of CO2]

pressure of CO2

[exercise-induced pulmonary artery pressure PASP increase]

exercise-induced pulmonary artery pressure PASP increase

[such as infarction with expansion]

such as infarction with expansion

[dysfunction in doxorubicin-induced heart failure]

dysfunction in doxorubicin-induced heart failure

[wedge]

wedge

[Peritoneal dialysis PD]

Peritoneal dialysis PD

[3 pharmacologic studies including calcium-sensitizing agents]

3 pharmacologic studies including calcium-sensitizing agents

[cell differentiation toward cells]

cell differentiation toward cells

[preventive measures]

preventive measures

[almost 7 kg with improvement]

almost 7 kg with improvement

[usefulness in such patients]

usefulness in such patients

[hypotheses addition μg]

hypotheses addition μg

[common underlying characteristics eg]

common underlying characteristics eg

[use of protocol-driven POC testing]

use of protocol-driven POC testing

[cause of death in patients]

cause of death in patients

[mean of months]

mean of months

[interquartile range 18.6]

interquartile range 18.6

[statistically significant change effect exercise]

statistically significant change effect exercise

[HDL-induced production by EC]

HDL-induced production by EC

[ventricular-pulmonary arterial coupling resistance]

ventricular-pulmonary arterial coupling resistance

[monitoring RM strategies]

monitoring RM strategies

[2900 HM II]

2900 HM II

[Incidence of renal disease in outpatients]

Incidence of renal disease in outpatients

[2 scaffolds in heart pathology]

2 scaffolds in heart pathology

[right heart failure with shock]

right heart failure with shock

[date death]

date death

[effects of treatment]

effects of treatment

[echocardiographic guidance under general anaesthesia]

echocardiographic guidance under general anaesthesia

[peak VO2 of mL]

peak VO2 of mL

[NYHA Class]

NYHA Class

[Risk Among New Users of Saxagliptin]

Risk Among New Users of Saxagliptin

[worsening function WRF]

worsening function WRF

[such as fractal scaling exponent]

such as fractal scaling exponent

[incidence in VAD groups]

incidence in VAD groups

[filling pressure response]

filling pressure response

[quality measures for conditions]

quality measures for conditions

[intact hearts in models]

intact hearts in models

[Western Australian health data]

Western Australian health data

[30 mm Hg PASP]

30 mm Hg PASP

[patients with hypertension PH]

patients with hypertension PH

[etiologies of HF in LA]

etiologies of HF in LA

[activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]

activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG

[thalassaemia major]

thalassaemia major

[outcome change scores for older adults]

outcome change scores for older adults

[multivariate regression analysis]

multivariate regression analysis

[advanced obstructive disease]

advanced obstructive disease

[transoesophageal echocardiographic guidance]

transoesophageal echocardiographic guidance

[consecutive consenting HF patients ejection fraction]

consecutive consenting HF patients ejection fraction

[central pressure 18]

central pressure 18

[Gly16]

Gly16

[little impact on morphological development]

little impact on morphological development

[Study Selection trials of blood transfusions]

Study Selection trials of blood transfusions

[transcriptional analysis of cardiac tissue]

transcriptional analysis of cardiac tissue

[heart failure with dialysis]

heart failure with dialysis

[cardiac index versus 2.8 L 2]

cardiac index versus 2.8 L 2

[increasing refill compliance P]

increasing refill compliance P

[negative value]

negative value

[patients with SD testosterone levels]

patients with SD testosterone levels

[quality-of-life score –17.4 points]

quality-of-life score –17.4 points

[Trial Investigating Outcomes]

Trial Investigating Outcomes

[trial design]

trial design

[mechanical cardiac support on function]

mechanical cardiac support on function

[use of pro-B-type natriuretic peptide]

use of pro-B-type natriuretic peptide

[non-diastolic abnormalities]

non-diastolic abnormalities

[Future of heart failure]

Future of heart failure

[Ventricular Assist System Treating Advanced HF]

Ventricular Assist System Treating Advanced HF

[treadmill testing VO2max]

treadmill testing VO2max

[roles in patients]

roles in patients

[Ten-year]

Ten-year

[patients in Heart Failure]

patients in Heart Failure

[5 age groups]

5 age groups

[simultaneous reduction in increase]

simultaneous reduction in increase

[Fifty consecutive patients with onset HFrEF]

Fifty consecutive patients with onset HFrEF

[length of stay 37]

length of stay 37

[fluctuations in QT intervals]

fluctuations in QT intervals

[mediator]

mediator

[fat ratio]

fat ratio

[event rates for myocardial infarction]

event rates for myocardial infarction

[ventricular strain as a major predictor]

ventricular strain as a major predictor

[exercise programme]

exercise programme

[Outcomes of Exercise Training HF-ACTION]

Outcomes of Exercise Training HF-ACTION

[characterization of one]

characterization of one

[extracellular flux analyzer]

extracellular flux analyzer

[sized LV]

sized LV

[1.02±0.18 mm for reference subjects]

1.02±0.18 mm for reference subjects

[significant effect on urine volume]

significant effect on urine volume

[cardiovascular event rate 2.08 events]

cardiovascular event rate 2.08 events

[acute settings]

acute settings

[Cox model analysis]

Cox model analysis

[dying in 30 days]

dying in 30 days

[stable severe heart failure]

stable severe heart failure

[novel percutaneous one model]

novel percutaneous one model

[Particular topics]

Particular topics

[β-Adrenergic]

β-Adrenergic

[Medicare coverage]

Medicare coverage

[effect on PB characteristics]

effect on PB characteristics

[endpoint of inappropriate therapy]

endpoint of inappropriate therapy

[breathing PB]

breathing PB

[CI for sitagliptin versus pioglitazone CI]

CI for sitagliptin versus pioglitazone CI

[adequate self-management training]

adequate self-management training

[changing association]

changing association

[benefit with adverse consequences]

benefit with adverse consequences

[main cause]

main cause

[benefits in patients]

benefits in patients

[scale dimensions]

scale dimensions

[primary culprit extending EMD]

primary culprit extending EMD

[treatment preferences]

treatment preferences

[Screening patients]

Screening patients

[physical activity controls]

physical activity controls

[jugular venous pressure]

jugular venous pressure

[better outcomes for patients]

better outcomes for patients

[non-diabetic patients with heart failure]

non-diabetic patients with heart failure

[acute embolism]

acute embolism

[favorable effects on function]

favorable effects on function

[stemming from ischemic cardiomyopathies]

stemming from ischemic cardiomyopathies

[mortality hazard ratio all hazard ratios]

mortality hazard ratio all hazard ratios

[Randomized trial of walking with moderate]

Randomized trial of walking with moderate

[10 transplant ineligible patients]

10 transplant ineligible patients

[changes in chromatin subproteomes]

changes in chromatin subproteomes

[capacity peak VO2]

capacity peak VO2

[arterial elastance Ea elastance Ees]

arterial elastance Ea elastance Ees

[higher risk of death]

higher risk of death

[cardiomyopathy DCM]

cardiomyopathy DCM

[ICD-HF patients]

ICD-HF patients

[E-wave early mitral annular velocity]

E-wave early mitral annular velocity

[thus giving rise in HF]

thus giving rise in HF

[administration of doxorubicin in rats]

administration of doxorubicin in rats

[patients with RAS]

patients with RAS

[LV end-diastolic volume LV]

LV end-diastolic volume LV

[explant-derived c-Kit]

explant-derived c-Kit

[worsening function in EMPHASIS-HF]

worsening function in EMPHASIS-HF

[ventricular-pulmonary coupling pulmonary resistance]

ventricular-pulmonary coupling pulmonary resistance

[hazard models]

hazard models

[levels in breast cancer patients]

levels in breast cancer patients

[least a moderate level]

least a moderate level

[Comparison of predictors]

Comparison of predictors

[outcome median vs milliseconds]

outcome median vs milliseconds

[patients with without diabetes]

patients with without diabetes

[new-onset ESRD]

new-onset ESRD

[study participants]

study participants

[amyloidosis about an atypical case]

amyloidosis about an atypical case

[important determinants of survival]

important determinants of survival

[hypothermic arrest]

hypothermic arrest

[hazard ratio in analyses]

hazard ratio in analyses

[Nordic walking in patients]

Nordic walking in patients

[two increase]

two increase

[telephone support STS programmes]

telephone support STS programmes

[2,462 events]

2,462 events

[GDMT treatment group for 6 months]

GDMT treatment group for 6 months

[evidence of left ventricular dyssynchrony]

evidence of left ventricular dyssynchrony

[ranging from 1]

ranging from 1

[period of fibrillation]

period of fibrillation

[neonatal rat]

neonatal rat

[Swedish Web-system]

Swedish Web-system

[research studies]

research studies

[medications for patients]

medications for patients

[insufficiency AI]

insufficiency AI

[number of risk factors]

number of risk factors

[ejection fraction on long-term mortality]

ejection fraction on long-term mortality

[management of heart failure in children]

management of heart failure in children

[ml odds ratio]

ml odds ratio

[N-terminal proBNP]

N-terminal proBNP

[Patient Management Interventions]

Patient Management Interventions

[contracting ventricles]

contracting ventricles

[QT variability]

QT variability

[hypotheses addition]

hypotheses addition

[interaction on outcomes]

interaction on outcomes

[Centers for Medicare readmission CMS]

Centers for Medicare readmission CMS

[cAMP-dependent protein kinase PKA signaling downstream]

cAMP-dependent protein kinase PKA signaling downstream

[50 mg dose]

50 mg dose

[reference values]

reference values

[threshold in heart failure]

threshold in heart failure

[basal resistin levels]

basal resistin levels

[chronic hypertension PAH]

chronic hypertension PAH

[Early treatment of fibrillation]

Early treatment of fibrillation

[left 3-vessel CAD]

left 3-vessel CAD

[Cox hazards analyses]

Cox hazards analyses, Cox hazard analyses

[addition of dopamine μg]

addition of dopamine μg

[BNP EF]

BNP EF

[continuous flow]

continuous flow

[initiative]

initiative

[Comparative effects of assist device]

Comparative effects of assist device

[factor-κB]

factor-κB

[centrifugal-flow LVAS]

centrifugal-flow LVAS

[hemodynamic features]

hemodynamic features

[ED visits mean age years]

ED visits mean age years

[power of various measures]

power of various measures

[reducing the risk]

reducing the risk

[variation in mortality]

variation in mortality

[ventricular tricuspid annular plane excursion TAPSE]

ventricular tricuspid annular plane excursion TAPSE

[significant collateral growth]

significant collateral growth

[effects of B]

effects of B

[significant change effect]

significant change effect

[describing a uniform nomenclature for failure]

describing a uniform nomenclature for failure

[ventricular dilatation during the years]

ventricular dilatation during the years

[seven abdominal problems]

seven abdominal problems

[6-wk periods]

6-wk periods

[including 3 samples]

including 3 samples

[available models]

available models

[interviews with care clinicians caring]

interviews with care clinicians caring

[entry milliseconds]

entry milliseconds

[interaction between these 2 receptors]

interaction between these 2 receptors

[human LV myocytes]

human LV myocytes

[good evidence for the treatment]

good evidence for the treatment

[pump-exchange technique]

pump-exchange technique

[elastance Ea elastance]

elastance Ea elastance

[Trastuzumab-related cardiotoxicity among patients]

Trastuzumab-related cardiotoxicity among patients

[outcomes in patients with heart failure]

outcomes in patients with heart failure

[proteomics analysis]

proteomics analysis

[inpatient conditions]

inpatient conditions

[patients with an cardiac defibrillator]

patients with an cardiac defibrillator

[selective beta-blockers on activity]

selective beta-blockers on activity

[variation in use of medications Insights]

variation in use of medications Insights

[Effects]

Effects

[mitral leaflet motions]

mitral leaflet motions

[transmitral E-wave early mitral velocity]

transmitral E-wave early mitral velocity

[per cent with five deaths]

per cent with five deaths

[advantage of the period]

advantage of the period

[hospital performance]

hospital performance

[trends in the risk]

trends in the risk

[median follow-up of days]

median follow-up of days

[PD initiation]

PD initiation

[Perturbations in muscle sarcomere structure]

Perturbations in muscle sarcomere structure

[age of the patients]

age of the patients

[dysfunction by 3 weeks]

dysfunction by 3 weeks

[Symptom domains]

Symptom domains

[intermediate odds ratios for cardiovascular events]

intermediate odds ratios for cardiovascular events

[adjustment hazard ratio]

adjustment hazard ratio

[robust predictor of HF]

robust predictor of HF

[response role of S1PR1 gene therapy]

response role of S1PR1 gene therapy

[targeting abnormal exercise status]

targeting abnormal exercise status

[preoperative serum albumin levels]

preoperative serum albumin levels

[outcome vs milliseconds 237 milliseconds]

outcome vs milliseconds 237 milliseconds

[presence of several N forms]

presence of several N forms

[mortality in women with HF]

mortality in women with HF

[incidence outcomes after acute infarction]

incidence outcomes after acute infarction

[mg daily dose]

mg daily dose

[reversal of detrimental alterations]

reversal of detrimental alterations

[study-related adverse events]

study-related adverse events

[patients aged 40 years]

patients aged 40 years

[extending EMD in the heart]

extending EMD in the heart

[LVAD implantation hazard ratio]

LVAD implantation hazard ratio

[small-molecule inhibitors c-Kit]

small-molecule inhibitors c-Kit

[treatment of severe-end-stage HF]

treatment of severe-end-stage HF

[placebo for 7 days]

placebo for 7 days

[home telemonitoring TM with medical support]

home telemonitoring TM with medical support

[limits of agreement mean difference]

limits of agreement mean difference

[24-hour pressure 155]

24-hour pressure 155

[heart failure irrespective]

heart failure irrespective

[mortality with HF]

mortality with HF

[indicating suboptimal care]

indicating suboptimal care

[non-urbanized Midwestern state]

non-urbanized Midwestern state

[training protocol]

training protocol

[versus without ventricular ejection fraction]

versus without ventricular ejection fraction

[largest series]

largest series

[heart filling]

heart filling

[P trend=0.08]

P trend=0.08

[academic center]

academic center

[revascularization with angioplasty]

revascularization with angioplasty

[endothelial function in chronic heart failure]

endothelial function in chronic heart failure

[novel one model]

novel one model

[method of aortic constriction]

method of aortic constriction

[402 patients with HFpEF geometry]

402 patients with HFpEF geometry

[STE analysis of regional strain]

STE analysis of regional strain

[degree]

degree

[management of HF in infancy]

management of HF in infancy

[ventricular assist device with support]

ventricular assist device with support

[last dose of doxorubicin]

last dose of doxorubicin

[chronic thromboembolic pulmonary hypertension]

chronic thromboembolic pulmonary hypertension

[749 black patients]

749 black patients

[right ventricular end-diastolic area index cm(2)]

right ventricular end-diastolic area index cm(2)

[significant decrease in re-hospitalization]

significant decrease in re-hospitalization

[enhancing management]

enhancing management

[cardiac energy metabolism]

cardiac energy metabolism

[predictors of CAD]

predictors of CAD

[left end diameter mm difference]

left end diameter mm difference

[comprising hospitalization among study patients]

comprising hospitalization among study patients

[infarction AMI]

infarction AMI

[Moderate-strength evidence from 3 trials]

Moderate-strength evidence from 3 trials

[weeks post-AAC]

weeks post-AAC

[SR Ca 2+)-uptake]

SR Ca 2+)-uptake

[outcomes in a cohort]

outcomes in a cohort

[cardioversions]

cardioversions

[average 3.2]

average 3.2

[electromechanical delay the time interval]

electromechanical delay the time interval

[effects on processes]

effects on processes

[valve surgery]

valve surgery

[systolic ventricular function]

systolic ventricular function

[allocation]

allocation

[Multicenter clinical trial]

Multicenter clinical trial

[nursing-sensitive outcome measures in prospective research]

nursing-sensitive outcome measures in prospective research

[Acute heart failure in pulmonary hypertension]

Acute heart failure in pulmonary hypertension

[roles of BNP in patients]

roles of BNP in patients

[versus best quintile]

versus best quintile

[complications in severe HF]

complications in severe HF

[chronotropic response the difference]

chronotropic response the difference

[area under the receiver curve AUC]

area under the receiver curve AUC

[5.0 g]

5.0 g

[heart failure in humans]

heart failure in humans

[promoting filling during exercise]

promoting filling during exercise

[guanosine monophosphate]

guanosine monophosphate

[Participation of apoptosis during the development]

Participation of apoptosis during the development

[14 studies HM]

14 studies HM

[including MEDLINE]

including MEDLINE

[reliable mortality predictors]

reliable mortality predictors

[AF type other than long-standing AF]

AF type other than long-standing AF

[function in the onset following infarction]

function in the onset following infarction

[Major ventricle overload]

Major ventricle overload

[global left ventricular systolic strain GLS]

global left ventricular systolic strain GLS

[events during the 3 months]

events during the 3 months

[lower status versus whites]

lower status versus whites

[measurement of transmitral flow velocities]

measurement of transmitral flow velocities

[describing a nomenclature for right failure]

describing a nomenclature for right failure

[home telemonitoring with medical support]

home telemonitoring with medical support

[main effect]

main effect

[Morpholino-based knockdown]

Morpholino-based knockdown

[effects via stimulation]

effects via stimulation

[diastolic dysfunction LV relaxation]

diastolic dysfunction LV relaxation

[10-year increase]

10-year increase

[clinical systolic parameters in AF]

clinical systolic parameters in AF

[Thoratec]

Thoratec

[end diameter mm]

end diameter mm

[significant gaps]

significant gaps

[lung weight P]

lung weight P

[mostly in functional class NYHA II-III]

mostly in functional class NYHA II-III

[Body composition body fat distribution]

Body composition body fat distribution

[elements of successful interventions]

elements of successful interventions

[Mena levels]

Mena levels

[Treatment of anemia a systematic review]

Treatment of anemia a systematic review

[Key role 2 molecular scaffolds]

Key role 2 molecular scaffolds

[treatments targeting exercise hemodynamic status]

treatments targeting exercise hemodynamic status

[negative value of E]

negative value of E

[function in the onset]

function in the onset

[higher blood pressure]

higher blood pressure

[pressure of CO2 PETCO2]

pressure of CO2 PETCO2

[mg HR]

mg HR

[Assessment GRADE]

Assessment GRADE

[bleeding in patients with assist devices]

bleeding in patients with assist devices

[sympathetic activity in patients]

sympathetic activity in patients

[underperfusion]

underperfusion

[imaging techniques]

imaging techniques

[Practice rates]

Practice rates

[patients below the PASP increase]

patients below the PASP increase

[follow-up period in patients]

follow-up period in patients

[glomerular]

glomerular

[prognostic benefit over parameters]

prognostic benefit over parameters

[right annular plane systolic excursion]

right annular plane systolic excursion

[management of ventricular dysfunction]

management of ventricular dysfunction

[pharmacologic studies including agents]

pharmacologic studies including agents

[Multicenter trial of patients]

Multicenter trial of patients

[approximately 3,000 patients with onset AF]

approximately 3,000 patients with onset AF

[candidates for cell therapy]

candidates for cell therapy

[left systolic function]

left systolic function

[heart rate HR reduction with ivabradine]

heart rate HR reduction with ivabradine

[having co-morbidities]

having co-morbidities

[persons]

persons

[main effect exercise]

main effect exercise

[blots with antibodies]

blots with antibodies

[function in the onset of HF]

function in the onset of HF

[efficacy of therapeutic left-to-right interatrial shunting]

efficacy of therapeutic left-to-right interatrial shunting

[Preoperative characteristics]

Preoperative characteristics

[nondiabetic patients]

nondiabetic patients

[undergoing isolated heart transplant]

undergoing isolated heart transplant

[significantly lower walking distance]

significantly lower walking distance

[heart failure 925 ED visits]

heart failure 925 ED visits

[Presentation Canadian Society guidelines]

Presentation Canadian Society guidelines

[Values of error]

Values of error

[indices ratio]

indices ratio

[LV relaxation]

LV relaxation

[days in this double-blind trial]

days in this double-blind trial

[early management]

early management

[paradigm shift]

paradigm shift

[surviving an infarction AMI]

surviving an infarction AMI

[3 studies including agents of endothelin]

3 studies including agents of endothelin

[remaining in deciles]

remaining in deciles

[serum potassium mmol]

serum potassium mmol

[cardiomyopathy including negative coronary angiography]

cardiomyopathy including negative coronary angiography

[cutoff of 8]

cutoff of 8

[mitral flow]

mitral flow

[mRNA levels of inflammatory genes]

mRNA levels of inflammatory genes

[acute pressure overload]

acute pressure overload

[Treatment Guidelines]

Treatment Guidelines

[disease modifying drug nbDMARD]

disease modifying drug nbDMARD

[clinical systolic parameters]

clinical systolic parameters

[large limits of agreement difference]

large limits of agreement difference

[high-density lipoprotein functional properties]

high-density lipoprotein functional properties

[surgeons]

surgeons

[10 heart failure HF]

10 heart failure HF

[ventricular end diameter difference]

ventricular end diameter difference

[predicting survival at the time]

predicting survival at the time

[assessment of body composition skinfold thickness]

assessment of body composition skinfold thickness

[adverse CV events in models]

adverse CV events in models

[framework determining individualized assessment]

framework determining individualized assessment

[gross national income per capita]

gross national income per capita

[major event-free rate]

major event-free rate

[signaling paradigms]

signaling paradigms

[paediatric heart failure concern]

paediatric heart failure concern

[secretion of arginine vasopressin AVP]

secretion of arginine vasopressin AVP

[mechanisms behind the development]

mechanisms behind the development

[tissue Doppler imaging]

tissue Doppler imaging

[aggressive treatment for heart failure]

aggressive treatment for heart failure

[common elements]

common elements

[decrease in score]

decrease in score

[pre-HCT chest radiation]

pre-HCT chest radiation

[end-stage heart failure CHF]

end-stage heart failure CHF

[45 centers]

45 centers

[US healthcare programmes]

US healthcare programmes

[Grade recommendation moderate-quality evidence]

Grade recommendation moderate-quality evidence

[contribution of nursing care]

contribution of nursing care

[impact on resources]

impact on resources

[HR dynamics]

HR dynamics

[involvement in a study]

involvement in a study

[type V]

type V

[TAPSE as individual measures]

TAPSE as individual measures

[ejection fraction LVEF]

ejection fraction LVEF

[relations between CPCs]

relations between CPCs

[QRS ms]

QRS ms

[812 patients]

812 patients

[improvement at advanced stages]

improvement at advanced stages

[LV end-diastolic dimension]

LV end-diastolic dimension

[body weight in CC]

body weight in CC

[ventricular function assessment]

ventricular function assessment

[Randomized trial of Nordic walking]

Randomized trial of Nordic walking

[National trends for common conditions]

National trends for common conditions

[policy]

policy

[health-related quality HRQoL]

health-related quality HRQoL

[indeterminable anaerobic threshold]

indeterminable anaerobic threshold

[advanced obstructive pulmonary disease]

advanced obstructive pulmonary disease

[nonglycosylated epitopes]

nonglycosylated epitopes

[E-wave diastolic mitral velocity ratio]

E-wave diastolic mitral velocity ratio

[history of hypertension]

history of hypertension

[worldwide increase]

worldwide increase

[assist device with support]

assist device with support

[Function Among Patients]

Function Among Patients

[candidate genes]

candidate genes

[strain as a major predictor]

strain as a major predictor

[treatment of acute heart failure]

treatment of acute heart failure

[chronic stable guideline-directed therapy GDMT]

chronic stable guideline-directed therapy GDMT

[annular plane systolic excursion TAPSE]

annular plane systolic excursion TAPSE

[patients with chronic obstructive disease]

patients with chronic obstructive disease

[significant stenosis]

significant stenosis

[left strain as a major predictor]

left strain as a major predictor

[patients with advanced pulmonary disease]

patients with advanced pulmonary disease

[several trials]

several trials

[single most important component]

single most important component

[percent of 7-day visits]

percent of 7-day visits

[percutaneous one model for ischemia]

percutaneous one model for ischemia

[system major adverse events]

system major adverse events

[multicenter trial PARADIGM-HF with 8000 individuals]

multicenter trial PARADIGM-HF with 8000 individuals

[effects of antioxidant]

effects of antioxidant

[196 AF patients]

196 AF patients

[well-being]

well-being

[number of inpatient admissions]

number of inpatient admissions

[global ventricular strain]

global ventricular strain

[systolic heart failure of etiology]

systolic heart failure of etiology

[start with B.]

start with B.

[negative cross talk]

negative cross talk

[mitochondrial proteome changes]

mitochondrial proteome changes

[monitoring after hospital discharge in patients]

monitoring after hospital discharge in patients

[events during the months]

events during the months

[activity (123)I-meta-iodobenzylguanidine]

activity (123)I-meta-iodobenzylguanidine

[non-biological disease modifying antirheumatic drug]

non-biological disease modifying antirheumatic drug

[distinct populations of patients]

distinct populations of patients

[awareness of cardioverter-defibrillator deactivation discussions]

awareness of cardioverter-defibrillator deactivation discussions

[acute care hospital]

acute care hospital

[patient needs]

patient needs

[renal failure]

renal failure

[low testosterone status a feasibility study]

low testosterone status a feasibility study

[changes in subjects]

changes in subjects

[Na current]

Na current

[prospective validation cohort]

prospective validation cohort

[Large-scale prospective multicenter trial with individuals]

Large-scale prospective multicenter trial with individuals

[Treating Advanced HF]

Treating Advanced HF

[effects via activation]

effects via activation

[society]

society

[glucose transporter]

glucose transporter

[plasma B-type natriuretic peptide levels]

plasma B-type natriuretic peptide levels

[Cardiac cachexia]

Cardiac cachexia

[occurring within 30 days]

occurring within 30 days

[ongoing GDMT treatment group]

ongoing GDMT treatment group

[aortic valve repairs]

aortic valve repairs

[results in HF trials]

results in HF trials

[predicting high performers]

predicting high performers

[1.6 vs. 0.8 reasons P]

1.6 vs. 0.8 reasons P

[common forms of left remodeling]

common forms of left remodeling

[echocardiographic assessment of function]

echocardiographic assessment of function

[large group]

large group

[Midwestern state]

Midwestern state

[individual associations among fitness CRF]

individual associations among fitness CRF

[gastrointestinal regions]

gastrointestinal regions

[tricuspid plane excursion]

tricuspid plane excursion

[cost-effectiveness ratios]

cost-effectiveness ratios

[action potential duration]

action potential duration

[Comments in acute heart failure]

Comments in acute heart failure

[electromechanical delay EMD]

electromechanical delay EMD

[high survival rates]

high survival rates

[safety end point]

safety end point

[Treatment of anemia in patients]

Treatment of anemia in patients

[predominantly asymptomatic pediatric Fontan PF patients]

predominantly asymptomatic pediatric Fontan PF patients

[Twenty-seven adult Fontan patients]

Twenty-seven adult Fontan patients

[aortic insufficiency AI]

aortic insufficiency AI

[pathological changes including hypertrophy]

pathological changes including hypertrophy

[Benefits with ejection fraction]

Benefits with ejection fraction

[ST2 in patients with heart failure]

ST2 in patients with heart failure

[involvement of receptor kinase-2]

involvement of receptor kinase-2

[C-index]

C-index

[Impact of resonance imaging]

Impact of resonance imaging

[6-minute walk distance]

6-minute walk distance

[giving rise]

giving rise

[several Medical Outcomes]

several Medical Outcomes

[ventricular fractional area change]

ventricular fractional area change

[first diagnosis]

first diagnosis

[range 22.8]

range 22.8

[chloride channel]

chloride channel

[serum albumin levels in patients]

serum albumin levels in patients

[Inpatient]

Inpatient

[potential usefulness of CRT]

potential usefulness of CRT

[dynamic resistance training]

dynamic resistance training

[gene expression profile]

gene expression profile

[right ventricular dysfunction]

right ventricular dysfunction

[median BNP EF]

median BNP EF

[usual care group]

usual care group

[end-point of mortality]

end-point of mortality

[grain intake]

grain intake

[clinical prognostic dysfunction]

clinical prognostic dysfunction

[possibly diminishing the ROS effects]

possibly diminishing the ROS effects

[survival 3.5 g]

survival 3.5 g

[lower median activities of lyso-PAF-AT]

lower median activities of lyso-PAF-AT

[receptor β-AR signaling in cardiomyocytes]

receptor β-AR signaling in cardiomyocytes

[contact HH]

contact HH

[Psychosocial Factors Insights]

Psychosocial Factors Insights

[interquartile range with COPD n=95]

interquartile range with COPD n=95

[Canadian Society guidelines]

Canadian Society guidelines

[good value]

good value

[useful technique detecting fibrosis]

useful technique detecting fibrosis

[overwhelming contribution of CAD]

overwhelming contribution of CAD

[amyloidosis about an case]

amyloidosis about an case

[hospitals from January]

hospitals from January

[chronic stable guideline-directed medical therapy]

chronic stable guideline-directed medical therapy

[English-language trials]

English-language trials

[flux analyzer]

flux analyzer

[Effects a analysis]

Effects a analysis

[AF type other]

AF type other

[filling formalism]

filling formalism

[prospective crossover study]

prospective crossover study

[mitral annular velocity 3.1 vs. 1.3]

mitral annular velocity 3.1 vs. 1.3

[changes on exercise]

changes on exercise

[60,000 patients]

60,000 patients

[IL6 hsCRP]

IL6 hsCRP

[control without exercise]

control without exercise

[vena cava]

vena cava

[right arterial coupling pulmonary resistance]

right arterial coupling pulmonary resistance

[studies with 1887]

studies with 1887

[practice-level variation in rates]

practice-level variation in rates

[class II]

class II

[impact on chelation choices]

impact on chelation choices

[incidence complicating AMI]

incidence complicating AMI

[medical staff responsible]

medical staff responsible

[favorable changes in ventricular function]

favorable changes in ventricular function

[remodeling after AMI]

remodeling after AMI

[30 days P-value for difference]

30 days P-value for difference

[systolic pressure relationship in heart failure]

systolic pressure relationship in heart failure

[BTES with exercise time]

BTES with exercise time

[non-biological disease modifying drug nbDMARD]

non-biological disease modifying drug nbDMARD

[median of mm Hg]

median of mm Hg

[Overall management]

Overall management

[major cause]

major cause

[impact on gross morphological development]

impact on gross morphological development

[significant change]

significant change

[smallest difference BNP EF]

smallest difference BNP EF

[current strategies]

current strategies

[protein kinase PKA signaling downstream]

protein kinase PKA signaling downstream

[patients with onset HFrEF]

patients with onset HFrEF

[university]

university

[group 30 mL per m 2]

group 30 mL per m 2

[Regular activity controls]

Regular activity controls

[glucocorticoids]

glucocorticoids

[Body composition with regard]

Body composition with regard

[composite response with CRT]

composite response with CRT

[hallmark of heart failure CHF]

hallmark of heart failure CHF

[Isoelectric focusing]

Isoelectric focusing

[differential relations in patients]

differential relations in patients

[CLCNKA polymorphism rs10927887]

CLCNKA polymorphism rs10927887

[experience with an interatrial shunt]

experience with an interatrial shunt

[impact on HDL-mediated effects]

impact on HDL-mediated effects

[Surgical correction of valve insufficiency]

Surgical correction of valve insufficiency

[technique detecting myocardial fibrosis]

technique detecting myocardial fibrosis

[patients surviving an infarction AMI]

patients surviving an infarction AMI

[absolute increase for infarction]

absolute increase for infarction

[Testosterone therapy]

Testosterone therapy

[monitoring a review]

monitoring a review

[first 3 postoperative months]

first 3 postoperative months

[substantial proportion]

substantial proportion

[gaps in impact on quality]

gaps in impact on quality

[rotor with blood-flow paths]

rotor with blood-flow paths

[patient safety initiatives]

patient safety initiatives

[events in patients with fibrillation]

events in patients with fibrillation

[NYHA class ranking]

NYHA class ranking

[chronic stable medical therapy]

chronic stable medical therapy

[clinical Doppler echocardiography]

clinical Doppler echocardiography

[important trigger of infarction]

important trigger of infarction

[improvements in functioning of evidence-based treatments]

improvements in functioning of evidence-based treatments

[several N forms]

several N forms

[tool for risk stratification]

tool for risk stratification

[lipoprotein functional properties]

lipoprotein functional properties

[degree early after surgery]

degree early after surgery

[phase of the disease]

phase of the disease

[residents of Olmsted County]

residents of Olmsted County

[CAD involving the proximal artery]

CAD involving the proximal artery

[arterial coupling resistance]

arterial coupling resistance

[optimizing progenitor function for application]

optimizing progenitor function for application

[Left Ventricular Assist System]

Left Ventricular Assist System

[systole s]

systole s

[medical management of HF in infancy]

medical management of HF in infancy

[receptor family]

receptor family

[assessment with the inclusion]

assessment with the inclusion

[thromboembolic hypertension]

thromboembolic hypertension

[range 22.8 with advanced COPD]

range 22.8 with advanced COPD

[biosynthetic enzymes]

biosynthetic enzymes

[impact on the incidence of]

impact on the incidence of

[antibodies targeting nonglycosylated epitopes]

antibodies targeting nonglycosylated epitopes

[TUNEL-positive cells]

TUNEL-positive cells

[cardiomyopathy IC]

cardiomyopathy IC

[basis of review]

basis of review

[long-term wk effects]

long-term wk effects

[procedures 146 vs. 238]

procedures 146 vs. 238

[endpoint death for heart failure]

endpoint death for heart failure

[principles]

principles

[AlphaLISA®]

AlphaLISA®

[nonstandardized pro-B-type natriuretic peptide NT-proBNP]

nonstandardized pro-B-type natriuretic peptide NT-proBNP

[Occurrence within days of the index]

Occurrence within days of the index

[York Heart Association NYHA Class]

York Heart Association NYHA Class

[management for HF]

management for HF

[transcriptional analysis of tissue]

transcriptional analysis of tissue

[inhibition of endothelial growth factor]

inhibition of endothelial growth factor

[peak capacity]

peak capacity

[tension]

tension

[LVAD insertion]

LVAD insertion

[phosphodiesterase-2]

phosphodiesterase-2

[plasma N-terminal pro-B-type peptide NT-proBNP]

plasma N-terminal pro-B-type peptide NT-proBNP

[pure HNO donor]

pure HNO donor

[undergoing chemotherapy]

undergoing chemotherapy

[surviving an infarction]

surviving an infarction

[novel therapeutic strategy]

novel therapeutic strategy

[malignancies including cancer]

malignancies including cancer

[10 heart failure]

10 heart failure

[–17.4 points vs. points]

–17.4 points vs. points

[One-year event-free rates]

One-year event-free rates

[major determinant]

major determinant

[change the percent remaining]

change the percent remaining

[longitudinal strain as a major predictor]

longitudinal strain as a major predictor

[difference histologically in the percentage]

difference histologically in the percentage

[lower median activities]

lower median activities

[aortocaval]

aortocaval

[156 consenting HF patients]

156 consenting HF patients

[strain of left ventricle]

strain of left ventricle

[prognosis of patients]

prognosis of patients

[rates by KCCQ category]

rates by KCCQ category

[progressive loss]

progressive loss

[two populations of patients]

two populations of patients

[other medical staff]

other medical staff

[effects of walking]

effects of walking

[chest model surrogates]

chest model surrogates

[plasma membrane]

plasma membrane

[therapy including anticoagulation]

therapy including anticoagulation

[exercise variables exercise oscillatory ventilation]

exercise variables exercise oscillatory ventilation

[pairs]

pairs

[noninvasive tools]

noninvasive tools

[intervention HR]

intervention HR

[odds ratio 1.76]

odds ratio 1.76

[percutaneous revascularization]

percutaneous revascularization

[risk developing certain malignancies]

risk developing certain malignancies

[circulatory derangement]

circulatory derangement

[users between 1996]

users between 1996

[Subjects receiving methotrexate]

Subjects receiving methotrexate

[anaerobic threshold in heart failure]

anaerobic threshold in heart failure

[use of agents]

use of agents

[important covariates]

important covariates

[PDE2-mediated effects on beta-adrenergic receptor signaling]

PDE2-mediated effects on beta-adrenergic receptor signaling

[ventricular end-diastolic area index cm(2)]

ventricular end-diastolic area index cm(2)

[consistent approach]

consistent approach

[receiving ventricular assist device support]

receiving ventricular assist device support

[pro-B-type peptide NT-proBNP]

pro-B-type peptide NT-proBNP

[suppression]

suppression

[Kv4.3 channel mRNAs]

Kv4.3 channel mRNAs

[3 studies including agents]

3 studies including agents

[Study Selection trials in adults]

Study Selection trials in adults

[1.39 times]

1.39 times

[patients with reduction in LVEF]

patients with reduction in LVEF, patients with reductions in LVEF

[right pacing]

right pacing

[crude 28-day case-fatality rate]

crude 28-day case-fatality rate

[Retn gene]

Retn gene

[several changes including cardiac hypertrophy]

several changes including cardiac hypertrophy

[Seattle Heart Failure]

Seattle Heart Failure

[ejection time complicating precapillary pulmonary hypertension]

ejection time complicating precapillary pulmonary hypertension

[non-diabetic patients]

non-diabetic patients

[experimental models]

experimental models

[improvements for patients]

improvements for patients

[risk as patients with reduction]

risk as patients with reduction

[local myocyte depolarization]

local myocyte depolarization

[Improving survival rates over decades]

Improving survival rates over decades

[absolute change MDC]

absolute change MDC

[Impact on the response]

Impact on the response

[thigh muscle]

thigh muscle

[obese ZSF1 with diet n=11]

obese ZSF1 with diet n=11

[anemia treatment]

anemia treatment

[medical therapy GDMT]

medical therapy GDMT

[selectively potentiating the response]

selectively potentiating the response

[diagnostic roles]

diagnostic roles

[routine NP assessment]

routine NP assessment

[advisors]

advisors

[Global strain as a predictor]

Global strain as a predictor

[right assist devices]

right assist devices

[right ventricular tricuspid plane excursion TAPSE]

right ventricular tricuspid plane excursion TAPSE

[Nicorandil mg]

Nicorandil mg

[few cells]

few cells

[Hence of importance]

Hence of importance

[T1 in swine]

T1 in swine

[human Retn gene]

human Retn gene

[outpatient assessments]

outpatient assessments

[canine model]

canine model

[ejection fraction EF]

ejection fraction EF

[focusing of RIα]

focusing of RIα

[relationship between broader QRS]

relationship between broader QRS

[expressing human resistin]

expressing human resistin

[inappropriate ATP HR]

inappropriate ATP HR

[mortality rates across the age categories]

mortality rates across the age categories

[1:1 allocation ratio]

1:1 allocation ratio

[Q waves]

Q waves

[only after 4 weeks]

only after 4 weeks

[systolic left ejection fraction HF]

systolic left ejection fraction HF

[adenylyl]

adenylyl

[prescribing]

prescribing

[care surgery ACS]

care surgery ACS

[common underlying characteristics]

common underlying characteristics

[stand-alone devices]

stand-alone devices

[Renin-angiotensin-aldosterone]

Renin-angiotensin-aldosterone

[Background—Heart]

Background—Heart

[Determination of risk]

Determination of risk

[right coupling]

right coupling

[burden of heart failure hospitalizations]

burden of heart failure hospitalizations

[ATP demand]

ATP demand

[Ivabradine]

Ivabradine

[pro-B-type peptide a biomarker approach]

pro-B-type peptide a biomarker approach

[vascular resistance hazard ratio]

vascular resistance hazard ratio

[right ventricle overload]

right ventricle overload

[Possible reasons]

Possible reasons

[ESRD from the Registry]

ESRD from the Registry

[global attenuation of proteomic alterations]

global attenuation of proteomic alterations

[Heart Failure Questionnaire score range]

Heart Failure Questionnaire score range

[8 months]

8 months

[Risk Among Users of Saxagliptin]

Risk Among Users of Saxagliptin

[flow velocities]

flow velocities

[Mixed-methods study of veterans]

Mixed-methods study of veterans

[interviews with 62 care clinicians]

interviews with 62 care clinicians

[showing minor improvement]

showing minor improvement

[evidence on effects]

evidence on effects

[patients HFrEF with ejection fraction]

patients HFrEF with ejection fraction

[score predicting CRT response]

score predicting CRT response

[tachycardia HFVT(+)]

tachycardia HFVT(+)

[factor analysis CFA]

factor analysis CFA

[therapeutic treatments]

therapeutic treatments

[50 mg equivalent dose]

50 mg equivalent dose

[E-wave diastolic mitral annular velocity ratio]

E-wave diastolic mitral annular velocity ratio

[normal systolic ventricular function]

normal systolic ventricular function

[management involving ventricular assist devices]

management involving ventricular assist devices

[lower stimulation]

lower stimulation

[value of E]

value of E

[public health]

public health

[interventions pacing]

interventions pacing

[ejection fraction HF]

ejection fraction HF

[interquartile range with advanced COPD n=95]

interquartile range with advanced COPD n=95

[diet in renal disease]

diet in renal disease

[symptomatic chronic heart failure patients]

symptomatic chronic heart failure patients

[independent predictor of favorable outcome]

independent predictor of favorable outcome

[robust predictor]

robust predictor

[lower gross national income]

lower gross national income

[Values of error of measurement]

Values of error of measurement

[myocyte-specific Mena overexpression TTA comparable]

myocyte-specific Mena overexpression TTA comparable

[advanced disease COPD]

advanced disease COPD

[Immunodetection]

Immunodetection

[vascular endothelial growth factor]

vascular endothelial growth factor

[circumflex]

circumflex

[powerful predictor of outcome period]

powerful predictor of outcome period

[small trial]

small trial

[improvement in response]

improvement in response

[valve area MVA]

valve area MVA

[53.2 years]

53.2 years

[absorption function in patients]

absorption function in patients

[per cent with five deaths occurring]

per cent with five deaths occurring

[region with HF risk factors]

region with HF risk factors

[lipoprotein-associated phospholipase A2]

lipoprotein-associated phospholipase A2

[last decade]

last decade

[good performance detecting filling pressures]

good performance detecting filling pressures

[helix-loop-helix bHLH transcription factor]

helix-loop-helix bHLH transcription factor

[institutional experience]

institutional experience

[Public reporting]

Public reporting

[germline]

germline

[peak work]

peak work

[ventricular hypertrophy in heart failure]

ventricular hypertrophy in heart failure

[efflux]

efflux

[measurable overall improvements]

measurable overall improvements

[MicroRNAs targets]

MicroRNAs targets

[sodium current]

sodium current

[activation of β1ARs]

activation of β1ARs

[ventricular remodeling in heart failure]

ventricular remodeling in heart failure

[moderate level]

moderate level

[deleterious effects on physiologic processes]

deleterious effects on physiologic processes

[cachectic heart failure]

cachectic heart failure

[baseline sST2 status]

baseline sST2 status

[adoption]

adoption

[odds ratios for cardiovascular events]

odds ratios for cardiovascular events

[Heart Failure Assessment]

Heart Failure Assessment

[exercise-induced artery systolic pressure increase]

exercise-induced artery systolic pressure increase

[108 HFpEF]

108 HFpEF

[effect with a physician]

effect with a physician

[268 inpatient records]

268 inpatient records

[modification of diet]

modification of diet

[STS HH with support]

STS HH with support

[microembolization-induced HF]

microembolization-induced HF

[effector]

effector

[kg with improvement in response]

kg with improvement in response

[intracellular strategy]

intracellular strategy

[change effect exercise]

change effect exercise

[left diastolic end diameter mm]

left diastolic end diameter mm

[palliation]

palliation

[749 self-identified patients]

749 self-identified patients

[23.7 ng range]

23.7 ng range

[impaired right pump function]

impaired right pump function

[studies evaluating predictors]

studies evaluating predictors

[epigenetic readers in biology]

epigenetic readers in biology

[atrioventricular delay AVD]

atrioventricular delay AVD

[hospitalization for acute coronary syndromes]

hospitalization for acute coronary syndromes

[genes coding]

genes coding

[drug-untreated failing hearts]

drug-untreated failing hearts

[cardiac response protective role]

cardiac response protective role

[adjusting for 20 clinical variables]

adjusting for 20 clinical variables

[time interval]

time interval

[longitudinal RV fiber shortening]

longitudinal RV fiber shortening

[hypotension]

hypotension

[performance in patients with s'lateral]

performance in patients with s'lateral

[one trial]

one trial

[hospitalization in patients]

hospitalization in patients

[quality measures for common conditions]

quality measures for common conditions

[relationships between right RV function]

relationships between right RV function

[surrogates for changes]

surrogates for changes

[191 mm Hg]

191 mm Hg

[lower mortality with HF]

lower mortality with HF

[multiple genes in HF]

multiple genes in HF

[age group mortality rates]

age group mortality rates

[proteomics analysis of heart failure]

proteomics analysis of heart failure

[favorable effects]

favorable effects

[groups of rats]

groups of rats

[severe perturbations in components]

severe perturbations in components

[left ventricular base]

left ventricular base

[prognostic factors at admission]

prognostic factors at admission

[shotgun proteomics approach]

shotgun proteomics approach

[common syndrome]

common syndrome

[arterial elastance Ea]

arterial elastance Ea

[binomial regression models]

binomial regression models

[amyloidotic pattern]

amyloidotic pattern

[central region]

central region

[rapid pacing]

rapid pacing

[regarding the forms of NT-proBNP]

regarding the forms of NT-proBNP

[area index 10.0 cm(2)]

area index 10.0 cm(2)

[intermediate outcomes]

intermediate outcomes

[intermuscular fat ratio]

intermuscular fat ratio

[major complications stroke]

major complications stroke

[useful technique detecting myocardial fibrosis]

useful technique detecting myocardial fibrosis

[subjects with structurally normal hearts]

subjects with structurally normal hearts

[cardiac resonance imaging]

cardiac resonance imaging

[risk developing malignancies including cancer]

risk developing malignancies including cancer

[disease groups]

disease groups

[achieving a level]

achieving a level

[sitagliptin versus sulfonylureas]

sitagliptin versus sulfonylureas

[hemodynamic disorder]

hemodynamic disorder

[Frailty an indicator in heart failure]

Frailty an indicator in heart failure

[V activity]

V activity

[role in coronary artery disease]

role in coronary artery disease

[multiple abnormalities]

multiple abnormalities

[limited success]

limited success

[Randomized trial]

Randomized trial

[previous revascularization coronary artery bypass surgery]

previous revascularization coronary artery bypass surgery

[prior stroke score]

prior stroke score

[patients undergoing VAD]

patients undergoing VAD

[cardiovascular CV events in fibrillation]

cardiovascular CV events in fibrillation

[sympathetic activity by ((123)I-MIBG]

sympathetic activity by ((123)I-MIBG

[review of the effects]

review of the effects

[ventricular RV tricuspid plane systolic excursion]

ventricular RV tricuspid plane systolic excursion

[viable option in heart failure]

viable option in heart failure

[New Zealand rabbits undergoing renal DNx]

New Zealand rabbits undergoing renal DNx

[simple model]

simple model

[taking advantage]

taking advantage

[changes in treatment]

changes in treatment

[weeks from infarction]

weeks from infarction

[minimal detectable change MDC values]

minimal detectable change MDC values

[using the Process Redesign framework]

using the Process Redesign framework

[lower income per capita]

lower income per capita

[SkM growth]

SkM growth

[parallel-group trial the effects]

parallel-group trial the effects

[validity replicating resource use from trials]

validity replicating resource use from trials

[Monitoring]

Monitoring

[left end diameter mm mean difference]

left end diameter mm mean difference

[HDL before ET]

HDL before ET

[ventricular fibrillation]

ventricular fibrillation

[five patients IL mg]

five patients IL mg

[supporting patients]

supporting patients

[patients with CHF-NYHA-II HDL]

patients with CHF-NYHA-II HDL

[treatment variation independent]

treatment variation independent

[9868 participants]

9868 participants

[pulmonary capillary wedge pressure]

pulmonary capillary wedge pressure

[sensitive measure]

sensitive measure

[mild disease from the population]

mild disease from the population

[Expression]

Expression

[patients respectively]

patients respectively

[heart failure in a state]

heart failure in a state

[testing of the Self-Care]

testing of the Self-Care

[data analysis]

data analysis

[device therapies]

device therapies

[Global left ventricular longitudinal strain]

Global left ventricular longitudinal strain

[twofold increase in LV pressure]

twofold increase in LV pressure

[neprilysin blocks renin-angiotensin-aldosteron axis]

neprilysin blocks renin-angiotensin-aldosteron axis

[pharmacologic studies of therapeutics including agents]

pharmacologic studies of therapeutics including agents

[nonstandardized N-terminal pro-B-type peptide]

nonstandardized N-terminal pro-B-type peptide

[months after CABG]

months after CABG

[medical treatment for heart failure]

medical treatment for heart failure

[knowledge on diuretic use]

knowledge on diuretic use

[good evidence]

good evidence

[resistive afterload]

resistive afterload

[cardiac inflammatory biomarkers]

cardiac inflammatory biomarkers

[stable heart failure patients ejection fraction]

stable heart failure patients ejection fraction

[prognostic markers hazard ratio for peak]

prognostic markers hazard ratio for peak

[Acute heart failure in hypertension]

Acute heart failure in hypertension

[2-vessel CAD involving the artery]

2-vessel CAD involving the artery

[hospitalization within the months]

hospitalization within the months

[Improving survival rates]

Improving survival rates

[study medication]

study medication

[exercise training ET]

exercise training ET

[period of years]

period of years

[predicting future performers]

predicting future performers

[bpm 17.5±5.5 versus 14.4±3.3 mL P]

bpm 17.5±5.5 versus 14.4±3.3 mL P

[following event rates HF hospitalization]

following event rates HF hospitalization

[choice for common applications]

choice for common applications

[RAS inhibition]

RAS inhibition

[pressure 155 35]

pressure 155 35

[heart failure care]

heart failure care

[Fifty patients with onset HFrEF]

Fifty patients with onset HFrEF

[156 consecutive consenting ambulatory HF patients]

156 consecutive consenting ambulatory HF patients

[infarction heart failure patients with ejection]

infarction heart failure patients with ejection

[non-HF populations]

non-HF populations

[Further elevation]

Further elevation

[LV systolic pressure]

LV systolic pressure

[valve plasty for MR]

valve plasty for MR

[treatment in all patients]

treatment in all patients

[L-DKO]

L-DKO

[promising targets]

promising targets

[common characteristics]

common characteristics

[descriptive study]

descriptive study

[class NYHA II-III]

class NYHA II-III

[pressure relationship an index of function]

pressure relationship an index of function

[PD initiation kg with improvement]

PD initiation kg with improvement

[ischemic problems]

ischemic problems

[medical support]

medical support

[von Willebrand factor concentrations]

von Willebrand factor concentrations

[Defibrillator Implantation Cardiac Resynchronization Therapy]

Defibrillator Implantation Cardiac Resynchronization Therapy

[patients men mean years]

patients men mean years

[heart failure tissue]

heart failure tissue

[event rate 2.08 events]

event rate 2.08 events

[cardiac Mena overexpression]

cardiac Mena overexpression

[hypertrophy antecedent]

hypertrophy antecedent

[3 evaluations HM II]

3 evaluations HM II

[receptor blocker therapy]

receptor blocker therapy

[All-cause mortality at 4 years]

All-cause mortality at 4 years

[growth factor VEGF]

growth factor VEGF

[outcome measures related]

outcome measures related

[measure of ventricular contractile reserve]

measure of ventricular contractile reserve

[Physio Ring Edwards Lifesciences]

Physio Ring Edwards Lifesciences

[various serum factors]

various serum factors

[determining individualized assessment for patients]

determining individualized assessment for patients

[kidney 293 cells overexpressing β1AR]

kidney 293 cells overexpressing β1AR

[using multivariable regression]

using multivariable regression

[Low muscle mass r=0.67]

Low muscle mass r=0.67

[Confirmatory tests]

Confirmatory tests

[Improving survival rates over 3 decades]

Improving survival rates over 3 decades

[stable coronary artery disease]

stable coronary artery disease

[CI 1.27]

CI 1.27

[Key role of ERK1]

Key role of ERK1

[Western blots with site-specific antibodies]

Western blots with site-specific antibodies

[Global proteomics analysis of heart failure]

Global proteomics analysis of heart failure

[events evaluation]

events evaluation

[development in candidate genes]

development in candidate genes

[Cardiorespiratory]

Cardiorespiratory

[NT-proBNP cutoff point]

NT-proBNP cutoff point

[role of Mena]

role of Mena

[Centers for Medicare readmission]

Centers for Medicare readmission

[heart failure-related hospitalization]

heart failure-related hospitalization

[53 patients]

53 patients

[Excessive secretion of arginine vasopressin]

Excessive secretion of arginine vasopressin

[angiogenesis in the post-myocardial infarction heart]

angiogenesis in the post-myocardial infarction heart

[first infarction in Australia]

first infarction in Australia

[effects of B on function]

effects of B on function

[grade holosystolic murmur]

grade holosystolic murmur

[Surgical correction after assist device implantation]

Surgical correction after assist device implantation

[continuous relationship between QRS duration]

continuous relationship between QRS duration

[such responses]

such responses

[Living with Heart Failure Questionnaire]

Living with Heart Failure Questionnaire

[data regarding the role]

data regarding the role

[decreases in LV fractional shortening]

decreases in LV fractional shortening

[HF in LA]

HF in LA

[time interval between local depolarization]

time interval between local depolarization

[Using logistic regression analysis]

Using logistic regression analysis

[increasing BTES]

increasing BTES

[resuscitation CPR]

resuscitation CPR

[typical event]

typical event

[cAMP-dependent protein kinase signaling downstream]

cAMP-dependent protein kinase signaling downstream

[low concentration]

low concentration

[minimal change MDC values]

minimal change MDC values

[left ventricular biopsies]

left ventricular biopsies

[Natriuretic peptide levels like biomarkers]

Natriuretic peptide levels like biomarkers

[manipulation via the targeting]

manipulation via the targeting

[controls CHF]

controls CHF

[diameters]

diameters

[high BNP group]

high BNP group

[Doppler ultrasonography]

Doppler ultrasonography

[levels pg high BNP group]

levels pg high BNP group

[percent of visits]

percent of visits

[Prognostic value of indeterminable threshold]

Prognostic value of indeterminable threshold

[optimization of diastolic filling time]

optimization of diastolic filling time

[ambulatory HF patients left ejection fraction]

ambulatory HF patients left ejection fraction

[strength as an predictor]

strength as an predictor

[HNO donor]

HNO donor

[short-term treatment]

short-term treatment

[performance in patients with heart failure]

performance in patients with heart failure

[median left ejection fraction]

median left ejection fraction

[time of inclusion]

time of inclusion

[global left ventricular longitudinal systolic strain]

global left ventricular longitudinal systolic strain

[advantage of the faster turnaround times]

advantage of the faster turnaround times

[ventricular tissue from control animals]

ventricular tissue from control animals

[chelation regimens]

chelation regimens

[rehospitalization of 1.56 percentage points]

rehospitalization of 1.56 percentage points

[HF tissue samples]

HF tissue samples

[(-)-epicatechin-rich cocoa]

(-)-epicatechin-rich cocoa

[reducing the endpoint in all subgroups]

reducing the endpoint in all subgroups

[recent onset AF]

recent onset AF

[hazard ratio 0.91]

hazard ratio 0.91

[methotrexate]

methotrexate

[type of cardiac tumors]

type of cardiac tumors

[clinical application of peptide drugs]

clinical application of peptide drugs

[p38α protein kinase p38]

p38α protein kinase p38

[kg with improvement]

kg with improvement

[symptoms in HFpEF]

symptoms in HFpEF

[high relevance in hypertension patients]

high relevance in hypertension patients

[Na current during human HF]

Na current during human HF

[acute care surgery ACS consultations]

acute care surgery ACS consultations

[3.5 g]

3.5 g

[Heart Association guidelines on evaluation]

Heart Association guidelines on evaluation

[trial involving centers]

trial involving centers

[PKA subunits]

PKA subunits

[post-translational modification]

post-translational modification

[such as pressure ulcers in patients]

such as pressure ulcers in patients

[heart muscle cells]

heart muscle cells

[reprogramming events]

reprogramming events

[LV mass versus 5.0 g P=0.04]

LV mass versus 5.0 g P=0.04

[difference between groups patients P]

difference between groups patients P

[cardiopulmonary exercise testing guide]

cardiopulmonary exercise testing guide

[cardiac activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]

cardiac activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG

[N-terminal pro-brain peptide]

N-terminal pro-brain peptide

[LVEF respectively]

LVEF respectively

[pulseless fibrillation]

pulseless fibrillation

[pulmonary disease COPD]

pulmonary disease COPD

[diagnosis of multiple myeloma]

diagnosis of multiple myeloma

[using CardioPulmonary Exercise Testing guide]

using CardioPulmonary Exercise Testing guide

[targeting exercise hemodynamic status]

targeting exercise hemodynamic status

[acute care surgery consultations]

acute care surgery consultations

[achievement]

achievement

[independent role]

independent role

[random-effects]

random-effects

[atrial myxoma]

atrial myxoma

[per cent]

per cent

[hypothermic circulatory arrest]

hypothermic circulatory arrest

[24 per cent]

24 per cent

[national Medicare data]

national Medicare data

[significant decline in event rates]

significant decline in event rates

[cardiorespiratory fitness CRF]

cardiorespiratory fitness CRF

[aerobic training period with trainings]

aerobic training period with trainings

[primary endpoint cardiovascular death]

primary endpoint cardiovascular death

[distinctive components]

distinctive components

[weeks of pacing]

weeks of pacing

[proANP MR-proANP]

proANP MR-proANP

[absence of coronary artery disease]

absence of coronary artery disease

[circumferential shortening]

circumferential shortening

[area of E ratios]

area of E ratios

[difference BNP]

difference BNP

[mortality in 90-day survivors]

mortality in 90-day survivors

[Safe effective off-pump sternal sparing approach]

Safe effective off-pump sternal sparing approach

[ischemic MR]

ischemic MR

[nondiabetes risk factors age men]

nondiabetes risk factors age men

[days range days]

days range days

[potential for deleterious effects]

potential for deleterious effects

[previous revascularization artery bypass surgery]

previous revascularization artery bypass surgery

[two-vessel disease model]

two-vessel disease model

[arterial compliance]

arterial compliance

[Frailty an prognostic indicator]

Frailty an prognostic indicator

[renal failure CRF]

renal failure CRF

[global strain GLS]

global strain GLS

[subunit]

subunit

[undergoing cardiac resynchronization therapy]

undergoing cardiac resynchronization therapy

[outflow]

outflow

[systolic parameters in AF]

systolic parameters in AF

[usually the result]

usually the result

[298 sitagliptin users]

298 sitagliptin users

[Healthcare]

Healthcare

[participants dopamine]

participants dopamine

[mortality in 28-day survivors]

mortality in 28-day survivors

[improvement after device implantation]

improvement after device implantation

[rates of changes]

rates of changes

[axis]

axis

[inhibitor JQ1]

inhibitor JQ1

[right annular plane excursion]

right annular plane excursion

[ventricular systolic strain GLS]

ventricular systolic strain GLS

[derangement with hemodynamic features similar]

derangement with hemodynamic features similar

[strong recommendation]

strong recommendation

[consecutive HF patients left ejection fraction]

consecutive HF patients left ejection fraction

[channel α-subunit]

channel α-subunit

[Ejection Fraction A Trial]

Ejection Fraction A Trial

[5.0 mmol]

5.0 mmol

[12-s recovery period]

12-s recovery period

[New York Heart Association functional class]

New York Heart Association functional class

[bpm with beta-blocker therapy]

bpm with beta-blocker therapy

[descending LAD]

descending LAD

[estimation]

estimation

[mouse HF model of HHD]

mouse HF model of HHD

[chronic medical therapy]

chronic medical therapy

[modifiable risk factors]

modifiable risk factors

[resting HR bpm]

resting HR bpm

[ranging from .85]

ranging from .85

[specific effector molecules]

specific effector molecules

[search of the databases]

search of the databases

[inotropic effects in vivo]

inotropic effects in vivo

[Baseline eGFR group P]

Baseline eGFR group P

[muscle sarcomere structure]

muscle sarcomere structure

[describing trends in HF]

describing trends in HF

[broad panel]

broad panel

[English-language trials of blood transfusions]

English-language trials of blood transfusions

[regarding the need for antiplatelet agents]

regarding the need for antiplatelet agents

[use of evidence-based medications]

use of evidence-based medications

[discrimination change in C-index]

discrimination change in C-index

[3 pharmacologic studies including agents]

3 pharmacologic studies including agents

[lower status]

lower status

[changes in the development]

changes in the development

[percent remaining in extreme deciles]

percent remaining in extreme deciles

[growth factor-β TGF-β signaling]

growth factor-β TGF-β signaling

[benefit with consequences]

benefit with consequences

[annulus velocity Sa]

annulus velocity Sa

[TAPSE relationship as a index]

TAPSE relationship as a index

[transcriptional pause release]

transcriptional pause release

[changes in diastolic function]

changes in diastolic function

[change in chronic heart failure]

change in chronic heart failure

[plane systolic excursion from the end]

plane systolic excursion from the end

[conventional systolic parameters]

conventional systolic parameters

[diagnosis of prognostic dysfunction leading]

diagnosis of prognostic dysfunction leading

[dogs with coronary HF]

dogs with coronary HF

[right ventricular ejection fraction]

right ventricular ejection fraction

[heart failure in practice]

heart failure in practice

[plasma B-type peptide BNP levels]

plasma B-type peptide BNP levels

[μmol L]

μmol L

[transmitral E-wave mitral annular velocity]

transmitral E-wave mitral annular velocity

[using simple procedures]

using simple procedures

[mass index]

mass index

[metabolic evaluations]

metabolic evaluations

[undergoing LVAD implantation]

undergoing LVAD implantation

[ICU admission]

ICU admission

[review protocol]

review protocol

[patients with recent onset]

patients with recent onset

[reflecting decreases period]

reflecting decreases period

[phenylephrine-mediated hypertrophy]

phenylephrine-mediated hypertrophy

[requiring revision by surgery]

requiring revision by surgery

[gene expression programme]

gene expression programme

[increasing volume index]

increasing volume index

[length 37]

length 37

[angiotensin-receptor neprilysin inhibitors]

angiotensin-receptor neprilysin inhibitors

[low mg equivalent dose]

low mg equivalent dose

[serum levels of brain natriuretic peptide]

serum levels of brain natriuretic peptide

[(Fpassive)-sarcomere length]

(Fpassive)-sarcomere length

[even in subgroups at risk]

even in subgroups at risk

[biomarker approach]

biomarker approach

[transmitral flow]

transmitral flow

[HRQoL changes]

HRQoL changes

[multisystem disease with comorbidities]

multisystem disease with comorbidities

[advanced obstructive pulmonary disease COPD]

advanced obstructive pulmonary disease COPD

[ventricular-pulmonary arterial coupling]

ventricular-pulmonary arterial coupling

[mechanism of cardioprotection]

mechanism of cardioprotection

[studies with long-term follow-up]

studies with long-term follow-up

[combination restricting the leaflet opening]

combination restricting the leaflet opening

[open chest model surrogates]

open chest model surrogates

[First-in-class angiotensin]

First-in-class angiotensin

[effect of ventricular ejection fraction]

effect of ventricular ejection fraction

[extra corporeal membrane oxygenation]

extra corporeal membrane oxygenation

[variation in use of medications]

variation in use of medications

[mild heart failure HF]

mild heart failure HF

[Heart Failure MLHF Questionnaire]

Heart Failure MLHF Questionnaire

[ejection fraction LVEF]

ejection fraction LVEF

[with ICC values ranging]

with ICC values ranging

[normal geometry no LV hypertrophy]

normal geometry no LV hypertrophy

[necessitating a better understanding]

necessitating a better understanding

[highest event rate events]

highest event rate events

[topics of debate]

topics of debate

[behavior]

behavior

[threshold AT]

threshold AT

[effectiveness of Chinese medicine CHM]

effectiveness of Chinese medicine CHM

[acute heart failure filtration rate]

acute heart failure filtration rate

[neurotransmission]

neurotransmission

[hypertrophy a robust predictor of HF]

hypertrophy a robust predictor of HF

[artery disease HR]

artery disease HR

[interval between local depolarization]

interval between local depolarization

[Hospital Anxiety]

Hospital Anxiety

[brain peptide levels pg BNP group]

brain peptide levels pg BNP group

[normal ventricular function]

normal ventricular function

[association of hypoalbuminemia]

association of hypoalbuminemia

[genes between heart failure samples]

genes between heart failure samples

[exercise training response]

exercise training response

[≥60 mL per m 2]

≥60 mL per m 2

[adverse event rates for infarction]

adverse event rates for infarction

[creating uncertainty]

creating uncertainty

[biventricular pacing]

biventricular pacing

[treatment for infarction AMI]

treatment for infarction AMI

[framework determining assessment for patients]

framework determining assessment for patients

[arginine]

arginine

[right ventricular area index 10.0 cm(2)]

right ventricular area index 10.0 cm(2)

[fitness]

fitness

[such as heart failure HF]

such as heart failure HF

[multiple abnormalities in cardiovascular function]

multiple abnormalities in cardiovascular function

[symptoms Hospital Anxiety]

symptoms Hospital Anxiety

[higher serum levels of peptide BNP]

higher serum levels of peptide BNP

[detectable change MDC values]

detectable change MDC values

[heart filling pressures]

heart filling pressures

[Health ABC Physical Performance Battery]

Health ABC Physical Performance Battery

[first infarction]

first infarction

[diastolic indices ratio at diastole]

diastolic indices ratio at diastole

[patients with idiopathic cardiomyopathy]

patients with idiopathic cardiomyopathy

[left base during baseline]

left base during baseline

[conditioning]

conditioning

[resulting in the suppression]

resulting in the suppression

[several pathological changes]

several pathological changes

[prognostic diastolic dysfunction]

prognostic diastolic dysfunction

[African Americans]

African Americans

[Single referral centre]

Single referral centre

[absolute change MDC values]

absolute change MDC values

[composite outcome of death]

composite outcome of death

[breakdown]

breakdown

[exercise hemodynamic status]

exercise hemodynamic status

[reactivation of gene programs]

reactivation of gene programs

[Functional stimulation FES]

Functional stimulation FES

[identifying death]

identifying death

[benefits of treatments for anemia]

benefits of treatments for anemia

[stretch]

stretch

[effect of left ejection fraction]

effect of left ejection fraction

[mean score]

mean score

[significant trends]

significant trends

[hypertension PH]

hypertension PH

[right atrial area]

right atrial area

[Emergency Department]

Emergency Department

[using the method of constriction]

using the method of constriction

[Danish Registry]

Danish Registry

[N2Bus segment]

N2Bus segment

[structurally normal hearts]

structurally normal hearts

[HeartWare patients]

HeartWare patients

[positive inotropic effects]

positive inotropic effects

[extracorporeal membrane oxygenation ECMO on function]

extracorporeal membrane oxygenation ECMO on function

[Cox modeling]

Cox modeling

[Objective criteriabased institution]

Objective criteriabased institution

[shock therapy HR]

shock therapy HR

[benefit with few consequences]

benefit with few consequences

[diastolic dysfunction impaired LV relaxation]

diastolic dysfunction impaired LV relaxation

[partial pressure of end-tidal CO2]

partial pressure of end-tidal CO2

[projecting costs]

projecting costs

[changes in pressure development]

changes in pressure development

[HeartMate LVADs]

HeartMate LVADs

[Addressing differences]

Addressing differences

[Hospital Compare]

Hospital Compare

[training period]

training period

[however an important disease]

however an important disease

[2.1 mL 2]

2.1 mL 2

[degree of MS]

degree of MS

[Grading Assessment GRADE methodology]

Grading Assessment GRADE methodology

[main 3-vessel CAD]

main 3-vessel CAD

[anthracycline-treated breast cancer patients]

anthracycline-treated breast cancer patients

[valid measure]

valid measure

[exercise testing guide]

exercise testing guide

[practitioners]

practitioners

[benefit over parameters in AF]

benefit over parameters in AF

[extracorporeal membrane oxygenation ECMO]

extracorporeal membrane oxygenation ECMO

[controls non-cachectic CHF]

controls non-cachectic CHF

[significant decrease]

significant decreases, significant decrease

[Cardiac-resynchronization therapy with a QRS complex]

Cardiac-resynchronization therapy with a QRS complex

[large limits of agreement]

large limits of agreement

[electromechanical delay the time]

electromechanical delay the time

[increase for myocardial infarction]

increase for myocardial infarction

[low-dose dopamine on end points]

low-dose dopamine on end points

[ventricular annular plane systolic excursion TAPSE]

ventricular annular plane systolic excursion TAPSE

[obese participants mean]

obese participants mean

[Toronto]

Toronto

[assay N-terminal pro-B-type peptide]

assay N-terminal pro-B-type peptide

[HR reduction 17±22 versus bpm]

HR reduction 17±22 versus bpm

[pacing on heart twist]

pacing on heart twist

[stress markers]

stress markers

[Classification of Diseases]

Classification of Diseases

[mandatory monitoring]

mandatory monitoring

[relative risk of heart failure]

relative risk of heart failure

[pro-adrenomedullin]

pro-adrenomedullin

[risk of death visit]

risk of death visit

[left area]

left area

[basis of left ventricle]

basis of left ventricle

[American College]

American College

[York Heart Association class HR]

York Heart Association class HR

[morbidity especially in elderly people]

morbidity especially in elderly people

[support for the concept appropriate]

support for the concept appropriate

[Extracellular matrix of left biopsies]

Extracellular matrix of left biopsies

[left ventricular strain as a predictor]

left ventricular strain as a predictor

[right ventricular pump function]

right ventricular pump function

[decline explant-derived c-Kit]

decline explant-derived c-Kit

[additive for peak VO2 effect]

additive for peak VO2 effect

[greater impact on patients]

greater impact on patients

[prior infarction-both n]

prior infarction-both n

[targets for the prevention]

targets for the prevention

[exercise variables exercise ventilation]

exercise variables exercise ventilation

[hospitals nationwide from January through September]

hospitals nationwide from January through September

[HFpEF with ejection fraction]

HFpEF with ejection fraction

[plane systolic excursion TAPSE]

plane systolic excursion TAPSE

[patients with breast cancer]

patients with breast cancer

[pulseless ventricular fibrillation]

pulseless ventricular fibrillation

[diagnosis of diastolic dysfunction]

diagnosis of diastolic dysfunction

[home telemonitoring TM]

home telemonitoring TM

[ventricular RV plane excursion TAPSE]

ventricular RV plane excursion TAPSE

[type V Na]

type V Na

[dipeptidyl peptidase-4 DPP-4]

dipeptidyl peptidase-4 DPP-4

[proANP]

proANP

[deleterious effects in CHF Inhibition]

deleterious effects in CHF Inhibition

[potential as targets]

potential as targets

[safety of receptor antagonists]

safety of receptor antagonists

[moderate-severe ventricular dysfunction]

moderate-severe ventricular dysfunction

[particularly in patients with dysfunction]

particularly in patients with dysfunction

[coronary intervention HR]

coronary intervention HR

[SCN5A mRNA splicing]

SCN5A mRNA splicing

[positive rates]

positive rates

[min 59.6 m vs. m]

min 59.6 m vs. m

[hospital readmission reduction]

hospital readmission reduction

[standard cardiac rehabilitation care on capacity]

standard cardiac rehabilitation care on capacity

[cause of RAS]

cause of RAS

[important factor in heart failure]

important factor in heart failure

[more data]

more data

[four-week aerobic training period]

four-week aerobic training period

[diastolic mitral velocity 3.1]

diastolic mitral velocity 3.1

[murine resistin]

murine resistin

[predictors of hospitalization]

predictors of hospitalization

[abnormal Ca handling]

abnormal Ca handling

[mandate]

mandate

[2.1 17.6 mL 2]

2.1 17.6 mL 2

[wave Doppler echocardiography]

wave Doppler echocardiography

[throughput of patients]

throughput of patients

[lower gross income per capita]

lower gross income per capita

[peptide assessment]

peptide assessment

[advanced pulmonary disease COPD]

advanced pulmonary disease COPD

[measurement of peptides NPs]

measurement of peptides NPs

[potential dysfunction]

potential dysfunction

[carotid baroreflex activation therapy]

carotid baroreflex activation therapy

[dying in 30 days P-value]

dying in 30 days P-value

[bHLH transcription]

bHLH transcription

[enzymes in patients]

enzymes in patients

[climate within the NHS]

climate within the NHS

[collagen density of the surviving ventricle]

collagen density of the surviving ventricle

[septum thickness]

septum thickness

[randomised studies]

randomised studies

[Six thousand five hundred thirty-seven hospitals]

Six thousand five hundred thirty-seven hospitals

[120 patients]

120 patients

[LV stiffness]

LV stiffness

[resulting in a higher SV]

resulting in a higher SV

[E-wave mitral annular velocity]

E-wave mitral annular velocity

[evaluation of patients]

evaluation of patients

[walk test 6-MWT]

walk test 6-MWT

[all-cause hospitalisations]

all-cause hospitalisations

[function in B-treated]

function in B-treated

[paediatric transplants in children]

paediatric transplants in children

[Effective elastance Ea elastance Ees]

Effective elastance Ea elastance Ees

[refill compliance for etidronate P]

refill compliance for etidronate P

[Using a HF registry]

Using a HF registry

[Safe off-pump sparing approach]

Safe off-pump sparing approach

[hand grip strength kg from baseline]

hand grip strength kg from baseline

[type of benign tumors]

type of benign tumors

[University Health Network]

University Health Network

[inappropriate cardioverter-defibrillator therapy Defibrillator Implantation]

inappropriate cardioverter-defibrillator therapy Defibrillator Implantation

[80 years]

80 years

[evidence for the treatment of HF]

evidence for the treatment of HF

[30 mm Hg]

30 mm Hg

[thrombotic obstruction of the artery]

thrombotic obstruction of the artery

[new-onset ESRD from the Danish Registry]

new-onset ESRD from the Danish Registry

[muscle strips]

muscle strips

[prognostic factor in heart failure]

prognostic factor in heart failure

[HDL particles]

HDL particles

[Fourteen databases including MEDLINE]

Fourteen databases including MEDLINE

[complexities]

complexities

[Population-based cohort study]

Population-based cohort study

[prognostic role]

prognostic role

[components regulating metabolism]

components regulating metabolism

[tool for assessment]

tool for assessment

[Remote ischemic conditioning]

Remote ischemic conditioning

[pulmonary hypertension PAH]

pulmonary hypertension PAH

[Extracellular matrix of ventricular biopsies]

Extracellular matrix of ventricular biopsies

[years versus 53.2 years]

years versus 53.2 years

[concept also appropriate]

concept also appropriate

[pre-HCT germline DNA]

pre-HCT germline DNA

[HeartMate exchange]

HeartMate exchange

[changes including hypertrophy]

changes including hypertrophy

[self-identified black patients]

self-identified black patients

[trials-Enriching]

trials-Enriching

[effects on physiologic processes]

effects on physiologic processes

[requiring RV support after LVAD insertion]

requiring RV support after LVAD insertion

[vascular resistance SVR index]

vascular resistance SVR index

[Outcomes In Patients]

Outcomes In Patients

[association with outcomes]

association with outcomes

[ethically complex situations]

ethically complex situations

[Left ventricular ejection time complicating hypertension]

Left ventricular ejection time complicating hypertension

[Xanthine]

Xanthine

[comparing B-treated with drug-untreated hearts]

comparing B-treated with drug-untreated hearts

[outcome from any cause]

outcome from any cause

[settings other]

settings other

[impact on the effectiveness]

impact on the effectiveness

[dietary recommendations for patients]

dietary recommendations for patients

[14 clinical studies 2900 HM]

14 clinical studies 2900 HM

[223 patients mean age]

223 patients mean age

[effects of types of LVADs]

effects of types of LVADs

[specialty hospital]

specialty hospital

[proximal left anterior descending]

proximal left anterior descending

[Multicenter double-blind trial of patients]

Multicenter double-blind trial of patients

[new targets for HHD]

new targets for HHD

[LCX later model]

LCX later model

[regarding treatment of adults]

regarding treatment of adults

[hyperkalemia in African Americans]

hyperkalemia in African Americans

[saxagliptin for saxagliptin versus insulin]

saxagliptin for saxagliptin versus insulin

[ZSF1 with high-fat diet]

ZSF1 with high-fat diet

[symptoms of heart failure at rest]

symptoms of heart failure at rest

[proteolysis]

proteolysis

[complicating precapillary pulmonary hypertension]

complicating precapillary pulmonary hypertension

[ANG infusion AT]

ANG infusion AT

[ventricular assist device support]

ventricular assist device support

[one model for ischemia]

one model for ischemia

[prognostic factor in patients]

prognostic factor in patients

[even volumes]

even volumes

[conditions such as infarction with expansion]

conditions such as infarction with expansion

[addition of dopamine]

addition of dopamine

[myofibrillar Ca]

myofibrillar Ca

[25th-75th]

25th-75th

[pluripotent stem cardiomyocytes]

pluripotent stem cardiomyocytes

[spectrometry]

spectrometry

[mRNA splicing of the type V]

mRNA splicing of the type V

[17.0 ml]

17.0 ml

[prospective research]

prospective research

[expenditure on health]

expenditure on health

[Heart failure data]

Heart failure data

[LVEF on mortality]

LVEF on mortality

[Reversal of cardiac dysfunction]

Reversal of cardiac dysfunction

[hospital change]

hospital change

[management of dysfunction]

management of dysfunction

[credible interval]

credible interval

[myocyte depolarization]

myocyte depolarization

[childhood malignant disease]

childhood malignant disease

[emergency room practice]

emergency room practice

[mitochondrial oxidation]

mitochondrial oxidation

[72-hour urine volume decongestion end point]

72-hour urine volume decongestion end point

[bpm 17.5±5.5 P]

bpm 17.5±5.5 P

[York Heart]

York Heart

[arterial disease]

arterial disease

[change in status]

change in status

[Effective arterial elastance elastance]

Effective arterial elastance elastance

[Practice Guideline recommendations]

Practice Guideline recommendations

[even mild diastolic dysfunction]

even mild diastolic dysfunction

[median stay]

median stay

[cardiac index score]

cardiac index score

[Effect of Caloric Restriction]

Effect of Caloric Restriction

[complications of therapy]

complications of therapy

[wall RS]

wall RS

[brief insight into the potential]

brief insight into the potential

[hypertrophy a robust predictor]

hypertrophy a robust predictor

[modulation of repolarization instability in patients]

modulation of repolarization instability in patients

[CHF rates]

CHF rates

[protective role]

protective role

[arterial coupling pulmonary resistance P]

arterial coupling pulmonary resistance P

[CRF after trials]

CRF after trials

[sympathetic control]

sympathetic control

[reticular Ca 2+)-uptake]

reticular Ca 2+)-uptake

[findings from Heart Failure]

findings from Heart Failure

[PDrelated complications]

PDrelated complications

[25mg kg ip]

25mg kg ip

[including death]

including death

[metoprolol treatment]

metoprolol treatment

[exercise test a quality]

exercise test a quality

[L-type Ca]

L-type Ca

[role 2 molecular scaffolds]

role 2 molecular scaffolds

[17.6 mL 2]

17.6 mL 2

[Eight-week-old C57BL]

Eight-week-old C57BL

[assessing ventricular filling pressure]

assessing ventricular filling pressure

[series of ACS problems]

series of ACS problems

[transmitral E-wave early mitral velocity ratio]

transmitral E-wave early mitral velocity ratio

[Usefulness of cardiac resynchronization therapy]

Usefulness of cardiac resynchronization therapy

[uniform nomenclature for failure]

uniform nomenclature for failure

[Peripheral artery disease]

Peripheral artery disease

[enhancing neoangiogenesis]

enhancing neoangiogenesis

[224 men years]

224 men years

[care delivery]

care delivery

[pre-specified analysis of subgroups]

pre-specified analysis of subgroups

[interaction with LVEF]

interaction with LVEF

[common contextual reasons]

common contextual reasons

[postoperative months after CABG]

postoperative months after CABG

[risk among trials]

risk among trials

[valve procedures bioprosthetic valve replacement]

valve procedures bioprosthetic valve replacement

[involving the proximal descending artery]

involving the proximal descending artery

[several Outcomes]

several Outcomes

[median activities]

median activities

[loss of fat mass]

loss of fat mass

[potential predictors biomarkers]

potential predictors biomarkers

[serum albumin levels]

serum albumin levels

[variables contributing]

variables contributing

[heart failure therapy in patients]

heart failure therapy in patients

[precipitating factor for clinical deterioration]

precipitating factor for clinical deterioration

[lean body]

lean body

[practice for a number of patients]

practice for a number of patients

[coronary HF]

coronary HF

[autonomic system activity]

autonomic system activity

[risk of IE]

risk of IE

[3 evaluations using simulation models]

3 evaluations using simulation models

[greater reduction of activity]

greater reduction of activity

[EAST treatment of Atrial fibrillation]

EAST treatment of Atrial fibrillation

[heart failure in rats]

heart failure in rats

[common characteristics eg using Cochrane Practice]

common characteristics eg using Cochrane Practice

[nomenclature for heart circulatory failure]

nomenclature for heart circulatory failure

[ventricular area index cm(2)]

ventricular area index cm(2)

[Global proteomics analysis]

Global proteomics analysis

[925 ED visits mean age years]

925 ED visits mean age years

[minimal detectable change values]

minimal detectable change values

[Robot-assisted gait therapy]

Robot-assisted gait therapy

[3 months after CABG]

3 months after CABG

[Key role of ERK1 2 scaffolds]

Key role of ERK1 2 scaffolds

[usefulness in patients]

usefulness in patients

[Multicenter trial Optimization Strategies Evaluation ROSE]

Multicenter trial Optimization Strategies Evaluation ROSE

[validation cohort]

validation cohort

[females Odds Ratio]

females Odds Ratio

[downregulation of Na]

downregulation of Na

[apparent concentration circulating NT-proBNP]

apparent concentration circulating NT-proBNP

[patient with right myxoma]

patient with right myxoma

[using an aldosterone antagonist]

using an aldosterone antagonist

[temporary ventricular support]

temporary ventricular support

[Understanding of chronic heart failure]

Understanding of chronic heart failure

[reticular SR Ca 2+)-uptake]

reticular SR Ca 2+)-uptake

[Pharmacological treatment of heart failure treatment]

Pharmacological treatment of heart failure treatment

[advanced chronic disease]

advanced chronic disease

[Effects of pacing]

Effects of pacing

[global attenuation of proteome changes]

global attenuation of proteome changes

[Left ventricular assist devices]

Left ventricular assist devices

[reduction of activity]

reduction of activity

[expressing resistin Retn]

expressing resistin Retn

[2-fold activity]

2-fold activity

[comprising hospitalization for acute coronary syndromes]

comprising hospitalization for acute coronary syndromes

[relevance in the clinical follow-up]

relevance in the clinical follow-up

[resonance imaging including T1 mapping]

resonance imaging including T1 mapping

[inotropes]

inotropes

[readmission metrics all-cause readmission]

readmission metrics all-cause readmission

[n=36]

n=36

[assist device use]

assist device use

[relations between CPCs in patients]

relations between CPCs in patients

[4 wk per os]

4 wk per os

[hRetn resistin mRNA]

hRetn resistin mRNA

[intubations for heart failure]

intubations for heart failure

[workload during stress]

workload during stress

[effect of follow-up]

effect of follow-up

[proteomic alterations]

proteomic alterations

[Remote conditioning]

Remote conditioning

[arterial pressure relationship]

arterial pressure relationship

[mg equivalent dose]

mg equivalent dose

[age categories]

age categories

[concrete data]

concrete data

[resistance index]

resistance index

[fewer admissions for individuals]

fewer admissions for individuals

[left ventricular diastolic end diameter mm]

left ventricular diastolic end diameter mm

[dysfunction treatment]

dysfunction treatment

[significant percent relative reduction]

significant percent relative reduction

[strain GLS]

strain GLS

[involving centers]

involving centers

[behavioural-change interventions]

behavioural-change interventions

[exercise status]

exercise status

[right plane excursion]

right plane excursion

[skeletal muscle mass r=0.67]

skeletal muscle mass r=0.67

[Addition discrimination change]

Addition discrimination change

[NAD(P) H-oxidase subunit]

NAD(P) H-oxidase subunit

[time-varying]

time-varying

[transforming growth factor-β signaling]

transforming growth factor-β signaling

[Implications of choice for common applications]

Implications of choice for common applications

[involving assist devices]

involving assist devices

[importance of follow-up]

importance of follow-up

[systematic search of the databases]

systematic search of the databases

[hypertrophy in TTA animals]

hypertrophy in TTA animals

[pulmonary hypertension patients]

pulmonary hypertension patients

[data regarding the role of stenting]

data regarding the role of stenting

[edge-to-edge]

edge-to-edge

[hypertrophic response protective role]

hypertrophic response protective role

[sitagliptin users]

sitagliptin users

[endothelial growth factor blockade]

endothelial growth factor blockade

[sonographic abnormalities of regions]

sonographic abnormalities of regions

[endothelial cell EC oxide production]

endothelial cell EC oxide production

[systolic pressure 155]

systolic pressure 155

[cardiac cells]

cardiac cells

[fragments of pro-B-type peptides]

fragments of pro-B-type peptides

[oxygen uptake]

oxygen uptake

[important prognostic factor]

important prognostic factor

[guideline-directed medical therapy]

guideline-directed medical therapy

[ventricular pressure overload]

ventricular pressure overload

[greater benefit from cardioverter defibrillator-CRT]

greater benefit from cardioverter defibrillator-CRT

[left ventricular function in volume overload]

left ventricular function in volume overload

[Investigating Outcomes study]

Investigating Outcomes study

[varying combinations]

varying combinations

[ventricular diastolic end diameter mm]

ventricular diastolic end diameter mm

[survival rates of patients]

survival rates of patients

[hemoglobin threshold of g]

hemoglobin threshold of g

[modestly lower mortality in women]

modestly lower mortality in women

[Incidence of renal disease]

Incidence of renal disease

[medical history]

medical history

[patients with advanced chronic disease]

patients with advanced chronic disease

[analysis of subgroups with eGFR]

analysis of subgroups with eGFR

[index of ventricular function]

index of ventricular function

[P decrease]

P decrease

[Psoriasis patients with disease]

Psoriasis patients with disease

[observation at the time]

observation at the time

[annular plane systolic excursion]

annular plane systolic excursion

[n=72]

n=72

[mild disease]

mild disease

[n=68]

n=68

[respective pathways in patients]

respective pathways in patients

[presence of clinical dysfunction]

presence of clinical dysfunction

[reasons prescribing angiotensin]

reasons prescribing angiotensin

[TTA mice]

TTA mice

[instituting circulatory support]

instituting circulatory support

[outcome-monitoring phase mean months]

outcome-monitoring phase mean months

[early mitral velocity 3.1]

early mitral velocity 3.1

[24-hour pressure]

24-hour pressure

[Reasons prescribing medications with heart failure]

Reasons prescribing medications with heart failure

[referent age group]

referent age group

[treatment for cardiomyopathy]

treatment for cardiomyopathy

[Italy]

Italy

[differences between patients]

differences between patients

[including better tools regarding the need]

including better tools regarding the need

[origin]

origin

[size reduction for MR]

size reduction for MR

[Variation in the use]

Variation in the use

[first time]

first time

[role of resistin]

role of resistin

[deterioration of HFPEF]

deterioration of HFPEF

[available data]

available data

[nonadherence in youngest]

nonadherence in youngest

[regional strain CS]

regional strain CS

[heart failure AHF studies]

heart failure AHF studies

[physician continuity on readmission]

physician continuity on readmission

[E-wave early mitral velocity ratio]

E-wave early mitral velocity ratio

[major determinant of quality QOL]

major determinant of quality QOL

[models of dyssynchronous nonfailing canine electromechanics]

models of dyssynchronous nonfailing canine electromechanics

[including ST-segment-elevation MIs]

including ST-segment-elevation MIs

[stable guideline-directed medical therapy]

stable guideline-directed medical therapy

[type of tumors]

type of tumors

[normal albumin concentration]

normal albumin concentration

[other indices]

other indices

[little influence on the burden]

little influence on the burden

[literature January]

literature January

[cost-effectiveness limits]

cost-effectiveness limits

[Studies on treatment]

Studies on treatment

[refill compliance P for trend]

refill compliance P for trend

[IRS1 IRS2 gene double-knockout H-DKO mice]

IRS1 IRS2 gene double-knockout H-DKO mice

[Contemporary trends]

Contemporary trends

[right patients]

right patients

[degree of MS]

degree of MS

[Impact of carvedilol on cardioverter-defibrillator therapy]

Impact of carvedilol on cardioverter-defibrillator therapy

[early management of HF]

early management of HF

[pulmonary pressure relationship in heart failure]

pulmonary pressure relationship in heart failure

[range years]

range years

[Contemporary options]

Contemporary options

[ventricular ejection fraction P]

ventricular ejection fraction P

[acute heart failure with dysfunction]

acute heart failure with dysfunction

[Gly16]

Gly16

[enormous clinical burden in medicine]

enormous clinical burden in medicine

[maximal treatment]

maximal treatment

[risk factors in fit]

risk factors in fit

[conservation]

conservation

[pyridostigmine administration]

pyridostigmine administration

[predictor of cardiovascular events]

predictor of cardiovascular events

[ECG in older athletes]

ECG in older athletes

[AMI between 1996]

AMI between 1996

[patient presentation]

patient presentation

[awareness of implantable cardioverter-defibrillator deactivation discussions]

awareness of implantable cardioverter-defibrillator deactivation discussions

[HeartMate assist system]

HeartMate assist system

[advanced heart failure therapy]

advanced heart failure therapy

[4 weeks of pacing]

4 weeks of pacing

[E-wave early diastolic mitral velocity]

E-wave early diastolic mitral velocity

[index score]

index score

[addition 2 μg]

addition 2 μg

[quartile of E e]

quartile of E e

[catheter ablation of fibrillation]

catheter ablation of fibrillation

[conditioning for patients]

conditioning for patients

[predictors of heart failure-related hospitalization]

predictors of heart failure-related hospitalization

[using HR variability]

using HR variability

[calcineurin]

calcineurin

[levels pg BNP group]

levels pg BNP group

[single component]

single component

[cardiomyopathy cohort]

cardiomyopathy cohort

[including negative angiography]

including negative angiography

[Assessing the link]

Assessing the link

[mortality at the worst versus quintile]

mortality at the worst versus quintile

[6-minute walking distance]

6-minute walking distance

[antiplatelet medication]

antiplatelet medication

[HFPEF LV ejection fraction]

HFPEF LV ejection fraction

[Bradycardia indicative of tone]

Bradycardia indicative of tone

[mechanism of action]

mechanism of action

[cutoff value for admission NT-proBNP]

cutoff value for admission NT-proBNP

[experienced electrocardiographers]

experienced electrocardiographers

[changes in the development of hypertrophy]

changes in the development of hypertrophy

[cognitive impairment with mortality]

cognitive impairment with mortality

[gait therapy with the Lokomat® System]

gait therapy with the Lokomat® System

[restriction of leaflet motion]

restriction of leaflet motion

[Complete occlusion]

Complete occlusion

[adults without inotropes]

adults without inotropes

[indicators of functional status]

indicators of functional status

[topics in heart failure concern]

topics in heart failure concern

[Cancer]

Cancer

[measurable improvements for patients]

measurable improvements for patients

[size reduction for degenerative MR]

size reduction for degenerative MR

[indicating suboptimal care of patients]

indicating suboptimal care of patients

[cumulative administration]

cumulative administration

[positive rates of changes]

positive rates of changes

[Objective criteriabased institution of PD]

Objective criteriabased institution of PD

[eGFR group P]

eGFR group P

[BB dose versus low mg dose]

BB dose versus low mg dose

[Grading of Recommendations]

Grading of Recommendations

[Acute right heart failure in hypertension]

Acute right heart failure in hypertension

[differential response in activity (123)I-meta-iodobenzylguanidine]

differential response in activity (123)I-meta-iodobenzylguanidine

[Advanced HF]

Advanced HF

[dosage prior HF hospitalisations]

dosage prior HF hospitalisations

[pressure-volume conductance]

pressure-volume conductance

[survival from the time through years]

survival from the time through years

[left diastolic end diameter mean difference]

left diastolic end diameter mean difference

[hRetn]

hRetn

[flow reserve]

flow reserve

[apoptotic signaling pathway]

apoptotic signaling pathway

[vivo RV]

vivo RV

[smallest difference median BNP in women]

smallest difference median BNP in women

[five deaths]

five deaths

[event rates HF hospitalization]

event rates HF hospitalization

[College of Cardiology ACC]

College of Cardiology ACC

[left longitudinal strain GLS]

left longitudinal strain GLS

[3-vessel CAD]

3-vessel CAD

[β2-receptor haplotype status]

β2-receptor haplotype status

[predictive value of E]

predictive value of E

[centre in Canada]

centre in Canada

[change MDC]

change MDC

[aerobic]

aerobic

[Briggs]

Briggs

[evaluation of the indications]

evaluation of the indications

[group II mL]

group II mL

[post-myocardial infarction heart failure patients]

post-myocardial infarction heart failure patients

[support using a HeartMate LVAD]

support using a HeartMate LVAD

[PAF enzymes]

PAF enzymes

[360 patients with heart failure]

360 patients with heart failure

[Twenty-seven symptomatic adult Fontan patients]

Twenty-seven symptomatic adult Fontan patients

[continuity of care]

continuity of care

[Contemporary use of devices]

Contemporary use of devices

[importance for DD]

importance for DD

[plateau phase]

plateau phase

[toxicity on blood pressure]

toxicity on blood pressure

[showing improvement]

showing improvement

[class CPG recommendations in HF]

class CPG recommendations in HF

[AF patients]

AF patients

[brief circulatory arrest]

brief circulatory arrest

[replicating resource use from 3 trials]

replicating resource use from 3 trials

[validation in studies]

validation in studies

[final BB dose high]

final BB dose high

[reduction in Ea]

reduction in Ea

[beta-adrenergic receptor]

beta-adrenergic receptor

[cerebrovascular events]

cerebrovascular events

[postmarketing]

postmarketing

[mild diastolic dysfunction]

mild diastolic dysfunction

[odds dying in 30 days]

odds dying in 30 days

[prescribing angiotensin]

prescribing angiotensin

[relationship with CV events in fibrillation]

relationship with CV events in fibrillation

[sarcoplasmic reticular SR Ca]

sarcoplasmic reticular SR Ca

[right plane systolic excursion TAPSE]

right plane systolic excursion TAPSE

[precapillary pulmonary hypertension]

precapillary pulmonary hypertension

[randomized outcome assessment trial]

randomized outcome assessment trial

[new-user cohort study]

new-user cohort study

[changes in treatment in subjects]

changes in treatment in subjects

[risk of outcomes in other patients]

risk of outcomes in other patients

[Akt→forkhead]

Akt→forkhead

[effect of left ventricular ejection fraction]

effect of left ventricular ejection fraction

[POC systems]

POC systems

[uncertainty about the safety]

uncertainty about the safety

[ventricular base]

ventricular base

[first 3 months]

first 3 months

[key regulator]

key regulator

[duration of biventricular support]

duration of biventricular support

[Effective arterial elastance end-systolic elastance Ees]

Effective arterial elastance end-systolic elastance Ees

[right ventricular reserve in patients]

right ventricular reserve in patients

[structure of records]

structure of records

[therapeutic interatrial shunting]

therapeutic interatrial shunting

[non-cachectic CHF]

non-cachectic CHF

[non-survivors years years]

non-survivors years years

[hypotheses addition of dopamine]

hypotheses addition of dopamine

[correlates of increase in exercise capacity]

correlates of increase in exercise capacity

[dysfunction LV relaxation]

dysfunction LV relaxation

[simple prediction rule]

simple prediction rule

[CV events in models]

CV events in models

[2-vessel CAD involving the descending artery]

2-vessel CAD involving the descending artery

[insight in dyssynchronous heart failure]

insight in dyssynchronous heart failure

[circulatory derangement with features]

circulatory derangement with features

[45 deaths in the CRT group]

45 deaths in the CRT group

[basis of ventricle pressure]

basis of ventricle pressure

[clinical studies approximately 2900 HM II]

clinical studies approximately 2900 HM II

[right tricuspid annular plane excursion]

right tricuspid annular plane excursion

[assessing filling pressure]

assessing filling pressure

[Na current during HF]

Na current during HF

[dyssynchronous heart failure a study]

dyssynchronous heart failure a study

[undiagnosed heart disease of HF]

undiagnosed heart disease of HF

[severe congestive heart failure]

severe congestive heart failure

[onset HFrEF]

onset HFrEF

[19 patients with heart failure]

19 patients with heart failure

[Treatment group effects]

Treatment group effects

[Fontan adults]

Fontan adults

[echocardiographic assessment]

echocardiographic assessment

[patients with this condition]

patients with this condition

[54 patients with heart failure]

54 patients with heart failure

[eccentric hypertrophy]

eccentric hypertrophy

[sympathetic tone resulting in imbalance]

sympathetic tone resulting in imbalance

[4.6 mm Hg]

4.6 mm Hg

[patients IL mg]

patients IL mg

[2 valve repairs]

2 valve repairs

[assist device with temporary support]

assist device with temporary support

[patients in NYHA functional class]

patients in NYHA functional class

[cardiac sodium]

cardiac sodium

[75 years with diabetes]

75 years with diabetes

[role in artery disease]

role in artery disease

[predictors for the development of IE]

predictors for the development of IE

[trials of blood transfusions in adults]

trials of blood transfusions in adults

[patients with disease COPD]

patients with disease COPD

[systemic vascular resistance SVR index]

systemic vascular resistance SVR index

[effectiveness of medicine CHM]

effectiveness of medicine CHM

[age of 62 years]

age of 62 years

[prognostic role in HF]

prognostic role in HF

[reliable diagnostic biomarkers]

reliable diagnostic biomarkers

[HF of unclear etiology]

HF of unclear etiology

[health outcomes in patients]

health outcomes in patients

[York Heart Association Class]

York Heart Association Class

[receptor 1]

receptor 1

[Cardiac magnetic resonance T1 time]

Cardiac magnetic resonance T1 time

[ventricular LV dilatation]

ventricular LV dilatation

[brain peptide]

brain peptide

[blood pressure HR]

blood pressure HR

[right tricuspid plane excursion TAPSE]

right tricuspid plane excursion TAPSE

[three readmission metrics]

three readmission metrics

[cardiac index versus 2.8 0.7 L]

cardiac index versus 2.8 0.7 L

[334 consecutive patients men mean]

334 consecutive patients men mean

[stable pure HNO donor]

stable pure HNO donor

[readmission metrics all-cause readmission ACR]

readmission metrics all-cause readmission ACR

[significant improvements in composite response P=0.02]

significant improvements in composite response P=0.02

[Anecdotal evidence]

Anecdotal evidence

[normal hearts HNorm]

normal hearts HNorm

[protection from norepinephrine-induced responses]

protection from norepinephrine-induced responses

[Case]

Case

[uptake of class CPG recommendations]

uptake of class CPG recommendations

[therapy of heart disease]

therapy of heart disease

[severe hypertension of mm Hg]

severe hypertension of mm Hg

[development of MS following ring annuloplasty]

development of MS following ring annuloplasty

[Grade strong recommendation]

Grade strong recommendation

[20 cm]

20 cm

[hall walk distance]

hall walk distance

[power index]

power index

[Heart Failure MLHF]

Heart Failure MLHF

[hypertension SH]

hypertension SH

[still a effective anti-neoplastic agent]

still a effective anti-neoplastic agent

[other exercise variables exercise ventilation]

other exercise variables exercise ventilation

[additional prognostic benefit over parameters]

additional prognostic benefit over parameters

[public health problem worldwide]

public health problem worldwide

[decrement]

decrement

[highest DRS deciles]

highest DRS deciles

[Neprilysin]

Neprilysin

[matrix of left biopsies n=9]

matrix of left biopsies n=9

[similar tissue from control animals]

similar tissue from control animals

[date]

date

[sitagliptin for sitagliptin versus insulin]

sitagliptin for sitagliptin versus insulin

[Many studies in practice settings]

Many studies in practice settings

[burden in medicine]

burden in medicine

[metoprolol hazard ratio]

metoprolol hazard ratio

[QRS duration of msec]

QRS duration of msec

[progressive development]

progressive development

[absorption function]

absorption function

[differential relations between CPCs in patients]

differential relations between CPCs in patients

[endothelial cell oxide production]

endothelial cell oxide production

[outcome measures in prospective research]

outcome measures in prospective research

[positron emission]

positron emission

[predictor of post-transplant mortality]

predictor of post-transplant mortality

[NYHA functional class IV]

NYHA functional class IV

[Killip class]

Killip class

[more than 8000 individuals]

more than 8000 individuals

[effect in patients]

effect in patients

[possible biomarker]

possible biomarker

[10.7 nmol ng]

10.7 nmol ng

[CI for sitagliptin versus pioglitazone]

CI for sitagliptin versus pioglitazone

[Fifty patients with onset]

Fifty patients with onset

[including nuclear factor]

including nuclear factor

[promoting filling in subjects]

promoting filling in subjects

[6-MWT of feet]

6-MWT of feet

[HeartMate]

HeartMate

[patients with first myocardial infarction]

patients with first myocardial infarction

[such as acute infarction with expansion]

such as acute infarction with expansion

[repression]

repression

[Multicenter Defibrillator Implantation Resynchronization Therapy]

Multicenter Defibrillator Implantation Resynchronization Therapy

[findings from Heart Failure a Trial]

findings from Heart Failure a Trial

[sitagliptin for sitagliptin versus sulfonylureas]

sitagliptin for sitagliptin versus sulfonylureas

[penalties]

penalties

[Data describing trends in HF]

Data describing trends in HF

[effect on IE risk]

effect on IE risk

[1:1 propensity]

1:1 propensity

[three age subjects]

three age subjects

[Impact of carvedilol]

Impact of carvedilol

[Hypertension diet scores with mortality]

Hypertension diet scores with mortality

[greater risk of cardiac events]

greater risk of cardiac events

[appendicular lean mass index]

appendicular lean mass index

[percent reduction]

percent reduction

[artery systolic pressure increase by means]

artery systolic pressure increase by means

[multiple non-diastolic abnormalities in function]

multiple non-diastolic abnormalities in function

[Key role]

Key role

[2 types of continuous-flow LVADs]

2 types of continuous-flow LVADs

[form of peripheral disease]

form of peripheral disease

[traditional enhancement imaging]

traditional enhancement imaging

[50 mg daily equivalent dose]

50 mg daily equivalent dose

[delay the time]

delay the time

[ruptures]

ruptures

[VO2max maximum oxygen consumption]

VO2max maximum oxygen consumption

[peptides NPs]

peptides NPs

[refractory end-stage heart failure CHF]

refractory end-stage heart failure CHF

[elastance Ea end-systolic elastance Ees]

elastance Ea end-systolic elastance Ees

[modulation of repolarization instability]

modulation of repolarization instability

[activating adaptive cardiac remodelling]

activating adaptive cardiac remodelling

[PDE2 in HF]

PDE2 in HF

[influence on the overall financial burden]

influence on the overall financial burden

[average length]

average length

[Effective arterial elastance end-systolic elastance]

Effective arterial elastance end-systolic elastance

[combination with factors]

combination with factors

[N-terminal proBNP midregional proANP MR-proANP]

N-terminal proBNP midregional proANP MR-proANP

[hypertension PAH]

hypertension PAH

[index 0.7 L 2]

index 0.7 L 2

[rate of inappropriate ATP]

rate of inappropriate ATP

[long-term 4-year survival]

long-term 4-year survival

[comanagement]

comanagement

[Renal denervation DNx]

Renal denervation DNx

[readmission rate following hospital stay]

readmission rate following hospital stay

[62 care clinicians]

62 care clinicians

[saxagliptin versus insulin]

saxagliptin versus insulin

[erasers]

erasers

[trend with ventricular dilatation]

trend with ventricular dilatation

[patients with onset HFrEF days]

patients with onset HFrEF days

[consultation for problems]

consultation for problems

[study-a multicenter study]

study-a multicenter study

[3,000 patients with recent onset AF]

3,000 patients with recent onset AF

[myeloma]

myeloma

[dilatation during the years]

dilatation during the years

[ventricular RV failure after the insertion]

ventricular RV failure after the insertion

[BNP levels pg BNP group]

BNP levels pg BNP group

[resistance hazard ratio]

resistance hazard ratio

[clinical circumstances]

clinical circumstances

[early annular velocity 3.1 vs. 1.3]

early annular velocity 3.1 vs. 1.3

[decline in event rates]

decline in event rates

[determining assessment for patients]

determining assessment for patients

[final multivariate models]

final multivariate models

[reasons for the reduction in MVA]

reasons for the reduction in MVA

[acceptable internal validity replicating resource use]

acceptable internal validity replicating resource use

[group IV 15 mL per m]

group IV 15 mL per m

[York Heart Association NYHA class]

York Heart Association NYHA class

[vasodilatory]

vasodilatory

[assessments within days of hospital discharge]

assessments within days of hospital discharge

[pressure of end-tidal CO2 PETCO2]

pressure of end-tidal CO2 PETCO2

[numbers in any]

numbers in any

[patients with outcome median]

patients with outcome median

[atrial peptide B-type peptide]

atrial peptide B-type peptide

[midregional proANP]

midregional proANP

[Frailty an important prognostic indicator]

Frailty an important prognostic indicator

[Cooper]

Cooper

[milliseconds 237 milliseconds]

milliseconds 237 milliseconds

[heart failure in pulmonary hypertension]

heart failure in pulmonary hypertension

[diagnosis of myeloma]

diagnosis of myeloma

[14 clinical studies HM II]

14 clinical studies HM II

[common form of peripheral disease]

common form of peripheral disease

[Multicenter double-blind clinical trial]

Multicenter double-blind clinical trial

[2 hypotheses]

2 hypotheses

[Average hospital rates]

Average hospital rates

[pro-brain-type natriuretic peptide assessment]

pro-brain-type natriuretic peptide assessment

[patients with obstructive disease COPD]

patients with obstructive disease COPD

[low resistance SVR index]

low resistance SVR index

[Wilcoxon matched-pairs]

Wilcoxon matched-pairs

[better well-being]

better well-being

[myocarditis versus cardiomyopathy]

myocarditis versus cardiomyopathy

[Patients with York Heart Association NYHA]

Patients with York Heart Association NYHA

[Dacron]

Dacron

[Incubation with HDL]

Incubation with HDL

[≥60 mL]

≥60 mL

[Ten-year experience]

Ten-year experience

[using Spearman correlations]

using Spearman correlations

[simultaneous reduction]

simultaneous reduction

[examining outcomes with this strategy]

examining outcomes with this strategy

[regurgitation MR]

regurgitation MR

[including inotropes]

including inotropes

[circumstances]

circumstances

[standard rehabilitation care]

standard rehabilitation care

[important disease]

important disease

[safe means]

safe means

[heart failure trials]

heart failure trials

[extra membrane oxygenation]

extra membrane oxygenation

[diastolic mitral velocity 3.1 vs. 1.3]

diastolic mitral velocity 3.1 vs. 1.3

[platelet-activating factor PAF]

platelet-activating factor PAF

[effect on heart rate]

effect on heart rate

[association between preoperative dysfunction]

association between preoperative dysfunction

[retrospective cohort study]

retrospective cohort study

[suggesting postcontrast T1 as biomarker]

suggesting postcontrast T1 as biomarker

[cell therapy]

cell therapy

[important role for microRNAs miRNAs]

important role for microRNAs miRNAs

[partial improvement of cardiac performance]

partial improvement of cardiac performance

[comprising hospitalization for syndromes]

comprising hospitalization for syndromes

[recognition of disease]

recognition of disease

[9868 participants without HF area]

9868 participants without HF area

[60,000 patients across 4372 hospitals]

60,000 patients across 4372 hospitals

[animal model of myocardial ischemia]

animal model of myocardial ischemia

[left ventricular LV pressure]

left ventricular LV pressure

[HF patients left ejection fraction]

HF patients left ejection fraction

[patient enrollment]

patient enrollment

[safety measures]

safety measures

[ATPase activity]

ATPase activity

[more recently for transplant-ineligible patients]

more recently for transplant-ineligible patients

[addition μg]

addition μg

[mouse heart failure model]

mouse heart failure model

[chronic kidney disease median filtration rate]

chronic kidney disease median filtration rate

[4.9 years for patients]

4.9 years for patients

[pressure 155]

pressure 155

[symptomatic advanced heart failure patients]

symptomatic advanced heart failure patients

[vivo phosphorylation sites]

vivo phosphorylation sites

[LV end volume index]

LV end volume index

[Benefits with ejection fraction pEF]

Benefits with ejection fraction pEF

[Candesartan]

Candesartan

[CAD involving the descending artery]

CAD involving the descending artery

[smallest difference among EF median BNP]

smallest difference among EF median BNP

[diastolic indices E]

diastolic indices E

[overview of trial design]

overview of trial design

[Aldosterone antagonism]

Aldosterone antagonism

[Wilcoxon]

Wilcoxon

[pulmonary systolic pressure relationship]

pulmonary systolic pressure relationship

[group II 30 mL per m]

group II 30 mL per m

[disease complex]

disease complex

[expression during hypertrophy]

expression during hypertrophy

[confirmation]

confirmation

[high-risk group]

high-risk group

[E-wave mitral velocity]

E-wave mitral velocity

[ATP production]

ATP production

[low resistance index]

low resistance index

[patients with syndromes]

patients with syndromes

[relevance carrying two increase]

relevance carrying two increase

[allocation ratio]

allocation ratio

[single-centre parallel-group trial]

single-centre parallel-group trial

[assist device support]

assist device support

[6-month risk]

6-month risk

[using the method of aortic constriction]

using the method of aortic constriction

[differences between patients with EF]

differences between patients with EF

[development of events IEs]

development of events IEs

[restoration of lipoprotein properties]

restoration of lipoprotein properties

[meeting inclusion]

meeting inclusion

[early changes]

early changes

[adjusting for variables]

adjusting for variables

[acute right pressure overload]

acute right pressure overload

[E-wave diastolic mitral annular velocity]

E-wave diastolic mitral annular velocity

[Effects of mechanical support on function]

Effects of mechanical support on function

[differential relations]

differential relations

[practice-level prescription rates]

practice-level prescription rates

[right ventricular pacing]

right ventricular pacing

[especially in the case]

especially in the case

[chemical instability]

chemical instability

[Heart Failure Model]

Heart Failure Model

[patients as destination therapy]

patients as destination therapy

[concrete data regarding the role]

concrete data regarding the role

[left ventricular longitudinal strain GLS]

left ventricular longitudinal strain GLS

[Concomitant treatment]

Concomitant treatment

[contribution of nursing]

contribution of nursing

[(eGFR)-group I mL per 1.73 m]

(eGFR)-group I mL per 1.73 m

[dysfunction REVERSE]

dysfunction REVERSE

[interaction between these receptors]

interaction between these receptors

[daily practice]

daily practice

[risk factor for cardiovascular disease]

risk factor for cardiovascular disease

[hazard ratio for increase]

hazard ratio for increase

[other exercise variables exercise oscillatory ventilation]

other exercise variables exercise oscillatory ventilation

[adjustment for all confounders]

adjustment for all confounders

[high consistency among patients with HFpEF]

high consistency among patients with HFpEF

[thirds of patients]

thirds of patients

[MADIT-CRT trial]

MADIT-CRT trial

[910 patients with plasma samples]

910 patients with plasma samples

[cardiac function in the onset]

cardiac function in the onset

[manner]

manner

[POC testing]

POC testing

[diverse cohort]

diverse cohort

[ABCC2]

ABCC2

[odds July]

odds July

[Overall ICU mortality stay]

Overall ICU mortality stay

[changes with varying regional strain contributions]

changes with varying regional strain contributions

[effect of interventions]

effect of interventions

[accumulation]

accumulation

[α-myosin chain]

α-myosin chain

[nitric oxide NO]

nitric oxide NO

[cardiac tissue from mice]

cardiac tissue from mice

[glycolysis rates]

glycolysis rates

[previous revascularization hazard ratio]

previous revascularization hazard ratio

[all-cause medical hospitalization]

all-cause medical hospitalization

[cardiac pathophysiology]

cardiac pathophysiology

[TM interventions]

TM interventions

[ventricular diastolic end diameter mean difference]

ventricular diastolic end diameter mean difference

[volume overload VO]

volume overload VO

[ST2 levels A Trial Investigating Outcomes]

ST2 levels A Trial Investigating Outcomes

[β1-adrenergic receptor]

β1-adrenergic receptor

[mistargeting]

mistargeting

[nonsignificant trend toward an association]

nonsignificant trend toward an association

[ventricular LV pressure]

ventricular LV pressure

[possible measure of reserve]

possible measure of reserve

[New-onset insufficiency AI]

New-onset insufficiency AI

[elastance end-systolic elastance]

elastance end-systolic elastance

[METs vs. METs]

METs vs. METs

[E wave ratio]

E wave ratio

[overall effects]

overall effects

[Department]

Department

[even accounting]

even accounting

[transmitral E-wave diastolic mitral annular velocity]

transmitral E-wave diastolic mitral annular velocity

[patients male gender]

patients male gender

[β2-receptor]

β2-receptor

[powerful predictor of favorable outcome]

powerful predictor of favorable outcome

[patients treatment with a contribution]

patients treatment with a contribution

[using regression]

using regression

[limits of agreement]

limits of agreement

[quotient]

quotient

[use of cardioverter defibrillator-CRT]

use of cardioverter defibrillator-CRT

[Affairs HF clinic VA cohort]

Affairs HF clinic VA cohort

[monoclonal antibodies]

monoclonal antibodies

[BET family bromodomain proteins]

BET family bromodomain proteins

[composite outcome]

composite outcome

[Peritoneal dialysis for management]

Peritoneal dialysis for management

[tension (Fpassive)-sarcomere length relations]

tension (Fpassive)-sarcomere length relations

[MI-induced decreases in septum thickness]

MI-induced decreases in septum thickness

[University Health Network Toronto]

University Health Network Toronto

[VO2max oxygen consumption]

VO2max oxygen consumption

[system adverse events]

system adverse events

[other subgroup analyses including quality]

other subgroup analyses including quality

[only after weeks]

only after weeks

[higher amount]

higher amount

[evidence of dysfunction]

evidence of dysfunction

[absorption]

absorption

[patient categorization]

patient categorization

[loss of fat mass FFM]

loss of fat mass FFM

[guideline-recommended drugs]

guideline-recommended drugs

[many reasons]

many reasons

[steady decline]

steady decline

[dilatation improvement]

dilatation improvement

[effects on rate]

effects on rate

[BB dose high]

BB dose high

[greater activity]

greater activity

[Four groups Wistar-Kyoto]

Four groups Wistar-Kyoto

[demonstration]

demonstration

[chronic thromboembolic hypertension]

chronic thromboembolic hypertension

[improvement in outcome ratings]

improvement in outcome ratings

[kidney disease]

kidney disease

[ratio Ees]

ratio Ees

[effects in CHF Inhibition]

effects in CHF Inhibition

[disease such as exercise programmes]

disease such as exercise programmes

[impaired ventricular pump function]

impaired ventricular pump function

[Kaiser Permanente California]

Kaiser Permanente California

[other exercise variables exercise ventilation EOV]

other exercise variables exercise ventilation EOV

[tachyarrhythmias]

tachyarrhythmias

[distinct derangement with features similar]

distinct derangement with features similar

[ankle-brachial]

ankle-brachial

[human tissue]

human tissue

[gradient]

gradient

[EAST treatment of fibrillation]

EAST treatment of fibrillation

[guanosine monophosphate cGMP]

guanosine monophosphate cGMP

[right ventricular pressure overload]

right ventricular pressure overload

[exercise protocol]

exercise protocol

[Effective elastance Ea end-systolic elastance]

Effective elastance Ea end-systolic elastance

[standing]

standing

[similar incidence MT]

similar incidence MT

[knowledge on use]

knowledge on use

[14.0 ml]

14.0 ml

[recent onset HFrEF]

recent onset HFrEF

[mortality among postmenopausal women]

mortality among postmenopausal women

[standard therapy]

standard therapy

[only partial attenuation]

only partial attenuation

[attenuation of proteomics changes]

attenuation of proteomics changes

[future hospital mortality]

future hospital mortality

[effective agent]

effective agent

[performance detecting normal filling pressures]

performance detecting normal filling pressures

[relevant health service provision]

relevant health service provision

[2.5 kg]

2.5 kg

[individuals aged 55]

individuals aged 55

[right ventricular ejection fraction P=0.01]

right ventricular ejection fraction P=0.01

[effects of exercise training ET]

effects of exercise training ET

[global ventricular strain GLS]

global ventricular strain GLS

[NP measurement]

NP measurement

[20 variables]

20 variables

[right ventricular RV plane excursion]

right ventricular RV plane excursion

[analysis matching]

analysis matching

[groups validity]

groups validity

[effect on quality]

effect on quality

[various processes]

various processes

[Risk for Heart Failure Among Users]

Risk for Heart Failure Among Users

[Patients requiring RV support]

Patients requiring RV support

[incidence outcomes of heart failure]

incidence outcomes of heart failure

[effect of CHF]

effect of CHF

[3058 patients]

3058 patients

[revascularization coronary artery bypass surgery]

revascularization coronary artery bypass surgery

[UV treatment]

UV treatment

[users of a TNF antagonist]

users of a TNF antagonist

[indicating possible suboptimal care]

indicating possible suboptimal care

[Hemodynamic phenotype of the Fontan]

Hemodynamic phenotype of the Fontan

[transmitral E-wave mitral velocity]

transmitral E-wave mitral velocity

[transforming growth factor-β TGF-β signaling]

transforming growth factor-β TGF-β signaling

[economic considerations]

economic considerations

[intermediate odds ratios for events]

intermediate odds ratios for events

[overview]

overview

[deaths in the experimental procedures]

deaths in the experimental procedures

[rotation]

rotations, rotation

[index 2.2]

index 2.2

[Society guidelines definition]

Society guidelines definition

[effective elastance]

effective elastance

[potential efficacy of left-to-right interatrial shunting]

potential efficacy of left-to-right interatrial shunting

[cardiac death in athletes]

cardiac death in athletes

[therapeutic potential]

therapeutic potential

[outcome change scores]

outcome change scores

[TAPSE RV fiber shortening]

TAPSE RV fiber shortening

[peak early mitral flow velocity]

peak early mitral flow velocity

[2-vessel CAD involving the left artery]

2-vessel CAD involving the left artery

[risk stratification with heart failure]

risk stratification with heart failure

[previous revascularization]

previous revascularization

[higher activities]

higher activities

[ventricular RV tricuspid annular plane excursion]

ventricular RV tricuspid annular plane excursion

[early diastolic mitral velocity 3.1]

early diastolic mitral velocity 3.1

[6-minute walking distance peak]

6-minute walking distance peak

[absolute change between performance]

absolute change between performance

[acute heart failure in patients]

acute heart failure in patients

[involving the proximal anterior descending artery]

involving the proximal anterior descending artery

[70 bpm 17.5±5.5 P]

70 bpm 17.5±5.5 P

[603 patients age]

603 patients age

[beneficial clinical outcomes]

beneficial clinical outcomes

[natriuretic peptide assessment]

natriuretic peptide assessment

[healthy pilot study]

healthy pilot study

[sympathetic activity (123)I-meta-iodobenzylguanidine]

sympathetic activity (123)I-meta-iodobenzylguanidine

[control adenovirus]

control adenovirus

[systolic annulus velocity]

systolic annulus velocity

[change in MLHF score effect]

change in MLHF score effect

[respective molecular pathways]

respective molecular pathways

[providing information for an clinical outcome]

providing information for an clinical outcome

[occurring Rad variant]

occurring Rad variant

[oral dosage]

oral dosage

[patients with stable CAD]

patients with stable CAD

[mitral annulus velocity Sa]

mitral annulus velocity Sa

[Moderate evidence from 17 trials]

Moderate evidence from 17 trials

[heart failure studies]

heart failure studies

[left area hazard ratio]

left area hazard ratio

[diagnosis of clinical dysfunction leading]

diagnosis of clinical dysfunction leading

[left ejection fraction LVEF]

left ejection fraction LVEF

[SDQT-to-SDRR]

SDQT-to-SDRR

[filtration rate 30 ml]

filtration rate 30 ml

[community HF cohort]

community HF cohort

[optimal cutoff level]

optimal cutoff level

[content-driven telehealth system]

content-driven telehealth system

[good performance in patients with s'lateral]

good performance in patients with s'lateral

[Heart Association class III]

Heart Association class III

[sitagliptin CI]

sitagliptin CI

[41-year-old man]

41-year-old man

[Successful approaches improving the prognosis]

Successful approaches improving the prognosis

[Further large-scale studies]

Further large-scale studies

[index of right contractile function]

index of right contractile function

[socioeconomic status]

socioeconomic status

[feasibility of a program]

feasibility of a program

[oedema]

oedema

[Mena overexpression TTA comparable]

Mena overexpression TTA comparable

[variation in use Insights]

variation in use Insights

[PAF of metabolic enzymes]

PAF of metabolic enzymes

[Clinical characteristics of young adults]

Clinical characteristics of young adults

[quality-of-life score points]

quality-of-life score points

[approach extrapolating outcomes]

approach extrapolating outcomes

[pressure curve]

pressure curve

[effective practice]

effective practice

[Multivariable regression models]

Multivariable regression models

[SkM muscle]

SkM muscle

[pressure gradient]

pressure gradient

[ischemia stent]

ischemia stent

[alendronate- patients]

alendronate- patients

[cardiac resonance postcontrast T1 time]

cardiac resonance postcontrast T1 time

[doxorubicin-induced heart failure]

doxorubicin-induced heart failure

[Management of patients stemming from cardiomyopathies]

Management of patients stemming from cardiomyopathies

[fragments of pro-B-type natriuretic peptides]

fragments of pro-B-type natriuretic peptides

[opening without any clear lesion]

opening without any clear lesion

[749 patients]

749 patients

[decisions about treatment]

decisions about treatment

[12 stroke]

12 stroke

[panel of assessments]

panel of assessments

[vasopressin type 2]

vasopressin type 2

[patients with mild reduction]

patients with mild reduction, patients with mild reductions

[important indicator in heart failure]

important indicator in heart failure

[future mortality]

future mortality

[disease with important comorbidities]

disease with important comorbidities

[Overall management of patients]

Overall management of patients

[ischemia open stent]

ischemia open stent

[adverse event profile]

adverse event profile

[additional benefit over clinical parameters]

additional benefit over clinical parameters

[≥3.5 g]

≥3.5 g

[role of clinical Doppler echocardiography]

role of clinical Doppler echocardiography

[transplant recipients]

transplant recipients

[targeting individuals with heart failure]

targeting individuals with heart failure

[functional characterization of one]

functional characterization of one

[induction of a gene program]

induction of a gene program

[surgical intervention]

surgical intervention

[event rate events]

event rate events

[TAPSE vs. PASP]

TAPSE vs. PASP

[ventricular assist device LVAD implantation]

ventricular assist device LVAD implantation

[recreational athletes]

recreational athletes

[quality-of-life score –17.4 points vs. points]

quality-of-life score –17.4 points vs. points

[right-sided catheterization]

right-sided catheterization

[guidance under anaesthesia]

guidance under anaesthesia

[L-DKO]

L-DKO

[HDL-mediated protective effects]

HDL-mediated protective effects

[coupling vascular resistance]

coupling vascular resistance

[receptor antagonist valsartan]

receptor antagonist valsartan

[body mass index of ethnicity]

body mass index of ethnicity

[symptoms despite treatment]

symptoms despite treatment

[angiotensin-receptor]

angiotensin-receptor

[therapy in heart failure patients]

therapy in heart failure patients

[chromatin remodeling events]

chromatin remodeling events

[morbidity in childhood]

morbidity in childhood

[hospitalization worsening heart failure]

hospitalization worsening heart failure

[improvement in effective rate risk]

improvement in effective rate risk

[Cardiovascular Outcomes]

Cardiovascular Outcomes

[diverse community-based cohort]

diverse community-based cohort

[stable artery disease]

stable artery disease

[best quintile of performance]

best quintile of performance

[45 deaths in the control group]

45 deaths in the control group

[using acid]

using acid

[redo sternotomy for aortic valve procedures]

redo sternotomy for aortic valve procedures

[224 men]

224 men

[beta-blockers on sympathetic activity]

beta-blockers on sympathetic activity

[patients with resting HR 70]

patients with resting HR 70

[ventricular LV myocytes]

ventricular LV myocytes

[herbal medicine CHM]

herbal medicine CHM

[PB in patients]

PB in patients

[trials in adults with anemia]

trials in adults with anemia

[receptor β1AR]

receptor β1AR

[multicenter trial with individuals]

multicenter trial with individuals

[approximately 2900 HM]

approximately 2900 HM

[adults aged years]

adults aged years

[novel therapeutic strategy in HF]

novel therapeutic strategy in HF

[mm Hg Fig]

mm Hg Fig

[Edwards Lifesciences]

Edwards Lifesciences

[support on function]

support on function

[perfusion in B-treated rats]

perfusion in B-treated rats

[antecedent weight loss]

antecedent weight loss

[patients in regions]

patients in regions

[transmitral E-wave diastolic mitral velocity ratio]

transmitral E-wave diastolic mitral velocity ratio

[patients spironolactone]

patients spironolactone

[Selective heart rate reduction]

Selective heart rate reduction

[terminal phase]

terminal phase

[testosterone status a double-blind feasibility study]

testosterone status a double-blind feasibility study

[serum cystatin C]

serum cystatin C

[follow-up of months]

follow-up of months

[total DEGs]

total DEGs

[systemic resistance SVR index]

systemic resistance SVR index

[HF with ventricular ejection fraction]

HF with ventricular ejection fraction

[testosterone status a feasibility study]

testosterone status a feasibility study

[comparing B-treated with hearts]

comparing B-treated with hearts

[improvement of performance at stages]

improvement of performance at stages

[Identifying CAD]

Identifying CAD

[SD testosterone levels of nmol]

SD testosterone levels of nmol

[right pressure overload RVPO]

right pressure overload RVPO

[heart dilatation after constriction]

heart dilatation after constriction

[velocity 3.1 vs. 1.3]

velocity 3.1 vs. 1.3

[consenting HF patients ventricular ejection fraction]

consenting HF patients ventricular ejection fraction

[exercise test investigations]

exercise test investigations

[independent hypotheses]

independent hypotheses

[Hand2 mice]

Hand2 mice

[improvement of cardiac inflammatory biomarkers]

improvement of cardiac inflammatory biomarkers

[associations among cardiorespiratory fitness]

associations among cardiorespiratory fitness

[Effective arterial elastance Ea end-systolic elastance]

Effective arterial elastance Ea end-systolic elastance

[proximal left descending]

proximal left descending

[relevance of ventricular reserve in patients]

relevance of ventricular reserve in patients

[Postoperative survival of patients with hypoalbuminemia]

Postoperative survival of patients with hypoalbuminemia

[receiving cardioverter defibrillator-CRT]

receiving cardioverter defibrillator-CRT

[consecutive patients with HFPEF]

consecutive patients with HFPEF

[peak oxygen uptake with reduction]

peak oxygen uptake with reduction

[better function]

better function

[channel mRNA splice variants]

channel mRNA splice variants

[development of novel approaches]

development of novel approaches

[Lesions]

Lesions

[HF hospitalization HR 1.58 CI]

HF hospitalization HR 1.58 CI

[current predictors]

current predictors

[cost-effective population-specific health interventions]

cost-effective population-specific health interventions

[predictor after admission]

predictor after admission

[site-specific antibodies]

site-specific antibodies

[IE risk]

IE risk

[B-type natriuretic peptide levels]

B-type natriuretic peptide levels

[four US healthcare programmes]

four US healthcare programmes

[factor-β]

factor-β

[Multicenter double-blind trial Optimization Strategies Evaluation]

Multicenter double-blind trial Optimization Strategies Evaluation

[pluripotent stem]

pluripotent stem

[receptor potential]

receptor potential

[body mass index strata]

body mass index strata

[refractory congestive heart failure CHF]

refractory congestive heart failure CHF

[effects of nonselective]

effects of nonselective

[several markers indicative]

several markers indicative

[cardiac gene expression programme]

cardiac gene expression programme

[LVEF hazard ratio]

LVEF hazard ratio

[8 patients]

8 patients

[subjects with normal hearts HNorm]

subjects with normal hearts HNorm

[indicating possible care of patients]

indicating possible care of patients

[especially in subjects]

especially in subjects

[Affairs HF clinic outcomes]

Affairs HF clinic outcomes

[veterans aged 50 years]

veterans aged 50 years

[insulin-signaling components regulating cellular metabolism]

insulin-signaling components regulating cellular metabolism

[ivabradine exercise capacity]

ivabradine exercise capacity

[differential response in activity]

differential response in activity

[nontreatment]

nontreatment

[resynchronization therapy in dialysis-dependent patients]

resynchronization therapy in dialysis-dependent patients

[HF mortality risk]

HF mortality risk

[0 days]

0 days

[case of a man]

case of a man

[Practice-level variation in use Insights]

Practice-level variation in use Insights

[distribution in HFrEF]

distribution in HFrEF

[402 patients geometry]

402 patients geometry

[patients with HFpEF normal geometry]

patients with HFpEF normal geometry

[treatment interaction]

treatment interaction

[presumably decreasing risk]

presumably decreasing risk

[maximal elastance]

maximal elastance

[including cancer]

including cancer

[diagnostic features such as early detection]

diagnostic features such as early detection

[evidence for potential usefulness in HF]

evidence for potential usefulness in HF

[accurate risk stratification of patient appropriate]

accurate risk stratification of patient appropriate

[incidence MT]

incidence MT

[hierarchical regression models]

hierarchical regression models

[potential of a strategy]

potential of a strategy

[aortic valve insufficiency]

aortic valve insufficiency

[characteristics The CHARM programme]

characteristics The CHARM programme

[approaches improving the prognosis of patients]

approaches improving the prognosis of patients

[HF units]

HF units

[gene control]

gene control

[tricuspid plane systolic excursion TAPSE]

tricuspid plane systolic excursion TAPSE

[lipid-lowering therapy]

lipid-lowering therapy

[DEGs]

DEGs

[Clinical characteristics The CHARM programme]

Clinical characteristics The CHARM programme

[current economic climate]

current economic climate

[patients in fibrillation]

patients in fibrillation

[ventricular midpapillary level]

ventricular midpapillary level

[PKC-βII]

PKC-βII

[younger patients with co-morbidity burden]

younger patients with co-morbidity burden

[outpatient assessments within days]

outpatient assessments within days

[prognostic diastolic dysfunction leading]

prognostic diastolic dysfunction leading

[transplant-ineligible patients]

transplant-ineligible patients

[patients with HFpEF α=0.96]

patients with HFpEF α=0.96

[cardiac sympathetic activity by ((123)I-MIBG]

cardiac sympathetic activity by ((123)I-MIBG

[pioglitazone for saxagliptin]

pioglitazone for saxagliptin

[reducing the composite endpoint]

reducing the composite endpoint

[atheromatous disease]

atheromatous disease

[left ejection fraction mean difference]

left ejection fraction mean difference

[benefits of spironolactone]

benefits of spironolactone

[highest hazard]

highest hazard

[forms of remodeling in heart failure]

forms of remodeling in heart failure

[clinical trials-Enriching patient identification]

clinical trials-Enriching patient identification

[fewer procedures 146 vs. 238]

fewer procedures 146 vs. 238

[CHARM programme]

CHARM programme

[mean of years]

mean of years

[ventricular power index]

ventricular power index

[comprising hospitalization for coronary syndromes]

comprising hospitalization for coronary syndromes

[measurable improvements]

measurable improvements

[bisoprolol reducing mortality]

bisoprolol reducing mortality

[spectrometric analysis]

spectrometric analysis

[suburban hospitals in New Jersey]

suburban hospitals in New Jersey

[criteriabased institution for the treatment]

criteriabased institution for the treatment

[urban center]

urban center

[Physio]

Physio

[dilatation diameter]

dilatation diameter

[organic lesion]

organic lesion

[outcomes using an aldosterone antagonist]

outcomes using an aldosterone antagonist

[treatment with a contribution]

treatment with a contribution

[decline c-Kit]

decline c-Kit

[GDMT for 6 months]

GDMT for 6 months

[median BNP]

median BNP

[ST2 in ambulatory patients]

ST2 in ambulatory patients

[Cross-talk]

Cross-talk

[Investigating Outcomes of Exercise Training]

Investigating Outcomes of Exercise Training

[all-cause mortality all hazard ratios]

all-cause mortality all hazard ratios

[373 patients]

373 patients

[disease accounting]

disease accounting

[microRNAs miRNAs]

microRNAs miRNAs

[infarction heart]

infarction heart

[Hum-Retn mice]

Hum-Retn mice

[percutaneous revascularization with angioplasty]

percutaneous revascularization with angioplasty

[receiving implantable cardioverter defibrillator-CRT]

receiving implantable cardioverter defibrillator-CRT

[sarcoplasmic Ca 2+)-uptake]

sarcoplasmic Ca 2+)-uptake

[perceptions of implantable cardioverter-defibrillator deactivation discussions]

perceptions of implantable cardioverter-defibrillator deactivation discussions

[diagnosis of clinical dysfunction]

diagnosis of clinical dysfunction

[HF-REF]

HF-REF

[adipose]

adipose

[therapeutic targets for HHD]

therapeutic targets for HHD

[hypotheses addition of low-dose dopamine]

hypotheses addition of low-dose dopamine

[technique detecting early myocardial fibrosis]

technique detecting early myocardial fibrosis

[worsening function WRF in EMPHASIS-HF]

worsening function WRF in EMPHASIS-HF

[initial diagnosis]

initial diagnosis

[mean of 0.25]

mean of 0.25

[providing information for an unfavourable outcome]

providing information for an unfavourable outcome

[activating PDE2]

activating PDE2

[prescribing medications]

prescribing medications

[long-acting insulin products]

long-acting insulin products

[arterial elastance end-systolic elastance]

arterial elastance end-systolic elastance

[writer]

writer

[changes in RS synchrony]

changes in RS synchrony

[7 kg with improvement in response]

7 kg with improvement in response

[HF patients HFVT(-)]

HF patients HFVT(-)

[individuals with chronic disease]

individuals with chronic disease

[Effectiveness for systolic heart failure]

Effectiveness for systolic heart failure

[advanced chronic obstructive disease COPD]

advanced chronic obstructive disease COPD

[β-AR drive]

β-AR drive

[study sample with 60,000 patients]

study sample with 60,000 patients

[Practice rates with angiotensin-converting enzyme inhibitors]

Practice rates with angiotensin-converting enzyme inhibitors

[care surgery consultations within year]

care surgery consultations within year

[hearts with levels]

hearts with levels

[transcatheter]

transcatheter

[Fontan SAF]

Fontan SAF

[outcomes of care]

outcomes of care

[using the flux analyzer]

using the flux analyzer

[nearly one million people]

nearly one million people

[interquartile range with COPD]

interquartile range with COPD

[POC measurement]

POC measurement

[normal function]

normal function

[mL 2]

mL 2

[patients receiving assist device support]

patients receiving assist device support

[2.8 L 2]

2.8 L 2

[Comparable performance]

Comparable performance

[existing measures explaining variation]

existing measures explaining variation

[70 bpm 17.5±5.5]

70 bpm 17.5±5.5

[regarding effective treatment]

regarding effective treatment

[risk-adjusted mortality at the worst]

risk-adjusted mortality at the worst

[proBNP]

proBNP

[patients with function]

patients with function

[Circulating fragments of pro-B-type natriuretic peptides]

Circulating fragments of pro-B-type natriuretic peptides

[improvements in composite response P=0.02]

improvements in composite response P=0.02

[cardiac procedures 146 vs. 238]

cardiac procedures 146 vs. 238

[Heart Association guidelines]

Heart Association guidelines

[patients with moderate]

patients with moderate

[recently for transplant-ineligible patients]

recently for transplant-ineligible patients

[changes in CO.]

changes in CO.

[clinical diastolic dysfunction leading]

clinical diastolic dysfunction leading

[beta-adrenergic receptor β-AR signaling]

beta-adrenergic receptor β-AR signaling

[metabolic enzymes over a follow-up period]

metabolic enzymes over a follow-up period

[presence of mild dysfunction]

presence of mild dysfunction

[Utilizing testimonies with participating nurses]

Utilizing testimonies with participating nurses

[CI for sitagliptin CI]

CI for sitagliptin CI

[patients with LV ejection fraction LVEF]

patients with LV ejection fraction LVEF

[diagnostic features]

diagnostic features

[2331 patients with left ejection fraction]

2331 patients with left ejection fraction

[defense mechanism during cardiac stress]

defense mechanism during cardiac stress

[outcomes using an antagonist]

outcomes using an antagonist

[patients with a ejection fraction]

patients with a ejection fraction

[Cardiovascular Outcomes in Atherosclerotic Lesions]

Cardiovascular Outcomes in Atherosclerotic Lesions

[volume overload of mitral regurgitation]

volume overload of mitral regurgitation

[cardiac index 0.7 L 2]

cardiac index 0.7 L 2

[ischemic cardiomyopathy IC]

ischemic cardiomyopathy IC

[fish]

fish

[Comparable performance in patients]

Comparable performance in patients

[congenital lesions]

congenital lesions

[targeting the patients]

targeting the patients

[EMPHASIS-HF study]

EMPHASIS-HF study

[Heart Association class]

Heart Association class

[more severe LV dysfunction]

more severe LV dysfunction

[forms of ventricular LV remodeling]

forms of ventricular LV remodeling

[proximal descending LAD]

proximal descending LAD

[volume groups]

volume groups

[area index]

area index

[evidence for potential usefulness]

evidence for potential usefulness

[selective β-blocker metoprolol]

selective β-blocker metoprolol

[EMPHASIS-HF]

EMPHASIS-HF

[determination of options]

determination of options

[cardiac hypertrophic response role]

cardiac hypertrophic response role

[mostly in class NYHA II-III]

mostly in class NYHA II-III

[including quality]

including quality

[therapeutic interruption]

therapeutic interruption

[single test for HFpEF]

single test for HFpEF

[adults with systolic heart failure]

adults with systolic heart failure

[prospective outcome assessment trial]

prospective outcome assessment trial

[Jersey]

Jersey

[Left ejection time complicating hypertension]

Left ejection time complicating hypertension

[metoprolol succinate]

metoprolol succinate

[date of participant contact]

date of participant contact

[10 weeks]

10 weeks

[having independent predictor]

having independent predictor

[Heart Failure Questionnaire]

Heart Failure Questionnaire

[Hypertension diet scores]

Hypertension diet scores

[systematic monitoring]

systematic monitoring

[Specific signalling pathways activating adaptive remodelling]

Specific signalling pathways activating adaptive remodelling

[EF r=-0.55]

EF r=-0.55

[prognostic relevance of ventricular reserve]

prognostic relevance of ventricular reserve

[one million people]

one million people

[cardioverter-defibrillator deactivation at implant]

cardioverter-defibrillator deactivation at implant

[status of NP measurement]

status of NP measurement

[mm Hg Fig 1A]

mm Hg Fig 1A

[regulating metabolism]

regulating metabolism

[hypotheses addition 2 μg]

hypotheses addition 2 μg

[presenting with a diagnosis]

presenting with a diagnosis

[novel intracellular antiadrenergic therapeutic strategy]

novel intracellular antiadrenergic therapeutic strategy

[Epidemiology]

Epidemiology, epidemiology

[incidence of liver texture changes]

incidence of liver texture changes

[hearts HNorm]

hearts HNorm

[2,538 patients with a follow-up]

2,538 patients with a follow-up

[Low-dose dopamine in acute heart failure]

Low-dose dopamine in acute heart failure

[home telemonitoring TM including monitoring devices]

home telemonitoring TM including monitoring devices

[use in HF]

use in HF

[STS HH credible interval CrI]

STS HH credible interval CrI

[including RELAX-AHF]

including RELAX-AHF

[cardiac sympathetic tone]

cardiac sympathetic tone

[ventricular RV annular plane systolic excursion]

ventricular RV annular plane systolic excursion

[dilation]

dilation

[carrying two increase]

carrying two increase

[Heart Foundation]

Heart Foundation

[24-hour brachial systolic pressure]

24-hour brachial systolic pressure

[panel of experienced electrocardiographers]

panel of experienced electrocardiographers

[significant improvement in effective rate risk]

significant improvement in effective rate risk

[caspase-3 activity]

caspase-3 activity

[stable heart failure patients]

stable heart failure patients

[noninvasive surrogates for changes During RVPO]

noninvasive surrogates for changes During RVPO

[Diagnosis of heart failure role]

Diagnosis of heart failure role

[Benefits in HF]

Benefits in HF

[mean follow-up]

mean follow-up

[antitumor activity]

antitumor activity

[sphingosine-1-phosphate receptor 1]

sphingosine-1-phosphate receptor 1

[matrix of left biopsies]

matrix of left biopsies

[first acute infarction]

first acute infarction

[effect of nervous system modulation]

effect of nervous system modulation

[RV function evaluation]

RV function evaluation

[Multicenter clinical trial Optimization Strategies Evaluation]

Multicenter clinical trial Optimization Strategies Evaluation

[ratio diastolic mitral annulus velocity]

ratio diastolic mitral annulus velocity

[left assist device with support]

left assist device with support

[80 years of age]

80 years of age

[left LV dilatation]

left LV dilatation

[years with diabetes]

years with diabetes

[primary symptom of HFPEF]

primary symptom of HFPEF

[Extracellular matrix of left ventricular biopsies]

Extracellular matrix of left ventricular biopsies

[right coupling vascular resistance]

right coupling vascular resistance

[19 patients]

19 patients

[types of LVADs]

types of LVADs

[median of days]

median of days

[mild regurgitation]

mild regurgitation

[only a amount]

only a amount

[weak recommendation]

weak recommendation

[promoting pause release during stress]

promoting pause release during stress

[role of Doppler echocardiography]

role of Doppler echocardiography

[major mechanism of HFPEF]

major mechanism of HFPEF

[kidney infection without complications]

kidney infection without complications

[severe systolic HF]

severe systolic HF

[survivors of childhood disease]

survivors of childhood disease

[ivabradine mg]

ivabradine mg

[tricuspid annular plane systolic excursion TAPSE]

tricuspid annular plane systolic excursion TAPSE

[catheterisation with transoesophageal echocardiographic guidance]

catheterisation with transoesophageal echocardiographic guidance

[therapy HR]

therapy HR

[value of indeterminable threshold]

value of indeterminable threshold

[resulting in a higher SV p]

resulting in a higher SV p

[P value=0.033]

P value=0.033

[observation period]

observation period

[total of individuals aged 55]

total of individuals aged 55

[chamber]

chamber

[role of ERK1]

role of ERK1

[human-to-human contact]

human-to-human contact

[resulting in the support score]

resulting in the support score

[Predictors of mortality a systematic review]

Predictors of mortality a systematic review

[degree early]

degree early

[12-week program of exercise]

12-week program of exercise

[acute myocardial infarction with complications]

acute myocardial infarction with complications

[N-terminal fragment]

N-terminal fragment

[four conditions]

four conditions

[capacity for CF LVAD patients]

capacity for CF LVAD patients

[Left ventricular ejection time]

Left ventricular ejection time

[arthritis]

arthritis

[Coding System]

Coding System

[cumulative urine volume decongestion end point]

cumulative urine volume decongestion end point

[endothelial cell oxide NO production]

endothelial cell oxide NO production

[hospitalizations in severe refractory heart failure]

hospitalizations in severe refractory heart failure

[tract]

tract

[new users of a nbDMARD]

new users of a nbDMARD

[PAF-acetylhydrolase]

PAF-acetylhydrolase

[patients with chronic organ failure]

patients with chronic organ failure

[MADIT-CRT study]

MADIT-CRT study

[proximal LCX model]

proximal LCX model

[high morbidity especially in people]

high morbidity especially in people

[basic relevance in the follow-up]

basic relevance in the follow-up

[consecutive patients with onset HFrEF]

consecutive patients with onset HFrEF

[HF patients without VT HFVT(-)]

HF patients without VT HFVT(-)

[presence of clinical diastolic dysfunction]

presence of clinical diastolic dysfunction

[endothelial cell]

endothelial cell

[therapy MT]

therapy MT

[Fig 1A]

Fig 1A

[224 men mean]

224 men mean

[frailty HR]

frailty HR

[risk predictor for cardiac death]

risk predictor for cardiac death

[STS HH interval]

STS HH interval

[statistically significant change]

statistically significant change

[Shortness]

Shortness

[women with a history of hypertension]

women with a history of hypertension

[small subgroup]

small subgroup

[survival from the time]

survival from the time

[adjusting for 20 variables]

adjusting for 20 variables

[patients 224 men 65±12 years]

patients 224 men 65±12 years

[open outcome assessment trial]

open outcome assessment trial

[largest increases]

largest increases

[including T1 mapping]

including T1 mapping

[littermate]

littermate

[bundle branch block odds ratio]

bundle branch block odds ratio

[STE analysis of circumferential strain]

STE analysis of circumferential strain

[Implications of metric choice]

Implications of metric choice

[National trends in patient safety]

National trends in patient safety

[VA cohort]

VA cohort

[patients experiencing implantable cardioverter-defibrillator shocks]

patients experiencing implantable cardioverter-defibrillator shocks

[HF-induced remodeling aspects]

HF-induced remodeling aspects

[center retrospective study]

center retrospective study

[matrix of biopsies]

matrix of biopsies

[N-terminal proBNP NT-proBNP midregional proANP]

N-terminal proBNP NT-proBNP midregional proANP

[only a amount of recent data]

only a amount of recent data

[actions of Rad]

actions of Rad

[cardiac Na current]

cardiac Na current

[periodic breathing]

periodic breathing

[anthracycline exposure]

anthracycline exposure

[exercise variables exercise oscillatory ventilation EOV]

exercise variables exercise oscillatory ventilation EOV

[heart failure patients ventricular ejection fraction]

heart failure patients ventricular ejection fraction

[functional decline]

functional decline

[interaction on outcomes P]

interaction on outcomes P

[hearts in experimental models]

hearts in experimental models

[medical management of heart failure]

medical management of heart failure

[191 104 mm Hg]

191 104 mm Hg

[serum potassium level]

serum potassium level

[time feasible]

time feasible

[uncertainty]

uncertainty

[ST2 levels with capacity A Trial]

ST2 levels with capacity A Trial

[hospital quality improvement]

hospital quality improvement

[optimal treatment for heart failure]

optimal treatment for heart failure

[cardiac index versus 2.8 L]

cardiac index versus 2.8 L

[annular velocity 3.1 vs. 1.3]

annular velocity 3.1 vs. 1.3

[difference median BNP in women]

difference median BNP in women

[HF resources]

HF resources

[cardiac mRNA levels]

cardiac mRNA levels

[other databases]

other databases

[dramatic induction of hRetn mRNA]

dramatic induction of hRetn mRNA

[non-survivors years]

non-survivors years

[velocity time]

velocity time

[two increase in risk]

two increase in risk

[9 subjects with structurally normal hearts]

9 subjects with structurally normal hearts

[significant improvement in outcome ratings]

significant improvement in outcome ratings

[nonterminal epitopes]

nonterminal epitopes

[outcome vs 257 milliseconds milliseconds]

outcome vs 257 milliseconds milliseconds

[development via direct effects]

development via direct effects

[conflicting results]

conflicting results

[burden in adult medicine]

burden in adult medicine

[significant cardioprotection]

significant cardioprotection

[pioglitazone for saxagliptin for saxagliptin]

pioglitazone for saxagliptin for saxagliptin

[lower stimulation of phosphorylation]

lower stimulation of phosphorylation

[Most events]

Most events

[attenuation by peptides]

attenuation by peptides

[role molecular scaffolds]

role molecular scaffolds

[regarding risk factors]

regarding risk factors

[current predictors of mortality]

current predictors of mortality

[tool in the diagnosis]

tool in the diagnosis

[still a highly effective anti-neoplastic agent]

still a highly effective anti-neoplastic agent

[ventricle the Fontan circulation]

ventricle the Fontan circulation

[resistin in heart failure in mice]

resistin in heart failure in mice

[crucial role]

crucial role

[patients male gender odds ratio]

patients male gender odds ratio

[regulator of actin dynamics]

regulator of actin dynamics

[consecutive patients men mean years]

consecutive patients men mean years

[9 subjects with normal hearts]

9 subjects with normal hearts

[SS31]

SS31

[improvement between baseline exercise capacity METs]

improvement between baseline exercise capacity METs

[undergoing β-adrenergic receptor stimulation]

undergoing β-adrenergic receptor stimulation

[stage I-III]

stage I-III

[Stage kidney disease CKD]

Stage kidney disease CKD

[oxidative metabolism]

oxidative metabolism

[valve plasty for degenerative MR]

valve plasty for degenerative MR

[Effective arterial elastance elastance Ees]

Effective arterial elastance elastance Ees

[area 26 cm]

area 26 cm

[neonatal rat ventricular cardiomyocytes]

neonatal rat ventricular cardiomyocytes

[Factors Insights From Heart Failure]

Factors Insights From Heart Failure

[HFPEF left LV ejection fraction]

HFPEF left LV ejection fraction

[pulmonary pressure relationship]

pulmonary pressure relationship

[Ca 2 handling in dyssynchronous HF]

Ca 2 handling in dyssynchronous HF

[individual component]

individual component

[common cause of cardiovascular hospitalization]

common cause of cardiovascular hospitalization

[Even on therapy]

Even on therapy

[range 22.8 with COPD]

range 22.8 with COPD

[variation Insights]

variation Insights

[odds of future 30-day]

odds of future 30-day

[Diagnostic role in stable artery disease]

Diagnostic role in stable artery disease

[nonpace DNx]

nonpace DNx

[nursing-sensitive outcome measures in research]

nursing-sensitive outcome measures in research

[often contextual factors]

often contextual factors

[Statewide Health]

Statewide Health

[mitral annulus velocities during systole]

mitral annulus velocities during systole

[systolic strain as a predictor]

systolic strain as a predictor

[including hypertrophy]

including hypertrophy

[exercise-induced pulmonary artery pressure increase]

exercise-induced pulmonary artery pressure increase

[impact of QRS morphology]

impact of QRS morphology

[costs related]

costs related

[efficacy of therapeutic interatrial shunting]

efficacy of therapeutic interatrial shunting

[early changes in the development]

early changes in the development

[cardiomyopathic restriction]

cardiomyopathic restriction

[80 mm]

80 mm

[Effectiveness of spironolactone for heart failure]

Effectiveness of spironolactone for heart failure

[agents in patients with anemia]

agents in patients with anemia

[potentiating the adaptive response]

potentiating the adaptive response

[causing a physiology]

causing a physiology

[association between renal dysfunction]

association between renal dysfunction

[important trigger of acute infarction]

important trigger of acute infarction

[patients with HFPEF]

patients with HFPEF

[Genetic susceptibility in survivors]

Genetic susceptibility in survivors

[pre-defined inclusion criteria]

pre-defined inclusion criteria

[standard rehabilitation care on capacity]

standard rehabilitation care on capacity

[100 participants mean]

100 participants mean

[hand grip strength kg]

hand grip strength kg

[CABG]

CABG

[novel antiadrenergic strategy]

novel antiadrenergic strategy

[higher readmission rates]

higher readmission rates

[AF type]

AF type

[encoding nonfunctional channels]

encoding nonfunctional channels

[N-terminal proBNP proANP]

N-terminal proBNP proANP

[HNO donor]

HNO donor

[concentric remodeling]

concentric remodeling

[time of second HF]

time of second HF

[Sudden death]

Sudden death

[NCDR]

NCDR

[Medicare 30-day readmission CMS]

Medicare 30-day readmission CMS

[BMI-matched volunteers]

BMI-matched volunteers

[Half of patients]

Half of patients

[onset of HF]

onset of HF

[idiopathic-dilated cardiomyopathy]

idiopathic-dilated cardiomyopathy

[vivo assessment of function]

vivo assessment of function

[approach for the treatment]

approach for the treatment

[2 G-protein-coupled receptors]

2 G-protein-coupled receptors

[patients IL]

patients IL

[occurring within days of ACS consultation]

occurring within days of ACS consultation

[156 consenting HF patients ejection fraction]

156 consenting HF patients ejection fraction

[multivariate Cox hazards regression modeling]

multivariate Cox hazards regression modeling

[use in practice]

use in practice

[patients with HFrEF]

patients with HFrEF

[N-terminal proBNP NT-proBNP proANP]

N-terminal proBNP NT-proBNP proANP

[left ventricular end diameter mm]

left ventricular end diameter mm

[0 days after MI]

0 days after MI

[Health Insurance]

Health Insurance

[doses of β-blocker]

doses of β-blocker

[fulfilling World Health Organization criteria]

fulfilling World Health Organization criteria

[reversal]

reversal, Reversal

[detecting early fibrosis]

detecting early fibrosis

[Pharmacological treatment treatment]

Pharmacological treatment treatment

[incident HF in participants aged years]

incident HF in participants aged years

[role determining the remodelling]

role determining the remodelling

[mitochondrial metabolism]

mitochondrial metabolism

[dopamine in acute heart failure]

dopamine in acute heart failure

[patients with arterial hypertension]

patients with arterial hypertension

[mitral valve plasty for regurgitation]

mitral valve plasty for regurgitation

[HFpEF patients aged 69 years]

HFpEF patients aged 69 years

[BNP measurements]

BNP measurements

[saxagliptin users]

saxagliptin users

[population-specific health interventions]

population-specific health interventions

[Society guidelines definition of HFPEF]

Society guidelines definition of HFPEF

[Short-Form quality]

Short-Form quality

[current climate]

current climate

[ischemic heart failure]

ischemic heart failure

[β-blockers therapy for treatment]

β-blockers therapy for treatment

[global attenuation of TAC-induced alterations]

global attenuation of TAC-induced alterations

[outcome measures in future research]

outcome measures in future research

[3,000 patients with onset AF]

3,000 patients with onset AF

[Affairs HF clinic 106 outcomes]

Affairs HF clinic 106 outcomes

[CV events in fibrillation AF]

CV events in fibrillation AF

[long-term management]

long-term management

[Validation studies]

Validation studies

[paucity of data]

paucity of data

[hazard ratio 0.521]

hazard ratio 0.521

[Data describing trends after MI]

Data describing trends after MI

[42 percent relative reduction]

42 percent relative reduction

[targeting specific effector molecules]

targeting specific effector molecules

[systolic dysfunction by weeks]

systolic dysfunction by weeks

[Society guidelines]

Society guidelines

[promoting transcriptional pause release during stress]

promoting transcriptional pause release during stress

[HF guidelines]

HF guidelines

[38 controls CHF]

38 controls CHF

[open chest model]

open chest model

[patients A Trial HF-ACTION]

patients A Trial HF-ACTION

[effects from exercise training]

effects from exercise training

[predicting 4-year survival]

predicting 4-year survival

[severe frailty]

severe frailty

[receiving PD solely]

receiving PD solely

[studies of therapeutics including agents]

studies of therapeutics including agents

[sarcomere]

sarcomere

[example antagonizing β-AR drive]

example antagonizing β-AR drive

[valve causing a physiology]

valve causing a physiology

[actions on adenylyl cyclase]

actions on adenylyl cyclase

[HF hospitalization HR CI 1.27]

HF hospitalization HR CI 1.27

[scenario of total expenditure]

scenario of total expenditure

[receiving methotrexate]

receiving methotrexate

[Shortness of Breath]

Shortness of Breath

[low co-morbidity burden]

low co-morbidity burden

[resulting in the ivabradine-treated patients]

resulting in the ivabradine-treated patients

[same time period]

same time period

[One hundred patients]

One hundred patients

[office-based emergency room practice]

office-based emergency room practice

[association with diet scores]

association with diet scores

[inpatient]

inpatient

[ANS]

ANS

[current knowledge of abnormalities]

current knowledge of abnormalities

[phospholipase A2 Lp-PLA2]

phospholipase A2 Lp-PLA2

[HeartMate assist system LVAS]

HeartMate assist system LVAS

[Comments in heart failure]

Comments in heart failure

[Multicenter placebo-controlled trial of 360 patients]

Multicenter placebo-controlled trial of 360 patients

[adverse impact]

adverse impact

[Medicare readmission CMS]

Medicare readmission CMS

[measure of left mechanics]

measure of left mechanics

[disease model]

disease model

[51 years]

51 years

[blood-flow paths]

blood-flow paths

[Clinical characteristics]

Clinical characteristics

[development of therapeutic strategies]

development of therapeutic strategies

[lower blood pressure]

lower blood pressure

[DAPC protein levels]

DAPC protein levels

[permanent breathing]

permanent breathing

[approaches improving the prognosis]

approaches improving the prognosis

[practical Recommendations]

practical Recommendations

[primary culprit]

primary culprit

[prognostic information for an outcome]

prognostic information for an outcome

[resort]

resort

[SkM muscle structure]

SkM muscle structure

[importance of diastolic dysfunction]

importance of diastolic dysfunction

[treatment current treatment]

treatment current treatment

[Frailty for heart failure the health]

Frailty for heart failure the health

[survival through 4 years]

survival through 4 years

[Left ejection time]

Left ejection time

[Practice Guideline]

Practice Guideline

[early clinical outcomes]

early clinical outcomes

[exercise capacity in obese older patients]

exercise capacity in obese older patients

[value of threshold]

value of threshold

[advanced stages]

advanced stages

[data among groups]

data among groups

[youngest age group]

youngest age group

[Cardiac resonance T1 time]

Cardiac resonance T1 time

[mortality among these subgroups]

mortality among these subgroups

[novel porcine model]

novel porcine model

[HeartMate 3 assist system LVAS]

HeartMate 3 assist system LVAS

[follow-up times]

follow-up times

[echocardiographic guidance under anaesthesia]

echocardiographic guidance under anaesthesia

[psoriasis systemic UV treatment]

psoriasis systemic UV treatment

[10 HF patients HFVT(-)]

10 HF patients HFVT(-)

[After revascularization]

After revascularization

[minutes walking]

minutes walking

[reduction of cardiac Na]

reduction of cardiac Na

[epithelial transition markers]

epithelial transition markers

[asymptomatic pediatric Fontan patients]

asymptomatic pediatric Fontan patients

[trends in event rates between 2005]

trends in event rates between 2005

[N forms]

N forms

[more data regarding the role]

more data regarding the role

[78 saxagliptin users]

78 saxagliptin users

[early metabolic changes in the development]

early metabolic changes in the development

[adenosine monophosphate cAMP]

adenosine monophosphate cAMP

[calf]

calf

[confirmatory factor analysis]

confirmatory factor analysis

[possible mechanism]

possible mechanism

[HVAD devices]

HVAD devices

[activating cardiac remodelling]

activating cardiac remodelling

[beta blockade]

beta blockade

[patient characteristics]

patient characteristics

[stable severe HF]

stable severe HF

[7-day visits]

7-day visits

[neutral results in HF trials]

neutral results in HF trials

[global proteomics changes in constriction]

global proteomics changes in constriction

[underlying characteristics using Cochrane Practice]

underlying characteristics using Cochrane Practice

[MRI-based models of nonfailing canine electromechanics]

MRI-based models of nonfailing canine electromechanics

[delay VVD]

delay VVD

[regulation in mouse hearts]

regulation in mouse hearts

[blood cell transfusion strategy]

blood cell transfusion strategy

[consecutive patients with PAD]

consecutive patients with PAD

[statistics]

statistics

[Nitroxyl]

Nitroxyl

[Advanced HF A Multicenter Study]

Advanced HF A Multicenter Study

[detecting filling pressures]

detecting filling pressures

[normal reference mean]

normal reference mean

[8-fluo-cAMP binding]

8-fluo-cAMP binding

[comparisons statistically significant]

comparisons statistically significant

[volunteers]

volunteers

[B-type]

B-type

[ventricular RV plane excursion]

ventricular RV plane excursion

[Health Planning]

Health Planning

[unadjusted prescription rates]

unadjusted prescription rates

[risk predictor for sudden death]

risk predictor for sudden death

[potential efficacy of interatrial shunting]

potential efficacy of interatrial shunting

[such as time-domain measures]

such as time-domain measures

[comparing B-treated]

comparing B-treated

[reduction of outflow]

reduction of outflow

[common consensus]

common consensus

[n=44 925 ED visits]

n=44 925 ED visits

[prognostic power of measures]

prognostic power of measures

[information for an clinical outcome]

information for an clinical outcome

[P 0.01]

P 0.01

[failing Fontan circulation]

failing Fontan circulation

[cardiomyopathy in Tuscany]

cardiomyopathy in Tuscany

[modern heart failure studies]

modern heart failure studies

[common cause]

common cause

[basal contractility]

basal contractility

[centers in the States]

centers in the States

[pre-participation screening of athletes]

pre-participation screening of athletes

[problem of current cardiology]

problem of current cardiology

[clinical trial registries]

clinical trial registries

[significant lesions]

significant lesions

[evidence for the treatment]

evidence for the treatment

[ventricular end-diastolic pressure]

ventricular end-diastolic pressure

[even lower volumes]

even lower volumes

[Key role of ERK1 scaffolds]

Key role of ERK1 scaffolds

[Rankin]

Rankin

[simple ECG parameters]

simple ECG parameters

[cell nitric oxide production]

cell nitric oxide production

[receiving drugs for heart failure]

receiving drugs for heart failure

[only after weeks of pacing]

only after weeks of pacing

[myocardial fibrosis]

myocardial fibrosis

[right pressure overload]

right pressure overload

[Other Drugs]

Other Drugs

[Effects of pacing on heart twist]

Effects of pacing on heart twist

[final models]

final models

[other medical staff responsible]

other medical staff responsible

[patients as control without exercise]

patients as control without exercise

[restoring functional capacity]

restoring functional capacity

[obese ZSF1 with diet]

obese ZSF1 with diet

[left ventricular dyssynchrony]

left ventricular dyssynchrony

[Contemporary heart failure]

Contemporary heart failure

[Only the ZSF1 groups]

Only the ZSF1 groups

[Specific signalling pathways]

Specific signalling pathways

[diuretic effect]

diuretic effect

[left biopsies n=9]

left biopsies n=9

[E-wave mitral velocity ratio]

E-wave mitral velocity ratio

[practitioners in emergency room practice]

practitioners in emergency room practice

[maintaining sinus rhythm]

maintaining sinus rhythm

[Possible reasons for the reduction]

Possible reasons for the reduction

[system major neurological events]

system major neurological events

[Investigation of apoptosis]

Investigation of apoptosis

[increase in exercise capacity]

increase in exercise capacity

[Wistar-Kyoto]

Wistar-Kyoto

[relationship between TAPSE]

relationship between TAPSE

[function WRF in EMPHASIS-HF]

function WRF in EMPHASIS-HF

[contribution of CAD]

contribution of CAD

[extracellular matrix accumulation]

extracellular matrix accumulation

[nmol ng]

nmol ng

[infarction AMI with complications]

infarction AMI with complications

[hypertension of 104 mm Hg]

hypertension of 104 mm Hg

[independent markers hazard ratio for peak]

independent markers hazard ratio for peak

[16 patients HDL before ET]

16 patients HDL before ET

[effect of autonomic system modulation]

effect of autonomic system modulation

[factors on physician adherence]

factors on physician adherence

[therapy cardiogenic shock]

therapy cardiogenic shock

[kidney 293 cells]

kidney 293 cells

[4 samples]

4 samples

[study end point oxygen uptake]

study end point oxygen uptake

[key enzymes lyso-PAF acetyltransferase]

key enzymes lyso-PAF acetyltransferase

[Detailed transcriptional analysis of cardiac tissue]

Detailed transcriptional analysis of cardiac tissue

[intracellular antiadrenergic therapeutic strategy]

intracellular antiadrenergic therapeutic strategy

[optimizing progenitor function]

optimizing progenitor function

[left ejection fraction LVEF]

left ejection fraction LVEF

[mitral annular velocity 3.1]

mitral annular velocity 3.1

[patients with resting HR]

patients with resting HR

[signed-rank]

signed-rank

[hospital discharge in patients]

hospital discharge in patients

[Left ejection time in heart failure]

Left ejection time in heart failure

[outcome in patients with HFrEF]

outcome in patients with HFrEF

[other medications]

other medications

[Global left strain]

Global left strain

[outcome assessment trial]

outcome assessment trial

[event rates for acute infarction]

event rates for acute infarction

[Department of cardiology]

Department of cardiology

[asymptomatic pediatric Fontan PF patients]

asymptomatic pediatric Fontan PF patients

[packages]

packages

[8 wk]

8 wk

[24-hour systolic pressure]

24-hour systolic pressure

[refill compliance for etidronate]

refill compliance for etidronate

[right ventricular end-diastolic area index]

right ventricular end-diastolic area index

[new-onset AI requiring intervention]

new-onset AI requiring intervention

[odds dying in days]

odds dying in days

[predictors of mortality in heart failure]

predictors of mortality in heart failure

[transfer]

transfer

[providing care]

providing care

[administration of doxorubicin]

administration of doxorubicin

[Grade strong recommendation evidence]

Grade strong recommendation evidence

[elastance Ea end-systolic elastance]

elastance Ea end-systolic elastance

[MicroRNAs new targets in disease management]

MicroRNAs new targets in disease management

[abnormalities of the heart]

abnormalities of the heart

[cost savings]

cost savings

[perturbations in components of the DAPC]

perturbations in components of the DAPC

[COPD n=95]

COPD n=95

[little influence on the financial burden]

little influence on the financial burden

[2 independent hypotheses addition]

2 independent hypotheses addition

[NT-proBNP cutoff point predicting survival]

NT-proBNP cutoff point predicting survival

[correction after ventricular assist device implantation]

correction after ventricular assist device implantation

[creatine kinase]

creatine kinase

[new understanding]

new understanding

[variation in future mortality]

variation in future mortality

[noninvasive surrogates]

noninvasive surrogates

[skeletal muscle sarcomere structure]

skeletal muscle sarcomere structure

[telehealth system]

telehealth system

[sandwich]

sandwich

[adult mouse myocytes]

adult mouse myocytes

[fewer admissions]

fewer admissions

[statitistical significance]

statitistical significance

[therapies in these patients]

therapies in these patients

[denervation DNx]

denervation DNx

[arginine vasopressin]

arginine vasopressin

[administration in rats]

administration in rats

[significant improvement between baseline exercise capacity]

significant improvement between baseline exercise capacity

[carrying increase]

carrying increase

[end-stage HF]

end-stage HF

[Mini-Sentinel]

Mini-Sentinel

[revealing a fundamental mechanism of dysfunction]

revealing a fundamental mechanism of dysfunction

[associations among fitness CRF]

associations among fitness CRF

[low vascular resistance index]

low vascular resistance index

[specifically on cardiomyopathy]

specifically on cardiomyopathy

[cAMP hydrolytic activity]

cAMP hydrolytic activity

[global left longitudinal strain GLS]

global left longitudinal strain GLS

[Abnormal cardiac T2]

Abnormal cardiac T2

[infarct]

infarct

[enhancement imaging]

enhancement imaging

[clinical signs]

clinical signs

[multicenter trial with 8000 individuals]

multicenter trial with 8000 individuals

[adverse cardiovascular CV events]

adverse cardiovascular CV events

[events P=0.001]

events P=0.001

[Improving outcomes in patients]

Improving outcomes in patients

[quality measures for inpatient medical conditions]

quality measures for inpatient medical conditions

[AAs]

AAs

[trend with less severe dilatation]

trend with less severe dilatation

[key regulator of actin dynamics]

key regulator of actin dynamics

[20,812 patients with myocardial infarction]

20,812 patients with myocardial infarction

[Cardiology-Cardiovascular Surgery]

Cardiology-Cardiovascular Surgery

[patients 48]

patients 48

[individual associations]

individual associations

[ACC]

ACC

[involving adults]

involving adults

[phosphorylation at eNOS-Thr]

phosphorylation at eNOS-Thr

[right ventricular support]

right ventricular support

[2.1 17.6 mL P=0.01]

2.1 17.6 mL P=0.01

[decreases in septum systolic thickness]

decreases in septum systolic thickness

[ejection time in acute heart failure]

ejection time in acute heart failure

[protocol-driven POC testing]

protocol-driven POC testing

[Renal Optimization]

Renal Optimization

[types of beta-blockers]

types of beta-blockers

[prior disease]

prior disease

[cardiac T2]

cardiac T2

[correlation of indices]

correlation of indices

[reduction in increase]

reduction in increase

[American College ACC]

American College ACC

[oral dosage prior HF hospitalisations]

oral dosage prior HF hospitalisations

[Main etiologies of HF]

Main etiologies of HF

[more hypertension]

more hypertension

[similar ventricular tissue]

similar ventricular tissue

[pilot trial]

pilot trial

[Age-dependent effect of left ejection fraction]

Age-dependent effect of left ejection fraction

[prognostic indicator in heart failure]

prognostic indicator in heart failure

[excitation-contraction EC]

excitation-contraction EC

[3 economic evaluations]

3 economic evaluations

[ED visits]

ED visits

[nonstandardized pro-B-type peptide]

nonstandardized pro-B-type peptide

[American College ACP]

American College ACP

[rates potassium]

rates potassium

[stable guideline-directed therapy]

stable guideline-directed therapy

[Multicenter placebo-controlled trial Optimization Strategies Evaluation]

Multicenter placebo-controlled trial Optimization Strategies Evaluation

[isolated heart rate HR reduction]

isolated heart rate HR reduction

[156 ambulatory HF patients]

156 ambulatory HF patients

[ventricular-arterial coupling in HFPEF]

ventricular-arterial coupling in HFPEF

[retrospective studies]

retrospective studies

[pure HNO donor]

pure HNO donor

[retrospective chart review]

retrospective chart review

[regulatory]

regulatory

[spironolactone in practice]

spironolactone in practice

[hand grip strength kg vs kg]

hand grip strength kg vs kg

[human kidney 293 cells]

human kidney 293 cells

[arterial pressure relationship in heart failure]

arterial pressure relationship in heart failure

[acute ischemic right heart failure]

acute ischemic right heart failure

[63 predictors on ICD patients]

63 predictors on ICD patients

[measures of quality]

measures of quality

[non-biological disease modifying drug]

non-biological disease modifying drug

[early measurement]

early measurement

[surgery patients]

surgery patients

[proximal anterior descending LAD]

proximal anterior descending LAD

[consecutive 74 patients]

consecutive 74 patients

[study of exercise training]

study of exercise training

[characteristics using Cochrane Practice]

characteristics using Cochrane Practice

[Disease Registry Innovation]

Disease Registry Innovation

[inducible ischemia]

inducible ischemia

[derangement albeit with limited ability]

derangement albeit with limited ability

[studies with 1887 patients]

studies with 1887 patients

[cardiovascular function with measures]

cardiovascular function with measures

[Frailty the health]

Frailty the health

[amount of malondialdehyde]

amount of malondialdehyde

[pg low BNP group]

pg low BNP group

[Emergency Department ED presentation]

Emergency Department ED presentation

[presence with proteolysis]

presence with proteolysis

[potentially beneficial new approach]

potentially beneficial new approach

[Benefits in HF with ejection fraction]

Benefits in HF with ejection fraction

[Lokomat® System]

Lokomat® System

[mitochondrial]

mitochondrial

[Relation between dysfunction within months]

Relation between dysfunction within months

[Impact of physician continuity on readmission]

Impact of physician continuity on readmission

[post-HCT]

post-HCT

[longitudinal outcome-monitoring phase mean]

longitudinal outcome-monitoring phase mean

[cardiac defibrillator]

cardiac defibrillator

[significant improvement in rate relative risk]

significant improvement in rate relative risk

[changes in chromatin structure]

changes in chromatin structure

[primary care clinicians caring]

primary care clinicians caring

[factor for deterioration of HFPEF]

factor for deterioration of HFPEF

[Reasons prescribing medications]

Reasons prescribing medications

[fewer cardiac procedures 146]

fewer cardiac procedures 146

[LV fractional shortening]

LV fractional shortening

[5 patients]

5 patients

['D HF]

'D HF

[benefits across all study participants]

benefits across all study participants

[ventricular HF tissue samples]

ventricular HF tissue samples

[filling time]

filling time

[prior myocardial n]

prior myocardial n

[current Cardiovascular Outcomes in Lesions]

current Cardiovascular Outcomes in Lesions

[early diastolic mitral annulus velocity]

early diastolic mitral annulus velocity

[total cost]

total cost

[promoting cardiac filling especially in subjects]

promoting cardiac filling especially in subjects

[sitagliptin for sitagliptin for sitagliptin]

sitagliptin for sitagliptin for sitagliptin

[Mixed-methods study of veterans aged years]

Mixed-methods study of veterans aged years

[patients with outcome vs milliseconds]

patients with outcome vs milliseconds

[carotid bodies]

carotid bodies

[prognostic composite HF index P]

prognostic composite HF index P

[difference between numbers]

difference between numbers

[proximal descending artery]

proximal descending artery

[precipitating factor for deterioration]

precipitating factor for deterioration

[ejection fraction HF-REF]

ejection fraction HF-REF

[β-adrenoceptor blockade with esmolol]

β-adrenoceptor blockade with esmolol

[few deaths]

few deaths

[outcome ratings]

outcome ratings

[evaluations at baseline]

evaluations at baseline

[regarding treatment of older adults]

regarding treatment of older adults

[Medical Outcomes Study Short-Form quality]

Medical Outcomes Study Short-Form quality

[biomarker studies]

biomarker studies

[TAPSE vs. PASP relationship]

TAPSE vs. PASP relationship

[outpatient models]

outpatient models

[heart dilatation]

heart dilatation

[quality-of-life score points vs. 2.1 points]

quality-of-life score points vs. 2.1 points

[base during baseline]

base during baseline

[aim of this prospective study]

aim of this prospective study

[appropriate follow-up]

appropriate follow-up

[ATP production rates]

ATP production rates

[encouraging declines]

encouraging declines

[402 patients with HFpEF normal geometry]

402 patients with HFpEF normal geometry

[epigenetic changes]

epigenetic changes

[impact on health-related quality HRQoL]

impact on health-related quality HRQoL

[analysis using medicare data]

analysis using medicare data

[TAPSE]

TAPSE

[end-diastolic area index 10.0 cm(2)]

end-diastolic area index 10.0 cm(2)

[using simple experimental procedures]

using simple experimental procedures

[reduction in hospital length]

reduction in hospital length

[ANG]

ANG

[forty-six patients]

forty-six patients

[use of the systems]

use of the systems

[hospitalization rates]

hospitalization rates

[even in subgroups]

even in subgroups

[considerable number]

considerable number

[unfavorable outcome median vs milliseconds]

unfavorable outcome median vs milliseconds

[hemoglobin Hgb]

hemoglobin Hgb

[2 ECG parameters]

2 ECG parameters

[powerful independent predictor]

powerful independent predictor

[mass analysis]

mass analysis

[Minnesota quality of life]

Minnesota quality of life

[pressure gradient of mm Hg]

pressure gradient of mm Hg

[prognostic relevance of right contractile reserve]

prognostic relevance of right contractile reserve

[reductions in LVEF respectively]

reductions in LVEF respectively

[histone deacetylases]

histone deacetylases

[patients with co-morbidity burden]

patients with co-morbidity burden

[differences between patients with HF]

differences between patients with HF

[common problem with mortality]

common problem with mortality

[desensitization]

desensitization

[procedures 146]

procedures 146

[ninety-three HF patients HFrEF]

ninety-three HF patients HFrEF

[percent body mass]

percent body mass

[0.28 mL]

0.28 mL

[value of NP assessment]

value of NP assessment

[growth factor-β signaling]

growth factor-β signaling

[cell oxide production]

cell oxide production

[predictor of favorable outcome]

predictor of favorable outcome

[potentially beneficial approach]

potentially beneficial approach

[similar tissue]

similar tissue

[improvements in functioning of treatments]

improvements in functioning of treatments

[risk in patients with IC]

risk in patients with IC

[low mg dose]

low mg dose

[three months]

three months

[such as scaling exponent]

such as scaling exponent

[HDL-induced production]

HDL-induced production

[composite end-point of mortality]

composite end-point of mortality

[cytotoxic effect]

cytotoxic effect

[prognostic dysfunction]

prognostic dysfunction

[powerful predictor of outcome]

powerful predictor of outcome

[risk of therapy]

risk of therapy

[PAF-CPT in parallel]

PAF-CPT in parallel

[use in patients]

use in patients

[alternative for heart failure therapy]

alternative for heart failure therapy

[Data describing trends]

Data describing trends

[changes in platelet-activating factor]

changes in platelet-activating factor

[224 men mean years]

224 men mean years

[vascular resistance index]

vascular resistance index

[requiring LVAD]

requiring LVAD

[myocardial matrix accumulation]

myocardial matrix accumulation

[adenosine monophosphate]

adenosine monophosphate

[risk stratification appropriate]

risk stratification appropriate

[aggressive treatment with vasodilators]

aggressive treatment with vasodilators

[atrial area hazard ratio]

atrial area hazard ratio

[right area index cm(2)]

right area index cm(2)

[relevance of ventricular contractile reserve]

relevance of ventricular contractile reserve

[right ventricular-pulmonary coupling]

right ventricular-pulmonary coupling

[brain peptide BNP]

brain peptide BNP

[endothelial function in heart failure]

endothelial function in heart failure

[recent trials in HF]

recent trials in HF

[Power analysis]

Power analysis

[body composition skinfold thickness]

body composition skinfold thickness

[response in cardiac sympathetic activity]

response in cardiac sympathetic activity

[feasibility study]

feasibility study

[tone resulting in imbalance]

tone resulting in imbalance

[HR 70 bpm P]

HR 70 bpm P

[cardiac insulin-resistance by 2 weeks]

cardiac insulin-resistance by 2 weeks

[outcomes 0.92 events]

outcomes 0.92 events

[anastomosis]

anastomosis

[≥1 predictor]

≥1 predictor

[significant 42 percent relative reduction]

significant 42 percent relative reduction

[human kidney cells]

human kidney cells

[larger HR reduction]

larger HR reduction

[hospital days for participants]

hospital days for participants

[reviewers]

reviewers

[ng range 18.6]

ng range 18.6

[option in refractory heart failure]

option in refractory heart failure

[gradient of HF risk]

gradient of HF risk

[30-day survival rates]

30-day survival rates

[cyclic adenosine monophosphate]

cyclic adenosine monophosphate

[0.7 L 2]

0.7 L 2

[muscle abnormalities in adults]

muscle abnormalities in adults

[including mortality]

including mortality

[levels of social support]

levels of social support

[achieving at least a level]

achieving at least a level

[hemoglobin threshold]

hemoglobin threshold

[addition indicating care]

addition indicating care

[overlapping part]

overlapping part

[mm Hg low PASP]

mm Hg low PASP

[factor in heart failure HF]

factor in heart failure HF

[behavioural-change interventions in disease]

behavioural-change interventions in disease

[scientific literature]

scientific literature

[median BNP in women EF]

median BNP in women EF

[Measuring heart failure care]

Measuring heart failure care

[patients with COPD]

patients with COPD

[1.35 kg]

1.35 kg

[CD34]

CD34

[approach for the acute treatment]

approach for the acute treatment

[characteristics The CHARM programme Candesartan]

characteristics The CHARM programme Candesartan

[consecutive patients age]

consecutive patients age

[patients with type diabetes]

patients with type diabetes

[pre-participation screening]

pre-participation screening

[lower costs]

lower costs

[agent therapy]

agent therapy

[Epidemiology of heart failure]

Epidemiology of heart failure

[natriuretic peptides NPs]

natriuretic peptides NPs

[interquartile range 22.8]

interquartile range 22.8

[relation with commissioning]

relation with commissioning

[start After weeks]

start After weeks

[absence of fibrillation]

absence of fibrillation

[class CPG recommendations]

class CPG recommendations

[favour in the pathogenesis]

favour in the pathogenesis

[Low-strength evidence]

Low-strength evidence

[patients HF]

patients HF

[association of impairment]

association of impairment

[for hearts]

for hearts

[decrease in rates]

decrease in rates

[CAD involving the left artery]

CAD involving the left artery

[Using rat ventricular cardiomyocytes]

Using rat ventricular cardiomyocytes

[analysis of subgroups at risk]

analysis of subgroups at risk

[Occurrence of HF within days]

Occurrence of HF within days

[other aspects]

other aspects

[functioning]

functioning

[organ failure]

organ failure

[vivo experiments]

vivo experiments

[depolarization]

depolarization

[impact on gene programs]

impact on gene programs

[forms of left remodeling]

forms of left remodeling

[cost-effective participatory health interventions]

cost-effective participatory health interventions

[dose of mg]

dose of mg

[subgroups at risk developing hyperkalemia]

subgroups at risk developing hyperkalemia

[average age of years]

average age of years

[odds ratio 1.76 after adjustment]

odds ratio 1.76 after adjustment

[history with arteries]

history with arteries

[left ventricular LV myocytes]

left ventricular LV myocytes

[Key role scaffolds in heart pathology]

Key role scaffolds in heart pathology

[effects on receptor signaling]

effects on receptor signaling

[onset HFrEF 30 days]

onset HFrEF 30 days

[describing a nomenclature with a view]

describing a nomenclature with a view

[arrest in humans]

arrest in humans

[LV pressure in 20 weeks]

LV pressure in 20 weeks

[Fifty-four Fontan PF patients]

Fifty-four Fontan PF patients

[age subjects from the general population]

age subjects from the general population

[brachial systolic pressure 155 35]

brachial systolic pressure 155 35

[pilot program]

pilot program

[only a limited amount]

only a limited amount

[effects of nonselective versus beta-blockers]

effects of nonselective versus beta-blockers

[other staff responsible for patient care]

other staff responsible for patient care

[consistency among patients with HFpEF]

consistency among patients with HFpEF

[independent prognostic markers hazard ratio]

independent prognostic markers hazard ratio

[change in readmission rate]

change in readmission rate

[population in rural South Dakota]

population in rural South Dakota

[circulatory derangement with hemodynamic features]

circulatory derangement with hemodynamic features

[aortic valve procedures valve replacement]

aortic valve procedures valve replacement

[suggesting T1]

suggesting T1

[BB dose high versus mg dose]

BB dose high versus mg dose

[targets for HHD]

targets for HHD

[effect of LVEF on mortality]

effect of LVEF on mortality

[single-payer perspective]

single-payer perspective

[Effective elastance elastance Ees]

Effective elastance elastance Ees

[method of transverse constriction TAC]

method of transverse constriction TAC

[antagonizing β-AR drive]

antagonizing β-AR drive

[chronic therapy]

chronic therapy

[L-type processes]

L-type processes

[group mL per 1.73 m]

group mL per 1.73 m

[increasing population]

increasing population

[age-specific CRF categories]

age-specific CRF categories

[Even on optimal therapy]

Even on optimal therapy

[using three metrics for disease groups]

using three metrics for disease groups

[rats mechanism]

rats mechanism

[nmol 309 ng]

nmol 309 ng

[Fontan circulation exhibit]

Fontan circulation exhibit

[reprogramming]

reprogramming

[fetal gene]

fetal gene

[0.53 events]

0.53 events

[follow-up medication]

follow-up medication

[predictor period]

predictor period

[arguments]

arguments

[start of the treatment]

start of the treatment

[impairment with 6-month mortality]

impairment with 6-month mortality

[healthy volunteers]

healthy volunteers

[Practice rates of treatment]

Practice rates of treatment

[induction of hRetn mRNA]

induction of hRetn mRNA

[chronic guideline-directed therapy]

chronic guideline-directed therapy

[women with HF]

women with HF

[role of timing]

role of timing

[age-by-LVEF]

age-by-LVEF

[male rats]

male rats

[changes including cardiac hypertrophy]

changes including cardiac hypertrophy

[30 days P-value 0.001]

30 days P-value 0.001

[thorough history]

thorough history

[nursing-sensitive outcome measures in experimental research]

nursing-sensitive outcome measures in experimental research

[ventricular ejection fraction difference]

ventricular ejection fraction difference

[right ventricular annular plane excursion TAPSE]

right ventricular annular plane excursion TAPSE

[mL in peak VO2 P]

mL in peak VO2 P

[prospective multicenter trial PARADIGM-HF]

prospective multicenter trial PARADIGM-HF

[acute heart failure studies]

acute heart failure studies

[cardiac procedures 146]

cardiac procedures 146

[use of N-terminal pro-B-type peptide]

use of N-terminal pro-B-type peptide

[improvement in rate]

improvement in rate

[Age-dependent effect of ventricular ejection fraction]

Age-dependent effect of ventricular ejection fraction

[patients with onset HFrEF 30 days]

patients with onset HFrEF 30 days

[inpatient records]

inpatient records

[RR intervals]

RR intervals

[hallmark feature]

hallmark feature

[such as detection of fluid overload]

such as detection of fluid overload

[only a amount of data]

only a amount of data

[hyponatremia in countries]

hyponatremia in countries

[limited valve opening]

limited valve opening

[addition of low-dose dopamine μg]

addition of low-dose dopamine μg

[effective anti-neoplastic agent]

effective anti-neoplastic agent

[patients with a ventricular ejection fraction]

patients with a ventricular ejection fraction

[risk-standardized mortality]

risk-standardized mortality

[CPET guiding]

CPET guiding

[crucial role including nuclear factor]

crucial role including nuclear factor

[human kidney cells overexpressing β1AR]

human kidney cells overexpressing β1AR

[nitroxyl HNO]

nitroxyl HNO

[fastest growing subclass]

fastest growing subclass

[pediatric cardiac support]

pediatric cardiac support

[Validating nursing-sensitive outcome measures]

Validating nursing-sensitive outcome measures

